data_1y7n_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1y7n _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 . . . . . 0 N--CA 1.433 -1.29 0 CA-C-O 121.408 0.623 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t -128.59 126.81 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.373 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.465 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.8 m -118.09 107.24 13.75 Favored 'General case' 0 C--N 1.251 -3.716 0 CA-C-N 113.628 -1.624 . . . . 0.0 107.661 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.9 m -79.07 140.74 37.81 Favored 'General case' 0 N--CA 1.401 -2.908 0 CA-C-N 115.487 -0.778 . . . . 0.0 109.8 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -122.45 136.68 58.49 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.117 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.322 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.442 ' O ' ' HA2' ' A' ' 47' ' ' GLY . 29.9 tp -115.64 115.96 27.29 Favored 'General case' 0 N--CA 1.396 -3.152 0 C-N-CA 120.205 -0.598 . . . . 0.0 109.446 173.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.493 HG22 HD12 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -98.59 130.95 46.66 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.05 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.661 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 55.5 mtp180 -115.57 101.38 8.81 Favored 'General case' 0 N--CA 1.408 -2.572 0 CA-C-O 122.446 1.117 . . . . 0.0 108.829 171.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.457 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.3 ttt180 -100.79 119.48 58.28 Favored Pre-proline 0 C--N 1.275 -2.656 0 CA-C-N 112.939 -1.937 . . . . 0.0 111.896 -174.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.89 -48.48 12.43 Favored 'Trans proline' 0 CA--C 1.545 1.029 0 C-N-CA 122.92 2.414 . . . . 0.0 112.983 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -165.92 -175.15 3.28 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.4 HD21 HG13 ' A' ' 79' ' ' VAL . 59.0 mt -73.7 -11.73 60.5 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 115.064 1.505 . . . . 0.0 115.064 -173.023 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -86.68 -12.42 48.43 Favored 'General case' 0 C--N 1.292 -1.901 0 CA-C-O 121.743 0.782 . . . . 0.0 111.0 177.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -97.25 89.93 4.93 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 173.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -77.47 161.76 27.7 Favored 'General case' 0 N--CA 1.415 -2.218 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.094 -177.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.516 ' H ' HD22 ' A' ' 26' ' ' LEU . 1.4 mm? -45.89 -48.84 16.03 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 125.444 1.498 . . . . 0.0 111.55 -171.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.08 13.65 45.17 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 119.714 -1.231 . . . . 0.0 111.568 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -137.31 148.57 46.44 Favored 'General case' 0 N--CA 1.426 -1.643 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 175.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.2 m -96.46 122.54 39.46 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -120.52 143.22 33.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -130.88 114.7 15.6 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 173.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.425 ' OD1' ' HB2' ' A' ' 68' ' ' HIS . 93.3 m-20 64.9 14.45 9.26 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.563 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.55 -3.21 34.46 Favored Glycine 0 N--CA 1.434 -1.48 0 C-N-CA 120.52 -0.847 . . . . 0.0 111.737 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.58 124.55 66.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 O-C-N 121.964 -0.727 . . . . 0.0 110.769 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 61.9 mt -69.05 116.72 10.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 114.513 -1.221 . . . . 0.0 110.576 -178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -97.59 -32.23 11.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.583 -177.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.9 t -155.01 153.47 31.04 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.3 tp -132.13 130.85 41.69 Favored 'General case' 0 C--O 1.243 0.718 0 C-N-CA 123.197 0.599 . . . . 0.0 110.478 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -84.75 115.54 22.76 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 175.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -70.84 134.96 47.77 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -177.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.14 -2.72 75.69 Favored Glycine 0 C--N 1.302 -1.317 0 C-N-CA 121.193 -0.527 . . . . 0.0 111.802 -175.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.04 168.6 31.45 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.0 pt -57.15 -36.82 52.88 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.51 78.13 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -66.28 -41.46 89.82 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -66.91 -31.76 72.57 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 114.254 -1.339 . . . . 0.0 109.891 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -70.93 -27.3 72.46 Favored Glycine 0 N--CA 1.44 -1.1 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.822 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.6 21.46 10.47 Favored Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 73.8 t -77.74 137.39 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 48.8 mmt-85 -136.07 146.89 47.55 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.92 140.51 19.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 CA-C-N 114.281 -1.327 . . . . 0.0 109.708 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 25.11 27.85 Favored Glycine 0 N--CA 1.431 -1.643 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 -178.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.8 m170 -119.18 144.95 46.4 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.901 -0.65 . . . . 0.0 110.227 176.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 43.4 ttp180 -107.21 124.06 49.19 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.338 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.434 HD11 HG22 ' A' ' 86' ' ' THR . 28.7 mm -72.96 115.09 13.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.2 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.431 HG22 ' SD ' ' A' ' 87' ' ' MET 0.275 2.1 pp -103.65 -18.08 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.752 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.416 ' O ' ' HA ' ' A' ' 84' ' ' MET . 33.1 tt0 -154.0 146.77 24.29 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.442 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.5 mt -139.47 119.47 13.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 O-C-N 124.25 0.969 . . . . 0.0 109.153 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.477 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 96.7 m-20 46.9 33.25 2.13 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 115.186 1.55 . . . . 0.0 115.186 178.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.84 -0.99 41.7 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.087 -1.054 . . . . 0.0 114.035 175.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -119.67 125.78 49.53 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 117.834 0.817 . . . . 0.0 109.95 175.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -69.28 110.76 4.78 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.55 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.2 m -103.11 13.56 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.707 0.765 . . . . 0.0 110.089 -174.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.8 -15.38 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.747 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.355 -176.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -117.32 14.63 14.77 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.794 0.807 . . . . 0.0 109.153 176.112 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.55 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.9 m -93.64 140.28 23.04 Favored Pre-proline 0 N--CA 1.411 -2.402 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -70.16 161.72 44.95 Favored 'Trans proline' 0 CA--C 1.544 1.024 0 C-N-CA 121.862 1.708 . . . . 0.0 113.225 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.425 ' HB2' ' OD1' ' A' ' 32' ' ' ASN . 4.2 t60 -42.63 -56.28 3.19 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.994 2.118 . . . . 0.0 111.997 -178.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.84 -50.97 71.49 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.298 0.999 . . . . 0.0 110.858 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.524 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 0.0 OUTLIER -58.75 -54.01 51.92 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.361 -178.82 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.7 mt -51.81 -45.12 38.13 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 O-C-N 123.978 0.799 . . . . 0.0 110.811 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.29 -39.52 76.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.291 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.1 t60 -68.39 -37.63 80.58 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.032 0.444 . . . . 0.0 109.881 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 24.1 mt -66.44 -49.79 72.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.198 177.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 79.9 mt -62.18 -40.05 94.72 Favored 'General case' 0 C--O 1.216 -0.693 0 CA-C-O 120.891 0.377 . . . . 0.0 111.538 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -63.85 -27.3 69.07 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -107.56 -7.19 16.59 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -175.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.457 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.14 135.51 33.92 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.382 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -134.97 177.12 7.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.162 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.76 -153.53 27.23 Favored Glycine 0 CA--C 1.477 -2.289 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.1 108.24 7.71 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.477 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 89.7 mt -111.41 119.39 59.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.955 -1.021 . . . . 0.0 109.991 -176.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 31.5 m80 -98.02 116.91 31.21 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.416 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 27.7 mtm -121.11 158.83 27.06 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -123.82 123.69 41.02 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.444 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 44.1 p -120.24 149.14 42.75 Favored 'General case' 0 C--N 1.262 -3.199 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.993 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.512 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -120.15 164.69 21.08 Favored Pre-proline 0 C--N 1.291 -1.94 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 176.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -70.27 28.71 0.19 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 123.308 2.672 . . . . 0.0 112.967 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.512 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.52 11.25 5.49 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.811 1.644 . . . . 0.0 113.671 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.302 -1.468 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.065 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 87' ' ' MET . 40.8 m-80 . . . . . 0 CA--C 1.477 -1.847 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.519 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 76.1 t -103.72 114.7 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.524 0 CA-C-N 114.32 -1.309 . . . . 0.0 108.732 -174.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 73.7 m -108.91 111.75 23.61 Favored 'General case' 2 C--N 1.223 -4.912 0 CA-C-N 112.723 -2.035 . . . . 0.0 106.89 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.6 m -80.44 140.54 35.93 Favored 'General case' 0 N--CA 1.394 -3.259 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.739 -178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.02 127.15 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.396 -3.133 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.113 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.527 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 25.6 tp -110.45 116.22 31.02 Favored 'General case' 0 N--CA 1.387 -3.583 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 172.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.454 ' CD1' ' HB ' ' A' ' 43' ' ' ILE . 0.4 OUTLIER -104.74 137.16 35.17 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.262 0 N-CA-C 106.074 -1.825 . . . . 0.0 106.074 178.16 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -109.3 104.02 13.07 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-O 121.839 0.828 . . . . 0.0 110.472 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.451 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.8 ttt180 -106.92 114.03 62.01 Favored Pre-proline 0 N--CA 1.415 -2.181 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.954 -177.021 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.88 -55.4 2.7 Favored 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 122.835 2.357 . . . . 0.0 112.982 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -161.5 -173.26 3.7 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -177.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 41.3 mt -71.01 -18.71 62.58 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -175.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 12.4 mmt-85 -61.58 -31.49 71.55 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.718 0.77 . . . . 0.0 109.544 174.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -94.45 130.69 40.72 Favored 'General case' 0 N--CA 1.419 -1.995 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -107.13 165.32 11.45 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 177.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.53 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.3 mm? -51.47 -53.63 35.34 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 124.754 1.283 . . . . 0.0 111.308 -172.446 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.407 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 99.3 32.17 5.89 Favored Glycine 0 N--CA 1.424 -2.148 0 C-N-CA 119.936 -1.126 . . . . 0.0 111.838 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -158.6 161.69 37.25 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -116.02 122.49 45.36 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -110.21 136.45 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.463 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -125.14 116.48 22.11 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.483 ' HA ' ' HB3' ' A' ' 68' ' ' HIS . 83.3 m-20 67.09 8.92 6.53 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.674 0.789 . . . . 0.0 112.336 -179.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.26 -0.93 40.45 Favored Glycine 0 N--CA 1.439 -1.136 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.86 123.43 65.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.935 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.42 HD11 HG13 ' A' ' 49' ' ' VAL . 72.6 mt -60.91 112.62 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 123.92 0.888 . . . . 0.0 110.951 178.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -83.35 -43.37 16.02 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.136 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.9 p -154.05 160.67 42.09 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.204 -179.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.407 HD12 ' O ' ' A' ' 27' ' ' GLY . 53.6 tp -125.92 133.26 51.92 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 123.773 0.67 . . . . 0.0 110.249 -178.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.8 ttt -74.31 107.33 6.41 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.1 tpt180 -60.98 119.58 8.56 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 124.375 1.07 . . . . 0.0 110.775 -176.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.63 1.42 74.17 Favored Glycine 0 N--CA 1.442 -0.911 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.116 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.65 174.44 46.46 Favored Glycine 0 C--O 1.25 1.107 0 C-N-CA 121.248 -0.501 . . . . 0.0 113.239 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.454 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.64 -33.83 64.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 112.839 0.681 . . . . 0.0 112.839 -177.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.17 -39.25 94.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.183 0.516 . . . . 0.0 110.932 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -71.45 -33.05 69.02 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 1.9 mmp_? -66.67 -33.08 74.85 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.485 172.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.87 -14.17 82.86 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.537 -0.756 . . . . 0.0 112.956 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.84 30.06 9.3 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.525 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.42 HG13 HD11 ' A' ' 35' ' ' ILE . 54.2 t -77.22 143.88 12.31 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.647 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.434 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 23.9 mmm180 -135.74 140.65 44.53 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-O 121.282 0.563 . . . . 0.0 109.745 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.8 t -73.12 143.49 13.78 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 114.232 -1.349 . . . . 0.0 110.375 -178.1 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.69 18.69 59.54 Favored Glycine 0 CA--C 1.501 -0.794 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -177.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.534 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.9 m170 -109.96 139.79 44.67 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.011 -0.594 . . . . 0.0 110.543 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 20.8 ttt180 -101.33 117.26 34.6 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.416 HG12 HG22 ' A' ' 86' ' ' THR . 33.6 mt -76.03 126.84 37.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.417 HG23 HD11 ' A' ' 56' ' ' ILE . 41.5 pt -107.78 -14.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.229 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.6 tt0 -156.28 144.6 19.87 Favored 'General case' 0 CA--C 1.491 -1.293 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.66 -173.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.417 ' CD1' HG23 ' A' ' 63' ' ' VAL . 80.6 mt -140.35 122.15 15.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 C-N-CA 124.367 1.067 . . . . 0.0 108.22 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.1 m120 65.5 4.76 2.89 Favored 'General case' 0 N--CA 1.501 2.081 0 C-N-CA 125.505 1.522 . . . . 0.0 112.671 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.96 5.5 35.39 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.418 ' O ' HG11 ' A' ' 63' ' ' VAL . 8.9 tt0 -104.79 116.32 31.81 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.466 1.106 . . . . 0.0 108.402 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.6 t -70.16 109.53 4.67 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.52 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.1 m -105.32 14.51 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.551 0 CA-C-O 121.64 0.733 . . . . 0.0 109.173 -175.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -69.51 -21.66 24.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.952 -175.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.79 -1.03 22.98 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.504 0.668 . . . . 0.0 109.91 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.52 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 90.4 m -78.96 137.04 57.52 Favored Pre-proline 0 N--CA 1.406 -2.662 0 C-N-CA 124.793 1.237 . . . . 0.0 108.755 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.2 147.18 91.87 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.051 1.834 . . . . 0.0 110.929 178.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HB3' ' HA ' ' A' ' 32' ' ' ASN . 6.7 p-80 -48.98 -39.08 25.18 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.092 0.957 . . . . 0.0 113.063 -176.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -68.64 -38.02 80.14 Favored 'General case' 0 N--CA 1.435 -1.192 0 O-C-N 123.491 0.494 . . . . 0.0 110.508 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 35.8 mttp -67.34 -46.14 74.32 Favored 'General case' 0 CA--C 1.478 -1.813 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.549 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.2 mt -53.24 -41.1 41.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 O-C-N 124.054 0.846 . . . . 0.0 109.549 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.2 t -71.75 -37.11 61.3 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.097 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -68.83 -40.67 79.34 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-O 121.315 0.579 . . . . 0.0 110.063 -176.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 37.2 mt -65.65 -51.51 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 CA-C-N 114.548 -1.206 . . . . 0.0 109.786 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.9 mt -58.45 -40.87 83.76 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.345 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -58.65 -28.61 65.85 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 123.381 0.672 . . . . 0.0 111.885 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -119.06 -6.11 10.48 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 115.16 1.541 . . . . 0.0 115.16 -172.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.451 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 130.75 36.28 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.923 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.04 177.02 6.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.5 -152.5 20.39 Favored Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.445 ' HB3' HD13 ' A' ' 16' ' ' LEU . 41.8 mt-10 -84.23 114.06 21.55 Favored 'General case' 0 N--CA 1.425 -1.724 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 174.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 65.2 mt -114.55 117.08 54.51 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.402 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -175.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -90.2 111.64 22.87 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.482 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 26.1 mtm -114.21 156.54 24.11 Favored 'General case' 0 C--N 1.269 -2.904 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 175.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.519 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 69.0 mmtt -122.48 124.6 43.97 Favored 'General case' 0 C--N 1.275 -2.671 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.534 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 43.8 p -121.61 141.22 51.32 Favored 'General case' 0 C--N 1.269 -2.935 0 C-N-CA 120.716 -0.393 . . . . 0.0 110.346 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.508 ' C ' ' H ' ' A' ' 89' ' ' ALA . 43.6 mtm -114.39 167.51 9.51 Favored Pre-proline 0 C--N 1.306 -1.296 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 72.6 Cg_endo -74.71 31.31 0.35 Allowed 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.374 2.05 . . . . 0.0 111.858 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.508 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.16 34.13 19.05 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.912 1.285 . . . . 0.0 110.66 -178.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.779 0 CA-C-N 114.142 -1.39 . . . . 0.0 107.932 178.636 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 87' ' ' MET . 21.1 m120 . . . . . 0 CA--C 1.482 -1.647 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 86' ' ' THR . 95.3 t -113.79 126.43 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.675 0 CA-C-O 121.932 0.872 . . . . 0.0 110.213 -174.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.3 m -118.62 121.02 39.19 Favored 'General case' 0 C--N 1.249 -3.79 0 CA-C-N 113.602 -1.635 . . . . 0.0 106.843 176.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -88.45 140.92 28.97 Favored 'General case' 0 N--CA 1.402 -2.871 0 CA-C-N 114.779 -1.1 . . . . 0.0 109.656 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.407 HG11 ' O ' ' A' ' 47' ' ' GLY . 54.5 t -119.0 137.78 51.87 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.594 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.463 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.464 HD12 ' HB3' ' A' ' 81' ' ' GLU . 24.5 tp -124.28 112.39 16.95 Favored 'General case' 0 N--CA 1.386 -3.653 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 172.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.439 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.01 138.75 21.84 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.946 0 N-CA-C 106.244 -1.762 . . . . 0.0 106.244 -179.364 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.28 108.98 19.77 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.463 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 67.2 ttt180 -116.58 110.08 42.98 Favored Pre-proline 0 C--N 1.284 -2.247 0 C-N-CA 120.249 -0.581 . . . . 0.0 112.024 -176.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -57.9 -41.02 73.37 Favored 'Trans proline' 0 CA--C 1.546 1.084 0 C-N-CA 122.634 2.223 . . . . 0.0 113.102 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.464 ' CG ' ' H ' ' A' ' 22' ' ' LEU . 17.6 t70 -171.71 -175.46 1.56 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -177.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.503 HD22 ' O ' ' A' ' 76' ' ' SER . 68.7 mt -81.1 -11.62 59.45 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 125.164 1.386 . . . . 0.0 110.39 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.412 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 76.8 mtt180 -73.74 -16.03 61.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.361 175.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -103.5 138.63 39.95 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -110.67 160.95 16.23 Favored 'General case' 0 C--N 1.277 -2.575 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.506 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -55.91 -55.6 30.7 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 124.635 1.209 . . . . 0.0 111.079 -172.152 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.0 19.54 14.68 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.995 -178.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -146.37 162.81 37.38 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 176.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.2 m -123.21 129.73 51.79 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -114.57 136.97 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -177.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -122.43 115.63 22.58 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 61.47 16.0 7.17 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 124.764 1.226 . . . . 0.0 112.091 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.92 3.6 45.59 Favored Glycine 0 C--O 1.219 -0.805 0 C-N-CA 121.002 -0.618 . . . . 0.0 111.689 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.34 123.12 71.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.434 HD13 HG13 ' A' ' 49' ' ' VAL . 57.6 mt -62.44 118.24 4.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 123.553 0.741 . . . . 0.0 109.524 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.2 t -110.56 -16.2 13.71 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.185 -174.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.2 t -153.74 154.34 33.87 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 tp -146.35 147.56 31.45 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -108.72 119.02 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 121.132 0.491 . . . . 0.0 110.573 177.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.6 tmt_? -61.03 131.43 50.59 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.337 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.04 -18.0 58.21 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.342 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.85 161.58 47.91 Favored Glycine 0 N--CA 1.436 -1.327 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -176.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.63 -33.38 39.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.9 0 N-CA-C 113.721 1.008 . . . . 0.0 113.721 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.15 -41.39 99.27 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 111.646 0.239 . . . . 0.0 111.646 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.63 -42.79 95.23 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-O 121.717 0.77 . . . . 0.0 109.204 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 25.1 mtp180 -71.98 -13.19 61.55 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.188 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.407 ' O ' HG11 ' A' ' 15' ' ' VAL . . . -89.01 -13.36 62.33 Favored Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.14 176.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.02 13.81 44.81 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.359 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.434 HG13 HD13 ' A' ' 35' ' ' ILE . 57.9 t -69.67 137.02 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -134.01 147.16 50.93 Favored 'General case' 0 CA--C 1.48 -1.715 0 CA-C-O 121.329 0.585 . . . . 0.0 109.555 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -78.79 141.76 14.98 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.744 0 CA-C-N 114.159 -1.382 . . . . 0.0 109.636 -177.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 24.41 38.33 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.46 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m-70 -118.86 134.84 54.89 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.064 -0.568 . . . . 0.0 110.876 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.8 ttm-85 -93.23 123.45 36.52 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.42 HD12 HG23 ' A' ' 55' ' ' ILE . 31.4 mt -79.22 125.86 38.73 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 39.2 pt -101.56 -16.44 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.413 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.2 tt0 -158.0 144.26 17.45 Favored 'General case' 0 CA--C 1.486 -1.497 0 C-N-CA 120.079 -0.649 . . . . 0.0 109.29 -176.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.435 HD12 HG21 ' A' ' 63' ' ' VAL . 79.1 mt -143.87 125.71 10.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 124.567 1.167 . . . . 0.0 108.256 178.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.75 18.73 8.87 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 124.04 0.936 . . . . 0.0 112.602 170.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.29 -0.34 40.6 Favored Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.833 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -119.07 132.78 56.05 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.931 -0.746 . . . . 0.0 110.173 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.3 m -75.32 107.87 7.72 Favored 'General case' 0 N--CA 1.422 -1.828 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.559 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.9 m -99.65 12.64 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 CA-C-O 121.857 0.837 . . . . 0.0 110.118 -172.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -66.48 -20.55 27.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.437 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.1 12.1 12.59 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.648 -0.706 . . . . 0.0 109.541 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 84.8 m -93.6 136.19 24.37 Favored Pre-proline 0 N--CA 1.415 -2.216 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.407 ' O ' HG13 ' A' ' 71' ' ' ILE . 61.9 Cg_endo -74.76 164.42 33.65 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 122.202 1.935 . . . . 0.0 112.553 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -43.19 -55.35 3.99 Favored 'General case' 0 C--O 1.218 -0.593 0 C-N-CA 126.034 1.734 . . . . 0.0 112.147 -178.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -55.27 -45.77 76.15 Favored 'General case' 0 C--N 1.316 -0.883 0 O-C-N 123.925 0.766 . . . . 0.0 111.387 -174.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.427 ' O ' HD12 ' A' ' 74' ' ' ILE . 12.4 mptt -66.12 -54.87 20.22 Favored 'General case' 0 CA--C 1.483 -1.615 0 O-C-N 123.964 0.79 . . . . 0.0 110.739 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.8 mt -51.98 -42.04 33.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 O-C-N 124.253 0.971 . . . . 0.0 109.857 -179.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.8 t -72.11 -43.29 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.566 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 71.2 t60 -64.87 -43.01 94.34 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.348 0.594 . . . . 0.0 110.184 -177.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.427 HD12 ' O ' ' A' ' 70' ' ' LYS . 14.3 mt -69.09 -42.24 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.524 -178.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 67.4 mt -61.91 -46.15 90.6 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.895 0.379 . . . . 0.0 110.84 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.503 ' O ' HD22 ' A' ' 22' ' ' LEU . 23.0 t -60.7 -27.69 68.07 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 124.209 1.004 . . . . 0.0 111.802 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -87.98 -36.56 16.99 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 120.626 -0.43 . . . . 0.0 112.045 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.463 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -77.93 136.33 37.99 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 113.401 0.889 . . . . 0.0 113.401 -172.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.402 HG12 HD21 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -131.98 175.26 11.7 Favored 'Isoleucine or valine' 0 C--O 1.245 0.849 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 175.622 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.57 -154.75 25.23 Favored Glycine 0 CA--C 1.483 -1.911 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.464 ' HB3' HD12 ' A' ' 16' ' ' LEU . 51.5 mt-10 -75.0 108.97 8.07 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 174.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.439 ' HB ' HG22 ' A' ' 17' ' ' ILE . 59.9 mt -112.36 118.15 57.06 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -84.54 130.53 34.73 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.458 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.515 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.0 mtm -135.34 152.31 51.34 Favored 'General case' 0 C--N 1.282 -2.344 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 170.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 8.9 mmmt -122.28 121.35 36.56 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.46 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.7 p -119.27 153.0 35.71 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.093 -176.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.512 ' C ' ' H ' ' A' ' 89' ' ' ALA . 50.3 mtm -123.06 169.13 10.52 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 7.7 Cg_exo -74.3 35.64 0.4 Allowed 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 123.158 2.572 . . . . 0.0 112.333 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.512 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.02 59.87 2.63 Favored 'General case' 0 N--CA 1.433 -1.302 0 C-N-CA 126.072 1.749 . . . . 0.0 112.958 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.161 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 171.316 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 . . . . . 0 CA--C 1.493 -1.212 0 CA-C-O 121.93 0.871 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.43 HG13 ' HD2' ' A' ' 85' ' ' LYS . 50.1 t -145.2 128.13 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 70.1 m -110.54 107.27 16.84 Favored 'General case' 0 C--N 1.245 -3.974 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 176.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 32.8 m -78.96 130.99 36.18 Favored 'General case' 0 N--CA 1.396 -3.132 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.8 t -111.02 137.54 43.05 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.717 0 CA-C-N 114.468 -1.242 . . . . 0.0 108.124 -177.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.4 tp -121.92 111.87 17.61 Favored 'General case' 1 N--CA 1.374 -4.266 0 C-N-CA 119.062 -1.055 . . . . 0.0 108.353 172.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.468 HD12 HG22 ' A' ' 17' ' ' ILE . 0.3 OUTLIER -97.25 128.61 48.34 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.292 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 178.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 67.4 mtp180 -115.04 102.14 9.66 Favored 'General case' 0 CA--C 1.457 -2.62 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 174.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.476 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.4 ttt180 -98.64 123.61 49.26 Favored Pre-proline 0 C--N 1.262 -3.214 0 CA-C-N 112.999 -1.91 . . . . 0.0 111.048 -174.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.39 -55.63 2.04 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 122.553 2.168 . . . . 0.0 113.457 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -166.15 -178.22 4.51 Favored 'General case' 0 C--O 1.247 0.963 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 -175.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.0 mt -68.31 -16.55 63.99 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -175.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -84.37 -12.25 54.83 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.876 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -93.48 128.42 39.57 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 176.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.289 0.0 OUTLIER -103.3 158.98 15.95 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.477 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.2 OUTLIER -58.91 -53.69 55.6 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.175 -168.318 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.01 26.7 8.24 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.338 -1.41 . . . . 0.0 112.789 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -145.79 154.26 41.83 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 173.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 10.2 m -106.78 122.12 45.74 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -114.71 139.91 38.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.224 -0.59 . . . . 0.0 110.385 -178.106 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -130.57 126.3 36.36 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 16.4 m120 62.0 6.85 1.86 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 124.391 1.076 . . . . 0.0 112.945 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 6.45 53.36 Favored Glycine 0 C--O 1.214 -1.102 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -175.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.42 128.12 70.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 52.6 mt -70.21 116.11 10.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 C-N-CA 124.407 1.083 . . . . 0.0 110.49 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.3 t -99.53 -24.41 14.77 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.064 -175.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 34.1 t -157.12 152.39 26.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 -178.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -133.84 140.51 46.92 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -94.6 115.68 27.85 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.435 ' HD2' ' N ' ' A' ' 41' ' ' GLY . 1.7 tmm_? -65.62 131.3 46.03 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.435 ' N ' ' HD2' ' A' ' 40' ' ' ARG . . . 91.89 -4.79 78.87 Favored Glycine 0 N--CA 1.437 -1.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.303 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.25 170.33 40.89 Favored Glycine 0 C--O 1.253 1.292 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -61.8 -34.85 64.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.935 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.19 94.36 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.196 0.31 . . . . 0.0 111.659 -179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -65.91 -41.59 91.23 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.094 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -66.28 -35.29 80.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.943 178.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.74 -29.76 75.21 Favored Glycine 0 N--CA 1.44 -1.065 0 CA-C-N 115.177 -0.92 . . . . 0.0 112.641 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 114.67 14.65 8.59 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.213 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 68.9 t -70.24 137.69 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.1 mmt85 -136.02 145.16 45.76 Favored 'General case' 0 CA--C 1.477 -1.853 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -178.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.1 t -74.23 139.9 18.5 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.84 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.608 -177.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.15 9.15 65.82 Favored Glycine 0 N--CA 1.436 -1.336 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -178.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.508 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -101.93 148.25 25.56 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.275 -0.462 . . . . 0.0 111.412 -179.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 70.7 ttt180 -105.46 123.39 47.81 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.416 HD12 HG22 ' A' ' 86' ' ' THR . 24.5 mm -74.11 117.98 18.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.005 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 24.5 pt -105.28 -20.34 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.681 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 179.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.3 tt0 -151.84 146.48 25.71 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.472 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.0 mt -143.56 121.69 6.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 O-C-N 124.362 1.039 . . . . 0.0 108.647 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 63.93 8.67 4.04 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 125.556 1.542 . . . . 0.0 111.953 173.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.13 1.35 23.74 Favored Glycine 0 N--CA 1.43 -1.754 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.615 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -116.58 136.56 52.87 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 117.797 0.799 . . . . 0.0 109.92 177.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.8 m -75.56 108.99 8.75 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.526 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.0 m -102.96 11.48 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.697 0 CA-C-O 122.145 0.974 . . . . 0.0 109.423 -174.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 p -70.93 -14.78 18.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 114.332 -1.304 . . . . 0.0 110.093 -179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.95 13.68 13.1 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.264 179.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.526 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.1 m -101.32 135.26 19.91 Favored Pre-proline 0 N--CA 1.416 -2.163 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -66.21 156.15 66.33 Favored 'Trans proline' 0 C--O 1.244 0.821 0 C-N-CA 121.916 1.744 . . . . 0.0 111.743 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -43.11 -52.5 5.4 Favored 'General case' 0 C--O 1.221 -0.442 0 C-N-CA 125.525 1.53 . . . . 0.0 112.903 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -58.33 -42.74 87.48 Favored 'General case' 0 C--N 1.311 -1.087 0 O-C-N 123.917 0.761 . . . . 0.0 111.068 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.494 ' HE3' ' HA ' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -66.8 -53.77 29.45 Favored 'General case' 0 C--O 1.202 -1.413 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 178.53 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 53.4 mt -50.14 -42.29 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-O 120.984 0.421 . . . . 0.0 110.338 178.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.1 t -70.03 -37.9 73.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.982 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -69.16 -39.71 78.62 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.42 -53.44 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 95.6 mt -60.58 -32.79 71.87 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-O 120.853 0.358 . . . . 0.0 111.531 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.8 t -63.72 -37.07 85.97 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 123.362 0.665 . . . . 0.0 111.282 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -110.24 -9.98 14.65 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -171.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.476 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.01 129.87 35.57 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 122.156 -0.34 . . . . 0.0 110.826 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.75 176.26 8.43 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 177.648 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 89.69 -161.21 29.48 Favored Glycine 0 CA--C 1.498 -0.98 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -75.57 108.66 8.54 Favored 'General case' 0 C--O 1.249 1.074 0 C-N-CA 124.048 0.939 . . . . 0.0 108.903 175.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.3 mt -116.25 117.52 55.76 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.42 -174.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 34.5 m80 -84.76 117.0 23.57 Favored 'General case' 0 CA--C 1.486 -1.491 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.497 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 14.2 mtp -118.49 145.18 45.48 Favored 'General case' 0 C--N 1.25 -3.735 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.145 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.43 ' HD2' HG13 ' A' ' 12' ' ' VAL . 69.3 mmtt -118.09 123.97 46.92 Favored 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.508 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 68.0 p -118.97 139.86 50.97 Favored 'General case' 0 C--N 1.27 -2.852 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.903 178.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.496 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -113.58 166.54 11.07 Favored Pre-proline 0 C--N 1.299 -1.626 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 178.287 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -72.74 31.49 0.29 Allowed 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 123.047 2.498 . . . . 0.0 112.49 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.496 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 56.33 57.23 5.1 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 122.536 1.16 . . . . 0.0 111.324 -177.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 113.492 -1.685 . . . . 0.0 107.321 176.757 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 . . . . . 0 CA--C 1.492 -1.26 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.412 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 57.2 t -114.88 126.88 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.946 0 CA-C-N 114.016 -1.447 . . . . 0.0 108.898 -173.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 53.7 m -116.05 113.63 23.45 Favored 'General case' 1 C--N 1.241 -4.137 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.627 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.5 m -82.39 138.65 34.4 Favored 'General case' 0 N--CA 1.406 -2.663 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.151 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 56.2 t -116.04 139.77 41.1 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.796 0 CA-C-N 114.574 -1.194 . . . . 0.0 108.582 178.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.473 HD12 ' HB3' ' A' ' 81' ' ' GLU . 17.8 tp -125.32 116.89 22.63 Favored 'General case' 0 N--CA 1.404 -2.762 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 81' ' ' GLU . 0.3 OUTLIER -98.11 141.63 15.82 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.782 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.859 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -113.61 102.98 10.79 Favored 'General case' 0 CA--C 1.489 -1.4 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.533 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 69.6 ttt180 -111.42 101.66 51.26 Favored Pre-proline 0 C--N 1.274 -2.686 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.765 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -58.6 -33.85 98.45 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.618 2.212 . . . . 0.0 113.985 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -169.15 175.58 5.64 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.435 HD21 HG12 ' A' ' 79' ' ' VAL . 63.4 mt -65.01 -18.23 65.12 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.9 mtt85 -74.25 -12.38 60.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 121.459 0.647 . . . . 0.0 112.084 178.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -99.54 95.75 7.2 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 174.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -84.58 152.29 23.96 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.763 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.55 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -41.68 -60.9 1.21 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 126.068 1.747 . . . . 0.0 111.654 -172.541 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 109.64 -3.81 30.79 Favored Glycine 0 N--CA 1.432 -1.614 0 C-N-CA 119.828 -1.177 . . . . 0.0 112.793 176.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -117.39 156.77 27.32 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 122.191 -0.593 . . . . 0.0 109.663 178.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.0 t -108.82 131.43 54.99 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.23 134.53 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 -177.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.405 ' HG3' ' HB2' ' A' ' 36' ' ' CYS 0.266 1.0 OUTLIER -126.17 120.39 29.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.046 0.45 . . . . 0.0 110.84 175.258 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 65.09 13.03 8.42 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 124.259 1.023 . . . . 0.0 110.81 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.68 -1.96 52.75 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.383 -177.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -108.08 121.57 61.25 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 O-C-N 122.315 -0.521 . . . . 0.0 110.303 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 64.3 mt -60.32 117.11 2.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 C-N-CA 124.746 1.219 . . . . 0.0 110.274 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.405 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 34.0 t -98.18 -44.03 6.76 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.689 -174.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 36.4 p -142.26 155.4 45.23 Favored 'General case' 0 C--O 1.248 1.011 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -131.91 146.24 51.99 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 123.25 0.62 . . . . 0.0 110.008 -177.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.8 ttt -90.3 112.48 24.06 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.44 ' HD3' ' N ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -75.57 123.73 26.0 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.759 -172.01 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.44 ' N ' ' HD3' ' A' ' 40' ' ' ARG . . . 103.65 -14.96 53.42 Favored Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.308 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.11 178.08 54.11 Favored Glycine 0 C--O 1.253 1.282 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -178.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 pt -53.72 -37.59 32.53 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.07 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.24 93.46 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -63.92 -46.5 84.51 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.464 0.649 . . . . 0.0 109.603 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -76.08 -17.4 59.64 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.979 -179.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.9 -29.38 63.1 Favored Glycine 0 N--CA 1.432 -1.569 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.794 175.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 111.43 12.19 15.76 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.027 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 73.1 t -67.94 134.26 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.6 mmt85 -131.03 142.5 50.32 Favored 'General case' 0 CA--C 1.487 -1.453 0 CA-C-O 121.155 0.503 . . . . 0.0 109.909 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 41.7 t -79.05 137.26 22.15 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.21 -176.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.36 22.71 33.82 Favored Glycine 0 CA--C 1.5 -0.865 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -175.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.531 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m170 -116.59 135.34 53.89 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.873 -0.664 . . . . 0.0 112.192 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.468 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 33.8 ttm-85 -92.59 122.69 35.27 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.406 HG12 HG22 ' A' ' 86' ' ' THR . 30.1 mt -80.64 127.82 39.15 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.42 HD11 HG23 ' A' ' 56' ' ' ILE . 35.2 pt -107.0 -16.5 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 84' ' ' MET . 32.1 tt0 -154.98 144.62 21.42 Favored 'General case' 0 CA--C 1.48 -1.717 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.382 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.451 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.5 mt -139.52 125.88 23.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 64.59 6.68 3.31 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.598 1.159 . . . . 0.0 112.31 173.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.4 -9.63 19.93 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.718 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.469 ' O ' HG12 ' A' ' 63' ' ' VAL . 17.4 pt20 -108.11 126.09 52.35 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-O 120.961 0.41 . . . . 0.0 110.989 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 31.9 t -64.85 113.46 3.83 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 177.153 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.615 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 30.9 m -110.61 13.53 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 121.169 0.509 . . . . 0.0 109.986 -176.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -67.54 -17.65 22.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 115.216 -0.902 . . . . 0.0 112.714 -173.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.64 16.64 5.88 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.708 0.766 . . . . 0.0 109.124 177.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.615 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.2 m -84.35 141.46 39.66 Favored Pre-proline 0 N--CA 1.416 -2.125 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.609 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.434 ' O ' HG13 ' A' ' 71' ' ' ILE . 71.6 Cg_exo -48.96 143.71 17.07 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.907 2.405 . . . . 0.0 112.247 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -49.91 -50.83 44.75 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 124.757 1.223 . . . . 0.0 111.529 -178.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -68.23 -32.23 72.29 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.1 mttm -62.91 -53.84 47.84 Favored 'General case' 0 CA--C 1.48 -1.718 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.793 176.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.434 HG13 ' O ' ' A' ' 67' ' ' PRO . 58.1 mt -50.01 -41.9 18.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 124.016 0.822 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 65.7 t -72.93 -37.19 53.47 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.533 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -65.23 -45.06 86.17 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 123.534 0.733 . . . . 0.0 109.594 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.74 -49.39 84.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.252 0 O-C-N 123.644 0.59 . . . . 0.0 109.412 178.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.2 mt -62.15 -45.31 94.01 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.7 t -61.98 -27.4 68.83 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 123.622 0.769 . . . . 0.0 112.144 -178.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -103.09 -13.23 16.9 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.666 0.987 . . . . 0.0 113.666 -176.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 134.63 34.16 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.047 -177.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.435 HG12 HD21 ' A' ' 22' ' ' LEU . 1.3 m -128.49 175.8 9.28 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 176.05 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.38 -159.66 27.46 Favored Glycine 0 N--CA 1.432 -1.605 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.473 ' HB3' HD12 ' A' ' 16' ' ' LEU . 44.9 mt-10 -79.35 113.4 17.46 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 173.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 67.7 mt -115.65 118.56 59.17 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.942 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.763 -172.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -81.18 135.94 35.82 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.501 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.7 mtm -133.34 150.63 51.85 Favored 'General case' 0 C--N 1.263 -3.178 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.412 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 66.1 mmtt -117.72 121.26 40.37 Favored 'General case' 0 C--N 1.262 -3.201 0 N-CA-C 106.238 -1.764 . . . . 0.0 106.238 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.2 p -122.6 146.24 47.62 Favored 'General case' 0 C--N 1.264 -3.116 0 C-N-CA 120.258 -0.577 . . . . 0.0 110.479 -178.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.552 ' C ' ' H ' ' A' ' 89' ' ' ALA . 58.3 mtm -120.41 168.16 11.17 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_exo -68.2 32.42 0.15 Allowed 'Trans proline' 0 N--CA 1.509 2.41 0 C-N-CA 123.49 2.794 . . . . 0.0 112.668 176.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.552 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.29 27.36 8.31 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 126.442 1.897 . . . . 0.0 113.422 177.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.409 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.483 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 . . . . . 0 CA--C 1.491 -1.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.619 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t -139.46 129.19 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.149 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 89.0 m -119.41 108.53 14.68 Favored 'General case' 0 N--CA 1.39 -3.46 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.185 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 18.6 m -78.69 134.25 37.12 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.934 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -115.86 136.86 51.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.137 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.378 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.44 HD13 ' HB3' ' A' ' 81' ' ' GLU . 25.9 tp -118.81 110.67 17.5 Favored 'General case' 0 N--CA 1.4 -2.958 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 174.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.49 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -99.23 137.89 25.31 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.312 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.219 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.12 103.38 12.57 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.1 ttt180 -109.03 111.53 60.45 Favored Pre-proline 0 C--N 1.291 -1.947 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.315 -177.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -58.93 -44.12 37.91 Favored 'Trans proline' 0 CA--C 1.549 1.241 0 C-N-CA 122.311 2.007 . . . . 0.0 113.743 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -167.21 -176.99 3.51 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -176.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 65.9 mt -76.88 -10.02 59.08 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 124.892 1.277 . . . . 0.0 110.292 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 34.5 mtt180 -69.03 -19.35 64.11 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 114.295 -1.32 . . . . 0.0 108.064 176.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -114.21 157.81 22.18 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 104.997 -2.223 . . . . 0.0 104.997 177.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -121.63 -168.42 1.69 Allowed 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.493 HD21 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -75.25 -57.61 3.79 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -175.58 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 110.06 20.21 7.67 Favored Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.788 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -143.84 148.8 36.03 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.0 t -99.84 131.43 45.81 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.54 138.45 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -176.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -117.94 105.91 12.4 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 176.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 61.29 23.23 13.48 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 122.015 0.912 . . . . 0.0 110.846 177.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.91 -4.91 39.24 Favored Glycine 0 N--CA 1.439 -1.125 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.413 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -105.93 120.13 56.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 O-C-N 122.18 -0.6 . . . . 0.0 110.013 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.42 HD12 HG11 ' A' ' 49' ' ' VAL . 55.1 mt -61.35 115.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 C-N-CA 123.447 0.699 . . . . 0.0 110.244 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -98.23 -31.77 11.9 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.042 -175.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.1 m -150.6 155.05 38.65 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.9 tp -136.7 138.88 41.5 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 123.534 0.734 . . . . 0.0 109.525 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 49.4 ttm -91.48 119.29 31.32 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.9 131.76 45.62 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.92 -8.45 79.78 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.34 162.98 37.02 Favored Glycine 0 N--CA 1.432 -1.582 0 C-N-CA 121.318 -0.467 . . . . 0.0 112.167 -178.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -30.43 41.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -179.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.02 -42.44 89.64 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.69 0.281 . . . . 0.0 110.889 178.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -63.71 -41.48 98.08 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.63 -8.44 55.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.673 -1.149 . . . . 0.0 111.281 178.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.55 -22.52 28.73 Favored Glycine 0 N--CA 1.429 -1.794 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 178.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.02 8.5 29.54 Favored Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.959 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.42 HG11 HD12 ' A' ' 35' ' ' ILE . 58.5 t -65.59 135.92 27.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 12.6 mmm180 -133.42 146.12 50.9 Favored 'General case' 0 CA--C 1.48 -1.738 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 77.0 t -77.37 139.9 17.95 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 114.181 -1.372 . . . . 0.0 109.202 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.4 -2.04 62.7 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -177.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.49 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 10.2 m170 -95.43 140.83 29.74 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 115.041 -0.58 . . . . 0.0 110.928 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 25.8 ttt85 -101.18 131.83 46.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.403 HD11 HG23 ' A' ' 55' ' ' ILE . 33.0 mt -82.99 127.27 39.84 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 30.9 pt -104.3 -15.34 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.268 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.944 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.417 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.7 tt0 -155.9 144.34 20.12 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 119.763 -0.775 . . . . 0.0 108.984 -174.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.454 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.1 mt -140.67 121.83 14.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 124.293 0.996 . . . . 0.0 108.475 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 68.29 7.68 6.09 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 124.095 0.958 . . . . 0.0 111.769 172.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.4 2.09 33.13 Favored Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.397 -178.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.454 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 21.1 pt20 -113.88 125.31 53.91 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 177.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 40.1 t -63.82 119.14 9.42 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.458 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 24.3 m -114.35 14.12 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.123 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.5 p -70.12 -20.76 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.802 -176.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.66 9.56 16.51 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.751 0.786 . . . . 0.0 109.453 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.458 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 76.8 m -86.37 138.51 34.11 Favored Pre-proline 0 N--CA 1.407 -2.621 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.742 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.29 158.09 58.65 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.185 1.923 . . . . 0.0 112.837 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 45.3 p-80 -48.6 -49.65 35.94 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.121 1.368 . . . . 0.0 114.042 -174.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.0 -37.89 78.96 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 120.451 0.167 . . . . 0.0 110.599 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mttm -61.9 -49.85 74.53 Favored 'General case' 0 CA--C 1.492 -1.258 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 177.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.8 mt -54.32 -42.56 58.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 O-C-N 123.896 0.748 . . . . 0.0 110.173 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.34 -35.88 69.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.544 178.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.8 t-80 -68.9 -42.92 76.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.237 0.541 . . . . 0.0 109.581 -177.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 35.7 mt -63.71 -47.19 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.635 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.882 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.2 mt -61.32 -45.99 92.12 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.399 176.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -62.32 -27.49 69.08 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 123.174 0.59 . . . . 0.0 111.887 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -104.65 1.34 29.41 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -177.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.444 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -107.04 134.61 49.93 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.967 178.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.408 HG21 ' N ' ' A' ' 80' ' ' GLY . 1.7 m -129.58 -177.34 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.408 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 85.96 -157.14 30.58 Favored Glycine 0 CA--C 1.484 -1.886 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.44 ' HB3' HD13 ' A' ' 16' ' ' LEU . 50.4 mt-10 -80.52 112.89 18.3 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.167 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.49 ' HB ' HG23 ' A' ' 17' ' ' ILE . 56.5 mt -117.3 118.12 57.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -173.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -90.49 118.43 29.96 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.417 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 24.3 mtm -117.54 158.42 24.61 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.298 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.3 mtmm -123.86 121.97 36.77 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.2 p -119.86 150.02 41.13 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.624 -175.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.519 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.6 mtp -130.13 168.63 15.96 Favored Pre-proline 0 C--N 1.313 -0.978 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 57.7 Cg_endo -71.04 29.5 0.22 Allowed 'Trans proline' 0 CA--C 1.565 2.058 0 C-N-CA 122.762 2.308 . . . . 0.0 112.61 175.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.519 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.0 -2.36 2.37 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 126.384 1.874 . . . . 0.0 112.59 179.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.474 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 178.235 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 . . . . . 0 N--CA 1.444 -0.736 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.3 t -133.13 134.86 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 123.554 0.742 . . . . 0.0 109.273 -174.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 34.4 m -121.74 120.13 33.76 Favored 'General case' 0 N--CA 1.391 -3.388 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 176.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.6 m -90.67 141.08 29.16 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.127 0.965 . . . . 0.0 110.091 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.42 135.96 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.06 0 CA-C-N 114.425 -1.261 . . . . 0.0 108.857 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.435 HD12 ' O ' ' A' ' 82' ' ' ILE . 24.9 tp -119.86 110.38 16.68 Favored 'General case' 0 N--CA 1.382 -3.87 0 C-N-CA 119.18 -1.008 . . . . 0.0 108.797 173.044 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.446 HD12 HG23 ' A' ' 17' ' ' ILE . 0.3 OUTLIER -98.14 125.94 51.28 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.021 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.081 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.529 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 82.1 mtp180 -113.29 102.77 10.66 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.506 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 48.2 ttt180 -98.3 112.8 63.04 Favored Pre-proline 0 C--N 1.269 -2.925 0 CA-C-N 112.77 -2.014 . . . . 0.0 110.846 -174.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.37 -39.2 86.19 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.833 2.355 . . . . 0.0 113.909 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -166.62 -178.72 4.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -177.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.596 HD21 ' CG1' ' A' ' 79' ' ' VAL . 52.8 mt -75.36 -18.09 60.06 Favored 'General case' 0 CA--C 1.495 -1.141 0 C-N-CA 124.954 1.301 . . . . 0.0 111.024 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.582 ' HD2' ' N ' ' A' ' 23' ' ' ARG . 4.8 mpt_? -82.02 -11.5 58.79 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.923 176.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -99.16 89.3 4.19 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.682 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.53 165.79 23.97 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 123.639 0.587 . . . . 0.0 110.938 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.479 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -69.31 -58.8 3.55 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.46 -169.785 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 103.19 38.28 2.9 Favored Glycine 0 N--CA 1.424 -2.114 0 C-N-CA 120.062 -1.066 . . . . 0.0 111.933 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -154.2 153.63 32.1 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 174.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 m -109.02 130.88 55.49 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -118.72 134.07 63.51 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 CA-C-O 121.36 0.6 . . . . 0.0 111.089 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -113.56 111.64 22.23 Favored 'General case' 0 C--N 1.312 -1.053 0 O-C-N 121.807 -0.558 . . . . 0.0 109.591 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.6 m-20 59.86 12.8 3.22 Favored 'General case' 0 N--CA 1.501 2.097 0 C-N-CA 125.076 1.35 . . . . 0.0 112.21 -177.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.59 0.42 30.79 Favored Glycine 0 C--O 1.215 -1.092 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.682 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.17 118.33 55.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 122.438 -0.448 . . . . 0.0 109.878 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.405 HD12 HG11 ' A' ' 49' ' ' VAL . 46.8 mt -59.15 122.38 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 123.888 0.875 . . . . 0.0 110.861 178.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 13.4 t -103.29 -31.75 9.91 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.983 -176.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 55.1 p -151.17 160.62 43.75 Favored 'General case' 0 C--O 1.245 0.862 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 54.5 tp -137.97 129.46 27.95 Favored 'General case' 0 N--CA 1.443 -0.812 0 O-C-N 123.785 0.678 . . . . 0.0 109.867 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -76.03 112.54 12.57 Favored 'General case' 0 C--N 1.317 -0.837 0 O-C-N 123.782 0.676 . . . . 0.0 109.878 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.433 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.3 tpp85 -55.32 125.0 18.92 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.564 1.146 . . . . 0.0 111.005 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.02 -7.63 81.73 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.311 -0.859 . . . . 0.0 113.408 177.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.12 171.6 55.15 Favored Glycine 0 C--O 1.246 0.888 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.501 -176.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.5 pt -62.15 -33.04 56.59 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -57.16 -46.12 83.03 Favored 'General case' 0 N--CA 1.447 -0.608 0 CA-C-O 120.909 0.385 . . . . 0.0 110.445 178.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.433 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 36.2 tt0 -62.88 -47.15 84.55 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.573 0.701 . . . . 0.0 109.758 179.113 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 40.5 mtt180 -69.62 -18.06 63.57 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.807 -178.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.24 -24.81 50.49 Favored Glycine 0 N--CA 1.438 -1.187 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.001 176.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.95 12.23 12.75 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 179.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.405 HG11 HD12 ' A' ' 35' ' ' ILE . 53.9 t -68.57 137.28 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -135.61 150.25 49.6 Favored 'General case' 0 CA--C 1.474 -1.953 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.15 141.2 15.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.066 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.98 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.14 25.92 42.53 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -177.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.488 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.2 m170 -117.48 132.87 56.48 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.124 -0.538 . . . . 0.0 110.944 179.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -95.79 121.66 37.74 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.428 HD13 HG23 ' A' ' 55' ' ' ILE . 44.7 mt -75.92 122.28 29.62 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.404 HG23 ' CG2' ' A' ' 64' ' ' VAL 0.265 2.4 pp -104.94 -5.93 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.76 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -178.314 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 84' ' ' MET . 26.6 tt0 -169.34 143.15 2.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.416 -179.325 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.448 ' CD1' HG21 ' A' ' 63' ' ' VAL . 88.4 mt -138.57 124.84 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 66.34 3.32 2.74 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.5 1.12 . . . . 0.0 112.436 172.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.26 -0.81 22.4 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.084 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.457 ' O ' HG13 ' A' ' 63' ' ' VAL . 12.7 pt20 -115.41 125.97 53.81 Favored 'General case' 0 CA--C 1.498 -1.022 0 O-C-N 122.273 -0.545 . . . . 0.0 110.166 176.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 m -71.03 109.6 5.22 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.519 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.6 m -101.77 18.28 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.993 0 CA-C-O 121.914 0.864 . . . . 0.0 110.538 -172.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.404 ' CG2' HG23 ' A' ' 56' ' ' ILE . 4.3 p -75.59 -8.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.91 -177.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -126.44 22.89 6.99 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.022 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.519 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 89.3 m -109.18 130.39 22.8 Favored Pre-proline 0 N--CA 1.407 -2.614 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -66.34 158.22 56.19 Favored 'Trans proline' 0 CA--C 1.543 0.925 0 C-N-CA 122.233 1.955 . . . . 0.0 112.797 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 33.1 t60 -42.86 -55.85 3.5 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.932 1.293 . . . . 0.0 113.5 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -65.83 -37.67 86.84 Favored 'General case' 0 N--CA 1.436 -1.16 0 O-C-N 123.42 0.45 . . . . 0.0 111.32 -173.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.427 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 6.5 mttm -61.75 -52.02 65.96 Favored 'General case' 0 N--CA 1.424 -1.728 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.345 174.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 55.7 mt -52.02 -45.61 41.14 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 O-C-N 124.026 0.829 . . . . 0.0 110.398 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.2 t -69.07 -34.04 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.818 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 17.3 t60 -72.41 -43.17 64.25 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 -176.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.6 mt -60.5 -49.75 83.1 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 CA-C-N 114.737 -1.12 . . . . 0.0 109.873 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.2 mt -58.96 -46.76 87.27 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.76 177.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.499 ' HA ' HH12 ' A' ' 19' ' ' ARG . 25.0 m -63.06 -26.5 68.87 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 113.08 0.77 . . . . 0.0 113.08 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.8 -18.85 20.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.506 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -98.8 133.92 42.43 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.535 0.207 . . . . 0.0 111.221 -176.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.596 ' CG1' HD21 ' A' ' 22' ' ' LEU . 2.2 m -134.27 179.65 4.12 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 87.88 -150.22 22.13 Favored Glycine 0 CA--C 1.497 -1.065 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.87 114.56 18.88 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.435 ' O ' HD12 ' A' ' 16' ' ' LEU . 79.5 mt -117.88 118.03 56.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -90.85 115.75 28.15 Favored 'General case' 0 CA--C 1.463 -2.376 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.464 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 7.8 ttp -122.56 138.47 54.56 Favored 'General case' 1 N--CA 1.376 -4.148 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.816 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 32.9 mtmt -121.26 131.86 54.47 Favored 'General case' 0 CA--C 1.444 -3.133 0 C-N-CA 119.497 -0.881 . . . . 0.0 108.784 -176.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.488 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 49.7 p -125.97 155.16 41.81 Favored 'General case' 0 C--N 1.271 -2.825 0 O-C-N 123.993 0.808 . . . . 0.0 110.369 -174.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.539 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.8 mtp -120.47 170.55 6.95 Favored Pre-proline 0 C--N 1.296 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -75.98 29.83 0.39 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.85 2.367 . . . . 0.0 111.077 176.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.539 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 60.89 31.6 20.01 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.249 1.42 . . . . 0.0 110.624 -179.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.178 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.636 178.733 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.441 -0.885 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.1 t -120.31 132.15 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.17 0 CA-C-O 122.083 0.944 . . . . 0.0 109.727 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -127.12 115.55 19.31 Favored 'General case' 0 N--CA 1.387 -3.616 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.2 m -80.97 140.95 34.93 Favored 'General case' 0 N--CA 1.395 -3.186 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.813 -176.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.4 t -118.12 139.29 45.89 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.943 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.248 177.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.496 HD12 ' HB3' ' A' ' 81' ' ' GLU . 7.5 tp -126.42 105.41 8.75 Favored 'General case' 0 N--CA 1.404 -2.732 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.497 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.3 OUTLIER -99.71 134.8 37.76 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -178.863 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 -113.75 117.32 31.17 Favored 'General case' 0 C--N 1.294 -1.831 0 CA-C-O 121.954 0.883 . . . . 0.0 112.114 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.587 HH21 ' HA ' ' A' ' 25' ' ' GLN . 27.2 ttm180 -119.2 113.1 35.6 Favored Pre-proline 0 C--N 1.284 -2.272 0 CA-C-N 113.961 -1.472 . . . . 0.0 110.957 -178.088 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -61.74 -31.68 86.04 Favored 'Trans proline' 0 CA--C 1.547 1.16 0 C-N-CA 122.653 2.235 . . . . 0.0 113.091 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -178.8 173.68 1.22 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.441 HD21 ' HD3' ' A' ' 19' ' ' ARG . 47.5 mt -65.28 -9.83 27.32 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 115.666 1.728 . . . . 0.0 115.666 -173.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -76.16 -11.59 59.96 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.564 0.697 . . . . 0.0 110.794 176.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -107.08 98.56 8.2 Favored 'General case' 0 N--CA 1.423 -1.812 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . 0.587 ' HA ' HH21 ' A' ' 19' ' ' ARG . 2.5 pt20 -86.08 164.28 17.4 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.133 -1.427 . . . . 0.0 112.177 -177.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.518 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.58 -64.86 0.69 Allowed 'General case' 0 C--N 1.32 -0.698 0 O-C-N 124.984 1.427 . . . . 0.0 110.714 -173.353 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 101.69 29.48 6.21 Favored Glycine 0 N--CA 1.426 -2.021 0 C-N-CA 120.262 -0.971 . . . . 0.0 111.464 -176.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -152.35 167.14 29.66 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.4 m -131.25 140.92 49.92 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.53 121.41 50.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.902 0.858 . . . . 0.0 113.184 -173.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -120.07 128.08 53.16 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 64.2 -1.14 0.74 Allowed 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 124.451 1.1 . . . . 0.0 112.634 -174.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.81 -3.74 34.1 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -175.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -101.09 131.12 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.104 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 71.4 mt -67.1 114.25 3.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 124.248 1.019 . . . . 0.0 110.615 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -85.54 -51.88 6.2 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.914 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.9 p -137.51 151.07 48.05 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.08 -176.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.63 141.37 46.58 Favored 'General case' 0 C--N 1.31 -1.109 0 O-C-N 123.779 0.674 . . . . 0.0 109.646 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.1 ttt -83.84 115.76 22.41 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -73.92 128.29 35.12 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 -177.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.4 -4.4 85.26 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.992 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.0 173.41 46.78 Favored Glycine 0 C--O 1.242 0.635 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.389 -178.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -61.84 -29.85 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.43 -48.69 71.89 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.309 177.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -65.93 -43.52 87.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.917 0.389 . . . . 0.0 110.796 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.5 mtp85 -72.37 -17.37 61.83 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 121.52 0.676 . . . . 0.0 110.153 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.03 -20.6 60.66 Favored Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.052 -0.976 . . . . 0.0 111.395 175.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.57 4.63 24.85 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 120.286 -0.959 . . . . 0.0 113.516 176.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.43 142.53 16.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.461 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 9.9 mmt180 -140.33 139.78 35.49 Favored 'General case' 0 CA--C 1.491 -1.324 0 CA-C-O 121.257 0.551 . . . . 0.0 110.809 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.3 t -75.13 136.39 25.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 114.499 -1.228 . . . . 0.0 109.348 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.1 10.5 64.3 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -176.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.51 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.7 m170 -104.33 143.71 32.62 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.048 0.451 . . . . 0.0 110.945 177.458 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.451 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 76.0 ttt180 -103.78 114.97 29.63 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.017 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.414 HG12 HG22 ' A' ' 86' ' ' THR . 23.1 mt -77.31 126.57 37.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-O 121.093 0.473 . . . . 0.0 110.048 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.424 HG22 ' CG2' ' A' ' 64' ' ' VAL . 2.4 pp -109.9 -5.43 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.945 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.985 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.437 ' O ' ' HA ' ' A' ' 84' ' ' MET . 17.2 tt0 -161.48 145.29 12.82 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.422 ' CD1' HG23 ' A' ' 63' ' ' VAL . 76.2 mt -145.12 120.5 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 O-C-N 124.454 1.096 . . . . 0.0 109.194 176.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 59.65 25.95 14.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.55 1.14 . . . . 0.0 112.276 169.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.39 -7.58 30.44 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 119.883 -1.151 . . . . 0.0 114.222 177.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -124.2 135.37 53.4 Favored 'General case' 0 CA--C 1.486 -1.487 0 CA-C-N 117.785 0.793 . . . . 0.0 110.672 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 21.6 t -74.05 120.14 19.22 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 177.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.589 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.0 m -110.43 19.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.541 0 CA-C-O 121.479 0.657 . . . . 0.0 110.757 -174.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.424 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.0 p -78.83 -18.32 13.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.619 0.723 . . . . 0.0 110.329 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.87 12.49 15.83 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.45 175.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.589 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.6 m -91.22 135.48 28.26 Favored Pre-proline 0 N--CA 1.414 -2.255 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.453 ' O ' HG13 ' A' ' 71' ' ' ILE . 10.0 Cg_endo -57.82 148.42 75.38 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 122.005 1.804 . . . . 0.0 111.789 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 26.4 t60 -48.17 -50.27 29.54 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.563 1.145 . . . . 0.0 112.775 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -61.7 -39.02 89.99 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.873 -177.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -63.49 -49.6 72.95 Favored 'General case' 0 CA--C 1.482 -1.638 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.678 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.4 mt -50.87 -45.75 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 O-C-N 124.3 1.0 . . . . 0.0 109.846 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.62 -35.44 61.15 Favored 'Isoleucine or valine' 0 C--O 1.242 0.664 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.041 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.3 t60 -70.4 -42.33 71.82 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -176.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 38.2 mt -64.97 -49.95 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.919 179.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 42.3 mt -55.75 -52.09 65.15 Favored 'General case' 0 CA--C 1.502 -0.882 0 O-C-N 123.756 0.66 . . . . 0.0 112.181 177.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.8 t -59.07 -26.03 64.28 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.654 0.612 . . . . 0.0 112.654 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.7 m-80 -111.2 4.28 19.11 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -175.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.421 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -98.86 125.87 44.37 Favored 'General case' 0 C--O 1.204 -1.314 0 O-C-N 121.333 -0.854 . . . . 0.0 110.813 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.457 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -118.08 174.08 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.77 -155.52 19.7 Favored Glycine 0 CA--C 1.497 -1.093 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.496 ' HB3' HD12 ' A' ' 16' ' ' LEU . 2.9 mp0 -89.49 109.61 20.53 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.497 ' HB ' HG23 ' A' ' 17' ' ' ILE . 65.4 mt -105.11 117.86 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.933 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -170.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.9 m80 -85.3 128.42 34.69 Favored 'General case' 0 CA--C 1.478 -1.801 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.437 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -129.29 153.55 47.71 Favored 'General case' 0 C--N 1.258 -3.38 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 170.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -120.4 120.54 36.24 Favored 'General case' 0 C--N 1.26 -3.316 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.51 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.8 p -119.35 143.59 47.32 Favored 'General case' 0 C--N 1.257 -3.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.598 -178.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.557 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.3 mtm -111.39 164.06 15.92 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 175.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.77 27.52 0.32 Allowed 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.57 2.18 . . . . 0.0 111.598 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.557 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 69.27 25.8 5.55 Favored 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 126.299 1.84 . . . . 0.0 112.866 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.42 -1.94 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 174.456 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.54 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 4.5 m-20 . . . . . 0 N--CA 1.469 0.504 0 CA-C-O 122.285 1.041 . . . . 0.0 111.824 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.5 t -114.38 126.84 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.445 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.59 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -116.92 117.55 30.01 Favored 'General case' 0 C--N 1.248 -3.807 0 CA-C-N 113.915 -1.493 . . . . 0.0 107.086 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 m -83.87 138.2 33.31 Favored 'General case' 0 N--CA 1.406 -2.641 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.422 -176.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.3 t -118.19 140.29 42.15 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.373 178.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.9 tp -122.68 116.42 23.76 Favored 'General case' 0 N--CA 1.399 -3.009 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.13 139.04 20.47 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -178.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.08 102.6 10.55 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 175.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.467 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.7 ttt180 -107.09 108.86 62.59 Favored Pre-proline 0 C--N 1.287 -2.121 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.241 -177.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -53.05 -55.87 3.3 Favored 'Trans proline' 0 CA--C 1.542 0.922 0 C-N-CA 122.788 2.325 . . . . 0.0 112.933 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -156.69 -176.98 6.27 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -177.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.576 HD21 ' CG1' ' A' ' 79' ' ' VAL . 68.7 mt -74.47 -14.37 60.82 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -172.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -82.11 -11.33 58.82 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-O 121.466 0.65 . . . . 0.0 110.15 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -94.7 121.07 35.89 Favored 'General case' 0 CA--C 1.487 -1.46 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.811 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -84.03 157.4 21.83 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 123.579 0.549 . . . . 0.0 110.353 177.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.46 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -61.15 -44.01 97.98 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 124.29 0.994 . . . . 0.0 111.36 -171.434 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.28 26.04 9.74 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 119.639 -1.267 . . . . 0.0 113.42 178.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -151.94 167.87 26.98 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -124.55 134.05 53.11 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -125.57 138.47 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -173.231 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 17.4 pt20 -105.44 92.79 4.34 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.794 0.806 . . . . 0.0 109.318 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 58.55 20.55 7.7 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 122.79 -10.23 9.02 Favored Glycine 0 C--O 1.218 -0.867 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.092 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -106.33 118.44 53.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.452 HD11 HG11 ' A' ' 49' ' ' VAL . 65.5 mt -59.61 114.74 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 123.244 0.618 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 52.5 t -95.29 -37.8 10.83 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.468 -175.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 14.8 m -149.8 151.23 33.22 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -178.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.9 tp -121.26 136.09 55.02 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.8 ttm -83.94 118.37 23.96 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -68.64 125.61 27.1 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.189 -175.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.47 0.41 79.51 Favored Glycine 0 N--CA 1.425 -2.046 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.55 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.62 171.25 45.13 Favored Glycine 0 C--O 1.241 0.586 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.14 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.89 -31.05 51.05 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.041 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.27 -39.61 93.48 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.891 0.377 . . . . 0.0 110.478 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -63.4 -44.01 95.91 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 176.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -72.28 -6.14 40.98 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.061 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -98.81 -18.01 26.41 Favored Glycine 0 N--CA 1.433 -1.536 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.03 19.56 18.9 Favored Glycine 0 N--CA 1.433 -1.518 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.442 -179.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.452 HG11 HD11 ' A' ' 35' ' ' ILE . 53.9 t -65.32 145.62 13.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-O 120.88 0.371 . . . . 0.0 110.036 177.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.419 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 19.9 mmt85 -136.86 138.71 41.03 Favored 'General case' 0 CA--C 1.488 -1.409 0 C-N-CA 123.963 0.905 . . . . 0.0 108.852 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.2 t -76.24 148.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.806 -177.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.05 47.67 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -178.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.529 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.7 m170 -122.19 136.39 54.9 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.994 -178.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -94.12 123.0 37.22 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.1 mt -79.24 121.17 31.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.44 HG23 ' SD ' ' A' ' 87' ' ' MET . 36.8 pt -100.63 -14.92 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.38 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.5 tt0 -156.79 141.16 16.62 Favored 'General case' 0 CA--C 1.477 -1.858 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -175.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.415 HD12 HG23 ' A' ' 63' ' ' VAL . 79.2 mt -140.75 126.34 19.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.14 14.52 9.68 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 124.058 0.943 . . . . 0.0 111.126 172.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.83 -1.96 48.51 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.877 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.457 ' O ' HG11 ' A' ' 63' ' ' VAL . 18.5 pt20 -115.57 130.6 56.93 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 117.106 0.453 . . . . 0.0 110.633 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.0 m -70.02 108.45 4.07 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.755 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.642 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.5 m -102.17 13.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.594 0 CA-C-O 122.133 0.968 . . . . 0.0 109.682 -175.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.9 p -73.53 -14.11 16.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 114.349 -1.296 . . . . 0.0 110.567 -177.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -125.68 19.82 7.9 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 122.21 1.005 . . . . 0.0 108.712 177.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.642 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.3 m -101.23 137.42 19.68 Favored Pre-proline 0 N--CA 1.413 -2.295 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.415 ' O ' HG13 ' A' ' 71' ' ' ILE . 57.3 Cg_endo -72.74 163.25 38.99 Favored 'Trans proline' 0 C--O 1.245 0.848 0 C-N-CA 122.035 1.824 . . . . 0.0 112.739 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -42.35 -57.85 2.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 127.249 2.22 . . . . 0.0 112.371 -177.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -68.15 -39.99 82.5 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.672 -174.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -59.18 -48.7 80.63 Favored 'General case' 0 CA--C 1.495 -1.164 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.535 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.415 HG13 ' O ' ' A' ' 67' ' ' PRO . 65.5 mt -51.9 -43.63 35.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 O-C-N 124.057 0.848 . . . . 0.0 110.329 178.558 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.1 t -73.09 -34.99 46.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.792 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.43 -46.08 77.68 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 123.517 0.727 . . . . 0.0 109.292 -177.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 23.6 mt -64.43 -47.06 90.99 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.706 0 CA-C-N 114.673 -1.149 . . . . 0.0 109.887 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 45.4 mt -58.43 -51.71 68.69 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.987 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 42.2 m -56.38 -27.84 57.41 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -102.31 -5.21 24.51 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.467 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -102.88 131.84 49.51 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.892 -0.505 . . . . 0.0 111.317 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.576 ' CG1' HD21 ' A' ' 22' ' ' LEU . 2.5 m -130.43 -174.78 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.411 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 85.19 -154.77 29.21 Favored Glycine 0 CA--C 1.484 -1.863 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 178.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -78.7 115.7 18.57 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 78.1 mt -119.33 117.82 55.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -85.53 126.24 33.7 Favored 'General case' 0 CA--C 1.487 -1.448 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.491 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 20.8 mtm -124.35 152.26 43.36 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 173.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -119.91 122.96 42.4 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.529 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 45.6 p -120.83 139.95 52.43 Favored 'General case' 0 C--N 1.271 -2.846 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.638 -177.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.501 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.7 mtp -110.33 169.76 6.02 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 11.7 Cg_exo -74.84 30.27 0.35 Allowed 'Trans proline' 0 N--CA 1.486 1.054 0 C-N-CA 122.914 2.409 . . . . 0.0 112.619 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.501 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.9 60.18 2.24 Favored 'General case' 0 CA--C 1.496 -1.132 0 C-N-CA 125.242 1.417 . . . . 0.0 111.583 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -2.013 0 CA-C-N 113.236 -1.802 . . . . 0.0 106.6 172.571 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 . . . . . 0 CA--C 1.48 -1.724 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.457 HG13 ' HE3' ' A' ' 85' ' ' LYS . 71.4 t -118.64 137.22 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.379 -3.976 0 CA-C-O 122.256 1.027 . . . . 0.0 108.881 -173.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 m -118.72 105.88 12.01 Favored 'General case' 2 N--CA 1.368 -4.562 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 174.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.8 m -83.55 136.75 34.14 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 114.764 -1.107 . . . . 0.0 109.272 -176.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.98 141.88 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.47 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.344 -175.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.415 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 18.2 tp -125.45 116.5 21.92 Favored 'General case' 0 N--CA 1.396 -3.137 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 174.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.476 HD12 HG21 ' A' ' 17' ' ' ILE . 1.0 OUTLIER -99.29 129.61 49.49 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 175.535 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.438 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 74.6 mtp180 -113.1 101.36 9.38 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 122.813 1.292 . . . . 0.0 109.059 169.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -105.04 111.27 65.21 Favored Pre-proline 0 C--N 1.272 -2.785 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.462 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -56.17 -47.88 22.27 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 122.598 2.199 . . . . 0.0 113.05 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.39 178.59 10.14 Favored 'General case' 0 C--O 1.246 0.916 0 CA-C-O 120.893 0.378 . . . . 0.0 110.72 -177.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.558 HD21 ' CG1' ' A' ' 79' ' ' VAL . 53.7 mt -65.05 -21.99 66.91 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 115.637 1.717 . . . . 0.0 115.637 -173.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -79.04 -11.12 59.99 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.17 0.509 . . . . 0.0 111.465 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -83.26 -20.34 34.68 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 57.05 -164.46 0.16 Allowed 'General case' 0 CA--C 1.511 -0.539 0 O-C-N 123.777 0.673 . . . . 0.0 111.648 -176.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.472 ' O ' HG13 ' A' ' 43' ' ' ILE . 0.4 OUTLIER -97.4 -49.43 4.92 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.92 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.21 11.54 Favored Glycine 0 N--CA 1.432 -1.595 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.097 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -143.48 164.26 30.84 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 50.3 m -118.19 133.7 55.67 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 123.89 0.743 . . . . 0.0 109.239 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.57 131.58 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.222 0 CA-C-O 121.69 0.757 . . . . 0.0 110.89 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -120.72 128.85 53.31 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 62.08 2.95 0.87 Allowed 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 124.248 1.019 . . . . 0.0 112.917 -176.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.99 3.05 45.61 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -174.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.406 HG13 ' HB2' ' A' ' 54' ' ' ARG . 3.5 mp -114.08 125.03 71.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.43 HD13 HG11 ' A' ' 49' ' ' VAL . 50.4 mt -61.41 117.97 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 123.834 0.854 . . . . 0.0 110.14 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.9 t -101.98 -34.42 9.35 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.309 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 p -143.35 148.49 36.34 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.3 tp -128.32 132.27 48.64 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.6 ttp -85.45 108.11 17.73 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.57 141.43 58.77 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.449 -177.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.04 -15.38 48.98 Favored Glycine 0 C--N 1.303 -1.252 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.531 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.61 175.45 50.74 Favored Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.472 HG13 ' O ' ' A' ' 26' ' ' LEU . 1.3 pt -59.96 -34.47 56.4 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.748 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.421 ' HA ' HD13 ' A' ' 17' ' ' ILE . . . -62.81 -40.06 96.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -68.11 -36.71 80.19 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.601 0.715 . . . . 0.0 109.12 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -76.58 -23.88 53.51 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.511 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.34 -23.24 63.41 Favored Glycine 0 N--CA 1.438 -1.204 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.507 178.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.98 10.63 22.27 Favored Glycine 0 CA--C 1.501 -0.811 0 C-N-CA 120.231 -0.985 . . . . 0.0 112.883 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.43 HG11 HD13 ' A' ' 35' ' ' ILE . 66.0 t -66.78 135.78 27.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 20.4 mmt180 -133.45 142.72 48.44 Favored 'General case' 0 CA--C 1.481 -1.681 0 CA-C-O 121.165 0.507 . . . . 0.0 110.293 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.5 t -72.65 145.25 12.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.967 -178.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.9 21.08 56.65 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 -178.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.8 m170 -117.21 135.96 53.41 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 115.08 -0.56 . . . . 0.0 111.37 -179.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.452 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 34.8 ttp180 -97.73 123.72 41.78 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 177.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 86' ' ' THR . 30.5 mt -78.62 123.43 35.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.3 pt -100.3 -16.69 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.848 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.449 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.6 tt0 -158.4 144.49 17.07 Favored 'General case' 0 CA--C 1.496 -1.134 0 C-N-CA 119.479 -0.889 . . . . 0.0 110.2 -174.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.415 ' CD1' HG22 ' A' ' 63' ' ' VAL . 82.2 mt -139.91 118.09 11.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 124.674 1.233 . . . . 0.0 108.077 178.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 53.79 27.24 6.81 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 125.299 1.44 . . . . 0.0 114.472 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.55 -10.4 38.68 Favored Glycine 0 CA--C 1.496 -1.106 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.82 175.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 35.5 tt0 -100.54 122.38 43.14 Favored 'General case' 0 C--N 1.292 -1.928 0 CA-C-N 115.488 -0.356 . . . . 0.0 110.393 -177.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -71.32 108.62 4.87 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.547 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.7 m -102.45 10.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-O 121.667 0.746 . . . . 0.0 110.08 -175.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.02 -13.5 16.74 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 114.669 -1.15 . . . . 0.0 111.111 -177.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -123.04 13.66 9.77 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.111 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.8 m -96.9 136.55 21.55 Favored Pre-proline 0 N--CA 1.409 -2.521 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.441 ' O ' HG13 ' A' ' 71' ' ' ILE . 9.5 Cg_endo -56.81 150.01 56.8 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.351 2.034 . . . . 0.0 112.386 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.2 t60 -48.62 -48.25 39.49 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.453 1.101 . . . . 0.0 112.733 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -67.58 -35.49 79.1 Favored 'General case' 0 N--CA 1.435 -1.199 0 O-C-N 123.487 0.492 . . . . 0.0 110.621 -175.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 mttm -63.59 -49.45 73.29 Favored 'General case' 0 CA--C 1.484 -1.586 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.365 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.441 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.0 mt -53.59 -43.15 53.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 O-C-N 124.083 0.865 . . . . 0.0 109.918 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.7 t -71.91 -31.86 42.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.728 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -74.56 -41.04 61.26 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -175.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.7 mt -64.29 -47.75 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 81.7 mt -62.48 -35.23 78.66 Favored 'General case' 0 C--O 1.211 -0.928 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.437 176.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.5 t -63.21 -31.11 72.18 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 122.805 0.442 . . . . 0.0 111.693 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.76 -31.71 13.65 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -175.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.08 130.58 35.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -172.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.558 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.8 m -129.89 -179.41 3.16 Favored 'Isoleucine or valine' 0 C--O 1.243 0.732 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 174.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 86.6 -151.34 24.1 Favored Glycine 0 CA--C 1.488 -1.65 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -79.06 108.78 12.8 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 79.9 mt -111.16 118.82 58.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.746 -175.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -94.56 131.18 40.58 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.449 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -133.11 156.2 47.87 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 172.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.457 ' HE3' HG13 ' A' ' 12' ' ' VAL . 23.2 mmmt -124.47 120.33 31.71 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 105.547 -2.019 . . . . 0.0 105.547 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 33.4 p -119.64 146.68 45.33 Favored 'General case' 0 C--N 1.27 -2.848 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.259 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.545 ' C ' ' H ' ' A' ' 89' ' ' ALA . 49.8 mtm -118.21 169.9 7.11 Favored Pre-proline 0 C--N 1.298 -1.631 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 176.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -69.71 26.26 0.17 Allowed 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 123.336 2.691 . . . . 0.0 112.575 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.545 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 74.86 -1.27 3.13 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 126.538 1.935 . . . . 0.0 113.466 178.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.113 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 . . . . . 0 CA--C 1.495 -1.16 0 CA-C-O 121.836 0.826 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -134.79 133.26 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.191 0 CA-C-N 114.603 -1.18 . . . . 0.0 108.033 -178.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 m -123.0 117.86 26.45 Favored 'General case' 0 C--N 1.261 -3.28 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 21.4 m -85.26 142.3 29.49 Favored 'General case' 0 C--N 1.265 -3.092 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.235 -175.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.63 132.0 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.129 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 13.8 tp -122.09 119.67 32.03 Favored 'General case' 0 N--CA 1.393 -3.281 0 CA-C-O 121.711 0.767 . . . . 0.0 109.991 173.543 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.488 HD12 HG23 ' A' ' 17' ' ' ILE . 1.1 mm -99.87 135.23 36.36 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.026 0 CA-C-N 114.24 -1.346 . . . . 0.0 108.652 176.134 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -115.16 101.24 8.79 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.503 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 73.4 ttt180 -99.22 115.23 65.86 Favored Pre-proline 0 C--N 1.284 -2.275 0 CA-C-N 113.621 -1.627 . . . . 0.0 110.94 -178.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_exo -61.29 -38.0 68.82 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.663 2.242 . . . . 0.0 114.065 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.91 -178.58 4.8 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.417 HD21 HG12 ' A' ' 79' ' ' VAL . 79.7 mt -76.69 -15.23 59.85 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 123.976 0.91 . . . . 0.0 111.277 -176.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -69.79 -16.15 63.24 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.993 176.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -97.97 121.27 39.69 Favored 'General case' 0 CA--C 1.481 -1.682 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 176.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 -97.48 156.96 16.26 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.611 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.512 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.0 OUTLIER -53.08 -65.62 0.53 Allowed 'General case' 0 C--N 1.323 -0.551 0 O-C-N 124.993 1.433 . . . . 0.0 110.778 -174.349 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.28 34.78 4.1 Favored Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 120.129 -1.034 . . . . 0.0 112.626 177.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -155.59 155.73 33.83 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.1 m -107.42 127.35 53.51 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -117.89 136.64 54.41 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 C-N-CA 119.839 -0.744 . . . . 0.0 109.203 179.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -121.92 109.95 15.26 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 60.33 13.34 3.94 Favored 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 124.036 0.934 . . . . 0.0 112.37 -176.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 113.09 -6.85 25.31 Favored Glycine 0 C--O 1.211 -1.323 0 C-N-CA 121.145 -0.55 . . . . 0.0 112.054 -178.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.5 mp -102.24 123.61 55.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.049 -0.677 . . . . 0.0 110.073 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.1 mt -64.14 112.13 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 C-N-CA 124.05 0.94 . . . . 0.0 109.71 178.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 22.6 t -91.59 -37.29 13.18 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.517 -174.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -152.8 157.33 40.61 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 66.4 tp -129.35 132.45 47.08 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 25.6 ttt -87.33 120.4 28.58 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.434 ' C ' ' HD3' ' A' ' 40' ' ' ARG . 0.3 OUTLIER -69.59 136.27 51.05 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.779 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.28 -2.21 74.36 Favored Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.4 164.58 28.26 Favored Glycine 0 N--CA 1.436 -1.308 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 pt -60.81 -36.66 72.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.44 -39.5 70.38 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.014 0.435 . . . . 0.0 111.062 -178.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -67.03 -42.78 84.3 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.023 178.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.89 -37.3 86.9 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.747 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.66 -24.32 76.31 Favored Glycine 0 CA--C 1.516 0.12 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.754 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.75 28.91 5.77 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.409 -0.9 . . . . 0.0 112.564 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.7 t -77.45 142.65 13.93 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -136.21 145.14 45.36 Favored 'General case' 0 CA--C 1.49 -1.338 0 CA-C-O 121.202 0.525 . . . . 0.0 109.623 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.0 t -73.42 144.7 12.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.206 -178.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.83 20.17 58.39 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -179.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.431 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 13.6 m-70 -115.2 144.67 43.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 115.121 -0.539 . . . . 0.0 110.194 178.161 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -104.97 117.48 34.12 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.424 HG12 HG22 ' A' ' 86' ' ' THR . 29.6 mt -73.96 123.79 29.95 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.478 HG23 ' SD ' ' A' ' 87' ' ' MET . 2.4 pp -109.48 -4.13 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.384 -178.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.513 ' O ' ' HA ' ' A' ' 84' ' ' MET . 20.0 tt0 -160.59 146.7 15.12 Favored 'General case' 0 CA--C 1.486 -1.506 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.515 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.462 ' N ' ' HG2' ' A' ' 57' ' ' GLU . 79.3 mt -142.71 120.69 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 172.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.421 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 8.5 m-20 55.07 27.45 9.42 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 177.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.75 -6.86 58.99 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.562 -0.828 . . . . 0.0 113.821 177.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.457 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 11.6 pt20 -107.96 136.36 47.8 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 t -80.98 108.86 15.02 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -178.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.599 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.1 m -100.02 15.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.88 0 CA-C-O 122.09 0.948 . . . . 0.0 109.455 -173.436 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.428 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.6 p -69.73 -21.79 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.876 -175.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.32 13.62 12.78 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.457 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.599 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.7 m -90.37 133.7 32.6 Favored Pre-proline 0 N--CA 1.412 -2.367 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -63.62 155.55 62.38 Favored 'Trans proline' 0 C--O 1.25 1.125 0 C-N-CA 122.178 1.919 . . . . 0.0 112.356 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.35 -53.38 8.65 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.04 1.336 . . . . 0.0 111.313 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -56.99 -43.43 81.71 Favored 'General case' 0 C--N 1.316 -0.855 0 O-C-N 123.903 0.752 . . . . 0.0 111.456 -176.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.45 -54.61 26.01 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.847 -178.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.4 mt -50.39 -43.04 21.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 O-C-N 123.862 0.726 . . . . 0.0 110.293 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 73.0 t -67.1 -40.93 86.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 72.5 t60 -64.74 -44.09 91.25 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.4 -50.93 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 O-C-N 123.592 0.558 . . . . 0.0 109.534 178.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.14 -31.56 72.73 Favored 'General case' 0 C--O 1.209 -1.054 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.4 ' O ' HD22 ' A' ' 22' ' ' LEU . 50.2 m -71.08 -27.45 63.63 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' HD21 ' A' ' 77' ' ' ASN . 0.8 OUTLIER -100.55 -11.46 20.07 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -174.845 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.503 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.77 132.56 38.04 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.237 -0.585 . . . . 0.0 112.031 -176.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.417 HG12 HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -131.4 172.62 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.534 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 78.4 -151.05 35.86 Favored Glycine 0 CA--C 1.496 -1.119 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -176.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -59.11 108.78 0.73 Allowed 'General case' 0 C--O 1.245 0.857 0 C-N-CA 124.417 1.087 . . . . 0.0 111.362 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.421 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 85.4 mt -115.79 118.36 58.54 Favored 'Isoleucine or valine' 0 CA--C 1.456 -2.639 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 11.7 t-80 -106.65 115.87 30.94 Favored 'General case' 0 N--CA 1.385 -3.68 0 CA-C-N 113.199 -1.819 . . . . 0.0 109.456 -170.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.513 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 22.4 mtm -123.91 155.19 38.57 Favored 'General case' 0 C--N 1.261 -3.269 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 177.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 57.1 mmtt -122.06 124.26 43.52 Favored 'General case' 0 C--N 1.265 -3.087 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 175.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.431 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 68.8 p -119.45 134.99 54.95 Favored 'General case' 0 C--N 1.262 -3.236 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.665 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.478 ' SD ' HG23 ' A' ' 56' ' ' ILE . 89.2 mtp -105.98 163.22 17.5 Favored Pre-proline 0 C--N 1.299 -1.619 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 176.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.64 14.48 0.32 Allowed 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 122.724 2.283 . . . . 0.0 113.157 178.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.443 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 65.37 22.94 12.02 Favored 'General case' 0 C--N 1.344 0.36 0 C-N-CA 124.427 1.091 . . . . 0.0 110.68 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.753 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.312 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 . . . . . 0 CA--C 1.506 -0.735 0 CA-C-O 121.933 0.873 . . . . 0.0 111.297 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -128.18 128.95 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.358 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.892 -175.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.7 m -115.58 108.19 16.11 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.178 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.4 m -78.7 135.83 37.27 Favored 'General case' 0 N--CA 1.395 -3.18 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.4 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.2 t -116.09 135.79 55.13 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.937 0 CA-C-N 114.793 -1.094 . . . . 0.0 108.478 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.5 tp -121.19 116.8 25.6 Favored 'General case' 0 N--CA 1.385 -3.698 0 C-N-CA 119.561 -0.856 . . . . 0.0 109.428 174.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.486 HD12 HG23 ' A' ' 17' ' ' ILE . 0.9 OUTLIER -97.55 133.94 37.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.352 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.592 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.6 mmm-85 -112.73 101.17 9.29 Favored 'General case' 0 N--CA 1.411 -2.398 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.531 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.2 ttt180 -100.88 110.8 61.95 Favored Pre-proline 0 C--N 1.282 -2.342 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.235 -178.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -54.88 -38.09 92.68 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 123.361 2.707 . . . . 0.0 113.663 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -176.73 -176.89 0.75 Allowed 'General case' 0 C--O 1.241 0.644 0 C-N-CA 123.367 0.667 . . . . 0.0 109.308 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.422 HD21 HG13 ' A' ' 79' ' ' VAL . 69.0 mt -73.28 -6.82 48.49 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -174.478 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -84.57 -13.98 50.18 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.06 0.457 . . . . 0.0 110.565 175.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -103.01 109.1 20.52 Favored 'General case' 0 CA--C 1.491 -1.326 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -82.4 162.73 22.05 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.275 178.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.498 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.1 mm? -52.14 -52.84 49.19 Favored 'General case' 0 C--N 1.321 -0.655 0 O-C-N 124.704 1.253 . . . . 0.0 110.65 -175.161 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.82 28.23 6.33 Favored Glycine 0 N--CA 1.436 -1.319 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.4 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -150.03 151.06 32.66 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m -104.57 124.64 49.67 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -113.95 141.64 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.528 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -177.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.422 ' NE2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp0? -119.06 102.04 8.45 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-O 121.711 0.767 . . . . 0.0 110.56 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 60.98 23.04 13.21 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-N 114.481 -1.236 . . . . 0.0 112.548 178.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.85 -11.01 20.87 Favored Glycine 0 N--CA 1.437 -1.268 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.421 178.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.422 ' HB ' ' NE2' ' A' ' 31' ' ' GLN . 3.1 mp -109.5 119.3 58.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 117.302 0.551 . . . . 0.0 110.781 -178.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.41 HD11 HG12 ' A' ' 49' ' ' VAL . 57.2 mt -59.43 111.93 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 124.193 0.997 . . . . 0.0 111.015 178.07 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 45.3 t -89.67 -38.26 14.01 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.595 -177.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.7 t -148.78 150.78 33.68 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 55.9 tp -122.57 137.55 54.86 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.3 tpp -86.2 120.1 27.19 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.73 129.46 39.86 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.306 -176.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.27 -3.05 86.86 Favored Glycine 0 N--CA 1.421 -2.319 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.419 176.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.5 173.55 47.88 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.38 -0.914 . . . . 0.0 111.923 -176.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 26' ' ' LEU . 2.7 pt -59.17 -34.67 54.25 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -60.91 -39.11 88.12 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.709 0.29 . . . . 0.0 111.272 179.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -66.76 -41.24 88.06 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.826 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.435 ' HG2' ' HA ' ' A' ' 43' ' ' ILE . 13.1 ptt180 -78.66 -16.22 57.57 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.012 -0.675 . . . . 0.0 111.81 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.95 -22.69 63.12 Favored Glycine 0 N--CA 1.433 -1.535 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.708 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.3 15.09 20.55 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.965 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.41 HG12 HD11 ' A' ' 35' ' ' ILE . 73.2 t -70.47 138.3 22.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.408 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 30.9 mmm180 -135.49 151.1 50.04 Favored 'General case' 0 CA--C 1.486 -1.484 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -79.68 145.52 9.16 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.106 -176.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.44 23.18 57.15 Favored Glycine 0 CA--C 1.501 -0.809 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -178.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.493 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.5 m170 -116.5 134.09 55.26 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 114.708 -0.746 . . . . 0.0 111.28 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.9 ttm180 -97.54 125.44 42.25 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 86' ' ' THR . 34.2 mt -78.15 126.95 38.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 177.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 31.0 pt -106.91 -15.48 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.41 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.4 tt0 -155.62 145.81 21.68 Favored 'General case' 0 CA--C 1.481 -1.703 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.386 -173.625 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.457 ' CD1' HG22 ' A' ' 63' ' ' VAL . 74.5 mt -142.22 125.53 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.418 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 87.1 m-20 51.62 24.63 2.41 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 115.837 1.791 . . . . 0.0 115.837 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.86 -5.65 34.72 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.254 -0.974 . . . . 0.0 113.416 176.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.425 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.1 pt20 -115.34 129.33 56.56 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 117.42 0.61 . . . . 0.0 111.009 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.4 m -70.46 108.48 4.31 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.538 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.3 m -100.8 12.8 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 121.734 0.778 . . . . 0.0 109.575 -174.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -66.85 -16.22 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.562 -177.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.93 10.06 10.1 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-O 121.427 0.632 . . . . 0.0 109.576 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.538 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.7 m -85.43 141.42 36.74 Favored Pre-proline 0 N--CA 1.422 -1.841 0 C-N-CA 123.812 0.845 . . . . 0.0 109.214 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.75 147.32 81.11 Favored 'Trans proline' 0 C--O 1.239 0.525 0 C-N-CA 122.642 2.228 . . . . 0.0 112.697 179.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -42.97 -55.22 3.86 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 126.212 1.805 . . . . 0.0 111.168 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -58.5 -44.94 89.62 Favored 'General case' 0 CA--C 1.497 -1.09 0 O-C-N 123.362 0.414 . . . . 0.0 110.845 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.43 -55.07 39.34 Favored 'General case' 0 C--O 1.201 -1.479 0 O-C-N 123.861 0.725 . . . . 0.0 110.087 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 59.8 mt -50.38 -43.45 22.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 C-N-CA 123.554 0.742 . . . . 0.0 110.952 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.1 t -72.43 -36.12 53.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.829 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -70.67 -40.01 73.21 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 123.323 0.649 . . . . 0.0 109.611 -177.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.33 -49.51 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 176.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 85.2 mt -62.05 -46.27 89.88 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.6 m -64.32 -26.89 68.68 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -91.28 -19.79 22.6 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.09 139.04 31.03 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.837 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.422 HG13 HD21 ' A' ' 22' ' ' LEU . 1.1 m -132.38 178.55 5.45 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 174.04 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.418 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 76.9 -151.3 38.89 Favored Glycine 0 CA--C 1.48 -2.136 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -65.33 114.86 5.06 Favored 'General case' 0 CA--C 1.497 -1.096 0 O-C-N 124.693 0.878 . . . . 0.0 110.175 174.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.418 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 83.5 mt -118.62 117.29 54.0 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.703 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 175.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -99.48 120.08 39.05 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 -174.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.435 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 25.2 mtm -126.32 157.28 38.82 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -121.98 125.12 45.61 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 176.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.493 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 44.6 p -121.26 144.08 48.81 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.372 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.48 ' C ' ' H ' ' A' ' 89' ' ' ALA . 54.5 mtm -116.73 168.96 7.87 Favored Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -71.29 29.58 0.23 Allowed 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 123.056 2.504 . . . . 0.0 112.861 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.48 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 57.4 50.48 11.29 Favored 'General case' 0 C--O 1.245 0.855 0 CA-C-O 122.496 1.141 . . . . 0.0 110.332 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.92 0 CA-C-N 113.782 -1.554 . . . . 0.0 108.026 179.621 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.3 p30 . . . . . 0 CA--C 1.474 -1.957 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 69.5 t -95.68 128.62 46.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.505 0 CA-C-N 113.35 -1.75 . . . . 0.0 109.466 -173.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.1 m -122.45 109.2 14.07 Favored 'General case' 2 C--N 1.236 -4.33 0 CA-C-N 113.291 -1.777 . . . . 0.0 106.865 177.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -79.01 138.66 38.13 Favored 'General case' 0 N--CA 1.406 -2.674 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.154 -176.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.57 133.41 62.0 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.547 177.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.419 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 14.4 tp -121.17 116.13 24.37 Favored 'General case' 0 N--CA 1.396 -3.134 0 C-N-CA 119.989 -0.684 . . . . 0.0 110.005 176.419 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.445 HD13 ' HA ' ' A' ' 44' ' ' ALA . 0.6 OUTLIER -98.89 138.64 22.79 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.978 0 CA-C-N 114.563 -1.198 . . . . 0.0 108.02 178.256 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -115.13 101.73 9.25 Favored 'General case' 0 N--CA 1.414 -2.252 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 168.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.517 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 65.3 ttt180 -97.89 116.28 65.7 Favored Pre-proline 0 C--N 1.284 -2.26 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.001 -177.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -49.36 -54.43 5.46 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.034 2.49 . . . . 0.0 112.602 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.582 ' OD2' ' HG3' ' A' ' 23' ' ' ARG . 2.7 p-10 -173.1 -170.49 0.64 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.454 ' HA ' ' NH2' ' A' ' 19' ' ' ARG . 54.1 mt -68.6 -16.65 63.92 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -173.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.582 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 27.0 mtt180 -71.34 -12.23 61.32 Favored 'General case' 0 N--CA 1.481 1.087 0 CA-C-O 121.167 0.508 . . . . 0.0 110.785 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -113.98 143.36 44.87 Favored 'General case' 0 N--CA 1.427 -1.614 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -116.96 171.56 7.83 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.243 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.559 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.4 OUTLIER -58.31 -61.93 2.21 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 125.124 1.369 . . . . 0.0 111.245 -173.081 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.61 37.99 3.1 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 119.794 -1.193 . . . . 0.0 112.129 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -154.7 163.02 40.86 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.8 m -117.94 128.62 54.98 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.47 138.76 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 120.864 0.364 . . . . 0.0 110.133 -176.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 19.9 pt20 -131.04 121.62 25.34 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.1 m120 63.58 13.44 7.28 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.206 1.002 . . . . 0.0 111.857 -175.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.51 1.91 58.93 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.412 -0.899 . . . . 0.0 111.138 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -106.07 119.88 56.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.442 HD13 HG12 ' A' ' 49' ' ' VAL . 62.3 mt -62.06 116.83 2.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 C-N-CA 124.369 1.068 . . . . 0.0 110.099 177.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.8 t -96.11 -38.18 10.28 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.27 -176.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 13.3 p -149.06 152.38 36.11 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.279 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 53.4 tp -127.46 145.38 50.85 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 123.576 0.75 . . . . 0.0 109.506 -178.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.8 ttp -93.42 115.88 28.42 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.148 0.499 . . . . 0.0 109.893 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.44 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.0 tpp85 -65.58 118.68 9.86 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 124.726 1.21 . . . . 0.0 109.463 -179.101 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -12.99 59.13 Favored Glycine 0 C--N 1.305 -1.142 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.793 -177.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.401 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -79.93 161.04 45.37 Favored Glycine 0 C--O 1.245 0.814 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.929 -177.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -54.22 -37.69 36.8 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.756 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.445 ' HA ' HD13 ' A' ' 17' ' ' ILE . . . -56.1 -44.2 78.82 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.199 0.524 . . . . 0.0 110.903 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.44 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 44.0 tt0 -70.14 -38.8 75.6 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.469 -179.52 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 48.3 mtt180 -66.59 -34.16 77.28 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.104 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.44 -20.61 79.54 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.782 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.08 20.29 7.62 Favored Glycine 0 C--O 1.24 0.489 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.696 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.442 HG12 HD13 ' A' ' 35' ' ' ILE . 45.0 t -71.34 144.29 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.455 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.4 mmt180 -132.61 142.66 49.24 Favored 'General case' 0 CA--C 1.484 -1.57 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.8 t -74.26 142.71 14.41 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.561 0 CA-C-N 114.583 -1.189 . . . . 0.0 109.192 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.16 22.25 55.15 Favored Glycine 0 CA--C 1.498 -0.989 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.1 m170 -114.67 135.2 54.42 Favored 'General case' 0 N--CA 1.424 -1.764 0 CA-C-N 115.129 -0.536 . . . . 0.0 111.066 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.6 ttm-85 -93.96 125.3 38.51 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.409 HG12 HG22 ' A' ' 86' ' ' THR . 26.1 mt -83.0 123.62 38.76 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.337 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 174.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.2 pt -103.25 -12.06 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.36 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.688 -178.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.499 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.2 tt0 -163.02 143.51 9.34 Favored 'General case' 0 CA--C 1.494 -1.176 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.633 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 90.8 mt -140.03 121.84 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 O-C-N 124.228 0.955 . . . . 0.0 109.222 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 53.32 32.48 13.71 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.203 1.401 . . . . 0.0 112.447 172.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.59 -1.34 52.97 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.284 -0.96 . . . . 0.0 114.551 177.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -123.89 130.44 52.61 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 118.311 1.056 . . . . 0.0 110.755 178.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.3 t -74.74 109.32 8.12 Favored 'General case' 0 N--CA 1.425 -1.692 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.452 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 29.2 m -99.68 16.6 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.387 0 CA-C-O 121.968 0.889 . . . . 0.0 109.661 -174.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.8 p -72.95 -9.82 13.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 114.44 -1.254 . . . . 0.0 111.194 -176.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.53 19.19 5.74 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.452 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.1 m -100.66 137.96 19.99 Favored Pre-proline 0 N--CA 1.412 -2.331 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.454 ' O ' HG13 ' A' ' 71' ' ' ILE . 50.1 Cg_endo -69.44 158.07 58.71 Favored 'Trans proline' 0 C--O 1.246 0.885 0 C-N-CA 122.435 2.09 . . . . 0.0 112.999 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -42.69 -56.19 3.26 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 126.7 2.0 . . . . 0.0 112.152 -178.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.84 -38.77 89.78 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.433 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -60.25 -51.83 67.87 Favored 'General case' 0 CA--C 1.485 -1.546 0 C-N-CA 119.974 -0.691 . . . . 0.0 110.93 177.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.454 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.5 mt -50.99 -44.9 28.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 O-C-N 124.329 1.018 . . . . 0.0 110.263 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.0 t -72.68 -35.13 49.42 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.087 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.9 t60 -69.67 -40.2 76.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.389 0.614 . . . . 0.0 109.586 -176.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 29.4 mt -70.19 -43.59 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 CA-C-N 114.829 -1.078 . . . . 0.0 109.931 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.5 mt -59.39 -46.34 88.95 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.632 175.031 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.3 t -57.92 -28.06 63.92 Favored 'General case' 0 C--O 1.215 -0.712 0 C-N-CA 124.122 0.969 . . . . 0.0 111.686 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -99.81 -6.42 26.93 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -178.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.517 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -101.28 130.55 47.44 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.893 -0.723 . . . . 0.0 111.484 -178.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.405 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -128.94 178.99 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.285 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.401 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 84.23 -153.59 29.33 Favored Glycine 0 CA--C 1.495 -1.178 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -77.61 110.37 12.37 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-O 121.403 0.62 . . . . 0.0 109.67 177.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 74.6 mt -112.94 117.64 55.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -93.76 118.76 31.85 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.499 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.9 mtm -118.13 156.03 29.41 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 174.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -121.54 121.38 37.35 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 42.9 p -121.29 146.62 46.64 Favored 'General case' 0 C--N 1.26 -3.297 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.765 -177.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.456 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.6 mtm -126.58 168.71 13.64 Favored Pre-proline 0 C--N 1.31 -1.142 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -70.79 38.76 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.145 0 C-N-CA 123.812 3.008 . . . . 0.0 113.654 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.456 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 54.79 56.03 7.17 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 125.58 1.552 . . . . 0.0 114.139 177.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.299 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.32 172.136 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 . . . . . 0 CA--C 1.487 -1.473 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -127.28 127.45 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.453 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -115.92 113.21 23.0 Favored 'General case' 0 C--N 1.246 -3.896 0 N-CA-C 106.222 -1.77 . . . . 0.0 106.222 177.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.2 m -86.39 137.82 32.27 Favored 'General case' 0 N--CA 1.395 -3.178 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.995 -175.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.9 t -118.49 141.81 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.629 0 CA-C-N 114.64 -1.164 . . . . 0.0 109.045 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.451 HD12 ' HB3' ' A' ' 81' ' ' GLU . 11.5 tp -129.23 105.69 8.32 Favored 'General case' 0 N--CA 1.386 -3.643 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 171.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.513 HG21 ' HB ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -99.57 127.99 51.81 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.033 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 -175.378 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.41 116.83 29.34 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.566 -177.099 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.437 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 61.6 ttt180 -119.15 116.06 34.15 Favored Pre-proline 0 C--N 1.292 -1.921 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.044 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -62.45 -48.93 6.62 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.422 2.082 . . . . 0.0 112.997 179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.429 ' OD1' ' HD3' ' A' ' 23' ' ' ARG . 2.8 p30 -159.76 -175.58 5.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.482 HD21 ' CG1' ' A' ' 79' ' ' VAL . 54.6 mt -71.43 -15.94 62.37 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -173.644 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.429 ' HD3' ' OD1' ' A' ' 21' ' ' ASP . 4.0 mpt_? -80.8 -11.95 59.52 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.47 0.652 . . . . 0.0 109.717 -179.051 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -95.26 116.16 28.38 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -86.56 150.13 24.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.605 177.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.507 ' H ' HD23 ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.31 -49.91 66.04 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 124.953 1.408 . . . . 0.0 111.188 -172.761 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.72 37.8 3.85 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.047 178.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -161.11 164.89 30.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.451 ' HB3' ' OG ' ' A' ' 37' ' ' SER . 34.8 t -123.4 130.15 52.3 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.448 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.445 ' O ' ' HE1' ' A' ' 68' ' ' HIS . 0.8 OUTLIER -115.46 143.74 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.878 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.856 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -130.54 128.76 41.78 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.4 t30 59.39 11.97 2.46 Favored 'General case' 0 CA--C 1.573 1.83 0 C-N-CA 123.559 0.744 . . . . 0.0 112.353 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.58 3.72 55.08 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.66 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -118.09 124.86 73.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.406 HD12 HG11 ' A' ' 49' ' ' VAL . 49.0 mt -65.12 121.71 14.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 123.876 0.87 . . . . 0.0 110.548 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.4 t -109.58 -25.96 10.17 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.752 -177.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.451 ' OG ' ' HB3' ' A' ' 29' ' ' SER . 12.9 p -146.32 144.38 29.76 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 122.168 -0.332 . . . . 0.0 110.548 177.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 51.0 tp -125.74 133.64 52.02 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 123.767 0.827 . . . . 0.0 109.758 -177.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.1 ttm -75.21 119.18 18.99 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.173 0.511 . . . . 0.0 109.839 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 18.6 tpp180 -66.99 122.09 16.99 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.547 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.6 1.99 82.6 Favored Glycine 0 C--N 1.312 -0.767 0 C-N-CA 120.898 -0.667 . . . . 0.0 111.999 -178.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 46' ' ' ARG . . . -86.12 165.49 37.82 Favored Glycine 0 C--O 1.252 1.239 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.288 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.1 pt -61.91 -30.88 49.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.59 -45.33 94.58 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 120.94 0.4 . . . . 0.0 110.282 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -64.86 -42.21 95.05 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.785 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.493 ' HG2' ' O ' ' A' ' 42' ' ' GLY . 6.7 mmp_? -61.11 -39.4 89.84 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.712 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.2 -16.97 78.57 Favored Glycine 0 CA--C 1.524 0.646 0 CA-C-N 115.59 -0.732 . . . . 0.0 113.903 -178.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.14 12.1 22.64 Favored Glycine 0 C--O 1.241 0.588 0 C-N-CA 119.749 -1.215 . . . . 0.0 113.033 177.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.406 HG11 HD12 ' A' ' 35' ' ' ILE . 80.6 t -72.63 142.82 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -140.8 154.99 46.47 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.49 142.35 14.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.77 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 13.75 58.6 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -177.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.492 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -109.55 135.53 50.39 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 121.151 0.5 . . . . 0.0 111.419 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -95.2 122.94 38.4 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 176.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.2 mt -82.78 122.73 37.7 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 62' ' ' SER . 32.4 pt -103.3 -14.97 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.004 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 178.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.581 ' O ' ' HA ' ' A' ' 84' ' ' MET . 30.7 tt0 -150.92 141.86 22.95 Favored 'General case' 0 CA--C 1.479 -1.762 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -176.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.479 ' CD1' HG23 ' A' ' 63' ' ' VAL . 69.8 mt -143.2 122.0 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.539 0 O-C-N 124.64 1.213 . . . . 0.0 108.127 176.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 66.69 18.57 10.74 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.663 1.185 . . . . 0.0 110.927 171.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.69 -12.06 30.08 Favored Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.75 177.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.424 ' O ' HG12 ' A' ' 63' ' ' VAL . 13.3 pt20 -115.89 143.34 45.55 Favored 'General case' 0 CA--C 1.501 -0.941 0 CA-C-N 117.732 0.766 . . . . 0.0 112.602 -178.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 49.9 m -75.86 108.87 9.03 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.233 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.566 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 23.3 m -102.09 15.02 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 122.124 0.964 . . . . 0.0 109.226 -174.422 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 p -72.97 -17.96 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-N 114.792 -1.094 . . . . 0.0 110.614 -177.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.59 9.32 16.56 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.954 0.883 . . . . 0.0 109.817 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.1 m -90.85 137.0 27.05 Favored Pre-proline 0 N--CA 1.411 -2.422 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.402 ' O ' HG13 ' A' ' 71' ' ' ILE . 12.0 Cg_endo -64.37 154.51 70.99 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 121.676 1.584 . . . . 0.0 111.585 178.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.445 ' HE1' ' O ' ' A' ' 30' ' ' VAL . 69.0 t60 -47.73 -53.49 15.02 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.375 1.07 . . . . 0.0 113.633 -176.461 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -67.97 -31.76 71.7 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.58 -175.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.436 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.0 mttm -63.62 -50.55 68.93 Favored 'General case' 0 C--O 1.189 -2.095 0 C-N-CA 120.197 -0.601 . . . . 0.0 110.035 173.098 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.8 mt -50.3 -43.97 22.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 O-C-N 123.533 0.521 . . . . 0.0 110.223 177.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 86.7 t -69.1 -34.13 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.691 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.642 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -70.87 -42.56 69.9 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 123.381 0.672 . . . . 0.0 109.78 -177.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.9 mp -60.91 -48.68 87.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 80.8 mt -61.39 -46.47 90.02 Favored 'General case' 0 C--O 1.215 -0.753 0 N-CA-C 113.103 0.779 . . . . 0.0 113.103 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -61.73 -27.47 68.74 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -178.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -101.48 -19.19 15.64 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -176.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.437 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -91.54 132.21 36.44 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 122.022 -0.424 . . . . 0.0 111.569 -176.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.482 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.5 m -126.7 -176.37 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.402 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.41 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 88.49 -163.29 32.46 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.451 ' HB3' HD12 ' A' ' 16' ' ' LEU . 2.4 mp0 -75.58 122.06 23.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 171.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.513 ' HB ' HG21 ' A' ' 17' ' ' ILE . 70.7 mt -115.57 119.81 62.91 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.278 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -84.61 112.02 20.06 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 113.43 -1.714 . . . . 0.0 110.372 -174.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.581 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 13.5 mtp -120.57 143.9 48.38 Favored 'General case' 0 C--N 1.253 -3.612 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.745 178.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 12.1 mmmt -120.87 118.5 30.11 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 177.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 65.0 p -119.14 145.55 45.88 Favored 'General case' 0 C--N 1.282 -2.359 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.355 -176.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.527 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.3 mtp -115.8 163.9 19.41 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 178.096 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.42 24.33 0.23 Allowed 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.035 2.49 . . . . 0.0 112.352 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.527 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.41 22.91 13.48 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.4 1.48 . . . . 0.0 111.891 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.904 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 175.765 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 87' ' ' MET . 28.3 t-20 . . . . . 0 N--CA 1.428 -1.559 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.8 t -108.77 117.76 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.79 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.877 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -115.64 114.86 25.47 Favored 'General case' 1 C--N 1.24 -4.174 0 CA-C-N 113.25 -1.795 . . . . 0.0 106.923 178.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.0 m -79.09 141.84 36.98 Favored 'General case' 0 N--CA 1.406 -2.67 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.217 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.419 HG13 ' CG2' ' A' ' 49' ' ' VAL . 57.1 t -121.86 128.28 75.64 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.363 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.506 178.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.428 HD13 ' HB3' ' A' ' 81' ' ' GLU . 22.3 tp -109.37 112.46 24.6 Favored 'General case' 0 N--CA 1.402 -2.836 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 173.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.522 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 134.83 47.32 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.546 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.015 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.73 103.36 12.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-O 121.102 0.477 . . . . 0.0 109.72 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.47 ' HD2' ' O ' ' A' ' 78' ' ' ALA . 34.0 ttm180 -100.83 113.74 65.73 Favored Pre-proline 0 C--N 1.29 -1.989 0 CA-C-N 115.63 -0.713 . . . . 0.0 110.307 177.76 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.61 -42.11 50.19 Favored 'Trans proline' 0 C--O 1.239 0.572 0 C-N-CA 122.281 1.987 . . . . 0.0 112.181 177.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -173.7 177.04 2.58 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -178.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.428 HD22 ' O ' ' A' ' 76' ' ' SER . 53.1 mt -67.01 -22.38 65.9 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 -171.528 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -71.67 -11.65 60.94 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-O 121.406 0.622 . . . . 0.0 111.426 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.3 -20.98 23.4 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.831 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . 0.464 ' C ' HH21 ' A' ' 19' ' ' ARG . 26.4 mt-30 54.09 -153.58 0.28 Allowed 'General case' 0 C--O 1.22 -0.453 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.448 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.429 ' O ' HG13 ' A' ' 43' ' ' ILE . 2.1 mm? -97.47 -57.55 2.22 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.802 0.811 . . . . 0.0 110.49 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.67 2.99 32.56 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 -174.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.41 ' CD1' ' HB3' ' A' ' 26' ' ' LEU . 39.1 p90 -137.83 152.18 48.84 Favored 'General case' 0 C--O 1.246 0.887 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 176.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -105.81 122.73 46.7 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -104.18 137.27 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -119.14 111.79 18.7 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 175.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.437 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 95.3 m-20 65.86 9.13 5.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.352 178.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.0 -3.74 24.1 Favored Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -112.82 122.12 66.39 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 48.2 mt -60.43 116.14 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 123.625 0.77 . . . . 0.0 110.56 179.314 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.1 t -98.08 -33.2 11.25 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.013 -173.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 56.9 p -150.91 151.66 32.5 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 60.2 tp -135.42 137.88 42.7 Favored 'General case' 0 N--CA 1.441 -0.906 0 O-C-N 123.482 0.489 . . . . 0.0 110.829 -178.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 63.0 mtt -92.76 116.78 29.34 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.074 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -69.68 126.77 30.73 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 174.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.38 -21.5 39.13 Favored Glycine 0 N--CA 1.42 -2.427 0 C-N-CA 120.412 -0.899 . . . . 0.0 110.984 -174.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.403 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -78.91 159.04 45.28 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 177.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.429 HG13 ' O ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -55.12 -30.7 24.53 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.866 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.315 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.75 -47.27 84.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 123.569 0.543 . . . . 0.0 111.099 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -67.15 -34.22 77.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.458 0.647 . . . . 0.0 109.492 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.403 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 47.8 mtt180 -75.51 -17.27 60.15 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.613 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.77 -37.57 8.53 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 121.74 17.76 3.77 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.026 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.419 ' CG2' HG13 ' A' ' 15' ' ' VAL . 59.2 t -71.1 141.56 16.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.8 mmm180 -137.64 146.14 43.54 Favored 'General case' 0 CA--C 1.483 -1.619 0 CA-C-O 121.267 0.556 . . . . 0.0 110.649 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.1 t -69.35 147.07 12.21 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.484 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.52 28.56 47.3 Favored Glycine 0 CA--C 1.487 -1.694 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.523 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -123.85 129.03 50.36 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.883 -0.659 . . . . 0.0 111.175 -179.069 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 ttm180 -89.23 124.13 34.1 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 175.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 55' ' ' ILE . 25.9 mt -81.54 124.51 39.02 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.141 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 43.1 pt -106.61 -12.5 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.503 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -154.33 145.42 22.75 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -177.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.421 ' CD1' HG23 ' A' ' 63' ' ' VAL . 80.2 mt -138.68 121.43 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.299 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 58.2 26.5 13.88 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.071 1.348 . . . . 0.0 111.711 174.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.88 -5.41 58.07 Favored Glycine 0 C--O 1.241 0.555 0 C-N-CA 120.025 -1.084 . . . . 0.0 113.774 177.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -110.91 128.74 55.91 Favored 'General case' 0 CA--C 1.499 -0.992 0 CA-C-N 117.609 0.705 . . . . 0.0 109.554 177.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -72.89 112.74 9.2 Favored 'General case' 0 N--CA 1.42 -1.949 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.5 ' O ' ' HB ' ' A' ' 66' ' ' THR . 32.7 m -102.21 10.77 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.964 0 CA-C-O 121.634 0.731 . . . . 0.0 109.64 -175.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 p -71.69 -16.46 18.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.608 -177.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.63 9.87 21.09 Favored 'General case' 0 C--O 1.244 0.796 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.511 177.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.5 ' HB ' ' O ' ' A' ' 63' ' ' VAL . 82.5 m -94.37 139.58 22.47 Favored Pre-proline 0 N--CA 1.405 -2.678 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -57.29 144.07 92.02 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.393 2.062 . . . . 0.0 110.483 177.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.437 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 35.0 p80 -51.73 -41.1 61.27 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 -177.796 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -68.01 -35.0 77.57 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 -178.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.43 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 15.4 tttm -68.87 -44.65 72.88 Favored 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.465 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 63.8 mt -53.1 -45.06 53.05 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 O-C-N 123.722 0.639 . . . . 0.0 109.747 176.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.5 t -68.79 -32.31 54.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.452 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.2 t-160 -72.7 -38.99 67.34 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -175.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.9 mt -67.99 -50.75 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.675 177.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.3 mt -59.95 -30.92 69.4 Favored 'General case' 0 C--O 1.199 -1.578 0 CA-C-O 120.964 0.411 . . . . 0.0 111.414 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.428 ' O ' HD22 ' A' ' 22' ' ' LEU . 34.1 t -70.41 -26.29 63.62 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.281 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -123.53 8.5 8.96 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -172.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -99.09 122.17 41.96 Favored 'General case' 0 C--O 1.204 -1.335 0 CA-C-N 118.259 0.481 . . . . 0.0 109.744 177.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.437 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -115.42 169.96 5.78 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 CA-C-N 119.058 0.844 . . . . 0.0 109.527 177.342 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.5 -159.27 19.23 Favored Glycine 0 N--CA 1.434 -1.496 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.428 ' HB3' HD13 ' A' ' 16' ' ' LEU . 38.6 mt-10 -80.65 111.92 17.54 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.522 ' HB ' HG23 ' A' ' 17' ' ' ILE . 62.0 mt -115.42 117.39 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -173.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -90.16 111.71 22.95 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 25.7 mtm -111.05 160.39 16.9 Favored 'General case' 0 C--N 1.278 -2.505 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -121.95 125.15 45.71 Favored 'General case' 0 CA--C 1.47 -2.12 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 176.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.523 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 66.1 p -123.68 141.6 51.87 Favored 'General case' 0 C--N 1.265 -3.108 0 C-N-CA 120.195 -0.602 . . . . 0.0 110.451 -177.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.487 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.2 mtp -116.53 171.38 4.82 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.158 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -75.51 29.67 0.37 Allowed 'Trans proline' 0 C--N 1.363 1.313 0 C-N-CA 122.823 2.348 . . . . 0.0 112.431 179.007 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.487 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.47 55.19 4.25 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.235 1.414 . . . . 0.0 111.526 -179.161 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.422 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 174.566 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 CA--C 1.501 -0.931 0 CA-C-O 122.587 1.184 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.407 HG22 ' HG2' ' A' ' 87' ' ' MET . 79.8 t -125.16 130.56 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.827 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -175.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.8 m -112.21 106.02 14.5 Favored 'General case' 2 N--CA 1.371 -4.395 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 178.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 28.9 m -79.47 135.28 36.61 Favored 'General case' 0 N--CA 1.395 -3.198 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.32 -179.067 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.2 t -114.47 134.38 57.61 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.024 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.142 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.47 HD13 ' HB3' ' A' ' 81' ' ' GLU . 15.4 tp -119.65 104.49 10.31 Favored 'General case' 0 N--CA 1.396 -3.166 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 172.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.519 HG21 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -103.15 126.79 57.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.054 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -175.09 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.441 ' HG2' HH11 ' A' ' 18' ' ' ARG . 0.5 OUTLIER -95.43 122.03 37.73 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.921 -178.32 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.484 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 64.8 ttt180 -128.04 105.43 20.22 Favored Pre-proline 0 C--N 1.285 -2.226 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.05 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -52.31 -48.03 23.86 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 122.721 2.281 . . . . 0.0 113.372 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -167.93 -172.34 1.8 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.403 HD21 ' CG1' ' A' ' 79' ' ' VAL . 46.5 mt -70.04 -21.48 63.17 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -173.698 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.1 mpt_? -72.48 -13.02 61.33 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.305 0.574 . . . . 0.0 110.87 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -103.91 121.94 44.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.251 69.3 mt-30 -103.6 157.54 16.99 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 119.048 -1.061 . . . . 0.0 113.652 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.526 ' H ' HD22 ' A' ' 26' ' ' LEU . 1.5 mm? -44.77 -58.42 3.1 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 126.708 2.003 . . . . 0.0 111.704 -174.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.64 32.43 6.59 Favored Glycine 0 N--CA 1.427 -1.908 0 C-N-CA 119.86 -1.162 . . . . 0.0 112.256 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -159.24 161.45 36.02 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.1 t -119.9 124.03 45.04 Favored 'General case' 0 N--CA 1.415 -2.189 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -117.86 135.01 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.287 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -178.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -120.88 112.53 18.9 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.808 176.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.38 12.27 8.27 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 114.597 -1.183 . . . . 0.0 110.97 177.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.47 -4.86 31.25 Favored Glycine 0 C--O 1.206 -1.635 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.106 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.8 mp -109.25 126.57 66.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 122.117 -0.637 . . . . 0.0 109.617 -178.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 54.6 mt -71.21 115.05 10.5 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.804 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 25.2 t -101.21 -28.98 12.36 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.294 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -150.49 150.42 31.27 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.273 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 154.84 45.16 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -178.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.0 ttt -101.89 121.67 42.56 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.448 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 1.2 tmt_? -69.22 128.88 38.16 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.617 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.71 86.41 Favored Glycine 0 C--N 1.311 -0.83 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 -178.172 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.488 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -82.48 161.96 41.28 Favored Glycine 0 N--CA 1.433 -1.542 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -60.8 -30.12 46.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.0 98.01 Favored 'General case' 0 N--CA 1.439 -1.002 0 O-C-N 123.264 0.353 . . . . 0.0 111.07 177.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.66 -47.84 83.07 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 177.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.488 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 22.3 mtt180 -63.16 -39.67 95.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.155 -1.384 . . . . 0.0 109.23 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -64.3 -30.82 78.89 Favored Glycine 0 C--O 1.248 0.979 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.48 -178.255 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 115.61 9.89 12.14 Favored Glycine 0 N--CA 1.439 -1.137 0 C-N-CA 120.073 -1.06 . . . . 0.0 111.489 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 88.5 t -71.84 134.7 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -143.51 146.32 33.28 Favored 'General case' 0 CA--C 1.495 -1.148 0 C-N-CA 123.666 0.786 . . . . 0.0 109.674 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -67.36 144.34 14.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 CA-C-N 114.15 -1.386 . . . . 0.0 111.136 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.94 61.79 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.911 -0.661 . . . . 0.0 111.475 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -120.39 148.65 43.5 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.482 ' O ' ' HA ' ' A' ' 86' ' ' THR . 42.2 ttp180 -106.35 132.53 52.27 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.536 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.426 HD11 HG22 ' A' ' 86' ' ' THR . 18.2 mm -75.48 114.61 15.78 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 175.584 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.1 pt -101.03 -15.23 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.808 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 179.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 84' ' ' MET . 38.1 tt0 -156.37 146.12 20.99 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.449 ' CD1' HG23 ' A' ' 63' ' ' VAL . 71.5 mt -140.8 122.5 14.63 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 O-C-N 124.388 1.055 . . . . 0.0 108.521 178.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 59.32 23.18 11.61 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.708 1.203 . . . . 0.0 111.626 172.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.01 -9.96 40.05 Favored Glycine 0 N--CA 1.439 -1.14 0 C-N-CA 120.535 -0.841 . . . . 0.0 114.061 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.13 134.44 52.72 Favored 'General case' 0 CA--C 1.494 -1.203 0 CA-C-N 118.34 1.07 . . . . 0.0 110.752 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -72.53 112.59 8.72 Favored 'General case' 0 N--CA 1.423 -1.787 0 CA-C-O 121.337 0.589 . . . . 0.0 109.692 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.641 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 25.1 m -109.15 19.38 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-O 122.312 1.053 . . . . 0.0 108.932 -175.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.12 -18.6 19.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.388 -176.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.88 12.03 12.76 Favored 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.669 0.747 . . . . 0.0 109.009 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.641 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 97.3 m -83.88 136.74 41.26 Favored Pre-proline 0 N--CA 1.417 -2.083 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.44 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_exo -60.12 154.87 48.58 Favored 'Trans proline' 0 C--O 1.241 0.662 0 C-N-CA 122.928 2.419 . . . . 0.0 112.912 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -45.3 -55.7 5.65 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.715 1.606 . . . . 0.0 111.151 178.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -58.85 -43.6 90.79 Favored 'General case' 0 C--N 1.311 -1.095 0 O-C-N 124.307 1.004 . . . . 0.0 110.546 -175.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -62.21 -54.34 42.35 Favored 'General case' 0 CA--C 1.477 -1.835 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.883 -178.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 73.0 mt -52.01 -42.74 35.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 O-C-N 124.177 0.923 . . . . 0.0 110.383 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 83.6 t -71.66 -39.32 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.657 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 53.8 t60 -69.8 -41.55 74.91 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.519 0.676 . . . . 0.0 109.903 -176.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.6 mt -69.52 -44.03 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 CA-C-N 114.674 -1.148 . . . . 0.0 110.314 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 60.1 mt -59.99 -44.05 94.76 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.829 0.347 . . . . 0.0 111.086 173.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.6 t -59.16 -27.44 65.66 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 123.49 0.716 . . . . 0.0 112.216 -179.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -109.39 -2.74 17.57 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -176.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.484 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -97.68 130.82 44.65 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.478 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.403 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.5 m -128.3 179.73 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.65 -161.96 28.78 Favored Glycine 0 CA--C 1.489 -1.563 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -178.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.47 ' HB3' HD13 ' A' ' 16' ' ' LEU . 27.9 mt-10 -75.89 119.15 19.47 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 172.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.519 ' HB ' HG21 ' A' ' 17' ' ' ILE . 63.1 mt -117.19 117.63 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.711 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.246 -173.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -82.98 111.8 19.17 Favored 'General case' 0 CA--C 1.492 -1.257 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.603 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.408 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 28.4 mtm -117.55 156.54 27.9 Favored 'General case' 0 C--N 1.269 -2.914 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 173.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 35.6 mmtm -123.07 121.65 36.55 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.482 ' HA ' ' O ' ' A' ' 54' ' ' ARG . 68.3 p -116.93 141.49 48.16 Favored 'General case' 0 C--N 1.266 -3.04 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.712 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.466 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.0 mtp -119.72 170.31 7.04 Favored Pre-proline 0 C--O 1.211 -0.937 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 178.259 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.69 26.64 0.2 Allowed 'Trans proline' 0 CA--C 1.559 1.767 0 C-N-CA 122.865 2.377 . . . . 0.0 113.286 178.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.466 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.39 34.83 18.11 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.586 1.154 . . . . 0.0 111.08 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.418 -2.027 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.396 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 16.8 m120 . . . . . 0 CA--C 1.487 -1.466 0 CA-C-O 121.715 0.769 . . . . 0.0 109.619 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 86' ' ' THR . 39.9 t -141.48 126.13 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.974 0 CA-C-N 114.328 -1.306 . . . . 0.0 108.765 -175.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 85.1 m -111.42 113.44 25.89 Favored 'General case' 2 N--CA 1.376 -4.137 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 176.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.6 m -85.23 137.94 32.66 Favored 'General case' 0 N--CA 1.398 -3.07 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.4 t -118.01 139.22 46.04 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.955 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.466 HD11 ' O ' ' A' ' 82' ' ' ILE . 19.4 tp -121.14 112.46 18.71 Favored 'General case' 0 N--CA 1.383 -3.803 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.976 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.47 HD12 HG22 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -98.61 122.44 50.31 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 N-CA-C 106.949 -1.5 . . . . 0.0 106.949 176.314 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.7 mtp180 -107.18 102.07 11.42 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-O 122.661 1.22 . . . . 0.0 109.276 173.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.498 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 74.1 ttt180 -103.75 109.46 62.18 Favored Pre-proline 0 C--N 1.272 -2.802 0 CA-C-N 112.523 -2.126 . . . . 0.0 109.716 -176.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -54.11 -50.8 12.34 Favored 'Trans proline' 0 CA--C 1.542 0.904 0 C-N-CA 122.602 2.201 . . . . 0.0 111.993 178.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -164.88 -172.57 2.64 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.41 HD21 ' CG1' ' A' ' 79' ' ' VAL . 55.6 mt -69.01 -17.26 63.89 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -173.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 -64.55 -23.04 67.14 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.3 0.571 . . . . 0.0 110.676 176.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -105.85 113.16 26.54 Favored 'General case' 0 N--CA 1.422 -1.859 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -178.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -92.14 161.93 14.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.524 ' H ' HD23 ' A' ' 26' ' ' LEU . 0.2 OUTLIER -52.75 -57.11 11.22 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 124.467 1.107 . . . . 0.0 110.662 -173.565 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.57 23.92 10.57 Favored Glycine 0 N--CA 1.434 -1.486 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.861 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -145.94 155.54 42.92 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.0 m -108.6 137.06 47.16 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.92 136.89 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-O 121.49 0.662 . . . . 0.0 110.622 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.41 121.15 28.37 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 176.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 63.56 4.27 1.74 Allowed 'General case' 0 N--CA 1.503 2.197 0 C-N-CA 125.101 1.36 . . . . 0.0 111.983 -172.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 104.58 1.07 43.34 Favored Glycine 0 N--CA 1.438 -1.205 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -174.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -102.35 124.05 56.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.508 HD11 HG13 ' A' ' 49' ' ' VAL . 68.1 mt -65.76 117.14 5.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 C-N-CA 124.184 0.994 . . . . 0.0 110.576 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.8 t -101.55 -28.33 12.6 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.851 -175.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.1 t -154.56 156.58 36.86 Favored 'General case' 0 C--O 1.246 0.876 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 57.5 tp -134.43 140.11 46.02 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 123.624 0.77 . . . . 0.0 109.826 -178.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.3 tpt -91.89 127.0 37.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -76.39 135.33 39.48 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -178.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.39 1.06 86.26 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 121.217 -0.516 . . . . 0.0 111.958 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -93.6 167.52 28.59 Favored Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.8 pt -56.75 -36.42 49.16 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.96 0 N-CA-C 113.226 0.825 . . . . 0.0 113.226 178.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -59.65 -37.61 79.17 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -178.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -61.26 -49.26 77.79 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.096 0.95 . . . . 0.0 108.822 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -76.77 -16.32 59.51 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 114.199 -1.364 . . . . 0.0 111.198 -176.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.59 -19.55 70.84 Favored Glycine 0 N--CA 1.432 -1.618 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.603 176.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.74 16.99 20.43 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.239 177.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.508 HG13 HD11 ' A' ' 35' ' ' ILE . 51.0 t -69.5 133.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 CA-C-O 120.922 0.391 . . . . 0.0 110.561 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 20.9 mmt180 -132.38 137.03 47.2 Favored 'General case' 0 CA--C 1.484 -1.577 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.335 178.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.7 t -72.23 147.51 10.32 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.68 0 CA-C-N 113.913 -1.494 . . . . 0.0 110.115 -178.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.0 23.38 45.5 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.505 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 17.1 m-70 -121.83 139.62 53.39 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.199 -0.5 . . . . 0.0 111.377 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.45 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 9.0 ttm180 -94.39 120.82 35.2 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.227 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 41.6 mt -76.24 122.09 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.9 pt -102.61 -14.5 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.552 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.251 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.5 tt0 -161.38 142.88 11.56 Favored 'General case' 0 CA--C 1.485 -1.531 0 C-N-CA 120.046 -0.661 . . . . 0.0 110.148 -174.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.441 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 75.4 mt -133.26 123.06 46.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 73.38 -21.18 0.26 Allowed 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.988 1.315 . . . . 0.0 112.663 172.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.418 ' H ' ' C ' ' A' ' 58' ' ' ILE . . . 143.42 -8.31 2.09 Favored Glycine 0 N--CA 1.438 -1.23 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -175.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 20.4 pt20 -107.87 123.48 48.65 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 m -69.79 111.76 5.77 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 121.512 0.672 . . . . 0.0 109.71 179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.455 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.0 m -103.47 16.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 CA-C-O 122.062 0.934 . . . . 0.0 109.346 -175.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -71.7 -17.91 19.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.56 -179.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.69 11.92 21.08 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.15 -0.932 . . . . 0.0 109.206 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.455 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.5 m -101.9 137.81 19.62 Favored Pre-proline 0 N--CA 1.408 -2.557 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.415 ' O ' HG13 ' A' ' 71' ' ' ILE . 73.9 Cg_endo -76.64 168.08 24.32 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 122.58 2.186 . . . . 0.0 112.551 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -44.62 -55.01 5.55 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 124.977 1.311 . . . . 0.0 111.617 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -56.82 -43.61 81.21 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.352 1.032 . . . . 0.0 110.824 -173.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.0 mtpt -73.54 -45.89 50.82 Favored 'General case' 0 CA--C 1.485 -1.521 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.415 HG13 ' O ' ' A' ' 67' ' ' PRO . 61.7 mt -54.67 -39.86 48.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 121.135 0.493 . . . . 0.0 109.741 178.402 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.74 -37.59 69.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.479 177.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -64.59 -39.75 94.29 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -177.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.9 mt -71.06 -53.34 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.675 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.979 -179.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.7 mt -56.39 -41.77 76.81 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 10.8 t -63.0 -29.42 70.81 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 123.336 0.655 . . . . 0.0 111.71 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -104.63 -13.39 15.98 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.498 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.87 133.99 34.8 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.316 -0.554 . . . . 0.0 112.494 -174.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.41 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.5 m -137.44 175.81 8.79 Favored 'Isoleucine or valine' 0 C--O 1.248 1.02 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.45 -161.94 19.75 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -77.29 107.76 9.93 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 173.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.466 ' O ' HD11 ' A' ' 16' ' ' LEU . 82.3 mt -107.86 116.67 51.83 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -174.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -97.78 110.2 22.82 Favored 'General case' 0 CA--C 1.453 -2.753 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.469 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 11.3 ttp -112.91 141.38 46.81 Favored 'General case' 1 C--N 1.242 -4.097 0 N-CA-C 105.739 -1.949 . . . . 0.0 105.739 -174.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm -121.42 130.39 53.56 Favored 'General case' 0 CA--C 1.452 -2.805 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 -177.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.505 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 38.5 p -126.34 153.17 45.25 Favored 'General case' 0 C--N 1.275 -2.656 0 O-C-N 123.532 0.52 . . . . 0.0 110.015 -174.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.509 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.8 mtp -122.08 168.76 10.78 Favored Pre-proline 0 C--N 1.301 -1.526 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 176.354 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.94 22.33 0.31 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 123.137 2.558 . . . . 0.0 112.595 178.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.509 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 73.28 3.51 4.64 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 126.075 1.75 . . . . 0.0 113.645 177.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.609 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 175.619 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.2 m120 . . . . . 0 CA--C 1.491 -1.304 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.451 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 55.7 t -128.58 129.68 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.628 -175.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.3 m -117.77 113.73 22.26 Favored 'General case' 0 N--CA 1.391 -3.392 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.602 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.3 m -81.42 128.83 34.29 Favored 'General case' 0 N--CA 1.398 -3.042 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.333 -178.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.423 HG13 ' CG2' ' A' ' 49' ' ' VAL . 53.1 t -110.2 136.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.767 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.058 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.444 HD12 ' HB3' ' A' ' 81' ' ' GLU . 21.3 tp -119.07 109.37 15.83 Favored 'General case' 0 N--CA 1.384 -3.767 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 172.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.458 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.7 136.07 31.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -115.45 103.75 11.07 Favored 'General case' 0 C--N 1.287 -2.13 0 CA-C-O 122.195 0.998 . . . . 0.0 110.796 178.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.422 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 66.0 ttt180 -103.12 113.42 65.85 Favored Pre-proline 0 C--N 1.283 -2.292 0 CA-C-N 113.408 -1.724 . . . . 0.0 109.952 -175.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.8 -56.06 2.49 Favored 'Trans proline' 0 CA--C 1.552 1.414 0 C-N-CA 122.937 2.425 . . . . 0.0 113.991 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.55 -175.59 5.49 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.588 HD21 ' CG1' ' A' ' 79' ' ' VAL . 61.3 mt -71.06 -17.87 62.58 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -173.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -79.0 -11.19 60.0 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 121.618 0.723 . . . . 0.0 111.04 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -97.66 143.01 28.75 Favored 'General case' 0 N--CA 1.403 -2.799 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -97.07 -157.27 0.58 Allowed 'General case' 0 C--N 1.26 -3.325 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.418 HD22 ' N ' ' A' ' 26' ' ' LEU . 1.3 mm? -93.83 -51.24 4.98 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 177.007 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.25 6.47 Favored Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.003 177.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -149.26 157.18 43.13 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.5 m -105.44 121.92 44.91 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 178.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.28 130.72 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.757 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -111.0 102.44 10.91 Favored 'General case' 0 C--N 1.287 -2.132 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 178.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 67.23 14.84 9.87 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.16 175.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.52 -3.17 23.39 Favored Glycine 0 N--CA 1.438 -1.208 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.94 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -114.48 122.27 68.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 O-C-N 122.389 -0.477 . . . . 0.0 109.869 -179.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.405 HD11 HG12 ' A' ' 49' ' ' VAL . 55.5 mt -65.24 111.22 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 123.647 0.779 . . . . 0.0 109.475 179.032 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -105.6 -19.41 13.78 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.988 -176.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 m -149.2 150.42 32.59 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 121.667 -0.645 . . . . 0.0 109.84 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.0 tp -135.63 141.51 45.07 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 120.88 0.371 . . . . 0.0 110.738 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.7 ttt -82.55 103.43 12.07 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -79.51 107.14 12.06 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.535 0.683 . . . . 0.0 110.082 -174.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.23 11.35 Favored Glycine 0 N--CA 1.433 -1.552 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -175.172 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.77 178.49 53.68 Favored Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.097 -0.551 . . . . 0.0 111.782 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.404 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.5 OUTLIER -58.1 -41.15 79.88 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.927 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -177.479 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.74 -37.91 88.44 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.635 0.255 . . . . 0.0 111.616 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -61.78 -46.4 89.71 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.9 mtt-85 -74.77 -25.1 58.84 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.615 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.5 -19.2 79.93 Favored Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.455 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.65 7.88 29.13 Favored Glycine 0 CA--C 1.507 -0.44 0 C-N-CA 120.137 -1.03 . . . . 0.0 112.256 177.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.423 ' CG2' HG13 ' A' ' 15' ' ' VAL . 73.2 t -73.58 135.47 27.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.1 mmt-85 -137.72 155.42 49.11 Favored 'General case' 0 CA--C 1.492 -1.283 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 176.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 74.1 t -80.7 139.38 18.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.382 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.141 -175.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.33 6.08 51.43 Favored Glycine 0 CA--C 1.497 -1.034 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.517 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 74.8 m-70 -106.23 142.88 35.17 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 115.099 -0.55 . . . . 0.0 111.228 179.234 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.474 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 39.2 ttm180 -99.18 132.66 44.34 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 171.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 28.0 mt -85.68 123.37 39.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.467 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.415 HD12 HG23 ' A' ' 56' ' ' ILE . 26.6 pt -102.99 -12.92 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.199 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.291 -179.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 84' ' ' MET . 36.9 tt0 -154.35 141.68 19.6 Favored 'General case' 0 CA--C 1.479 -1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -178.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.45 ' CD1' HG23 ' A' ' 63' ' ' VAL . 71.8 mt -140.91 124.4 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 124.407 1.067 . . . . 0.0 108.155 177.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 68.55 13.92 9.01 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.892 0.853 . . . . 0.0 110.287 171.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.7 -2.73 49.07 Favored Glycine 0 N--CA 1.437 -1.25 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.934 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.44 ' O ' HG11 ' A' ' 63' ' ' VAL . 20.4 pt20 -112.85 130.98 55.9 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.617 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 33.2 t -68.38 114.23 6.64 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.604 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.7 m -108.84 17.08 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 CA-C-O 121.884 0.85 . . . . 0.0 109.394 -176.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -71.34 -15.22 18.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.841 -1.072 . . . . 0.0 112.04 -175.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -120.01 7.31 10.86 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.216 0.531 . . . . 0.0 109.568 175.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.604 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.9 m -80.8 138.07 50.4 Favored Pre-proline 0 N--CA 1.418 -2.042 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.243 -177.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.98 157.27 44.64 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 123.081 2.52 . . . . 0.0 113.223 178.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -45.96 -55.86 6.24 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 125.972 1.709 . . . . 0.0 110.61 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -54.09 -51.83 62.9 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 124.492 1.117 . . . . 0.0 110.813 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.9 mptt -58.93 -54.0 52.09 Favored 'General case' 0 CA--C 1.486 -1.482 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.812 -176.427 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 70.4 mt -50.71 -43.28 23.9 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 124.312 1.007 . . . . 0.0 110.358 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.0 t -73.2 -36.86 51.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.744 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -73.45 -37.69 65.73 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.348 0.594 . . . . 0.0 109.903 -175.097 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.1 mt -68.53 -47.64 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.307 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 59.2 mt -58.28 -40.32 81.59 Favored 'General case' 0 C--O 1.212 -0.905 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.492 176.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.3 t -62.25 -26.99 68.69 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -105.98 -17.3 14.39 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.422 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.9 127.25 35.97 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.688 -176.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.588 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.8 m -127.53 -179.38 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.11 -155.61 24.58 Favored Glycine 0 CA--C 1.493 -1.292 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.444 ' HB3' HD12 ' A' ' 16' ' ' LEU . 45.3 mt-10 -77.69 108.52 10.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 174.741 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.458 ' HB ' HG23 ' A' ' 17' ' ' ILE . 64.6 mt -109.63 117.72 55.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -176.154 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 39.8 m-70 -93.05 116.93 29.5 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 -178.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.473 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.0 mtm -120.2 156.84 30.32 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 177.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.451 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 68.8 mmtt -121.47 123.81 42.93 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 176.35 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.517 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 72.1 p -119.36 139.84 51.33 Favored 'General case' 0 C--N 1.27 -2.875 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.208 -177.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.484 ' C ' ' H ' ' A' ' 89' ' ' ALA . 82.9 mtp -120.85 171.72 5.57 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -72.1 24.91 0.26 Allowed 'Trans proline' 0 N--CA 1.497 1.728 0 C-N-CA 123.09 2.527 . . . . 0.0 112.88 177.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.484 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.33 20.59 4.93 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 125.127 1.371 . . . . 0.0 112.803 177.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.762 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.021 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 CA--C 1.49 -1.344 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -130.66 133.7 63.06 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 CA-C-O 122.315 1.055 . . . . 0.0 111.861 -172.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.4 m -127.9 121.94 31.27 Favored 'General case' 0 N--CA 1.392 -3.355 0 CA-C-N 113.262 -1.79 . . . . 0.0 106.864 176.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 m -82.82 141.92 31.93 Favored 'General case' 0 N--CA 1.404 -2.774 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.574 -176.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 56.1 t -116.47 136.65 52.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.067 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 176.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.403 HD11 ' O ' ' A' ' 82' ' ' ILE . 29.1 tp -122.1 119.73 32.2 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-O 121.961 0.886 . . . . 0.0 109.886 175.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.46 HG22 HD12 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -97.49 134.13 36.68 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.098 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.418 178.594 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.02 101.34 10.16 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 171.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.525 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.0 ttt180 -108.31 107.97 60.67 Favored Pre-proline 0 C--N 1.282 -2.341 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.451 -178.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -58.03 -41.09 71.71 Favored 'Trans proline' 0 CA--C 1.546 1.117 0 C-N-CA 122.607 2.205 . . . . 0.0 113.423 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -167.17 176.64 6.67 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.53 HD21 ' CG1' ' A' ' 79' ' ' VAL . 73.1 mt -68.95 -22.39 64.13 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 125.152 1.381 . . . . 0.0 111.213 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.416 ' NE ' ' HA ' ' A' ' 23' ' ' ARG . 7.3 mmp_? -59.11 -21.89 59.98 Favored 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.058 0.848 . . . . 0.0 110.233 174.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -103.89 118.35 36.49 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 104.899 -2.26 . . . . 0.0 104.899 178.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.22 168.79 10.69 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.48 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.4 OUTLIER -64.05 -59.85 3.97 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.221 0.534 . . . . 0.0 111.282 -171.014 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.434 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 103.45 34.63 3.82 Favored Glycine 0 N--CA 1.431 -1.658 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.287 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -155.43 157.39 36.94 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.6 m -117.34 136.04 53.42 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.85 128.15 64.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.772 0.796 . . . . 0.0 112.923 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -121.45 115.44 22.88 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.454 176.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 68.99 2.6 3.65 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 125.538 1.535 . . . . 0.0 112.283 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 118.42 -12.6 12.38 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -96.43 128.17 47.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 O-C-N 122.385 -0.479 . . . . 0.0 110.548 -179.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.425 HD11 HG11 ' A' ' 49' ' ' VAL . 72.9 mt -68.31 114.45 5.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 124.458 1.103 . . . . 0.0 109.608 176.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.5 t -98.63 -23.78 15.34 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.006 -177.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.8 p -156.52 152.06 26.87 Favored 'General case' 0 C--N 1.322 -0.629 0 O-C-N 122.297 -0.252 . . . . 0.0 111.316 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.434 HD12 ' O ' ' A' ' 27' ' ' GLY . 48.7 tp -125.91 148.55 49.18 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 124.356 1.062 . . . . 0.0 109.072 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -105.88 123.52 48.09 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.376 0.608 . . . . 0.0 110.692 -179.312 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 20.4 tpp85 -60.36 130.84 48.59 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.23 176.587 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.05 5.99 89.25 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.856 178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.58 161.2 27.15 Favored Glycine 0 N--CA 1.423 -2.179 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 pt -60.24 -32.61 51.12 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.98 0 C-N-CA 120.764 -0.375 . . . . 0.0 111.947 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -60.83 -38.85 86.88 Favored 'General case' 0 N--CA 1.443 -0.779 0 C-N-CA 122.986 0.514 . . . . 0.0 111.812 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -64.31 -38.88 92.6 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.759 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -90.48 -0.41 57.65 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.902 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.31 -19.56 38.35 Favored Glycine 0 N--CA 1.433 -1.504 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 175.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.16 9.01 26.6 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.103 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.425 HG11 HD11 ' A' ' 35' ' ' ILE . 60.0 t -69.82 140.01 19.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.458 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 13.9 mmt180 -145.08 141.8 29.14 Favored 'General case' 0 CA--C 1.49 -1.354 0 C-N-CA 123.406 0.682 . . . . 0.0 110.989 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.74 139.9 20.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.783 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.18 14.29 59.17 Favored Glycine 0 C--N 1.305 -1.147 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.531 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -108.71 133.85 52.23 Favored 'General case' 0 N--CA 1.428 -1.575 0 CA-C-O 121.32 0.581 . . . . 0.0 111.611 178.284 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -92.76 114.79 27.44 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.492 -1.231 . . . . 0.0 108.085 177.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.413 HG12 HG22 ' A' ' 86' ' ' THR . 30.2 mt -78.54 122.9 34.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 37.2 pt -106.43 -11.79 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.505 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.568 179.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.449 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.8 tt0 -154.76 144.91 21.87 Favored 'General case' 0 CA--C 1.479 -1.778 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.107 -177.015 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.448 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -141.82 125.15 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 174.57 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 69.43 -2.72 1.8 Allowed 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.991 1.317 . . . . 0.0 112.846 172.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.43 -4.11 10.25 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.968 -178.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -112.28 130.68 55.86 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 p -73.0 108.3 5.82 Favored 'General case' 0 N--CA 1.425 -1.68 0 CA-C-O 121.795 0.807 . . . . 0.0 110.285 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.547 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.6 m -98.86 16.52 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-O 122.271 1.034 . . . . 0.0 110.053 -172.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.6 p -75.58 -10.27 13.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.072 -177.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.95 16.33 10.88 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.063 -0.972 . . . . 0.0 108.495 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.7 m -103.26 135.22 19.43 Favored Pre-proline 0 N--CA 1.407 -2.577 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.49 159.81 52.18 Favored 'Trans proline' 0 C--O 1.244 0.802 0 C-N-CA 122.258 1.972 . . . . 0.0 112.596 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -43.15 -54.84 4.22 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.87 1.668 . . . . 0.0 112.177 -178.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -56.39 -47.03 79.79 Favored 'General case' 0 CA--C 1.497 -1.067 0 O-C-N 124.027 0.83 . . . . 0.0 110.663 -175.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.432 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 12.6 mptt -63.76 -54.21 38.92 Favored 'General case' 0 N--CA 1.426 -1.639 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.682 -177.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.5 mt -51.08 -44.75 29.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 O-C-N 124.098 0.874 . . . . 0.0 110.112 179.335 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.4 t -71.53 -36.82 61.67 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.746 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -72.81 -40.57 65.74 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -174.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 46.0 mt -66.0 -46.26 88.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.895 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.9 mt -58.5 -41.04 84.47 Favored 'General case' 0 C--O 1.214 -0.811 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.554 175.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 50.8 m -63.06 -27.61 69.52 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.2 m-80 -104.45 -10.65 17.55 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -175.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.525 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.39 133.4 36.68 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.76 -178.409 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.53 ' CG1' HD21 ' A' ' 22' ' ' LEU . 3.1 m -129.69 -178.57 2.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.583 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 175.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.57 -154.82 33.14 Favored Glycine 0 CA--C 1.488 -1.624 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -73.51 112.64 9.79 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 121.592 0.711 . . . . 0.0 109.722 174.28 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.403 ' O ' HD11 ' A' ' 16' ' ' LEU . 74.9 mt -118.11 117.47 54.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.358 0 CA-C-N 115.328 -0.851 . . . . 0.0 108.711 -177.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -88.38 129.98 35.27 Favored 'General case' 0 CA--C 1.473 -2.013 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.201 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.449 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.3 mtm -129.19 153.3 47.87 Favored 'General case' 0 C--N 1.262 -3.209 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 171.148 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 62.9 mmtt -119.18 122.61 42.39 Favored 'General case' 0 C--N 1.268 -2.975 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 177.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 52.7 p -121.82 143.61 49.3 Favored 'General case' 0 C--N 1.267 -2.992 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.102 -177.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.583 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.3 mtp -111.22 164.07 15.85 Favored Pre-proline 0 C--N 1.303 -1.421 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 178.152 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -78.33 29.68 0.45 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 122.786 2.324 . . . . 0.0 109.3 172.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.583 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.97 11.5 8.39 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 127.015 2.126 . . . . 0.0 112.017 -178.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.204 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.419 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 88.9 m-20 . . . . . 0 CA--C 1.502 -0.894 0 CA-C-O 121.844 0.831 . . . . 0.0 109.853 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.4 t -122.79 122.19 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 CA-C-O 121.885 0.85 . . . . 0.0 109.518 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.9 m -108.49 108.81 19.89 Favored 'General case' 0 C--N 1.246 -3.916 0 CA-C-N 113.332 -1.758 . . . . 0.0 107.133 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.9 m -79.43 132.63 36.43 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.435 178.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.2 t -111.17 140.65 29.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.335 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 15.1 tp -122.83 112.76 18.27 Favored 'General case' 0 N--CA 1.379 -3.983 0 C-N-CA 119.286 -0.966 . . . . 0.0 108.814 172.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.49 HG21 HD11 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -98.89 129.21 49.58 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.968 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.58 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -111.84 102.78 11.03 Favored 'General case' 0 N--CA 1.406 -2.64 0 CA-C-O 122.506 1.145 . . . . 0.0 109.667 174.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.595 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.3 ttt180 -112.38 110.79 52.9 Favored Pre-proline 0 C--N 1.276 -2.609 0 CA-C-N 112.752 -2.022 . . . . 0.0 110.718 -176.596 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -57.46 -51.88 7.49 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 122.567 2.178 . . . . 0.0 112.577 178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.458 ' OD2' ' HG2' ' A' ' 23' ' ' ARG . 1.0 OUTLIER -158.56 -174.0 4.57 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.838 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.6 mt -72.08 -14.16 61.78 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 -174.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.458 ' HG2' ' OD2' ' A' ' 21' ' ' ASP . 18.5 mmt180 -66.31 -23.95 66.46 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -94.4 110.18 21.98 Favored 'General case' 0 CA--C 1.48 -1.72 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 176.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -92.19 155.44 18.01 Favored 'General case' 0 C--N 1.281 -2.388 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.806 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.53 ' H ' HD21 ' A' ' 26' ' ' LEU . 1.2 mm? -50.78 -61.76 2.02 Favored 'General case' 0 C--O 1.237 0.428 0 O-C-N 124.913 1.383 . . . . 0.0 110.642 -175.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.48 -10.77 35.95 Favored Glycine 0 N--CA 1.434 -1.496 0 C-N-CA 120.66 -0.781 . . . . 0.0 111.579 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.411 ' CE1' ' HB3' ' A' ' 26' ' ' LEU . 50.6 p90 -112.89 151.76 30.1 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.023 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 t -107.08 122.38 46.36 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -112.44 131.35 64.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 CA-C-O 121.576 0.703 . . . . 0.0 112.18 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -131.52 122.14 25.65 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 114.495 -1.229 . . . . 0.0 107.843 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.463 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 88.0 m-20 66.89 13.98 9.65 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-O 121.902 0.858 . . . . 0.0 111.752 177.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.46 -6.72 65.71 Favored Glycine 0 N--CA 1.432 -1.616 0 CA-C-N 115.175 -0.92 . . . . 0.0 111.313 -178.179 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.14 128.82 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-O 121.223 0.535 . . . . 0.0 110.22 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.11 111.01 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.221 175.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -95.57 -27.99 15.07 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.645 -175.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.4 m -150.47 158.91 44.69 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 121.959 -0.463 . . . . 0.0 110.072 -177.65 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.2 tp -142.85 135.44 27.71 Favored 'General case' 0 C--O 1.239 0.529 0 O-C-N 123.835 0.709 . . . . 0.0 111.258 -178.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ttt -82.3 121.92 27.29 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 176.125 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -74.33 122.86 23.57 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.056 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.17 -3.22 72.63 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -177.462 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -83.47 170.31 48.43 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.7 pt -63.03 -37.29 78.98 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.399 0 CA-C-N 117.311 0.556 . . . . 0.0 111.899 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.23 -45.56 75.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -62.78 -43.15 99.56 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.507 0.67 . . . . 0.0 109.936 178.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -73.76 -20.25 60.55 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.125 -0.943 . . . . 0.0 111.778 -179.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.26 -19.13 57.82 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.963 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.62 15.59 22.33 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.277 -0.963 . . . . 0.0 112.456 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.403 ' O ' ' HD2' ' A' ' 50' ' ' ARG . 79.2 t -75.39 122.8 29.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 8.1 mmm180 -122.39 150.87 41.84 Favored 'General case' 0 CA--C 1.474 -1.957 0 CA-C-O 121.348 0.594 . . . . 0.0 110.416 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 78.1 t -78.25 141.4 15.53 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.772 0 CA-C-N 114.018 -1.446 . . . . 0.0 109.424 -176.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.85 30.03 33.22 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -175.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.2 m170 -123.31 135.06 54.03 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.803 -0.698 . . . . 0.0 109.915 177.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.7 ttp180 -97.91 123.89 42.1 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 177.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.435 HG12 HG22 ' A' ' 86' ' ' THR . 32.6 mt -79.04 127.12 39.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 O-C-N 123.852 0.72 . . . . 0.0 109.779 178.087 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 41.6 pt -109.75 -13.93 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.95 143.11 16.74 Favored 'General case' 0 CA--C 1.483 -1.634 0 C-N-CA 120.025 -0.67 . . . . 0.0 109.314 -175.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.444 ' CD1' HG23 ' A' ' 63' ' ' VAL . 66.3 mt -137.71 127.84 36.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 70.84 -18.66 0.25 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.846 1.259 . . . . 0.0 113.485 172.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 58' ' ' ILE . . . 130.59 8.41 3.16 Favored Glycine 0 C--N 1.299 -1.52 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -176.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -118.74 139.85 50.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 176.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.7 t -77.44 108.11 10.36 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.515 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.8 m -101.04 8.57 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.231 0 CA-C-O 121.966 0.889 . . . . 0.0 109.384 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.03 -12.19 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.783 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.156 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.19 14.52 16.97 Favored 'General case' 0 N--CA 1.437 -1.093 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.735 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.515 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 80.3 m -102.9 138.63 19.62 Favored Pre-proline 0 N--CA 1.409 -2.511 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.401 ' O ' HG13 ' A' ' 71' ' ' ILE . 59.4 Cg_exo -49.94 139.9 32.44 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.813 2.342 . . . . 0.0 110.751 176.442 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.463 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 32.6 p80 -51.66 -42.76 62.35 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -176.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -69.26 -37.59 77.98 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.665 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 tttm -60.13 -44.88 94.58 Favored 'General case' 0 CA--C 1.492 -1.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.907 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.401 HG13 ' O ' ' A' ' 67' ' ' PRO . 66.1 mt -52.05 -44.5 39.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 O-C-N 124.006 0.816 . . . . 0.0 109.762 178.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 96.8 t -67.24 -34.92 72.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.69 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.3 t-160 -74.29 -39.51 62.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 54.1 mt -65.7 -49.16 79.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.84 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 77.6 mt -57.12 -41.14 78.46 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.105 0.479 . . . . 0.0 110.985 175.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.5 t -57.08 -36.7 70.9 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 123.808 0.843 . . . . 0.0 111.53 178.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -98.6 -11.45 22.11 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -176.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.595 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -86.89 131.01 34.23 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -173.501 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 80' ' ' GLY . 1.1 m -134.64 179.01 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.415 ' N ' HG23 ' A' ' 79' ' ' VAL . . . 95.99 -159.74 22.18 Favored Glycine 0 CA--C 1.496 -1.13 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.98 108.11 12.22 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 171.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 88.6 mt -104.47 117.27 49.78 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.471 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -175.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -100.02 111.3 23.6 Favored 'General case' 0 CA--C 1.479 -1.788 0 N-CA-C 105.014 -2.217 . . . . 0.0 105.014 -176.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 23.2 ttp -122.95 148.63 45.26 Favored 'General case' 0 C--N 1.257 -3.45 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -173.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 29.0 mmtm -117.88 128.36 54.75 Favored 'General case' 0 CA--C 1.474 -1.971 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -177.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 54.0 p -127.74 143.39 51.14 Favored 'General case' 0 C--N 1.277 -2.567 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.429 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.552 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.5 mtp -112.9 168.72 7.27 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 177.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 12.8 Cg_exo -74.48 30.05 0.34 Allowed 'Trans proline' 0 N--CA 1.489 1.238 0 C-N-CA 122.997 2.465 . . . . 0.0 111.578 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.552 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 68.31 23.46 7.69 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 126.308 1.843 . . . . 0.0 111.815 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.419 -1.984 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.991 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.504 -0.819 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.8 m 61.22 77.13 0.34 Allowed 'General case' 0 C--O 1.246 0.895 0 O-C-N 124.285 0.99 . . . . 0.0 110.166 -178.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 50.2 mtt -119.2 141.6 48.74 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.744 -174.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.68 -125.65 8.47 Favored Glycine 0 CA--C 1.487 -1.665 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.254 169.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -96.54 91.74 5.92 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.408 0.623 . . . . 0.0 110.588 -177.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t -128.59 126.81 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.373 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.465 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.8 m -118.09 107.24 13.75 Favored 'General case' 0 C--N 1.251 -3.716 0 CA-C-N 113.628 -1.624 . . . . 0.0 107.661 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.9 m -79.07 140.74 37.81 Favored 'General case' 0 N--CA 1.401 -2.908 0 CA-C-N 115.487 -0.778 . . . . 0.0 109.8 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -122.45 136.68 58.49 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.117 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.322 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.442 ' O ' ' HA2' ' A' ' 47' ' ' GLY . 29.9 tp -115.64 115.96 27.29 Favored 'General case' 0 N--CA 1.396 -3.152 0 C-N-CA 120.205 -0.598 . . . . 0.0 109.446 173.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.493 HG22 HD12 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -98.59 130.95 46.66 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.05 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.661 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 55.5 mtp180 -115.57 101.38 8.81 Favored 'General case' 0 N--CA 1.408 -2.572 0 CA-C-O 122.446 1.117 . . . . 0.0 108.829 171.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.457 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.3 ttt180 -100.79 119.48 58.28 Favored Pre-proline 0 C--N 1.275 -2.656 0 CA-C-N 112.939 -1.937 . . . . 0.0 111.896 -174.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.89 -48.48 12.43 Favored 'Trans proline' 0 CA--C 1.545 1.029 0 C-N-CA 122.92 2.414 . . . . 0.0 112.983 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -165.92 -175.15 3.28 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.4 HD21 HG13 ' A' ' 79' ' ' VAL . 59.0 mt -73.7 -11.73 60.5 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 115.064 1.505 . . . . 0.0 115.064 -173.023 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -86.68 -12.42 48.43 Favored 'General case' 0 C--N 1.292 -1.901 0 CA-C-O 121.743 0.782 . . . . 0.0 111.0 177.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -97.25 89.93 4.93 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 173.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -77.47 161.76 27.7 Favored 'General case' 0 N--CA 1.415 -2.218 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.094 -177.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.516 ' H ' HD22 ' A' ' 26' ' ' LEU . 1.4 mm? -45.89 -48.84 16.03 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 125.444 1.498 . . . . 0.0 111.55 -171.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.08 13.65 45.17 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 119.714 -1.231 . . . . 0.0 111.568 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -137.31 148.57 46.44 Favored 'General case' 0 N--CA 1.426 -1.643 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 175.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.2 m -96.46 122.54 39.46 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -120.52 143.22 33.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -130.88 114.7 15.6 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 173.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.425 ' OD1' ' HB2' ' A' ' 68' ' ' HIS . 93.3 m-20 64.9 14.45 9.26 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.563 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.55 -3.21 34.46 Favored Glycine 0 N--CA 1.434 -1.48 0 C-N-CA 120.52 -0.847 . . . . 0.0 111.737 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.58 124.55 66.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 O-C-N 121.964 -0.727 . . . . 0.0 110.769 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 61.9 mt -69.05 116.72 10.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 114.513 -1.221 . . . . 0.0 110.576 -178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -97.59 -32.23 11.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.583 -177.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.9 t -155.01 153.47 31.04 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.3 tp -132.13 130.85 41.69 Favored 'General case' 0 C--O 1.243 0.718 0 C-N-CA 123.197 0.599 . . . . 0.0 110.478 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -84.75 115.54 22.76 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 175.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -70.84 134.96 47.77 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -177.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.14 -2.72 75.69 Favored Glycine 0 C--N 1.302 -1.317 0 C-N-CA 121.193 -0.527 . . . . 0.0 111.802 -175.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.04 168.6 31.45 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.0 pt -57.15 -36.82 52.88 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.51 78.13 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -66.28 -41.46 89.82 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -66.91 -31.76 72.57 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 114.254 -1.339 . . . . 0.0 109.891 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -70.93 -27.3 72.46 Favored Glycine 0 N--CA 1.44 -1.1 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.822 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.6 21.46 10.47 Favored Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 73.8 t -77.74 137.39 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 48.8 mmt-85 -136.07 146.89 47.55 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.92 140.51 19.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 CA-C-N 114.281 -1.327 . . . . 0.0 109.708 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 25.11 27.85 Favored Glycine 0 N--CA 1.431 -1.643 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 -178.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.8 m170 -119.18 144.95 46.4 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.901 -0.65 . . . . 0.0 110.227 176.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 43.4 ttp180 -107.21 124.06 49.19 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.338 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.434 HD11 HG22 ' A' ' 86' ' ' THR . 28.7 mm -72.96 115.09 13.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.2 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.431 HG22 ' SD ' ' A' ' 87' ' ' MET 0.275 2.1 pp -103.65 -18.08 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.752 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.416 ' O ' ' HA ' ' A' ' 84' ' ' MET . 33.1 tt0 -154.0 146.77 24.29 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.442 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.5 mt -139.47 119.47 13.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 O-C-N 124.25 0.969 . . . . 0.0 109.153 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.477 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 96.7 m-20 46.9 33.25 2.13 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 115.186 1.55 . . . . 0.0 115.186 178.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.84 -0.99 41.7 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.087 -1.054 . . . . 0.0 114.035 175.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -119.67 125.78 49.53 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 117.834 0.817 . . . . 0.0 109.95 175.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -69.28 110.76 4.78 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.55 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.2 m -103.11 13.56 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.707 0.765 . . . . 0.0 110.089 -174.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.8 -15.38 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.747 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.355 -176.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -117.32 14.63 14.77 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.794 0.807 . . . . 0.0 109.153 176.112 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.55 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.9 m -93.64 140.28 23.04 Favored Pre-proline 0 N--CA 1.411 -2.402 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -70.16 161.72 44.95 Favored 'Trans proline' 0 CA--C 1.544 1.024 0 C-N-CA 121.862 1.708 . . . . 0.0 113.225 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.425 ' HB2' ' OD1' ' A' ' 32' ' ' ASN . 4.2 t60 -42.63 -56.28 3.19 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.994 2.118 . . . . 0.0 111.997 -178.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.84 -50.97 71.49 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.298 0.999 . . . . 0.0 110.858 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.524 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 0.0 OUTLIER -58.75 -54.01 51.92 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.361 -178.82 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.7 mt -51.81 -45.12 38.13 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 O-C-N 123.978 0.799 . . . . 0.0 110.811 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.29 -39.52 76.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.291 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.1 t60 -68.39 -37.63 80.58 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.032 0.444 . . . . 0.0 109.881 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 24.1 mt -66.44 -49.79 72.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.198 177.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 79.9 mt -62.18 -40.05 94.72 Favored 'General case' 0 C--O 1.216 -0.693 0 CA-C-O 120.891 0.377 . . . . 0.0 111.538 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -63.85 -27.3 69.07 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -107.56 -7.19 16.59 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -175.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.457 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.14 135.51 33.92 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.382 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -134.97 177.12 7.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.162 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.76 -153.53 27.23 Favored Glycine 0 CA--C 1.477 -2.289 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.1 108.24 7.71 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.477 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 89.7 mt -111.41 119.39 59.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.955 -1.021 . . . . 0.0 109.991 -176.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 31.5 m80 -98.02 116.91 31.21 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.416 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 27.7 mtm -121.11 158.83 27.06 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -123.82 123.69 41.02 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.444 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 44.1 p -120.24 149.14 42.75 Favored 'General case' 0 C--N 1.262 -3.199 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.993 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.512 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -120.15 164.69 21.08 Favored Pre-proline 0 C--N 1.291 -1.94 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 176.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -70.27 28.71 0.19 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 123.308 2.672 . . . . 0.0 112.967 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.512 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.52 11.25 5.49 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.811 1.644 . . . . 0.0 113.671 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.302 -1.468 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.065 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 . . . . . 0 C--O 1.219 -0.547 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 18.5 m -77.42 -44.17 30.04 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 17.0 ptp -113.48 165.78 12.15 Favored 'General case' 0 C--O 1.249 1.078 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.104 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.66 -145.73 16.36 Favored Glycine 0 N--CA 1.422 -2.292 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 174.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 87' ' ' MET . 40.8 m-80 -107.18 85.84 2.2 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 174.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.519 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 76.1 t -103.72 114.7 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.524 0 CA-C-N 114.32 -1.309 . . . . 0.0 108.732 -174.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 73.7 m -108.91 111.75 23.61 Favored 'General case' 2 C--N 1.223 -4.912 0 CA-C-N 112.723 -2.035 . . . . 0.0 106.89 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.6 m -80.44 140.54 35.93 Favored 'General case' 0 N--CA 1.394 -3.259 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.739 -178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.02 127.15 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.396 -3.133 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.113 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.527 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 25.6 tp -110.45 116.22 31.02 Favored 'General case' 0 N--CA 1.387 -3.583 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 172.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.454 ' CD1' ' HB ' ' A' ' 43' ' ' ILE . 0.4 OUTLIER -104.74 137.16 35.17 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.262 0 N-CA-C 106.074 -1.825 . . . . 0.0 106.074 178.16 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -109.3 104.02 13.07 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-O 121.839 0.828 . . . . 0.0 110.472 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.451 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.8 ttt180 -106.92 114.03 62.01 Favored Pre-proline 0 N--CA 1.415 -2.181 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.954 -177.021 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.88 -55.4 2.7 Favored 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 122.835 2.357 . . . . 0.0 112.982 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -161.5 -173.26 3.7 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -177.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 41.3 mt -71.01 -18.71 62.58 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -175.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 12.4 mmt-85 -61.58 -31.49 71.55 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.718 0.77 . . . . 0.0 109.544 174.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -94.45 130.69 40.72 Favored 'General case' 0 N--CA 1.419 -1.995 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -107.13 165.32 11.45 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 177.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.53 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.3 mm? -51.47 -53.63 35.34 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 124.754 1.283 . . . . 0.0 111.308 -172.446 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.407 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 99.3 32.17 5.89 Favored Glycine 0 N--CA 1.424 -2.148 0 C-N-CA 119.936 -1.126 . . . . 0.0 111.838 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -158.6 161.69 37.25 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -116.02 122.49 45.36 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -110.21 136.45 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.463 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -125.14 116.48 22.11 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.483 ' HA ' ' HB3' ' A' ' 68' ' ' HIS . 83.3 m-20 67.09 8.92 6.53 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.674 0.789 . . . . 0.0 112.336 -179.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.26 -0.93 40.45 Favored Glycine 0 N--CA 1.439 -1.136 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.86 123.43 65.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.935 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.42 HD11 HG13 ' A' ' 49' ' ' VAL . 72.6 mt -60.91 112.62 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 123.92 0.888 . . . . 0.0 110.951 178.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -83.35 -43.37 16.02 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.136 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.9 p -154.05 160.67 42.09 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.204 -179.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.407 HD12 ' O ' ' A' ' 27' ' ' GLY . 53.6 tp -125.92 133.26 51.92 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 123.773 0.67 . . . . 0.0 110.249 -178.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.8 ttt -74.31 107.33 6.41 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.1 tpt180 -60.98 119.58 8.56 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 124.375 1.07 . . . . 0.0 110.775 -176.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.63 1.42 74.17 Favored Glycine 0 N--CA 1.442 -0.911 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.116 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.65 174.44 46.46 Favored Glycine 0 C--O 1.25 1.107 0 C-N-CA 121.248 -0.501 . . . . 0.0 113.239 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.454 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.64 -33.83 64.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 112.839 0.681 . . . . 0.0 112.839 -177.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.17 -39.25 94.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.183 0.516 . . . . 0.0 110.932 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -71.45 -33.05 69.02 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 1.9 mmp_? -66.67 -33.08 74.85 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.485 172.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.87 -14.17 82.86 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.537 -0.756 . . . . 0.0 112.956 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.84 30.06 9.3 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.525 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.42 HG13 HD11 ' A' ' 35' ' ' ILE . 54.2 t -77.22 143.88 12.31 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.647 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.434 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 23.9 mmm180 -135.74 140.65 44.53 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-O 121.282 0.563 . . . . 0.0 109.745 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.8 t -73.12 143.49 13.78 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 114.232 -1.349 . . . . 0.0 110.375 -178.1 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.69 18.69 59.54 Favored Glycine 0 CA--C 1.501 -0.794 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -177.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.534 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.9 m170 -109.96 139.79 44.67 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.011 -0.594 . . . . 0.0 110.543 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 20.8 ttt180 -101.33 117.26 34.6 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.416 HG12 HG22 ' A' ' 86' ' ' THR . 33.6 mt -76.03 126.84 37.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.417 HG23 HD11 ' A' ' 56' ' ' ILE . 41.5 pt -107.78 -14.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.229 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.6 tt0 -156.28 144.6 19.87 Favored 'General case' 0 CA--C 1.491 -1.293 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.66 -173.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.417 ' CD1' HG23 ' A' ' 63' ' ' VAL . 80.6 mt -140.35 122.15 15.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 C-N-CA 124.367 1.067 . . . . 0.0 108.22 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.1 m120 65.5 4.76 2.89 Favored 'General case' 0 N--CA 1.501 2.081 0 C-N-CA 125.505 1.522 . . . . 0.0 112.671 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.96 5.5 35.39 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.418 ' O ' HG11 ' A' ' 63' ' ' VAL . 8.9 tt0 -104.79 116.32 31.81 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.466 1.106 . . . . 0.0 108.402 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.6 t -70.16 109.53 4.67 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.52 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.1 m -105.32 14.51 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.551 0 CA-C-O 121.64 0.733 . . . . 0.0 109.173 -175.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -69.51 -21.66 24.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.952 -175.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.79 -1.03 22.98 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.504 0.668 . . . . 0.0 109.91 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.52 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 90.4 m -78.96 137.04 57.52 Favored Pre-proline 0 N--CA 1.406 -2.662 0 C-N-CA 124.793 1.237 . . . . 0.0 108.755 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.2 147.18 91.87 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.051 1.834 . . . . 0.0 110.929 178.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HB3' ' HA ' ' A' ' 32' ' ' ASN . 6.7 p-80 -48.98 -39.08 25.18 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.092 0.957 . . . . 0.0 113.063 -176.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -68.64 -38.02 80.14 Favored 'General case' 0 N--CA 1.435 -1.192 0 O-C-N 123.491 0.494 . . . . 0.0 110.508 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 35.8 mttp -67.34 -46.14 74.32 Favored 'General case' 0 CA--C 1.478 -1.813 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.549 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.2 mt -53.24 -41.1 41.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 O-C-N 124.054 0.846 . . . . 0.0 109.549 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.2 t -71.75 -37.11 61.3 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.097 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -68.83 -40.67 79.34 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-O 121.315 0.579 . . . . 0.0 110.063 -176.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 37.2 mt -65.65 -51.51 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 CA-C-N 114.548 -1.206 . . . . 0.0 109.786 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.9 mt -58.45 -40.87 83.76 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.345 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -58.65 -28.61 65.85 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 123.381 0.672 . . . . 0.0 111.885 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -119.06 -6.11 10.48 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 115.16 1.541 . . . . 0.0 115.16 -172.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.451 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 130.75 36.28 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.923 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.04 177.02 6.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.5 -152.5 20.39 Favored Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.445 ' HB3' HD13 ' A' ' 16' ' ' LEU . 41.8 mt-10 -84.23 114.06 21.55 Favored 'General case' 0 N--CA 1.425 -1.724 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 174.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 65.2 mt -114.55 117.08 54.51 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.402 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -175.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -90.2 111.64 22.87 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.482 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 26.1 mtm -114.21 156.54 24.11 Favored 'General case' 0 C--N 1.269 -2.904 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 175.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.519 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 69.0 mmtt -122.48 124.6 43.97 Favored 'General case' 0 C--N 1.275 -2.671 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.534 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 43.8 p -121.61 141.22 51.32 Favored 'General case' 0 C--N 1.269 -2.935 0 C-N-CA 120.716 -0.393 . . . . 0.0 110.346 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.508 ' C ' ' H ' ' A' ' 89' ' ' ALA . 43.6 mtm -114.39 167.51 9.51 Favored Pre-proline 0 C--N 1.306 -1.296 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 72.6 Cg_endo -74.71 31.31 0.35 Allowed 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.374 2.05 . . . . 0.0 111.858 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.508 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.16 34.13 19.05 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.912 1.285 . . . . 0.0 110.66 -178.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.779 0 CA-C-N 114.142 -1.39 . . . . 0.0 107.932 178.636 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.496 -1.132 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.8 m 62.59 27.59 16.27 Favored 'General case' 0 CA--C 1.562 1.434 0 CA-C-O 122.369 1.081 . . . . 0.0 109.048 -178.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 45.6 ttm -140.78 94.49 2.72 Favored 'General case' 0 N--CA 1.439 -0.987 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -177.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.85 -99.07 0.41 Allowed Glycine 0 N--CA 1.429 -1.826 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 87' ' ' MET . 21.1 m120 -125.94 97.06 4.96 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 176.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 86' ' ' THR . 95.3 t -113.79 126.43 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.675 0 CA-C-O 121.932 0.872 . . . . 0.0 110.213 -174.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.3 m -118.62 121.02 39.19 Favored 'General case' 0 C--N 1.249 -3.79 0 CA-C-N 113.602 -1.635 . . . . 0.0 106.843 176.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -88.45 140.92 28.97 Favored 'General case' 0 N--CA 1.402 -2.871 0 CA-C-N 114.779 -1.1 . . . . 0.0 109.656 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.407 HG11 ' O ' ' A' ' 47' ' ' GLY . 54.5 t -119.0 137.78 51.87 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.594 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.463 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.464 HD12 ' HB3' ' A' ' 81' ' ' GLU . 24.5 tp -124.28 112.39 16.95 Favored 'General case' 0 N--CA 1.386 -3.653 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 172.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.439 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.01 138.75 21.84 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.946 0 N-CA-C 106.244 -1.762 . . . . 0.0 106.244 -179.364 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.28 108.98 19.77 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.463 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 67.2 ttt180 -116.58 110.08 42.98 Favored Pre-proline 0 C--N 1.284 -2.247 0 C-N-CA 120.249 -0.581 . . . . 0.0 112.024 -176.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -57.9 -41.02 73.37 Favored 'Trans proline' 0 CA--C 1.546 1.084 0 C-N-CA 122.634 2.223 . . . . 0.0 113.102 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.464 ' CG ' ' H ' ' A' ' 22' ' ' LEU . 17.6 t70 -171.71 -175.46 1.56 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -177.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.503 HD22 ' O ' ' A' ' 76' ' ' SER . 68.7 mt -81.1 -11.62 59.45 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 125.164 1.386 . . . . 0.0 110.39 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.412 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 76.8 mtt180 -73.74 -16.03 61.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.361 175.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -103.5 138.63 39.95 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -110.67 160.95 16.23 Favored 'General case' 0 C--N 1.277 -2.575 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.506 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -55.91 -55.6 30.7 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 124.635 1.209 . . . . 0.0 111.079 -172.152 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.0 19.54 14.68 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.995 -178.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -146.37 162.81 37.38 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 176.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.2 m -123.21 129.73 51.79 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -114.57 136.97 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -177.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -122.43 115.63 22.58 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 61.47 16.0 7.17 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 124.764 1.226 . . . . 0.0 112.091 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.92 3.6 45.59 Favored Glycine 0 C--O 1.219 -0.805 0 C-N-CA 121.002 -0.618 . . . . 0.0 111.689 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.34 123.12 71.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.434 HD13 HG13 ' A' ' 49' ' ' VAL . 57.6 mt -62.44 118.24 4.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 123.553 0.741 . . . . 0.0 109.524 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.2 t -110.56 -16.2 13.71 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.185 -174.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.2 t -153.74 154.34 33.87 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 tp -146.35 147.56 31.45 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -108.72 119.02 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 121.132 0.491 . . . . 0.0 110.573 177.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.6 tmt_? -61.03 131.43 50.59 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.337 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.04 -18.0 58.21 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.342 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.85 161.58 47.91 Favored Glycine 0 N--CA 1.436 -1.327 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -176.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.63 -33.38 39.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.9 0 N-CA-C 113.721 1.008 . . . . 0.0 113.721 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.15 -41.39 99.27 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 111.646 0.239 . . . . 0.0 111.646 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.63 -42.79 95.23 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-O 121.717 0.77 . . . . 0.0 109.204 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 25.1 mtp180 -71.98 -13.19 61.55 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.188 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.407 ' O ' HG11 ' A' ' 15' ' ' VAL . . . -89.01 -13.36 62.33 Favored Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.14 176.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.02 13.81 44.81 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.359 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.434 HG13 HD13 ' A' ' 35' ' ' ILE . 57.9 t -69.67 137.02 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -134.01 147.16 50.93 Favored 'General case' 0 CA--C 1.48 -1.715 0 CA-C-O 121.329 0.585 . . . . 0.0 109.555 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -78.79 141.76 14.98 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.744 0 CA-C-N 114.159 -1.382 . . . . 0.0 109.636 -177.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 24.41 38.33 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.46 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m-70 -118.86 134.84 54.89 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.064 -0.568 . . . . 0.0 110.876 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.8 ttm-85 -93.23 123.45 36.52 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.42 HD12 HG23 ' A' ' 55' ' ' ILE . 31.4 mt -79.22 125.86 38.73 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 39.2 pt -101.56 -16.44 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.413 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.2 tt0 -158.0 144.26 17.45 Favored 'General case' 0 CA--C 1.486 -1.497 0 C-N-CA 120.079 -0.649 . . . . 0.0 109.29 -176.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.435 HD12 HG21 ' A' ' 63' ' ' VAL . 79.1 mt -143.87 125.71 10.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 124.567 1.167 . . . . 0.0 108.256 178.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.75 18.73 8.87 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 124.04 0.936 . . . . 0.0 112.602 170.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.29 -0.34 40.6 Favored Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.833 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -119.07 132.78 56.05 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.931 -0.746 . . . . 0.0 110.173 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.3 m -75.32 107.87 7.72 Favored 'General case' 0 N--CA 1.422 -1.828 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.559 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.9 m -99.65 12.64 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 CA-C-O 121.857 0.837 . . . . 0.0 110.118 -172.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -66.48 -20.55 27.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.437 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.1 12.1 12.59 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.648 -0.706 . . . . 0.0 109.541 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 84.8 m -93.6 136.19 24.37 Favored Pre-proline 0 N--CA 1.415 -2.216 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.407 ' O ' HG13 ' A' ' 71' ' ' ILE . 61.9 Cg_endo -74.76 164.42 33.65 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 122.202 1.935 . . . . 0.0 112.553 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -43.19 -55.35 3.99 Favored 'General case' 0 C--O 1.218 -0.593 0 C-N-CA 126.034 1.734 . . . . 0.0 112.147 -178.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -55.27 -45.77 76.15 Favored 'General case' 0 C--N 1.316 -0.883 0 O-C-N 123.925 0.766 . . . . 0.0 111.387 -174.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.427 ' O ' HD12 ' A' ' 74' ' ' ILE . 12.4 mptt -66.12 -54.87 20.22 Favored 'General case' 0 CA--C 1.483 -1.615 0 O-C-N 123.964 0.79 . . . . 0.0 110.739 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.8 mt -51.98 -42.04 33.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 O-C-N 124.253 0.971 . . . . 0.0 109.857 -179.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.8 t -72.11 -43.29 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.566 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 71.2 t60 -64.87 -43.01 94.34 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.348 0.594 . . . . 0.0 110.184 -177.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.427 HD12 ' O ' ' A' ' 70' ' ' LYS . 14.3 mt -69.09 -42.24 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.524 -178.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 67.4 mt -61.91 -46.15 90.6 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.895 0.379 . . . . 0.0 110.84 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.503 ' O ' HD22 ' A' ' 22' ' ' LEU . 23.0 t -60.7 -27.69 68.07 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 124.209 1.004 . . . . 0.0 111.802 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -87.98 -36.56 16.99 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 120.626 -0.43 . . . . 0.0 112.045 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.463 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -77.93 136.33 37.99 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 113.401 0.889 . . . . 0.0 113.401 -172.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.402 HG12 HD21 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -131.98 175.26 11.7 Favored 'Isoleucine or valine' 0 C--O 1.245 0.849 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 175.622 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.57 -154.75 25.23 Favored Glycine 0 CA--C 1.483 -1.911 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.464 ' HB3' HD12 ' A' ' 16' ' ' LEU . 51.5 mt-10 -75.0 108.97 8.07 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 174.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.439 ' HB ' HG22 ' A' ' 17' ' ' ILE . 59.9 mt -112.36 118.15 57.06 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -84.54 130.53 34.73 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.458 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.515 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.0 mtm -135.34 152.31 51.34 Favored 'General case' 0 C--N 1.282 -2.344 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 170.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 8.9 mmmt -122.28 121.35 36.56 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.46 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.7 p -119.27 153.0 35.71 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.093 -176.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.512 ' C ' ' H ' ' A' ' 89' ' ' ALA . 50.3 mtm -123.06 169.13 10.52 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 7.7 Cg_exo -74.3 35.64 0.4 Allowed 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 123.158 2.572 . . . . 0.0 112.333 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.512 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.02 59.87 2.63 Favored 'General case' 0 N--CA 1.433 -1.302 0 C-N-CA 126.072 1.749 . . . . 0.0 112.958 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.161 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 171.316 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 . . . . . 0 C--O 1.235 0.319 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 25.2 m -120.17 100.93 7.48 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 64.9 mtt -94.23 -25.63 16.99 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.663 -177.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.77 -91.2 0.54 Allowed Glycine 0 N--CA 1.439 -1.123 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -77.91 82.71 4.26 Favored 'General case' 0 CA--C 1.493 -1.212 0 CA-C-O 121.93 0.871 . . . . 0.0 111.247 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.43 HG13 ' HD2' ' A' ' 85' ' ' LYS . 50.1 t -145.2 128.13 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 70.1 m -110.54 107.27 16.84 Favored 'General case' 0 C--N 1.245 -3.974 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 176.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 32.8 m -78.96 130.99 36.18 Favored 'General case' 0 N--CA 1.396 -3.132 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.8 t -111.02 137.54 43.05 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.717 0 CA-C-N 114.468 -1.242 . . . . 0.0 108.124 -177.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.4 tp -121.92 111.87 17.61 Favored 'General case' 1 N--CA 1.374 -4.266 0 C-N-CA 119.062 -1.055 . . . . 0.0 108.353 172.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.468 HD12 HG22 ' A' ' 17' ' ' ILE . 0.3 OUTLIER -97.25 128.61 48.34 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.292 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 178.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 67.4 mtp180 -115.04 102.14 9.66 Favored 'General case' 0 CA--C 1.457 -2.62 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 174.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.476 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.4 ttt180 -98.64 123.61 49.26 Favored Pre-proline 0 C--N 1.262 -3.214 0 CA-C-N 112.999 -1.91 . . . . 0.0 111.048 -174.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.39 -55.63 2.04 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 122.553 2.168 . . . . 0.0 113.457 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -166.15 -178.22 4.51 Favored 'General case' 0 C--O 1.247 0.963 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 -175.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.0 mt -68.31 -16.55 63.99 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -175.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -84.37 -12.25 54.83 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.876 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -93.48 128.42 39.57 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 176.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.289 0.0 OUTLIER -103.3 158.98 15.95 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.477 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.2 OUTLIER -58.91 -53.69 55.6 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.175 -168.318 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.01 26.7 8.24 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.338 -1.41 . . . . 0.0 112.789 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -145.79 154.26 41.83 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 173.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 10.2 m -106.78 122.12 45.74 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -114.71 139.91 38.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.224 -0.59 . . . . 0.0 110.385 -178.106 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -130.57 126.3 36.36 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 16.4 m120 62.0 6.85 1.86 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 124.391 1.076 . . . . 0.0 112.945 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 6.45 53.36 Favored Glycine 0 C--O 1.214 -1.102 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -175.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.42 128.12 70.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 52.6 mt -70.21 116.11 10.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 C-N-CA 124.407 1.083 . . . . 0.0 110.49 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.3 t -99.53 -24.41 14.77 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.064 -175.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 34.1 t -157.12 152.39 26.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 -178.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -133.84 140.51 46.92 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -94.6 115.68 27.85 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.435 ' HD2' ' N ' ' A' ' 41' ' ' GLY . 1.7 tmm_? -65.62 131.3 46.03 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.435 ' N ' ' HD2' ' A' ' 40' ' ' ARG . . . 91.89 -4.79 78.87 Favored Glycine 0 N--CA 1.437 -1.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.303 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.25 170.33 40.89 Favored Glycine 0 C--O 1.253 1.292 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -61.8 -34.85 64.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.935 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.19 94.36 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.196 0.31 . . . . 0.0 111.659 -179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -65.91 -41.59 91.23 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.094 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -66.28 -35.29 80.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.943 178.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.74 -29.76 75.21 Favored Glycine 0 N--CA 1.44 -1.065 0 CA-C-N 115.177 -0.92 . . . . 0.0 112.641 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 114.67 14.65 8.59 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.213 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 68.9 t -70.24 137.69 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.1 mmt85 -136.02 145.16 45.76 Favored 'General case' 0 CA--C 1.477 -1.853 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -178.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.1 t -74.23 139.9 18.5 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.84 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.608 -177.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.15 9.15 65.82 Favored Glycine 0 N--CA 1.436 -1.336 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -178.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.508 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -101.93 148.25 25.56 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.275 -0.462 . . . . 0.0 111.412 -179.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 70.7 ttt180 -105.46 123.39 47.81 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.416 HD12 HG22 ' A' ' 86' ' ' THR . 24.5 mm -74.11 117.98 18.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.005 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 24.5 pt -105.28 -20.34 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.681 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 179.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.3 tt0 -151.84 146.48 25.71 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.472 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.0 mt -143.56 121.69 6.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 O-C-N 124.362 1.039 . . . . 0.0 108.647 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 63.93 8.67 4.04 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 125.556 1.542 . . . . 0.0 111.953 173.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.13 1.35 23.74 Favored Glycine 0 N--CA 1.43 -1.754 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.615 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -116.58 136.56 52.87 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 117.797 0.799 . . . . 0.0 109.92 177.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.8 m -75.56 108.99 8.75 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.526 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.0 m -102.96 11.48 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.697 0 CA-C-O 122.145 0.974 . . . . 0.0 109.423 -174.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 p -70.93 -14.78 18.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 114.332 -1.304 . . . . 0.0 110.093 -179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.95 13.68 13.1 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.264 179.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.526 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.1 m -101.32 135.26 19.91 Favored Pre-proline 0 N--CA 1.416 -2.163 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -66.21 156.15 66.33 Favored 'Trans proline' 0 C--O 1.244 0.821 0 C-N-CA 121.916 1.744 . . . . 0.0 111.743 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -43.11 -52.5 5.4 Favored 'General case' 0 C--O 1.221 -0.442 0 C-N-CA 125.525 1.53 . . . . 0.0 112.903 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -58.33 -42.74 87.48 Favored 'General case' 0 C--N 1.311 -1.087 0 O-C-N 123.917 0.761 . . . . 0.0 111.068 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.494 ' HE3' ' HA ' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -66.8 -53.77 29.45 Favored 'General case' 0 C--O 1.202 -1.413 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 178.53 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 53.4 mt -50.14 -42.29 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-O 120.984 0.421 . . . . 0.0 110.338 178.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.1 t -70.03 -37.9 73.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.982 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -69.16 -39.71 78.62 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.42 -53.44 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 95.6 mt -60.58 -32.79 71.87 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-O 120.853 0.358 . . . . 0.0 111.531 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.8 t -63.72 -37.07 85.97 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 123.362 0.665 . . . . 0.0 111.282 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -110.24 -9.98 14.65 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -171.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.476 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.01 129.87 35.57 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 122.156 -0.34 . . . . 0.0 110.826 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.75 176.26 8.43 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 177.648 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 89.69 -161.21 29.48 Favored Glycine 0 CA--C 1.498 -0.98 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -75.57 108.66 8.54 Favored 'General case' 0 C--O 1.249 1.074 0 C-N-CA 124.048 0.939 . . . . 0.0 108.903 175.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.3 mt -116.25 117.52 55.76 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.42 -174.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 34.5 m80 -84.76 117.0 23.57 Favored 'General case' 0 CA--C 1.486 -1.491 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.497 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 14.2 mtp -118.49 145.18 45.48 Favored 'General case' 0 C--N 1.25 -3.735 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.145 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.43 ' HD2' HG13 ' A' ' 12' ' ' VAL . 69.3 mmtt -118.09 123.97 46.92 Favored 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.508 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 68.0 p -118.97 139.86 50.97 Favored 'General case' 0 C--N 1.27 -2.852 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.903 178.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.496 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -113.58 166.54 11.07 Favored Pre-proline 0 C--N 1.299 -1.626 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 178.287 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -72.74 31.49 0.29 Allowed 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 123.047 2.498 . . . . 0.0 112.49 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.496 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 56.33 57.23 5.1 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 122.536 1.16 . . . . 0.0 111.324 -177.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 113.492 -1.685 . . . . 0.0 107.321 176.757 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 49.4 m -101.63 -24.36 14.12 Favored 'General case' 0 CA--C 1.551 1.006 0 CA-C-O 121.211 0.529 . . . . 0.0 110.242 174.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 60.4 ttp -173.95 -46.24 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.07 -132.19 2.36 Favored Glycine 0 N--CA 1.421 -2.36 0 N-CA-C 108.477 -1.849 . . . . 0.0 108.477 175.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -89.16 89.96 8.17 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.412 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 57.2 t -114.88 126.88 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.946 0 CA-C-N 114.016 -1.447 . . . . 0.0 108.898 -173.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 53.7 m -116.05 113.63 23.45 Favored 'General case' 1 C--N 1.241 -4.137 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.627 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.5 m -82.39 138.65 34.4 Favored 'General case' 0 N--CA 1.406 -2.663 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.151 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 56.2 t -116.04 139.77 41.1 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.796 0 CA-C-N 114.574 -1.194 . . . . 0.0 108.582 178.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.473 HD12 ' HB3' ' A' ' 81' ' ' GLU . 17.8 tp -125.32 116.89 22.63 Favored 'General case' 0 N--CA 1.404 -2.762 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 81' ' ' GLU . 0.3 OUTLIER -98.11 141.63 15.82 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.782 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.859 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -113.61 102.98 10.79 Favored 'General case' 0 CA--C 1.489 -1.4 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.533 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 69.6 ttt180 -111.42 101.66 51.26 Favored Pre-proline 0 C--N 1.274 -2.686 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.765 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -58.6 -33.85 98.45 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.618 2.212 . . . . 0.0 113.985 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -169.15 175.58 5.64 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.435 HD21 HG12 ' A' ' 79' ' ' VAL . 63.4 mt -65.01 -18.23 65.12 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.9 mtt85 -74.25 -12.38 60.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 121.459 0.647 . . . . 0.0 112.084 178.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -99.54 95.75 7.2 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 174.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -84.58 152.29 23.96 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.763 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.55 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -41.68 -60.9 1.21 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 126.068 1.747 . . . . 0.0 111.654 -172.541 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 109.64 -3.81 30.79 Favored Glycine 0 N--CA 1.432 -1.614 0 C-N-CA 119.828 -1.177 . . . . 0.0 112.793 176.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -117.39 156.77 27.32 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 122.191 -0.593 . . . . 0.0 109.663 178.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.0 t -108.82 131.43 54.99 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.23 134.53 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 -177.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.405 ' HG3' ' HB2' ' A' ' 36' ' ' CYS 0.266 1.0 OUTLIER -126.17 120.39 29.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.046 0.45 . . . . 0.0 110.84 175.258 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 65.09 13.03 8.42 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 124.259 1.023 . . . . 0.0 110.81 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.68 -1.96 52.75 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.383 -177.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -108.08 121.57 61.25 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 O-C-N 122.315 -0.521 . . . . 0.0 110.303 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 64.3 mt -60.32 117.11 2.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 C-N-CA 124.746 1.219 . . . . 0.0 110.274 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.405 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 34.0 t -98.18 -44.03 6.76 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.689 -174.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 36.4 p -142.26 155.4 45.23 Favored 'General case' 0 C--O 1.248 1.011 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -131.91 146.24 51.99 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 123.25 0.62 . . . . 0.0 110.008 -177.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.8 ttt -90.3 112.48 24.06 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.44 ' HD3' ' N ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -75.57 123.73 26.0 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.759 -172.01 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.44 ' N ' ' HD3' ' A' ' 40' ' ' ARG . . . 103.65 -14.96 53.42 Favored Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.308 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.11 178.08 54.11 Favored Glycine 0 C--O 1.253 1.282 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -178.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 pt -53.72 -37.59 32.53 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.07 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.24 93.46 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -63.92 -46.5 84.51 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.464 0.649 . . . . 0.0 109.603 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -76.08 -17.4 59.64 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.979 -179.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.9 -29.38 63.1 Favored Glycine 0 N--CA 1.432 -1.569 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.794 175.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 111.43 12.19 15.76 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.027 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 73.1 t -67.94 134.26 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.6 mmt85 -131.03 142.5 50.32 Favored 'General case' 0 CA--C 1.487 -1.453 0 CA-C-O 121.155 0.503 . . . . 0.0 109.909 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 41.7 t -79.05 137.26 22.15 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.21 -176.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.36 22.71 33.82 Favored Glycine 0 CA--C 1.5 -0.865 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -175.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.531 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m170 -116.59 135.34 53.89 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.873 -0.664 . . . . 0.0 112.192 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.468 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 33.8 ttm-85 -92.59 122.69 35.27 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.406 HG12 HG22 ' A' ' 86' ' ' THR . 30.1 mt -80.64 127.82 39.15 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.42 HD11 HG23 ' A' ' 56' ' ' ILE . 35.2 pt -107.0 -16.5 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 84' ' ' MET . 32.1 tt0 -154.98 144.62 21.42 Favored 'General case' 0 CA--C 1.48 -1.717 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.382 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.451 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.5 mt -139.52 125.88 23.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 64.59 6.68 3.31 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.598 1.159 . . . . 0.0 112.31 173.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.4 -9.63 19.93 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.718 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.469 ' O ' HG12 ' A' ' 63' ' ' VAL . 17.4 pt20 -108.11 126.09 52.35 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-O 120.961 0.41 . . . . 0.0 110.989 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 31.9 t -64.85 113.46 3.83 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 177.153 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.615 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 30.9 m -110.61 13.53 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 121.169 0.509 . . . . 0.0 109.986 -176.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -67.54 -17.65 22.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 115.216 -0.902 . . . . 0.0 112.714 -173.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.64 16.64 5.88 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.708 0.766 . . . . 0.0 109.124 177.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.615 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.2 m -84.35 141.46 39.66 Favored Pre-proline 0 N--CA 1.416 -2.125 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.609 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.434 ' O ' HG13 ' A' ' 71' ' ' ILE . 71.6 Cg_exo -48.96 143.71 17.07 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.907 2.405 . . . . 0.0 112.247 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -49.91 -50.83 44.75 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 124.757 1.223 . . . . 0.0 111.529 -178.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -68.23 -32.23 72.29 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.1 mttm -62.91 -53.84 47.84 Favored 'General case' 0 CA--C 1.48 -1.718 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.793 176.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.434 HG13 ' O ' ' A' ' 67' ' ' PRO . 58.1 mt -50.01 -41.9 18.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 124.016 0.822 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 65.7 t -72.93 -37.19 53.47 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.533 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -65.23 -45.06 86.17 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 123.534 0.733 . . . . 0.0 109.594 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.74 -49.39 84.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.252 0 O-C-N 123.644 0.59 . . . . 0.0 109.412 178.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.2 mt -62.15 -45.31 94.01 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.7 t -61.98 -27.4 68.83 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 123.622 0.769 . . . . 0.0 112.144 -178.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -103.09 -13.23 16.9 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.666 0.987 . . . . 0.0 113.666 -176.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 134.63 34.16 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.047 -177.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.435 HG12 HD21 ' A' ' 22' ' ' LEU . 1.3 m -128.49 175.8 9.28 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 176.05 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.38 -159.66 27.46 Favored Glycine 0 N--CA 1.432 -1.605 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.473 ' HB3' HD12 ' A' ' 16' ' ' LEU . 44.9 mt-10 -79.35 113.4 17.46 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 173.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 67.7 mt -115.65 118.56 59.17 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.942 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.763 -172.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -81.18 135.94 35.82 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.501 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.7 mtm -133.34 150.63 51.85 Favored 'General case' 0 C--N 1.263 -3.178 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.412 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 66.1 mmtt -117.72 121.26 40.37 Favored 'General case' 0 C--N 1.262 -3.201 0 N-CA-C 106.238 -1.764 . . . . 0.0 106.238 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.2 p -122.6 146.24 47.62 Favored 'General case' 0 C--N 1.264 -3.116 0 C-N-CA 120.258 -0.577 . . . . 0.0 110.479 -178.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.552 ' C ' ' H ' ' A' ' 89' ' ' ALA . 58.3 mtm -120.41 168.16 11.17 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_exo -68.2 32.42 0.15 Allowed 'Trans proline' 0 N--CA 1.509 2.41 0 C-N-CA 123.49 2.794 . . . . 0.0 112.668 176.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.552 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.29 27.36 8.31 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 126.442 1.897 . . . . 0.0 113.422 177.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.409 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.483 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.505 -0.754 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.43 HG23 ' SD ' ' A' ' 87' ' ' MET . 13.9 t -98.75 171.08 8.32 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 41.4 ttm -162.72 156.94 21.05 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -176.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.28 -95.41 0.55 Allowed Glycine 0 N--CA 1.432 -1.615 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.518 178.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -103.55 101.18 11.04 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 120.95 0.405 . . . . 0.0 110.619 -178.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t -139.46 129.19 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.149 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 89.0 m -119.41 108.53 14.68 Favored 'General case' 0 N--CA 1.39 -3.46 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.185 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 18.6 m -78.69 134.25 37.12 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.934 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -115.86 136.86 51.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.137 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.378 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.44 HD13 ' HB3' ' A' ' 81' ' ' GLU . 25.9 tp -118.81 110.67 17.5 Favored 'General case' 0 N--CA 1.4 -2.958 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 174.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.49 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -99.23 137.89 25.31 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.312 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.219 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.12 103.38 12.57 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.1 ttt180 -109.03 111.53 60.45 Favored Pre-proline 0 C--N 1.291 -1.947 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.315 -177.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -58.93 -44.12 37.91 Favored 'Trans proline' 0 CA--C 1.549 1.241 0 C-N-CA 122.311 2.007 . . . . 0.0 113.743 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -167.21 -176.99 3.51 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -176.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 65.9 mt -76.88 -10.02 59.08 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 124.892 1.277 . . . . 0.0 110.292 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 34.5 mtt180 -69.03 -19.35 64.11 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 114.295 -1.32 . . . . 0.0 108.064 176.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -114.21 157.81 22.18 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 104.997 -2.223 . . . . 0.0 104.997 177.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -121.63 -168.42 1.69 Allowed 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.493 HD21 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -75.25 -57.61 3.79 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -175.58 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 110.06 20.21 7.67 Favored Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.788 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -143.84 148.8 36.03 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.0 t -99.84 131.43 45.81 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.54 138.45 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -176.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -117.94 105.91 12.4 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 176.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 61.29 23.23 13.48 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 122.015 0.912 . . . . 0.0 110.846 177.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.91 -4.91 39.24 Favored Glycine 0 N--CA 1.439 -1.125 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.413 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -105.93 120.13 56.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 O-C-N 122.18 -0.6 . . . . 0.0 110.013 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.42 HD12 HG11 ' A' ' 49' ' ' VAL . 55.1 mt -61.35 115.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 C-N-CA 123.447 0.699 . . . . 0.0 110.244 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -98.23 -31.77 11.9 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.042 -175.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.1 m -150.6 155.05 38.65 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.9 tp -136.7 138.88 41.5 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 123.534 0.734 . . . . 0.0 109.525 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 49.4 ttm -91.48 119.29 31.32 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.9 131.76 45.62 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.92 -8.45 79.78 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.34 162.98 37.02 Favored Glycine 0 N--CA 1.432 -1.582 0 C-N-CA 121.318 -0.467 . . . . 0.0 112.167 -178.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -30.43 41.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -179.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.02 -42.44 89.64 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.69 0.281 . . . . 0.0 110.889 178.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -63.71 -41.48 98.08 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.63 -8.44 55.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.673 -1.149 . . . . 0.0 111.281 178.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.55 -22.52 28.73 Favored Glycine 0 N--CA 1.429 -1.794 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 178.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.02 8.5 29.54 Favored Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.959 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.42 HG11 HD12 ' A' ' 35' ' ' ILE . 58.5 t -65.59 135.92 27.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 12.6 mmm180 -133.42 146.12 50.9 Favored 'General case' 0 CA--C 1.48 -1.738 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 77.0 t -77.37 139.9 17.95 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 114.181 -1.372 . . . . 0.0 109.202 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.4 -2.04 62.7 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -177.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.49 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 10.2 m170 -95.43 140.83 29.74 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 115.041 -0.58 . . . . 0.0 110.928 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 25.8 ttt85 -101.18 131.83 46.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.403 HD11 HG23 ' A' ' 55' ' ' ILE . 33.0 mt -82.99 127.27 39.84 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 30.9 pt -104.3 -15.34 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.268 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.944 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.417 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.7 tt0 -155.9 144.34 20.12 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 119.763 -0.775 . . . . 0.0 108.984 -174.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.454 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.1 mt -140.67 121.83 14.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 124.293 0.996 . . . . 0.0 108.475 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 68.29 7.68 6.09 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 124.095 0.958 . . . . 0.0 111.769 172.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.4 2.09 33.13 Favored Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.397 -178.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.454 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 21.1 pt20 -113.88 125.31 53.91 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 177.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 40.1 t -63.82 119.14 9.42 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.458 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 24.3 m -114.35 14.12 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.123 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.5 p -70.12 -20.76 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.802 -176.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.66 9.56 16.51 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.751 0.786 . . . . 0.0 109.453 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.458 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 76.8 m -86.37 138.51 34.11 Favored Pre-proline 0 N--CA 1.407 -2.621 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.742 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.29 158.09 58.65 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.185 1.923 . . . . 0.0 112.837 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 45.3 p-80 -48.6 -49.65 35.94 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.121 1.368 . . . . 0.0 114.042 -174.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.0 -37.89 78.96 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 120.451 0.167 . . . . 0.0 110.599 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mttm -61.9 -49.85 74.53 Favored 'General case' 0 CA--C 1.492 -1.258 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 177.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.8 mt -54.32 -42.56 58.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 O-C-N 123.896 0.748 . . . . 0.0 110.173 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.34 -35.88 69.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.544 178.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.8 t-80 -68.9 -42.92 76.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.237 0.541 . . . . 0.0 109.581 -177.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 35.7 mt -63.71 -47.19 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.635 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.882 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.2 mt -61.32 -45.99 92.12 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.399 176.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -62.32 -27.49 69.08 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 123.174 0.59 . . . . 0.0 111.887 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -104.65 1.34 29.41 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -177.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.444 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -107.04 134.61 49.93 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.967 178.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.408 HG21 ' N ' ' A' ' 80' ' ' GLY . 1.7 m -129.58 -177.34 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.408 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 85.96 -157.14 30.58 Favored Glycine 0 CA--C 1.484 -1.886 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.44 ' HB3' HD13 ' A' ' 16' ' ' LEU . 50.4 mt-10 -80.52 112.89 18.3 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.167 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.49 ' HB ' HG23 ' A' ' 17' ' ' ILE . 56.5 mt -117.3 118.12 57.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -173.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -90.49 118.43 29.96 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.417 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 24.3 mtm -117.54 158.42 24.61 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.298 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.3 mtmm -123.86 121.97 36.77 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.2 p -119.86 150.02 41.13 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.624 -175.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.519 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.6 mtp -130.13 168.63 15.96 Favored Pre-proline 0 C--N 1.313 -0.978 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 57.7 Cg_endo -71.04 29.5 0.22 Allowed 'Trans proline' 0 CA--C 1.565 2.058 0 C-N-CA 122.762 2.308 . . . . 0.0 112.61 175.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.519 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.0 -2.36 2.37 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 126.384 1.874 . . . . 0.0 112.59 179.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.474 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 178.235 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.506 -0.717 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' SD ' ' A' ' 87' ' ' MET . 65.5 m -89.97 125.16 35.28 Favored 'General case' 0 N--CA 1.417 -2.101 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 176.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 65.9 mtt -116.22 125.59 52.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.76 -116.11 0.7 Allowed Glycine 0 N--CA 1.428 -1.864 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -109.74 106.03 15.51 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.3 t -133.13 134.86 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 123.554 0.742 . . . . 0.0 109.273 -174.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 34.4 m -121.74 120.13 33.76 Favored 'General case' 0 N--CA 1.391 -3.388 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 176.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.6 m -90.67 141.08 29.16 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.127 0.965 . . . . 0.0 110.091 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.42 135.96 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.06 0 CA-C-N 114.425 -1.261 . . . . 0.0 108.857 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.435 HD12 ' O ' ' A' ' 82' ' ' ILE . 24.9 tp -119.86 110.38 16.68 Favored 'General case' 0 N--CA 1.382 -3.87 0 C-N-CA 119.18 -1.008 . . . . 0.0 108.797 173.044 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.446 HD12 HG23 ' A' ' 17' ' ' ILE . 0.3 OUTLIER -98.14 125.94 51.28 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.021 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.081 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.529 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 82.1 mtp180 -113.29 102.77 10.66 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.506 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 48.2 ttt180 -98.3 112.8 63.04 Favored Pre-proline 0 C--N 1.269 -2.925 0 CA-C-N 112.77 -2.014 . . . . 0.0 110.846 -174.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.37 -39.2 86.19 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.833 2.355 . . . . 0.0 113.909 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -166.62 -178.72 4.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -177.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.596 HD21 ' CG1' ' A' ' 79' ' ' VAL . 52.8 mt -75.36 -18.09 60.06 Favored 'General case' 0 CA--C 1.495 -1.141 0 C-N-CA 124.954 1.301 . . . . 0.0 111.024 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.582 ' HD2' ' N ' ' A' ' 23' ' ' ARG . 4.8 mpt_? -82.02 -11.5 58.79 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.923 176.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -99.16 89.3 4.19 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.682 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.53 165.79 23.97 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 123.639 0.587 . . . . 0.0 110.938 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.479 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -69.31 -58.8 3.55 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.46 -169.785 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 103.19 38.28 2.9 Favored Glycine 0 N--CA 1.424 -2.114 0 C-N-CA 120.062 -1.066 . . . . 0.0 111.933 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -154.2 153.63 32.1 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 174.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 m -109.02 130.88 55.49 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -118.72 134.07 63.51 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 CA-C-O 121.36 0.6 . . . . 0.0 111.089 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -113.56 111.64 22.23 Favored 'General case' 0 C--N 1.312 -1.053 0 O-C-N 121.807 -0.558 . . . . 0.0 109.591 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.6 m-20 59.86 12.8 3.22 Favored 'General case' 0 N--CA 1.501 2.097 0 C-N-CA 125.076 1.35 . . . . 0.0 112.21 -177.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.59 0.42 30.79 Favored Glycine 0 C--O 1.215 -1.092 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.682 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.17 118.33 55.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 122.438 -0.448 . . . . 0.0 109.878 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.405 HD12 HG11 ' A' ' 49' ' ' VAL . 46.8 mt -59.15 122.38 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 123.888 0.875 . . . . 0.0 110.861 178.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 13.4 t -103.29 -31.75 9.91 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.983 -176.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 55.1 p -151.17 160.62 43.75 Favored 'General case' 0 C--O 1.245 0.862 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 54.5 tp -137.97 129.46 27.95 Favored 'General case' 0 N--CA 1.443 -0.812 0 O-C-N 123.785 0.678 . . . . 0.0 109.867 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -76.03 112.54 12.57 Favored 'General case' 0 C--N 1.317 -0.837 0 O-C-N 123.782 0.676 . . . . 0.0 109.878 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.433 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.3 tpp85 -55.32 125.0 18.92 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.564 1.146 . . . . 0.0 111.005 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.02 -7.63 81.73 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.311 -0.859 . . . . 0.0 113.408 177.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.12 171.6 55.15 Favored Glycine 0 C--O 1.246 0.888 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.501 -176.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.5 pt -62.15 -33.04 56.59 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -57.16 -46.12 83.03 Favored 'General case' 0 N--CA 1.447 -0.608 0 CA-C-O 120.909 0.385 . . . . 0.0 110.445 178.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.433 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 36.2 tt0 -62.88 -47.15 84.55 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.573 0.701 . . . . 0.0 109.758 179.113 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 40.5 mtt180 -69.62 -18.06 63.57 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.807 -178.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.24 -24.81 50.49 Favored Glycine 0 N--CA 1.438 -1.187 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.001 176.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.95 12.23 12.75 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 179.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.405 HG11 HD12 ' A' ' 35' ' ' ILE . 53.9 t -68.57 137.28 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -135.61 150.25 49.6 Favored 'General case' 0 CA--C 1.474 -1.953 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.15 141.2 15.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.066 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.98 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.14 25.92 42.53 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -177.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.488 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.2 m170 -117.48 132.87 56.48 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.124 -0.538 . . . . 0.0 110.944 179.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -95.79 121.66 37.74 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.428 HD13 HG23 ' A' ' 55' ' ' ILE . 44.7 mt -75.92 122.28 29.62 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.404 HG23 ' CG2' ' A' ' 64' ' ' VAL 0.265 2.4 pp -104.94 -5.93 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.76 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -178.314 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 84' ' ' MET . 26.6 tt0 -169.34 143.15 2.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.416 -179.325 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.448 ' CD1' HG21 ' A' ' 63' ' ' VAL . 88.4 mt -138.57 124.84 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 66.34 3.32 2.74 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.5 1.12 . . . . 0.0 112.436 172.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.26 -0.81 22.4 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.084 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.457 ' O ' HG13 ' A' ' 63' ' ' VAL . 12.7 pt20 -115.41 125.97 53.81 Favored 'General case' 0 CA--C 1.498 -1.022 0 O-C-N 122.273 -0.545 . . . . 0.0 110.166 176.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 m -71.03 109.6 5.22 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.519 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.6 m -101.77 18.28 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.993 0 CA-C-O 121.914 0.864 . . . . 0.0 110.538 -172.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.404 ' CG2' HG23 ' A' ' 56' ' ' ILE . 4.3 p -75.59 -8.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.91 -177.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -126.44 22.89 6.99 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.022 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.519 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 89.3 m -109.18 130.39 22.8 Favored Pre-proline 0 N--CA 1.407 -2.614 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -66.34 158.22 56.19 Favored 'Trans proline' 0 CA--C 1.543 0.925 0 C-N-CA 122.233 1.955 . . . . 0.0 112.797 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 33.1 t60 -42.86 -55.85 3.5 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.932 1.293 . . . . 0.0 113.5 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -65.83 -37.67 86.84 Favored 'General case' 0 N--CA 1.436 -1.16 0 O-C-N 123.42 0.45 . . . . 0.0 111.32 -173.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.427 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 6.5 mttm -61.75 -52.02 65.96 Favored 'General case' 0 N--CA 1.424 -1.728 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.345 174.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 55.7 mt -52.02 -45.61 41.14 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 O-C-N 124.026 0.829 . . . . 0.0 110.398 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.2 t -69.07 -34.04 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.818 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 17.3 t60 -72.41 -43.17 64.25 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 -176.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.6 mt -60.5 -49.75 83.1 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 CA-C-N 114.737 -1.12 . . . . 0.0 109.873 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.2 mt -58.96 -46.76 87.27 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.76 177.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.499 ' HA ' HH12 ' A' ' 19' ' ' ARG . 25.0 m -63.06 -26.5 68.87 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 113.08 0.77 . . . . 0.0 113.08 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.8 -18.85 20.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.506 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -98.8 133.92 42.43 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.535 0.207 . . . . 0.0 111.221 -176.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.596 ' CG1' HD21 ' A' ' 22' ' ' LEU . 2.2 m -134.27 179.65 4.12 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 87.88 -150.22 22.13 Favored Glycine 0 CA--C 1.497 -1.065 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.87 114.56 18.88 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.435 ' O ' HD12 ' A' ' 16' ' ' LEU . 79.5 mt -117.88 118.03 56.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -90.85 115.75 28.15 Favored 'General case' 0 CA--C 1.463 -2.376 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.464 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 7.8 ttp -122.56 138.47 54.56 Favored 'General case' 1 N--CA 1.376 -4.148 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.816 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 32.9 mtmt -121.26 131.86 54.47 Favored 'General case' 0 CA--C 1.444 -3.133 0 C-N-CA 119.497 -0.881 . . . . 0.0 108.784 -176.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.488 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 49.7 p -125.97 155.16 41.81 Favored 'General case' 0 C--N 1.271 -2.825 0 O-C-N 123.993 0.808 . . . . 0.0 110.369 -174.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.539 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.8 mtp -120.47 170.55 6.95 Favored Pre-proline 0 C--N 1.296 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -75.98 29.83 0.39 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.85 2.367 . . . . 0.0 111.077 176.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.539 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 60.89 31.6 20.01 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.249 1.42 . . . . 0.0 110.624 -179.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.178 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.636 178.733 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.483 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.403 HG21 ' HB ' ' A' ' 12' ' ' VAL . 97.4 m 83.29 93.69 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 124.253 1.021 . . . . 0.0 112.561 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.2 mmt -136.94 83.11 1.98 Allowed 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.005 171.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 154.85 -141.22 7.97 Favored Glycine 0 N--CA 1.412 -2.955 0 N-CA-C 108.502 -1.839 . . . . 0.0 108.502 -177.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -112.83 98.2 7.04 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.403 ' HB ' HG21 ' A' ' 8' ' ' THR . 70.1 t -120.31 132.15 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.17 0 CA-C-O 122.083 0.944 . . . . 0.0 109.727 -173.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -127.12 115.55 19.31 Favored 'General case' 0 N--CA 1.387 -3.616 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.2 m -80.97 140.95 34.93 Favored 'General case' 0 N--CA 1.395 -3.186 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.813 -176.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.4 t -118.12 139.29 45.89 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.943 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.248 177.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.496 HD12 ' HB3' ' A' ' 81' ' ' GLU . 7.5 tp -126.42 105.41 8.75 Favored 'General case' 0 N--CA 1.404 -2.732 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.497 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.3 OUTLIER -99.71 134.8 37.76 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -178.863 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 -113.75 117.32 31.17 Favored 'General case' 0 C--N 1.294 -1.831 0 CA-C-O 121.954 0.883 . . . . 0.0 112.114 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.587 HH21 ' HA ' ' A' ' 25' ' ' GLN . 27.2 ttm180 -119.2 113.1 35.6 Favored Pre-proline 0 C--N 1.284 -2.272 0 CA-C-N 113.961 -1.472 . . . . 0.0 110.957 -178.088 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -61.74 -31.68 86.04 Favored 'Trans proline' 0 CA--C 1.547 1.16 0 C-N-CA 122.653 2.235 . . . . 0.0 113.091 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -178.8 173.68 1.22 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.441 HD21 ' HD3' ' A' ' 19' ' ' ARG . 47.5 mt -65.28 -9.83 27.32 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 115.666 1.728 . . . . 0.0 115.666 -173.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -76.16 -11.59 59.96 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.564 0.697 . . . . 0.0 110.794 176.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -107.08 98.56 8.2 Favored 'General case' 0 N--CA 1.423 -1.812 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . 0.587 ' HA ' HH21 ' A' ' 19' ' ' ARG . 2.5 pt20 -86.08 164.28 17.4 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.133 -1.427 . . . . 0.0 112.177 -177.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.518 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.58 -64.86 0.69 Allowed 'General case' 0 C--N 1.32 -0.698 0 O-C-N 124.984 1.427 . . . . 0.0 110.714 -173.353 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 101.69 29.48 6.21 Favored Glycine 0 N--CA 1.426 -2.021 0 C-N-CA 120.262 -0.971 . . . . 0.0 111.464 -176.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -152.35 167.14 29.66 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.4 m -131.25 140.92 49.92 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.53 121.41 50.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.902 0.858 . . . . 0.0 113.184 -173.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -120.07 128.08 53.16 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 64.2 -1.14 0.74 Allowed 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 124.451 1.1 . . . . 0.0 112.634 -174.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.81 -3.74 34.1 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -175.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -101.09 131.12 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.104 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 71.4 mt -67.1 114.25 3.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 124.248 1.019 . . . . 0.0 110.615 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -85.54 -51.88 6.2 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.914 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.9 p -137.51 151.07 48.05 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.08 -176.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.63 141.37 46.58 Favored 'General case' 0 C--N 1.31 -1.109 0 O-C-N 123.779 0.674 . . . . 0.0 109.646 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.1 ttt -83.84 115.76 22.41 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -73.92 128.29 35.12 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 -177.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.4 -4.4 85.26 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.992 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.0 173.41 46.78 Favored Glycine 0 C--O 1.242 0.635 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.389 -178.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -61.84 -29.85 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.43 -48.69 71.89 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.309 177.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -65.93 -43.52 87.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.917 0.389 . . . . 0.0 110.796 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.5 mtp85 -72.37 -17.37 61.83 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 121.52 0.676 . . . . 0.0 110.153 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.03 -20.6 60.66 Favored Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.052 -0.976 . . . . 0.0 111.395 175.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.57 4.63 24.85 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 120.286 -0.959 . . . . 0.0 113.516 176.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.43 142.53 16.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.461 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 9.9 mmt180 -140.33 139.78 35.49 Favored 'General case' 0 CA--C 1.491 -1.324 0 CA-C-O 121.257 0.551 . . . . 0.0 110.809 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.3 t -75.13 136.39 25.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 114.499 -1.228 . . . . 0.0 109.348 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.1 10.5 64.3 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -176.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.51 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.7 m170 -104.33 143.71 32.62 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.048 0.451 . . . . 0.0 110.945 177.458 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.451 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 76.0 ttt180 -103.78 114.97 29.63 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.017 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.414 HG12 HG22 ' A' ' 86' ' ' THR . 23.1 mt -77.31 126.57 37.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-O 121.093 0.473 . . . . 0.0 110.048 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.424 HG22 ' CG2' ' A' ' 64' ' ' VAL . 2.4 pp -109.9 -5.43 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.945 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.985 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.437 ' O ' ' HA ' ' A' ' 84' ' ' MET . 17.2 tt0 -161.48 145.29 12.82 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.422 ' CD1' HG23 ' A' ' 63' ' ' VAL . 76.2 mt -145.12 120.5 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 O-C-N 124.454 1.096 . . . . 0.0 109.194 176.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 59.65 25.95 14.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.55 1.14 . . . . 0.0 112.276 169.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.39 -7.58 30.44 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 119.883 -1.151 . . . . 0.0 114.222 177.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -124.2 135.37 53.4 Favored 'General case' 0 CA--C 1.486 -1.487 0 CA-C-N 117.785 0.793 . . . . 0.0 110.672 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 21.6 t -74.05 120.14 19.22 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 177.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.589 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.0 m -110.43 19.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.541 0 CA-C-O 121.479 0.657 . . . . 0.0 110.757 -174.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.424 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.0 p -78.83 -18.32 13.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.619 0.723 . . . . 0.0 110.329 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.87 12.49 15.83 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.45 175.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.589 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.6 m -91.22 135.48 28.26 Favored Pre-proline 0 N--CA 1.414 -2.255 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.453 ' O ' HG13 ' A' ' 71' ' ' ILE . 10.0 Cg_endo -57.82 148.42 75.38 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 122.005 1.804 . . . . 0.0 111.789 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 26.4 t60 -48.17 -50.27 29.54 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.563 1.145 . . . . 0.0 112.775 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -61.7 -39.02 89.99 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.873 -177.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -63.49 -49.6 72.95 Favored 'General case' 0 CA--C 1.482 -1.638 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.678 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.4 mt -50.87 -45.75 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 O-C-N 124.3 1.0 . . . . 0.0 109.846 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.62 -35.44 61.15 Favored 'Isoleucine or valine' 0 C--O 1.242 0.664 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.041 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.3 t60 -70.4 -42.33 71.82 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -176.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 38.2 mt -64.97 -49.95 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.919 179.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 42.3 mt -55.75 -52.09 65.15 Favored 'General case' 0 CA--C 1.502 -0.882 0 O-C-N 123.756 0.66 . . . . 0.0 112.181 177.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.8 t -59.07 -26.03 64.28 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.654 0.612 . . . . 0.0 112.654 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.7 m-80 -111.2 4.28 19.11 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -175.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.421 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -98.86 125.87 44.37 Favored 'General case' 0 C--O 1.204 -1.314 0 O-C-N 121.333 -0.854 . . . . 0.0 110.813 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.457 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -118.08 174.08 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.77 -155.52 19.7 Favored Glycine 0 CA--C 1.497 -1.093 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.496 ' HB3' HD12 ' A' ' 16' ' ' LEU . 2.9 mp0 -89.49 109.61 20.53 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.497 ' HB ' HG23 ' A' ' 17' ' ' ILE . 65.4 mt -105.11 117.86 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.933 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -170.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.9 m80 -85.3 128.42 34.69 Favored 'General case' 0 CA--C 1.478 -1.801 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.437 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -129.29 153.55 47.71 Favored 'General case' 0 C--N 1.258 -3.38 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 170.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -120.4 120.54 36.24 Favored 'General case' 0 C--N 1.26 -3.316 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.51 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.8 p -119.35 143.59 47.32 Favored 'General case' 0 C--N 1.257 -3.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.598 -178.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.557 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.3 mtm -111.39 164.06 15.92 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 175.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.77 27.52 0.32 Allowed 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.57 2.18 . . . . 0.0 111.598 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.557 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 69.27 25.8 5.55 Favored 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 126.299 1.84 . . . . 0.0 112.866 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.42 -1.94 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 174.456 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 . . . . . 0 CA--C 1.541 0.625 0 CA-C-O 121.6 0.714 . . . . 0.0 109.222 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.1 t -146.89 148.22 31.6 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.139 -0.976 . . . . 0.0 110.984 -178.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.9 mtm -115.4 6.84 14.91 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 173.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.79 84.88 0.26 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.648 -179.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.54 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 4.5 m-20 63.22 88.26 0.1 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 122.285 1.041 . . . . 0.0 111.824 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.5 t -114.38 126.84 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.445 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.59 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -116.92 117.55 30.01 Favored 'General case' 0 C--N 1.248 -3.807 0 CA-C-N 113.915 -1.493 . . . . 0.0 107.086 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 m -83.87 138.2 33.31 Favored 'General case' 0 N--CA 1.406 -2.641 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.422 -176.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.3 t -118.19 140.29 42.15 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.373 178.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.9 tp -122.68 116.42 23.76 Favored 'General case' 0 N--CA 1.399 -3.009 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.13 139.04 20.47 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -178.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.08 102.6 10.55 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 175.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.467 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.7 ttt180 -107.09 108.86 62.59 Favored Pre-proline 0 C--N 1.287 -2.121 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.241 -177.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -53.05 -55.87 3.3 Favored 'Trans proline' 0 CA--C 1.542 0.922 0 C-N-CA 122.788 2.325 . . . . 0.0 112.933 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -156.69 -176.98 6.27 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -177.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.576 HD21 ' CG1' ' A' ' 79' ' ' VAL . 68.7 mt -74.47 -14.37 60.82 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -172.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -82.11 -11.33 58.82 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-O 121.466 0.65 . . . . 0.0 110.15 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -94.7 121.07 35.89 Favored 'General case' 0 CA--C 1.487 -1.46 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.811 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -84.03 157.4 21.83 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 123.579 0.549 . . . . 0.0 110.353 177.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.46 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -61.15 -44.01 97.98 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 124.29 0.994 . . . . 0.0 111.36 -171.434 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.28 26.04 9.74 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 119.639 -1.267 . . . . 0.0 113.42 178.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -151.94 167.87 26.98 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -124.55 134.05 53.11 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -125.57 138.47 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -173.231 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 17.4 pt20 -105.44 92.79 4.34 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.794 0.806 . . . . 0.0 109.318 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 58.55 20.55 7.7 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 122.79 -10.23 9.02 Favored Glycine 0 C--O 1.218 -0.867 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.092 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -106.33 118.44 53.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.452 HD11 HG11 ' A' ' 49' ' ' VAL . 65.5 mt -59.61 114.74 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 123.244 0.618 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 52.5 t -95.29 -37.8 10.83 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.468 -175.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 14.8 m -149.8 151.23 33.22 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -178.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.9 tp -121.26 136.09 55.02 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.8 ttm -83.94 118.37 23.96 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -68.64 125.61 27.1 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.189 -175.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.47 0.41 79.51 Favored Glycine 0 N--CA 1.425 -2.046 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.55 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.62 171.25 45.13 Favored Glycine 0 C--O 1.241 0.586 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.14 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.89 -31.05 51.05 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.041 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.27 -39.61 93.48 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.891 0.377 . . . . 0.0 110.478 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -63.4 -44.01 95.91 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 176.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -72.28 -6.14 40.98 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.061 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -98.81 -18.01 26.41 Favored Glycine 0 N--CA 1.433 -1.536 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.03 19.56 18.9 Favored Glycine 0 N--CA 1.433 -1.518 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.442 -179.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.452 HG11 HD11 ' A' ' 35' ' ' ILE . 53.9 t -65.32 145.62 13.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-O 120.88 0.371 . . . . 0.0 110.036 177.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.419 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 19.9 mmt85 -136.86 138.71 41.03 Favored 'General case' 0 CA--C 1.488 -1.409 0 C-N-CA 123.963 0.905 . . . . 0.0 108.852 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.2 t -76.24 148.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.806 -177.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.05 47.67 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -178.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.529 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.7 m170 -122.19 136.39 54.9 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.994 -178.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -94.12 123.0 37.22 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.1 mt -79.24 121.17 31.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.44 HG23 ' SD ' ' A' ' 87' ' ' MET . 36.8 pt -100.63 -14.92 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.38 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.5 tt0 -156.79 141.16 16.62 Favored 'General case' 0 CA--C 1.477 -1.858 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -175.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.415 HD12 HG23 ' A' ' 63' ' ' VAL . 79.2 mt -140.75 126.34 19.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.14 14.52 9.68 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 124.058 0.943 . . . . 0.0 111.126 172.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.83 -1.96 48.51 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.877 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.457 ' O ' HG11 ' A' ' 63' ' ' VAL . 18.5 pt20 -115.57 130.6 56.93 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 117.106 0.453 . . . . 0.0 110.633 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.0 m -70.02 108.45 4.07 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.755 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.642 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.5 m -102.17 13.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.594 0 CA-C-O 122.133 0.968 . . . . 0.0 109.682 -175.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.9 p -73.53 -14.11 16.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 114.349 -1.296 . . . . 0.0 110.567 -177.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -125.68 19.82 7.9 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 122.21 1.005 . . . . 0.0 108.712 177.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.642 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.3 m -101.23 137.42 19.68 Favored Pre-proline 0 N--CA 1.413 -2.295 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.415 ' O ' HG13 ' A' ' 71' ' ' ILE . 57.3 Cg_endo -72.74 163.25 38.99 Favored 'Trans proline' 0 C--O 1.245 0.848 0 C-N-CA 122.035 1.824 . . . . 0.0 112.739 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -42.35 -57.85 2.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 127.249 2.22 . . . . 0.0 112.371 -177.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -68.15 -39.99 82.5 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.672 -174.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -59.18 -48.7 80.63 Favored 'General case' 0 CA--C 1.495 -1.164 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.535 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.415 HG13 ' O ' ' A' ' 67' ' ' PRO . 65.5 mt -51.9 -43.63 35.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 O-C-N 124.057 0.848 . . . . 0.0 110.329 178.558 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.1 t -73.09 -34.99 46.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.792 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.43 -46.08 77.68 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 123.517 0.727 . . . . 0.0 109.292 -177.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 23.6 mt -64.43 -47.06 90.99 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.706 0 CA-C-N 114.673 -1.149 . . . . 0.0 109.887 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 45.4 mt -58.43 -51.71 68.69 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.987 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 42.2 m -56.38 -27.84 57.41 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -102.31 -5.21 24.51 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.467 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -102.88 131.84 49.51 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.892 -0.505 . . . . 0.0 111.317 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.576 ' CG1' HD21 ' A' ' 22' ' ' LEU . 2.5 m -130.43 -174.78 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.411 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 85.19 -154.77 29.21 Favored Glycine 0 CA--C 1.484 -1.863 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 178.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -78.7 115.7 18.57 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 78.1 mt -119.33 117.82 55.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -85.53 126.24 33.7 Favored 'General case' 0 CA--C 1.487 -1.448 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.491 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 20.8 mtm -124.35 152.26 43.36 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 173.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -119.91 122.96 42.4 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.529 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 45.6 p -120.83 139.95 52.43 Favored 'General case' 0 C--N 1.271 -2.846 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.638 -177.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.501 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.7 mtp -110.33 169.76 6.02 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 11.7 Cg_exo -74.84 30.27 0.35 Allowed 'Trans proline' 0 N--CA 1.486 1.054 0 C-N-CA 122.914 2.409 . . . . 0.0 112.619 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.501 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.9 60.18 2.24 Favored 'General case' 0 CA--C 1.496 -1.132 0 C-N-CA 125.242 1.417 . . . . 0.0 111.583 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -2.013 0 CA-C-N 113.236 -1.802 . . . . 0.0 106.6 172.571 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 . . . . . 0 C--O 1.234 0.282 0 CA-C-O 120.652 0.263 . . . . 0.0 110.833 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.1 t -131.71 157.25 44.26 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 178.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.5 tpt 57.55 63.88 1.72 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 121.975 0.893 . . . . 0.0 110.128 -177.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.58 -119.69 4.15 Favored Glycine 0 CA--C 1.499 -0.951 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -103.48 96.2 6.58 Favored 'General case' 0 CA--C 1.48 -1.724 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.457 HG13 ' HE3' ' A' ' 85' ' ' LYS . 71.4 t -118.64 137.22 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.379 -3.976 0 CA-C-O 122.256 1.027 . . . . 0.0 108.881 -173.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 m -118.72 105.88 12.01 Favored 'General case' 2 N--CA 1.368 -4.562 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 174.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.8 m -83.55 136.75 34.14 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 114.764 -1.107 . . . . 0.0 109.272 -176.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.98 141.88 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.47 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.344 -175.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.415 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 18.2 tp -125.45 116.5 21.92 Favored 'General case' 0 N--CA 1.396 -3.137 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 174.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.476 HD12 HG21 ' A' ' 17' ' ' ILE . 1.0 OUTLIER -99.29 129.61 49.49 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 175.535 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.438 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 74.6 mtp180 -113.1 101.36 9.38 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 122.813 1.292 . . . . 0.0 109.059 169.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -105.04 111.27 65.21 Favored Pre-proline 0 C--N 1.272 -2.785 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.462 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -56.17 -47.88 22.27 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 122.598 2.199 . . . . 0.0 113.05 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.39 178.59 10.14 Favored 'General case' 0 C--O 1.246 0.916 0 CA-C-O 120.893 0.378 . . . . 0.0 110.72 -177.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.558 HD21 ' CG1' ' A' ' 79' ' ' VAL . 53.7 mt -65.05 -21.99 66.91 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 115.637 1.717 . . . . 0.0 115.637 -173.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -79.04 -11.12 59.99 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.17 0.509 . . . . 0.0 111.465 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -83.26 -20.34 34.68 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 57.05 -164.46 0.16 Allowed 'General case' 0 CA--C 1.511 -0.539 0 O-C-N 123.777 0.673 . . . . 0.0 111.648 -176.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.472 ' O ' HG13 ' A' ' 43' ' ' ILE . 0.4 OUTLIER -97.4 -49.43 4.92 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.92 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.21 11.54 Favored Glycine 0 N--CA 1.432 -1.595 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.097 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -143.48 164.26 30.84 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 50.3 m -118.19 133.7 55.67 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 123.89 0.743 . . . . 0.0 109.239 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.57 131.58 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.222 0 CA-C-O 121.69 0.757 . . . . 0.0 110.89 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -120.72 128.85 53.31 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 62.08 2.95 0.87 Allowed 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 124.248 1.019 . . . . 0.0 112.917 -176.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.99 3.05 45.61 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -174.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.406 HG13 ' HB2' ' A' ' 54' ' ' ARG . 3.5 mp -114.08 125.03 71.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.43 HD13 HG11 ' A' ' 49' ' ' VAL . 50.4 mt -61.41 117.97 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 123.834 0.854 . . . . 0.0 110.14 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.9 t -101.98 -34.42 9.35 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.309 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 p -143.35 148.49 36.34 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.3 tp -128.32 132.27 48.64 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.6 ttp -85.45 108.11 17.73 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.57 141.43 58.77 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.449 -177.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.04 -15.38 48.98 Favored Glycine 0 C--N 1.303 -1.252 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.531 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.61 175.45 50.74 Favored Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.472 HG13 ' O ' ' A' ' 26' ' ' LEU . 1.3 pt -59.96 -34.47 56.4 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.748 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.421 ' HA ' HD13 ' A' ' 17' ' ' ILE . . . -62.81 -40.06 96.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -68.11 -36.71 80.19 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.601 0.715 . . . . 0.0 109.12 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -76.58 -23.88 53.51 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.511 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.34 -23.24 63.41 Favored Glycine 0 N--CA 1.438 -1.204 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.507 178.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.98 10.63 22.27 Favored Glycine 0 CA--C 1.501 -0.811 0 C-N-CA 120.231 -0.985 . . . . 0.0 112.883 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.43 HG11 HD13 ' A' ' 35' ' ' ILE . 66.0 t -66.78 135.78 27.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 20.4 mmt180 -133.45 142.72 48.44 Favored 'General case' 0 CA--C 1.481 -1.681 0 CA-C-O 121.165 0.507 . . . . 0.0 110.293 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.5 t -72.65 145.25 12.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.967 -178.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.9 21.08 56.65 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 -178.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.8 m170 -117.21 135.96 53.41 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 115.08 -0.56 . . . . 0.0 111.37 -179.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.452 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 34.8 ttp180 -97.73 123.72 41.78 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 177.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 86' ' ' THR . 30.5 mt -78.62 123.43 35.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.3 pt -100.3 -16.69 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.848 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.449 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.6 tt0 -158.4 144.49 17.07 Favored 'General case' 0 CA--C 1.496 -1.134 0 C-N-CA 119.479 -0.889 . . . . 0.0 110.2 -174.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.415 ' CD1' HG22 ' A' ' 63' ' ' VAL . 82.2 mt -139.91 118.09 11.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 124.674 1.233 . . . . 0.0 108.077 178.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 53.79 27.24 6.81 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 125.299 1.44 . . . . 0.0 114.472 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.55 -10.4 38.68 Favored Glycine 0 CA--C 1.496 -1.106 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.82 175.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 35.5 tt0 -100.54 122.38 43.14 Favored 'General case' 0 C--N 1.292 -1.928 0 CA-C-N 115.488 -0.356 . . . . 0.0 110.393 -177.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -71.32 108.62 4.87 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.547 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.7 m -102.45 10.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-O 121.667 0.746 . . . . 0.0 110.08 -175.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.02 -13.5 16.74 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 114.669 -1.15 . . . . 0.0 111.111 -177.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -123.04 13.66 9.77 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.111 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.8 m -96.9 136.55 21.55 Favored Pre-proline 0 N--CA 1.409 -2.521 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.441 ' O ' HG13 ' A' ' 71' ' ' ILE . 9.5 Cg_endo -56.81 150.01 56.8 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.351 2.034 . . . . 0.0 112.386 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.2 t60 -48.62 -48.25 39.49 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.453 1.101 . . . . 0.0 112.733 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -67.58 -35.49 79.1 Favored 'General case' 0 N--CA 1.435 -1.199 0 O-C-N 123.487 0.492 . . . . 0.0 110.621 -175.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 mttm -63.59 -49.45 73.29 Favored 'General case' 0 CA--C 1.484 -1.586 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.365 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.441 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.0 mt -53.59 -43.15 53.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 O-C-N 124.083 0.865 . . . . 0.0 109.918 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.7 t -71.91 -31.86 42.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.728 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -74.56 -41.04 61.26 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -175.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.7 mt -64.29 -47.75 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 81.7 mt -62.48 -35.23 78.66 Favored 'General case' 0 C--O 1.211 -0.928 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.437 176.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.5 t -63.21 -31.11 72.18 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 122.805 0.442 . . . . 0.0 111.693 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.76 -31.71 13.65 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -175.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.08 130.58 35.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -172.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.558 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.8 m -129.89 -179.41 3.16 Favored 'Isoleucine or valine' 0 C--O 1.243 0.732 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 174.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 86.6 -151.34 24.1 Favored Glycine 0 CA--C 1.488 -1.65 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -79.06 108.78 12.8 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 79.9 mt -111.16 118.82 58.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.746 -175.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -94.56 131.18 40.58 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.449 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -133.11 156.2 47.87 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 172.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.457 ' HE3' HG13 ' A' ' 12' ' ' VAL . 23.2 mmmt -124.47 120.33 31.71 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 105.547 -2.019 . . . . 0.0 105.547 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 33.4 p -119.64 146.68 45.33 Favored 'General case' 0 C--N 1.27 -2.848 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.259 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.545 ' C ' ' H ' ' A' ' 89' ' ' ALA . 49.8 mtm -118.21 169.9 7.11 Favored Pre-proline 0 C--N 1.298 -1.631 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 176.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -69.71 26.26 0.17 Allowed 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 123.336 2.691 . . . . 0.0 112.575 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.545 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 74.86 -1.27 3.13 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 126.538 1.935 . . . . 0.0 113.466 178.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.113 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 . . . . . 0 CA--C 1.531 0.227 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.1 p -72.15 93.1 1.4 Allowed 'General case' 0 N--CA 1.438 -1.055 0 CA-C-O 121.137 0.494 . . . . 0.0 111.183 176.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 25.1 ttt -81.02 -57.62 3.45 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.436 0.636 . . . . 0.0 109.825 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.44 -155.16 6.54 Favored Glycine 0 N--CA 1.425 -2.056 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.078 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.03 96.07 7.63 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-O 121.836 0.826 . . . . 0.0 110.196 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -134.79 133.26 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.191 0 CA-C-N 114.603 -1.18 . . . . 0.0 108.033 -178.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 m -123.0 117.86 26.45 Favored 'General case' 0 C--N 1.261 -3.28 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 21.4 m -85.26 142.3 29.49 Favored 'General case' 0 C--N 1.265 -3.092 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.235 -175.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.63 132.0 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.129 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 13.8 tp -122.09 119.67 32.03 Favored 'General case' 0 N--CA 1.393 -3.281 0 CA-C-O 121.711 0.767 . . . . 0.0 109.991 173.543 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.488 HD12 HG23 ' A' ' 17' ' ' ILE . 1.1 mm -99.87 135.23 36.36 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.026 0 CA-C-N 114.24 -1.346 . . . . 0.0 108.652 176.134 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -115.16 101.24 8.79 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.503 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 73.4 ttt180 -99.22 115.23 65.86 Favored Pre-proline 0 C--N 1.284 -2.275 0 CA-C-N 113.621 -1.627 . . . . 0.0 110.94 -178.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_exo -61.29 -38.0 68.82 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.663 2.242 . . . . 0.0 114.065 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.91 -178.58 4.8 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.417 HD21 HG12 ' A' ' 79' ' ' VAL . 79.7 mt -76.69 -15.23 59.85 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 123.976 0.91 . . . . 0.0 111.277 -176.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -69.79 -16.15 63.24 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.993 176.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -97.97 121.27 39.69 Favored 'General case' 0 CA--C 1.481 -1.682 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 176.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 -97.48 156.96 16.26 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.611 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.512 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.0 OUTLIER -53.08 -65.62 0.53 Allowed 'General case' 0 C--N 1.323 -0.551 0 O-C-N 124.993 1.433 . . . . 0.0 110.778 -174.349 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.28 34.78 4.1 Favored Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 120.129 -1.034 . . . . 0.0 112.626 177.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -155.59 155.73 33.83 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.1 m -107.42 127.35 53.51 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -117.89 136.64 54.41 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 C-N-CA 119.839 -0.744 . . . . 0.0 109.203 179.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -121.92 109.95 15.26 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 60.33 13.34 3.94 Favored 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 124.036 0.934 . . . . 0.0 112.37 -176.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 113.09 -6.85 25.31 Favored Glycine 0 C--O 1.211 -1.323 0 C-N-CA 121.145 -0.55 . . . . 0.0 112.054 -178.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.5 mp -102.24 123.61 55.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.049 -0.677 . . . . 0.0 110.073 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.1 mt -64.14 112.13 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 C-N-CA 124.05 0.94 . . . . 0.0 109.71 178.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 22.6 t -91.59 -37.29 13.18 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.517 -174.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -152.8 157.33 40.61 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 66.4 tp -129.35 132.45 47.08 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 25.6 ttt -87.33 120.4 28.58 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.434 ' C ' ' HD3' ' A' ' 40' ' ' ARG . 0.3 OUTLIER -69.59 136.27 51.05 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.779 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.28 -2.21 74.36 Favored Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.4 164.58 28.26 Favored Glycine 0 N--CA 1.436 -1.308 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 pt -60.81 -36.66 72.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.44 -39.5 70.38 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.014 0.435 . . . . 0.0 111.062 -178.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -67.03 -42.78 84.3 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.023 178.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.89 -37.3 86.9 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.747 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.66 -24.32 76.31 Favored Glycine 0 CA--C 1.516 0.12 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.754 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.75 28.91 5.77 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.409 -0.9 . . . . 0.0 112.564 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.7 t -77.45 142.65 13.93 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -136.21 145.14 45.36 Favored 'General case' 0 CA--C 1.49 -1.338 0 CA-C-O 121.202 0.525 . . . . 0.0 109.623 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.0 t -73.42 144.7 12.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.206 -178.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.83 20.17 58.39 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -179.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.431 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 13.6 m-70 -115.2 144.67 43.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 115.121 -0.539 . . . . 0.0 110.194 178.161 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -104.97 117.48 34.12 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.424 HG12 HG22 ' A' ' 86' ' ' THR . 29.6 mt -73.96 123.79 29.95 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.478 HG23 ' SD ' ' A' ' 87' ' ' MET . 2.4 pp -109.48 -4.13 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.384 -178.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.513 ' O ' ' HA ' ' A' ' 84' ' ' MET . 20.0 tt0 -160.59 146.7 15.12 Favored 'General case' 0 CA--C 1.486 -1.506 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.515 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.462 ' N ' ' HG2' ' A' ' 57' ' ' GLU . 79.3 mt -142.71 120.69 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 172.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.421 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 8.5 m-20 55.07 27.45 9.42 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 177.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.75 -6.86 58.99 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.562 -0.828 . . . . 0.0 113.821 177.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.457 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 11.6 pt20 -107.96 136.36 47.8 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 t -80.98 108.86 15.02 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -178.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.599 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.1 m -100.02 15.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.88 0 CA-C-O 122.09 0.948 . . . . 0.0 109.455 -173.436 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.428 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.6 p -69.73 -21.79 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.876 -175.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.32 13.62 12.78 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.457 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.599 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.7 m -90.37 133.7 32.6 Favored Pre-proline 0 N--CA 1.412 -2.367 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -63.62 155.55 62.38 Favored 'Trans proline' 0 C--O 1.25 1.125 0 C-N-CA 122.178 1.919 . . . . 0.0 112.356 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.35 -53.38 8.65 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.04 1.336 . . . . 0.0 111.313 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -56.99 -43.43 81.71 Favored 'General case' 0 C--N 1.316 -0.855 0 O-C-N 123.903 0.752 . . . . 0.0 111.456 -176.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.45 -54.61 26.01 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.847 -178.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.4 mt -50.39 -43.04 21.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 O-C-N 123.862 0.726 . . . . 0.0 110.293 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 73.0 t -67.1 -40.93 86.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 72.5 t60 -64.74 -44.09 91.25 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.4 -50.93 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 O-C-N 123.592 0.558 . . . . 0.0 109.534 178.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.14 -31.56 72.73 Favored 'General case' 0 C--O 1.209 -1.054 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.4 ' O ' HD22 ' A' ' 22' ' ' LEU . 50.2 m -71.08 -27.45 63.63 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' HD21 ' A' ' 77' ' ' ASN . 0.8 OUTLIER -100.55 -11.46 20.07 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -174.845 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.503 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.77 132.56 38.04 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.237 -0.585 . . . . 0.0 112.031 -176.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.417 HG12 HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -131.4 172.62 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.534 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 78.4 -151.05 35.86 Favored Glycine 0 CA--C 1.496 -1.119 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -176.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -59.11 108.78 0.73 Allowed 'General case' 0 C--O 1.245 0.857 0 C-N-CA 124.417 1.087 . . . . 0.0 111.362 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.421 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 85.4 mt -115.79 118.36 58.54 Favored 'Isoleucine or valine' 0 CA--C 1.456 -2.639 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 11.7 t-80 -106.65 115.87 30.94 Favored 'General case' 0 N--CA 1.385 -3.68 0 CA-C-N 113.199 -1.819 . . . . 0.0 109.456 -170.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.513 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 22.4 mtm -123.91 155.19 38.57 Favored 'General case' 0 C--N 1.261 -3.269 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 177.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 57.1 mmtt -122.06 124.26 43.52 Favored 'General case' 0 C--N 1.265 -3.087 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 175.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.431 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 68.8 p -119.45 134.99 54.95 Favored 'General case' 0 C--N 1.262 -3.236 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.665 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.478 ' SD ' HG23 ' A' ' 56' ' ' ILE . 89.2 mtp -105.98 163.22 17.5 Favored Pre-proline 0 C--N 1.299 -1.619 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 176.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.64 14.48 0.32 Allowed 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 122.724 2.283 . . . . 0.0 113.157 178.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.443 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 65.37 22.94 12.02 Favored 'General case' 0 C--N 1.344 0.36 0 C-N-CA 124.427 1.091 . . . . 0.0 110.68 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.753 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.312 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 CA--C 1.509 -0.615 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 58.5 m 64.93 140.11 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 CA-C-O 122.11 0.957 . . . . 0.0 113.545 175.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' MET . . . . . 0.415 ' HB2' ' SD ' ' A' ' 87' ' ' MET . 1.5 mpt? -87.56 -68.3 0.76 Allowed 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 174.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.63 122.51 0.69 Allowed Glycine 0 CA--C 1.489 -1.584 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 62.19 92.09 0.06 Allowed 'General case' 0 CA--C 1.506 -0.735 0 CA-C-O 121.933 0.873 . . . . 0.0 111.297 -175.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -128.18 128.95 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.358 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.892 -175.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.7 m -115.58 108.19 16.11 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.178 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.4 m -78.7 135.83 37.27 Favored 'General case' 0 N--CA 1.395 -3.18 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.4 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.2 t -116.09 135.79 55.13 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.937 0 CA-C-N 114.793 -1.094 . . . . 0.0 108.478 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.5 tp -121.19 116.8 25.6 Favored 'General case' 0 N--CA 1.385 -3.698 0 C-N-CA 119.561 -0.856 . . . . 0.0 109.428 174.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.486 HD12 HG23 ' A' ' 17' ' ' ILE . 0.9 OUTLIER -97.55 133.94 37.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.352 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.592 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.6 mmm-85 -112.73 101.17 9.29 Favored 'General case' 0 N--CA 1.411 -2.398 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.531 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.2 ttt180 -100.88 110.8 61.95 Favored Pre-proline 0 C--N 1.282 -2.342 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.235 -178.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -54.88 -38.09 92.68 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 123.361 2.707 . . . . 0.0 113.663 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -176.73 -176.89 0.75 Allowed 'General case' 0 C--O 1.241 0.644 0 C-N-CA 123.367 0.667 . . . . 0.0 109.308 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.422 HD21 HG13 ' A' ' 79' ' ' VAL . 69.0 mt -73.28 -6.82 48.49 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -174.478 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -84.57 -13.98 50.18 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.06 0.457 . . . . 0.0 110.565 175.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -103.01 109.1 20.52 Favored 'General case' 0 CA--C 1.491 -1.326 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -82.4 162.73 22.05 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.275 178.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.498 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.1 mm? -52.14 -52.84 49.19 Favored 'General case' 0 C--N 1.321 -0.655 0 O-C-N 124.704 1.253 . . . . 0.0 110.65 -175.161 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.82 28.23 6.33 Favored Glycine 0 N--CA 1.436 -1.319 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.4 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -150.03 151.06 32.66 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m -104.57 124.64 49.67 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -113.95 141.64 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.528 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -177.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.422 ' NE2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp0? -119.06 102.04 8.45 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-O 121.711 0.767 . . . . 0.0 110.56 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 60.98 23.04 13.21 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-N 114.481 -1.236 . . . . 0.0 112.548 178.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.85 -11.01 20.87 Favored Glycine 0 N--CA 1.437 -1.268 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.421 178.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.422 ' HB ' ' NE2' ' A' ' 31' ' ' GLN . 3.1 mp -109.5 119.3 58.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 117.302 0.551 . . . . 0.0 110.781 -178.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.41 HD11 HG12 ' A' ' 49' ' ' VAL . 57.2 mt -59.43 111.93 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 124.193 0.997 . . . . 0.0 111.015 178.07 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 45.3 t -89.67 -38.26 14.01 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.595 -177.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.7 t -148.78 150.78 33.68 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 55.9 tp -122.57 137.55 54.86 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.3 tpp -86.2 120.1 27.19 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.73 129.46 39.86 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.306 -176.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.27 -3.05 86.86 Favored Glycine 0 N--CA 1.421 -2.319 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.419 176.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.5 173.55 47.88 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.38 -0.914 . . . . 0.0 111.923 -176.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 26' ' ' LEU . 2.7 pt -59.17 -34.67 54.25 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -60.91 -39.11 88.12 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.709 0.29 . . . . 0.0 111.272 179.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -66.76 -41.24 88.06 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.826 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.435 ' HG2' ' HA ' ' A' ' 43' ' ' ILE . 13.1 ptt180 -78.66 -16.22 57.57 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.012 -0.675 . . . . 0.0 111.81 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.95 -22.69 63.12 Favored Glycine 0 N--CA 1.433 -1.535 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.708 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.3 15.09 20.55 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.965 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.41 HG12 HD11 ' A' ' 35' ' ' ILE . 73.2 t -70.47 138.3 22.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.408 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 30.9 mmm180 -135.49 151.1 50.04 Favored 'General case' 0 CA--C 1.486 -1.484 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -79.68 145.52 9.16 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.106 -176.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.44 23.18 57.15 Favored Glycine 0 CA--C 1.501 -0.809 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -178.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.493 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.5 m170 -116.5 134.09 55.26 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 114.708 -0.746 . . . . 0.0 111.28 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.9 ttm180 -97.54 125.44 42.25 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 86' ' ' THR . 34.2 mt -78.15 126.95 38.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 177.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 31.0 pt -106.91 -15.48 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.41 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.4 tt0 -155.62 145.81 21.68 Favored 'General case' 0 CA--C 1.481 -1.703 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.386 -173.625 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.457 ' CD1' HG22 ' A' ' 63' ' ' VAL . 74.5 mt -142.22 125.53 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.418 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 87.1 m-20 51.62 24.63 2.41 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 115.837 1.791 . . . . 0.0 115.837 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.86 -5.65 34.72 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.254 -0.974 . . . . 0.0 113.416 176.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.425 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.1 pt20 -115.34 129.33 56.56 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 117.42 0.61 . . . . 0.0 111.009 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.4 m -70.46 108.48 4.31 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.538 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.3 m -100.8 12.8 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 121.734 0.778 . . . . 0.0 109.575 -174.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -66.85 -16.22 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.562 -177.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.93 10.06 10.1 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-O 121.427 0.632 . . . . 0.0 109.576 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.538 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.7 m -85.43 141.42 36.74 Favored Pre-proline 0 N--CA 1.422 -1.841 0 C-N-CA 123.812 0.845 . . . . 0.0 109.214 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.75 147.32 81.11 Favored 'Trans proline' 0 C--O 1.239 0.525 0 C-N-CA 122.642 2.228 . . . . 0.0 112.697 179.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -42.97 -55.22 3.86 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 126.212 1.805 . . . . 0.0 111.168 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -58.5 -44.94 89.62 Favored 'General case' 0 CA--C 1.497 -1.09 0 O-C-N 123.362 0.414 . . . . 0.0 110.845 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.43 -55.07 39.34 Favored 'General case' 0 C--O 1.201 -1.479 0 O-C-N 123.861 0.725 . . . . 0.0 110.087 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 59.8 mt -50.38 -43.45 22.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 C-N-CA 123.554 0.742 . . . . 0.0 110.952 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.1 t -72.43 -36.12 53.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.829 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -70.67 -40.01 73.21 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 123.323 0.649 . . . . 0.0 109.611 -177.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.33 -49.51 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 176.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 85.2 mt -62.05 -46.27 89.88 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.6 m -64.32 -26.89 68.68 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -91.28 -19.79 22.6 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.09 139.04 31.03 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.837 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.422 HG13 HD21 ' A' ' 22' ' ' LEU . 1.1 m -132.38 178.55 5.45 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 174.04 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.418 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 76.9 -151.3 38.89 Favored Glycine 0 CA--C 1.48 -2.136 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -65.33 114.86 5.06 Favored 'General case' 0 CA--C 1.497 -1.096 0 O-C-N 124.693 0.878 . . . . 0.0 110.175 174.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.418 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 83.5 mt -118.62 117.29 54.0 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.703 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 175.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -99.48 120.08 39.05 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 -174.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.435 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 25.2 mtm -126.32 157.28 38.82 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -121.98 125.12 45.61 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 176.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.493 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 44.6 p -121.26 144.08 48.81 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.372 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.48 ' C ' ' H ' ' A' ' 89' ' ' ALA . 54.5 mtm -116.73 168.96 7.87 Favored Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -71.29 29.58 0.23 Allowed 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 123.056 2.504 . . . . 0.0 112.861 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.48 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 57.4 50.48 11.29 Favored 'General case' 0 C--O 1.245 0.855 0 CA-C-O 122.496 1.141 . . . . 0.0 110.332 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.92 0 CA-C-N 113.782 -1.554 . . . . 0.0 108.026 179.621 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 . . . . . 0 C--O 1.241 0.628 0 CA-C-O 121.309 0.575 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 t -115.39 146.61 41.43 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 172.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 43.4 ttm -147.42 127.65 13.85 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 118.315 -1.354 . . . . 0.0 113.401 -170.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.4 -79.2 0.07 OUTLIER Glycine 0 CA--C 1.491 -1.455 0 N-CA-C 106.84 -2.504 . . . . 0.0 106.84 172.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -150.4 110.54 4.15 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 168.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 69.5 t -95.68 128.62 46.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.505 0 CA-C-N 113.35 -1.75 . . . . 0.0 109.466 -173.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.1 m -122.45 109.2 14.07 Favored 'General case' 2 C--N 1.236 -4.33 0 CA-C-N 113.291 -1.777 . . . . 0.0 106.865 177.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -79.01 138.66 38.13 Favored 'General case' 0 N--CA 1.406 -2.674 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.154 -176.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.57 133.41 62.0 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.547 177.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.419 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 14.4 tp -121.17 116.13 24.37 Favored 'General case' 0 N--CA 1.396 -3.134 0 C-N-CA 119.989 -0.684 . . . . 0.0 110.005 176.419 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.445 HD13 ' HA ' ' A' ' 44' ' ' ALA . 0.6 OUTLIER -98.89 138.64 22.79 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.978 0 CA-C-N 114.563 -1.198 . . . . 0.0 108.02 178.256 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -115.13 101.73 9.25 Favored 'General case' 0 N--CA 1.414 -2.252 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 168.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.517 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 65.3 ttt180 -97.89 116.28 65.7 Favored Pre-proline 0 C--N 1.284 -2.26 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.001 -177.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -49.36 -54.43 5.46 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.034 2.49 . . . . 0.0 112.602 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.582 ' OD2' ' HG3' ' A' ' 23' ' ' ARG . 2.7 p-10 -173.1 -170.49 0.64 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.454 ' HA ' ' NH2' ' A' ' 19' ' ' ARG . 54.1 mt -68.6 -16.65 63.92 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -173.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.582 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 27.0 mtt180 -71.34 -12.23 61.32 Favored 'General case' 0 N--CA 1.481 1.087 0 CA-C-O 121.167 0.508 . . . . 0.0 110.785 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -113.98 143.36 44.87 Favored 'General case' 0 N--CA 1.427 -1.614 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -116.96 171.56 7.83 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.243 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.559 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.4 OUTLIER -58.31 -61.93 2.21 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 125.124 1.369 . . . . 0.0 111.245 -173.081 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.61 37.99 3.1 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 119.794 -1.193 . . . . 0.0 112.129 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -154.7 163.02 40.86 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.8 m -117.94 128.62 54.98 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.47 138.76 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 120.864 0.364 . . . . 0.0 110.133 -176.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 19.9 pt20 -131.04 121.62 25.34 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.1 m120 63.58 13.44 7.28 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.206 1.002 . . . . 0.0 111.857 -175.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.51 1.91 58.93 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.412 -0.899 . . . . 0.0 111.138 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -106.07 119.88 56.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.442 HD13 HG12 ' A' ' 49' ' ' VAL . 62.3 mt -62.06 116.83 2.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 C-N-CA 124.369 1.068 . . . . 0.0 110.099 177.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.8 t -96.11 -38.18 10.28 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.27 -176.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 13.3 p -149.06 152.38 36.11 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.279 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 53.4 tp -127.46 145.38 50.85 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 123.576 0.75 . . . . 0.0 109.506 -178.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.8 ttp -93.42 115.88 28.42 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.148 0.499 . . . . 0.0 109.893 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.44 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.0 tpp85 -65.58 118.68 9.86 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 124.726 1.21 . . . . 0.0 109.463 -179.101 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -12.99 59.13 Favored Glycine 0 C--N 1.305 -1.142 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.793 -177.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.401 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -79.93 161.04 45.37 Favored Glycine 0 C--O 1.245 0.814 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.929 -177.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -54.22 -37.69 36.8 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.756 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.445 ' HA ' HD13 ' A' ' 17' ' ' ILE . . . -56.1 -44.2 78.82 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.199 0.524 . . . . 0.0 110.903 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.44 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 44.0 tt0 -70.14 -38.8 75.6 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.469 -179.52 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 48.3 mtt180 -66.59 -34.16 77.28 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.104 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.44 -20.61 79.54 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.782 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.08 20.29 7.62 Favored Glycine 0 C--O 1.24 0.489 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.696 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.442 HG12 HD13 ' A' ' 35' ' ' ILE . 45.0 t -71.34 144.29 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.455 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.4 mmt180 -132.61 142.66 49.24 Favored 'General case' 0 CA--C 1.484 -1.57 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.8 t -74.26 142.71 14.41 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.561 0 CA-C-N 114.583 -1.189 . . . . 0.0 109.192 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.16 22.25 55.15 Favored Glycine 0 CA--C 1.498 -0.989 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.1 m170 -114.67 135.2 54.42 Favored 'General case' 0 N--CA 1.424 -1.764 0 CA-C-N 115.129 -0.536 . . . . 0.0 111.066 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.6 ttm-85 -93.96 125.3 38.51 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.409 HG12 HG22 ' A' ' 86' ' ' THR . 26.1 mt -83.0 123.62 38.76 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.337 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 174.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.2 pt -103.25 -12.06 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.36 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.688 -178.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.499 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.2 tt0 -163.02 143.51 9.34 Favored 'General case' 0 CA--C 1.494 -1.176 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.633 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 90.8 mt -140.03 121.84 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 O-C-N 124.228 0.955 . . . . 0.0 109.222 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 53.32 32.48 13.71 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.203 1.401 . . . . 0.0 112.447 172.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.59 -1.34 52.97 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.284 -0.96 . . . . 0.0 114.551 177.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -123.89 130.44 52.61 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 118.311 1.056 . . . . 0.0 110.755 178.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.3 t -74.74 109.32 8.12 Favored 'General case' 0 N--CA 1.425 -1.692 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.452 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 29.2 m -99.68 16.6 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.387 0 CA-C-O 121.968 0.889 . . . . 0.0 109.661 -174.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.8 p -72.95 -9.82 13.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 114.44 -1.254 . . . . 0.0 111.194 -176.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.53 19.19 5.74 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.452 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.1 m -100.66 137.96 19.99 Favored Pre-proline 0 N--CA 1.412 -2.331 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.454 ' O ' HG13 ' A' ' 71' ' ' ILE . 50.1 Cg_endo -69.44 158.07 58.71 Favored 'Trans proline' 0 C--O 1.246 0.885 0 C-N-CA 122.435 2.09 . . . . 0.0 112.999 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -42.69 -56.19 3.26 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 126.7 2.0 . . . . 0.0 112.152 -178.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.84 -38.77 89.78 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.433 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -60.25 -51.83 67.87 Favored 'General case' 0 CA--C 1.485 -1.546 0 C-N-CA 119.974 -0.691 . . . . 0.0 110.93 177.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.454 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.5 mt -50.99 -44.9 28.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 O-C-N 124.329 1.018 . . . . 0.0 110.263 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.0 t -72.68 -35.13 49.42 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.087 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.9 t60 -69.67 -40.2 76.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.389 0.614 . . . . 0.0 109.586 -176.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 29.4 mt -70.19 -43.59 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 CA-C-N 114.829 -1.078 . . . . 0.0 109.931 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.5 mt -59.39 -46.34 88.95 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.632 175.031 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.3 t -57.92 -28.06 63.92 Favored 'General case' 0 C--O 1.215 -0.712 0 C-N-CA 124.122 0.969 . . . . 0.0 111.686 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -99.81 -6.42 26.93 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -178.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.517 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -101.28 130.55 47.44 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.893 -0.723 . . . . 0.0 111.484 -178.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.405 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -128.94 178.99 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.285 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.401 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 84.23 -153.59 29.33 Favored Glycine 0 CA--C 1.495 -1.178 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -77.61 110.37 12.37 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-O 121.403 0.62 . . . . 0.0 109.67 177.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 74.6 mt -112.94 117.64 55.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -93.76 118.76 31.85 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.499 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.9 mtm -118.13 156.03 29.41 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 174.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -121.54 121.38 37.35 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 42.9 p -121.29 146.62 46.64 Favored 'General case' 0 C--N 1.26 -3.297 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.765 -177.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.456 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.6 mtm -126.58 168.71 13.64 Favored Pre-proline 0 C--N 1.31 -1.142 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -70.79 38.76 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.145 0 C-N-CA 123.812 3.008 . . . . 0.0 113.654 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.456 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 54.79 56.03 7.17 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 125.58 1.552 . . . . 0.0 114.139 177.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.299 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.32 172.136 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.238 0.476 0 CA-C-O 120.874 0.369 . . . . 0.0 111.806 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.2 t -139.63 107.06 5.54 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 122.113 0.959 . . . . 0.0 108.937 175.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 26.8 ttt -108.83 -34.69 6.59 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.111 -177.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.2 -107.46 0.2 Allowed Glycine 0 N--CA 1.417 -2.57 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -127.1 106.99 9.64 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -127.28 127.45 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.453 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -115.92 113.21 23.0 Favored 'General case' 0 C--N 1.246 -3.896 0 N-CA-C 106.222 -1.77 . . . . 0.0 106.222 177.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.2 m -86.39 137.82 32.27 Favored 'General case' 0 N--CA 1.395 -3.178 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.995 -175.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.9 t -118.49 141.81 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.629 0 CA-C-N 114.64 -1.164 . . . . 0.0 109.045 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.451 HD12 ' HB3' ' A' ' 81' ' ' GLU . 11.5 tp -129.23 105.69 8.32 Favored 'General case' 0 N--CA 1.386 -3.643 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 171.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.513 HG21 ' HB ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -99.57 127.99 51.81 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.033 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 -175.378 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.41 116.83 29.34 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.566 -177.099 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.437 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 61.6 ttt180 -119.15 116.06 34.15 Favored Pre-proline 0 C--N 1.292 -1.921 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.044 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -62.45 -48.93 6.62 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.422 2.082 . . . . 0.0 112.997 179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.429 ' OD1' ' HD3' ' A' ' 23' ' ' ARG . 2.8 p30 -159.76 -175.58 5.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.482 HD21 ' CG1' ' A' ' 79' ' ' VAL . 54.6 mt -71.43 -15.94 62.37 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -173.644 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.429 ' HD3' ' OD1' ' A' ' 21' ' ' ASP . 4.0 mpt_? -80.8 -11.95 59.52 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.47 0.652 . . . . 0.0 109.717 -179.051 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -95.26 116.16 28.38 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -86.56 150.13 24.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.605 177.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.507 ' H ' HD23 ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.31 -49.91 66.04 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 124.953 1.408 . . . . 0.0 111.188 -172.761 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.72 37.8 3.85 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.047 178.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -161.11 164.89 30.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.451 ' HB3' ' OG ' ' A' ' 37' ' ' SER . 34.8 t -123.4 130.15 52.3 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.448 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.445 ' O ' ' HE1' ' A' ' 68' ' ' HIS . 0.8 OUTLIER -115.46 143.74 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.878 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.856 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -130.54 128.76 41.78 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.4 t30 59.39 11.97 2.46 Favored 'General case' 0 CA--C 1.573 1.83 0 C-N-CA 123.559 0.744 . . . . 0.0 112.353 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.58 3.72 55.08 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.66 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -118.09 124.86 73.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.406 HD12 HG11 ' A' ' 49' ' ' VAL . 49.0 mt -65.12 121.71 14.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 123.876 0.87 . . . . 0.0 110.548 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.4 t -109.58 -25.96 10.17 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.752 -177.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.451 ' OG ' ' HB3' ' A' ' 29' ' ' SER . 12.9 p -146.32 144.38 29.76 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 122.168 -0.332 . . . . 0.0 110.548 177.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 51.0 tp -125.74 133.64 52.02 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 123.767 0.827 . . . . 0.0 109.758 -177.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.1 ttm -75.21 119.18 18.99 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.173 0.511 . . . . 0.0 109.839 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 18.6 tpp180 -66.99 122.09 16.99 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.547 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.6 1.99 82.6 Favored Glycine 0 C--N 1.312 -0.767 0 C-N-CA 120.898 -0.667 . . . . 0.0 111.999 -178.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 46' ' ' ARG . . . -86.12 165.49 37.82 Favored Glycine 0 C--O 1.252 1.239 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.288 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.1 pt -61.91 -30.88 49.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.59 -45.33 94.58 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 120.94 0.4 . . . . 0.0 110.282 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -64.86 -42.21 95.05 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.785 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.493 ' HG2' ' O ' ' A' ' 42' ' ' GLY . 6.7 mmp_? -61.11 -39.4 89.84 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.712 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.2 -16.97 78.57 Favored Glycine 0 CA--C 1.524 0.646 0 CA-C-N 115.59 -0.732 . . . . 0.0 113.903 -178.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.14 12.1 22.64 Favored Glycine 0 C--O 1.241 0.588 0 C-N-CA 119.749 -1.215 . . . . 0.0 113.033 177.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.406 HG11 HD12 ' A' ' 35' ' ' ILE . 80.6 t -72.63 142.82 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -140.8 154.99 46.47 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.49 142.35 14.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.77 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 13.75 58.6 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -177.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.492 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -109.55 135.53 50.39 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 121.151 0.5 . . . . 0.0 111.419 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -95.2 122.94 38.4 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 176.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.2 mt -82.78 122.73 37.7 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 62' ' ' SER . 32.4 pt -103.3 -14.97 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.004 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 178.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.581 ' O ' ' HA ' ' A' ' 84' ' ' MET . 30.7 tt0 -150.92 141.86 22.95 Favored 'General case' 0 CA--C 1.479 -1.762 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -176.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.479 ' CD1' HG23 ' A' ' 63' ' ' VAL . 69.8 mt -143.2 122.0 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.539 0 O-C-N 124.64 1.213 . . . . 0.0 108.127 176.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 66.69 18.57 10.74 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.663 1.185 . . . . 0.0 110.927 171.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.69 -12.06 30.08 Favored Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.75 177.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.424 ' O ' HG12 ' A' ' 63' ' ' VAL . 13.3 pt20 -115.89 143.34 45.55 Favored 'General case' 0 CA--C 1.501 -0.941 0 CA-C-N 117.732 0.766 . . . . 0.0 112.602 -178.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 49.9 m -75.86 108.87 9.03 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.233 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.566 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 23.3 m -102.09 15.02 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 122.124 0.964 . . . . 0.0 109.226 -174.422 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 p -72.97 -17.96 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-N 114.792 -1.094 . . . . 0.0 110.614 -177.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.59 9.32 16.56 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.954 0.883 . . . . 0.0 109.817 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.1 m -90.85 137.0 27.05 Favored Pre-proline 0 N--CA 1.411 -2.422 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.402 ' O ' HG13 ' A' ' 71' ' ' ILE . 12.0 Cg_endo -64.37 154.51 70.99 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 121.676 1.584 . . . . 0.0 111.585 178.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.445 ' HE1' ' O ' ' A' ' 30' ' ' VAL . 69.0 t60 -47.73 -53.49 15.02 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.375 1.07 . . . . 0.0 113.633 -176.461 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -67.97 -31.76 71.7 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.58 -175.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.436 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.0 mttm -63.62 -50.55 68.93 Favored 'General case' 0 C--O 1.189 -2.095 0 C-N-CA 120.197 -0.601 . . . . 0.0 110.035 173.098 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.8 mt -50.3 -43.97 22.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 O-C-N 123.533 0.521 . . . . 0.0 110.223 177.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 86.7 t -69.1 -34.13 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.691 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.642 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -70.87 -42.56 69.9 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 123.381 0.672 . . . . 0.0 109.78 -177.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.9 mp -60.91 -48.68 87.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 80.8 mt -61.39 -46.47 90.02 Favored 'General case' 0 C--O 1.215 -0.753 0 N-CA-C 113.103 0.779 . . . . 0.0 113.103 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -61.73 -27.47 68.74 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -178.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -101.48 -19.19 15.64 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -176.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.437 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -91.54 132.21 36.44 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 122.022 -0.424 . . . . 0.0 111.569 -176.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.482 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.5 m -126.7 -176.37 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.402 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.41 ' N ' HG21 ' A' ' 79' ' ' VAL . . . 88.49 -163.29 32.46 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.451 ' HB3' HD12 ' A' ' 16' ' ' LEU . 2.4 mp0 -75.58 122.06 23.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 171.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.513 ' HB ' HG21 ' A' ' 17' ' ' ILE . 70.7 mt -115.57 119.81 62.91 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.278 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -84.61 112.02 20.06 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 113.43 -1.714 . . . . 0.0 110.372 -174.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.581 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 13.5 mtp -120.57 143.9 48.38 Favored 'General case' 0 C--N 1.253 -3.612 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.745 178.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 12.1 mmmt -120.87 118.5 30.11 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 177.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 65.0 p -119.14 145.55 45.88 Favored 'General case' 0 C--N 1.282 -2.359 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.355 -176.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.527 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.3 mtp -115.8 163.9 19.41 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 178.096 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.42 24.33 0.23 Allowed 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.035 2.49 . . . . 0.0 112.352 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.527 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.41 22.91 13.48 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.4 1.48 . . . . 0.0 111.891 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.904 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 175.765 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 . . . . . 0 CA--C 1.509 -0.606 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -150.07 103.2 3.17 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 124.23 1.012 . . . . 0.0 108.603 173.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 16.2 tpt -88.27 123.56 33.0 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 121.179 0.514 . . . . 0.0 111.631 -177.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.92 -165.27 23.98 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 176.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 87' ' ' MET . 28.3 t-20 -94.62 87.12 4.98 Favored 'General case' 0 C--N 1.28 -2.419 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.8 t -108.77 117.76 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.79 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.877 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -115.64 114.86 25.47 Favored 'General case' 1 C--N 1.24 -4.174 0 CA-C-N 113.25 -1.795 . . . . 0.0 106.923 178.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.0 m -79.09 141.84 36.98 Favored 'General case' 0 N--CA 1.406 -2.67 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.217 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.419 HG13 ' CG2' ' A' ' 49' ' ' VAL . 57.1 t -121.86 128.28 75.64 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.363 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.506 178.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.428 HD13 ' HB3' ' A' ' 81' ' ' GLU . 22.3 tp -109.37 112.46 24.6 Favored 'General case' 0 N--CA 1.402 -2.836 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 173.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.522 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 134.83 47.32 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.546 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.015 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.73 103.36 12.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-O 121.102 0.477 . . . . 0.0 109.72 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.47 ' HD2' ' O ' ' A' ' 78' ' ' ALA . 34.0 ttm180 -100.83 113.74 65.73 Favored Pre-proline 0 C--N 1.29 -1.989 0 CA-C-N 115.63 -0.713 . . . . 0.0 110.307 177.76 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.61 -42.11 50.19 Favored 'Trans proline' 0 C--O 1.239 0.572 0 C-N-CA 122.281 1.987 . . . . 0.0 112.181 177.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -173.7 177.04 2.58 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -178.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.428 HD22 ' O ' ' A' ' 76' ' ' SER . 53.1 mt -67.01 -22.38 65.9 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 -171.528 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -71.67 -11.65 60.94 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-O 121.406 0.622 . . . . 0.0 111.426 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.3 -20.98 23.4 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.831 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . 0.464 ' C ' HH21 ' A' ' 19' ' ' ARG . 26.4 mt-30 54.09 -153.58 0.28 Allowed 'General case' 0 C--O 1.22 -0.453 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.448 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.429 ' O ' HG13 ' A' ' 43' ' ' ILE . 2.1 mm? -97.47 -57.55 2.22 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.802 0.811 . . . . 0.0 110.49 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.67 2.99 32.56 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 -174.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.41 ' CD1' ' HB3' ' A' ' 26' ' ' LEU . 39.1 p90 -137.83 152.18 48.84 Favored 'General case' 0 C--O 1.246 0.887 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 176.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -105.81 122.73 46.7 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -104.18 137.27 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -119.14 111.79 18.7 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 175.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.437 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 95.3 m-20 65.86 9.13 5.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.352 178.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.0 -3.74 24.1 Favored Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -112.82 122.12 66.39 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 48.2 mt -60.43 116.14 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 123.625 0.77 . . . . 0.0 110.56 179.314 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.1 t -98.08 -33.2 11.25 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.013 -173.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 56.9 p -150.91 151.66 32.5 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 60.2 tp -135.42 137.88 42.7 Favored 'General case' 0 N--CA 1.441 -0.906 0 O-C-N 123.482 0.489 . . . . 0.0 110.829 -178.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 63.0 mtt -92.76 116.78 29.34 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.074 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -69.68 126.77 30.73 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 174.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.38 -21.5 39.13 Favored Glycine 0 N--CA 1.42 -2.427 0 C-N-CA 120.412 -0.899 . . . . 0.0 110.984 -174.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.403 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -78.91 159.04 45.28 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 177.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.429 HG13 ' O ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -55.12 -30.7 24.53 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.866 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.315 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.75 -47.27 84.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 123.569 0.543 . . . . 0.0 111.099 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -67.15 -34.22 77.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.458 0.647 . . . . 0.0 109.492 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.403 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 47.8 mtt180 -75.51 -17.27 60.15 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.613 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.77 -37.57 8.53 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 121.74 17.76 3.77 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.026 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.419 ' CG2' HG13 ' A' ' 15' ' ' VAL . 59.2 t -71.1 141.56 16.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.8 mmm180 -137.64 146.14 43.54 Favored 'General case' 0 CA--C 1.483 -1.619 0 CA-C-O 121.267 0.556 . . . . 0.0 110.649 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.1 t -69.35 147.07 12.21 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.484 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.52 28.56 47.3 Favored Glycine 0 CA--C 1.487 -1.694 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.523 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -123.85 129.03 50.36 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.883 -0.659 . . . . 0.0 111.175 -179.069 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 ttm180 -89.23 124.13 34.1 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 175.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 55' ' ' ILE . 25.9 mt -81.54 124.51 39.02 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.141 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 43.1 pt -106.61 -12.5 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.503 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -154.33 145.42 22.75 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -177.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.421 ' CD1' HG23 ' A' ' 63' ' ' VAL . 80.2 mt -138.68 121.43 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.299 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 58.2 26.5 13.88 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.071 1.348 . . . . 0.0 111.711 174.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.88 -5.41 58.07 Favored Glycine 0 C--O 1.241 0.555 0 C-N-CA 120.025 -1.084 . . . . 0.0 113.774 177.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -110.91 128.74 55.91 Favored 'General case' 0 CA--C 1.499 -0.992 0 CA-C-N 117.609 0.705 . . . . 0.0 109.554 177.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -72.89 112.74 9.2 Favored 'General case' 0 N--CA 1.42 -1.949 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.5 ' O ' ' HB ' ' A' ' 66' ' ' THR . 32.7 m -102.21 10.77 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.964 0 CA-C-O 121.634 0.731 . . . . 0.0 109.64 -175.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 p -71.69 -16.46 18.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.608 -177.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.63 9.87 21.09 Favored 'General case' 0 C--O 1.244 0.796 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.511 177.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.5 ' HB ' ' O ' ' A' ' 63' ' ' VAL . 82.5 m -94.37 139.58 22.47 Favored Pre-proline 0 N--CA 1.405 -2.678 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -57.29 144.07 92.02 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.393 2.062 . . . . 0.0 110.483 177.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.437 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 35.0 p80 -51.73 -41.1 61.27 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 -177.796 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -68.01 -35.0 77.57 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 -178.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.43 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 15.4 tttm -68.87 -44.65 72.88 Favored 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.465 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 63.8 mt -53.1 -45.06 53.05 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 O-C-N 123.722 0.639 . . . . 0.0 109.747 176.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.5 t -68.79 -32.31 54.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.452 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.2 t-160 -72.7 -38.99 67.34 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -175.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.9 mt -67.99 -50.75 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.675 177.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.3 mt -59.95 -30.92 69.4 Favored 'General case' 0 C--O 1.199 -1.578 0 CA-C-O 120.964 0.411 . . . . 0.0 111.414 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.428 ' O ' HD22 ' A' ' 22' ' ' LEU . 34.1 t -70.41 -26.29 63.62 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.281 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -123.53 8.5 8.96 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -172.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -99.09 122.17 41.96 Favored 'General case' 0 C--O 1.204 -1.335 0 CA-C-N 118.259 0.481 . . . . 0.0 109.744 177.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.437 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -115.42 169.96 5.78 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 CA-C-N 119.058 0.844 . . . . 0.0 109.527 177.342 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.5 -159.27 19.23 Favored Glycine 0 N--CA 1.434 -1.496 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.428 ' HB3' HD13 ' A' ' 16' ' ' LEU . 38.6 mt-10 -80.65 111.92 17.54 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.522 ' HB ' HG23 ' A' ' 17' ' ' ILE . 62.0 mt -115.42 117.39 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -173.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -90.16 111.71 22.95 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 25.7 mtm -111.05 160.39 16.9 Favored 'General case' 0 C--N 1.278 -2.505 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -121.95 125.15 45.71 Favored 'General case' 0 CA--C 1.47 -2.12 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 176.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.523 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 66.1 p -123.68 141.6 51.87 Favored 'General case' 0 C--N 1.265 -3.108 0 C-N-CA 120.195 -0.602 . . . . 0.0 110.451 -177.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.487 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.2 mtp -116.53 171.38 4.82 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.158 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -75.51 29.67 0.37 Allowed 'Trans proline' 0 C--N 1.363 1.313 0 C-N-CA 122.823 2.348 . . . . 0.0 112.431 179.007 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.487 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.47 55.19 4.25 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.235 1.414 . . . . 0.0 111.526 -179.161 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.422 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 174.566 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.509 -0.611 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 97.9 m -110.34 109.13 19.44 Favored 'General case' 0 N--CA 1.421 -1.908 0 CA-C-O 121.21 0.528 . . . . 0.0 110.774 -179.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -102.26 -18.56 15.41 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.296 175.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 130.16 73.1 0.13 Allowed Glycine 0 CA--C 1.491 -1.417 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 68.91 86.79 0.13 Allowed 'General case' 0 CA--C 1.501 -0.931 0 CA-C-O 122.587 1.184 . . . . 0.0 110.937 -175.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.407 HG22 ' HG2' ' A' ' 87' ' ' MET . 79.8 t -125.16 130.56 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.827 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -175.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.8 m -112.21 106.02 14.5 Favored 'General case' 2 N--CA 1.371 -4.395 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 178.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 28.9 m -79.47 135.28 36.61 Favored 'General case' 0 N--CA 1.395 -3.198 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.32 -179.067 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.2 t -114.47 134.38 57.61 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.024 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.142 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.47 HD13 ' HB3' ' A' ' 81' ' ' GLU . 15.4 tp -119.65 104.49 10.31 Favored 'General case' 0 N--CA 1.396 -3.166 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 172.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.519 HG21 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -103.15 126.79 57.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.054 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -175.09 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.441 ' HG2' HH11 ' A' ' 18' ' ' ARG . 0.5 OUTLIER -95.43 122.03 37.73 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.921 -178.32 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.484 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 64.8 ttt180 -128.04 105.43 20.22 Favored Pre-proline 0 C--N 1.285 -2.226 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.05 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -52.31 -48.03 23.86 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 122.721 2.281 . . . . 0.0 113.372 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -167.93 -172.34 1.8 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.403 HD21 ' CG1' ' A' ' 79' ' ' VAL . 46.5 mt -70.04 -21.48 63.17 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -173.698 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.1 mpt_? -72.48 -13.02 61.33 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.305 0.574 . . . . 0.0 110.87 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -103.91 121.94 44.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.251 69.3 mt-30 -103.6 157.54 16.99 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 119.048 -1.061 . . . . 0.0 113.652 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.526 ' H ' HD22 ' A' ' 26' ' ' LEU . 1.5 mm? -44.77 -58.42 3.1 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 126.708 2.003 . . . . 0.0 111.704 -174.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.64 32.43 6.59 Favored Glycine 0 N--CA 1.427 -1.908 0 C-N-CA 119.86 -1.162 . . . . 0.0 112.256 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -159.24 161.45 36.02 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.1 t -119.9 124.03 45.04 Favored 'General case' 0 N--CA 1.415 -2.189 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -117.86 135.01 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.287 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -178.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -120.88 112.53 18.9 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.808 176.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.38 12.27 8.27 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 114.597 -1.183 . . . . 0.0 110.97 177.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.47 -4.86 31.25 Favored Glycine 0 C--O 1.206 -1.635 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.106 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.8 mp -109.25 126.57 66.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 122.117 -0.637 . . . . 0.0 109.617 -178.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 54.6 mt -71.21 115.05 10.5 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.804 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 25.2 t -101.21 -28.98 12.36 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.294 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -150.49 150.42 31.27 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.273 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 154.84 45.16 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -178.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.0 ttt -101.89 121.67 42.56 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.448 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 1.2 tmt_? -69.22 128.88 38.16 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.617 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.71 86.41 Favored Glycine 0 C--N 1.311 -0.83 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 -178.172 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.488 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -82.48 161.96 41.28 Favored Glycine 0 N--CA 1.433 -1.542 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -60.8 -30.12 46.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.0 98.01 Favored 'General case' 0 N--CA 1.439 -1.002 0 O-C-N 123.264 0.353 . . . . 0.0 111.07 177.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.66 -47.84 83.07 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 177.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.488 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 22.3 mtt180 -63.16 -39.67 95.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.155 -1.384 . . . . 0.0 109.23 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -64.3 -30.82 78.89 Favored Glycine 0 C--O 1.248 0.979 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.48 -178.255 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 115.61 9.89 12.14 Favored Glycine 0 N--CA 1.439 -1.137 0 C-N-CA 120.073 -1.06 . . . . 0.0 111.489 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 88.5 t -71.84 134.7 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -143.51 146.32 33.28 Favored 'General case' 0 CA--C 1.495 -1.148 0 C-N-CA 123.666 0.786 . . . . 0.0 109.674 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -67.36 144.34 14.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 CA-C-N 114.15 -1.386 . . . . 0.0 111.136 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.94 61.79 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.911 -0.661 . . . . 0.0 111.475 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -120.39 148.65 43.5 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.482 ' O ' ' HA ' ' A' ' 86' ' ' THR . 42.2 ttp180 -106.35 132.53 52.27 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.536 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.426 HD11 HG22 ' A' ' 86' ' ' THR . 18.2 mm -75.48 114.61 15.78 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 175.584 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.1 pt -101.03 -15.23 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.808 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 179.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 84' ' ' MET . 38.1 tt0 -156.37 146.12 20.99 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.449 ' CD1' HG23 ' A' ' 63' ' ' VAL . 71.5 mt -140.8 122.5 14.63 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 O-C-N 124.388 1.055 . . . . 0.0 108.521 178.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 59.32 23.18 11.61 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.708 1.203 . . . . 0.0 111.626 172.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.01 -9.96 40.05 Favored Glycine 0 N--CA 1.439 -1.14 0 C-N-CA 120.535 -0.841 . . . . 0.0 114.061 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.13 134.44 52.72 Favored 'General case' 0 CA--C 1.494 -1.203 0 CA-C-N 118.34 1.07 . . . . 0.0 110.752 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -72.53 112.59 8.72 Favored 'General case' 0 N--CA 1.423 -1.787 0 CA-C-O 121.337 0.589 . . . . 0.0 109.692 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.641 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 25.1 m -109.15 19.38 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-O 122.312 1.053 . . . . 0.0 108.932 -175.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.12 -18.6 19.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.388 -176.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.88 12.03 12.76 Favored 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.669 0.747 . . . . 0.0 109.009 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.641 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 97.3 m -83.88 136.74 41.26 Favored Pre-proline 0 N--CA 1.417 -2.083 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.44 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_exo -60.12 154.87 48.58 Favored 'Trans proline' 0 C--O 1.241 0.662 0 C-N-CA 122.928 2.419 . . . . 0.0 112.912 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -45.3 -55.7 5.65 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.715 1.606 . . . . 0.0 111.151 178.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -58.85 -43.6 90.79 Favored 'General case' 0 C--N 1.311 -1.095 0 O-C-N 124.307 1.004 . . . . 0.0 110.546 -175.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -62.21 -54.34 42.35 Favored 'General case' 0 CA--C 1.477 -1.835 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.883 -178.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 73.0 mt -52.01 -42.74 35.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 O-C-N 124.177 0.923 . . . . 0.0 110.383 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 83.6 t -71.66 -39.32 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.657 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 53.8 t60 -69.8 -41.55 74.91 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.519 0.676 . . . . 0.0 109.903 -176.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.6 mt -69.52 -44.03 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 CA-C-N 114.674 -1.148 . . . . 0.0 110.314 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 60.1 mt -59.99 -44.05 94.76 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.829 0.347 . . . . 0.0 111.086 173.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.6 t -59.16 -27.44 65.66 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 123.49 0.716 . . . . 0.0 112.216 -179.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -109.39 -2.74 17.57 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -176.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.484 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -97.68 130.82 44.65 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.478 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.403 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.5 m -128.3 179.73 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.65 -161.96 28.78 Favored Glycine 0 CA--C 1.489 -1.563 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -178.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.47 ' HB3' HD13 ' A' ' 16' ' ' LEU . 27.9 mt-10 -75.89 119.15 19.47 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 172.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.519 ' HB ' HG21 ' A' ' 17' ' ' ILE . 63.1 mt -117.19 117.63 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.711 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.246 -173.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -82.98 111.8 19.17 Favored 'General case' 0 CA--C 1.492 -1.257 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.603 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.408 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 28.4 mtm -117.55 156.54 27.9 Favored 'General case' 0 C--N 1.269 -2.914 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 173.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 35.6 mmtm -123.07 121.65 36.55 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.482 ' HA ' ' O ' ' A' ' 54' ' ' ARG . 68.3 p -116.93 141.49 48.16 Favored 'General case' 0 C--N 1.266 -3.04 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.712 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.466 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.0 mtp -119.72 170.31 7.04 Favored Pre-proline 0 C--O 1.211 -0.937 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 178.259 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.69 26.64 0.2 Allowed 'Trans proline' 0 CA--C 1.559 1.767 0 C-N-CA 122.865 2.377 . . . . 0.0 113.286 178.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.466 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.39 34.83 18.11 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.586 1.154 . . . . 0.0 111.08 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.418 -2.027 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.396 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 . . . . . 0 CA--C 1.497 -1.071 0 CA-C-O 121.518 0.675 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 t -148.72 158.37 44.1 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 179.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 26.3 mmt -85.14 82.25 8.49 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.558 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.65 145.13 17.76 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 16.8 m120 62.52 58.82 1.6 Allowed 'General case' 0 CA--C 1.487 -1.466 0 C-N-CA 123.872 0.869 . . . . 0.0 109.619 -176.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 86' ' ' THR . 39.9 t -141.48 126.13 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.974 0 CA-C-N 114.328 -1.306 . . . . 0.0 108.765 -175.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 85.1 m -111.42 113.44 25.89 Favored 'General case' 2 N--CA 1.376 -4.137 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 176.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.6 m -85.23 137.94 32.66 Favored 'General case' 0 N--CA 1.398 -3.07 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.4 t -118.01 139.22 46.04 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.955 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.466 HD11 ' O ' ' A' ' 82' ' ' ILE . 19.4 tp -121.14 112.46 18.71 Favored 'General case' 0 N--CA 1.383 -3.803 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.976 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.47 HD12 HG22 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -98.61 122.44 50.31 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 N-CA-C 106.949 -1.5 . . . . 0.0 106.949 176.314 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.7 mtp180 -107.18 102.07 11.42 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-O 122.661 1.22 . . . . 0.0 109.276 173.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.498 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 74.1 ttt180 -103.75 109.46 62.18 Favored Pre-proline 0 C--N 1.272 -2.802 0 CA-C-N 112.523 -2.126 . . . . 0.0 109.716 -176.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -54.11 -50.8 12.34 Favored 'Trans proline' 0 CA--C 1.542 0.904 0 C-N-CA 122.602 2.201 . . . . 0.0 111.993 178.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -164.88 -172.57 2.64 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.41 HD21 ' CG1' ' A' ' 79' ' ' VAL . 55.6 mt -69.01 -17.26 63.89 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -173.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 -64.55 -23.04 67.14 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.3 0.571 . . . . 0.0 110.676 176.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -105.85 113.16 26.54 Favored 'General case' 0 N--CA 1.422 -1.859 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -178.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -92.14 161.93 14.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.524 ' H ' HD23 ' A' ' 26' ' ' LEU . 0.2 OUTLIER -52.75 -57.11 11.22 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 124.467 1.107 . . . . 0.0 110.662 -173.565 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.57 23.92 10.57 Favored Glycine 0 N--CA 1.434 -1.486 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.861 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -145.94 155.54 42.92 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.0 m -108.6 137.06 47.16 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.92 136.89 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-O 121.49 0.662 . . . . 0.0 110.622 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.41 121.15 28.37 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 176.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 63.56 4.27 1.74 Allowed 'General case' 0 N--CA 1.503 2.197 0 C-N-CA 125.101 1.36 . . . . 0.0 111.983 -172.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 104.58 1.07 43.34 Favored Glycine 0 N--CA 1.438 -1.205 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -174.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -102.35 124.05 56.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.508 HD11 HG13 ' A' ' 49' ' ' VAL . 68.1 mt -65.76 117.14 5.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 C-N-CA 124.184 0.994 . . . . 0.0 110.576 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.8 t -101.55 -28.33 12.6 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.851 -175.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.1 t -154.56 156.58 36.86 Favored 'General case' 0 C--O 1.246 0.876 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 57.5 tp -134.43 140.11 46.02 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 123.624 0.77 . . . . 0.0 109.826 -178.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.3 tpt -91.89 127.0 37.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -76.39 135.33 39.48 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -178.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.39 1.06 86.26 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 121.217 -0.516 . . . . 0.0 111.958 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -93.6 167.52 28.59 Favored Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.8 pt -56.75 -36.42 49.16 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.96 0 N-CA-C 113.226 0.825 . . . . 0.0 113.226 178.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -59.65 -37.61 79.17 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -178.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -61.26 -49.26 77.79 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.096 0.95 . . . . 0.0 108.822 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -76.77 -16.32 59.51 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 114.199 -1.364 . . . . 0.0 111.198 -176.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.59 -19.55 70.84 Favored Glycine 0 N--CA 1.432 -1.618 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.603 176.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.74 16.99 20.43 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.239 177.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.508 HG13 HD11 ' A' ' 35' ' ' ILE . 51.0 t -69.5 133.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 CA-C-O 120.922 0.391 . . . . 0.0 110.561 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 20.9 mmt180 -132.38 137.03 47.2 Favored 'General case' 0 CA--C 1.484 -1.577 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.335 178.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.7 t -72.23 147.51 10.32 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.68 0 CA-C-N 113.913 -1.494 . . . . 0.0 110.115 -178.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.0 23.38 45.5 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.505 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 17.1 m-70 -121.83 139.62 53.39 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.199 -0.5 . . . . 0.0 111.377 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.45 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 9.0 ttm180 -94.39 120.82 35.2 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.227 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 41.6 mt -76.24 122.09 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.9 pt -102.61 -14.5 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.552 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.251 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.5 tt0 -161.38 142.88 11.56 Favored 'General case' 0 CA--C 1.485 -1.531 0 C-N-CA 120.046 -0.661 . . . . 0.0 110.148 -174.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.441 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 75.4 mt -133.26 123.06 46.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 73.38 -21.18 0.26 Allowed 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.988 1.315 . . . . 0.0 112.663 172.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.418 ' H ' ' C ' ' A' ' 58' ' ' ILE . . . 143.42 -8.31 2.09 Favored Glycine 0 N--CA 1.438 -1.23 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -175.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 20.4 pt20 -107.87 123.48 48.65 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 m -69.79 111.76 5.77 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 121.512 0.672 . . . . 0.0 109.71 179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.455 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.0 m -103.47 16.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 CA-C-O 122.062 0.934 . . . . 0.0 109.346 -175.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -71.7 -17.91 19.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.56 -179.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.69 11.92 21.08 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.15 -0.932 . . . . 0.0 109.206 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.455 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.5 m -101.9 137.81 19.62 Favored Pre-proline 0 N--CA 1.408 -2.557 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.415 ' O ' HG13 ' A' ' 71' ' ' ILE . 73.9 Cg_endo -76.64 168.08 24.32 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 122.58 2.186 . . . . 0.0 112.551 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -44.62 -55.01 5.55 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 124.977 1.311 . . . . 0.0 111.617 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -56.82 -43.61 81.21 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.352 1.032 . . . . 0.0 110.824 -173.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.0 mtpt -73.54 -45.89 50.82 Favored 'General case' 0 CA--C 1.485 -1.521 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.415 HG13 ' O ' ' A' ' 67' ' ' PRO . 61.7 mt -54.67 -39.86 48.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 121.135 0.493 . . . . 0.0 109.741 178.402 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.74 -37.59 69.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.479 177.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -64.59 -39.75 94.29 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -177.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.9 mt -71.06 -53.34 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.675 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.979 -179.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.7 mt -56.39 -41.77 76.81 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 10.8 t -63.0 -29.42 70.81 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 123.336 0.655 . . . . 0.0 111.71 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -104.63 -13.39 15.98 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.498 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.87 133.99 34.8 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.316 -0.554 . . . . 0.0 112.494 -174.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.41 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.5 m -137.44 175.81 8.79 Favored 'Isoleucine or valine' 0 C--O 1.248 1.02 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.45 -161.94 19.75 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -77.29 107.76 9.93 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 173.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.466 ' O ' HD11 ' A' ' 16' ' ' LEU . 82.3 mt -107.86 116.67 51.83 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -174.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -97.78 110.2 22.82 Favored 'General case' 0 CA--C 1.453 -2.753 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.469 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 11.3 ttp -112.91 141.38 46.81 Favored 'General case' 1 C--N 1.242 -4.097 0 N-CA-C 105.739 -1.949 . . . . 0.0 105.739 -174.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm -121.42 130.39 53.56 Favored 'General case' 0 CA--C 1.452 -2.805 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 -177.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.505 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 38.5 p -126.34 153.17 45.25 Favored 'General case' 0 C--N 1.275 -2.656 0 O-C-N 123.532 0.52 . . . . 0.0 110.015 -174.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.509 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.8 mtp -122.08 168.76 10.78 Favored Pre-proline 0 C--N 1.301 -1.526 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 176.354 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.94 22.33 0.31 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 123.137 2.558 . . . . 0.0 112.595 178.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.509 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 73.28 3.51 4.64 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 126.075 1.75 . . . . 0.0 113.645 177.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.609 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 175.619 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 . . . . . 0 CA--C 1.516 -0.353 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -99.82 122.25 42.5 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -90.37 137.16 32.58 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.368 0.418 . . . . 0.0 110.717 -173.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.15 -150.68 18.14 Favored Glycine 0 C--N 1.303 -1.299 0 C-N-CA 120.794 -0.717 . . . . 0.0 111.71 175.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.2 m120 -91.29 99.54 12.5 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.451 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 55.7 t -128.58 129.68 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.628 -175.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.3 m -117.77 113.73 22.26 Favored 'General case' 0 N--CA 1.391 -3.392 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.602 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.3 m -81.42 128.83 34.29 Favored 'General case' 0 N--CA 1.398 -3.042 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.333 -178.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.423 HG13 ' CG2' ' A' ' 49' ' ' VAL . 53.1 t -110.2 136.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.767 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.058 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.444 HD12 ' HB3' ' A' ' 81' ' ' GLU . 21.3 tp -119.07 109.37 15.83 Favored 'General case' 0 N--CA 1.384 -3.767 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 172.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.458 HG23 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.7 136.07 31.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -115.45 103.75 11.07 Favored 'General case' 0 C--N 1.287 -2.13 0 CA-C-O 122.195 0.998 . . . . 0.0 110.796 178.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.422 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 66.0 ttt180 -103.12 113.42 65.85 Favored Pre-proline 0 C--N 1.283 -2.292 0 CA-C-N 113.408 -1.724 . . . . 0.0 109.952 -175.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.8 -56.06 2.49 Favored 'Trans proline' 0 CA--C 1.552 1.414 0 C-N-CA 122.937 2.425 . . . . 0.0 113.991 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.55 -175.59 5.49 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.588 HD21 ' CG1' ' A' ' 79' ' ' VAL . 61.3 mt -71.06 -17.87 62.58 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -173.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -79.0 -11.19 60.0 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 121.618 0.723 . . . . 0.0 111.04 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -97.66 143.01 28.75 Favored 'General case' 0 N--CA 1.403 -2.799 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -97.07 -157.27 0.58 Allowed 'General case' 0 C--N 1.26 -3.325 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.418 HD22 ' N ' ' A' ' 26' ' ' LEU . 1.3 mm? -93.83 -51.24 4.98 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 177.007 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.25 6.47 Favored Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.003 177.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -149.26 157.18 43.13 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.5 m -105.44 121.92 44.91 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 178.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.28 130.72 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.757 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -111.0 102.44 10.91 Favored 'General case' 0 C--N 1.287 -2.132 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 178.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 67.23 14.84 9.87 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.16 175.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.52 -3.17 23.39 Favored Glycine 0 N--CA 1.438 -1.208 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.94 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -114.48 122.27 68.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 O-C-N 122.389 -0.477 . . . . 0.0 109.869 -179.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.405 HD11 HG12 ' A' ' 49' ' ' VAL . 55.5 mt -65.24 111.22 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 123.647 0.779 . . . . 0.0 109.475 179.032 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -105.6 -19.41 13.78 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.988 -176.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 m -149.2 150.42 32.59 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 121.667 -0.645 . . . . 0.0 109.84 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.0 tp -135.63 141.51 45.07 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 120.88 0.371 . . . . 0.0 110.738 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.7 ttt -82.55 103.43 12.07 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -79.51 107.14 12.06 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.535 0.683 . . . . 0.0 110.082 -174.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.23 11.35 Favored Glycine 0 N--CA 1.433 -1.552 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -175.172 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.77 178.49 53.68 Favored Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.097 -0.551 . . . . 0.0 111.782 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.404 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.5 OUTLIER -58.1 -41.15 79.88 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.927 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -177.479 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.74 -37.91 88.44 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.635 0.255 . . . . 0.0 111.616 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -61.78 -46.4 89.71 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.9 mtt-85 -74.77 -25.1 58.84 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.615 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.5 -19.2 79.93 Favored Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.455 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.65 7.88 29.13 Favored Glycine 0 CA--C 1.507 -0.44 0 C-N-CA 120.137 -1.03 . . . . 0.0 112.256 177.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.423 ' CG2' HG13 ' A' ' 15' ' ' VAL . 73.2 t -73.58 135.47 27.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.1 mmt-85 -137.72 155.42 49.11 Favored 'General case' 0 CA--C 1.492 -1.283 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 176.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 74.1 t -80.7 139.38 18.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.382 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.141 -175.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.33 6.08 51.43 Favored Glycine 0 CA--C 1.497 -1.034 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.517 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 74.8 m-70 -106.23 142.88 35.17 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 115.099 -0.55 . . . . 0.0 111.228 179.234 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.474 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 39.2 ttm180 -99.18 132.66 44.34 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 171.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 28.0 mt -85.68 123.37 39.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.467 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.415 HD12 HG23 ' A' ' 56' ' ' ILE . 26.6 pt -102.99 -12.92 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.199 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.291 -179.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 84' ' ' MET . 36.9 tt0 -154.35 141.68 19.6 Favored 'General case' 0 CA--C 1.479 -1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -178.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.45 ' CD1' HG23 ' A' ' 63' ' ' VAL . 71.8 mt -140.91 124.4 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 124.407 1.067 . . . . 0.0 108.155 177.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 68.55 13.92 9.01 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.892 0.853 . . . . 0.0 110.287 171.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.7 -2.73 49.07 Favored Glycine 0 N--CA 1.437 -1.25 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.934 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.44 ' O ' HG11 ' A' ' 63' ' ' VAL . 20.4 pt20 -112.85 130.98 55.9 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.617 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 33.2 t -68.38 114.23 6.64 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.604 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.7 m -108.84 17.08 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 CA-C-O 121.884 0.85 . . . . 0.0 109.394 -176.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -71.34 -15.22 18.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.841 -1.072 . . . . 0.0 112.04 -175.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -120.01 7.31 10.86 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.216 0.531 . . . . 0.0 109.568 175.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.604 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.9 m -80.8 138.07 50.4 Favored Pre-proline 0 N--CA 1.418 -2.042 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.243 -177.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.98 157.27 44.64 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 123.081 2.52 . . . . 0.0 113.223 178.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -45.96 -55.86 6.24 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 125.972 1.709 . . . . 0.0 110.61 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -54.09 -51.83 62.9 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 124.492 1.117 . . . . 0.0 110.813 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.9 mptt -58.93 -54.0 52.09 Favored 'General case' 0 CA--C 1.486 -1.482 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.812 -176.427 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 70.4 mt -50.71 -43.28 23.9 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 124.312 1.007 . . . . 0.0 110.358 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.0 t -73.2 -36.86 51.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.744 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -73.45 -37.69 65.73 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.348 0.594 . . . . 0.0 109.903 -175.097 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.1 mt -68.53 -47.64 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.307 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 59.2 mt -58.28 -40.32 81.59 Favored 'General case' 0 C--O 1.212 -0.905 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.492 176.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.3 t -62.25 -26.99 68.69 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -105.98 -17.3 14.39 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.422 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.9 127.25 35.97 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.688 -176.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.588 ' CG1' HD21 ' A' ' 22' ' ' LEU . 1.8 m -127.53 -179.38 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.11 -155.61 24.58 Favored Glycine 0 CA--C 1.493 -1.292 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.444 ' HB3' HD12 ' A' ' 16' ' ' LEU . 45.3 mt-10 -77.69 108.52 10.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 174.741 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.458 ' HB ' HG23 ' A' ' 17' ' ' ILE . 64.6 mt -109.63 117.72 55.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -176.154 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 39.8 m-70 -93.05 116.93 29.5 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 -178.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.473 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.0 mtm -120.2 156.84 30.32 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 177.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.451 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 68.8 mmtt -121.47 123.81 42.93 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 176.35 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.517 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 72.1 p -119.36 139.84 51.33 Favored 'General case' 0 C--N 1.27 -2.875 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.208 -177.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.484 ' C ' ' H ' ' A' ' 89' ' ' ALA . 82.9 mtp -120.85 171.72 5.57 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -72.1 24.91 0.26 Allowed 'Trans proline' 0 N--CA 1.497 1.728 0 C-N-CA 123.09 2.527 . . . . 0.0 112.88 177.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.484 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.33 20.59 4.93 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 125.127 1.371 . . . . 0.0 112.803 177.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.762 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.021 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 . . . . . 0 CA--C 1.514 -0.416 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.1 t -135.69 159.41 41.72 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.15 0.5 . . . . 0.0 109.763 -178.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 25.5 mmt -120.26 -177.74 3.51 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -178.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.72 -103.28 0.89 Allowed Glycine 0 CA--C 1.501 -0.817 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.405 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -101.27 108.1 19.66 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -130.66 133.7 63.06 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 CA-C-O 122.315 1.055 . . . . 0.0 111.861 -172.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.4 m -127.9 121.94 31.27 Favored 'General case' 0 N--CA 1.392 -3.355 0 CA-C-N 113.262 -1.79 . . . . 0.0 106.864 176.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 m -82.82 141.92 31.93 Favored 'General case' 0 N--CA 1.404 -2.774 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.574 -176.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 56.1 t -116.47 136.65 52.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.067 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 176.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.403 HD11 ' O ' ' A' ' 82' ' ' ILE . 29.1 tp -122.1 119.73 32.2 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-O 121.961 0.886 . . . . 0.0 109.886 175.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.46 HG22 HD12 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -97.49 134.13 36.68 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.098 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.418 178.594 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.02 101.34 10.16 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 171.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.525 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.0 ttt180 -108.31 107.97 60.67 Favored Pre-proline 0 C--N 1.282 -2.341 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.451 -178.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -58.03 -41.09 71.71 Favored 'Trans proline' 0 CA--C 1.546 1.117 0 C-N-CA 122.607 2.205 . . . . 0.0 113.423 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -167.17 176.64 6.67 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.53 HD21 ' CG1' ' A' ' 79' ' ' VAL . 73.1 mt -68.95 -22.39 64.13 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 125.152 1.381 . . . . 0.0 111.213 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.416 ' NE ' ' HA ' ' A' ' 23' ' ' ARG . 7.3 mmp_? -59.11 -21.89 59.98 Favored 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.058 0.848 . . . . 0.0 110.233 174.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -103.89 118.35 36.49 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 104.899 -2.26 . . . . 0.0 104.899 178.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.22 168.79 10.69 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.48 ' H ' HD22 ' A' ' 26' ' ' LEU . 0.4 OUTLIER -64.05 -59.85 3.97 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.221 0.534 . . . . 0.0 111.282 -171.014 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.434 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 103.45 34.63 3.82 Favored Glycine 0 N--CA 1.431 -1.658 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.287 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -155.43 157.39 36.94 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.6 m -117.34 136.04 53.42 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.85 128.15 64.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.772 0.796 . . . . 0.0 112.923 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -121.45 115.44 22.88 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.454 176.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 68.99 2.6 3.65 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 125.538 1.535 . . . . 0.0 112.283 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 118.42 -12.6 12.38 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -96.43 128.17 47.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 O-C-N 122.385 -0.479 . . . . 0.0 110.548 -179.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.425 HD11 HG11 ' A' ' 49' ' ' VAL . 72.9 mt -68.31 114.45 5.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 124.458 1.103 . . . . 0.0 109.608 176.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.5 t -98.63 -23.78 15.34 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.006 -177.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.8 p -156.52 152.06 26.87 Favored 'General case' 0 C--N 1.322 -0.629 0 O-C-N 122.297 -0.252 . . . . 0.0 111.316 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.434 HD12 ' O ' ' A' ' 27' ' ' GLY . 48.7 tp -125.91 148.55 49.18 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 124.356 1.062 . . . . 0.0 109.072 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -105.88 123.52 48.09 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.376 0.608 . . . . 0.0 110.692 -179.312 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 20.4 tpp85 -60.36 130.84 48.59 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.23 176.587 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.05 5.99 89.25 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.856 178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.58 161.2 27.15 Favored Glycine 0 N--CA 1.423 -2.179 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 pt -60.24 -32.61 51.12 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.98 0 C-N-CA 120.764 -0.375 . . . . 0.0 111.947 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -60.83 -38.85 86.88 Favored 'General case' 0 N--CA 1.443 -0.779 0 C-N-CA 122.986 0.514 . . . . 0.0 111.812 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -64.31 -38.88 92.6 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.759 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -90.48 -0.41 57.65 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.902 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.31 -19.56 38.35 Favored Glycine 0 N--CA 1.433 -1.504 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 175.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.16 9.01 26.6 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.103 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.425 HG11 HD11 ' A' ' 35' ' ' ILE . 60.0 t -69.82 140.01 19.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.458 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 13.9 mmt180 -145.08 141.8 29.14 Favored 'General case' 0 CA--C 1.49 -1.354 0 C-N-CA 123.406 0.682 . . . . 0.0 110.989 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.74 139.9 20.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.783 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.18 14.29 59.17 Favored Glycine 0 C--N 1.305 -1.147 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.531 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -108.71 133.85 52.23 Favored 'General case' 0 N--CA 1.428 -1.575 0 CA-C-O 121.32 0.581 . . . . 0.0 111.611 178.284 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -92.76 114.79 27.44 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.492 -1.231 . . . . 0.0 108.085 177.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.413 HG12 HG22 ' A' ' 86' ' ' THR . 30.2 mt -78.54 122.9 34.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 37.2 pt -106.43 -11.79 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.505 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.568 179.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.449 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.8 tt0 -154.76 144.91 21.87 Favored 'General case' 0 CA--C 1.479 -1.778 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.107 -177.015 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.448 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -141.82 125.15 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 174.57 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 69.43 -2.72 1.8 Allowed 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.991 1.317 . . . . 0.0 112.846 172.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.43 -4.11 10.25 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.968 -178.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -112.28 130.68 55.86 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 p -73.0 108.3 5.82 Favored 'General case' 0 N--CA 1.425 -1.68 0 CA-C-O 121.795 0.807 . . . . 0.0 110.285 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.547 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.6 m -98.86 16.52 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-O 122.271 1.034 . . . . 0.0 110.053 -172.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.6 p -75.58 -10.27 13.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.072 -177.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.95 16.33 10.88 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.063 -0.972 . . . . 0.0 108.495 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.7 m -103.26 135.22 19.43 Favored Pre-proline 0 N--CA 1.407 -2.577 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.49 159.81 52.18 Favored 'Trans proline' 0 C--O 1.244 0.802 0 C-N-CA 122.258 1.972 . . . . 0.0 112.596 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -43.15 -54.84 4.22 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.87 1.668 . . . . 0.0 112.177 -178.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -56.39 -47.03 79.79 Favored 'General case' 0 CA--C 1.497 -1.067 0 O-C-N 124.027 0.83 . . . . 0.0 110.663 -175.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.432 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 12.6 mptt -63.76 -54.21 38.92 Favored 'General case' 0 N--CA 1.426 -1.639 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.682 -177.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.5 mt -51.08 -44.75 29.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 O-C-N 124.098 0.874 . . . . 0.0 110.112 179.335 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.4 t -71.53 -36.82 61.67 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.746 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -72.81 -40.57 65.74 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -174.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 46.0 mt -66.0 -46.26 88.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.895 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.9 mt -58.5 -41.04 84.47 Favored 'General case' 0 C--O 1.214 -0.811 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.554 175.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 50.8 m -63.06 -27.61 69.52 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.2 m-80 -104.45 -10.65 17.55 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -175.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.525 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.39 133.4 36.68 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.76 -178.409 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.53 ' CG1' HD21 ' A' ' 22' ' ' LEU . 3.1 m -129.69 -178.57 2.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.583 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 175.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.57 -154.82 33.14 Favored Glycine 0 CA--C 1.488 -1.624 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -73.51 112.64 9.79 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 121.592 0.711 . . . . 0.0 109.722 174.28 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.403 ' O ' HD11 ' A' ' 16' ' ' LEU . 74.9 mt -118.11 117.47 54.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.358 0 CA-C-N 115.328 -0.851 . . . . 0.0 108.711 -177.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -88.38 129.98 35.27 Favored 'General case' 0 CA--C 1.473 -2.013 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.201 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.449 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.3 mtm -129.19 153.3 47.87 Favored 'General case' 0 C--N 1.262 -3.209 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 171.148 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 62.9 mmtt -119.18 122.61 42.39 Favored 'General case' 0 C--N 1.268 -2.975 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 177.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 52.7 p -121.82 143.61 49.3 Favored 'General case' 0 C--N 1.267 -2.992 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.102 -177.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.583 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.3 mtp -111.22 164.07 15.85 Favored Pre-proline 0 C--N 1.303 -1.421 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 178.152 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -78.33 29.68 0.45 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 122.786 2.324 . . . . 0.0 109.3 172.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.583 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.97 11.5 8.39 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 127.015 2.126 . . . . 0.0 112.017 -178.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.204 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.517 -0.293 0 CA-C-O 121.405 0.621 . . . . 0.0 110.006 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.8 m -155.61 93.51 1.49 Allowed 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 175.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 28.3 ttt -64.81 -60.49 3.02 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.41 ' O ' ' HE1' ' A' ' 87' ' ' MET . . . 179.65 99.96 0.13 Allowed Glycine 0 CA--C 1.493 -1.325 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.098 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.419 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 88.9 m-20 63.48 89.88 0.09 Allowed 'General case' 0 CA--C 1.502 -0.894 0 CA-C-O 121.844 0.831 . . . . 0.0 109.853 -175.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.4 t -122.79 122.19 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 CA-C-O 121.885 0.85 . . . . 0.0 109.518 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.9 m -108.49 108.81 19.89 Favored 'General case' 0 C--N 1.246 -3.916 0 CA-C-N 113.332 -1.758 . . . . 0.0 107.133 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.9 m -79.43 132.63 36.43 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.435 178.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.2 t -111.17 140.65 29.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.335 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 15.1 tp -122.83 112.76 18.27 Favored 'General case' 0 N--CA 1.379 -3.983 0 C-N-CA 119.286 -0.966 . . . . 0.0 108.814 172.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.49 HG21 HD11 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -98.89 129.21 49.58 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.968 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.58 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -111.84 102.78 11.03 Favored 'General case' 0 N--CA 1.406 -2.64 0 CA-C-O 122.506 1.145 . . . . 0.0 109.667 174.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.595 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.3 ttt180 -112.38 110.79 52.9 Favored Pre-proline 0 C--N 1.276 -2.609 0 CA-C-N 112.752 -2.022 . . . . 0.0 110.718 -176.596 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -57.46 -51.88 7.49 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 122.567 2.178 . . . . 0.0 112.577 178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.458 ' OD2' ' HG2' ' A' ' 23' ' ' ARG . 1.0 OUTLIER -158.56 -174.0 4.57 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.838 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.6 mt -72.08 -14.16 61.78 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 -174.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.458 ' HG2' ' OD2' ' A' ' 21' ' ' ASP . 18.5 mmt180 -66.31 -23.95 66.46 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -94.4 110.18 21.98 Favored 'General case' 0 CA--C 1.48 -1.72 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 176.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -92.19 155.44 18.01 Favored 'General case' 0 C--N 1.281 -2.388 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.806 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.53 ' H ' HD21 ' A' ' 26' ' ' LEU . 1.2 mm? -50.78 -61.76 2.02 Favored 'General case' 0 C--O 1.237 0.428 0 O-C-N 124.913 1.383 . . . . 0.0 110.642 -175.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.48 -10.77 35.95 Favored Glycine 0 N--CA 1.434 -1.496 0 C-N-CA 120.66 -0.781 . . . . 0.0 111.579 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.411 ' CE1' ' HB3' ' A' ' 26' ' ' LEU . 50.6 p90 -112.89 151.76 30.1 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.023 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 t -107.08 122.38 46.36 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -112.44 131.35 64.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 CA-C-O 121.576 0.703 . . . . 0.0 112.18 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -131.52 122.14 25.65 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 114.495 -1.229 . . . . 0.0 107.843 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.463 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 88.0 m-20 66.89 13.98 9.65 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-O 121.902 0.858 . . . . 0.0 111.752 177.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.46 -6.72 65.71 Favored Glycine 0 N--CA 1.432 -1.616 0 CA-C-N 115.175 -0.92 . . . . 0.0 111.313 -178.179 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.14 128.82 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-O 121.223 0.535 . . . . 0.0 110.22 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.11 111.01 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.221 175.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -95.57 -27.99 15.07 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.645 -175.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.4 m -150.47 158.91 44.69 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 121.959 -0.463 . . . . 0.0 110.072 -177.65 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.2 tp -142.85 135.44 27.71 Favored 'General case' 0 C--O 1.239 0.529 0 O-C-N 123.835 0.709 . . . . 0.0 111.258 -178.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ttt -82.3 121.92 27.29 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 176.125 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -74.33 122.86 23.57 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.056 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.17 -3.22 72.63 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -177.462 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -83.47 170.31 48.43 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.7 pt -63.03 -37.29 78.98 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.399 0 CA-C-N 117.311 0.556 . . . . 0.0 111.899 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.23 -45.56 75.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -62.78 -43.15 99.56 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.507 0.67 . . . . 0.0 109.936 178.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -73.76 -20.25 60.55 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.125 -0.943 . . . . 0.0 111.778 -179.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.26 -19.13 57.82 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.963 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.62 15.59 22.33 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.277 -0.963 . . . . 0.0 112.456 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.403 ' O ' ' HD2' ' A' ' 50' ' ' ARG . 79.2 t -75.39 122.8 29.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 8.1 mmm180 -122.39 150.87 41.84 Favored 'General case' 0 CA--C 1.474 -1.957 0 CA-C-O 121.348 0.594 . . . . 0.0 110.416 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 78.1 t -78.25 141.4 15.53 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.772 0 CA-C-N 114.018 -1.446 . . . . 0.0 109.424 -176.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.85 30.03 33.22 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -175.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.2 m170 -123.31 135.06 54.03 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.803 -0.698 . . . . 0.0 109.915 177.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.7 ttp180 -97.91 123.89 42.1 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 177.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.435 HG12 HG22 ' A' ' 86' ' ' THR . 32.6 mt -79.04 127.12 39.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 O-C-N 123.852 0.72 . . . . 0.0 109.779 178.087 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 41.6 pt -109.75 -13.93 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.95 143.11 16.74 Favored 'General case' 0 CA--C 1.483 -1.634 0 C-N-CA 120.025 -0.67 . . . . 0.0 109.314 -175.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.444 ' CD1' HG23 ' A' ' 63' ' ' VAL . 66.3 mt -137.71 127.84 36.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 70.84 -18.66 0.25 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.846 1.259 . . . . 0.0 113.485 172.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 58' ' ' ILE . . . 130.59 8.41 3.16 Favored Glycine 0 C--N 1.299 -1.52 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -176.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -118.74 139.85 50.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 176.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.7 t -77.44 108.11 10.36 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.515 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.8 m -101.04 8.57 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.231 0 CA-C-O 121.966 0.889 . . . . 0.0 109.384 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.03 -12.19 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.783 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.156 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.19 14.52 16.97 Favored 'General case' 0 N--CA 1.437 -1.093 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.735 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.515 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 80.3 m -102.9 138.63 19.62 Favored Pre-proline 0 N--CA 1.409 -2.511 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.401 ' O ' HG13 ' A' ' 71' ' ' ILE . 59.4 Cg_exo -49.94 139.9 32.44 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.813 2.342 . . . . 0.0 110.751 176.442 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.463 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 32.6 p80 -51.66 -42.76 62.35 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -176.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -69.26 -37.59 77.98 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.665 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 tttm -60.13 -44.88 94.58 Favored 'General case' 0 CA--C 1.492 -1.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.907 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.401 HG13 ' O ' ' A' ' 67' ' ' PRO . 66.1 mt -52.05 -44.5 39.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 O-C-N 124.006 0.816 . . . . 0.0 109.762 178.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 96.8 t -67.24 -34.92 72.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.69 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.3 t-160 -74.29 -39.51 62.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 54.1 mt -65.7 -49.16 79.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.84 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 77.6 mt -57.12 -41.14 78.46 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.105 0.479 . . . . 0.0 110.985 175.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.5 t -57.08 -36.7 70.9 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 123.808 0.843 . . . . 0.0 111.53 178.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -98.6 -11.45 22.11 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -176.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.595 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -86.89 131.01 34.23 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -173.501 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 80' ' ' GLY . 1.1 m -134.64 179.01 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.415 ' N ' HG23 ' A' ' 79' ' ' VAL . . . 95.99 -159.74 22.18 Favored Glycine 0 CA--C 1.496 -1.13 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.98 108.11 12.22 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 171.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 88.6 mt -104.47 117.27 49.78 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.471 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -175.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -100.02 111.3 23.6 Favored 'General case' 0 CA--C 1.479 -1.788 0 N-CA-C 105.014 -2.217 . . . . 0.0 105.014 -176.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 23.2 ttp -122.95 148.63 45.26 Favored 'General case' 0 C--N 1.257 -3.45 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -173.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 29.0 mmtm -117.88 128.36 54.75 Favored 'General case' 0 CA--C 1.474 -1.971 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -177.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 54.0 p -127.74 143.39 51.14 Favored 'General case' 0 C--N 1.277 -2.567 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.429 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.552 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.5 mtp -112.9 168.72 7.27 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 177.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 12.8 Cg_exo -74.48 30.05 0.34 Allowed 'Trans proline' 0 N--CA 1.489 1.238 0 C-N-CA 122.997 2.465 . . . . 0.0 111.578 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.552 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 68.31 23.46 7.69 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 126.308 1.843 . . . . 0.0 111.815 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.419 -1.984 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.991 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 . . . . . 0 N--CA 1.433 -1.29 0 CA-C-O 121.408 0.623 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t -128.59 126.81 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.373 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.465 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.8 m -118.09 107.24 13.75 Favored 'General case' 0 C--N 1.251 -3.716 0 CA-C-N 113.628 -1.624 . . . . 0.0 107.661 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.9 m -79.07 140.74 37.81 Favored 'General case' 0 N--CA 1.401 -2.908 0 CA-C-N 115.487 -0.778 . . . . 0.0 109.8 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -122.45 136.68 58.49 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.117 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.322 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.464 ' O ' ' HA2' ' A' ' 47' ' ' GLY . 29.9 tp -115.64 115.96 27.29 Favored 'General case' 0 N--CA 1.396 -3.152 0 C-N-CA 120.205 -0.598 . . . . 0.0 109.446 173.409 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.611 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -98.59 130.95 46.66 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.05 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.661 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 55.5 mtp180 -115.57 101.38 8.81 Favored 'General case' 0 N--CA 1.408 -2.572 0 CA-C-O 122.446 1.117 . . . . 0.0 108.829 171.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.475 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 75.3 ttt180 -100.79 119.48 58.28 Favored Pre-proline 0 C--N 1.275 -2.656 0 CA-C-N 112.939 -1.937 . . . . 0.0 111.896 -174.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.89 -48.48 12.43 Favored 'Trans proline' 0 CA--C 1.545 1.029 0 C-N-CA 122.92 2.414 . . . . 0.0 112.983 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -165.92 -175.15 3.28 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.427 HD22 ' O ' ' A' ' 76' ' ' SER . 59.0 mt -73.7 -11.73 60.5 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 115.064 1.505 . . . . 0.0 115.064 -173.023 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -86.68 -12.42 48.43 Favored 'General case' 0 C--N 1.292 -1.901 0 CA-C-O 121.743 0.782 . . . . 0.0 111.0 177.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -97.25 89.93 4.93 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 173.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -77.47 161.76 27.7 Favored 'General case' 0 N--CA 1.415 -2.218 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.094 -177.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.713 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.4 mm? -45.89 -48.84 16.03 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 125.444 1.498 . . . . 0.0 111.55 -171.266 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.08 13.65 45.17 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 119.714 -1.231 . . . . 0.0 111.568 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -137.31 148.57 46.44 Favored 'General case' 0 N--CA 1.426 -1.643 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 175.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.2 m -96.46 122.54 39.46 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -120.52 143.22 33.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.119 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -130.88 114.7 15.6 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 173.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 68' ' ' HIS . 93.3 m-20 64.9 14.45 9.26 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.563 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.55 -3.21 34.46 Favored Glycine 0 N--CA 1.434 -1.48 0 C-N-CA 120.52 -0.847 . . . . 0.0 111.737 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.58 124.55 66.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 O-C-N 121.964 -0.727 . . . . 0.0 110.769 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.662 HD13 HG13 ' A' ' 49' ' ' VAL . 61.9 mt -69.05 116.72 10.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 114.513 -1.221 . . . . 0.0 110.576 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -97.59 -32.23 11.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.583 -177.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.9 t -155.01 153.47 31.04 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.121 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.3 tp -132.13 130.85 41.69 Favored 'General case' 0 C--O 1.243 0.718 0 C-N-CA 123.197 0.599 . . . . 0.0 110.478 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -84.75 115.54 22.76 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 175.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -70.84 134.96 47.77 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -177.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.14 -2.72 75.69 Favored Glycine 0 C--N 1.302 -1.317 0 C-N-CA 121.193 -0.527 . . . . 0.0 111.802 -175.645 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.04 168.6 31.45 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.411 HG13 ' O ' ' A' ' 26' ' ' LEU . 3.0 pt -57.15 -36.82 52.88 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.611 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -61.65 -35.51 78.13 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -66.28 -41.46 89.82 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -66.91 -31.76 72.57 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 114.254 -1.339 . . . . 0.0 109.891 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -70.93 -27.3 72.46 Favored Glycine 0 N--CA 1.44 -1.1 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.822 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.6 21.46 10.47 Favored Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.662 HG13 HD13 ' A' ' 35' ' ' ILE . 73.8 t -77.74 137.39 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 48.8 mmt-85 -136.07 146.89 47.55 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.92 140.51 19.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 CA-C-N 114.281 -1.327 . . . . 0.0 109.708 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 25.11 27.85 Favored Glycine 0 N--CA 1.431 -1.643 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 -178.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.546 ' HB2' HD12 ' A' ' 35' ' ' ILE . 6.8 m170 -119.18 144.95 46.4 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.901 -0.65 . . . . 0.0 110.227 176.844 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 43.4 ttp180 -107.21 124.06 49.19 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.338 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 86' ' ' THR . 28.7 mm -72.96 115.09 13.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.2 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.444 HG21 ' SD ' ' A' ' 87' ' ' MET 0.275 2.1 pp -103.65 -18.08 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.752 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' MET . 33.1 tt0 -154.0 146.77 24.29 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.468 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.5 mt -139.47 119.47 13.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 O-C-N 124.25 0.969 . . . . 0.0 109.153 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 96.7 m-20 46.9 33.25 2.13 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 115.186 1.55 . . . . 0.0 115.186 178.28 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.84 -0.99 41.7 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.087 -1.054 . . . . 0.0 114.035 175.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -119.67 125.78 49.53 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 117.834 0.817 . . . . 0.0 109.95 175.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -69.28 110.76 4.78 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.071 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.549 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.2 m -103.11 13.56 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.707 0.765 . . . . 0.0 110.089 -174.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.8 -15.38 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.747 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.355 -176.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -117.32 14.63 14.77 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.794 0.807 . . . . 0.0 109.153 176.112 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.549 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.9 m -93.64 140.28 23.04 Favored Pre-proline 0 N--CA 1.411 -2.402 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -70.16 161.72 44.95 Favored 'Trans proline' 0 CA--C 1.544 1.024 0 C-N-CA 121.862 1.708 . . . . 0.0 113.225 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.428 ' HB2' ' OD1' ' A' ' 32' ' ' ASN . 4.2 t60 -42.63 -56.28 3.19 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.994 2.118 . . . . 0.0 111.997 -178.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.84 -50.97 71.49 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.298 0.999 . . . . 0.0 110.858 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.583 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -58.75 -54.01 51.92 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.361 -178.82 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.7 mt -51.81 -45.12 38.13 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 O-C-N 123.978 0.799 . . . . 0.0 110.811 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.29 -39.52 76.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.291 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.1 t60 -68.39 -37.63 80.58 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.032 0.444 . . . . 0.0 109.881 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 24.1 mt -66.44 -49.79 72.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.198 177.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 79.9 mt -62.18 -40.05 94.72 Favored 'General case' 0 C--O 1.216 -0.693 0 CA-C-O 120.891 0.377 . . . . 0.0 111.538 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 22.8 t -63.85 -27.3 69.07 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -107.56 -7.19 16.59 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -175.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.466 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.14 135.51 33.92 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.382 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.475 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -134.97 177.12 7.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.162 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.76 -153.53 27.23 Favored Glycine 0 CA--C 1.477 -2.289 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.1 108.24 7.71 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.479 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 89.7 mt -111.41 119.39 59.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.955 -1.021 . . . . 0.0 109.991 -176.162 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 31.5 m80 -98.02 116.91 31.21 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.403 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 27.7 mtm -121.11 158.83 27.06 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -123.82 123.69 41.02 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.666 HG22 HD13 ' A' ' 55' ' ' ILE . 44.1 p -120.24 149.14 42.75 Favored 'General case' 0 C--N 1.262 -3.199 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.993 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.462 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -120.15 164.69 21.08 Favored Pre-proline 0 C--N 1.291 -1.94 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 176.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -70.27 28.71 0.19 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 123.308 2.672 . . . . 0.0 112.967 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.462 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.52 11.25 5.49 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.811 1.644 . . . . 0.0 113.671 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.302 -1.468 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.065 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.515 ' O ' ' HA ' ' A' ' 87' ' ' MET . 40.8 m-80 . . . . . 0 CA--C 1.477 -1.847 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.533 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 76.1 t -103.72 114.7 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.524 0 CA-C-N 114.32 -1.309 . . . . 0.0 108.732 -174.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 73.7 m -108.91 111.75 23.61 Favored 'General case' 2 C--N 1.223 -4.912 0 CA-C-N 112.723 -2.035 . . . . 0.0 106.89 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.6 m -80.44 140.54 35.93 Favored 'General case' 0 N--CA 1.394 -3.259 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.739 -178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.422 HG11 ' CG2' ' A' ' 49' ' ' VAL . 54.3 t -122.02 127.15 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.396 -3.133 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.113 178.29 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.515 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 25.6 tp -110.45 116.22 31.02 Favored 'General case' 0 N--CA 1.387 -3.583 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 172.447 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.623 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -104.74 137.16 35.17 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.262 0 N-CA-C 106.074 -1.825 . . . . 0.0 106.074 178.16 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -109.3 104.02 13.07 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-O 121.839 0.828 . . . . 0.0 110.472 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.463 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.8 ttt180 -106.92 114.03 62.01 Favored Pre-proline 0 N--CA 1.415 -2.181 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.954 -177.021 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.88 -55.4 2.7 Favored 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 122.835 2.357 . . . . 0.0 112.982 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -161.5 -173.26 3.7 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -177.248 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 41.3 mt -71.01 -18.71 62.58 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -175.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 12.4 mmt-85 -61.58 -31.49 71.55 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.718 0.77 . . . . 0.0 109.544 174.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -94.45 130.69 40.72 Favored 'General case' 0 N--CA 1.419 -1.995 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -107.13 165.32 11.45 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 177.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.703 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.3 mm? -51.47 -53.63 35.34 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 124.754 1.283 . . . . 0.0 111.308 -172.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.414 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 99.3 32.17 5.89 Favored Glycine 0 N--CA 1.424 -2.148 0 C-N-CA 119.936 -1.126 . . . . 0.0 111.838 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -158.6 161.69 37.25 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -116.02 122.49 45.36 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -110.21 136.45 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.463 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -125.14 116.48 22.11 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' HIS . 83.3 m-20 67.09 8.92 6.53 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.674 0.789 . . . . 0.0 112.336 -179.461 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.26 -0.93 40.45 Favored Glycine 0 N--CA 1.439 -1.136 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.128 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.86 123.43 65.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.935 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.653 HD13 HG13 ' A' ' 49' ' ' VAL . 72.6 mt -60.91 112.62 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 123.92 0.888 . . . . 0.0 110.951 178.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -83.35 -43.37 16.02 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.136 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.9 p -154.05 160.67 42.09 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.204 -179.155 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.414 HD12 ' O ' ' A' ' 27' ' ' GLY . 53.6 tp -125.92 133.26 51.92 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 123.773 0.67 . . . . 0.0 110.249 -178.297 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.8 ttt -74.31 107.33 6.41 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.1 tpt180 -60.98 119.58 8.56 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 124.375 1.07 . . . . 0.0 110.775 -176.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.63 1.42 74.17 Favored Glycine 0 N--CA 1.442 -0.911 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.116 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.65 174.44 46.46 Favored Glycine 0 C--O 1.25 1.107 0 C-N-CA 121.248 -0.501 . . . . 0.0 113.239 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.464 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.64 -33.83 64.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 112.839 0.681 . . . . 0.0 112.839 -177.989 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.17 -39.25 94.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.183 0.516 . . . . 0.0 110.932 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -71.45 -33.05 69.02 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.405 ' HA ' ' NE ' ' A' ' 46' ' ' ARG . 1.9 mmp_? -66.67 -33.08 74.85 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.485 172.763 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.87 -14.17 82.86 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.537 -0.756 . . . . 0.0 112.956 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.84 30.06 9.3 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.525 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.653 HG13 HD13 ' A' ' 35' ' ' ILE . 54.2 t -77.22 143.88 12.31 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.647 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.415 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 23.9 mmm180 -135.74 140.65 44.53 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-O 121.282 0.563 . . . . 0.0 109.745 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.8 t -73.12 143.49 13.78 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 114.232 -1.349 . . . . 0.0 110.375 -178.1 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.69 18.69 59.54 Favored Glycine 0 CA--C 1.501 -0.794 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -177.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.9 m170 -109.96 139.79 44.67 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.011 -0.594 . . . . 0.0 110.543 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 20.8 ttt180 -101.33 117.26 34.6 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.599 HG12 HG22 ' A' ' 86' ' ' THR . 33.6 mt -76.03 126.84 37.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.424 HG13 ' HB2' ' A' ' 85' ' ' LYS . 41.5 pt -107.78 -14.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.229 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.6 tt0 -156.28 144.6 19.87 Favored 'General case' 0 CA--C 1.491 -1.293 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.66 -173.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.461 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.6 mt -140.35 122.15 15.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 C-N-CA 124.367 1.067 . . . . 0.0 108.22 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.1 m120 65.5 4.76 2.89 Favored 'General case' 0 N--CA 1.501 2.081 0 C-N-CA 125.505 1.522 . . . . 0.0 112.671 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.96 5.5 35.39 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.432 ' O ' HG13 ' A' ' 63' ' ' VAL . 59.2 tt0 -104.79 116.32 31.81 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.466 1.106 . . . . 0.0 108.402 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.6 t -70.16 109.53 4.67 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.52 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.1 m -105.32 14.51 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.551 0 CA-C-O 121.64 0.733 . . . . 0.0 109.173 -175.195 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -69.51 -21.66 24.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.952 -175.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.79 -1.03 22.98 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.504 0.668 . . . . 0.0 109.91 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.52 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 90.4 m -78.96 137.04 57.52 Favored Pre-proline 0 N--CA 1.406 -2.662 0 C-N-CA 124.793 1.237 . . . . 0.0 108.755 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.2 147.18 91.87 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.051 1.834 . . . . 0.0 110.929 178.006 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.569 ' HB3' ' HA ' ' A' ' 32' ' ' ASN . 6.7 p-80 -48.98 -39.08 25.18 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.092 0.957 . . . . 0.0 113.063 -176.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -68.64 -38.02 80.14 Favored 'General case' 0 N--CA 1.435 -1.192 0 O-C-N 123.491 0.494 . . . . 0.0 110.508 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 35.8 mttp -67.34 -46.14 74.32 Favored 'General case' 0 CA--C 1.478 -1.813 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.549 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.2 mt -53.24 -41.1 41.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 O-C-N 124.054 0.846 . . . . 0.0 109.549 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.2 t -71.75 -37.11 61.3 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.097 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -68.83 -40.67 79.34 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-O 121.315 0.579 . . . . 0.0 110.063 -176.511 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 37.2 mt -65.65 -51.51 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 CA-C-N 114.548 -1.206 . . . . 0.0 109.786 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.9 mt -58.45 -40.87 83.76 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.345 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -58.65 -28.61 65.85 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 123.381 0.672 . . . . 0.0 111.885 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -119.06 -6.11 10.48 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 115.16 1.541 . . . . 0.0 115.16 -172.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.463 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 130.75 36.28 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.923 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.2 m -127.04 177.02 6.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.5 -152.5 20.39 Favored Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.472 ' HB3' HD11 ' A' ' 16' ' ' LEU . 41.8 mt-10 -84.23 114.06 21.55 Favored 'General case' 0 N--CA 1.425 -1.724 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 174.755 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.623 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.2 mt -114.55 117.08 54.51 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.402 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -175.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -90.2 111.64 22.87 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.478 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 26.1 mtm -114.21 156.54 24.11 Favored 'General case' 0 C--N 1.269 -2.904 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 175.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.533 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 69.0 mmtt -122.48 124.6 43.97 Favored 'General case' 0 C--N 1.275 -2.671 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.308 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.599 HG22 HG12 ' A' ' 55' ' ' ILE . 43.8 p -121.61 141.22 51.32 Favored 'General case' 0 C--N 1.269 -2.935 0 C-N-CA 120.716 -0.393 . . . . 0.0 110.346 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.515 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 43.6 mtm -114.39 167.51 9.51 Favored Pre-proline 0 C--N 1.306 -1.296 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 72.6 Cg_endo -74.71 31.31 0.35 Allowed 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.374 2.05 . . . . 0.0 111.858 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.439 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.16 34.13 19.05 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.912 1.285 . . . . 0.0 110.66 -178.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.779 0 CA-C-N 114.142 -1.39 . . . . 0.0 107.932 178.636 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' A' ' 87' ' ' MET . 21.1 m120 . . . . . 0 CA--C 1.482 -1.647 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 86' ' ' THR . 95.3 t -113.79 126.43 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.675 0 CA-C-O 121.932 0.872 . . . . 0.0 110.213 -174.363 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.3 m -118.62 121.02 39.19 Favored 'General case' 0 C--N 1.249 -3.79 0 CA-C-N 113.602 -1.635 . . . . 0.0 106.843 176.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -88.45 140.92 28.97 Favored 'General case' 0 N--CA 1.402 -2.871 0 CA-C-N 114.779 -1.1 . . . . 0.0 109.656 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 47' ' ' GLY . 54.5 t -119.0 137.78 51.87 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.594 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.463 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.508 HD11 ' HB3' ' A' ' 81' ' ' GLU . 24.5 tp -124.28 112.39 16.95 Favored 'General case' 0 N--CA 1.386 -3.653 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 172.443 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.61 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.01 138.75 21.84 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.946 0 N-CA-C 106.244 -1.762 . . . . 0.0 106.244 -179.364 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.28 108.98 19.77 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 67.2 ttt180 -116.58 110.08 42.98 Favored Pre-proline 0 C--N 1.284 -2.247 0 C-N-CA 120.249 -0.581 . . . . 0.0 112.024 -176.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -57.9 -41.02 73.37 Favored 'Trans proline' 0 CA--C 1.546 1.084 0 C-N-CA 122.634 2.223 . . . . 0.0 113.102 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 22' ' ' LEU . 17.6 t70 -171.71 -175.46 1.56 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -177.491 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.507 HD22 ' O ' ' A' ' 76' ' ' SER . 68.7 mt -81.1 -11.62 59.45 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 125.164 1.386 . . . . 0.0 110.39 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.418 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 76.8 mtt180 -73.74 -16.03 61.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.361 175.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -103.5 138.63 39.95 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -110.67 160.95 16.23 Favored 'General case' 0 C--N 1.277 -2.575 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.656 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -55.91 -55.6 30.7 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 124.635 1.209 . . . . 0.0 111.079 -172.152 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.0 19.54 14.68 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.995 -178.549 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -146.37 162.81 37.38 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 176.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.2 m -123.21 129.73 51.79 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -114.57 136.97 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -122.43 115.63 22.58 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 61.47 16.0 7.17 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 124.764 1.226 . . . . 0.0 112.091 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.92 3.6 45.59 Favored Glycine 0 C--O 1.219 -0.805 0 C-N-CA 121.002 -0.618 . . . . 0.0 111.689 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.34 123.12 71.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.763 HD13 HG13 ' A' ' 49' ' ' VAL . 57.6 mt -62.44 118.24 4.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 123.553 0.741 . . . . 0.0 109.524 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.2 t -110.56 -16.2 13.71 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.185 -174.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.2 t -153.74 154.34 33.87 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 tp -146.35 147.56 31.45 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -108.72 119.02 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 121.132 0.491 . . . . 0.0 110.573 177.22 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.6 tmt_? -61.03 131.43 50.59 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.337 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.04 -18.0 58.21 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.342 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.85 161.58 47.91 Favored Glycine 0 N--CA 1.436 -1.327 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -176.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.63 -33.38 39.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.9 0 N-CA-C 113.721 1.008 . . . . 0.0 113.721 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.15 -41.39 99.27 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 111.646 0.239 . . . . 0.0 111.646 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.63 -42.79 95.23 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-O 121.717 0.77 . . . . 0.0 109.204 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 25.1 mtp180 -71.98 -13.19 61.55 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.188 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.41 ' O ' HG13 ' A' ' 15' ' ' VAL . . . -89.01 -13.36 62.33 Favored Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.14 176.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.02 13.81 44.81 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.359 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.763 HG13 HD13 ' A' ' 35' ' ' ILE . 57.9 t -69.67 137.02 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -134.01 147.16 50.93 Favored 'General case' 0 CA--C 1.48 -1.715 0 CA-C-O 121.329 0.585 . . . . 0.0 109.555 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -78.79 141.76 14.98 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.744 0 CA-C-N 114.159 -1.382 . . . . 0.0 109.636 -177.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 24.41 38.33 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.185 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m-70 -118.86 134.84 54.89 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.064 -0.568 . . . . 0.0 110.876 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.465 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 47.8 ttm-85 -93.23 123.45 36.52 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.447 HG12 HG22 ' A' ' 86' ' ' THR . 31.4 mt -79.22 125.86 38.73 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 39.2 pt -101.56 -16.44 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.413 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.2 tt0 -158.0 144.26 17.45 Favored 'General case' 0 CA--C 1.486 -1.497 0 C-N-CA 120.079 -0.649 . . . . 0.0 109.29 -176.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 63' ' ' VAL . 79.1 mt -143.87 125.71 10.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 124.567 1.167 . . . . 0.0 108.256 178.391 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.75 18.73 8.87 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 124.04 0.936 . . . . 0.0 112.602 170.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.29 -0.34 40.6 Favored Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.833 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -119.07 132.78 56.05 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.931 -0.746 . . . . 0.0 110.173 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.3 m -75.32 107.87 7.72 Favored 'General case' 0 N--CA 1.422 -1.828 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.568 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.9 m -99.65 12.64 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 CA-C-O 121.857 0.837 . . . . 0.0 110.118 -172.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -66.48 -20.55 27.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.437 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.1 12.1 12.59 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.648 -0.706 . . . . 0.0 109.541 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 84.8 m -93.6 136.19 24.37 Favored Pre-proline 0 N--CA 1.415 -2.216 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.409 ' O ' HG13 ' A' ' 71' ' ' ILE . 61.9 Cg_endo -74.76 164.42 33.65 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 122.202 1.935 . . . . 0.0 112.553 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -43.19 -55.35 3.99 Favored 'General case' 0 C--O 1.218 -0.593 0 C-N-CA 126.034 1.734 . . . . 0.0 112.147 -178.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -55.27 -45.77 76.15 Favored 'General case' 0 C--N 1.316 -0.883 0 O-C-N 123.925 0.766 . . . . 0.0 111.387 -174.494 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.418 ' O ' HD12 ' A' ' 74' ' ' ILE . 12.4 mptt -66.12 -54.87 20.22 Favored 'General case' 0 CA--C 1.483 -1.615 0 O-C-N 123.964 0.79 . . . . 0.0 110.739 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.409 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.8 mt -51.98 -42.04 33.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 O-C-N 124.253 0.971 . . . . 0.0 109.857 -179.328 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.8 t -72.11 -43.29 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.566 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 71.2 t60 -64.87 -43.01 94.34 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.348 0.594 . . . . 0.0 110.184 -177.623 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.418 HD12 ' O ' ' A' ' 70' ' ' LYS . 14.3 mt -69.09 -42.24 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.524 -178.674 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 67.4 mt -61.91 -46.15 90.6 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.895 0.379 . . . . 0.0 110.84 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.507 ' O ' HD22 ' A' ' 22' ' ' LEU . 23.0 t -60.7 -27.69 68.07 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 124.209 1.004 . . . . 0.0 111.802 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -87.98 -36.56 16.99 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 120.626 -0.43 . . . . 0.0 112.045 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.481 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -77.93 136.33 37.99 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 113.401 0.889 . . . . 0.0 113.401 -172.322 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.467 HG12 HD23 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -131.98 175.26 11.7 Favored 'Isoleucine or valine' 0 C--O 1.245 0.849 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 175.622 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.57 -154.75 25.23 Favored Glycine 0 CA--C 1.483 -1.911 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.508 ' HB3' HD11 ' A' ' 16' ' ' LEU . 51.5 mt-10 -75.0 108.97 8.07 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 174.359 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 17' ' ' ILE . 59.9 mt -112.36 118.15 57.06 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -84.54 130.53 34.73 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.458 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.0 mtm -135.34 152.31 51.34 Favored 'General case' 0 C--N 1.282 -2.344 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 170.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 8.9 mmmt -122.28 121.35 36.56 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.481 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.7 p -119.27 153.0 35.71 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.093 -176.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.541 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 50.3 mtm -123.06 169.13 10.52 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.422 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 7.7 Cg_exo -74.3 35.64 0.4 Allowed 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 123.158 2.572 . . . . 0.0 112.333 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.465 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.02 59.87 2.63 Favored 'General case' 0 N--CA 1.433 -1.302 0 C-N-CA 126.072 1.749 . . . . 0.0 112.958 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.161 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 171.316 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 . . . . . 0 CA--C 1.493 -1.212 0 CA-C-O 121.93 0.871 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.476 HG11 ' HD2' ' A' ' 85' ' ' LYS . 50.1 t -145.2 128.13 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 70.1 m -110.54 107.27 16.84 Favored 'General case' 0 C--N 1.245 -3.974 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 176.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 32.8 m -78.96 130.99 36.18 Favored 'General case' 0 N--CA 1.396 -3.132 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.484 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.8 t -111.02 137.54 43.05 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.717 0 CA-C-N 114.468 -1.242 . . . . 0.0 108.124 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.4 tp -121.92 111.87 17.61 Favored 'General case' 1 N--CA 1.374 -4.266 0 C-N-CA 119.062 -1.055 . . . . 0.0 108.353 172.655 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.521 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.25 128.61 48.34 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.292 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 178.592 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 67.4 mtp180 -115.04 102.14 9.66 Favored 'General case' 0 CA--C 1.457 -2.62 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 174.026 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.4 ttt180 -98.64 123.61 49.26 Favored Pre-proline 0 C--N 1.262 -3.214 0 CA-C-N 112.999 -1.91 . . . . 0.0 111.048 -174.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.39 -55.63 2.04 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 122.553 2.168 . . . . 0.0 113.457 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -166.15 -178.22 4.51 Favored 'General case' 0 C--O 1.247 0.963 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 -175.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.41 HD23 HG12 ' A' ' 79' ' ' VAL . 46.0 mt -68.31 -16.55 63.99 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -175.199 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -84.37 -12.25 54.83 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.876 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -93.48 128.42 39.57 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 176.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.289 3.1 pp0? -103.3 158.98 15.95 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.209 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.571 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -58.91 -53.69 55.6 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.175 -168.318 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.01 26.7 8.24 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.338 -1.41 . . . . 0.0 112.789 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -145.79 154.26 41.83 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 173.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 10.2 m -106.78 122.12 45.74 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -114.71 139.91 38.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.224 -0.59 . . . . 0.0 110.385 -178.106 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.413 ' HG2' ' HB2' ' A' ' 36' ' ' CYS . 16.8 pt20 -130.57 126.3 36.36 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.061 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 16.4 m120 62.0 6.85 1.86 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 124.391 1.076 . . . . 0.0 112.945 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 6.45 53.36 Favored Glycine 0 C--O 1.214 -1.102 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -175.261 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.42 128.12 70.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.656 HD13 HG13 ' A' ' 49' ' ' VAL . 52.6 mt -70.21 116.11 10.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 C-N-CA 124.407 1.083 . . . . 0.0 110.49 -177.105 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.413 ' HB2' ' HG2' ' A' ' 31' ' ' GLN . 36.3 t -99.53 -24.41 14.77 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.064 -175.717 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 34.1 t -157.12 152.39 26.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 -178.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -133.84 140.51 46.92 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.221 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -94.6 115.68 27.85 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.437 ' HD2' ' N ' ' A' ' 41' ' ' GLY . 1.7 tmm_? -65.62 131.3 46.03 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' ' HD2' ' A' ' 40' ' ' ARG . . . 91.89 -4.79 78.87 Favored Glycine 0 N--CA 1.437 -1.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.303 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.25 170.33 40.89 Favored Glycine 0 C--O 1.253 1.292 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -61.8 -34.85 64.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.935 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.74 -43.19 94.36 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.196 0.31 . . . . 0.0 111.659 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -65.91 -41.59 91.23 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.094 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -66.28 -35.29 80.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.943 178.196 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.74 -29.76 75.21 Favored Glycine 0 N--CA 1.44 -1.065 0 CA-C-N 115.177 -0.92 . . . . 0.0 112.641 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 114.67 14.65 8.59 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.213 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.656 HG13 HD13 ' A' ' 35' ' ' ILE . 68.9 t -70.24 137.69 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.458 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.1 mmt85 -136.02 145.16 45.76 Favored 'General case' 0 CA--C 1.477 -1.853 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -178.509 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.1 t -74.23 139.9 18.5 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.84 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.608 -177.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.15 9.15 65.82 Favored Glycine 0 N--CA 1.436 -1.336 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -178.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.543 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -101.93 148.25 25.56 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.275 -0.462 . . . . 0.0 111.412 -179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 70.7 ttt180 -105.46 123.39 47.81 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.65 HD13 HG22 ' A' ' 86' ' ' THR . 24.5 mm -74.11 117.98 18.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.005 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.439 HG13 ' HB2' ' A' ' 85' ' ' LYS . 24.5 pt -105.28 -20.34 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.681 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 179.433 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.3 tt0 -151.84 146.48 25.71 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.801 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.49 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.0 mt -143.56 121.69 6.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 O-C-N 124.362 1.039 . . . . 0.0 108.647 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.2 t30 63.93 8.67 4.04 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 125.556 1.542 . . . . 0.0 111.953 173.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.13 1.35 23.74 Favored Glycine 0 N--CA 1.43 -1.754 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.615 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -116.58 136.56 52.87 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 117.797 0.799 . . . . 0.0 109.92 177.318 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.8 m -75.56 108.99 8.75 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.539 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.0 m -102.96 11.48 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.697 0 CA-C-O 122.145 0.974 . . . . 0.0 109.423 -174.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 p -70.93 -14.78 18.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 114.332 -1.304 . . . . 0.0 110.093 -179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.95 13.68 13.1 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.264 179.428 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.539 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.1 m -101.32 135.26 19.91 Favored Pre-proline 0 N--CA 1.416 -2.163 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -66.21 156.15 66.33 Favored 'Trans proline' 0 C--O 1.244 0.821 0 C-N-CA 121.916 1.744 . . . . 0.0 111.743 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -43.11 -52.5 5.4 Favored 'General case' 0 C--O 1.221 -0.442 0 C-N-CA 125.525 1.53 . . . . 0.0 112.903 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -58.33 -42.74 87.48 Favored 'General case' 0 C--N 1.311 -1.087 0 O-C-N 123.917 0.761 . . . . 0.0 111.068 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.552 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -66.8 -53.77 29.45 Favored 'General case' 0 C--O 1.202 -1.413 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 178.53 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 53.4 mt -50.14 -42.29 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-O 120.984 0.421 . . . . 0.0 110.338 178.002 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.1 t -70.03 -37.9 73.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.982 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -69.16 -39.71 78.62 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.42 -53.44 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 95.6 mt -60.58 -32.79 71.87 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-O 120.853 0.358 . . . . 0.0 111.531 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.8 t -63.72 -37.07 85.97 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 123.362 0.665 . . . . 0.0 111.282 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -110.24 -9.98 14.65 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -171.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.49 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.01 129.87 35.57 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 122.156 -0.34 . . . . 0.0 110.826 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.428 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -128.75 176.26 8.43 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 177.648 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 89.69 -161.21 29.48 Favored Glycine 0 CA--C 1.498 -0.98 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -75.57 108.66 8.54 Favored 'General case' 0 C--O 1.249 1.074 0 C-N-CA 124.048 0.939 . . . . 0.0 108.903 175.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.487 HD12 HG22 ' A' ' 17' ' ' ILE . 72.3 mt -116.25 117.52 55.76 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.42 -174.464 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -84.76 117.0 23.57 Favored 'General case' 0 CA--C 1.486 -1.491 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.31 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.505 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 14.2 mtp -118.49 145.18 45.48 Favored 'General case' 0 C--N 1.25 -3.735 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.145 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' HG11 ' A' ' 12' ' ' VAL . 69.3 mmtt -118.09 123.97 46.92 Favored 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.65 HG22 HD13 ' A' ' 55' ' ' ILE . 68.0 p -118.97 139.86 50.97 Favored 'General case' 0 C--N 1.27 -2.852 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.903 178.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.46 ' HG2' HG22 ' A' ' 12' ' ' VAL . 90.6 mtp -113.58 166.54 11.07 Favored Pre-proline 0 C--N 1.299 -1.626 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 178.287 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -72.74 31.49 0.29 Allowed 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 123.047 2.498 . . . . 0.0 112.49 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 56.33 57.23 5.1 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 122.536 1.16 . . . . 0.0 111.324 -177.828 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 113.492 -1.685 . . . . 0.0 107.321 176.757 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 . . . . . 0 CA--C 1.492 -1.26 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.424 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 57.2 t -114.88 126.88 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.946 0 CA-C-N 114.016 -1.447 . . . . 0.0 108.898 -173.276 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 53.7 m -116.05 113.63 23.45 Favored 'General case' 1 C--N 1.241 -4.137 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.627 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.5 m -82.39 138.65 34.4 Favored 'General case' 0 N--CA 1.406 -2.663 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.151 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 49' ' ' VAL . 56.2 t -116.04 139.77 41.1 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.796 0 CA-C-N 114.574 -1.194 . . . . 0.0 108.582 178.18 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.52 HD11 ' HB3' ' A' ' 81' ' ' GLU . 17.8 tp -125.32 116.89 22.63 Favored 'General case' 0 N--CA 1.404 -2.762 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 81' ' ' GLU . 0.3 OUTLIER -98.11 141.63 15.82 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.782 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.859 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -113.61 102.98 10.79 Favored 'General case' 0 CA--C 1.489 -1.4 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 69.6 ttt180 -111.42 101.66 51.26 Favored Pre-proline 0 C--N 1.274 -2.686 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.765 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -58.6 -33.85 98.45 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.618 2.212 . . . . 0.0 113.985 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -169.15 175.58 5.64 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.516 HD23 HG12 ' A' ' 79' ' ' VAL . 63.4 mt -65.01 -18.23 65.12 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.274 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.9 mtt85 -74.25 -12.38 60.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 121.459 0.647 . . . . 0.0 112.084 178.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -99.54 95.75 7.2 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 174.411 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -84.58 152.29 23.96 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.763 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -41.68 -60.9 1.21 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 126.068 1.747 . . . . 0.0 111.654 -172.541 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 109.64 -3.81 30.79 Favored Glycine 0 N--CA 1.432 -1.614 0 C-N-CA 119.828 -1.177 . . . . 0.0 112.793 176.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -117.39 156.77 27.32 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 122.191 -0.593 . . . . 0.0 109.663 178.075 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.0 t -108.82 131.43 54.99 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.23 134.53 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 -177.275 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.457 ' HG3' ' HB2' ' A' ' 36' ' ' CYS 0.266 1.0 OUTLIER -126.17 120.39 29.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.046 0.45 . . . . 0.0 110.84 175.258 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 65.09 13.03 8.42 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 124.259 1.023 . . . . 0.0 110.81 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.68 -1.96 52.75 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.383 -177.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -108.08 121.57 61.25 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 O-C-N 122.315 -0.521 . . . . 0.0 110.303 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.724 HD13 HG13 ' A' ' 49' ' ' VAL . 64.3 mt -60.32 117.11 2.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 C-N-CA 124.746 1.219 . . . . 0.0 110.274 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.457 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 34.0 t -98.18 -44.03 6.76 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.689 -174.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 36.4 p -142.26 155.4 45.23 Favored 'General case' 0 C--O 1.248 1.011 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -131.91 146.24 51.99 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 123.25 0.62 . . . . 0.0 110.008 -177.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.8 ttt -90.3 112.48 24.06 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.446 ' HD3' ' N ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -75.57 123.73 26.0 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.759 -172.01 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.446 ' N ' ' HD3' ' A' ' 40' ' ' ARG . . . 103.65 -14.96 53.42 Favored Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.308 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.11 178.08 54.11 Favored Glycine 0 C--O 1.253 1.282 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -178.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 pt -53.72 -37.59 32.53 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.07 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.36 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.24 93.46 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -63.92 -46.5 84.51 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.464 0.649 . . . . 0.0 109.603 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -76.08 -17.4 59.64 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.979 -179.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -73.9 -29.38 63.1 Favored Glycine 0 N--CA 1.432 -1.569 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.794 175.669 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 111.43 12.19 15.76 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.027 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.724 HG13 HD13 ' A' ' 35' ' ' ILE . 73.1 t -67.94 134.26 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.6 mmt85 -131.03 142.5 50.32 Favored 'General case' 0 CA--C 1.487 -1.453 0 CA-C-O 121.155 0.503 . . . . 0.0 109.909 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 41.7 t -79.05 137.26 22.15 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.21 -176.171 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.36 22.71 33.82 Favored Glycine 0 CA--C 1.5 -0.865 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -175.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m170 -116.59 135.34 53.89 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.873 -0.664 . . . . 0.0 112.192 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.583 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 33.8 ttm-85 -92.59 122.69 35.27 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.565 HG12 HG22 ' A' ' 86' ' ' THR . 30.1 mt -80.64 127.82 39.15 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 35.2 pt -107.0 -16.5 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 84' ' ' MET . 32.1 tt0 -154.98 144.62 21.42 Favored 'General case' 0 CA--C 1.48 -1.717 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.382 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 67.5 mt -139.52 125.88 23.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 64.59 6.68 3.31 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.598 1.159 . . . . 0.0 112.31 173.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.4 -9.63 19.93 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.718 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.474 ' O ' HG13 ' A' ' 63' ' ' VAL . 17.4 pt20 -108.11 126.09 52.35 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-O 120.961 0.41 . . . . 0.0 110.989 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 31.9 t -64.85 113.46 3.83 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 177.153 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.618 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 30.9 m -110.61 13.53 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 121.169 0.509 . . . . 0.0 109.986 -176.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -67.54 -17.65 22.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 115.216 -0.902 . . . . 0.0 112.714 -173.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.64 16.64 5.88 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.708 0.766 . . . . 0.0 109.124 177.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.618 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.2 m -84.35 141.46 39.66 Favored Pre-proline 0 N--CA 1.416 -2.125 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.609 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.437 ' O ' HG13 ' A' ' 71' ' ' ILE . 71.6 Cg_exo -48.96 143.71 17.07 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.907 2.405 . . . . 0.0 112.247 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 70.1 t60 -49.91 -50.83 44.75 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 124.757 1.223 . . . . 0.0 111.529 -178.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -68.23 -32.23 72.29 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.1 mttm -62.91 -53.84 47.84 Favored 'General case' 0 CA--C 1.48 -1.718 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.793 176.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.437 HG13 ' O ' ' A' ' 67' ' ' PRO . 58.1 mt -50.01 -41.9 18.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 124.016 0.822 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 65.7 t -72.93 -37.19 53.47 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.533 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -65.23 -45.06 86.17 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 123.534 0.733 . . . . 0.0 109.594 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.74 -49.39 84.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.252 0 O-C-N 123.644 0.59 . . . . 0.0 109.412 178.136 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.2 mt -62.15 -45.31 94.01 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.7 t -61.98 -27.4 68.83 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 123.622 0.769 . . . . 0.0 112.144 -178.167 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -103.09 -13.23 16.9 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.666 0.987 . . . . 0.0 113.666 -176.195 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 134.63 34.16 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.047 -177.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.516 HG12 HD23 ' A' ' 22' ' ' LEU . 1.3 m -128.49 175.8 9.28 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 176.05 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.38 -159.66 27.46 Favored Glycine 0 N--CA 1.432 -1.605 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.52 ' HB3' HD11 ' A' ' 16' ' ' LEU . 44.9 mt-10 -79.35 113.4 17.46 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 173.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 67.7 mt -115.65 118.56 59.17 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.942 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.763 -172.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -81.18 135.94 35.82 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.497 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.7 mtm -133.34 150.63 51.85 Favored 'General case' 0 C--N 1.263 -3.178 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.424 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 66.1 mmtt -117.72 121.26 40.37 Favored 'General case' 0 C--N 1.262 -3.201 0 N-CA-C 106.238 -1.764 . . . . 0.0 106.238 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.566 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.2 p -122.6 146.24 47.62 Favored 'General case' 0 C--N 1.264 -3.116 0 C-N-CA 120.258 -0.577 . . . . 0.0 110.479 -178.225 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.495 ' C ' ' H ' ' A' ' 89' ' ' ALA . 58.3 mtm -120.41 168.16 11.17 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_exo -68.2 32.42 0.15 Allowed 'Trans proline' 0 N--CA 1.509 2.41 0 C-N-CA 123.49 2.794 . . . . 0.0 112.668 176.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.583 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 67.29 27.36 8.31 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 126.442 1.897 . . . . 0.0 113.422 177.506 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.409 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.483 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 . . . . . 0 CA--C 1.491 -1.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.619 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.453 HG22 ' HG2' ' A' ' 87' ' ' MET . 54.0 t -139.46 129.19 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.149 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 89.0 m -119.41 108.53 14.68 Favored 'General case' 0 N--CA 1.39 -3.46 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.185 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 18.6 m -78.69 134.25 37.12 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.934 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.412 HG11 ' CG2' ' A' ' 49' ' ' VAL . 51.3 t -115.86 136.86 51.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.137 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.378 -177.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.474 HD11 ' HB3' ' A' ' 81' ' ' GLU . 25.9 tp -118.81 110.67 17.5 Favored 'General case' 0 N--CA 1.4 -2.958 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 174.63 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -99.23 137.89 25.31 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.312 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.219 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.12 103.38 12.57 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.455 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.1 ttt180 -109.03 111.53 60.45 Favored Pre-proline 0 C--N 1.291 -1.947 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.315 -177.054 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -58.93 -44.12 37.91 Favored 'Trans proline' 0 CA--C 1.549 1.241 0 C-N-CA 122.311 2.007 . . . . 0.0 113.743 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -167.21 -176.99 3.51 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -176.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.4 HD23 HG12 ' A' ' 79' ' ' VAL . 65.9 mt -76.88 -10.02 59.08 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 124.892 1.277 . . . . 0.0 110.292 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 34.5 mtt180 -69.03 -19.35 64.11 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 114.295 -1.32 . . . . 0.0 108.064 176.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -114.21 157.81 22.18 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 104.997 -2.223 . . . . 0.0 104.997 177.177 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -121.63 -168.42 1.69 Allowed 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.489 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.596 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -75.25 -57.61 3.79 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -175.58 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 110.06 20.21 7.67 Favored Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.788 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -143.84 148.8 36.03 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.0 t -99.84 131.43 45.81 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.54 138.45 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -176.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -117.94 105.91 12.4 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 176.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 61.29 23.23 13.48 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 122.015 0.912 . . . . 0.0 110.846 177.473 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.91 -4.91 39.24 Favored Glycine 0 N--CA 1.439 -1.125 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.413 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.425 HG13 ' HB2' ' A' ' 54' ' ' ARG . 2.7 mp -105.93 120.13 56.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 O-C-N 122.18 -0.6 . . . . 0.0 110.013 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.774 HD13 HG13 ' A' ' 49' ' ' VAL . 55.1 mt -61.35 115.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 C-N-CA 123.447 0.699 . . . . 0.0 110.244 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -98.23 -31.77 11.9 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.042 -175.519 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.1 m -150.6 155.05 38.65 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.9 tp -136.7 138.88 41.5 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 123.534 0.734 . . . . 0.0 109.525 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 49.4 ttm -91.48 119.29 31.32 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.9 131.76 45.62 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.92 -8.45 79.78 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.34 162.98 37.02 Favored Glycine 0 N--CA 1.432 -1.582 0 C-N-CA 121.318 -0.467 . . . . 0.0 112.167 -178.089 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -30.43 41.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -179.565 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.02 -42.44 89.64 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.69 0.281 . . . . 0.0 110.889 178.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -63.71 -41.48 98.08 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.63 -8.44 55.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.673 -1.149 . . . . 0.0 111.281 178.161 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.55 -22.52 28.73 Favored Glycine 0 N--CA 1.429 -1.794 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 178.358 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.02 8.5 29.54 Favored Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.959 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.774 HG13 HD13 ' A' ' 35' ' ' ILE . 58.5 t -65.59 135.92 27.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 12.6 mmm180 -133.42 146.12 50.9 Favored 'General case' 0 CA--C 1.48 -1.738 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 77.0 t -77.37 139.9 17.95 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 114.181 -1.372 . . . . 0.0 109.202 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.4 -2.04 62.7 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -177.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.524 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 10.2 m170 -95.43 140.83 29.74 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 115.041 -0.58 . . . . 0.0 110.928 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.441 ' HB3' ' HA ' ' A' ' 89' ' ' ALA . 25.8 ttt85 -101.18 131.83 46.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 173.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.522 HG12 HG22 ' A' ' 86' ' ' THR . 33.0 mt -82.99 127.27 39.84 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 30.9 pt -104.3 -15.34 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.268 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.944 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.404 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.7 tt0 -155.9 144.34 20.12 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 119.763 -0.775 . . . . 0.0 108.984 -174.714 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.1 mt -140.67 121.83 14.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 124.293 0.996 . . . . 0.0 108.475 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 68.29 7.68 6.09 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 124.095 0.958 . . . . 0.0 111.769 172.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.4 2.09 33.13 Favored Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.397 -178.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 21.1 pt20 -113.88 125.31 53.91 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 177.225 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 40.1 t -63.82 119.14 9.42 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.015 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.469 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 24.3 m -114.35 14.12 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.123 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.5 p -70.12 -20.76 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.802 -176.192 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.66 9.56 16.51 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.751 0.786 . . . . 0.0 109.453 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 76.8 m -86.37 138.51 34.11 Favored Pre-proline 0 N--CA 1.407 -2.621 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.742 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.29 158.09 58.65 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.185 1.923 . . . . 0.0 112.837 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 45.3 p-80 -48.6 -49.65 35.94 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.121 1.368 . . . . 0.0 114.042 -174.089 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.0 -37.89 78.96 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 120.451 0.167 . . . . 0.0 110.599 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 9.9 mttm -61.9 -49.85 74.53 Favored 'General case' 0 CA--C 1.492 -1.258 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 177.31 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.8 mt -54.32 -42.56 58.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 O-C-N 123.896 0.748 . . . . 0.0 110.173 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.34 -35.88 69.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.544 178.297 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.8 t-80 -68.9 -42.92 76.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.237 0.541 . . . . 0.0 109.581 -177.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 35.7 mt -63.71 -47.19 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.635 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.882 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.2 mt -61.32 -45.99 92.12 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.399 176.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -62.32 -27.49 69.08 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 123.174 0.59 . . . . 0.0 111.887 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -104.65 1.34 29.41 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -177.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.455 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -107.04 134.61 49.93 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.967 178.272 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.448 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.7 m -129.58 -177.34 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.044 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -157.14 30.58 Favored Glycine 0 CA--C 1.484 -1.886 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.023 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.474 ' HB3' HD11 ' A' ' 16' ' ' LEU . 50.4 mt-10 -80.52 112.89 18.3 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.167 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.653 ' HB ' HG22 ' A' ' 17' ' ' ILE . 56.5 mt -117.3 118.12 57.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -173.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -90.49 118.43 29.96 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.404 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 24.3 mtm -117.54 158.42 24.61 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.298 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.3 mtmm -123.86 121.97 36.77 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.524 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.2 p -119.86 150.02 41.13 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.624 -175.674 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.466 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.6 mtp -130.13 168.63 15.96 Favored Pre-proline 0 C--N 1.313 -0.978 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 57.7 Cg_endo -71.04 29.5 0.22 Allowed 'Trans proline' 0 CA--C 1.565 2.058 0 C-N-CA 122.762 2.308 . . . . 0.0 112.61 175.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.466 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.0 -2.36 2.37 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 126.384 1.874 . . . . 0.0 112.59 179.062 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.474 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 178.235 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 . . . . . 0 N--CA 1.444 -0.736 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.3 t -133.13 134.86 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 123.554 0.742 . . . . 0.0 109.273 -174.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 34.4 m -121.74 120.13 33.76 Favored 'General case' 0 N--CA 1.391 -3.388 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 176.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.6 m -90.67 141.08 29.16 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.127 0.965 . . . . 0.0 110.091 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.608 HG11 ' HE2' ' A' ' 84' ' ' MET . 43.8 t -118.42 135.96 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.06 0 CA-C-N 114.425 -1.261 . . . . 0.0 108.857 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.451 HD12 ' O ' ' A' ' 82' ' ' ILE . 24.9 tp -119.86 110.38 16.68 Favored 'General case' 0 N--CA 1.382 -3.87 0 C-N-CA 119.18 -1.008 . . . . 0.0 108.797 173.044 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.476 HG22 HD12 ' A' ' 82' ' ' ILE . 0.3 OUTLIER -98.14 125.94 51.28 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.021 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.081 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 82.1 mtp180 -113.29 102.77 10.66 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.106 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.541 HH12 ' HA ' ' A' ' 76' ' ' SER . 48.2 ttt180 -98.3 112.8 63.04 Favored Pre-proline 0 C--N 1.269 -2.925 0 CA-C-N 112.77 -2.014 . . . . 0.0 110.846 -174.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.37 -39.2 86.19 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.833 2.355 . . . . 0.0 113.909 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -166.62 -178.72 4.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -177.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.545 HD23 ' CG1' ' A' ' 79' ' ' VAL . 52.8 mt -75.36 -18.09 60.06 Favored 'General case' 0 CA--C 1.495 -1.141 0 C-N-CA 124.954 1.301 . . . . 0.0 111.024 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.59 ' HD2' ' N ' ' A' ' 23' ' ' ARG . 4.8 mpt_? -82.02 -11.5 58.79 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.923 176.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -99.16 89.3 4.19 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.682 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? -72.53 165.79 23.97 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 123.639 0.587 . . . . 0.0 110.938 -178.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -69.31 -58.8 3.55 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.46 -169.785 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 103.19 38.28 2.9 Favored Glycine 0 N--CA 1.424 -2.114 0 C-N-CA 120.062 -1.066 . . . . 0.0 111.933 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -154.2 153.63 32.1 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 174.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 m -109.02 130.88 55.49 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -118.72 134.07 63.51 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 CA-C-O 121.36 0.6 . . . . 0.0 111.089 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -113.56 111.64 22.23 Favored 'General case' 0 C--N 1.312 -1.053 0 O-C-N 121.807 -0.558 . . . . 0.0 109.591 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.6 m-20 59.86 12.8 3.22 Favored 'General case' 0 N--CA 1.501 2.097 0 C-N-CA 125.076 1.35 . . . . 0.0 112.21 -177.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.59 0.42 30.79 Favored Glycine 0 C--O 1.215 -1.092 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.682 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 2.9 mp -108.17 118.33 55.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 122.438 -0.448 . . . . 0.0 109.878 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.779 HD13 HG13 ' A' ' 49' ' ' VAL . 46.8 mt -59.15 122.38 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 123.888 0.875 . . . . 0.0 110.861 178.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 13.4 t -103.29 -31.75 9.91 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.983 -176.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 55.1 p -151.17 160.62 43.75 Favored 'General case' 0 C--O 1.245 0.862 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 54.5 tp -137.97 129.46 27.95 Favored 'General case' 0 N--CA 1.443 -0.812 0 O-C-N 123.785 0.678 . . . . 0.0 109.867 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -76.03 112.54 12.57 Favored 'General case' 0 C--N 1.317 -0.837 0 O-C-N 123.782 0.676 . . . . 0.0 109.878 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.427 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.3 tpp85 -55.32 125.0 18.92 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.564 1.146 . . . . 0.0 111.005 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.02 -7.63 81.73 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.311 -0.859 . . . . 0.0 113.408 177.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.12 171.6 55.15 Favored Glycine 0 C--O 1.246 0.888 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.501 -176.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.5 pt -62.15 -33.04 56.59 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -57.16 -46.12 83.03 Favored 'General case' 0 N--CA 1.447 -0.608 0 CA-C-O 120.909 0.385 . . . . 0.0 110.445 178.701 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.427 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 36.2 tt0 -62.88 -47.15 84.55 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.573 0.701 . . . . 0.0 109.758 179.113 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 40.5 mtt180 -69.62 -18.06 63.57 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.807 -178.237 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.24 -24.81 50.49 Favored Glycine 0 N--CA 1.438 -1.187 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.001 176.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.95 12.23 12.75 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 179.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.779 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -68.57 137.28 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -135.61 150.25 49.6 Favored 'General case' 0 CA--C 1.474 -1.953 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.15 141.2 15.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.066 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.98 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.14 25.92 42.53 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -177.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.5 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.2 m170 -117.48 132.87 56.48 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.124 -0.538 . . . . 0.0 110.944 179.349 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 44.4 ttp180 -95.79 121.66 37.74 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.527 HG12 HG22 ' A' ' 86' ' ' THR . 44.7 mt -75.92 122.28 29.62 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.1 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.418 HG22 ' CG2' ' A' ' 64' ' ' VAL 0.265 2.4 pp -104.94 -5.93 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.76 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -178.314 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 26.6 tt0 -169.34 143.15 2.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.416 -179.325 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 84' ' ' MET . 88.4 mt -138.57 124.84 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 66.34 3.32 2.74 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.5 1.12 . . . . 0.0 112.436 172.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.26 -0.81 22.4 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.084 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.45 ' O ' HG13 ' A' ' 63' ' ' VAL . 12.7 pt20 -115.41 125.97 53.81 Favored 'General case' 0 CA--C 1.498 -1.022 0 O-C-N 122.273 -0.545 . . . . 0.0 110.166 176.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 m -71.03 109.6 5.22 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.519 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.6 m -101.77 18.28 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.993 0 CA-C-O 121.914 0.864 . . . . 0.0 110.538 -172.415 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.418 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.3 p -75.59 -8.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.91 -177.484 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -126.44 22.89 6.99 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.022 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.519 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 89.3 m -109.18 130.39 22.8 Favored Pre-proline 0 N--CA 1.407 -2.614 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -66.34 158.22 56.19 Favored 'Trans proline' 0 CA--C 1.543 0.925 0 C-N-CA 122.233 1.955 . . . . 0.0 112.797 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 33.1 t60 -42.86 -55.85 3.5 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.932 1.293 . . . . 0.0 113.5 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -65.83 -37.67 86.84 Favored 'General case' 0 N--CA 1.436 -1.16 0 O-C-N 123.42 0.45 . . . . 0.0 111.32 -173.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 6.5 mttm -61.75 -52.02 65.96 Favored 'General case' 0 N--CA 1.424 -1.728 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.345 174.634 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 55.7 mt -52.02 -45.61 41.14 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 O-C-N 124.026 0.829 . . . . 0.0 110.398 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.2 t -69.07 -34.04 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.818 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 17.3 t60 -72.41 -43.17 64.25 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 -176.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.6 mt -60.5 -49.75 83.1 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 CA-C-N 114.737 -1.12 . . . . 0.0 109.873 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.2 mt -58.96 -46.76 87.27 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.76 177.256 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.541 ' HA ' HH12 ' A' ' 19' ' ' ARG . 25.0 m -63.06 -26.5 68.87 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 113.08 0.77 . . . . 0.0 113.08 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -94.8 -18.85 20.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.148 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -98.8 133.92 42.43 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.535 0.207 . . . . 0.0 111.221 -176.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.545 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.2 m -134.27 179.65 4.12 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.397 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 87.88 -150.22 22.13 Favored Glycine 0 CA--C 1.497 -1.065 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.87 114.56 18.88 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.476 HD12 HG22 ' A' ' 17' ' ' ILE . 79.5 mt -117.88 118.03 56.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -90.85 115.75 28.15 Favored 'General case' 0 CA--C 1.463 -2.376 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.608 ' HE2' HG11 ' A' ' 15' ' ' VAL . 7.8 ttp -122.56 138.47 54.56 Favored 'General case' 1 N--CA 1.376 -4.148 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.816 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 32.9 mtmt -121.26 131.86 54.47 Favored 'General case' 0 CA--C 1.444 -3.133 0 C-N-CA 119.497 -0.881 . . . . 0.0 108.784 -176.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.527 HG22 HG12 ' A' ' 55' ' ' ILE . 49.7 p -125.97 155.16 41.81 Favored 'General case' 0 C--N 1.271 -2.825 0 O-C-N 123.993 0.808 . . . . 0.0 110.369 -174.567 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.472 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.8 mtp -120.47 170.55 6.95 Favored Pre-proline 0 C--N 1.296 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -75.98 29.83 0.39 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.85 2.367 . . . . 0.0 111.077 176.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.472 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 60.89 31.6 20.01 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.249 1.42 . . . . 0.0 110.624 -179.128 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.178 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.636 178.733 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.425 HD21 ' N ' ' A' ' 11' ' ' ASN . 0.7 OUTLIER . . . . . 0 N--CA 1.441 -0.885 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.1 t -120.31 132.15 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.17 0 CA-C-O 122.083 0.944 . . . . 0.0 109.727 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -127.12 115.55 19.31 Favored 'General case' 0 N--CA 1.387 -3.616 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.2 m -80.97 140.95 34.93 Favored 'General case' 0 N--CA 1.395 -3.186 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.813 -176.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.429 HG11 HG22 ' A' ' 49' ' ' VAL . 53.4 t -118.12 139.29 45.89 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.943 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.248 177.626 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.539 HD11 ' HB3' ' A' ' 81' ' ' GLU . 7.5 tp -126.42 105.41 8.75 Favored 'General case' 0 N--CA 1.404 -2.732 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.856 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.3 OUTLIER -99.71 134.8 37.76 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -178.863 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 -113.75 117.32 31.17 Favored 'General case' 0 C--N 1.294 -1.831 0 CA-C-O 121.954 0.883 . . . . 0.0 112.114 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.649 HH21 ' HA ' ' A' ' 25' ' ' GLN . 27.2 ttm180 -119.2 113.1 35.6 Favored Pre-proline 0 C--N 1.284 -2.272 0 CA-C-N 113.961 -1.472 . . . . 0.0 110.957 -178.088 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -61.74 -31.68 86.04 Favored 'Trans proline' 0 CA--C 1.547 1.16 0 C-N-CA 122.653 2.235 . . . . 0.0 113.091 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -178.8 173.68 1.22 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' HD3' ' A' ' 19' ' ' ARG . 47.5 mt -65.28 -9.83 27.32 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 115.666 1.728 . . . . 0.0 115.666 -173.244 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -76.16 -11.59 59.96 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.564 0.697 . . . . 0.0 110.794 176.349 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -107.08 98.56 8.2 Favored 'General case' 0 N--CA 1.423 -1.812 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLN . . . . . 0.649 ' HA ' HH21 ' A' ' 19' ' ' ARG . 6.4 pt20 -86.08 164.28 17.4 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.133 -1.427 . . . . 0.0 112.177 -177.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.638 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.58 -64.86 0.69 Allowed 'General case' 0 C--N 1.32 -0.698 0 O-C-N 124.984 1.427 . . . . 0.0 110.714 -173.353 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 101.69 29.48 6.21 Favored Glycine 0 N--CA 1.426 -2.021 0 C-N-CA 120.262 -0.971 . . . . 0.0 111.464 -176.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -152.35 167.14 29.66 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.655 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.4 m -131.25 140.92 49.92 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.53 121.41 50.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.902 0.858 . . . . 0.0 113.184 -173.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -120.07 128.08 53.16 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 64.2 -1.14 0.74 Allowed 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 124.451 1.1 . . . . 0.0 112.634 -174.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.81 -3.74 34.1 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -175.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -101.09 131.12 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.104 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 49' ' ' VAL . 71.4 mt -67.1 114.25 3.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 124.248 1.019 . . . . 0.0 110.615 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -85.54 -51.88 6.2 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.914 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.9 p -137.51 151.07 48.05 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.08 -176.491 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.63 141.37 46.58 Favored 'General case' 0 C--N 1.31 -1.109 0 O-C-N 123.779 0.674 . . . . 0.0 109.646 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.1 ttt -83.84 115.76 22.41 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -73.92 128.29 35.12 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 -177.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.4 -4.4 85.26 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.992 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.0 173.41 46.78 Favored Glycine 0 C--O 1.242 0.635 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.389 -178.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -61.84 -29.85 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.43 -48.69 71.89 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.309 177.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -65.93 -43.52 87.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.917 0.389 . . . . 0.0 110.796 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.5 mtp85 -72.37 -17.37 61.83 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 121.52 0.676 . . . . 0.0 110.153 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.03 -20.6 60.66 Favored Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.052 -0.976 . . . . 0.0 111.395 175.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.57 4.63 24.85 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 120.286 -0.959 . . . . 0.0 113.516 176.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 35' ' ' ILE . 69.7 t -64.43 142.53 16.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 9.9 mmt180 -140.33 139.78 35.49 Favored 'General case' 0 CA--C 1.491 -1.324 0 CA-C-O 121.257 0.551 . . . . 0.0 110.809 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.3 t -75.13 136.39 25.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 114.499 -1.228 . . . . 0.0 109.348 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.1 10.5 64.3 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -176.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.7 m170 -104.33 143.71 32.62 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.048 0.451 . . . . 0.0 110.945 177.458 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.518 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 76.0 ttt180 -103.78 114.97 29.63 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.017 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 86' ' ' THR . 23.1 mt -77.31 126.57 37.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-O 121.093 0.473 . . . . 0.0 110.048 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.44 HG22 ' CG2' ' A' ' 64' ' ' VAL . 2.4 pp -109.9 -5.43 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.945 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.985 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 17.2 tt0 -161.48 145.29 12.82 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.519 HD12 HG21 ' A' ' 63' ' ' VAL . 76.2 mt -145.12 120.5 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 O-C-N 124.454 1.096 . . . . 0.0 109.194 176.681 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.3 t30 59.65 25.95 14.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.55 1.14 . . . . 0.0 112.276 169.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.39 -7.58 30.44 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 119.883 -1.151 . . . . 0.0 114.222 177.179 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -124.2 135.37 53.4 Favored 'General case' 0 CA--C 1.486 -1.487 0 CA-C-N 117.785 0.793 . . . . 0.0 110.672 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 21.6 t -74.05 120.14 19.22 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 177.664 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.599 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.0 m -110.43 19.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.541 0 CA-C-O 121.479 0.657 . . . . 0.0 110.757 -174.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.44 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.0 p -78.83 -18.32 13.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.619 0.723 . . . . 0.0 110.329 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.87 12.49 15.83 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.45 175.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.599 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.6 m -91.22 135.48 28.26 Favored Pre-proline 0 N--CA 1.414 -2.255 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.458 ' O ' HG13 ' A' ' 71' ' ' ILE . 10.0 Cg_endo -57.82 148.42 75.38 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 122.005 1.804 . . . . 0.0 111.789 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 26.4 t60 -48.17 -50.27 29.54 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.563 1.145 . . . . 0.0 112.775 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -61.7 -39.02 89.99 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.873 -177.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -63.49 -49.6 72.95 Favored 'General case' 0 CA--C 1.482 -1.638 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.678 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.458 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.4 mt -50.87 -45.75 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 O-C-N 124.3 1.0 . . . . 0.0 109.846 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.62 -35.44 61.15 Favored 'Isoleucine or valine' 0 C--O 1.242 0.664 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.041 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.3 t60 -70.4 -42.33 71.82 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -176.563 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 38.2 mt -64.97 -49.95 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.919 179.028 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 42.3 mt -55.75 -52.09 65.15 Favored 'General case' 0 CA--C 1.502 -0.882 0 O-C-N 123.756 0.66 . . . . 0.0 112.181 177.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.8 t -59.07 -26.03 64.28 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.654 0.612 . . . . 0.0 112.654 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.7 m-80 -111.2 4.28 19.11 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -175.521 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.425 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -98.86 125.87 44.37 Favored 'General case' 0 C--O 1.204 -1.314 0 O-C-N 121.333 -0.854 . . . . 0.0 110.813 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.516 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -118.08 174.08 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.77 -155.52 19.7 Favored Glycine 0 CA--C 1.497 -1.093 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.539 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.9 mp0 -89.49 109.61 20.53 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.856 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.4 mt -105.11 117.86 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.933 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -170.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.9 m80 -85.3 128.42 34.69 Favored 'General case' 0 CA--C 1.478 -1.801 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.442 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -129.29 153.55 47.71 Favored 'General case' 0 C--N 1.258 -3.38 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 170.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -120.4 120.54 36.24 Favored 'General case' 0 C--N 1.26 -3.316 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.575 HG22 HG12 ' A' ' 55' ' ' ILE . 46.8 p -119.35 143.59 47.32 Favored 'General case' 0 C--N 1.257 -3.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.598 -178.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.51 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.3 mtm -111.39 164.06 15.92 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 175.44 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.77 27.52 0.32 Allowed 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.57 2.18 . . . . 0.0 111.598 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 69.27 25.8 5.55 Favored 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 126.299 1.84 . . . . 0.0 112.866 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.42 -1.94 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 174.456 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.553 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 4.5 m-20 . . . . . 0 N--CA 1.469 0.504 0 CA-C-O 122.285 1.041 . . . . 0.0 111.824 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.5 t -114.38 126.84 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.445 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.59 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -116.92 117.55 30.01 Favored 'General case' 0 C--N 1.248 -3.807 0 CA-C-N 113.915 -1.493 . . . . 0.0 107.086 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 m -83.87 138.2 33.31 Favored 'General case' 0 N--CA 1.406 -2.641 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.422 -176.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.3 t -118.19 140.29 42.15 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.373 178.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 81' ' ' GLU . 23.9 tp -122.68 116.42 23.76 Favored 'General case' 0 N--CA 1.399 -3.009 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.132 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.455 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.13 139.04 20.47 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -178.945 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.4 HH11 HD23 ' A' ' 16' ' ' LEU . 0.0 OUTLIER -113.08 102.6 10.55 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 175.393 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.474 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.7 ttt180 -107.09 108.86 62.59 Favored Pre-proline 0 C--N 1.287 -2.121 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.241 -177.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -53.05 -55.87 3.3 Favored 'Trans proline' 0 CA--C 1.542 0.922 0 C-N-CA 122.788 2.325 . . . . 0.0 112.933 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -156.69 -176.98 6.27 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -177.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.464 HD23 ' CG1' ' A' ' 79' ' ' VAL . 68.7 mt -74.47 -14.37 60.82 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -172.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -82.11 -11.33 58.82 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-O 121.466 0.65 . . . . 0.0 110.15 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -94.7 121.07 35.89 Favored 'General case' 0 CA--C 1.487 -1.46 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.811 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -84.03 157.4 21.83 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 123.579 0.549 . . . . 0.0 110.353 177.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.576 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER -61.15 -44.01 97.98 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 124.29 0.994 . . . . 0.0 111.36 -171.434 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.28 26.04 9.74 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 119.639 -1.267 . . . . 0.0 113.42 178.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -151.94 167.87 26.98 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -124.55 134.05 53.11 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -125.57 138.47 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -173.231 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.407 ' HG2' ' O ' ' A' ' 34' ' ' ILE . 17.4 pt20 -105.44 92.79 4.34 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.794 0.806 . . . . 0.0 109.318 176.38 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 58.55 20.55 7.7 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 122.79 -10.23 9.02 Favored Glycine 0 C--O 1.218 -0.867 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.092 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.407 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 2.4 mp -106.33 118.44 53.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.742 HD13 HG13 ' A' ' 49' ' ' VAL . 65.5 mt -59.61 114.74 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 123.244 0.618 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 52.5 t -95.29 -37.8 10.83 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.468 -175.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 14.8 m -149.8 151.23 33.22 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -178.178 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.9 tp -121.26 136.09 55.02 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.8 ttm -83.94 118.37 23.96 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -68.64 125.61 27.1 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.189 -175.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.47 0.41 79.51 Favored Glycine 0 N--CA 1.425 -2.046 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.55 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.62 171.25 45.13 Favored Glycine 0 C--O 1.241 0.586 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.14 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.89 -31.05 51.05 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.041 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.455 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.27 -39.61 93.48 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.891 0.377 . . . . 0.0 110.478 177.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -63.4 -44.01 95.91 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 176.433 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -72.28 -6.14 40.98 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.061 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -98.81 -18.01 26.41 Favored Glycine 0 N--CA 1.433 -1.536 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.03 19.56 18.9 Favored Glycine 0 N--CA 1.433 -1.518 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.442 -179.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.742 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -65.32 145.62 13.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-O 120.88 0.371 . . . . 0.0 110.036 177.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 19.9 mmt85 -136.86 138.71 41.03 Favored 'General case' 0 CA--C 1.488 -1.409 0 C-N-CA 123.963 0.905 . . . . 0.0 108.852 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.2 t -76.24 148.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.806 -177.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.05 47.67 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -178.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.571 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.7 m170 -122.19 136.39 54.9 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.994 -178.66 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -94.12 123.0 37.22 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.505 HG12 HG22 ' A' ' 86' ' ' THR . 33.1 mt -79.24 121.17 31.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.45 HG21 ' SD ' ' A' ' 87' ' ' MET . 36.8 pt -100.63 -14.92 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.38 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.5 tt0 -156.79 141.16 16.62 Favored 'General case' 0 CA--C 1.477 -1.858 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -175.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.453 HD12 HG21 ' A' ' 63' ' ' VAL . 79.2 mt -140.75 126.34 19.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.14 14.52 9.68 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 124.058 0.943 . . . . 0.0 111.126 172.468 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.83 -1.96 48.51 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.877 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.445 ' O ' HG13 ' A' ' 63' ' ' VAL . 18.5 pt20 -115.57 130.6 56.93 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 117.106 0.453 . . . . 0.0 110.633 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.0 m -70.02 108.45 4.07 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.755 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.649 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.5 m -102.17 13.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.594 0 CA-C-O 122.133 0.968 . . . . 0.0 109.682 -175.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.9 p -73.53 -14.11 16.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 114.349 -1.296 . . . . 0.0 110.567 -177.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -125.68 19.82 7.9 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 122.21 1.005 . . . . 0.0 108.712 177.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.649 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.3 m -101.23 137.42 19.68 Favored Pre-proline 0 N--CA 1.413 -2.295 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.418 ' O ' HG13 ' A' ' 71' ' ' ILE . 57.3 Cg_endo -72.74 163.25 38.99 Favored 'Trans proline' 0 C--O 1.245 0.848 0 C-N-CA 122.035 1.824 . . . . 0.0 112.739 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -42.35 -57.85 2.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 127.249 2.22 . . . . 0.0 112.371 -177.327 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -68.15 -39.99 82.5 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.672 -174.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -59.18 -48.7 80.63 Favored 'General case' 0 CA--C 1.495 -1.164 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.535 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 67' ' ' PRO . 65.5 mt -51.9 -43.63 35.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 O-C-N 124.057 0.848 . . . . 0.0 110.329 178.558 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.1 t -73.09 -34.99 46.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.792 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.43 -46.08 77.68 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 123.517 0.727 . . . . 0.0 109.292 -177.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 23.6 mt -64.43 -47.06 90.99 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.706 0 CA-C-N 114.673 -1.149 . . . . 0.0 109.887 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 45.4 mt -58.43 -51.71 68.69 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.987 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 42.2 m -56.38 -27.84 57.41 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.105 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -102.31 -5.21 24.51 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.474 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -102.88 131.84 49.51 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.892 -0.505 . . . . 0.0 111.317 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.464 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.5 m -130.43 -174.78 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -154.77 29.21 Favored Glycine 0 CA--C 1.484 -1.863 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.412 ' HB3' HD11 ' A' ' 16' ' ' LEU . 34.4 mt-10 -78.7 115.7 18.57 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 78.1 mt -119.33 117.82 55.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -85.53 126.24 33.7 Favored 'General case' 0 CA--C 1.487 -1.448 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.484 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 20.8 mtm -124.35 152.26 43.36 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 173.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -119.91 122.96 42.4 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.571 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 45.6 p -120.83 139.95 52.43 Favored 'General case' 0 C--N 1.271 -2.846 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.638 -177.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.45 ' SD ' HG21 ' A' ' 56' ' ' ILE . 81.7 mtp -110.33 169.76 6.02 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.553 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 11.7 Cg_exo -74.84 30.27 0.35 Allowed 'Trans proline' 0 N--CA 1.486 1.054 0 C-N-CA 122.914 2.409 . . . . 0.0 112.619 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.436 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.9 60.18 2.24 Favored 'General case' 0 CA--C 1.496 -1.132 0 C-N-CA 125.242 1.417 . . . . 0.0 111.583 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -2.013 0 CA-C-N 113.236 -1.802 . . . . 0.0 106.6 172.571 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 . . . . . 0 CA--C 1.48 -1.724 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.525 HG11 ' HE3' ' A' ' 85' ' ' LYS . 71.4 t -118.64 137.22 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.379 -3.976 0 CA-C-O 122.256 1.027 . . . . 0.0 108.881 -173.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 m -118.72 105.88 12.01 Favored 'General case' 2 N--CA 1.368 -4.562 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 174.097 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.8 m -83.55 136.75 34.14 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 114.764 -1.107 . . . . 0.0 109.272 -176.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.98 141.88 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.47 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.344 -175.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 18.2 tp -125.45 116.5 21.92 Favored 'General case' 0 N--CA 1.396 -3.137 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.696 HD11 ' HA ' ' A' ' 44' ' ' ALA . 1.0 OUTLIER -99.29 129.61 49.49 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 175.535 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 74.6 mtp180 -113.1 101.36 9.38 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 122.813 1.292 . . . . 0.0 109.059 169.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -105.04 111.27 65.21 Favored Pre-proline 0 C--N 1.272 -2.785 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.462 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -56.17 -47.88 22.27 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 122.598 2.199 . . . . 0.0 113.05 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.39 178.59 10.14 Favored 'General case' 0 C--O 1.246 0.916 0 CA-C-O 120.893 0.378 . . . . 0.0 110.72 -177.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 ' CG1' ' A' ' 79' ' ' VAL . 53.7 mt -65.05 -21.99 66.91 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 115.637 1.717 . . . . 0.0 115.637 -173.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.402 ' HD3' ' HA ' ' A' ' 23' ' ' ARG . 67.2 mmt-85 -79.04 -11.12 59.99 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.17 0.509 . . . . 0.0 111.465 -179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -83.26 -20.34 34.68 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLN . . . . . 0.407 ' HB3' ' H ' ' A' ' 26' ' ' LEU . 15.0 mm100 57.05 -164.46 0.16 Allowed 'General case' 0 CA--C 1.511 -0.539 0 O-C-N 123.777 0.673 . . . . 0.0 111.648 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.479 ' O ' HG13 ' A' ' 43' ' ' ILE . 0.4 OUTLIER -97.4 -49.43 4.92 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.92 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.21 11.54 Favored Glycine 0 N--CA 1.432 -1.595 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.097 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -143.48 164.26 30.84 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 50.3 m -118.19 133.7 55.67 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 123.89 0.743 . . . . 0.0 109.239 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.57 131.58 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.222 0 CA-C-O 121.69 0.757 . . . . 0.0 110.89 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -120.72 128.85 53.31 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 62.08 2.95 0.87 Allowed 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 124.248 1.019 . . . . 0.0 112.917 -176.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.99 3.05 45.61 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -174.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.452 HG13 ' HB2' ' A' ' 54' ' ' ARG . 3.5 mp -114.08 125.03 71.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.732 HD13 HG13 ' A' ' 49' ' ' VAL . 50.4 mt -61.41 117.97 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 123.834 0.854 . . . . 0.0 110.14 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.9 t -101.98 -34.42 9.35 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.309 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 p -143.35 148.49 36.34 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.3 tp -128.32 132.27 48.64 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.6 ttp -85.45 108.11 17.73 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.57 141.43 58.77 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.449 -177.079 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.04 -15.38 48.98 Favored Glycine 0 C--N 1.303 -1.252 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.531 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.61 175.45 50.74 Favored Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.479 HG13 ' O ' ' A' ' 26' ' ' LEU . 1.3 pt -59.96 -34.47 56.4 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.748 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.696 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.81 -40.06 96.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -68.11 -36.71 80.19 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.601 0.715 . . . . 0.0 109.12 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -76.58 -23.88 53.51 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.511 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.34 -23.24 63.41 Favored Glycine 0 N--CA 1.438 -1.204 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.507 178.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.98 10.63 22.27 Favored Glycine 0 CA--C 1.501 -0.811 0 C-N-CA 120.231 -0.985 . . . . 0.0 112.883 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.732 HG13 HD13 ' A' ' 35' ' ' ILE . 66.0 t -66.78 135.78 27.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.418 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 20.4 mmt180 -133.45 142.72 48.44 Favored 'General case' 0 CA--C 1.481 -1.681 0 CA-C-O 121.165 0.507 . . . . 0.0 110.293 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.5 t -72.65 145.25 12.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.967 -178.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.9 21.08 56.65 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 -178.112 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.8 m170 -117.21 135.96 53.41 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 115.08 -0.56 . . . . 0.0 111.37 -179.099 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.469 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 34.8 ttp180 -97.73 123.72 41.78 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 177.18 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.587 HG12 HG22 ' A' ' 86' ' ' THR . 30.5 mt -78.62 123.43 35.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.359 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.401 ' HA ' ' HB ' ' A' ' 64' ' ' VAL . 36.3 pt -100.3 -16.69 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.848 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.322 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.6 tt0 -158.4 144.49 17.07 Favored 'General case' 0 CA--C 1.496 -1.134 0 C-N-CA 119.479 -0.889 . . . . 0.0 110.2 -174.413 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 63' ' ' VAL . 82.2 mt -139.91 118.09 11.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 124.674 1.233 . . . . 0.0 108.077 178.277 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 53.79 27.24 6.81 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 125.299 1.44 . . . . 0.0 114.472 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.55 -10.4 38.68 Favored Glycine 0 CA--C 1.496 -1.106 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.82 175.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 35.5 tt0 -100.54 122.38 43.14 Favored 'General case' 0 C--N 1.292 -1.928 0 CA-C-N 115.488 -0.356 . . . . 0.0 110.393 -177.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -71.32 108.62 4.87 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.555 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.7 m -102.45 10.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-O 121.667 0.746 . . . . 0.0 110.08 -175.133 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.401 ' HB ' ' HA ' ' A' ' 56' ' ' ILE . 4.0 p -72.02 -13.5 16.74 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 114.669 -1.15 . . . . 0.0 111.111 -177.275 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -123.04 13.66 9.77 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.111 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.555 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.8 m -96.9 136.55 21.55 Favored Pre-proline 0 N--CA 1.409 -2.521 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.449 ' O ' HG13 ' A' ' 71' ' ' ILE . 9.5 Cg_endo -56.81 150.01 56.8 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.351 2.034 . . . . 0.0 112.386 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.2 t60 -48.62 -48.25 39.49 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.453 1.101 . . . . 0.0 112.733 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -67.58 -35.49 79.1 Favored 'General case' 0 N--CA 1.435 -1.199 0 O-C-N 123.487 0.492 . . . . 0.0 110.621 -175.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 mttm -63.59 -49.45 73.29 Favored 'General case' 0 CA--C 1.484 -1.586 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.365 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.449 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.0 mt -53.59 -43.15 53.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 O-C-N 124.083 0.865 . . . . 0.0 109.918 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.7 t -71.91 -31.86 42.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.728 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -74.56 -41.04 61.26 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -175.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.7 mt -64.29 -47.75 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.407 ' HB3' HD21 ' A' ' 26' ' ' LEU . 81.7 mt -62.48 -35.23 78.66 Favored 'General case' 0 C--O 1.211 -0.928 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.437 176.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.5 t -63.21 -31.11 72.18 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 122.805 0.442 . . . . 0.0 111.693 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -94.76 -31.71 13.65 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -175.188 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.08 130.58 35.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -172.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.478 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -129.89 -179.41 3.16 Favored 'Isoleucine or valine' 0 C--O 1.243 0.732 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 174.819 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 86.6 -151.34 24.1 Favored Glycine 0 CA--C 1.488 -1.65 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -79.06 108.78 12.8 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.441 HD12 HG22 ' A' ' 17' ' ' ILE . 79.9 mt -111.16 118.82 58.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.746 -175.411 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -94.56 131.18 40.58 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -133.11 156.2 47.87 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 172.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.525 ' HE3' HG11 ' A' ' 12' ' ' VAL . 23.2 mmmt -124.47 120.33 31.71 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 105.547 -2.019 . . . . 0.0 105.547 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.587 HG22 HG12 ' A' ' 55' ' ' ILE . 33.4 p -119.64 146.68 45.33 Favored 'General case' 0 C--N 1.27 -2.848 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.259 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.501 ' C ' ' H ' ' A' ' 89' ' ' ALA . 49.8 mtm -118.21 169.9 7.11 Favored Pre-proline 0 C--N 1.298 -1.631 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 176.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -69.71 26.26 0.17 Allowed 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 123.336 2.691 . . . . 0.0 112.575 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.501 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 74.86 -1.27 3.13 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 126.538 1.935 . . . . 0.0 113.466 178.009 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.113 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 . . . . . 0 CA--C 1.495 -1.16 0 CA-C-O 121.836 0.826 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.4 HG22 ' HG2' ' A' ' 87' ' ' MET . 46.3 t -134.79 133.26 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.191 0 CA-C-N 114.603 -1.18 . . . . 0.0 108.033 -178.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 m -123.0 117.86 26.45 Favored 'General case' 0 C--N 1.261 -3.28 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 21.4 m -85.26 142.3 29.49 Favored 'General case' 0 C--N 1.265 -3.092 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.235 -175.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.63 132.0 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.129 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 13.8 tp -122.09 119.67 32.03 Favored 'General case' 0 N--CA 1.393 -3.281 0 CA-C-O 121.711 0.767 . . . . 0.0 109.991 173.543 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.485 HD12 ' HB ' ' A' ' 43' ' ' ILE . 1.1 mm -99.87 135.23 36.36 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.026 0 CA-C-N 114.24 -1.346 . . . . 0.0 108.652 176.134 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -115.16 101.24 8.79 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.514 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 73.4 ttt180 -99.22 115.23 65.86 Favored Pre-proline 0 C--N 1.284 -2.275 0 CA-C-N 113.621 -1.627 . . . . 0.0 110.94 -178.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_exo -61.29 -38.0 68.82 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.663 2.242 . . . . 0.0 114.065 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.91 -178.58 4.8 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.484 HD23 HG12 ' A' ' 79' ' ' VAL . 79.7 mt -76.69 -15.23 59.85 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 123.976 0.91 . . . . 0.0 111.277 -176.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -69.79 -16.15 63.24 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.993 176.057 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -97.97 121.27 39.69 Favored 'General case' 0 CA--C 1.481 -1.682 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 176.111 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 -97.48 156.96 16.26 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.611 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.659 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.0 OUTLIER -53.08 -65.62 0.53 Allowed 'General case' 0 C--N 1.323 -0.551 0 O-C-N 124.993 1.433 . . . . 0.0 110.778 -174.349 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.28 34.78 4.1 Favored Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 120.129 -1.034 . . . . 0.0 112.626 177.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -155.59 155.73 33.83 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.1 m -107.42 127.35 53.51 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -117.89 136.64 54.41 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 C-N-CA 119.839 -0.744 . . . . 0.0 109.203 179.23 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -121.92 109.95 15.26 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.425 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 60.33 13.34 3.94 Favored 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 124.036 0.934 . . . . 0.0 112.37 -176.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 113.09 -6.85 25.31 Favored Glycine 0 C--O 1.211 -1.323 0 C-N-CA 121.145 -0.55 . . . . 0.0 112.054 -178.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.5 mp -102.24 123.61 55.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.049 -0.677 . . . . 0.0 110.073 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.678 HD13 HG13 ' A' ' 49' ' ' VAL . 66.1 mt -64.14 112.13 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 C-N-CA 124.05 0.94 . . . . 0.0 109.71 178.328 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 22.6 t -91.59 -37.29 13.18 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.517 -174.54 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -152.8 157.33 40.61 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 66.4 tp -129.35 132.45 47.08 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 25.6 ttt -87.33 120.4 28.58 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.432 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 0.3 OUTLIER -69.59 136.27 51.05 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.779 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.28 -2.21 74.36 Favored Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.4 164.58 28.26 Favored Glycine 0 N--CA 1.436 -1.308 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.485 ' HB ' HD12 ' A' ' 17' ' ' ILE . 3.2 pt -60.81 -36.66 72.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.44 -39.5 70.38 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.014 0.435 . . . . 0.0 111.062 -178.472 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -67.03 -42.78 84.3 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.023 178.145 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.89 -37.3 86.9 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.747 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.66 -24.32 76.31 Favored Glycine 0 CA--C 1.516 0.12 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.754 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.75 28.91 5.77 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.409 -0.9 . . . . 0.0 112.564 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.678 HG13 HD13 ' A' ' 35' ' ' ILE . 60.7 t -77.45 142.65 13.93 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -136.21 145.14 45.36 Favored 'General case' 0 CA--C 1.49 -1.338 0 CA-C-O 121.202 0.525 . . . . 0.0 109.623 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.0 t -73.42 144.7 12.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.206 -178.45 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.83 20.17 58.39 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -179.02 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.458 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 13.6 m-70 -115.2 144.67 43.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 115.121 -0.539 . . . . 0.0 110.194 178.161 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -104.97 117.48 34.12 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.602 HG12 HG22 ' A' ' 86' ' ' THR . 29.6 mt -73.96 123.79 29.95 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.482 HG21 ' SD ' ' A' ' 87' ' ' MET . 2.4 pp -109.48 -4.13 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.384 -178.726 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 84' ' ' MET . 20.0 tt0 -160.59 146.7 15.12 Favored 'General case' 0 CA--C 1.486 -1.506 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.515 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.487 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.3 mt -142.71 120.69 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 172.303 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.447 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 8.5 m-20 55.07 27.45 9.42 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 177.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.75 -6.86 58.99 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.562 -0.828 . . . . 0.0 113.821 177.303 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.477 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 11.6 pt20 -107.96 136.36 47.8 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 t -80.98 108.86 15.02 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -178.785 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.612 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.1 m -100.02 15.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.88 0 CA-C-O 122.09 0.948 . . . . 0.0 109.455 -173.436 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.442 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.6 p -69.73 -21.79 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.876 -175.144 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.32 13.62 12.78 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.457 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.612 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.7 m -90.37 133.7 32.6 Favored Pre-proline 0 N--CA 1.412 -2.367 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -63.62 155.55 62.38 Favored 'Trans proline' 0 C--O 1.25 1.125 0 C-N-CA 122.178 1.919 . . . . 0.0 112.356 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.35 -53.38 8.65 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.04 1.336 . . . . 0.0 111.313 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -56.99 -43.43 81.71 Favored 'General case' 0 C--N 1.316 -0.855 0 O-C-N 123.903 0.752 . . . . 0.0 111.456 -176.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.45 -54.61 26.01 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.847 -178.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.4 mt -50.39 -43.04 21.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 O-C-N 123.862 0.726 . . . . 0.0 110.293 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 73.0 t -67.1 -40.93 86.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 72.5 t60 -64.74 -44.09 91.25 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.4 -50.93 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 O-C-N 123.592 0.558 . . . . 0.0 109.534 178.287 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.14 -31.56 72.73 Favored 'General case' 0 C--O 1.209 -1.054 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.418 ' O ' HD22 ' A' ' 22' ' ' LEU . 50.2 m -71.08 -27.45 63.63 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -100.55 -11.46 20.07 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -174.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.514 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.77 132.56 38.04 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.237 -0.585 . . . . 0.0 112.031 -176.583 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.484 HG12 HD23 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -131.4 172.62 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.534 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 78.4 -151.05 35.86 Favored Glycine 0 CA--C 1.496 -1.119 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -176.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -59.11 108.78 0.73 Allowed 'General case' 0 C--O 1.245 0.857 0 C-N-CA 124.417 1.087 . . . . 0.0 111.362 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.447 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 85.4 mt -115.79 118.36 58.54 Favored 'Isoleucine or valine' 0 CA--C 1.456 -2.639 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 11.7 t-80 -106.65 115.87 30.94 Favored 'General case' 0 N--CA 1.385 -3.68 0 CA-C-N 113.199 -1.819 . . . . 0.0 109.456 -170.257 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 22.4 mtm -123.91 155.19 38.57 Favored 'General case' 0 C--N 1.261 -3.269 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 177.56 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 57.1 mmtt -122.06 124.26 43.52 Favored 'General case' 0 C--N 1.265 -3.087 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 175.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 55' ' ' ILE . 68.8 p -119.45 134.99 54.95 Favored 'General case' 0 C--N 1.262 -3.236 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.665 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.482 ' SD ' HG21 ' A' ' 56' ' ' ILE . 89.2 mtp -105.98 163.22 17.5 Favored Pre-proline 0 C--N 1.299 -1.619 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 176.551 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.64 14.48 0.32 Allowed 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 122.724 2.283 . . . . 0.0 113.157 178.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.402 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 65.37 22.94 12.02 Favored 'General case' 0 C--N 1.344 0.36 0 C-N-CA 124.427 1.091 . . . . 0.0 110.68 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.753 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.312 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 . . . . . 0 CA--C 1.506 -0.735 0 CA-C-O 121.933 0.873 . . . . 0.0 111.297 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -128.18 128.95 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.358 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.892 -175.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.7 m -115.58 108.19 16.11 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.178 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.4 m -78.7 135.83 37.27 Favored 'General case' 0 N--CA 1.395 -3.18 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.4 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.2 t -116.09 135.79 55.13 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.937 0 CA-C-N 114.793 -1.094 . . . . 0.0 108.478 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.5 tp -121.19 116.8 25.6 Favored 'General case' 0 N--CA 1.385 -3.698 0 C-N-CA 119.561 -0.856 . . . . 0.0 109.428 174.3 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.582 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.9 OUTLIER -97.55 133.94 37.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.352 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.592 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.6 mmm-85 -112.73 101.17 9.29 Favored 'General case' 0 N--CA 1.411 -2.398 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.2 ttt180 -100.88 110.8 61.95 Favored Pre-proline 0 C--N 1.282 -2.342 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.235 -178.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -54.88 -38.09 92.68 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 123.361 2.707 . . . . 0.0 113.663 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -176.73 -176.89 0.75 Allowed 'General case' 0 C--O 1.241 0.644 0 C-N-CA 123.367 0.667 . . . . 0.0 109.308 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 HG12 ' A' ' 79' ' ' VAL . 69.0 mt -73.28 -6.82 48.49 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -174.478 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -84.57 -13.98 50.18 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.06 0.457 . . . . 0.0 110.565 175.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -103.01 109.1 20.52 Favored 'General case' 0 CA--C 1.491 -1.326 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.164 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -82.4 162.73 22.05 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.275 178.613 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.1 mm? -52.14 -52.84 49.19 Favored 'General case' 0 C--N 1.321 -0.655 0 O-C-N 124.704 1.253 . . . . 0.0 110.65 -175.161 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.82 28.23 6.33 Favored Glycine 0 N--CA 1.436 -1.319 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.4 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -150.03 151.06 32.66 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.116 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m -104.57 124.64 49.67 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -113.95 141.64 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.528 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -177.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -119.06 102.04 8.45 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-O 121.711 0.767 . . . . 0.0 110.56 174.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 60.98 23.04 13.21 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-N 114.481 -1.236 . . . . 0.0 112.548 178.248 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.85 -11.01 20.87 Favored Glycine 0 N--CA 1.437 -1.268 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.421 178.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.5 119.3 58.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 117.302 0.551 . . . . 0.0 110.781 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.703 HD13 HG13 ' A' ' 49' ' ' VAL . 57.2 mt -59.43 111.93 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 124.193 0.997 . . . . 0.0 111.015 178.07 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 45.3 t -89.67 -38.26 14.01 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.595 -177.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.7 t -148.78 150.78 33.68 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 55.9 tp -122.57 137.55 54.86 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.3 tpp -86.2 120.1 27.19 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.73 129.46 39.86 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.306 -176.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.407 ' H ' ' CD ' ' A' ' 45' ' ' GLU . . . 87.27 -3.05 86.86 Favored Glycine 0 N--CA 1.421 -2.319 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.419 176.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.5 173.55 47.88 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.38 -0.914 . . . . 0.0 111.923 -176.621 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 26' ' ' LEU . 2.7 pt -59.17 -34.67 54.25 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.582 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.91 -39.11 88.12 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.709 0.29 . . . . 0.0 111.272 179.085 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 41' ' ' GLY . 45.0 tt0 -66.76 -41.24 88.06 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.826 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 43' ' ' ILE . 13.1 ptt180 -78.66 -16.22 57.57 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.012 -0.675 . . . . 0.0 111.81 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.95 -22.69 63.12 Favored Glycine 0 N--CA 1.433 -1.535 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.708 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.3 15.09 20.55 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.965 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.703 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -70.47 138.3 22.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.403 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 30.9 mmm180 -135.49 151.1 50.04 Favored 'General case' 0 CA--C 1.486 -1.484 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -79.68 145.52 9.16 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.106 -176.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.44 23.18 57.15 Favored Glycine 0 CA--C 1.501 -0.809 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -178.349 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.5 m170 -116.5 134.09 55.26 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 114.708 -0.746 . . . . 0.0 111.28 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.9 ttm180 -97.54 125.44 42.25 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.552 HG12 HG22 ' A' ' 86' ' ' THR . 34.2 mt -78.15 126.95 38.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 177.563 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 62' ' ' SER . 31.0 pt -106.91 -15.48 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.41 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.4 tt0 -155.62 145.81 21.68 Favored 'General case' 0 CA--C 1.481 -1.703 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.386 -173.625 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 74.5 mt -142.22 125.53 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.437 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 87.1 m-20 51.62 24.63 2.41 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 115.837 1.791 . . . . 0.0 115.837 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.86 -5.65 34.72 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.254 -0.974 . . . . 0.0 113.416 176.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.42 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.1 pt20 -115.34 129.33 56.56 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 117.42 0.61 . . . . 0.0 111.009 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 19.4 m -70.46 108.48 4.31 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.062 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.542 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.3 m -100.8 12.8 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 121.734 0.778 . . . . 0.0 109.575 -174.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -66.85 -16.22 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.562 -177.124 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.93 10.06 10.1 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-O 121.427 0.632 . . . . 0.0 109.576 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.7 m -85.43 141.42 36.74 Favored Pre-proline 0 N--CA 1.422 -1.841 0 C-N-CA 123.812 0.845 . . . . 0.0 109.214 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.75 147.32 81.11 Favored 'Trans proline' 0 C--O 1.239 0.525 0 C-N-CA 122.642 2.228 . . . . 0.0 112.697 179.284 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -42.97 -55.22 3.86 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 126.212 1.805 . . . . 0.0 111.168 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -58.5 -44.94 89.62 Favored 'General case' 0 CA--C 1.497 -1.09 0 O-C-N 123.362 0.414 . . . . 0.0 110.845 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.43 -55.07 39.34 Favored 'General case' 0 C--O 1.201 -1.479 0 O-C-N 123.861 0.725 . . . . 0.0 110.087 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 59.8 mt -50.38 -43.45 22.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 C-N-CA 123.554 0.742 . . . . 0.0 110.952 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.1 t -72.43 -36.12 53.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.829 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -70.67 -40.01 73.21 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 123.323 0.649 . . . . 0.0 109.611 -177.232 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.33 -49.51 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 176.468 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 85.2 mt -62.05 -46.27 89.88 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.6 m -64.32 -26.89 68.68 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -91.28 -19.79 22.6 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.09 139.04 31.03 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.837 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.478 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -132.38 178.55 5.45 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 174.04 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.9 -151.3 38.89 Favored Glycine 0 CA--C 1.48 -2.136 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -65.33 114.86 5.06 Favored 'General case' 0 CA--C 1.497 -1.096 0 O-C-N 124.693 0.878 . . . . 0.0 110.175 174.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.437 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 83.5 mt -118.62 117.29 54.0 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.703 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 175.518 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -99.48 120.08 39.05 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 -174.318 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.411 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 25.2 mtm -126.32 157.28 38.82 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -121.98 125.12 45.61 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 176.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.552 HG22 HG12 ' A' ' 55' ' ' ILE . 44.6 p -121.26 144.08 48.81 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.372 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.403 ' C ' ' H ' ' A' ' 89' ' ' ALA . 54.5 mtm -116.73 168.96 7.87 Favored Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -71.29 29.58 0.23 Allowed 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 123.056 2.504 . . . . 0.0 112.861 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.403 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 57.4 50.48 11.29 Favored 'General case' 0 C--O 1.245 0.855 0 CA-C-O 122.496 1.141 . . . . 0.0 110.332 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.92 0 CA-C-N 113.782 -1.554 . . . . 0.0 108.026 179.621 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 . . . . . 0 CA--C 1.474 -1.957 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 69.5 t -95.68 128.62 46.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.505 0 CA-C-N 113.35 -1.75 . . . . 0.0 109.466 -173.267 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.1 m -122.45 109.2 14.07 Favored 'General case' 2 C--N 1.236 -4.33 0 CA-C-N 113.291 -1.777 . . . . 0.0 106.865 177.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -79.01 138.66 38.13 Favored 'General case' 0 N--CA 1.406 -2.674 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.154 -176.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.421 HG11 ' CG2' ' A' ' 49' ' ' VAL . 52.9 t -115.57 133.41 62.0 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.547 177.316 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.426 HD11 ' HB3' ' A' ' 81' ' ' GLU . 14.4 tp -121.17 116.13 24.37 Favored 'General case' 0 N--CA 1.396 -3.134 0 C-N-CA 119.989 -0.684 . . . . 0.0 110.005 176.419 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.57 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.6 OUTLIER -98.89 138.64 22.79 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.978 0 CA-C-N 114.563 -1.198 . . . . 0.0 108.02 178.256 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -115.13 101.73 9.25 Favored 'General case' 0 N--CA 1.414 -2.252 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 168.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.533 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 65.3 ttt180 -97.89 116.28 65.7 Favored Pre-proline 0 C--N 1.284 -2.26 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.001 -177.832 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -49.36 -54.43 5.46 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.034 2.49 . . . . 0.0 112.602 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.58 ' OD2' ' HG3' ' A' ' 23' ' ' ARG . 2.7 p-10 -173.1 -170.49 0.64 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.325 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.465 ' HA ' ' NH2' ' A' ' 19' ' ' ARG . 54.1 mt -68.6 -16.65 63.92 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -173.501 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.58 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 27.0 mtt180 -71.34 -12.23 61.32 Favored 'General case' 0 N--CA 1.481 1.087 0 CA-C-O 121.167 0.508 . . . . 0.0 110.785 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -113.98 143.36 44.87 Favored 'General case' 0 N--CA 1.427 -1.614 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -116.96 171.56 7.83 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.243 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.686 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -58.31 -61.93 2.21 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 125.124 1.369 . . . . 0.0 111.245 -173.081 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.61 37.99 3.1 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 119.794 -1.193 . . . . 0.0 112.129 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -154.7 163.02 40.86 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.8 m -117.94 128.62 54.98 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.47 138.76 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 120.864 0.364 . . . . 0.0 110.133 -176.626 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 19.9 pt20 -131.04 121.62 25.34 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.824 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.1 m120 63.58 13.44 7.28 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.206 1.002 . . . . 0.0 111.857 -175.325 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.51 1.91 58.93 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.412 -0.899 . . . . 0.0 111.138 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -106.07 119.88 56.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.726 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -62.06 116.83 2.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 C-N-CA 124.369 1.068 . . . . 0.0 110.099 177.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.8 t -96.11 -38.18 10.28 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.27 -176.642 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 13.3 p -149.06 152.38 36.11 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.279 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 53.4 tp -127.46 145.38 50.85 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 123.576 0.75 . . . . 0.0 109.506 -178.318 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.8 ttp -93.42 115.88 28.42 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.148 0.499 . . . . 0.0 109.893 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.425 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.0 tpp85 -65.58 118.68 9.86 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 124.726 1.21 . . . . 0.0 109.463 -179.101 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -12.99 59.13 Favored Glycine 0 C--N 1.305 -1.142 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.793 -177.449 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -79.93 161.04 45.37 Favored Glycine 0 C--O 1.245 0.814 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.929 -177.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -54.22 -37.69 36.8 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.756 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.57 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -56.1 -44.2 78.82 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.199 0.524 . . . . 0.0 110.903 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.425 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 44.0 tt0 -70.14 -38.8 75.6 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.469 -179.52 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 48.3 mtt180 -66.59 -34.16 77.28 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.104 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.44 -20.61 79.54 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.782 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.08 20.29 7.62 Favored Glycine 0 C--O 1.24 0.489 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.696 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.726 HG13 HD13 ' A' ' 35' ' ' ILE . 45.0 t -71.34 144.29 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.447 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.4 mmt180 -132.61 142.66 49.24 Favored 'General case' 0 CA--C 1.484 -1.57 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.8 t -74.26 142.71 14.41 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.561 0 CA-C-N 114.583 -1.189 . . . . 0.0 109.192 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.16 22.25 55.15 Favored Glycine 0 CA--C 1.498 -0.989 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.1 m170 -114.67 135.2 54.42 Favored 'General case' 0 N--CA 1.424 -1.764 0 CA-C-N 115.129 -0.536 . . . . 0.0 111.066 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.45 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 12.6 ttm-85 -93.96 125.3 38.51 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.008 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 26.1 mt -83.0 123.62 38.76 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.337 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 174.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.2 pt -103.25 -12.06 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.36 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.688 -178.437 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.2 tt0 -163.02 143.51 9.34 Favored 'General case' 0 CA--C 1.494 -1.176 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.633 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.428 HD12 HG21 ' A' ' 63' ' ' VAL . 90.8 mt -140.03 121.84 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 O-C-N 124.228 0.955 . . . . 0.0 109.222 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 53.32 32.48 13.71 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.203 1.401 . . . . 0.0 112.447 172.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.59 -1.34 52.97 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.284 -0.96 . . . . 0.0 114.551 177.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -123.89 130.44 52.61 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 118.311 1.056 . . . . 0.0 110.755 178.147 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.3 t -74.74 109.32 8.12 Favored 'General case' 0 N--CA 1.425 -1.692 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.464 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 29.2 m -99.68 16.6 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.387 0 CA-C-O 121.968 0.889 . . . . 0.0 109.661 -174.664 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.438 HG23 ' HD3' ' A' ' 54' ' ' ARG . 3.8 p -72.95 -9.82 13.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 114.44 -1.254 . . . . 0.0 111.194 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.53 19.19 5.74 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.464 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.1 m -100.66 137.96 19.99 Favored Pre-proline 0 N--CA 1.412 -2.331 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.456 ' O ' HG13 ' A' ' 71' ' ' ILE . 50.1 Cg_endo -69.44 158.07 58.71 Favored 'Trans proline' 0 C--O 1.246 0.885 0 C-N-CA 122.435 2.09 . . . . 0.0 112.999 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -42.69 -56.19 3.26 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 126.7 2.0 . . . . 0.0 112.152 -178.289 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.84 -38.77 89.78 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.433 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -60.25 -51.83 67.87 Favored 'General case' 0 CA--C 1.485 -1.546 0 C-N-CA 119.974 -0.691 . . . . 0.0 110.93 177.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.456 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.5 mt -50.99 -44.9 28.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 O-C-N 124.329 1.018 . . . . 0.0 110.263 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.0 t -72.68 -35.13 49.42 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.087 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.9 t60 -69.67 -40.2 76.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.389 0.614 . . . . 0.0 109.586 -176.028 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 29.4 mt -70.19 -43.59 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 CA-C-N 114.829 -1.078 . . . . 0.0 109.931 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.5 mt -59.39 -46.34 88.95 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.632 175.031 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.3 t -57.92 -28.06 63.92 Favored 'General case' 0 C--O 1.215 -0.712 0 C-N-CA 124.122 0.969 . . . . 0.0 111.686 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -99.81 -6.42 26.93 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -178.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -101.28 130.55 47.44 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.893 -0.723 . . . . 0.0 111.484 -178.697 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.429 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -128.94 178.99 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.285 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.23 -153.59 29.33 Favored Glycine 0 CA--C 1.495 -1.178 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.426 ' HB3' HD11 ' A' ' 16' ' ' LEU . 47.7 mt-10 -77.61 110.37 12.37 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-O 121.403 0.62 . . . . 0.0 109.67 177.304 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 74.6 mt -112.94 117.64 55.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -93.76 118.76 31.85 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.494 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.9 mtm -118.13 156.03 29.41 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 174.257 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -121.54 121.38 37.35 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 42.9 p -121.29 146.62 46.64 Favored 'General case' 0 C--N 1.26 -3.297 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.765 -177.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 41.6 mtm -126.58 168.71 13.64 Favored Pre-proline 0 C--N 1.31 -1.142 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.566 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -70.79 38.76 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.145 0 C-N-CA 123.812 3.008 . . . . 0.0 113.654 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 54.79 56.03 7.17 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 125.58 1.552 . . . . 0.0 114.139 177.434 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.299 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.32 172.136 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 . . . . . 0 CA--C 1.487 -1.473 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -127.28 127.45 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.453 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -115.92 113.21 23.0 Favored 'General case' 0 C--N 1.246 -3.896 0 N-CA-C 106.222 -1.77 . . . . 0.0 106.222 177.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.2 m -86.39 137.82 32.27 Favored 'General case' 0 N--CA 1.395 -3.178 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.995 -175.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.436 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.9 t -118.49 141.81 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.629 0 CA-C-N 114.64 -1.164 . . . . 0.0 109.045 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.495 HD11 ' HB3' ' A' ' 81' ' ' GLU . 11.5 tp -129.23 105.69 8.32 Favored 'General case' 0 N--CA 1.386 -3.643 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 171.357 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.652 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -99.57 127.99 51.81 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.033 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 -175.378 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.41 116.83 29.34 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.566 -177.099 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.467 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 61.6 ttt180 -119.15 116.06 34.15 Favored Pre-proline 0 C--N 1.292 -1.921 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.044 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -62.45 -48.93 6.62 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.422 2.082 . . . . 0.0 112.997 179.586 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 23' ' ' ARG . 2.8 p30 -159.76 -175.58 5.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.413 HD23 ' CG1' ' A' ' 79' ' ' VAL . 54.6 mt -71.43 -15.94 62.37 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -173.644 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 21' ' ' ASP . 4.0 mpt_? -80.8 -11.95 59.52 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.47 0.652 . . . . 0.0 109.717 -179.051 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -95.26 116.16 28.38 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -86.56 150.13 24.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.605 177.3 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.602 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.31 -49.91 66.04 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 124.953 1.408 . . . . 0.0 111.188 -172.761 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.72 37.8 3.85 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.047 178.485 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -161.11 164.89 30.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.488 ' HB3' ' OG ' ' A' ' 37' ' ' SER . 34.8 t -123.4 130.15 52.3 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.448 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.46 143.74 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.878 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -130.54 128.76 41.78 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.4 t30 59.39 11.97 2.46 Favored 'General case' 0 CA--C 1.573 1.83 0 C-N-CA 123.559 0.744 . . . . 0.0 112.353 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.58 3.72 55.08 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.66 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -118.09 124.86 73.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.291 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 49.0 mt -65.12 121.71 14.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 123.876 0.87 . . . . 0.0 110.548 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.4 t -109.58 -25.96 10.17 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.752 -177.003 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.488 ' OG ' ' HB3' ' A' ' 29' ' ' SER . 12.9 p -146.32 144.38 29.76 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 122.168 -0.332 . . . . 0.0 110.548 177.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 51.0 tp -125.74 133.64 52.02 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 123.767 0.827 . . . . 0.0 109.758 -177.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.1 ttm -75.21 119.18 18.99 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.173 0.511 . . . . 0.0 109.839 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 18.6 tpp180 -66.99 122.09 16.99 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.547 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.6 1.99 82.6 Favored Glycine 0 C--N 1.312 -0.767 0 C-N-CA 120.898 -0.667 . . . . 0.0 111.999 -178.218 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 46' ' ' ARG . . . -86.12 165.49 37.82 Favored Glycine 0 C--O 1.252 1.239 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.288 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.452 ' HB ' HD11 ' A' ' 17' ' ' ILE . 1.1 pt -61.91 -30.88 49.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.59 -45.33 94.58 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 120.94 0.4 . . . . 0.0 110.282 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -64.86 -42.21 95.05 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.785 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.5 ' HG2' ' O ' ' A' ' 42' ' ' GLY . 6.7 mmp_? -61.11 -39.4 89.84 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.712 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.2 -16.97 78.57 Favored Glycine 0 CA--C 1.524 0.646 0 CA-C-N 115.59 -0.732 . . . . 0.0 113.903 -178.245 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.14 12.1 22.64 Favored Glycine 0 C--O 1.241 0.588 0 C-N-CA 119.749 -1.215 . . . . 0.0 113.033 177.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 80.6 t -72.63 142.82 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.454 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -140.8 154.99 46.47 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.49 142.35 14.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.77 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 13.75 58.6 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -177.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -109.55 135.53 50.39 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 121.151 0.5 . . . . 0.0 111.419 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -95.2 122.94 38.4 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 176.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.415 HG12 HG22 ' A' ' 86' ' ' THR . 40.2 mt -82.78 122.73 37.7 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 62' ' ' SER . 32.4 pt -103.3 -14.97 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.004 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 178.709 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 84' ' ' MET . 30.7 tt0 -150.92 141.86 22.95 Favored 'General case' 0 CA--C 1.479 -1.762 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -176.634 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.513 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -143.2 122.0 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.539 0 O-C-N 124.64 1.213 . . . . 0.0 108.127 176.218 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 66.69 18.57 10.74 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.663 1.185 . . . . 0.0 110.927 171.171 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.69 -12.06 30.08 Favored Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.75 177.608 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.419 ' O ' HG13 ' A' ' 63' ' ' VAL . 13.3 pt20 -115.89 143.34 45.55 Favored 'General case' 0 CA--C 1.501 -0.941 0 CA-C-N 117.732 0.766 . . . . 0.0 112.602 -178.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 49.9 m -75.86 108.87 9.03 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.233 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.575 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 23.3 m -102.09 15.02 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 122.124 0.964 . . . . 0.0 109.226 -174.422 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 p -72.97 -17.96 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-N 114.792 -1.094 . . . . 0.0 110.614 -177.418 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.59 9.32 16.56 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.954 0.883 . . . . 0.0 109.817 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.575 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.1 m -90.85 137.0 27.05 Favored Pre-proline 0 N--CA 1.411 -2.422 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.302 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' ILE . 12.0 Cg_endo -64.37 154.51 70.99 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 121.676 1.584 . . . . 0.0 111.585 178.104 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 32.1 t-80 -47.73 -53.49 15.02 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.375 1.07 . . . . 0.0 113.633 -176.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -67.97 -31.76 71.7 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.58 -175.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.0 mttm -63.62 -50.55 68.93 Favored 'General case' 0 C--O 1.189 -2.095 0 C-N-CA 120.197 -0.601 . . . . 0.0 110.035 173.098 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.8 mt -50.3 -43.97 22.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 O-C-N 123.533 0.521 . . . . 0.0 110.223 177.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 86.7 t -69.1 -34.13 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.691 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.642 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -70.87 -42.56 69.9 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 123.381 0.672 . . . . 0.0 109.78 -177.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.9 mp -60.91 -48.68 87.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.378 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 80.8 mt -61.39 -46.47 90.02 Favored 'General case' 0 C--O 1.215 -0.753 0 N-CA-C 113.103 0.779 . . . . 0.0 113.103 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -61.73 -27.47 68.74 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -178.544 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -101.48 -19.19 15.64 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -176.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.447 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -91.54 132.21 36.44 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 122.022 -0.424 . . . . 0.0 111.569 -176.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.5 m -126.7 -176.37 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.402 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.49 -163.29 32.46 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.495 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.4 mp0 -75.58 122.06 23.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 171.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.652 ' HB ' HG22 ' A' ' 17' ' ' ILE . 70.7 mt -115.57 119.81 62.91 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.278 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -84.61 112.02 20.06 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 113.43 -1.714 . . . . 0.0 110.372 -174.547 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.602 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 13.5 mtp -120.57 143.9 48.38 Favored 'General case' 0 C--N 1.253 -3.612 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.745 178.415 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 12.1 mmmt -120.87 118.5 30.11 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 177.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 65.0 p -119.14 145.55 45.88 Favored 'General case' 0 C--N 1.282 -2.359 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.355 -176.094 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.464 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.3 mtp -115.8 163.9 19.41 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 178.096 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.42 24.33 0.23 Allowed 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.035 2.49 . . . . 0.0 112.352 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.464 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.41 22.91 13.48 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.4 1.48 . . . . 0.0 111.891 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.904 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 175.765 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.448 ' O ' ' HA ' ' A' ' 87' ' ' MET . 28.3 t-20 . . . . . 0 N--CA 1.428 -1.559 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.8 t -108.77 117.76 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.79 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.877 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -115.64 114.86 25.47 Favored 'General case' 1 C--N 1.24 -4.174 0 CA-C-N 113.25 -1.795 . . . . 0.0 106.923 178.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.0 m -79.09 141.84 36.98 Favored 'General case' 0 N--CA 1.406 -2.67 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.217 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.45 HG11 ' CG2' ' A' ' 49' ' ' VAL . 57.1 t -121.86 128.28 75.64 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.363 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.506 178.82 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.461 HD11 ' HB3' ' A' ' 81' ' ' GLU . 22.3 tp -109.37 112.46 24.6 Favored 'General case' 0 N--CA 1.402 -2.836 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 173.226 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.76 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 134.83 47.32 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.546 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.015 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.73 103.36 12.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-O 121.102 0.477 . . . . 0.0 109.72 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' HD2' ' HA ' ' A' ' 79' ' ' VAL . 34.0 ttm180 -100.83 113.74 65.73 Favored Pre-proline 0 C--N 1.29 -1.989 0 CA-C-N 115.63 -0.713 . . . . 0.0 110.307 177.76 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.61 -42.11 50.19 Favored 'Trans proline' 0 C--O 1.239 0.572 0 C-N-CA 122.281 1.987 . . . . 0.0 112.181 177.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -173.7 177.04 2.58 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -178.096 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.449 HD23 HG12 ' A' ' 79' ' ' VAL . 53.1 mt -67.01 -22.38 65.9 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 -171.528 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -71.67 -11.65 60.94 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-O 121.406 0.622 . . . . 0.0 111.426 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.3 -20.98 23.4 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.831 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLN . . . . . 0.495 ' C ' HH21 ' A' ' 19' ' ' ARG . 78.4 mt-30 54.09 -153.58 0.28 Allowed 'General case' 0 C--O 1.22 -0.453 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.448 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.432 ' O ' HG13 ' A' ' 43' ' ' ILE . 2.1 mm? -97.47 -57.55 2.22 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.802 0.811 . . . . 0.0 110.49 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.67 2.99 32.56 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 -174.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.415 ' CD1' ' HB3' ' A' ' 26' ' ' LEU . 39.1 p90 -137.83 152.18 48.84 Favored 'General case' 0 C--O 1.246 0.887 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 176.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -105.81 122.73 46.7 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -104.18 137.27 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -119.14 111.79 18.7 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 175.236 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 68' ' ' HIS . 95.3 m-20 65.86 9.13 5.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.352 178.428 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.0 -3.74 24.1 Favored Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -112.82 122.12 66.39 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.695 HD13 HG13 ' A' ' 49' ' ' VAL . 48.2 mt -60.43 116.14 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 123.625 0.77 . . . . 0.0 110.56 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.1 t -98.08 -33.2 11.25 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.013 -173.048 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 56.9 p -150.91 151.66 32.5 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 60.2 tp -135.42 137.88 42.7 Favored 'General case' 0 N--CA 1.441 -0.906 0 O-C-N 123.482 0.489 . . . . 0.0 110.829 -178.326 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 63.0 mtt -92.76 116.78 29.34 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.074 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -69.68 126.77 30.73 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 174.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.38 -21.5 39.13 Favored Glycine 0 N--CA 1.42 -2.427 0 C-N-CA 120.412 -0.899 . . . . 0.0 110.984 -174.543 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -78.91 159.04 45.28 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 177.635 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.567 ' HB ' HD11 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -55.12 -30.7 24.53 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.866 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.315 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.75 -47.27 84.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 123.569 0.543 . . . . 0.0 111.099 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -67.15 -34.22 77.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.458 0.647 . . . . 0.0 109.492 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 47.8 mtt180 -75.51 -17.27 60.15 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.613 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.77 -37.57 8.53 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 121.74 17.76 3.77 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.026 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.695 HG13 HD13 ' A' ' 35' ' ' ILE . 59.2 t -71.1 141.56 16.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.492 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.462 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.8 mmm180 -137.64 146.14 43.54 Favored 'General case' 0 CA--C 1.483 -1.619 0 CA-C-O 121.267 0.556 . . . . 0.0 110.649 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.1 t -69.35 147.07 12.21 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.484 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.52 28.56 47.3 Favored Glycine 0 CA--C 1.487 -1.694 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -123.85 129.03 50.36 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.883 -0.659 . . . . 0.0 111.175 -179.069 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.456 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 10.2 ttm180 -89.23 124.13 34.1 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 175.327 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.58 HG12 HG22 ' A' ' 86' ' ' THR . 25.9 mt -81.54 124.51 39.02 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.141 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.434 HG13 ' HB2' ' A' ' 85' ' ' LYS . 43.1 pt -106.61 -12.5 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.503 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -154.33 145.42 22.75 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -177.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.465 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.2 mt -138.68 121.43 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.299 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.647 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 58.2 26.5 13.88 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.071 1.348 . . . . 0.0 111.711 174.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.88 -5.41 58.07 Favored Glycine 0 C--O 1.241 0.555 0 C-N-CA 120.025 -1.084 . . . . 0.0 113.774 177.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.401 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.8 pt20 -110.91 128.74 55.91 Favored 'General case' 0 CA--C 1.499 -0.992 0 CA-C-N 117.609 0.705 . . . . 0.0 109.554 177.668 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -72.89 112.74 9.2 Favored 'General case' 0 N--CA 1.42 -1.949 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -179.634 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 32.7 m -102.21 10.77 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.964 0 CA-C-O 121.634 0.731 . . . . 0.0 109.64 -175.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 p -71.69 -16.46 18.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.608 -177.241 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.63 9.87 21.09 Favored 'General case' 0 C--O 1.244 0.796 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.511 177.769 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' ' 63' ' ' VAL . 82.5 m -94.37 139.58 22.47 Favored Pre-proline 0 N--CA 1.405 -2.678 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -57.29 144.07 92.02 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.393 2.062 . . . . 0.0 110.483 177.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HB2' ' HA ' ' A' ' 32' ' ' ASN . 35.0 p80 -51.73 -41.1 61.27 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 -177.796 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -68.01 -35.0 77.57 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 -178.545 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 15.4 tttm -68.87 -44.65 72.88 Favored 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.465 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 63.8 mt -53.1 -45.06 53.05 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 O-C-N 123.722 0.639 . . . . 0.0 109.747 176.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.5 t -68.79 -32.31 54.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.452 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.2 t-160 -72.7 -38.99 67.34 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -175.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.9 mt -67.99 -50.75 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.675 177.415 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.3 mt -59.95 -30.92 69.4 Favored 'General case' 0 C--O 1.199 -1.578 0 CA-C-O 120.964 0.411 . . . . 0.0 111.414 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.448 ' O ' HD22 ' A' ' 22' ' ' LEU . 34.1 t -70.41 -26.29 63.62 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.281 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -123.53 8.5 8.96 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -172.186 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -99.09 122.17 41.96 Favored 'General case' 0 C--O 1.204 -1.335 0 CA-C-N 118.259 0.481 . . . . 0.0 109.744 177.539 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.504 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -115.42 169.96 5.78 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 CA-C-N 119.058 0.844 . . . . 0.0 109.527 177.342 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.5 -159.27 19.23 Favored Glycine 0 N--CA 1.434 -1.496 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 16' ' ' LEU . 38.6 mt-10 -80.65 111.92 17.54 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.76 ' HB ' HG22 ' A' ' 17' ' ' ILE . 62.0 mt -115.42 117.39 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -173.444 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -90.16 111.71 22.95 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 25.7 mtm -111.05 160.39 16.9 Favored 'General case' 0 C--N 1.278 -2.505 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.434 ' HB2' HG13 ' A' ' 56' ' ' ILE . 70.1 mmtt -121.95 125.15 45.71 Favored 'General case' 0 CA--C 1.47 -2.12 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 176.499 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.58 HG22 HG12 ' A' ' 55' ' ' ILE . 66.1 p -123.68 141.6 51.87 Favored 'General case' 0 C--N 1.265 -3.108 0 C-N-CA 120.195 -0.602 . . . . 0.0 110.451 -177.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 53' ' ' HIS . 75.2 mtp -116.53 171.38 4.82 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.158 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -75.51 29.67 0.37 Allowed 'Trans proline' 0 C--N 1.363 1.313 0 C-N-CA 122.823 2.348 . . . . 0.0 112.431 179.007 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.456 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.47 55.19 4.25 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.235 1.414 . . . . 0.0 111.526 -179.161 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.422 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 174.566 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 CA--C 1.501 -0.931 0 CA-C-O 122.587 1.184 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.493 HG22 ' HG2' ' A' ' 87' ' ' MET . 79.8 t -125.16 130.56 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.827 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -175.382 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.8 m -112.21 106.02 14.5 Favored 'General case' 2 N--CA 1.371 -4.395 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 178.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.432 HG23 ' HD3' ' A' ' 85' ' ' LYS . 28.9 m -79.47 135.28 36.61 Favored 'General case' 0 N--CA 1.395 -3.198 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.32 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.2 t -114.47 134.38 57.61 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.024 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.142 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 81' ' ' GLU . 15.4 tp -119.65 104.49 10.31 Favored 'General case' 0 N--CA 1.396 -3.166 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 172.603 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -103.15 126.79 57.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.054 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -175.09 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.497 ' HG2' HH11 ' A' ' 18' ' ' ARG . 0.5 OUTLIER -95.43 122.03 37.73 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.921 -178.32 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.496 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 64.8 ttt180 -128.04 105.43 20.22 Favored Pre-proline 0 C--N 1.285 -2.226 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.05 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -52.31 -48.03 23.86 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 122.721 2.281 . . . . 0.0 113.372 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -167.93 -172.34 1.8 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.5 mt -70.04 -21.48 63.17 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -173.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.1 mpt_? -72.48 -13.02 61.33 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.305 0.574 . . . . 0.0 110.87 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -103.91 121.94 44.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.251 69.3 mt-30 -103.6 157.54 16.99 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 119.048 -1.061 . . . . 0.0 113.652 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.707 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.5 mm? -44.77 -58.42 3.1 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 126.708 2.003 . . . . 0.0 111.704 -174.13 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.64 32.43 6.59 Favored Glycine 0 N--CA 1.427 -1.908 0 C-N-CA 119.86 -1.162 . . . . 0.0 112.256 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -159.24 161.45 36.02 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.245 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.1 t -119.9 124.03 45.04 Favored 'General case' 0 N--CA 1.415 -2.189 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -117.86 135.01 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.287 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -178.371 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -120.88 112.53 18.9 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.808 176.034 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.38 12.27 8.27 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 114.597 -1.183 . . . . 0.0 110.97 177.272 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.47 -4.86 31.25 Favored Glycine 0 C--O 1.206 -1.635 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.106 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.8 mp -109.25 126.57 66.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 122.117 -0.637 . . . . 0.0 109.617 -178.615 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 54.6 mt -71.21 115.05 10.5 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.804 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 25.2 t -101.21 -28.98 12.36 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.294 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -150.49 150.42 31.27 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.273 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 154.84 45.16 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -178.467 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.0 ttt -101.89 121.67 42.56 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.65 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.445 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 1.2 tmt_? -69.22 128.88 38.16 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.617 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.71 86.41 Favored Glycine 0 C--N 1.311 -0.83 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 -178.172 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.497 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -82.48 161.96 41.28 Favored Glycine 0 N--CA 1.433 -1.542 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.778 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -60.8 -30.12 46.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.0 98.01 Favored 'General case' 0 N--CA 1.439 -1.002 0 O-C-N 123.264 0.353 . . . . 0.0 111.07 177.109 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.438 ' OE2' ' HA ' ' A' ' 40' ' ' ARG . 36.4 tt0 -58.66 -47.84 83.07 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 177.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.497 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 22.3 mtt180 -63.16 -39.67 95.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.155 -1.384 . . . . 0.0 109.23 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -64.3 -30.82 78.89 Favored Glycine 0 C--O 1.248 0.979 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.48 -178.255 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 115.61 9.89 12.14 Favored Glycine 0 N--CA 1.439 -1.137 0 C-N-CA 120.073 -1.06 . . . . 0.0 111.489 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 88.5 t -71.84 134.7 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.084 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -143.51 146.32 33.28 Favored 'General case' 0 CA--C 1.495 -1.148 0 C-N-CA 123.666 0.786 . . . . 0.0 109.674 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -67.36 144.34 14.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 CA-C-N 114.15 -1.386 . . . . 0.0 111.136 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.94 61.79 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.911 -0.661 . . . . 0.0 111.475 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -120.39 148.65 43.5 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' THR . 42.2 ttp180 -106.35 132.53 52.27 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.536 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.63 HD13 HG22 ' A' ' 86' ' ' THR . 18.2 mm -75.48 114.61 15.78 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 175.584 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.1 pt -101.03 -15.23 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.808 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 179.001 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 84' ' ' MET . 38.1 tt0 -156.37 146.12 20.99 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.619 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.489 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.5 mt -140.8 122.5 14.63 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 O-C-N 124.388 1.055 . . . . 0.0 108.521 178.302 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 59.32 23.18 11.61 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.708 1.203 . . . . 0.0 111.626 172.19 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.01 -9.96 40.05 Favored Glycine 0 N--CA 1.439 -1.14 0 C-N-CA 120.535 -0.841 . . . . 0.0 114.061 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.13 134.44 52.72 Favored 'General case' 0 CA--C 1.494 -1.203 0 CA-C-N 118.34 1.07 . . . . 0.0 110.752 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -72.53 112.59 8.72 Favored 'General case' 0 N--CA 1.423 -1.787 0 CA-C-O 121.337 0.589 . . . . 0.0 109.692 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.65 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 25.1 m -109.15 19.38 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-O 122.312 1.053 . . . . 0.0 108.932 -175.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.12 -18.6 19.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.388 -176.546 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.88 12.03 12.76 Favored 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.669 0.747 . . . . 0.0 109.009 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.65 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 97.3 m -83.88 136.74 41.26 Favored Pre-proline 0 N--CA 1.417 -2.083 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.44 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' THR . 43.0 Cg_exo -60.12 154.87 48.58 Favored 'Trans proline' 0 C--O 1.241 0.662 0 C-N-CA 122.928 2.419 . . . . 0.0 112.912 177.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -45.3 -55.7 5.65 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.715 1.606 . . . . 0.0 111.151 178.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -58.85 -43.6 90.79 Favored 'General case' 0 C--N 1.311 -1.095 0 O-C-N 124.307 1.004 . . . . 0.0 110.546 -175.727 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -62.21 -54.34 42.35 Favored 'General case' 0 CA--C 1.477 -1.835 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.883 -178.738 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 73.0 mt -52.01 -42.74 35.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 O-C-N 124.177 0.923 . . . . 0.0 110.383 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 83.6 t -71.66 -39.32 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.657 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 53.8 t60 -69.8 -41.55 74.91 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.519 0.676 . . . . 0.0 109.903 -176.685 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.6 mt -69.52 -44.03 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 CA-C-N 114.674 -1.148 . . . . 0.0 110.314 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 60.1 mt -59.99 -44.05 94.76 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.829 0.347 . . . . 0.0 111.086 173.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.404 ' C ' HH12 ' A' ' 19' ' ' ARG . 34.6 t -59.16 -27.44 65.66 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 123.49 0.716 . . . . 0.0 112.216 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -109.39 -2.74 17.57 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -176.611 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.496 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -97.68 130.82 44.65 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.478 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 m -128.3 179.73 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.65 -161.96 28.78 Favored Glycine 0 CA--C 1.489 -1.563 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -178.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.505 ' HB3' HD11 ' A' ' 16' ' ' LEU . 27.9 mt-10 -75.89 119.15 19.47 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 172.633 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.7 ' HB ' HG22 ' A' ' 17' ' ' ILE . 63.1 mt -117.19 117.63 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.711 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.246 -173.601 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -82.98 111.8 19.17 Favored 'General case' 0 CA--C 1.492 -1.257 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.603 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.413 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 28.4 mtm -117.55 156.54 27.9 Favored 'General case' 0 C--N 1.269 -2.914 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 173.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.432 ' HD3' HG23 ' A' ' 14' ' ' THR . 35.6 mmtm -123.07 121.65 36.55 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.63 HG22 HD13 ' A' ' 55' ' ' ILE . 68.3 p -116.93 141.49 48.16 Favored 'General case' 0 C--N 1.266 -3.04 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.712 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.493 ' HG2' HG22 ' A' ' 12' ' ' VAL . 85.0 mtp -119.72 170.31 7.04 Favored Pre-proline 0 C--O 1.211 -0.937 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 178.259 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.69 26.64 0.2 Allowed 'Trans proline' 0 CA--C 1.559 1.767 0 C-N-CA 122.865 2.377 . . . . 0.0 113.286 178.252 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.41 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.39 34.83 18.11 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.586 1.154 . . . . 0.0 111.08 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.418 -2.027 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.396 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 16.8 m120 . . . . . 0 CA--C 1.487 -1.466 0 CA-C-O 121.715 0.769 . . . . 0.0 109.619 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 86' ' ' THR . 39.9 t -141.48 126.13 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.974 0 CA-C-N 114.328 -1.306 . . . . 0.0 108.765 -175.099 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 85.1 m -111.42 113.44 25.89 Favored 'General case' 2 N--CA 1.376 -4.137 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 176.458 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.6 m -85.23 137.94 32.66 Favored 'General case' 0 N--CA 1.398 -3.07 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.468 HG11 ' HE2' ' A' ' 84' ' ' MET . 25.4 t -118.01 139.22 46.04 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.955 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.737 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 82' ' ' ILE . 19.4 tp -121.14 112.46 18.71 Favored 'General case' 0 N--CA 1.383 -3.803 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.976 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.581 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -98.61 122.44 50.31 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 N-CA-C 106.949 -1.5 . . . . 0.0 106.949 176.314 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.7 mtp180 -107.18 102.07 11.42 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-O 122.661 1.22 . . . . 0.0 109.276 173.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.509 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 74.1 ttt180 -103.75 109.46 62.18 Favored Pre-proline 0 C--N 1.272 -2.802 0 CA-C-N 112.523 -2.126 . . . . 0.0 109.716 -176.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -54.11 -50.8 12.34 Favored 'Trans proline' 0 CA--C 1.542 0.904 0 C-N-CA 122.602 2.201 . . . . 0.0 111.993 178.783 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -164.88 -172.57 2.64 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.406 HD23 ' CG1' ' A' ' 79' ' ' VAL . 55.6 mt -69.01 -17.26 63.89 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -173.241 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 -64.55 -23.04 67.14 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.3 0.571 . . . . 0.0 110.676 176.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -105.85 113.16 26.54 Favored 'General case' 0 N--CA 1.422 -1.859 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -178.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -92.14 161.93 14.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.78 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.618 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -52.75 -57.11 11.22 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 124.467 1.107 . . . . 0.0 110.662 -173.565 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.57 23.92 10.57 Favored Glycine 0 N--CA 1.434 -1.486 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.861 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -145.94 155.54 42.92 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.0 m -108.6 137.06 47.16 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.92 136.89 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-O 121.49 0.662 . . . . 0.0 110.622 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.468 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 4.2 pp0? -128.41 121.15 28.37 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 176.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 63.56 4.27 1.74 Allowed 'General case' 0 N--CA 1.503 2.197 0 C-N-CA 125.101 1.36 . . . . 0.0 111.983 -172.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 104.58 1.07 43.34 Favored Glycine 0 N--CA 1.438 -1.205 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -174.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -102.35 124.05 56.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.622 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.688 HD13 HG13 ' A' ' 49' ' ' VAL . 68.1 mt -65.76 117.14 5.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 C-N-CA 124.184 0.994 . . . . 0.0 110.576 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 41.8 t -101.55 -28.33 12.6 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.851 -175.516 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.1 t -154.56 156.58 36.86 Favored 'General case' 0 C--O 1.246 0.876 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.4 HD21 ' HA ' ' A' ' 45' ' ' GLU . 57.5 tp -134.43 140.11 46.02 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 123.624 0.77 . . . . 0.0 109.826 -178.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.3 tpt -91.89 127.0 37.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.152 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -76.39 135.33 39.48 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -178.099 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.39 1.06 86.26 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 121.217 -0.516 . . . . 0.0 111.958 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -93.6 167.52 28.59 Favored Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.8 pt -56.75 -36.42 49.16 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.96 0 N-CA-C 113.226 0.825 . . . . 0.0 113.226 178.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.581 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.65 -37.61 79.17 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.4 ' HA ' HD21 ' A' ' 38' ' ' LEU . 14.1 tt0 -61.26 -49.26 77.79 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.096 0.95 . . . . 0.0 108.822 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -76.77 -16.32 59.51 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 114.199 -1.364 . . . . 0.0 111.198 -176.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.59 -19.55 70.84 Favored Glycine 0 N--CA 1.432 -1.618 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.603 176.826 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.74 16.99 20.43 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.239 177.401 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.688 HG13 HD13 ' A' ' 35' ' ' ILE . 51.0 t -69.5 133.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 CA-C-O 120.922 0.391 . . . . 0.0 110.561 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 20.9 mmt180 -132.38 137.03 47.2 Favored 'General case' 0 CA--C 1.484 -1.577 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.335 178.515 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.7 t -72.23 147.51 10.32 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.68 0 CA-C-N 113.913 -1.494 . . . . 0.0 110.115 -178.484 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.0 23.38 45.5 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.538 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 17.1 m-70 -121.83 139.62 53.39 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.199 -0.5 . . . . 0.0 111.377 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.555 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 9.0 ttm180 -94.39 120.82 35.2 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.227 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 86' ' ' THR . 41.6 mt -76.24 122.09 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 175.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.9 pt -102.61 -14.5 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.552 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.251 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.524 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.5 tt0 -161.38 142.88 11.56 Favored 'General case' 0 CA--C 1.485 -1.531 0 C-N-CA 120.046 -0.661 . . . . 0.0 110.148 -174.685 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 75.4 mt -133.26 123.06 46.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 t30 73.38 -21.18 0.26 Allowed 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.988 1.315 . . . . 0.0 112.663 172.752 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 143.42 -8.31 2.09 Favored Glycine 0 N--CA 1.438 -1.23 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -175.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.466 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 20.4 pt20 -107.87 123.48 48.65 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.112 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 m -69.79 111.76 5.77 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 121.512 0.672 . . . . 0.0 109.71 179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 34.0 m -103.47 16.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 CA-C-O 122.062 0.934 . . . . 0.0 109.346 -175.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -71.7 -17.91 19.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.56 -179.263 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.69 11.92 21.08 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.15 -0.932 . . . . 0.0 109.206 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.461 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.5 m -101.9 137.81 19.62 Favored Pre-proline 0 N--CA 1.408 -2.557 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.413 ' O ' HG13 ' A' ' 71' ' ' ILE . 73.9 Cg_endo -76.64 168.08 24.32 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 122.58 2.186 . . . . 0.0 112.551 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -44.62 -55.01 5.55 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 124.977 1.311 . . . . 0.0 111.617 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -56.82 -43.61 81.21 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.352 1.032 . . . . 0.0 110.824 -173.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.0 mtpt -73.54 -45.89 50.82 Favored 'General case' 0 CA--C 1.485 -1.521 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 67' ' ' PRO . 61.7 mt -54.67 -39.86 48.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 121.135 0.493 . . . . 0.0 109.741 178.402 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.74 -37.59 69.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.479 177.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -64.59 -39.75 94.29 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -177.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.9 mt -71.06 -53.34 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.675 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.979 -179.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.7 mt -56.39 -41.77 76.81 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 10.8 t -63.0 -29.42 70.81 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 123.336 0.655 . . . . 0.0 111.71 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -104.63 -13.39 15.98 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.46 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.509 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.87 133.99 34.8 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.316 -0.554 . . . . 0.0 112.494 -174.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.406 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.5 m -137.44 175.81 8.79 Favored 'Isoleucine or valine' 0 C--O 1.248 1.02 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.45 -161.94 19.75 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -77.29 107.76 9.93 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 173.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.481 ' O ' HD12 ' A' ' 16' ' ' LEU . 82.3 mt -107.86 116.67 51.83 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -174.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -97.78 110.2 22.82 Favored 'General case' 0 CA--C 1.453 -2.753 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.524 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 11.3 ttp -112.91 141.38 46.81 Favored 'General case' 1 C--N 1.242 -4.097 0 N-CA-C 105.739 -1.949 . . . . 0.0 105.739 -174.965 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm -121.42 130.39 53.56 Favored 'General case' 0 CA--C 1.452 -2.805 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 -177.002 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 38.5 p -126.34 153.17 45.25 Favored 'General case' 0 C--N 1.275 -2.656 0 O-C-N 123.532 0.52 . . . . 0.0 110.015 -174.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.453 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.8 mtp -122.08 168.76 10.78 Favored Pre-proline 0 C--N 1.301 -1.526 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 176.354 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.94 22.33 0.31 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 123.137 2.558 . . . . 0.0 112.595 178.642 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.555 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 73.28 3.51 4.64 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 126.075 1.75 . . . . 0.0 113.645 177.687 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.609 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 175.619 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.2 m120 . . . . . 0 CA--C 1.491 -1.304 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.471 HG22 ' HG2' ' A' ' 87' ' ' MET . 55.7 t -128.58 129.68 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.628 -175.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.3 m -117.77 113.73 22.26 Favored 'General case' 0 N--CA 1.391 -3.392 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.602 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.3 m -81.42 128.83 34.29 Favored 'General case' 0 N--CA 1.398 -3.042 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.333 -178.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.456 HG11 ' CG2' ' A' ' 49' ' ' VAL . 53.1 t -110.2 136.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.767 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.058 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.491 HD11 ' HB3' ' A' ' 81' ' ' GLU . 21.3 tp -119.07 109.37 15.83 Favored 'General case' 0 N--CA 1.384 -3.767 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 172.776 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.587 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.7 136.07 31.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -115.45 103.75 11.07 Favored 'General case' 0 C--N 1.287 -2.13 0 CA-C-O 122.195 0.998 . . . . 0.0 110.796 178.137 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.433 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 66.0 ttt180 -103.12 113.42 65.85 Favored Pre-proline 0 C--N 1.283 -2.292 0 CA-C-N 113.408 -1.724 . . . . 0.0 109.952 -175.262 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.8 -56.06 2.49 Favored 'Trans proline' 0 CA--C 1.552 1.414 0 C-N-CA 122.937 2.425 . . . . 0.0 113.991 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.55 -175.59 5.49 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' CG1' ' A' ' 79' ' ' VAL . 61.3 mt -71.06 -17.87 62.58 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -173.036 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -79.0 -11.19 60.0 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 121.618 0.723 . . . . 0.0 111.04 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -97.66 143.01 28.75 Favored 'General case' 0 N--CA 1.403 -2.799 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.678 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -97.07 -157.27 0.58 Allowed 'General case' 0 C--N 1.26 -3.325 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -93.83 -51.24 4.98 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.25 6.47 Favored Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.003 177.153 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -149.26 157.18 43.13 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.5 m -105.44 121.92 44.91 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 178.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.28 130.72 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.757 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.332 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -111.0 102.44 10.91 Favored 'General case' 0 C--N 1.287 -2.132 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 178.242 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 67.23 14.84 9.87 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.16 175.726 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.52 -3.17 23.39 Favored Glycine 0 N--CA 1.438 -1.208 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.94 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 3.1 mp -114.48 122.27 68.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 O-C-N 122.389 -0.477 . . . . 0.0 109.869 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.721 HD13 HG13 ' A' ' 49' ' ' VAL . 55.5 mt -65.24 111.22 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 123.647 0.779 . . . . 0.0 109.475 179.032 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -105.6 -19.41 13.78 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.988 -176.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 m -149.2 150.42 32.59 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 121.667 -0.645 . . . . 0.0 109.84 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.414 HD21 ' HA ' ' A' ' 45' ' ' GLU . 65.0 tp -135.63 141.51 45.07 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 120.88 0.371 . . . . 0.0 110.738 -177.796 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.7 ttt -82.55 103.43 12.07 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -79.51 107.14 12.06 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.535 0.683 . . . . 0.0 110.082 -174.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.23 11.35 Favored Glycine 0 N--CA 1.433 -1.552 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -175.172 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.77 178.49 53.68 Favored Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.097 -0.551 . . . . 0.0 111.782 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.414 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.5 OUTLIER -58.1 -41.15 79.88 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.927 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -177.479 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.74 -37.91 88.44 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.635 0.255 . . . . 0.0 111.616 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.414 ' HA ' HD21 ' A' ' 38' ' ' LEU . 3.6 tm-20 -61.78 -46.4 89.71 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 178.339 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.9 mtt-85 -74.77 -25.1 58.84 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.615 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.5 -19.2 79.93 Favored Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.455 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.65 7.88 29.13 Favored Glycine 0 CA--C 1.507 -0.44 0 C-N-CA 120.137 -1.03 . . . . 0.0 112.256 177.184 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.721 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -73.58 135.47 27.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.1 mmt-85 -137.72 155.42 49.11 Favored 'General case' 0 CA--C 1.492 -1.283 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 176.589 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 74.1 t -80.7 139.38 18.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.382 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.141 -175.186 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.33 6.08 51.43 Favored Glycine 0 CA--C 1.497 -1.034 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.479 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.581 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 47.6 m80 -106.23 142.88 35.17 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 115.099 -0.55 . . . . 0.0 111.228 179.234 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.49 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 39.2 ttm180 -99.18 132.66 44.34 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 171.618 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.481 HG12 HG22 ' A' ' 86' ' ' THR . 28.0 mt -85.68 123.37 39.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.467 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 176.768 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.6 pt -102.99 -12.92 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.199 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.291 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 84' ' ' MET . 36.9 tt0 -154.35 141.68 19.6 Favored 'General case' 0 CA--C 1.479 -1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -178.774 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.495 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.8 mt -140.91 124.4 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 124.407 1.067 . . . . 0.0 108.155 177.196 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 68.55 13.92 9.01 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.892 0.853 . . . . 0.0 110.287 171.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.7 -2.73 49.07 Favored Glycine 0 N--CA 1.437 -1.25 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.934 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.441 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.4 pt20 -112.85 130.98 55.9 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.617 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 33.2 t -68.38 114.23 6.64 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.602 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.7 m -108.84 17.08 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 CA-C-O 121.884 0.85 . . . . 0.0 109.394 -176.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -71.34 -15.22 18.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.841 -1.072 . . . . 0.0 112.04 -175.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -120.01 7.31 10.86 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.216 0.531 . . . . 0.0 109.568 175.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.602 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.9 m -80.8 138.07 50.4 Favored Pre-proline 0 N--CA 1.418 -2.042 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.243 -177.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.98 157.27 44.64 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 123.081 2.52 . . . . 0.0 113.223 178.582 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -45.96 -55.86 6.24 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 125.972 1.709 . . . . 0.0 110.61 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -54.09 -51.83 62.9 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 124.492 1.117 . . . . 0.0 110.813 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.536 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.9 mptt -58.93 -54.0 52.09 Favored 'General case' 0 CA--C 1.486 -1.482 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.812 -176.427 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 70.4 mt -50.71 -43.28 23.9 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 124.312 1.007 . . . . 0.0 110.358 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.0 t -73.2 -36.86 51.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.744 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -73.45 -37.69 65.73 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.348 0.594 . . . . 0.0 109.903 -175.097 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.1 mt -68.53 -47.64 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.307 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 59.2 mt -58.28 -40.32 81.59 Favored 'General case' 0 C--O 1.212 -0.905 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.492 176.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.3 t -62.25 -26.99 68.69 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -105.98 -17.3 14.39 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.433 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.9 127.25 35.97 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.688 -176.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.5 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -127.53 -179.38 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.11 -155.61 24.58 Favored Glycine 0 CA--C 1.493 -1.292 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.491 ' HB3' HD11 ' A' ' 16' ' ' LEU . 45.3 mt-10 -77.69 108.52 10.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 174.741 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.587 ' HB ' HG22 ' A' ' 17' ' ' ILE . 64.6 mt -109.63 117.72 55.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -176.154 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 39.8 m-70 -93.05 116.93 29.5 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 -178.512 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.465 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.0 mtm -120.2 156.84 30.32 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 177.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.467 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 68.8 mmtt -121.47 123.81 42.93 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 176.35 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.581 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 72.1 p -119.36 139.84 51.33 Favored 'General case' 0 C--N 1.27 -2.875 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.208 -177.437 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.471 ' HG2' HG22 ' A' ' 12' ' ' VAL . 82.9 mtp -120.85 171.72 5.57 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -72.1 24.91 0.26 Allowed 'Trans proline' 0 N--CA 1.497 1.728 0 C-N-CA 123.09 2.527 . . . . 0.0 112.88 177.881 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.49 ' HA ' ' CB ' ' A' ' 54' ' ' ARG . . . 71.33 20.59 4.93 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 125.127 1.371 . . . . 0.0 112.803 177.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.762 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.021 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 CA--C 1.49 -1.344 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -130.66 133.7 63.06 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 CA-C-O 122.315 1.055 . . . . 0.0 111.861 -172.298 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.4 m -127.9 121.94 31.27 Favored 'General case' 0 N--CA 1.392 -3.355 0 CA-C-N 113.262 -1.79 . . . . 0.0 106.864 176.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 m -82.82 141.92 31.93 Favored 'General case' 0 N--CA 1.404 -2.774 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.574 -176.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' CG2' ' A' ' 49' ' ' VAL . 56.1 t -116.47 136.65 52.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.067 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.412 HD12 ' O ' ' A' ' 82' ' ' ILE . 29.1 tp -122.1 119.73 32.2 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-O 121.961 0.886 . . . . 0.0 109.886 175.445 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.557 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -97.49 134.13 36.68 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.098 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.418 178.594 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.02 101.34 10.16 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 171.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.531 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.0 ttt180 -108.31 107.97 60.67 Favored Pre-proline 0 C--N 1.282 -2.341 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.451 -178.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -58.03 -41.09 71.71 Favored 'Trans proline' 0 CA--C 1.546 1.117 0 C-N-CA 122.607 2.205 . . . . 0.0 113.423 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -167.17 176.64 6.67 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.45 HD23 ' CG1' ' A' ' 79' ' ' VAL . 73.1 mt -68.95 -22.39 64.13 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 125.152 1.381 . . . . 0.0 111.213 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.424 ' HA ' ' NE ' ' A' ' 23' ' ' ARG . 7.3 mmp_? -59.11 -21.89 59.98 Favored 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.058 0.848 . . . . 0.0 110.233 174.234 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -103.89 118.35 36.49 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 104.899 -2.26 . . . . 0.0 104.899 178.467 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.22 168.79 10.69 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.587 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -64.05 -59.85 3.97 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.221 0.534 . . . . 0.0 111.282 -171.014 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.445 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 103.45 34.63 3.82 Favored Glycine 0 N--CA 1.431 -1.658 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.287 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -155.43 157.39 36.94 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.6 m -117.34 136.04 53.42 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.85 128.15 64.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.772 0.796 . . . . 0.0 112.923 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -121.45 115.44 22.88 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.454 176.641 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 68.99 2.6 3.65 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 125.538 1.535 . . . . 0.0 112.283 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 118.42 -12.6 12.38 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -96.43 128.17 47.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 O-C-N 122.385 -0.479 . . . . 0.0 110.548 -179.109 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.746 HD13 HG13 ' A' ' 49' ' ' VAL . 72.9 mt -68.31 114.45 5.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 124.458 1.103 . . . . 0.0 109.608 176.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.5 t -98.63 -23.78 15.34 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.006 -177.287 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.8 p -156.52 152.06 26.87 Favored 'General case' 0 C--N 1.322 -0.629 0 O-C-N 122.297 -0.252 . . . . 0.0 111.316 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.445 HD12 ' O ' ' A' ' 27' ' ' GLY . 48.7 tp -125.91 148.55 49.18 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 124.356 1.062 . . . . 0.0 109.072 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -105.88 123.52 48.09 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.376 0.608 . . . . 0.0 110.692 -179.312 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 20.4 tpp85 -60.36 130.84 48.59 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.23 176.587 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.05 5.99 89.25 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.856 178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.58 161.2 27.15 Favored Glycine 0 N--CA 1.423 -2.179 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 pt -60.24 -32.61 51.12 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.98 0 C-N-CA 120.764 -0.375 . . . . 0.0 111.947 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.83 -38.85 86.88 Favored 'General case' 0 N--CA 1.443 -0.779 0 C-N-CA 122.986 0.514 . . . . 0.0 111.812 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.44 ' HA ' HD21 ' A' ' 38' ' ' LEU . 44.4 tt0 -64.31 -38.88 92.6 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -90.48 -0.41 57.65 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.902 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.31 -19.56 38.35 Favored Glycine 0 N--CA 1.433 -1.504 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 175.783 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.16 9.01 26.6 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.103 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.746 HG13 HD13 ' A' ' 35' ' ' ILE . 60.0 t -69.82 140.01 19.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 13.9 mmt180 -145.08 141.8 29.14 Favored 'General case' 0 CA--C 1.49 -1.354 0 C-N-CA 123.406 0.682 . . . . 0.0 110.989 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.74 139.9 20.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.783 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.18 14.29 59.17 Favored Glycine 0 C--N 1.305 -1.147 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.558 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -108.71 133.85 52.23 Favored 'General case' 0 N--CA 1.428 -1.575 0 CA-C-O 121.32 0.581 . . . . 0.0 111.611 178.284 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -92.76 114.79 27.44 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.492 -1.231 . . . . 0.0 108.085 177.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 30.2 mt -78.54 122.9 34.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.312 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 62' ' ' SER . 37.2 pt -106.43 -11.79 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.505 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.568 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.8 tt0 -154.76 144.91 21.87 Favored 'General case' 0 CA--C 1.479 -1.778 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.107 -177.015 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -141.82 125.15 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 174.57 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 69.43 -2.72 1.8 Allowed 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.991 1.317 . . . . 0.0 112.846 172.583 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.43 -4.11 10.25 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.968 -178.27 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -112.28 130.68 55.86 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 10.5 p -73.0 108.3 5.82 Favored 'General case' 0 N--CA 1.425 -1.68 0 CA-C-O 121.795 0.807 . . . . 0.0 110.285 177.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.552 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.6 m -98.86 16.52 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-O 122.271 1.034 . . . . 0.0 110.053 -172.567 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.6 p -75.58 -10.27 13.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.072 -177.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.95 16.33 10.88 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.063 -0.972 . . . . 0.0 108.495 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.7 m -103.26 135.22 19.43 Favored Pre-proline 0 N--CA 1.407 -2.577 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.49 159.81 52.18 Favored 'Trans proline' 0 C--O 1.244 0.802 0 C-N-CA 122.258 1.972 . . . . 0.0 112.596 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -43.15 -54.84 4.22 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.87 1.668 . . . . 0.0 112.177 -178.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -56.39 -47.03 79.79 Favored 'General case' 0 CA--C 1.497 -1.067 0 O-C-N 124.027 0.83 . . . . 0.0 110.663 -175.219 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.468 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 12.6 mptt -63.76 -54.21 38.92 Favored 'General case' 0 N--CA 1.426 -1.639 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.682 -177.919 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.5 mt -51.08 -44.75 29.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 O-C-N 124.098 0.874 . . . . 0.0 110.112 179.335 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.4 t -71.53 -36.82 61.67 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.746 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -72.81 -40.57 65.74 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -174.806 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 46.0 mt -66.0 -46.26 88.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.895 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.9 mt -58.5 -41.04 84.47 Favored 'General case' 0 C--O 1.214 -0.811 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.554 175.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 50.8 m -63.06 -27.61 69.52 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.2 m-80 -104.45 -10.65 17.55 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -175.34 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.39 133.4 36.68 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.76 -178.409 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.45 ' CG1' HD23 ' A' ' 22' ' ' LEU . 3.1 m -129.69 -178.57 2.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.583 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 175.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.57 -154.82 33.14 Favored Glycine 0 CA--C 1.488 -1.624 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -73.51 112.64 9.79 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 121.592 0.711 . . . . 0.0 109.722 174.28 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.412 ' O ' HD12 ' A' ' 16' ' ' LEU . 74.9 mt -118.11 117.47 54.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.358 0 CA-C-N 115.328 -0.851 . . . . 0.0 108.711 -177.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -88.38 129.98 35.27 Favored 'General case' 0 CA--C 1.473 -2.013 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.201 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.453 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.3 mtm -129.19 153.3 47.87 Favored 'General case' 0 C--N 1.262 -3.209 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 171.148 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 62.9 mmtt -119.18 122.61 42.39 Favored 'General case' 0 C--N 1.268 -2.975 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 177.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 52.7 p -121.82 143.61 49.3 Favored 'General case' 0 C--N 1.267 -2.992 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.102 -177.332 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.556 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.3 mtp -111.22 164.07 15.85 Favored Pre-proline 0 C--N 1.303 -1.421 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 178.152 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -78.33 29.68 0.45 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 122.786 2.324 . . . . 0.0 109.3 172.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.556 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.97 11.5 8.39 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 127.015 2.126 . . . . 0.0 112.017 -178.7 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.204 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.438 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 88.9 m-20 . . . . . 0 CA--C 1.502 -0.894 0 CA-C-O 121.844 0.831 . . . . 0.0 109.853 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.4 t -122.79 122.19 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 CA-C-O 121.885 0.85 . . . . 0.0 109.518 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.9 m -108.49 108.81 19.89 Favored 'General case' 0 C--N 1.246 -3.916 0 CA-C-N 113.332 -1.758 . . . . 0.0 107.133 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 85' ' ' LYS . 15.9 m -79.43 132.63 36.43 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.435 178.447 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.479 HG11 ' HE2' ' A' ' 84' ' ' MET . 37.2 t -111.17 140.65 29.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.335 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.517 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 15.1 tp -122.83 112.76 18.27 Favored 'General case' 0 N--CA 1.379 -3.983 0 C-N-CA 119.286 -0.966 . . . . 0.0 108.814 172.781 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.89 129.21 49.58 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.968 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.58 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -111.84 102.78 11.03 Favored 'General case' 0 N--CA 1.406 -2.64 0 CA-C-O 122.506 1.145 . . . . 0.0 109.667 174.076 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.612 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.3 ttt180 -112.38 110.79 52.9 Favored Pre-proline 0 C--N 1.276 -2.609 0 CA-C-N 112.752 -2.022 . . . . 0.0 110.718 -176.596 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -57.46 -51.88 7.49 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 122.567 2.178 . . . . 0.0 112.577 178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.47 ' OD2' ' HG2' ' A' ' 23' ' ' ARG . 1.0 OUTLIER -158.56 -174.0 4.57 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.838 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.427 HD23 HG12 ' A' ' 79' ' ' VAL . 46.6 mt -72.08 -14.16 61.78 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.47 ' HG2' ' OD2' ' A' ' 21' ' ' ASP . 18.5 mmt180 -66.31 -23.95 66.46 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.828 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -94.4 110.18 21.98 Favored 'General case' 0 CA--C 1.48 -1.72 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 176.051 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -92.19 155.44 18.01 Favored 'General case' 0 C--N 1.281 -2.388 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.806 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.657 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.2 mm? -50.78 -61.76 2.02 Favored 'General case' 0 C--O 1.237 0.428 0 O-C-N 124.913 1.383 . . . . 0.0 110.642 -175.143 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.48 -10.77 35.95 Favored Glycine 0 N--CA 1.434 -1.496 0 C-N-CA 120.66 -0.781 . . . . 0.0 111.579 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.422 ' CE1' ' HB3' ' A' ' 26' ' ' LEU . 50.6 p90 -112.89 151.76 30.1 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.023 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 t -107.08 122.38 46.36 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -112.44 131.35 64.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 CA-C-O 121.576 0.703 . . . . 0.0 112.18 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -131.52 122.14 25.65 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 114.495 -1.229 . . . . 0.0 107.843 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.46 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 88.0 m-20 66.89 13.98 9.65 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-O 121.902 0.858 . . . . 0.0 111.752 177.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.46 -6.72 65.71 Favored Glycine 0 N--CA 1.432 -1.616 0 CA-C-N 115.175 -0.92 . . . . 0.0 111.313 -178.179 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.14 128.82 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-O 121.223 0.535 . . . . 0.0 110.22 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.645 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -67.11 111.01 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.221 175.289 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -95.57 -27.99 15.07 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.645 -175.005 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.4 m -150.47 158.91 44.69 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 121.959 -0.463 . . . . 0.0 110.072 -177.65 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.2 tp -142.85 135.44 27.71 Favored 'General case' 0 C--O 1.239 0.529 0 O-C-N 123.835 0.709 . . . . 0.0 111.258 -178.014 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ttt -82.3 121.92 27.29 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 176.125 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -74.33 122.86 23.57 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.056 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.17 -3.22 72.63 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -177.462 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -83.47 170.31 48.43 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.7 pt -63.03 -37.29 78.98 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.399 0 CA-C-N 117.311 0.556 . . . . 0.0 111.899 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.497 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -55.23 -45.56 75.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.521 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -62.78 -43.15 99.56 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.507 0.67 . . . . 0.0 109.936 178.878 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -73.76 -20.25 60.55 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.125 -0.943 . . . . 0.0 111.778 -179.679 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.26 -19.13 57.82 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.963 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.62 15.59 22.33 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.277 -0.963 . . . . 0.0 112.456 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.645 HG13 HD13 ' A' ' 35' ' ' ILE . 79.2 t -75.39 122.8 29.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 8.1 mmm180 -122.39 150.87 41.84 Favored 'General case' 0 CA--C 1.474 -1.957 0 CA-C-O 121.348 0.594 . . . . 0.0 110.416 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 78.1 t -78.25 141.4 15.53 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.772 0 CA-C-N 114.018 -1.446 . . . . 0.0 109.424 -176.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.85 30.03 33.22 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -175.128 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.2 m170 -123.31 135.06 54.03 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.803 -0.698 . . . . 0.0 109.915 177.823 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.7 ttp180 -97.91 123.89 42.1 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 177.553 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.603 HG12 HG22 ' A' ' 86' ' ' THR . 32.6 mt -79.04 127.12 39.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 O-C-N 123.852 0.72 . . . . 0.0 109.779 178.087 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 41.6 pt -109.75 -13.93 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.95 143.11 16.74 Favored 'General case' 0 CA--C 1.483 -1.634 0 C-N-CA 120.025 -0.67 . . . . 0.0 109.314 -175.593 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.467 ' CD1' HG21 ' A' ' 63' ' ' VAL . 66.3 mt -137.71 127.84 36.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.206 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 70.84 -18.66 0.25 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.846 1.259 . . . . 0.0 113.485 172.692 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 130.59 8.41 3.16 Favored Glycine 0 C--N 1.299 -1.52 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -176.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -118.74 139.85 50.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 176.034 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.7 t -77.44 108.11 10.36 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.537 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.8 m -101.04 8.57 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.231 0 CA-C-O 121.966 0.889 . . . . 0.0 109.384 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.03 -12.19 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.783 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.156 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.19 14.52 16.97 Favored 'General case' 0 N--CA 1.437 -1.093 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.735 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 80.3 m -102.9 138.63 19.62 Favored Pre-proline 0 N--CA 1.409 -2.511 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.407 ' O ' HG13 ' A' ' 71' ' ' ILE . 59.4 Cg_exo -49.94 139.9 32.44 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.813 2.342 . . . . 0.0 110.751 176.442 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.46 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 32.6 p80 -51.66 -42.76 62.35 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -176.533 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -69.26 -37.59 77.98 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.665 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 tttm -60.13 -44.88 94.58 Favored 'General case' 0 CA--C 1.492 -1.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.907 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 67' ' ' PRO . 66.1 mt -52.05 -44.5 39.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 O-C-N 124.006 0.816 . . . . 0.0 109.762 178.662 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 96.8 t -67.24 -34.92 72.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.69 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.3 t-160 -74.29 -39.51 62.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 54.1 mt -65.7 -49.16 79.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.84 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 77.6 mt -57.12 -41.14 78.46 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.105 0.479 . . . . 0.0 110.985 175.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.5 t -57.08 -36.7 70.9 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 123.808 0.843 . . . . 0.0 111.53 178.381 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -98.6 -11.45 22.11 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -176.459 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.612 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -86.89 131.01 34.23 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -173.501 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.427 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -134.64 179.01 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.454 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.99 -159.74 22.18 Favored Glycine 0 CA--C 1.496 -1.13 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.413 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.2 mp0 -78.98 108.11 12.22 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 171.409 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 17' ' ' ILE . 88.6 mt -104.47 117.27 49.78 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.471 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -175.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -100.02 111.3 23.6 Favored 'General case' 0 CA--C 1.479 -1.788 0 N-CA-C 105.014 -2.217 . . . . 0.0 105.014 -176.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.479 ' HE2' HG11 ' A' ' 15' ' ' VAL . 23.2 ttp -122.95 148.63 45.26 Favored 'General case' 0 C--N 1.257 -3.45 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -173.379 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.465 ' HD3' HG23 ' A' ' 14' ' ' THR . 29.0 mmtm -117.88 128.36 54.75 Favored 'General case' 0 CA--C 1.474 -1.971 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -177.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.603 HG22 HG12 ' A' ' 55' ' ' ILE . 54.0 p -127.74 143.39 51.14 Favored 'General case' 0 C--N 1.277 -2.567 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.429 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.498 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.5 mtp -112.9 168.72 7.27 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 177.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 12.8 Cg_exo -74.48 30.05 0.34 Allowed 'Trans proline' 0 N--CA 1.489 1.238 0 C-N-CA 122.997 2.465 . . . . 0.0 111.578 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.498 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 68.31 23.46 7.69 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 126.308 1.843 . . . . 0.0 111.815 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.419 -1.984 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.991 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.504 -0.819 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.8 m 61.22 77.13 0.34 Allowed 'General case' 0 C--O 1.246 0.895 0 O-C-N 124.285 0.99 . . . . 0.0 110.166 -178.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 50.2 mtt -119.2 141.6 48.74 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.744 -174.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.68 -125.65 8.47 Favored Glycine 0 CA--C 1.487 -1.665 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.254 169.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -96.54 91.74 5.92 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.408 0.623 . . . . 0.0 110.588 -177.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t -128.59 126.81 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.373 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.465 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.8 m -118.09 107.24 13.75 Favored 'General case' 0 C--N 1.251 -3.716 0 CA-C-N 113.628 -1.624 . . . . 0.0 107.661 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.9 m -79.07 140.74 37.81 Favored 'General case' 0 N--CA 1.401 -2.908 0 CA-C-N 115.487 -0.778 . . . . 0.0 109.8 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -122.45 136.68 58.49 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.117 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.322 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.464 ' O ' ' HA2' ' A' ' 47' ' ' GLY . 29.9 tp -115.64 115.96 27.29 Favored 'General case' 0 N--CA 1.396 -3.152 0 C-N-CA 120.205 -0.598 . . . . 0.0 109.446 173.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.611 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -98.59 130.95 46.66 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.05 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.661 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 55.5 mtp180 -115.57 101.38 8.81 Favored 'General case' 0 N--CA 1.408 -2.572 0 CA-C-O 122.446 1.117 . . . . 0.0 108.829 171.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.475 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 75.3 ttt180 -100.79 119.48 58.28 Favored Pre-proline 0 C--N 1.275 -2.656 0 CA-C-N 112.939 -1.937 . . . . 0.0 111.896 -174.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.89 -48.48 12.43 Favored 'Trans proline' 0 CA--C 1.545 1.029 0 C-N-CA 122.92 2.414 . . . . 0.0 112.983 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -165.92 -175.15 3.28 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.427 HD22 ' O ' ' A' ' 76' ' ' SER . 59.0 mt -73.7 -11.73 60.5 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 115.064 1.505 . . . . 0.0 115.064 -173.023 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -86.68 -12.42 48.43 Favored 'General case' 0 C--N 1.292 -1.901 0 CA-C-O 121.743 0.782 . . . . 0.0 111.0 177.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -97.25 89.93 4.93 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 173.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -77.47 161.76 27.7 Favored 'General case' 0 N--CA 1.415 -2.218 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.094 -177.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.713 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.4 mm? -45.89 -48.84 16.03 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 125.444 1.498 . . . . 0.0 111.55 -171.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.08 13.65 45.17 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 119.714 -1.231 . . . . 0.0 111.568 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -137.31 148.57 46.44 Favored 'General case' 0 N--CA 1.426 -1.643 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 175.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.2 m -96.46 122.54 39.46 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -120.52 143.22 33.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -130.88 114.7 15.6 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 173.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 68' ' ' HIS . 93.3 m-20 64.9 14.45 9.26 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.563 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.55 -3.21 34.46 Favored Glycine 0 N--CA 1.434 -1.48 0 C-N-CA 120.52 -0.847 . . . . 0.0 111.737 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.58 124.55 66.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 O-C-N 121.964 -0.727 . . . . 0.0 110.769 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.662 HD13 HG13 ' A' ' 49' ' ' VAL . 61.9 mt -69.05 116.72 10.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 114.513 -1.221 . . . . 0.0 110.576 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -97.59 -32.23 11.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.583 -177.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.9 t -155.01 153.47 31.04 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.3 tp -132.13 130.85 41.69 Favored 'General case' 0 C--O 1.243 0.718 0 C-N-CA 123.197 0.599 . . . . 0.0 110.478 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -84.75 115.54 22.76 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 175.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -70.84 134.96 47.77 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -177.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.14 -2.72 75.69 Favored Glycine 0 C--N 1.302 -1.317 0 C-N-CA 121.193 -0.527 . . . . 0.0 111.802 -175.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.04 168.6 31.45 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.411 HG13 ' O ' ' A' ' 26' ' ' LEU . 3.0 pt -57.15 -36.82 52.88 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.611 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -61.65 -35.51 78.13 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -66.28 -41.46 89.82 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -66.91 -31.76 72.57 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 114.254 -1.339 . . . . 0.0 109.891 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -70.93 -27.3 72.46 Favored Glycine 0 N--CA 1.44 -1.1 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.822 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.6 21.46 10.47 Favored Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.662 HG13 HD13 ' A' ' 35' ' ' ILE . 73.8 t -77.74 137.39 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 48.8 mmt-85 -136.07 146.89 47.55 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.92 140.51 19.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 CA-C-N 114.281 -1.327 . . . . 0.0 109.708 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 25.11 27.85 Favored Glycine 0 N--CA 1.431 -1.643 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 -178.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.546 ' HB2' HD12 ' A' ' 35' ' ' ILE . 6.8 m170 -119.18 144.95 46.4 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.901 -0.65 . . . . 0.0 110.227 176.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 43.4 ttp180 -107.21 124.06 49.19 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.338 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 86' ' ' THR . 28.7 mm -72.96 115.09 13.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.2 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.444 HG21 ' SD ' ' A' ' 87' ' ' MET 0.275 2.1 pp -103.65 -18.08 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.752 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' MET . 33.1 tt0 -154.0 146.77 24.29 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.468 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.5 mt -139.47 119.47 13.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 O-C-N 124.25 0.969 . . . . 0.0 109.153 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 96.7 m-20 46.9 33.25 2.13 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 115.186 1.55 . . . . 0.0 115.186 178.28 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.84 -0.99 41.7 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.087 -1.054 . . . . 0.0 114.035 175.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -119.67 125.78 49.53 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 117.834 0.817 . . . . 0.0 109.95 175.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -69.28 110.76 4.78 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.549 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.2 m -103.11 13.56 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.707 0.765 . . . . 0.0 110.089 -174.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.8 -15.38 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.747 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.355 -176.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -117.32 14.63 14.77 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.794 0.807 . . . . 0.0 109.153 176.112 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.549 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.9 m -93.64 140.28 23.04 Favored Pre-proline 0 N--CA 1.411 -2.402 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -70.16 161.72 44.95 Favored 'Trans proline' 0 CA--C 1.544 1.024 0 C-N-CA 121.862 1.708 . . . . 0.0 113.225 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.428 ' HB2' ' OD1' ' A' ' 32' ' ' ASN . 4.2 t60 -42.63 -56.28 3.19 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.994 2.118 . . . . 0.0 111.997 -178.493 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.84 -50.97 71.49 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.298 0.999 . . . . 0.0 110.858 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.583 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -58.75 -54.01 51.92 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.361 -178.82 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.7 mt -51.81 -45.12 38.13 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 O-C-N 123.978 0.799 . . . . 0.0 110.811 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.29 -39.52 76.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.291 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.1 t60 -68.39 -37.63 80.58 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.032 0.444 . . . . 0.0 109.881 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 24.1 mt -66.44 -49.79 72.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.198 177.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 79.9 mt -62.18 -40.05 94.72 Favored 'General case' 0 C--O 1.216 -0.693 0 CA-C-O 120.891 0.377 . . . . 0.0 111.538 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 22.8 t -63.85 -27.3 69.07 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -107.56 -7.19 16.59 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -175.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.466 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.14 135.51 33.92 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.382 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.475 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -134.97 177.12 7.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.162 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.76 -153.53 27.23 Favored Glycine 0 CA--C 1.477 -2.289 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.1 108.24 7.71 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.479 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 89.7 mt -111.41 119.39 59.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.955 -1.021 . . . . 0.0 109.991 -176.162 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 31.5 m80 -98.02 116.91 31.21 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.403 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 27.7 mtm -121.11 158.83 27.06 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -123.82 123.69 41.02 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.666 HG22 HD13 ' A' ' 55' ' ' ILE . 44.1 p -120.24 149.14 42.75 Favored 'General case' 0 C--N 1.262 -3.199 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.993 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.462 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -120.15 164.69 21.08 Favored Pre-proline 0 C--N 1.291 -1.94 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 176.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -70.27 28.71 0.19 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 123.308 2.672 . . . . 0.0 112.967 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.462 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.52 11.25 5.49 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.811 1.644 . . . . 0.0 113.671 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.302 -1.468 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.065 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.554 ' HA ' HD12 ' A' ' 56' ' ' ILE . 2.7 tm-20 . . . . . 0 C--O 1.219 -0.547 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 18.5 m -77.42 -44.17 30.04 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 17.0 ptp -113.48 165.78 12.15 Favored 'General case' 0 C--O 1.249 1.078 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.104 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.66 -145.73 16.36 Favored Glycine 0 N--CA 1.422 -2.292 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 174.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.515 ' O ' ' HA ' ' A' ' 87' ' ' MET . 40.8 m-80 -107.18 85.84 2.2 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 174.451 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.533 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 76.1 t -103.72 114.7 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.524 0 CA-C-N 114.32 -1.309 . . . . 0.0 108.732 -174.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 73.7 m -108.91 111.75 23.61 Favored 'General case' 2 C--N 1.223 -4.912 0 CA-C-N 112.723 -2.035 . . . . 0.0 106.89 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.6 m -80.44 140.54 35.93 Favored 'General case' 0 N--CA 1.394 -3.259 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.739 -178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.422 HG11 ' CG2' ' A' ' 49' ' ' VAL . 54.3 t -122.02 127.15 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.396 -3.133 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.113 178.29 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.515 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 25.6 tp -110.45 116.22 31.02 Favored 'General case' 0 N--CA 1.387 -3.583 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 172.447 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.623 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -104.74 137.16 35.17 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.262 0 N-CA-C 106.074 -1.825 . . . . 0.0 106.074 178.16 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -109.3 104.02 13.07 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-O 121.839 0.828 . . . . 0.0 110.472 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.463 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.8 ttt180 -106.92 114.03 62.01 Favored Pre-proline 0 N--CA 1.415 -2.181 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.954 -177.021 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.88 -55.4 2.7 Favored 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 122.835 2.357 . . . . 0.0 112.982 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -161.5 -173.26 3.7 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -177.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 41.3 mt -71.01 -18.71 62.58 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -175.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 12.4 mmt-85 -61.58 -31.49 71.55 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.718 0.77 . . . . 0.0 109.544 174.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -94.45 130.69 40.72 Favored 'General case' 0 N--CA 1.419 -1.995 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -107.13 165.32 11.45 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 177.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.703 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.3 mm? -51.47 -53.63 35.34 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 124.754 1.283 . . . . 0.0 111.308 -172.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.414 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 99.3 32.17 5.89 Favored Glycine 0 N--CA 1.424 -2.148 0 C-N-CA 119.936 -1.126 . . . . 0.0 111.838 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -158.6 161.69 37.25 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -116.02 122.49 45.36 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -110.21 136.45 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.463 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -125.14 116.48 22.11 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' HIS . 83.3 m-20 67.09 8.92 6.53 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.674 0.789 . . . . 0.0 112.336 -179.461 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.26 -0.93 40.45 Favored Glycine 0 N--CA 1.439 -1.136 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.128 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.86 123.43 65.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.935 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.653 HD13 HG13 ' A' ' 49' ' ' VAL . 72.6 mt -60.91 112.62 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 123.92 0.888 . . . . 0.0 110.951 178.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -83.35 -43.37 16.02 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.136 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.9 p -154.05 160.67 42.09 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.204 -179.155 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.414 HD12 ' O ' ' A' ' 27' ' ' GLY . 53.6 tp -125.92 133.26 51.92 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 123.773 0.67 . . . . 0.0 110.249 -178.297 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.8 ttt -74.31 107.33 6.41 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.1 tpt180 -60.98 119.58 8.56 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 124.375 1.07 . . . . 0.0 110.775 -176.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.63 1.42 74.17 Favored Glycine 0 N--CA 1.442 -0.911 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.116 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.65 174.44 46.46 Favored Glycine 0 C--O 1.25 1.107 0 C-N-CA 121.248 -0.501 . . . . 0.0 113.239 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.464 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.64 -33.83 64.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 112.839 0.681 . . . . 0.0 112.839 -177.989 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.17 -39.25 94.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.183 0.516 . . . . 0.0 110.932 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -71.45 -33.05 69.02 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.405 ' HA ' ' NE ' ' A' ' 46' ' ' ARG . 1.9 mmp_? -66.67 -33.08 74.85 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.485 172.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.87 -14.17 82.86 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.537 -0.756 . . . . 0.0 112.956 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.84 30.06 9.3 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.525 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.653 HG13 HD13 ' A' ' 35' ' ' ILE . 54.2 t -77.22 143.88 12.31 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.647 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.415 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 23.9 mmm180 -135.74 140.65 44.53 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-O 121.282 0.563 . . . . 0.0 109.745 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.8 t -73.12 143.49 13.78 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 114.232 -1.349 . . . . 0.0 110.375 -178.1 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.69 18.69 59.54 Favored Glycine 0 CA--C 1.501 -0.794 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -177.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.9 m170 -109.96 139.79 44.67 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.011 -0.594 . . . . 0.0 110.543 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 20.8 ttt180 -101.33 117.26 34.6 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.599 HG12 HG22 ' A' ' 86' ' ' THR . 33.6 mt -76.03 126.84 37.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.554 HD12 ' HA ' ' A' ' 7' ' ' GLU . 41.5 pt -107.78 -14.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.229 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.6 tt0 -156.28 144.6 19.87 Favored 'General case' 0 CA--C 1.491 -1.293 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.66 -173.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.461 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.6 mt -140.35 122.15 15.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 C-N-CA 124.367 1.067 . . . . 0.0 108.22 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.1 m120 65.5 4.76 2.89 Favored 'General case' 0 N--CA 1.501 2.081 0 C-N-CA 125.505 1.522 . . . . 0.0 112.671 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.96 5.5 35.39 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.432 ' O ' HG13 ' A' ' 63' ' ' VAL . 59.2 tt0 -104.79 116.32 31.81 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.466 1.106 . . . . 0.0 108.402 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.6 t -70.16 109.53 4.67 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.52 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.1 m -105.32 14.51 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.551 0 CA-C-O 121.64 0.733 . . . . 0.0 109.173 -175.195 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -69.51 -21.66 24.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.952 -175.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.79 -1.03 22.98 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.504 0.668 . . . . 0.0 109.91 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.52 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 90.4 m -78.96 137.04 57.52 Favored Pre-proline 0 N--CA 1.406 -2.662 0 C-N-CA 124.793 1.237 . . . . 0.0 108.755 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.2 147.18 91.87 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.051 1.834 . . . . 0.0 110.929 178.006 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.569 ' HB3' ' HA ' ' A' ' 32' ' ' ASN . 6.7 p-80 -48.98 -39.08 25.18 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.092 0.957 . . . . 0.0 113.063 -176.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -68.64 -38.02 80.14 Favored 'General case' 0 N--CA 1.435 -1.192 0 O-C-N 123.491 0.494 . . . . 0.0 110.508 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 35.8 mttp -67.34 -46.14 74.32 Favored 'General case' 0 CA--C 1.478 -1.813 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.549 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.2 mt -53.24 -41.1 41.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 O-C-N 124.054 0.846 . . . . 0.0 109.549 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.2 t -71.75 -37.11 61.3 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.097 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -68.83 -40.67 79.34 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-O 121.315 0.579 . . . . 0.0 110.063 -176.511 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 37.2 mt -65.65 -51.51 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 CA-C-N 114.548 -1.206 . . . . 0.0 109.786 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.9 mt -58.45 -40.87 83.76 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.345 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -58.65 -28.61 65.85 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 123.381 0.672 . . . . 0.0 111.885 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -119.06 -6.11 10.48 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 115.16 1.541 . . . . 0.0 115.16 -172.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.463 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 130.75 36.28 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.923 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.2 m -127.04 177.02 6.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.5 -152.5 20.39 Favored Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.472 ' HB3' HD11 ' A' ' 16' ' ' LEU . 41.8 mt-10 -84.23 114.06 21.55 Favored 'General case' 0 N--CA 1.425 -1.724 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 174.755 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.623 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.2 mt -114.55 117.08 54.51 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.402 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -175.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -90.2 111.64 22.87 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.478 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 26.1 mtm -114.21 156.54 24.11 Favored 'General case' 0 C--N 1.269 -2.904 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 175.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.533 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 69.0 mmtt -122.48 124.6 43.97 Favored 'General case' 0 C--N 1.275 -2.671 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.308 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.599 HG22 HG12 ' A' ' 55' ' ' ILE . 43.8 p -121.61 141.22 51.32 Favored 'General case' 0 C--N 1.269 -2.935 0 C-N-CA 120.716 -0.393 . . . . 0.0 110.346 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.515 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 43.6 mtm -114.39 167.51 9.51 Favored Pre-proline 0 C--N 1.306 -1.296 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 72.6 Cg_endo -74.71 31.31 0.35 Allowed 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.374 2.05 . . . . 0.0 111.858 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.439 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.16 34.13 19.05 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.912 1.285 . . . . 0.0 110.66 -178.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.779 0 CA-C-N 114.142 -1.39 . . . . 0.0 107.932 178.636 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.496 -1.132 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.8 m 62.59 27.59 16.27 Favored 'General case' 0 CA--C 1.562 1.434 0 CA-C-O 122.369 1.081 . . . . 0.0 109.048 -178.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 45.6 ttm -140.78 94.49 2.72 Favored 'General case' 0 N--CA 1.439 -0.987 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -177.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.85 -99.07 0.41 Allowed Glycine 0 N--CA 1.429 -1.826 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' A' ' 87' ' ' MET . 21.1 m120 -125.94 97.06 4.96 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 176.027 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 86' ' ' THR . 95.3 t -113.79 126.43 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.675 0 CA-C-O 121.932 0.872 . . . . 0.0 110.213 -174.363 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.3 m -118.62 121.02 39.19 Favored 'General case' 0 C--N 1.249 -3.79 0 CA-C-N 113.602 -1.635 . . . . 0.0 106.843 176.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -88.45 140.92 28.97 Favored 'General case' 0 N--CA 1.402 -2.871 0 CA-C-N 114.779 -1.1 . . . . 0.0 109.656 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 47' ' ' GLY . 54.5 t -119.0 137.78 51.87 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.594 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.463 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.508 HD11 ' HB3' ' A' ' 81' ' ' GLU . 24.5 tp -124.28 112.39 16.95 Favored 'General case' 0 N--CA 1.386 -3.653 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 172.443 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.61 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.01 138.75 21.84 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.946 0 N-CA-C 106.244 -1.762 . . . . 0.0 106.244 -179.364 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.28 108.98 19.77 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 67.2 ttt180 -116.58 110.08 42.98 Favored Pre-proline 0 C--N 1.284 -2.247 0 C-N-CA 120.249 -0.581 . . . . 0.0 112.024 -176.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -57.9 -41.02 73.37 Favored 'Trans proline' 0 CA--C 1.546 1.084 0 C-N-CA 122.634 2.223 . . . . 0.0 113.102 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 22' ' ' LEU . 17.6 t70 -171.71 -175.46 1.56 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -177.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.507 HD22 ' O ' ' A' ' 76' ' ' SER . 68.7 mt -81.1 -11.62 59.45 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 125.164 1.386 . . . . 0.0 110.39 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.418 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 76.8 mtt180 -73.74 -16.03 61.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.361 175.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -103.5 138.63 39.95 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -110.67 160.95 16.23 Favored 'General case' 0 C--N 1.277 -2.575 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.656 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -55.91 -55.6 30.7 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 124.635 1.209 . . . . 0.0 111.079 -172.152 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.0 19.54 14.68 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.995 -178.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -146.37 162.81 37.38 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 176.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.2 m -123.21 129.73 51.79 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -114.57 136.97 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -122.43 115.63 22.58 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 61.47 16.0 7.17 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 124.764 1.226 . . . . 0.0 112.091 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.92 3.6 45.59 Favored Glycine 0 C--O 1.219 -0.805 0 C-N-CA 121.002 -0.618 . . . . 0.0 111.689 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.34 123.12 71.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.763 HD13 HG13 ' A' ' 49' ' ' VAL . 57.6 mt -62.44 118.24 4.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 123.553 0.741 . . . . 0.0 109.524 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.2 t -110.56 -16.2 13.71 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.185 -174.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.2 t -153.74 154.34 33.87 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 tp -146.35 147.56 31.45 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -108.72 119.02 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 121.132 0.491 . . . . 0.0 110.573 177.22 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.6 tmt_? -61.03 131.43 50.59 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.337 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.04 -18.0 58.21 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.342 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.85 161.58 47.91 Favored Glycine 0 N--CA 1.436 -1.327 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -176.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.63 -33.38 39.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.9 0 N-CA-C 113.721 1.008 . . . . 0.0 113.721 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.15 -41.39 99.27 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 111.646 0.239 . . . . 0.0 111.646 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.63 -42.79 95.23 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-O 121.717 0.77 . . . . 0.0 109.204 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 25.1 mtp180 -71.98 -13.19 61.55 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.188 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.41 ' O ' HG13 ' A' ' 15' ' ' VAL . . . -89.01 -13.36 62.33 Favored Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.14 176.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.02 13.81 44.81 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.359 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.763 HG13 HD13 ' A' ' 35' ' ' ILE . 57.9 t -69.67 137.02 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -134.01 147.16 50.93 Favored 'General case' 0 CA--C 1.48 -1.715 0 CA-C-O 121.329 0.585 . . . . 0.0 109.555 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -78.79 141.76 14.98 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.744 0 CA-C-N 114.159 -1.382 . . . . 0.0 109.636 -177.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 24.41 38.33 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.185 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m-70 -118.86 134.84 54.89 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.064 -0.568 . . . . 0.0 110.876 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.465 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 47.8 ttm-85 -93.23 123.45 36.52 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.447 HG12 HG22 ' A' ' 86' ' ' THR . 31.4 mt -79.22 125.86 38.73 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 39.2 pt -101.56 -16.44 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.413 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.2 tt0 -158.0 144.26 17.45 Favored 'General case' 0 CA--C 1.486 -1.497 0 C-N-CA 120.079 -0.649 . . . . 0.0 109.29 -176.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 63' ' ' VAL . 79.1 mt -143.87 125.71 10.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 124.567 1.167 . . . . 0.0 108.256 178.391 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.75 18.73 8.87 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 124.04 0.936 . . . . 0.0 112.602 170.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.29 -0.34 40.6 Favored Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.833 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -119.07 132.78 56.05 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.931 -0.746 . . . . 0.0 110.173 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.3 m -75.32 107.87 7.72 Favored 'General case' 0 N--CA 1.422 -1.828 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.568 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.9 m -99.65 12.64 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 CA-C-O 121.857 0.837 . . . . 0.0 110.118 -172.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -66.48 -20.55 27.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.437 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.1 12.1 12.59 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.648 -0.706 . . . . 0.0 109.541 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 84.8 m -93.6 136.19 24.37 Favored Pre-proline 0 N--CA 1.415 -2.216 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.409 ' O ' HG13 ' A' ' 71' ' ' ILE . 61.9 Cg_endo -74.76 164.42 33.65 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 122.202 1.935 . . . . 0.0 112.553 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -43.19 -55.35 3.99 Favored 'General case' 0 C--O 1.218 -0.593 0 C-N-CA 126.034 1.734 . . . . 0.0 112.147 -178.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -55.27 -45.77 76.15 Favored 'General case' 0 C--N 1.316 -0.883 0 O-C-N 123.925 0.766 . . . . 0.0 111.387 -174.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.418 ' O ' HD12 ' A' ' 74' ' ' ILE . 12.4 mptt -66.12 -54.87 20.22 Favored 'General case' 0 CA--C 1.483 -1.615 0 O-C-N 123.964 0.79 . . . . 0.0 110.739 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.409 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.8 mt -51.98 -42.04 33.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 O-C-N 124.253 0.971 . . . . 0.0 109.857 -179.328 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.8 t -72.11 -43.29 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.566 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 71.2 t60 -64.87 -43.01 94.34 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.348 0.594 . . . . 0.0 110.184 -177.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.418 HD12 ' O ' ' A' ' 70' ' ' LYS . 14.3 mt -69.09 -42.24 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.524 -178.674 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 67.4 mt -61.91 -46.15 90.6 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.895 0.379 . . . . 0.0 110.84 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.507 ' O ' HD22 ' A' ' 22' ' ' LEU . 23.0 t -60.7 -27.69 68.07 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 124.209 1.004 . . . . 0.0 111.802 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -87.98 -36.56 16.99 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 120.626 -0.43 . . . . 0.0 112.045 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.481 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -77.93 136.33 37.99 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 113.401 0.889 . . . . 0.0 113.401 -172.322 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.467 HG12 HD23 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -131.98 175.26 11.7 Favored 'Isoleucine or valine' 0 C--O 1.245 0.849 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 175.622 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.57 -154.75 25.23 Favored Glycine 0 CA--C 1.483 -1.911 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.508 ' HB3' HD11 ' A' ' 16' ' ' LEU . 51.5 mt-10 -75.0 108.97 8.07 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 174.359 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 17' ' ' ILE . 59.9 mt -112.36 118.15 57.06 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -84.54 130.53 34.73 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.458 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.0 mtm -135.34 152.31 51.34 Favored 'General case' 0 C--N 1.282 -2.344 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 170.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 8.9 mmmt -122.28 121.35 36.56 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.481 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.7 p -119.27 153.0 35.71 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.093 -176.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.541 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 50.3 mtm -123.06 169.13 10.52 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.422 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 7.7 Cg_exo -74.3 35.64 0.4 Allowed 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 123.158 2.572 . . . . 0.0 112.333 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.465 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.02 59.87 2.63 Favored 'General case' 0 N--CA 1.433 -1.302 0 C-N-CA 126.072 1.749 . . . . 0.0 112.958 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.161 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 171.316 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 . . . . . 0 C--O 1.235 0.319 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 25.2 m -120.17 100.93 7.48 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 64.9 mtt -94.23 -25.63 16.99 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.663 -177.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.77 -91.2 0.54 Allowed Glycine 0 N--CA 1.439 -1.123 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -77.91 82.71 4.26 Favored 'General case' 0 CA--C 1.493 -1.212 0 CA-C-O 121.93 0.871 . . . . 0.0 111.247 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.476 HG11 ' HD2' ' A' ' 85' ' ' LYS . 50.1 t -145.2 128.13 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 70.1 m -110.54 107.27 16.84 Favored 'General case' 0 C--N 1.245 -3.974 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 176.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 32.8 m -78.96 130.99 36.18 Favored 'General case' 0 N--CA 1.396 -3.132 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.484 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.8 t -111.02 137.54 43.05 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.717 0 CA-C-N 114.468 -1.242 . . . . 0.0 108.124 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.4 tp -121.92 111.87 17.61 Favored 'General case' 1 N--CA 1.374 -4.266 0 C-N-CA 119.062 -1.055 . . . . 0.0 108.353 172.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.521 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.25 128.61 48.34 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.292 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 178.592 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 67.4 mtp180 -115.04 102.14 9.66 Favored 'General case' 0 CA--C 1.457 -2.62 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 174.026 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.4 ttt180 -98.64 123.61 49.26 Favored Pre-proline 0 C--N 1.262 -3.214 0 CA-C-N 112.999 -1.91 . . . . 0.0 111.048 -174.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.39 -55.63 2.04 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 122.553 2.168 . . . . 0.0 113.457 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -166.15 -178.22 4.51 Favored 'General case' 0 C--O 1.247 0.963 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 -175.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.41 HD23 HG12 ' A' ' 79' ' ' VAL . 46.0 mt -68.31 -16.55 63.99 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -175.199 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -84.37 -12.25 54.83 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.876 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -93.48 128.42 39.57 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 176.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.289 3.1 pp0? -103.3 158.98 15.95 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.571 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -58.91 -53.69 55.6 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.175 -168.318 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.01 26.7 8.24 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.338 -1.41 . . . . 0.0 112.789 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -145.79 154.26 41.83 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 173.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 10.2 m -106.78 122.12 45.74 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -114.71 139.91 38.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.224 -0.59 . . . . 0.0 110.385 -178.106 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.413 ' HG2' ' HB2' ' A' ' 36' ' ' CYS . 16.8 pt20 -130.57 126.3 36.36 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.061 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 16.4 m120 62.0 6.85 1.86 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 124.391 1.076 . . . . 0.0 112.945 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 6.45 53.36 Favored Glycine 0 C--O 1.214 -1.102 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -175.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.42 128.12 70.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.656 HD13 HG13 ' A' ' 49' ' ' VAL . 52.6 mt -70.21 116.11 10.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 C-N-CA 124.407 1.083 . . . . 0.0 110.49 -177.105 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.413 ' HB2' ' HG2' ' A' ' 31' ' ' GLN . 36.3 t -99.53 -24.41 14.77 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.064 -175.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 34.1 t -157.12 152.39 26.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 -178.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -133.84 140.51 46.92 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.221 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -94.6 115.68 27.85 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.437 ' HD2' ' N ' ' A' ' 41' ' ' GLY . 1.7 tmm_? -65.62 131.3 46.03 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' ' HD2' ' A' ' 40' ' ' ARG . . . 91.89 -4.79 78.87 Favored Glycine 0 N--CA 1.437 -1.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.303 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.25 170.33 40.89 Favored Glycine 0 C--O 1.253 1.292 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -61.8 -34.85 64.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.935 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.74 -43.19 94.36 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.196 0.31 . . . . 0.0 111.659 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -65.91 -41.59 91.23 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.094 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -66.28 -35.29 80.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.943 178.196 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.74 -29.76 75.21 Favored Glycine 0 N--CA 1.44 -1.065 0 CA-C-N 115.177 -0.92 . . . . 0.0 112.641 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 114.67 14.65 8.59 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.213 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.656 HG13 HD13 ' A' ' 35' ' ' ILE . 68.9 t -70.24 137.69 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.458 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.1 mmt85 -136.02 145.16 45.76 Favored 'General case' 0 CA--C 1.477 -1.853 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -178.509 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.1 t -74.23 139.9 18.5 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.84 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.608 -177.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.15 9.15 65.82 Favored Glycine 0 N--CA 1.436 -1.336 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -178.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.543 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -101.93 148.25 25.56 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.275 -0.462 . . . . 0.0 111.412 -179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 70.7 ttt180 -105.46 123.39 47.81 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.65 HD13 HG22 ' A' ' 86' ' ' THR . 24.5 mm -74.11 117.98 18.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.005 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.439 HG13 ' HB2' ' A' ' 85' ' ' LYS . 24.5 pt -105.28 -20.34 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.681 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 179.433 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.3 tt0 -151.84 146.48 25.71 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.49 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.0 mt -143.56 121.69 6.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 O-C-N 124.362 1.039 . . . . 0.0 108.647 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.2 t30 63.93 8.67 4.04 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 125.556 1.542 . . . . 0.0 111.953 173.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.13 1.35 23.74 Favored Glycine 0 N--CA 1.43 -1.754 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.615 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -116.58 136.56 52.87 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 117.797 0.799 . . . . 0.0 109.92 177.318 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.8 m -75.56 108.99 8.75 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.539 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.0 m -102.96 11.48 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.697 0 CA-C-O 122.145 0.974 . . . . 0.0 109.423 -174.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 p -70.93 -14.78 18.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 114.332 -1.304 . . . . 0.0 110.093 -179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.95 13.68 13.1 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.264 179.428 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.539 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.1 m -101.32 135.26 19.91 Favored Pre-proline 0 N--CA 1.416 -2.163 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -66.21 156.15 66.33 Favored 'Trans proline' 0 C--O 1.244 0.821 0 C-N-CA 121.916 1.744 . . . . 0.0 111.743 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -43.11 -52.5 5.4 Favored 'General case' 0 C--O 1.221 -0.442 0 C-N-CA 125.525 1.53 . . . . 0.0 112.903 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -58.33 -42.74 87.48 Favored 'General case' 0 C--N 1.311 -1.087 0 O-C-N 123.917 0.761 . . . . 0.0 111.068 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.552 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -66.8 -53.77 29.45 Favored 'General case' 0 C--O 1.202 -1.413 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 178.53 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 53.4 mt -50.14 -42.29 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-O 120.984 0.421 . . . . 0.0 110.338 178.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.1 t -70.03 -37.9 73.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.982 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -69.16 -39.71 78.62 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.42 -53.44 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 95.6 mt -60.58 -32.79 71.87 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-O 120.853 0.358 . . . . 0.0 111.531 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.8 t -63.72 -37.07 85.97 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 123.362 0.665 . . . . 0.0 111.282 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -110.24 -9.98 14.65 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -171.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.49 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.01 129.87 35.57 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 122.156 -0.34 . . . . 0.0 110.826 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.428 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -128.75 176.26 8.43 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 177.648 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 89.69 -161.21 29.48 Favored Glycine 0 CA--C 1.498 -0.98 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -75.57 108.66 8.54 Favored 'General case' 0 C--O 1.249 1.074 0 C-N-CA 124.048 0.939 . . . . 0.0 108.903 175.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.487 HD12 HG22 ' A' ' 17' ' ' ILE . 72.3 mt -116.25 117.52 55.76 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.42 -174.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -84.76 117.0 23.57 Favored 'General case' 0 CA--C 1.486 -1.491 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.505 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 14.2 mtp -118.49 145.18 45.48 Favored 'General case' 0 C--N 1.25 -3.735 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.145 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' HG11 ' A' ' 12' ' ' VAL . 69.3 mmtt -118.09 123.97 46.92 Favored 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.65 HG22 HD13 ' A' ' 55' ' ' ILE . 68.0 p -118.97 139.86 50.97 Favored 'General case' 0 C--N 1.27 -2.852 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.903 178.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.46 ' HG2' HG22 ' A' ' 12' ' ' VAL . 90.6 mtp -113.58 166.54 11.07 Favored Pre-proline 0 C--N 1.299 -1.626 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 178.287 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -72.74 31.49 0.29 Allowed 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 123.047 2.498 . . . . 0.0 112.49 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 56.33 57.23 5.1 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 122.536 1.16 . . . . 0.0 111.324 -177.828 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 113.492 -1.685 . . . . 0.0 107.321 176.757 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 49.4 m -101.63 -24.36 14.12 Favored 'General case' 0 CA--C 1.551 1.006 0 CA-C-O 121.211 0.529 . . . . 0.0 110.242 174.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 60.4 ttp -173.95 -46.24 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.07 -132.19 2.36 Favored Glycine 0 N--CA 1.421 -2.36 0 N-CA-C 108.477 -1.849 . . . . 0.0 108.477 175.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -89.16 89.96 8.17 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.424 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 57.2 t -114.88 126.88 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.946 0 CA-C-N 114.016 -1.447 . . . . 0.0 108.898 -173.276 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 53.7 m -116.05 113.63 23.45 Favored 'General case' 1 C--N 1.241 -4.137 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.627 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.5 m -82.39 138.65 34.4 Favored 'General case' 0 N--CA 1.406 -2.663 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.151 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 49' ' ' VAL . 56.2 t -116.04 139.77 41.1 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.796 0 CA-C-N 114.574 -1.194 . . . . 0.0 108.582 178.18 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.52 HD11 ' HB3' ' A' ' 81' ' ' GLU . 17.8 tp -125.32 116.89 22.63 Favored 'General case' 0 N--CA 1.404 -2.762 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 81' ' ' GLU . 0.3 OUTLIER -98.11 141.63 15.82 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.782 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.859 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -113.61 102.98 10.79 Favored 'General case' 0 CA--C 1.489 -1.4 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 69.6 ttt180 -111.42 101.66 51.26 Favored Pre-proline 0 C--N 1.274 -2.686 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.765 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -58.6 -33.85 98.45 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.618 2.212 . . . . 0.0 113.985 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -169.15 175.58 5.64 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.516 HD23 HG12 ' A' ' 79' ' ' VAL . 63.4 mt -65.01 -18.23 65.12 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.274 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.9 mtt85 -74.25 -12.38 60.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 121.459 0.647 . . . . 0.0 112.084 178.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -99.54 95.75 7.2 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 174.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -84.58 152.29 23.96 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.763 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -41.68 -60.9 1.21 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 126.068 1.747 . . . . 0.0 111.654 -172.541 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 109.64 -3.81 30.79 Favored Glycine 0 N--CA 1.432 -1.614 0 C-N-CA 119.828 -1.177 . . . . 0.0 112.793 176.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -117.39 156.77 27.32 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 122.191 -0.593 . . . . 0.0 109.663 178.075 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.0 t -108.82 131.43 54.99 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.23 134.53 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 -177.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.457 ' HG3' ' HB2' ' A' ' 36' ' ' CYS 0.266 1.0 OUTLIER -126.17 120.39 29.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.046 0.45 . . . . 0.0 110.84 175.258 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 65.09 13.03 8.42 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 124.259 1.023 . . . . 0.0 110.81 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.68 -1.96 52.75 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.383 -177.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -108.08 121.57 61.25 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 O-C-N 122.315 -0.521 . . . . 0.0 110.303 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.724 HD13 HG13 ' A' ' 49' ' ' VAL . 64.3 mt -60.32 117.11 2.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 C-N-CA 124.746 1.219 . . . . 0.0 110.274 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.457 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 34.0 t -98.18 -44.03 6.76 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.689 -174.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 36.4 p -142.26 155.4 45.23 Favored 'General case' 0 C--O 1.248 1.011 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -131.91 146.24 51.99 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 123.25 0.62 . . . . 0.0 110.008 -177.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.8 ttt -90.3 112.48 24.06 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.446 ' HD3' ' N ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -75.57 123.73 26.0 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.759 -172.01 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.446 ' N ' ' HD3' ' A' ' 40' ' ' ARG . . . 103.65 -14.96 53.42 Favored Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.308 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.11 178.08 54.11 Favored Glycine 0 C--O 1.253 1.282 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -178.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 pt -53.72 -37.59 32.53 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.07 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.36 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.24 93.46 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -63.92 -46.5 84.51 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.464 0.649 . . . . 0.0 109.603 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -76.08 -17.4 59.64 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.979 -179.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -73.9 -29.38 63.1 Favored Glycine 0 N--CA 1.432 -1.569 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.794 175.669 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 111.43 12.19 15.76 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.027 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.724 HG13 HD13 ' A' ' 35' ' ' ILE . 73.1 t -67.94 134.26 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.6 mmt85 -131.03 142.5 50.32 Favored 'General case' 0 CA--C 1.487 -1.453 0 CA-C-O 121.155 0.503 . . . . 0.0 109.909 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 41.7 t -79.05 137.26 22.15 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.21 -176.171 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.36 22.71 33.82 Favored Glycine 0 CA--C 1.5 -0.865 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -175.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m170 -116.59 135.34 53.89 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.873 -0.664 . . . . 0.0 112.192 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.583 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 33.8 ttm-85 -92.59 122.69 35.27 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.565 HG12 HG22 ' A' ' 86' ' ' THR . 30.1 mt -80.64 127.82 39.15 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 35.2 pt -107.0 -16.5 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 84' ' ' MET . 32.1 tt0 -154.98 144.62 21.42 Favored 'General case' 0 CA--C 1.48 -1.717 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.382 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 67.5 mt -139.52 125.88 23.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 64.59 6.68 3.31 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.598 1.159 . . . . 0.0 112.31 173.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.4 -9.63 19.93 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.718 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.474 ' O ' HG13 ' A' ' 63' ' ' VAL . 17.4 pt20 -108.11 126.09 52.35 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-O 120.961 0.41 . . . . 0.0 110.989 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 31.9 t -64.85 113.46 3.83 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 177.153 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.618 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 30.9 m -110.61 13.53 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 121.169 0.509 . . . . 0.0 109.986 -176.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -67.54 -17.65 22.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 115.216 -0.902 . . . . 0.0 112.714 -173.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.64 16.64 5.88 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.708 0.766 . . . . 0.0 109.124 177.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.618 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.2 m -84.35 141.46 39.66 Favored Pre-proline 0 N--CA 1.416 -2.125 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.609 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.437 ' O ' HG13 ' A' ' 71' ' ' ILE . 71.6 Cg_exo -48.96 143.71 17.07 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.907 2.405 . . . . 0.0 112.247 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 70.1 t60 -49.91 -50.83 44.75 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 124.757 1.223 . . . . 0.0 111.529 -178.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -68.23 -32.23 72.29 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.1 mttm -62.91 -53.84 47.84 Favored 'General case' 0 CA--C 1.48 -1.718 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.793 176.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.437 HG13 ' O ' ' A' ' 67' ' ' PRO . 58.1 mt -50.01 -41.9 18.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 124.016 0.822 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 65.7 t -72.93 -37.19 53.47 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.533 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -65.23 -45.06 86.17 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 123.534 0.733 . . . . 0.0 109.594 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.74 -49.39 84.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.252 0 O-C-N 123.644 0.59 . . . . 0.0 109.412 178.136 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.2 mt -62.15 -45.31 94.01 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.7 t -61.98 -27.4 68.83 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 123.622 0.769 . . . . 0.0 112.144 -178.167 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -103.09 -13.23 16.9 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.666 0.987 . . . . 0.0 113.666 -176.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 134.63 34.16 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.047 -177.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.516 HG12 HD23 ' A' ' 22' ' ' LEU . 1.3 m -128.49 175.8 9.28 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 176.05 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.38 -159.66 27.46 Favored Glycine 0 N--CA 1.432 -1.605 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.52 ' HB3' HD11 ' A' ' 16' ' ' LEU . 44.9 mt-10 -79.35 113.4 17.46 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 173.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 67.7 mt -115.65 118.56 59.17 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.942 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.763 -172.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -81.18 135.94 35.82 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.497 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.7 mtm -133.34 150.63 51.85 Favored 'General case' 0 C--N 1.263 -3.178 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.424 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 66.1 mmtt -117.72 121.26 40.37 Favored 'General case' 0 C--N 1.262 -3.201 0 N-CA-C 106.238 -1.764 . . . . 0.0 106.238 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.566 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.2 p -122.6 146.24 47.62 Favored 'General case' 0 C--N 1.264 -3.116 0 C-N-CA 120.258 -0.577 . . . . 0.0 110.479 -178.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.495 ' C ' ' H ' ' A' ' 89' ' ' ALA . 58.3 mtm -120.41 168.16 11.17 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.649 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_exo -68.2 32.42 0.15 Allowed 'Trans proline' 0 N--CA 1.509 2.41 0 C-N-CA 123.49 2.794 . . . . 0.0 112.668 176.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.583 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 67.29 27.36 8.31 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 126.442 1.897 . . . . 0.0 113.422 177.506 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.409 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.483 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.505 -0.754 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.432 HG21 ' SD ' ' A' ' 87' ' ' MET . 13.9 t -98.75 171.08 8.32 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 41.4 ttm -162.72 156.94 21.05 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -176.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.28 -95.41 0.55 Allowed Glycine 0 N--CA 1.432 -1.615 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.518 178.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -103.55 101.18 11.04 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 120.95 0.405 . . . . 0.0 110.619 -178.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.453 HG22 ' HG2' ' A' ' 87' ' ' MET . 54.0 t -139.46 129.19 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.149 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 89.0 m -119.41 108.53 14.68 Favored 'General case' 0 N--CA 1.39 -3.46 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.185 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 18.6 m -78.69 134.25 37.12 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.934 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.412 HG11 ' CG2' ' A' ' 49' ' ' VAL . 51.3 t -115.86 136.86 51.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.137 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.378 -177.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.474 HD11 ' HB3' ' A' ' 81' ' ' GLU . 25.9 tp -118.81 110.67 17.5 Favored 'General case' 0 N--CA 1.4 -2.958 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 174.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -99.23 137.89 25.31 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.312 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.219 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.12 103.38 12.57 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.455 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.1 ttt180 -109.03 111.53 60.45 Favored Pre-proline 0 C--N 1.291 -1.947 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.315 -177.054 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -58.93 -44.12 37.91 Favored 'Trans proline' 0 CA--C 1.549 1.241 0 C-N-CA 122.311 2.007 . . . . 0.0 113.743 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -167.21 -176.99 3.51 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -176.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.4 HD23 HG12 ' A' ' 79' ' ' VAL . 65.9 mt -76.88 -10.02 59.08 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 124.892 1.277 . . . . 0.0 110.292 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 34.5 mtt180 -69.03 -19.35 64.11 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 114.295 -1.32 . . . . 0.0 108.064 176.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -114.21 157.81 22.18 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 104.997 -2.223 . . . . 0.0 104.997 177.177 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -121.63 -168.42 1.69 Allowed 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.596 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -75.25 -57.61 3.79 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -175.58 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 110.06 20.21 7.67 Favored Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.788 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -143.84 148.8 36.03 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.0 t -99.84 131.43 45.81 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.54 138.45 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -176.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -117.94 105.91 12.4 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 176.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 61.29 23.23 13.48 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 122.015 0.912 . . . . 0.0 110.846 177.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.91 -4.91 39.24 Favored Glycine 0 N--CA 1.439 -1.125 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.413 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.425 HG13 ' HB2' ' A' ' 54' ' ' ARG . 2.7 mp -105.93 120.13 56.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 O-C-N 122.18 -0.6 . . . . 0.0 110.013 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.774 HD13 HG13 ' A' ' 49' ' ' VAL . 55.1 mt -61.35 115.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 C-N-CA 123.447 0.699 . . . . 0.0 110.244 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -98.23 -31.77 11.9 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.042 -175.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.1 m -150.6 155.05 38.65 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.9 tp -136.7 138.88 41.5 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 123.534 0.734 . . . . 0.0 109.525 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 49.4 ttm -91.48 119.29 31.32 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.9 131.76 45.62 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.92 -8.45 79.78 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.34 162.98 37.02 Favored Glycine 0 N--CA 1.432 -1.582 0 C-N-CA 121.318 -0.467 . . . . 0.0 112.167 -178.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -30.43 41.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -179.565 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.02 -42.44 89.64 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.69 0.281 . . . . 0.0 110.889 178.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -63.71 -41.48 98.08 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.29 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.63 -8.44 55.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.673 -1.149 . . . . 0.0 111.281 178.161 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.55 -22.52 28.73 Favored Glycine 0 N--CA 1.429 -1.794 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 178.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.02 8.5 29.54 Favored Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.959 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.774 HG13 HD13 ' A' ' 35' ' ' ILE . 58.5 t -65.59 135.92 27.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 12.6 mmm180 -133.42 146.12 50.9 Favored 'General case' 0 CA--C 1.48 -1.738 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 77.0 t -77.37 139.9 17.95 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 114.181 -1.372 . . . . 0.0 109.202 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.4 -2.04 62.7 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -177.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.524 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 10.2 m170 -95.43 140.83 29.74 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 115.041 -0.58 . . . . 0.0 110.928 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.441 ' HB3' ' HA ' ' A' ' 89' ' ' ALA . 25.8 ttt85 -101.18 131.83 46.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 173.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.522 HG12 HG22 ' A' ' 86' ' ' THR . 33.0 mt -82.99 127.27 39.84 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 30.9 pt -104.3 -15.34 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.268 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.944 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.404 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.7 tt0 -155.9 144.34 20.12 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 119.763 -0.775 . . . . 0.0 108.984 -174.714 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.1 mt -140.67 121.83 14.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 124.293 0.996 . . . . 0.0 108.475 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 68.29 7.68 6.09 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 124.095 0.958 . . . . 0.0 111.769 172.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.4 2.09 33.13 Favored Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.397 -178.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 21.1 pt20 -113.88 125.31 53.91 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 177.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 40.1 t -63.82 119.14 9.42 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.469 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 24.3 m -114.35 14.12 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.123 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.5 p -70.12 -20.76 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.802 -176.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.66 9.56 16.51 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.751 0.786 . . . . 0.0 109.453 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 76.8 m -86.37 138.51 34.11 Favored Pre-proline 0 N--CA 1.407 -2.621 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.742 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.29 158.09 58.65 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.185 1.923 . . . . 0.0 112.837 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 45.3 p-80 -48.6 -49.65 35.94 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.121 1.368 . . . . 0.0 114.042 -174.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.0 -37.89 78.96 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 120.451 0.167 . . . . 0.0 110.599 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 9.9 mttm -61.9 -49.85 74.53 Favored 'General case' 0 CA--C 1.492 -1.258 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 177.31 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.8 mt -54.32 -42.56 58.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 O-C-N 123.896 0.748 . . . . 0.0 110.173 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.34 -35.88 69.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.544 178.297 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.8 t-80 -68.9 -42.92 76.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.237 0.541 . . . . 0.0 109.581 -177.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 35.7 mt -63.71 -47.19 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.635 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.882 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.2 mt -61.32 -45.99 92.12 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.399 176.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -62.32 -27.49 69.08 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 123.174 0.59 . . . . 0.0 111.887 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -104.65 1.34 29.41 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -177.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.455 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -107.04 134.61 49.93 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.967 178.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.448 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.7 m -129.58 -177.34 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.044 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -157.14 30.58 Favored Glycine 0 CA--C 1.484 -1.886 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.023 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.474 ' HB3' HD11 ' A' ' 16' ' ' LEU . 50.4 mt-10 -80.52 112.89 18.3 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.167 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.653 ' HB ' HG22 ' A' ' 17' ' ' ILE . 56.5 mt -117.3 118.12 57.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -173.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -90.49 118.43 29.96 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.404 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 24.3 mtm -117.54 158.42 24.61 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.298 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.3 mtmm -123.86 121.97 36.77 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.524 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.2 p -119.86 150.02 41.13 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.624 -175.674 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.466 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.6 mtp -130.13 168.63 15.96 Favored Pre-proline 0 C--N 1.313 -0.978 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 57.7 Cg_endo -71.04 29.5 0.22 Allowed 'Trans proline' 0 CA--C 1.565 2.058 0 C-N-CA 122.762 2.308 . . . . 0.0 112.61 175.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.466 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.0 -2.36 2.37 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 126.384 1.874 . . . . 0.0 112.59 179.062 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.474 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 178.235 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.506 -0.717 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.483 HG21 ' SD ' ' A' ' 87' ' ' MET . 65.5 m -89.97 125.16 35.28 Favored 'General case' 0 N--CA 1.417 -2.101 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 176.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 65.9 mtt -116.22 125.59 52.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.76 -116.11 0.7 Allowed Glycine 0 N--CA 1.428 -1.864 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -109.74 106.03 15.51 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.3 t -133.13 134.86 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 123.554 0.742 . . . . 0.0 109.273 -174.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 34.4 m -121.74 120.13 33.76 Favored 'General case' 0 N--CA 1.391 -3.388 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 176.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.6 m -90.67 141.08 29.16 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.127 0.965 . . . . 0.0 110.091 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.608 HG11 ' HE2' ' A' ' 84' ' ' MET . 43.8 t -118.42 135.96 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.06 0 CA-C-N 114.425 -1.261 . . . . 0.0 108.857 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.451 HD12 ' O ' ' A' ' 82' ' ' ILE . 24.9 tp -119.86 110.38 16.68 Favored 'General case' 0 N--CA 1.382 -3.87 0 C-N-CA 119.18 -1.008 . . . . 0.0 108.797 173.044 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.476 HG22 HD12 ' A' ' 82' ' ' ILE . 0.3 OUTLIER -98.14 125.94 51.28 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.021 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.081 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 82.1 mtp180 -113.29 102.77 10.66 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.541 HH12 ' HA ' ' A' ' 76' ' ' SER . 48.2 ttt180 -98.3 112.8 63.04 Favored Pre-proline 0 C--N 1.269 -2.925 0 CA-C-N 112.77 -2.014 . . . . 0.0 110.846 -174.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.37 -39.2 86.19 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.833 2.355 . . . . 0.0 113.909 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -166.62 -178.72 4.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -177.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.545 HD23 ' CG1' ' A' ' 79' ' ' VAL . 52.8 mt -75.36 -18.09 60.06 Favored 'General case' 0 CA--C 1.495 -1.141 0 C-N-CA 124.954 1.301 . . . . 0.0 111.024 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.59 ' HD2' ' N ' ' A' ' 23' ' ' ARG . 4.8 mpt_? -82.02 -11.5 58.79 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.923 176.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -99.16 89.3 4.19 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.682 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? -72.53 165.79 23.97 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 123.639 0.587 . . . . 0.0 110.938 -178.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -69.31 -58.8 3.55 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.46 -169.785 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 103.19 38.28 2.9 Favored Glycine 0 N--CA 1.424 -2.114 0 C-N-CA 120.062 -1.066 . . . . 0.0 111.933 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -154.2 153.63 32.1 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 174.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 m -109.02 130.88 55.49 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -118.72 134.07 63.51 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 CA-C-O 121.36 0.6 . . . . 0.0 111.089 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -113.56 111.64 22.23 Favored 'General case' 0 C--N 1.312 -1.053 0 O-C-N 121.807 -0.558 . . . . 0.0 109.591 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.6 m-20 59.86 12.8 3.22 Favored 'General case' 0 N--CA 1.501 2.097 0 C-N-CA 125.076 1.35 . . . . 0.0 112.21 -177.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.59 0.42 30.79 Favored Glycine 0 C--O 1.215 -1.092 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.682 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 2.9 mp -108.17 118.33 55.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 122.438 -0.448 . . . . 0.0 109.878 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.779 HD13 HG13 ' A' ' 49' ' ' VAL . 46.8 mt -59.15 122.38 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 123.888 0.875 . . . . 0.0 110.861 178.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 13.4 t -103.29 -31.75 9.91 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.983 -176.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 55.1 p -151.17 160.62 43.75 Favored 'General case' 0 C--O 1.245 0.862 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 54.5 tp -137.97 129.46 27.95 Favored 'General case' 0 N--CA 1.443 -0.812 0 O-C-N 123.785 0.678 . . . . 0.0 109.867 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -76.03 112.54 12.57 Favored 'General case' 0 C--N 1.317 -0.837 0 O-C-N 123.782 0.676 . . . . 0.0 109.878 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.427 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.3 tpp85 -55.32 125.0 18.92 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.564 1.146 . . . . 0.0 111.005 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.02 -7.63 81.73 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.311 -0.859 . . . . 0.0 113.408 177.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.12 171.6 55.15 Favored Glycine 0 C--O 1.246 0.888 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.501 -176.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.5 pt -62.15 -33.04 56.59 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -57.16 -46.12 83.03 Favored 'General case' 0 N--CA 1.447 -0.608 0 CA-C-O 120.909 0.385 . . . . 0.0 110.445 178.701 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.427 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 36.2 tt0 -62.88 -47.15 84.55 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.573 0.701 . . . . 0.0 109.758 179.113 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 40.5 mtt180 -69.62 -18.06 63.57 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.807 -178.237 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.24 -24.81 50.49 Favored Glycine 0 N--CA 1.438 -1.187 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.001 176.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.95 12.23 12.75 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 179.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.779 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -68.57 137.28 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -135.61 150.25 49.6 Favored 'General case' 0 CA--C 1.474 -1.953 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.15 141.2 15.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.066 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.98 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.14 25.92 42.53 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -177.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.5 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.2 m170 -117.48 132.87 56.48 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.124 -0.538 . . . . 0.0 110.944 179.349 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 44.4 ttp180 -95.79 121.66 37.74 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.527 HG12 HG22 ' A' ' 86' ' ' THR . 44.7 mt -75.92 122.28 29.62 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.1 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.418 HG22 ' CG2' ' A' ' 64' ' ' VAL 0.265 2.4 pp -104.94 -5.93 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.76 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -178.314 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 26.6 tt0 -169.34 143.15 2.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.416 -179.325 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 84' ' ' MET . 88.4 mt -138.57 124.84 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 66.34 3.32 2.74 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.5 1.12 . . . . 0.0 112.436 172.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.26 -0.81 22.4 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.084 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.45 ' O ' HG13 ' A' ' 63' ' ' VAL . 12.7 pt20 -115.41 125.97 53.81 Favored 'General case' 0 CA--C 1.498 -1.022 0 O-C-N 122.273 -0.545 . . . . 0.0 110.166 176.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 m -71.03 109.6 5.22 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.519 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.6 m -101.77 18.28 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.993 0 CA-C-O 121.914 0.864 . . . . 0.0 110.538 -172.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.418 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.3 p -75.59 -8.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.91 -177.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -126.44 22.89 6.99 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.022 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.519 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 89.3 m -109.18 130.39 22.8 Favored Pre-proline 0 N--CA 1.407 -2.614 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -66.34 158.22 56.19 Favored 'Trans proline' 0 CA--C 1.543 0.925 0 C-N-CA 122.233 1.955 . . . . 0.0 112.797 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 33.1 t60 -42.86 -55.85 3.5 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.932 1.293 . . . . 0.0 113.5 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -65.83 -37.67 86.84 Favored 'General case' 0 N--CA 1.436 -1.16 0 O-C-N 123.42 0.45 . . . . 0.0 111.32 -173.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 6.5 mttm -61.75 -52.02 65.96 Favored 'General case' 0 N--CA 1.424 -1.728 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.345 174.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 55.7 mt -52.02 -45.61 41.14 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 O-C-N 124.026 0.829 . . . . 0.0 110.398 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.2 t -69.07 -34.04 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.818 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 17.3 t60 -72.41 -43.17 64.25 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 -176.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.6 mt -60.5 -49.75 83.1 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 CA-C-N 114.737 -1.12 . . . . 0.0 109.873 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.2 mt -58.96 -46.76 87.27 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.76 177.256 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.541 ' HA ' HH12 ' A' ' 19' ' ' ARG . 25.0 m -63.06 -26.5 68.87 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 113.08 0.77 . . . . 0.0 113.08 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -94.8 -18.85 20.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -98.8 133.92 42.43 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.535 0.207 . . . . 0.0 111.221 -176.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.545 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.2 m -134.27 179.65 4.12 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 87.88 -150.22 22.13 Favored Glycine 0 CA--C 1.497 -1.065 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.87 114.56 18.88 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.476 HD12 HG22 ' A' ' 17' ' ' ILE . 79.5 mt -117.88 118.03 56.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -90.85 115.75 28.15 Favored 'General case' 0 CA--C 1.463 -2.376 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.608 ' HE2' HG11 ' A' ' 15' ' ' VAL . 7.8 ttp -122.56 138.47 54.56 Favored 'General case' 1 N--CA 1.376 -4.148 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.816 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 32.9 mtmt -121.26 131.86 54.47 Favored 'General case' 0 CA--C 1.444 -3.133 0 C-N-CA 119.497 -0.881 . . . . 0.0 108.784 -176.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.527 HG22 HG12 ' A' ' 55' ' ' ILE . 49.7 p -125.97 155.16 41.81 Favored 'General case' 0 C--N 1.271 -2.825 0 O-C-N 123.993 0.808 . . . . 0.0 110.369 -174.567 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.483 ' SD ' HG21 ' A' ' 8' ' ' THR . 88.8 mtp -120.47 170.55 6.95 Favored Pre-proline 0 C--N 1.296 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -75.98 29.83 0.39 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.85 2.367 . . . . 0.0 111.077 176.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.472 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 60.89 31.6 20.01 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.249 1.42 . . . . 0.0 110.624 -179.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.178 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.636 178.733 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.483 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.499 HG23 ' HB ' ' A' ' 12' ' ' VAL . 97.4 m 83.29 93.69 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 124.253 1.021 . . . . 0.0 112.561 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.2 mmt -136.94 83.11 1.98 Allowed 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.005 171.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 154.85 -141.22 7.97 Favored Glycine 0 N--CA 1.412 -2.955 0 N-CA-C 108.502 -1.839 . . . . 0.0 108.502 -177.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -112.83 98.2 7.04 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.499 ' HB ' HG23 ' A' ' 8' ' ' THR . 70.1 t -120.31 132.15 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.17 0 CA-C-O 122.083 0.944 . . . . 0.0 109.727 -173.598 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -127.12 115.55 19.31 Favored 'General case' 0 N--CA 1.387 -3.616 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.2 m -80.97 140.95 34.93 Favored 'General case' 0 N--CA 1.395 -3.186 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.813 -176.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.429 HG11 HG22 ' A' ' 49' ' ' VAL . 53.4 t -118.12 139.29 45.89 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.943 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.248 177.626 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.539 HD11 ' HB3' ' A' ' 81' ' ' GLU . 7.5 tp -126.42 105.41 8.75 Favored 'General case' 0 N--CA 1.404 -2.732 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.856 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.3 OUTLIER -99.71 134.8 37.76 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -178.863 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 -113.75 117.32 31.17 Favored 'General case' 0 C--N 1.294 -1.831 0 CA-C-O 121.954 0.883 . . . . 0.0 112.114 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.649 HH21 ' HA ' ' A' ' 25' ' ' GLN . 27.2 ttm180 -119.2 113.1 35.6 Favored Pre-proline 0 C--N 1.284 -2.272 0 CA-C-N 113.961 -1.472 . . . . 0.0 110.957 -178.088 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -61.74 -31.68 86.04 Favored 'Trans proline' 0 CA--C 1.547 1.16 0 C-N-CA 122.653 2.235 . . . . 0.0 113.091 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -178.8 173.68 1.22 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' HD3' ' A' ' 19' ' ' ARG . 47.5 mt -65.28 -9.83 27.32 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 115.666 1.728 . . . . 0.0 115.666 -173.244 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -76.16 -11.59 59.96 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.564 0.697 . . . . 0.0 110.794 176.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -107.08 98.56 8.2 Favored 'General case' 0 N--CA 1.423 -1.812 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLN . . . . . 0.649 ' HA ' HH21 ' A' ' 19' ' ' ARG . 6.4 pt20 -86.08 164.28 17.4 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.133 -1.427 . . . . 0.0 112.177 -177.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.638 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.58 -64.86 0.69 Allowed 'General case' 0 C--N 1.32 -0.698 0 O-C-N 124.984 1.427 . . . . 0.0 110.714 -173.353 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 101.69 29.48 6.21 Favored Glycine 0 N--CA 1.426 -2.021 0 C-N-CA 120.262 -0.971 . . . . 0.0 111.464 -176.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -152.35 167.14 29.66 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.4 m -131.25 140.92 49.92 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.53 121.41 50.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.902 0.858 . . . . 0.0 113.184 -173.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -120.07 128.08 53.16 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.522 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 64.2 -1.14 0.74 Allowed 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 124.451 1.1 . . . . 0.0 112.634 -174.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.81 -3.74 34.1 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -175.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -101.09 131.12 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.104 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 49' ' ' VAL . 71.4 mt -67.1 114.25 3.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 124.248 1.019 . . . . 0.0 110.615 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -85.54 -51.88 6.2 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.914 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.9 p -137.51 151.07 48.05 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.08 -176.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.63 141.37 46.58 Favored 'General case' 0 C--N 1.31 -1.109 0 O-C-N 123.779 0.674 . . . . 0.0 109.646 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.1 ttt -83.84 115.76 22.41 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -73.92 128.29 35.12 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 -177.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.4 -4.4 85.26 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.992 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.0 173.41 46.78 Favored Glycine 0 C--O 1.242 0.635 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.389 -178.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -61.84 -29.85 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.43 -48.69 71.89 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.309 177.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -65.93 -43.52 87.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.917 0.389 . . . . 0.0 110.796 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.5 mtp85 -72.37 -17.37 61.83 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 121.52 0.676 . . . . 0.0 110.153 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.03 -20.6 60.66 Favored Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.052 -0.976 . . . . 0.0 111.395 175.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.57 4.63 24.85 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 120.286 -0.959 . . . . 0.0 113.516 176.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 35' ' ' ILE . 69.7 t -64.43 142.53 16.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 9.9 mmt180 -140.33 139.78 35.49 Favored 'General case' 0 CA--C 1.491 -1.324 0 CA-C-O 121.257 0.551 . . . . 0.0 110.809 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.3 t -75.13 136.39 25.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 114.499 -1.228 . . . . 0.0 109.348 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.1 10.5 64.3 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -176.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.7 m170 -104.33 143.71 32.62 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.048 0.451 . . . . 0.0 110.945 177.458 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.518 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 76.0 ttt180 -103.78 114.97 29.63 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.017 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 86' ' ' THR . 23.1 mt -77.31 126.57 37.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-O 121.093 0.473 . . . . 0.0 110.048 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.44 HG22 ' CG2' ' A' ' 64' ' ' VAL . 2.4 pp -109.9 -5.43 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.945 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.985 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 17.2 tt0 -161.48 145.29 12.82 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.519 HD12 HG21 ' A' ' 63' ' ' VAL . 76.2 mt -145.12 120.5 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 O-C-N 124.454 1.096 . . . . 0.0 109.194 176.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.3 t30 59.65 25.95 14.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.55 1.14 . . . . 0.0 112.276 169.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.39 -7.58 30.44 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 119.883 -1.151 . . . . 0.0 114.222 177.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -124.2 135.37 53.4 Favored 'General case' 0 CA--C 1.486 -1.487 0 CA-C-N 117.785 0.793 . . . . 0.0 110.672 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 21.6 t -74.05 120.14 19.22 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 177.664 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.599 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.0 m -110.43 19.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.541 0 CA-C-O 121.479 0.657 . . . . 0.0 110.757 -174.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.44 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.0 p -78.83 -18.32 13.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.619 0.723 . . . . 0.0 110.329 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.87 12.49 15.83 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.45 175.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.599 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.6 m -91.22 135.48 28.26 Favored Pre-proline 0 N--CA 1.414 -2.255 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.458 ' O ' HG13 ' A' ' 71' ' ' ILE . 10.0 Cg_endo -57.82 148.42 75.38 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 122.005 1.804 . . . . 0.0 111.789 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 26.4 t60 -48.17 -50.27 29.54 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.563 1.145 . . . . 0.0 112.775 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -61.7 -39.02 89.99 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.873 -177.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -63.49 -49.6 72.95 Favored 'General case' 0 CA--C 1.482 -1.638 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.678 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.458 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.4 mt -50.87 -45.75 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 O-C-N 124.3 1.0 . . . . 0.0 109.846 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.62 -35.44 61.15 Favored 'Isoleucine or valine' 0 C--O 1.242 0.664 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.041 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.3 t60 -70.4 -42.33 71.82 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -176.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 38.2 mt -64.97 -49.95 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.919 179.028 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 42.3 mt -55.75 -52.09 65.15 Favored 'General case' 0 CA--C 1.502 -0.882 0 O-C-N 123.756 0.66 . . . . 0.0 112.181 177.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.8 t -59.07 -26.03 64.28 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.654 0.612 . . . . 0.0 112.654 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.7 m-80 -111.2 4.28 19.11 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -175.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.425 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -98.86 125.87 44.37 Favored 'General case' 0 C--O 1.204 -1.314 0 O-C-N 121.333 -0.854 . . . . 0.0 110.813 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.516 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -118.08 174.08 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.77 -155.52 19.7 Favored Glycine 0 CA--C 1.497 -1.093 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.539 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.9 mp0 -89.49 109.61 20.53 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.856 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.4 mt -105.11 117.86 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.933 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -170.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.9 m80 -85.3 128.42 34.69 Favored 'General case' 0 CA--C 1.478 -1.801 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.442 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -129.29 153.55 47.71 Favored 'General case' 0 C--N 1.258 -3.38 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 170.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -120.4 120.54 36.24 Favored 'General case' 0 C--N 1.26 -3.316 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.575 HG22 HG12 ' A' ' 55' ' ' ILE . 46.8 p -119.35 143.59 47.32 Favored 'General case' 0 C--N 1.257 -3.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.598 -178.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.51 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.3 mtm -111.39 164.06 15.92 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 175.44 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.77 27.52 0.32 Allowed 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.57 2.18 . . . . 0.0 111.598 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 69.27 25.8 5.55 Favored 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 126.299 1.84 . . . . 0.0 112.866 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.42 -1.94 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 174.456 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 . . . . . 0 CA--C 1.541 0.625 0 CA-C-O 121.6 0.714 . . . . 0.0 109.222 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.1 t -146.89 148.22 31.6 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.139 -0.976 . . . . 0.0 110.984 -178.182 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.9 mtm -115.4 6.84 14.91 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 173.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.79 84.88 0.26 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.648 -179.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.553 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 4.5 m-20 63.22 88.26 0.1 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 122.285 1.041 . . . . 0.0 111.824 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.5 t -114.38 126.84 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.445 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.59 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -116.92 117.55 30.01 Favored 'General case' 0 C--N 1.248 -3.807 0 CA-C-N 113.915 -1.493 . . . . 0.0 107.086 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 m -83.87 138.2 33.31 Favored 'General case' 0 N--CA 1.406 -2.641 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.422 -176.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.3 t -118.19 140.29 42.15 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.373 178.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 81' ' ' GLU . 23.9 tp -122.68 116.42 23.76 Favored 'General case' 0 N--CA 1.399 -3.009 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.132 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.455 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.13 139.04 20.47 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -178.945 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.4 HH11 HD23 ' A' ' 16' ' ' LEU . 0.0 OUTLIER -113.08 102.6 10.55 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 175.393 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.474 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.7 ttt180 -107.09 108.86 62.59 Favored Pre-proline 0 C--N 1.287 -2.121 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.241 -177.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -53.05 -55.87 3.3 Favored 'Trans proline' 0 CA--C 1.542 0.922 0 C-N-CA 122.788 2.325 . . . . 0.0 112.933 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -156.69 -176.98 6.27 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -177.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.464 HD23 ' CG1' ' A' ' 79' ' ' VAL . 68.7 mt -74.47 -14.37 60.82 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -172.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -82.11 -11.33 58.82 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-O 121.466 0.65 . . . . 0.0 110.15 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -94.7 121.07 35.89 Favored 'General case' 0 CA--C 1.487 -1.46 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.811 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -84.03 157.4 21.83 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 123.579 0.549 . . . . 0.0 110.353 177.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.576 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER -61.15 -44.01 97.98 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 124.29 0.994 . . . . 0.0 111.36 -171.434 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.28 26.04 9.74 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 119.639 -1.267 . . . . 0.0 113.42 178.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -151.94 167.87 26.98 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -124.55 134.05 53.11 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -125.57 138.47 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -173.231 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.407 ' HG2' ' O ' ' A' ' 34' ' ' ILE . 17.4 pt20 -105.44 92.79 4.34 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.794 0.806 . . . . 0.0 109.318 176.38 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 58.55 20.55 7.7 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 122.79 -10.23 9.02 Favored Glycine 0 C--O 1.218 -0.867 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.092 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.407 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 2.4 mp -106.33 118.44 53.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.742 HD13 HG13 ' A' ' 49' ' ' VAL . 65.5 mt -59.61 114.74 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 123.244 0.618 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 52.5 t -95.29 -37.8 10.83 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.468 -175.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 14.8 m -149.8 151.23 33.22 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -178.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.9 tp -121.26 136.09 55.02 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.8 ttm -83.94 118.37 23.96 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -68.64 125.61 27.1 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.189 -175.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.47 0.41 79.51 Favored Glycine 0 N--CA 1.425 -2.046 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.55 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.62 171.25 45.13 Favored Glycine 0 C--O 1.241 0.586 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.14 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.89 -31.05 51.05 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.041 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.455 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.27 -39.61 93.48 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.891 0.377 . . . . 0.0 110.478 177.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -63.4 -44.01 95.91 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 176.433 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -72.28 -6.14 40.98 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.061 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -98.81 -18.01 26.41 Favored Glycine 0 N--CA 1.433 -1.536 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.03 19.56 18.9 Favored Glycine 0 N--CA 1.433 -1.518 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.442 -179.578 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.742 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -65.32 145.62 13.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-O 120.88 0.371 . . . . 0.0 110.036 177.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 19.9 mmt85 -136.86 138.71 41.03 Favored 'General case' 0 CA--C 1.488 -1.409 0 C-N-CA 123.963 0.905 . . . . 0.0 108.852 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.2 t -76.24 148.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.806 -177.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.05 47.67 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -178.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.571 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.7 m170 -122.19 136.39 54.9 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.994 -178.66 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -94.12 123.0 37.22 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.505 HG12 HG22 ' A' ' 86' ' ' THR . 33.1 mt -79.24 121.17 31.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.45 HG21 ' SD ' ' A' ' 87' ' ' MET . 36.8 pt -100.63 -14.92 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.38 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.5 tt0 -156.79 141.16 16.62 Favored 'General case' 0 CA--C 1.477 -1.858 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -175.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.453 HD12 HG21 ' A' ' 63' ' ' VAL . 79.2 mt -140.75 126.34 19.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.14 14.52 9.68 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 124.058 0.943 . . . . 0.0 111.126 172.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.83 -1.96 48.51 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.877 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.445 ' O ' HG13 ' A' ' 63' ' ' VAL . 18.5 pt20 -115.57 130.6 56.93 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 117.106 0.453 . . . . 0.0 110.633 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.0 m -70.02 108.45 4.07 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.755 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.649 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.5 m -102.17 13.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.594 0 CA-C-O 122.133 0.968 . . . . 0.0 109.682 -175.061 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.9 p -73.53 -14.11 16.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 114.349 -1.296 . . . . 0.0 110.567 -177.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -125.68 19.82 7.9 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 122.21 1.005 . . . . 0.0 108.712 177.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.649 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.3 m -101.23 137.42 19.68 Favored Pre-proline 0 N--CA 1.413 -2.295 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.418 ' O ' HG13 ' A' ' 71' ' ' ILE . 57.3 Cg_endo -72.74 163.25 38.99 Favored 'Trans proline' 0 C--O 1.245 0.848 0 C-N-CA 122.035 1.824 . . . . 0.0 112.739 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -42.35 -57.85 2.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 127.249 2.22 . . . . 0.0 112.371 -177.327 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -68.15 -39.99 82.5 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.672 -174.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -59.18 -48.7 80.63 Favored 'General case' 0 CA--C 1.495 -1.164 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.535 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 67' ' ' PRO . 65.5 mt -51.9 -43.63 35.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 O-C-N 124.057 0.848 . . . . 0.0 110.329 178.558 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.1 t -73.09 -34.99 46.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.792 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.43 -46.08 77.68 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 123.517 0.727 . . . . 0.0 109.292 -177.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 23.6 mt -64.43 -47.06 90.99 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.706 0 CA-C-N 114.673 -1.149 . . . . 0.0 109.887 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 45.4 mt -58.43 -51.71 68.69 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.987 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 42.2 m -56.38 -27.84 57.41 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.105 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -102.31 -5.21 24.51 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.474 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -102.88 131.84 49.51 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.892 -0.505 . . . . 0.0 111.317 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.464 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.5 m -130.43 -174.78 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -154.77 29.21 Favored Glycine 0 CA--C 1.484 -1.863 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.412 ' HB3' HD11 ' A' ' 16' ' ' LEU . 34.4 mt-10 -78.7 115.7 18.57 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 78.1 mt -119.33 117.82 55.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -85.53 126.24 33.7 Favored 'General case' 0 CA--C 1.487 -1.448 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.484 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 20.8 mtm -124.35 152.26 43.36 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 173.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -119.91 122.96 42.4 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.571 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 45.6 p -120.83 139.95 52.43 Favored 'General case' 0 C--N 1.271 -2.846 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.638 -177.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.45 ' SD ' HG21 ' A' ' 56' ' ' ILE . 81.7 mtp -110.33 169.76 6.02 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.553 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 11.7 Cg_exo -74.84 30.27 0.35 Allowed 'Trans proline' 0 N--CA 1.486 1.054 0 C-N-CA 122.914 2.409 . . . . 0.0 112.619 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.436 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.9 60.18 2.24 Favored 'General case' 0 CA--C 1.496 -1.132 0 C-N-CA 125.242 1.417 . . . . 0.0 111.583 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -2.013 0 CA-C-N 113.236 -1.802 . . . . 0.0 106.6 172.571 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 . . . . . 0 C--O 1.234 0.282 0 CA-C-O 120.652 0.263 . . . . 0.0 110.833 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.1 t -131.71 157.25 44.26 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 178.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.5 tpt 57.55 63.88 1.72 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 121.975 0.893 . . . . 0.0 110.128 -177.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.58 -119.69 4.15 Favored Glycine 0 CA--C 1.499 -0.951 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -103.48 96.2 6.58 Favored 'General case' 0 CA--C 1.48 -1.724 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.158 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.525 HG11 ' HE3' ' A' ' 85' ' ' LYS . 71.4 t -118.64 137.22 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.379 -3.976 0 CA-C-O 122.256 1.027 . . . . 0.0 108.881 -173.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 m -118.72 105.88 12.01 Favored 'General case' 2 N--CA 1.368 -4.562 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 174.097 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.8 m -83.55 136.75 34.14 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 114.764 -1.107 . . . . 0.0 109.272 -176.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.98 141.88 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.47 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.344 -175.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 18.2 tp -125.45 116.5 21.92 Favored 'General case' 0 N--CA 1.396 -3.137 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.696 HD11 ' HA ' ' A' ' 44' ' ' ALA . 1.0 OUTLIER -99.29 129.61 49.49 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 175.535 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 74.6 mtp180 -113.1 101.36 9.38 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 122.813 1.292 . . . . 0.0 109.059 169.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -105.04 111.27 65.21 Favored Pre-proline 0 C--N 1.272 -2.785 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.462 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -56.17 -47.88 22.27 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 122.598 2.199 . . . . 0.0 113.05 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.39 178.59 10.14 Favored 'General case' 0 C--O 1.246 0.916 0 CA-C-O 120.893 0.378 . . . . 0.0 110.72 -177.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 ' CG1' ' A' ' 79' ' ' VAL . 53.7 mt -65.05 -21.99 66.91 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 115.637 1.717 . . . . 0.0 115.637 -173.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.402 ' HD3' ' HA ' ' A' ' 23' ' ' ARG . 67.2 mmt-85 -79.04 -11.12 59.99 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.17 0.509 . . . . 0.0 111.465 -179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -83.26 -20.34 34.68 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLN . . . . . 0.407 ' HB3' ' H ' ' A' ' 26' ' ' LEU . 15.0 mm100 57.05 -164.46 0.16 Allowed 'General case' 0 CA--C 1.511 -0.539 0 O-C-N 123.777 0.673 . . . . 0.0 111.648 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.479 ' O ' HG13 ' A' ' 43' ' ' ILE . 0.4 OUTLIER -97.4 -49.43 4.92 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.92 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.21 11.54 Favored Glycine 0 N--CA 1.432 -1.595 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.097 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -143.48 164.26 30.84 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 50.3 m -118.19 133.7 55.67 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 123.89 0.743 . . . . 0.0 109.239 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.57 131.58 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.222 0 CA-C-O 121.69 0.757 . . . . 0.0 110.89 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -120.72 128.85 53.31 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 62.08 2.95 0.87 Allowed 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 124.248 1.019 . . . . 0.0 112.917 -176.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.99 3.05 45.61 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -174.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.452 HG13 ' HB2' ' A' ' 54' ' ' ARG . 3.5 mp -114.08 125.03 71.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.732 HD13 HG13 ' A' ' 49' ' ' VAL . 50.4 mt -61.41 117.97 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 123.834 0.854 . . . . 0.0 110.14 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.9 t -101.98 -34.42 9.35 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.309 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 p -143.35 148.49 36.34 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.3 tp -128.32 132.27 48.64 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.6 ttp -85.45 108.11 17.73 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.57 141.43 58.77 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.449 -177.079 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.04 -15.38 48.98 Favored Glycine 0 C--N 1.303 -1.252 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.531 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.61 175.45 50.74 Favored Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.479 HG13 ' O ' ' A' ' 26' ' ' LEU . 1.3 pt -59.96 -34.47 56.4 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.748 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.696 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.81 -40.06 96.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -68.11 -36.71 80.19 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.601 0.715 . . . . 0.0 109.12 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -76.58 -23.88 53.51 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.511 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.34 -23.24 63.41 Favored Glycine 0 N--CA 1.438 -1.204 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.507 178.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.98 10.63 22.27 Favored Glycine 0 CA--C 1.501 -0.811 0 C-N-CA 120.231 -0.985 . . . . 0.0 112.883 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.732 HG13 HD13 ' A' ' 35' ' ' ILE . 66.0 t -66.78 135.78 27.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.418 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 20.4 mmt180 -133.45 142.72 48.44 Favored 'General case' 0 CA--C 1.481 -1.681 0 CA-C-O 121.165 0.507 . . . . 0.0 110.293 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.5 t -72.65 145.25 12.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.967 -178.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.9 21.08 56.65 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 -178.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.8 m170 -117.21 135.96 53.41 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 115.08 -0.56 . . . . 0.0 111.37 -179.099 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.469 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 34.8 ttp180 -97.73 123.72 41.78 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 177.18 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.587 HG12 HG22 ' A' ' 86' ' ' THR . 30.5 mt -78.62 123.43 35.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.359 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.401 ' HA ' ' HB ' ' A' ' 64' ' ' VAL . 36.3 pt -100.3 -16.69 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.848 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.322 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.6 tt0 -158.4 144.49 17.07 Favored 'General case' 0 CA--C 1.496 -1.134 0 C-N-CA 119.479 -0.889 . . . . 0.0 110.2 -174.413 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 63' ' ' VAL . 82.2 mt -139.91 118.09 11.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 124.674 1.233 . . . . 0.0 108.077 178.277 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 53.79 27.24 6.81 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 125.299 1.44 . . . . 0.0 114.472 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.55 -10.4 38.68 Favored Glycine 0 CA--C 1.496 -1.106 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.82 175.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 35.5 tt0 -100.54 122.38 43.14 Favored 'General case' 0 C--N 1.292 -1.928 0 CA-C-N 115.488 -0.356 . . . . 0.0 110.393 -177.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -71.32 108.62 4.87 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.555 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.7 m -102.45 10.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-O 121.667 0.746 . . . . 0.0 110.08 -175.133 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.401 ' HB ' ' HA ' ' A' ' 56' ' ' ILE . 4.0 p -72.02 -13.5 16.74 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 114.669 -1.15 . . . . 0.0 111.111 -177.275 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -123.04 13.66 9.77 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.111 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.555 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.8 m -96.9 136.55 21.55 Favored Pre-proline 0 N--CA 1.409 -2.521 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.449 ' O ' HG13 ' A' ' 71' ' ' ILE . 9.5 Cg_endo -56.81 150.01 56.8 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.351 2.034 . . . . 0.0 112.386 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.2 t60 -48.62 -48.25 39.49 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.453 1.101 . . . . 0.0 112.733 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -67.58 -35.49 79.1 Favored 'General case' 0 N--CA 1.435 -1.199 0 O-C-N 123.487 0.492 . . . . 0.0 110.621 -175.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 mttm -63.59 -49.45 73.29 Favored 'General case' 0 CA--C 1.484 -1.586 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.365 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.449 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.0 mt -53.59 -43.15 53.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 O-C-N 124.083 0.865 . . . . 0.0 109.918 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.7 t -71.91 -31.86 42.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.728 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -74.56 -41.04 61.26 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -175.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.7 mt -64.29 -47.75 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.407 ' HB3' HD21 ' A' ' 26' ' ' LEU . 81.7 mt -62.48 -35.23 78.66 Favored 'General case' 0 C--O 1.211 -0.928 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.437 176.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.5 t -63.21 -31.11 72.18 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 122.805 0.442 . . . . 0.0 111.693 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -94.76 -31.71 13.65 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -175.188 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.08 130.58 35.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -172.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.478 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -129.89 -179.41 3.16 Favored 'Isoleucine or valine' 0 C--O 1.243 0.732 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 174.819 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 86.6 -151.34 24.1 Favored Glycine 0 CA--C 1.488 -1.65 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -79.06 108.78 12.8 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.441 HD12 HG22 ' A' ' 17' ' ' ILE . 79.9 mt -111.16 118.82 58.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.746 -175.411 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -94.56 131.18 40.58 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -133.11 156.2 47.87 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 172.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.525 ' HE3' HG11 ' A' ' 12' ' ' VAL . 23.2 mmmt -124.47 120.33 31.71 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 105.547 -2.019 . . . . 0.0 105.547 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.587 HG22 HG12 ' A' ' 55' ' ' ILE . 33.4 p -119.64 146.68 45.33 Favored 'General case' 0 C--N 1.27 -2.848 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.259 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.501 ' C ' ' H ' ' A' ' 89' ' ' ALA . 49.8 mtm -118.21 169.9 7.11 Favored Pre-proline 0 C--N 1.298 -1.631 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 176.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -69.71 26.26 0.17 Allowed 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 123.336 2.691 . . . . 0.0 112.575 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.501 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 74.86 -1.27 3.13 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 126.538 1.935 . . . . 0.0 113.466 178.009 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.113 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 . . . . . 0 CA--C 1.531 0.227 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.1 p -72.15 93.1 1.4 Allowed 'General case' 0 N--CA 1.438 -1.055 0 CA-C-O 121.137 0.494 . . . . 0.0 111.183 176.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 25.1 ttt -81.02 -57.62 3.45 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.436 0.636 . . . . 0.0 109.825 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.44 -155.16 6.54 Favored Glycine 0 N--CA 1.425 -2.056 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.078 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.03 96.07 7.63 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-O 121.836 0.826 . . . . 0.0 110.196 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.4 HG22 ' HG2' ' A' ' 87' ' ' MET . 46.3 t -134.79 133.26 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.191 0 CA-C-N 114.603 -1.18 . . . . 0.0 108.033 -178.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 m -123.0 117.86 26.45 Favored 'General case' 0 C--N 1.261 -3.28 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 21.4 m -85.26 142.3 29.49 Favored 'General case' 0 C--N 1.265 -3.092 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.235 -175.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.63 132.0 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.129 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 13.8 tp -122.09 119.67 32.03 Favored 'General case' 0 N--CA 1.393 -3.281 0 CA-C-O 121.711 0.767 . . . . 0.0 109.991 173.543 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.485 HD12 ' HB ' ' A' ' 43' ' ' ILE . 1.1 mm -99.87 135.23 36.36 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.026 0 CA-C-N 114.24 -1.346 . . . . 0.0 108.652 176.134 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -115.16 101.24 8.79 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.514 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 73.4 ttt180 -99.22 115.23 65.86 Favored Pre-proline 0 C--N 1.284 -2.275 0 CA-C-N 113.621 -1.627 . . . . 0.0 110.94 -178.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_exo -61.29 -38.0 68.82 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.663 2.242 . . . . 0.0 114.065 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.91 -178.58 4.8 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.484 HD23 HG12 ' A' ' 79' ' ' VAL . 79.7 mt -76.69 -15.23 59.85 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 123.976 0.91 . . . . 0.0 111.277 -176.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -69.79 -16.15 63.24 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.993 176.057 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -97.97 121.27 39.69 Favored 'General case' 0 CA--C 1.481 -1.682 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 176.111 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 -97.48 156.96 16.26 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.611 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.659 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.0 OUTLIER -53.08 -65.62 0.53 Allowed 'General case' 0 C--N 1.323 -0.551 0 O-C-N 124.993 1.433 . . . . 0.0 110.778 -174.349 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.28 34.78 4.1 Favored Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 120.129 -1.034 . . . . 0.0 112.626 177.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -155.59 155.73 33.83 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.1 m -107.42 127.35 53.51 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -117.89 136.64 54.41 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 C-N-CA 119.839 -0.744 . . . . 0.0 109.203 179.23 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -121.92 109.95 15.26 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.425 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 60.33 13.34 3.94 Favored 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 124.036 0.934 . . . . 0.0 112.37 -176.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 113.09 -6.85 25.31 Favored Glycine 0 C--O 1.211 -1.323 0 C-N-CA 121.145 -0.55 . . . . 0.0 112.054 -178.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.5 mp -102.24 123.61 55.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.049 -0.677 . . . . 0.0 110.073 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.678 HD13 HG13 ' A' ' 49' ' ' VAL . 66.1 mt -64.14 112.13 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 C-N-CA 124.05 0.94 . . . . 0.0 109.71 178.328 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 22.6 t -91.59 -37.29 13.18 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.517 -174.54 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -152.8 157.33 40.61 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 66.4 tp -129.35 132.45 47.08 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 25.6 ttt -87.33 120.4 28.58 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.432 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 0.3 OUTLIER -69.59 136.27 51.05 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.779 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.28 -2.21 74.36 Favored Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.4 164.58 28.26 Favored Glycine 0 N--CA 1.436 -1.308 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.485 ' HB ' HD12 ' A' ' 17' ' ' ILE . 3.2 pt -60.81 -36.66 72.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.44 -39.5 70.38 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.014 0.435 . . . . 0.0 111.062 -178.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -67.03 -42.78 84.3 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.023 178.145 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.89 -37.3 86.9 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.747 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.66 -24.32 76.31 Favored Glycine 0 CA--C 1.516 0.12 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.754 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.75 28.91 5.77 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.409 -0.9 . . . . 0.0 112.564 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.678 HG13 HD13 ' A' ' 35' ' ' ILE . 60.7 t -77.45 142.65 13.93 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -136.21 145.14 45.36 Favored 'General case' 0 CA--C 1.49 -1.338 0 CA-C-O 121.202 0.525 . . . . 0.0 109.623 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.0 t -73.42 144.7 12.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.206 -178.45 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.83 20.17 58.39 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -179.02 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.458 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 13.6 m-70 -115.2 144.67 43.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 115.121 -0.539 . . . . 0.0 110.194 178.161 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -104.97 117.48 34.12 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.602 HG12 HG22 ' A' ' 86' ' ' THR . 29.6 mt -73.96 123.79 29.95 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.482 HG21 ' SD ' ' A' ' 87' ' ' MET . 2.4 pp -109.48 -4.13 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.384 -178.726 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 84' ' ' MET . 20.0 tt0 -160.59 146.7 15.12 Favored 'General case' 0 CA--C 1.486 -1.506 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.515 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.487 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.3 mt -142.71 120.69 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 172.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.447 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 8.5 m-20 55.07 27.45 9.42 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 177.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.75 -6.86 58.99 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.562 -0.828 . . . . 0.0 113.821 177.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.477 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 11.6 pt20 -107.96 136.36 47.8 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 t -80.98 108.86 15.02 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -178.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.612 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.1 m -100.02 15.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.88 0 CA-C-O 122.09 0.948 . . . . 0.0 109.455 -173.436 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.442 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.6 p -69.73 -21.79 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.876 -175.144 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.32 13.62 12.78 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.457 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.612 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.7 m -90.37 133.7 32.6 Favored Pre-proline 0 N--CA 1.412 -2.367 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -63.62 155.55 62.38 Favored 'Trans proline' 0 C--O 1.25 1.125 0 C-N-CA 122.178 1.919 . . . . 0.0 112.356 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.35 -53.38 8.65 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.04 1.336 . . . . 0.0 111.313 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -56.99 -43.43 81.71 Favored 'General case' 0 C--N 1.316 -0.855 0 O-C-N 123.903 0.752 . . . . 0.0 111.456 -176.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.45 -54.61 26.01 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.847 -178.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.4 mt -50.39 -43.04 21.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 O-C-N 123.862 0.726 . . . . 0.0 110.293 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 73.0 t -67.1 -40.93 86.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 72.5 t60 -64.74 -44.09 91.25 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.4 -50.93 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 O-C-N 123.592 0.558 . . . . 0.0 109.534 178.287 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.14 -31.56 72.73 Favored 'General case' 0 C--O 1.209 -1.054 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.418 ' O ' HD22 ' A' ' 22' ' ' LEU . 50.2 m -71.08 -27.45 63.63 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -100.55 -11.46 20.07 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -174.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.514 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.77 132.56 38.04 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.237 -0.585 . . . . 0.0 112.031 -176.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.484 HG12 HD23 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -131.4 172.62 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.534 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 78.4 -151.05 35.86 Favored Glycine 0 CA--C 1.496 -1.119 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -176.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -59.11 108.78 0.73 Allowed 'General case' 0 C--O 1.245 0.857 0 C-N-CA 124.417 1.087 . . . . 0.0 111.362 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.447 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 85.4 mt -115.79 118.36 58.54 Favored 'Isoleucine or valine' 0 CA--C 1.456 -2.639 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 11.7 t-80 -106.65 115.87 30.94 Favored 'General case' 0 N--CA 1.385 -3.68 0 CA-C-N 113.199 -1.819 . . . . 0.0 109.456 -170.257 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 22.4 mtm -123.91 155.19 38.57 Favored 'General case' 0 C--N 1.261 -3.269 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 177.56 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 57.1 mmtt -122.06 124.26 43.52 Favored 'General case' 0 C--N 1.265 -3.087 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 175.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 55' ' ' ILE . 68.8 p -119.45 134.99 54.95 Favored 'General case' 0 C--N 1.262 -3.236 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.665 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.482 ' SD ' HG21 ' A' ' 56' ' ' ILE . 89.2 mtp -105.98 163.22 17.5 Favored Pre-proline 0 C--N 1.299 -1.619 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 176.551 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.64 14.48 0.32 Allowed 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 122.724 2.283 . . . . 0.0 113.157 178.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.402 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 65.37 22.94 12.02 Favored 'General case' 0 C--N 1.344 0.36 0 C-N-CA 124.427 1.091 . . . . 0.0 110.68 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.753 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.312 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 CA--C 1.509 -0.615 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 58.5 m 64.93 140.11 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 CA-C-O 122.11 0.957 . . . . 0.0 113.545 175.282 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' MET . . . . . 0.431 ' HB2' ' SD ' ' A' ' 87' ' ' MET . 1.5 mpt? -87.56 -68.3 0.76 Allowed 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 174.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.63 122.51 0.69 Allowed Glycine 0 CA--C 1.489 -1.584 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 62.19 92.09 0.06 Allowed 'General case' 0 CA--C 1.506 -0.735 0 CA-C-O 121.933 0.873 . . . . 0.0 111.297 -175.22 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -128.18 128.95 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.358 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.892 -175.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.7 m -115.58 108.19 16.11 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.178 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.4 m -78.7 135.83 37.27 Favored 'General case' 0 N--CA 1.395 -3.18 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.4 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.2 t -116.09 135.79 55.13 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.937 0 CA-C-N 114.793 -1.094 . . . . 0.0 108.478 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.5 tp -121.19 116.8 25.6 Favored 'General case' 0 N--CA 1.385 -3.698 0 C-N-CA 119.561 -0.856 . . . . 0.0 109.428 174.3 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.582 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.9 OUTLIER -97.55 133.94 37.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.352 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.592 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.6 mmm-85 -112.73 101.17 9.29 Favored 'General case' 0 N--CA 1.411 -2.398 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.2 ttt180 -100.88 110.8 61.95 Favored Pre-proline 0 C--N 1.282 -2.342 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.235 -178.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -54.88 -38.09 92.68 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 123.361 2.707 . . . . 0.0 113.663 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -176.73 -176.89 0.75 Allowed 'General case' 0 C--O 1.241 0.644 0 C-N-CA 123.367 0.667 . . . . 0.0 109.308 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 HG12 ' A' ' 79' ' ' VAL . 69.0 mt -73.28 -6.82 48.49 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -174.478 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -84.57 -13.98 50.18 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.06 0.457 . . . . 0.0 110.565 175.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -103.01 109.1 20.52 Favored 'General case' 0 CA--C 1.491 -1.326 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.164 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -82.4 162.73 22.05 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.275 178.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.1 mm? -52.14 -52.84 49.19 Favored 'General case' 0 C--N 1.321 -0.655 0 O-C-N 124.704 1.253 . . . . 0.0 110.65 -175.161 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.82 28.23 6.33 Favored Glycine 0 N--CA 1.436 -1.319 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.4 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -150.03 151.06 32.66 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.116 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m -104.57 124.64 49.67 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -113.95 141.64 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.528 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -177.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -119.06 102.04 8.45 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-O 121.711 0.767 . . . . 0.0 110.56 174.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 60.98 23.04 13.21 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-N 114.481 -1.236 . . . . 0.0 112.548 178.248 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.85 -11.01 20.87 Favored Glycine 0 N--CA 1.437 -1.268 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.421 178.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.5 119.3 58.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 117.302 0.551 . . . . 0.0 110.781 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.703 HD13 HG13 ' A' ' 49' ' ' VAL . 57.2 mt -59.43 111.93 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 124.193 0.997 . . . . 0.0 111.015 178.07 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 45.3 t -89.67 -38.26 14.01 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.595 -177.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.7 t -148.78 150.78 33.68 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 55.9 tp -122.57 137.55 54.86 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.3 tpp -86.2 120.1 27.19 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.73 129.46 39.86 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.306 -176.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.407 ' H ' ' CD ' ' A' ' 45' ' ' GLU . . . 87.27 -3.05 86.86 Favored Glycine 0 N--CA 1.421 -2.319 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.419 176.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.5 173.55 47.88 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.38 -0.914 . . . . 0.0 111.923 -176.621 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 26' ' ' LEU . 2.7 pt -59.17 -34.67 54.25 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.582 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.91 -39.11 88.12 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.709 0.29 . . . . 0.0 111.272 179.085 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 41' ' ' GLY . 45.0 tt0 -66.76 -41.24 88.06 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.826 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 43' ' ' ILE . 13.1 ptt180 -78.66 -16.22 57.57 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.012 -0.675 . . . . 0.0 111.81 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.95 -22.69 63.12 Favored Glycine 0 N--CA 1.433 -1.535 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.708 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.3 15.09 20.55 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.965 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.703 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -70.47 138.3 22.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.403 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 30.9 mmm180 -135.49 151.1 50.04 Favored 'General case' 0 CA--C 1.486 -1.484 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -79.68 145.52 9.16 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.106 -176.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.44 23.18 57.15 Favored Glycine 0 CA--C 1.501 -0.809 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -178.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.5 m170 -116.5 134.09 55.26 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 114.708 -0.746 . . . . 0.0 111.28 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.9 ttm180 -97.54 125.44 42.25 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.552 HG12 HG22 ' A' ' 86' ' ' THR . 34.2 mt -78.15 126.95 38.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 177.563 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 62' ' ' SER . 31.0 pt -106.91 -15.48 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.41 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.4 tt0 -155.62 145.81 21.68 Favored 'General case' 0 CA--C 1.481 -1.703 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.386 -173.625 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 74.5 mt -142.22 125.53 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.437 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 87.1 m-20 51.62 24.63 2.41 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 115.837 1.791 . . . . 0.0 115.837 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.86 -5.65 34.72 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.254 -0.974 . . . . 0.0 113.416 176.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.42 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.1 pt20 -115.34 129.33 56.56 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 117.42 0.61 . . . . 0.0 111.009 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 19.4 m -70.46 108.48 4.31 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.062 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.542 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.3 m -100.8 12.8 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 121.734 0.778 . . . . 0.0 109.575 -174.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -66.85 -16.22 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.562 -177.124 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.93 10.06 10.1 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-O 121.427 0.632 . . . . 0.0 109.576 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.7 m -85.43 141.42 36.74 Favored Pre-proline 0 N--CA 1.422 -1.841 0 C-N-CA 123.812 0.845 . . . . 0.0 109.214 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.75 147.32 81.11 Favored 'Trans proline' 0 C--O 1.239 0.525 0 C-N-CA 122.642 2.228 . . . . 0.0 112.697 179.284 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -42.97 -55.22 3.86 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 126.212 1.805 . . . . 0.0 111.168 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -58.5 -44.94 89.62 Favored 'General case' 0 CA--C 1.497 -1.09 0 O-C-N 123.362 0.414 . . . . 0.0 110.845 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.43 -55.07 39.34 Favored 'General case' 0 C--O 1.201 -1.479 0 O-C-N 123.861 0.725 . . . . 0.0 110.087 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 59.8 mt -50.38 -43.45 22.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 C-N-CA 123.554 0.742 . . . . 0.0 110.952 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.1 t -72.43 -36.12 53.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.829 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -70.67 -40.01 73.21 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 123.323 0.649 . . . . 0.0 109.611 -177.232 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.33 -49.51 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 176.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 85.2 mt -62.05 -46.27 89.88 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.6 m -64.32 -26.89 68.68 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -91.28 -19.79 22.6 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.09 139.04 31.03 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.837 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.478 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -132.38 178.55 5.45 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 174.04 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.9 -151.3 38.89 Favored Glycine 0 CA--C 1.48 -2.136 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -65.33 114.86 5.06 Favored 'General case' 0 CA--C 1.497 -1.096 0 O-C-N 124.693 0.878 . . . . 0.0 110.175 174.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.437 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 83.5 mt -118.62 117.29 54.0 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.703 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 175.518 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -99.48 120.08 39.05 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 -174.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.411 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 25.2 mtm -126.32 157.28 38.82 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -121.98 125.12 45.61 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 176.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.552 HG22 HG12 ' A' ' 55' ' ' ILE . 44.6 p -121.26 144.08 48.81 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.372 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.431 ' SD ' ' HB2' ' A' ' 9' ' ' MET . 54.5 mtm -116.73 168.96 7.87 Favored Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -71.29 29.58 0.23 Allowed 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 123.056 2.504 . . . . 0.0 112.861 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.403 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 57.4 50.48 11.29 Favored 'General case' 0 C--O 1.245 0.855 0 CA-C-O 122.496 1.141 . . . . 0.0 110.332 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.92 0 CA-C-N 113.782 -1.554 . . . . 0.0 108.026 179.621 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 . . . . . 0 C--O 1.241 0.628 0 CA-C-O 121.309 0.575 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 t -115.39 146.61 41.43 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 172.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 43.4 ttm -147.42 127.65 13.85 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 118.315 -1.354 . . . . 0.0 113.401 -170.297 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.4 -79.2 0.07 OUTLIER Glycine 0 CA--C 1.491 -1.455 0 N-CA-C 106.84 -2.504 . . . . 0.0 106.84 172.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -150.4 110.54 4.15 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 168.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 69.5 t -95.68 128.62 46.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.505 0 CA-C-N 113.35 -1.75 . . . . 0.0 109.466 -173.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.1 m -122.45 109.2 14.07 Favored 'General case' 2 C--N 1.236 -4.33 0 CA-C-N 113.291 -1.777 . . . . 0.0 106.865 177.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -79.01 138.66 38.13 Favored 'General case' 0 N--CA 1.406 -2.674 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.154 -176.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.421 HG11 ' CG2' ' A' ' 49' ' ' VAL . 52.9 t -115.57 133.41 62.0 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.547 177.316 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.426 HD11 ' HB3' ' A' ' 81' ' ' GLU . 14.4 tp -121.17 116.13 24.37 Favored 'General case' 0 N--CA 1.396 -3.134 0 C-N-CA 119.989 -0.684 . . . . 0.0 110.005 176.419 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.57 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.6 OUTLIER -98.89 138.64 22.79 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.978 0 CA-C-N 114.563 -1.198 . . . . 0.0 108.02 178.256 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -115.13 101.73 9.25 Favored 'General case' 0 N--CA 1.414 -2.252 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 168.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.533 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 65.3 ttt180 -97.89 116.28 65.7 Favored Pre-proline 0 C--N 1.284 -2.26 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.001 -177.832 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -49.36 -54.43 5.46 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.034 2.49 . . . . 0.0 112.602 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.58 ' OD2' ' HG3' ' A' ' 23' ' ' ARG . 2.7 p-10 -173.1 -170.49 0.64 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.325 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.465 ' HA ' ' NH2' ' A' ' 19' ' ' ARG . 54.1 mt -68.6 -16.65 63.92 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -173.501 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.58 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 27.0 mtt180 -71.34 -12.23 61.32 Favored 'General case' 0 N--CA 1.481 1.087 0 CA-C-O 121.167 0.508 . . . . 0.0 110.785 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -113.98 143.36 44.87 Favored 'General case' 0 N--CA 1.427 -1.614 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -116.96 171.56 7.83 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.243 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.686 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -58.31 -61.93 2.21 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 125.124 1.369 . . . . 0.0 111.245 -173.081 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.61 37.99 3.1 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 119.794 -1.193 . . . . 0.0 112.129 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -154.7 163.02 40.86 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.8 m -117.94 128.62 54.98 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.47 138.76 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 120.864 0.364 . . . . 0.0 110.133 -176.626 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 19.9 pt20 -131.04 121.62 25.34 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.1 m120 63.58 13.44 7.28 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.206 1.002 . . . . 0.0 111.857 -175.325 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.51 1.91 58.93 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.412 -0.899 . . . . 0.0 111.138 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -106.07 119.88 56.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.726 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -62.06 116.83 2.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 C-N-CA 124.369 1.068 . . . . 0.0 110.099 177.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.8 t -96.11 -38.18 10.28 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.27 -176.642 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 13.3 p -149.06 152.38 36.11 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.279 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 53.4 tp -127.46 145.38 50.85 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 123.576 0.75 . . . . 0.0 109.506 -178.318 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.8 ttp -93.42 115.88 28.42 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.148 0.499 . . . . 0.0 109.893 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.425 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.0 tpp85 -65.58 118.68 9.86 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 124.726 1.21 . . . . 0.0 109.463 -179.101 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -12.99 59.13 Favored Glycine 0 C--N 1.305 -1.142 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.793 -177.449 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -79.93 161.04 45.37 Favored Glycine 0 C--O 1.245 0.814 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.929 -177.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -54.22 -37.69 36.8 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.756 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.57 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -56.1 -44.2 78.82 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.199 0.524 . . . . 0.0 110.903 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.425 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 44.0 tt0 -70.14 -38.8 75.6 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.469 -179.52 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 48.3 mtt180 -66.59 -34.16 77.28 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.104 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.44 -20.61 79.54 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.782 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.08 20.29 7.62 Favored Glycine 0 C--O 1.24 0.489 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.696 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.726 HG13 HD13 ' A' ' 35' ' ' ILE . 45.0 t -71.34 144.29 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.447 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.4 mmt180 -132.61 142.66 49.24 Favored 'General case' 0 CA--C 1.484 -1.57 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.8 t -74.26 142.71 14.41 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.561 0 CA-C-N 114.583 -1.189 . . . . 0.0 109.192 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.16 22.25 55.15 Favored Glycine 0 CA--C 1.498 -0.989 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.1 m170 -114.67 135.2 54.42 Favored 'General case' 0 N--CA 1.424 -1.764 0 CA-C-N 115.129 -0.536 . . . . 0.0 111.066 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.45 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 12.6 ttm-85 -93.96 125.3 38.51 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.008 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 26.1 mt -83.0 123.62 38.76 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.337 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 174.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.2 pt -103.25 -12.06 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.36 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.688 -178.437 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.2 tt0 -163.02 143.51 9.34 Favored 'General case' 0 CA--C 1.494 -1.176 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.633 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.428 HD12 HG21 ' A' ' 63' ' ' VAL . 90.8 mt -140.03 121.84 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 O-C-N 124.228 0.955 . . . . 0.0 109.222 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 53.32 32.48 13.71 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.203 1.401 . . . . 0.0 112.447 172.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.59 -1.34 52.97 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.284 -0.96 . . . . 0.0 114.551 177.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -123.89 130.44 52.61 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 118.311 1.056 . . . . 0.0 110.755 178.147 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.3 t -74.74 109.32 8.12 Favored 'General case' 0 N--CA 1.425 -1.692 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.464 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 29.2 m -99.68 16.6 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.387 0 CA-C-O 121.968 0.889 . . . . 0.0 109.661 -174.664 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.438 HG23 ' HD3' ' A' ' 54' ' ' ARG . 3.8 p -72.95 -9.82 13.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 114.44 -1.254 . . . . 0.0 111.194 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.53 19.19 5.74 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.464 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.1 m -100.66 137.96 19.99 Favored Pre-proline 0 N--CA 1.412 -2.331 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.456 ' O ' HG13 ' A' ' 71' ' ' ILE . 50.1 Cg_endo -69.44 158.07 58.71 Favored 'Trans proline' 0 C--O 1.246 0.885 0 C-N-CA 122.435 2.09 . . . . 0.0 112.999 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -42.69 -56.19 3.26 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 126.7 2.0 . . . . 0.0 112.152 -178.289 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.84 -38.77 89.78 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.433 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -60.25 -51.83 67.87 Favored 'General case' 0 CA--C 1.485 -1.546 0 C-N-CA 119.974 -0.691 . . . . 0.0 110.93 177.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.456 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.5 mt -50.99 -44.9 28.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 O-C-N 124.329 1.018 . . . . 0.0 110.263 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.0 t -72.68 -35.13 49.42 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.087 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.9 t60 -69.67 -40.2 76.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.389 0.614 . . . . 0.0 109.586 -176.028 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 29.4 mt -70.19 -43.59 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 CA-C-N 114.829 -1.078 . . . . 0.0 109.931 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.5 mt -59.39 -46.34 88.95 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.632 175.031 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.3 t -57.92 -28.06 63.92 Favored 'General case' 0 C--O 1.215 -0.712 0 C-N-CA 124.122 0.969 . . . . 0.0 111.686 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -99.81 -6.42 26.93 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -178.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -101.28 130.55 47.44 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.893 -0.723 . . . . 0.0 111.484 -178.697 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.429 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -128.94 178.99 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.285 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.23 -153.59 29.33 Favored Glycine 0 CA--C 1.495 -1.178 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.426 ' HB3' HD11 ' A' ' 16' ' ' LEU . 47.7 mt-10 -77.61 110.37 12.37 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-O 121.403 0.62 . . . . 0.0 109.67 177.304 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 74.6 mt -112.94 117.64 55.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -93.76 118.76 31.85 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.494 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.9 mtm -118.13 156.03 29.41 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 174.257 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -121.54 121.38 37.35 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 42.9 p -121.29 146.62 46.64 Favored 'General case' 0 C--N 1.26 -3.297 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.765 -177.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 41.6 mtm -126.58 168.71 13.64 Favored Pre-proline 0 C--N 1.31 -1.142 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -70.79 38.76 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.145 0 C-N-CA 123.812 3.008 . . . . 0.0 113.654 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 54.79 56.03 7.17 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 125.58 1.552 . . . . 0.0 114.139 177.434 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.299 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.32 172.136 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.238 0.476 0 CA-C-O 120.874 0.369 . . . . 0.0 111.806 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.2 t -139.63 107.06 5.54 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 122.113 0.959 . . . . 0.0 108.937 175.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 26.8 ttt -108.83 -34.69 6.59 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.111 -177.24 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.2 -107.46 0.2 Allowed Glycine 0 N--CA 1.417 -2.57 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -127.1 106.99 9.64 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -127.28 127.45 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.453 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -115.92 113.21 23.0 Favored 'General case' 0 C--N 1.246 -3.896 0 N-CA-C 106.222 -1.77 . . . . 0.0 106.222 177.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.2 m -86.39 137.82 32.27 Favored 'General case' 0 N--CA 1.395 -3.178 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.995 -175.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.436 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.9 t -118.49 141.81 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.629 0 CA-C-N 114.64 -1.164 . . . . 0.0 109.045 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.495 HD11 ' HB3' ' A' ' 81' ' ' GLU . 11.5 tp -129.23 105.69 8.32 Favored 'General case' 0 N--CA 1.386 -3.643 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 171.357 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.652 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -99.57 127.99 51.81 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.033 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 -175.378 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.41 116.83 29.34 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.566 -177.099 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.467 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 61.6 ttt180 -119.15 116.06 34.15 Favored Pre-proline 0 C--N 1.292 -1.921 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.044 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -62.45 -48.93 6.62 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.422 2.082 . . . . 0.0 112.997 179.586 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 23' ' ' ARG . 2.8 p30 -159.76 -175.58 5.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.413 HD23 ' CG1' ' A' ' 79' ' ' VAL . 54.6 mt -71.43 -15.94 62.37 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -173.644 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 21' ' ' ASP . 4.0 mpt_? -80.8 -11.95 59.52 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.47 0.652 . . . . 0.0 109.717 -179.051 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -95.26 116.16 28.38 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -86.56 150.13 24.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.605 177.3 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.602 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.31 -49.91 66.04 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 124.953 1.408 . . . . 0.0 111.188 -172.761 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.72 37.8 3.85 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.047 178.485 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -161.11 164.89 30.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.488 ' HB3' ' OG ' ' A' ' 37' ' ' SER . 34.8 t -123.4 130.15 52.3 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.448 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.46 143.74 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.878 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -130.54 128.76 41.78 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.4 t30 59.39 11.97 2.46 Favored 'General case' 0 CA--C 1.573 1.83 0 C-N-CA 123.559 0.744 . . . . 0.0 112.353 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.58 3.72 55.08 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.66 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -118.09 124.86 73.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.291 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 49.0 mt -65.12 121.71 14.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 123.876 0.87 . . . . 0.0 110.548 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.4 t -109.58 -25.96 10.17 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.752 -177.003 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.488 ' OG ' ' HB3' ' A' ' 29' ' ' SER . 12.9 p -146.32 144.38 29.76 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 122.168 -0.332 . . . . 0.0 110.548 177.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 51.0 tp -125.74 133.64 52.02 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 123.767 0.827 . . . . 0.0 109.758 -177.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.1 ttm -75.21 119.18 18.99 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.173 0.511 . . . . 0.0 109.839 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 18.6 tpp180 -66.99 122.09 16.99 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.547 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.6 1.99 82.6 Favored Glycine 0 C--N 1.312 -0.767 0 C-N-CA 120.898 -0.667 . . . . 0.0 111.999 -178.218 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 46' ' ' ARG . . . -86.12 165.49 37.82 Favored Glycine 0 C--O 1.252 1.239 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.288 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.452 ' HB ' HD11 ' A' ' 17' ' ' ILE . 1.1 pt -61.91 -30.88 49.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.59 -45.33 94.58 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 120.94 0.4 . . . . 0.0 110.282 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -64.86 -42.21 95.05 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.785 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.5 ' HG2' ' O ' ' A' ' 42' ' ' GLY . 6.7 mmp_? -61.11 -39.4 89.84 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.712 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.2 -16.97 78.57 Favored Glycine 0 CA--C 1.524 0.646 0 CA-C-N 115.59 -0.732 . . . . 0.0 113.903 -178.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.14 12.1 22.64 Favored Glycine 0 C--O 1.241 0.588 0 C-N-CA 119.749 -1.215 . . . . 0.0 113.033 177.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 80.6 t -72.63 142.82 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.454 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -140.8 154.99 46.47 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.49 142.35 14.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.77 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 13.75 58.6 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -177.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -109.55 135.53 50.39 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 121.151 0.5 . . . . 0.0 111.419 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -95.2 122.94 38.4 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 176.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.415 HG12 HG22 ' A' ' 86' ' ' THR . 40.2 mt -82.78 122.73 37.7 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 62' ' ' SER . 32.4 pt -103.3 -14.97 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.004 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 178.709 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 84' ' ' MET . 30.7 tt0 -150.92 141.86 22.95 Favored 'General case' 0 CA--C 1.479 -1.762 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -176.634 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.513 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -143.2 122.0 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.539 0 O-C-N 124.64 1.213 . . . . 0.0 108.127 176.218 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 66.69 18.57 10.74 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.663 1.185 . . . . 0.0 110.927 171.171 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.69 -12.06 30.08 Favored Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.75 177.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.419 ' O ' HG13 ' A' ' 63' ' ' VAL . 13.3 pt20 -115.89 143.34 45.55 Favored 'General case' 0 CA--C 1.501 -0.941 0 CA-C-N 117.732 0.766 . . . . 0.0 112.602 -178.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 49.9 m -75.86 108.87 9.03 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.233 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.575 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 23.3 m -102.09 15.02 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 122.124 0.964 . . . . 0.0 109.226 -174.422 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 p -72.97 -17.96 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-N 114.792 -1.094 . . . . 0.0 110.614 -177.418 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.59 9.32 16.56 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.954 0.883 . . . . 0.0 109.817 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.575 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.1 m -90.85 137.0 27.05 Favored Pre-proline 0 N--CA 1.411 -2.422 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.302 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' ILE . 12.0 Cg_endo -64.37 154.51 70.99 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 121.676 1.584 . . . . 0.0 111.585 178.104 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 32.1 t-80 -47.73 -53.49 15.02 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.375 1.07 . . . . 0.0 113.633 -176.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -67.97 -31.76 71.7 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.58 -175.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.0 mttm -63.62 -50.55 68.93 Favored 'General case' 0 C--O 1.189 -2.095 0 C-N-CA 120.197 -0.601 . . . . 0.0 110.035 173.098 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.8 mt -50.3 -43.97 22.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 O-C-N 123.533 0.521 . . . . 0.0 110.223 177.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 86.7 t -69.1 -34.13 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.691 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.642 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -70.87 -42.56 69.9 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 123.381 0.672 . . . . 0.0 109.78 -177.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.9 mp -60.91 -48.68 87.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.378 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 80.8 mt -61.39 -46.47 90.02 Favored 'General case' 0 C--O 1.215 -0.753 0 N-CA-C 113.103 0.779 . . . . 0.0 113.103 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -61.73 -27.47 68.74 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -178.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -101.48 -19.19 15.64 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -176.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.447 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -91.54 132.21 36.44 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 122.022 -0.424 . . . . 0.0 111.569 -176.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.5 m -126.7 -176.37 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.402 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.49 -163.29 32.46 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.495 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.4 mp0 -75.58 122.06 23.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 171.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.652 ' HB ' HG22 ' A' ' 17' ' ' ILE . 70.7 mt -115.57 119.81 62.91 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.278 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -84.61 112.02 20.06 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 113.43 -1.714 . . . . 0.0 110.372 -174.547 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.602 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 13.5 mtp -120.57 143.9 48.38 Favored 'General case' 0 C--N 1.253 -3.612 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.745 178.415 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 12.1 mmmt -120.87 118.5 30.11 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 177.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 65.0 p -119.14 145.55 45.88 Favored 'General case' 0 C--N 1.282 -2.359 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.355 -176.094 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.464 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.3 mtp -115.8 163.9 19.41 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 178.096 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.42 24.33 0.23 Allowed 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.035 2.49 . . . . 0.0 112.352 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.464 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.41 22.91 13.48 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.4 1.48 . . . . 0.0 111.891 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.904 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 175.765 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 . . . . . 0 CA--C 1.509 -0.606 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -150.07 103.2 3.17 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 124.23 1.012 . . . . 0.0 108.603 173.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 16.2 tpt -88.27 123.56 33.0 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 121.179 0.514 . . . . 0.0 111.631 -177.419 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.92 -165.27 23.98 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 176.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.448 ' O ' ' HA ' ' A' ' 87' ' ' MET . 28.3 t-20 -94.62 87.12 4.98 Favored 'General case' 0 C--N 1.28 -2.419 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.8 t -108.77 117.76 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.79 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.877 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -115.64 114.86 25.47 Favored 'General case' 1 C--N 1.24 -4.174 0 CA-C-N 113.25 -1.795 . . . . 0.0 106.923 178.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.0 m -79.09 141.84 36.98 Favored 'General case' 0 N--CA 1.406 -2.67 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.217 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.45 HG11 ' CG2' ' A' ' 49' ' ' VAL . 57.1 t -121.86 128.28 75.64 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.363 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.506 178.82 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.461 HD11 ' HB3' ' A' ' 81' ' ' GLU . 22.3 tp -109.37 112.46 24.6 Favored 'General case' 0 N--CA 1.402 -2.836 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 173.226 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.76 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 134.83 47.32 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.546 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.015 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.73 103.36 12.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-O 121.102 0.477 . . . . 0.0 109.72 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' HD2' ' HA ' ' A' ' 79' ' ' VAL . 34.0 ttm180 -100.83 113.74 65.73 Favored Pre-proline 0 C--N 1.29 -1.989 0 CA-C-N 115.63 -0.713 . . . . 0.0 110.307 177.76 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.61 -42.11 50.19 Favored 'Trans proline' 0 C--O 1.239 0.572 0 C-N-CA 122.281 1.987 . . . . 0.0 112.181 177.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -173.7 177.04 2.58 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -178.096 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.449 HD23 HG12 ' A' ' 79' ' ' VAL . 53.1 mt -67.01 -22.38 65.9 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 -171.528 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -71.67 -11.65 60.94 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-O 121.406 0.622 . . . . 0.0 111.426 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.3 -20.98 23.4 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.831 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLN . . . . . 0.495 ' C ' HH21 ' A' ' 19' ' ' ARG . 78.4 mt-30 54.09 -153.58 0.28 Allowed 'General case' 0 C--O 1.22 -0.453 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.448 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.432 ' O ' HG13 ' A' ' 43' ' ' ILE . 2.1 mm? -97.47 -57.55 2.22 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.802 0.811 . . . . 0.0 110.49 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.67 2.99 32.56 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 -174.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.415 ' CD1' ' HB3' ' A' ' 26' ' ' LEU . 39.1 p90 -137.83 152.18 48.84 Favored 'General case' 0 C--O 1.246 0.887 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 176.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -105.81 122.73 46.7 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -104.18 137.27 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -119.14 111.79 18.7 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 175.236 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 68' ' ' HIS . 95.3 m-20 65.86 9.13 5.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.352 178.428 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.0 -3.74 24.1 Favored Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -112.82 122.12 66.39 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.695 HD13 HG13 ' A' ' 49' ' ' VAL . 48.2 mt -60.43 116.14 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 123.625 0.77 . . . . 0.0 110.56 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.1 t -98.08 -33.2 11.25 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.013 -173.048 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 56.9 p -150.91 151.66 32.5 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 60.2 tp -135.42 137.88 42.7 Favored 'General case' 0 N--CA 1.441 -0.906 0 O-C-N 123.482 0.489 . . . . 0.0 110.829 -178.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 63.0 mtt -92.76 116.78 29.34 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.074 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -69.68 126.77 30.73 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 174.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.38 -21.5 39.13 Favored Glycine 0 N--CA 1.42 -2.427 0 C-N-CA 120.412 -0.899 . . . . 0.0 110.984 -174.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -78.91 159.04 45.28 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 177.635 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.567 ' HB ' HD11 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -55.12 -30.7 24.53 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.866 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.315 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.75 -47.27 84.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 123.569 0.543 . . . . 0.0 111.099 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -67.15 -34.22 77.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.458 0.647 . . . . 0.0 109.492 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 47.8 mtt180 -75.51 -17.27 60.15 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.613 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.77 -37.57 8.53 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 121.74 17.76 3.77 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.026 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.695 HG13 HD13 ' A' ' 35' ' ' ILE . 59.2 t -71.1 141.56 16.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.492 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.462 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.8 mmm180 -137.64 146.14 43.54 Favored 'General case' 0 CA--C 1.483 -1.619 0 CA-C-O 121.267 0.556 . . . . 0.0 110.649 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.1 t -69.35 147.07 12.21 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.484 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.52 28.56 47.3 Favored Glycine 0 CA--C 1.487 -1.694 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -123.85 129.03 50.36 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.883 -0.659 . . . . 0.0 111.175 -179.069 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.456 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 10.2 ttm180 -89.23 124.13 34.1 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 175.327 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.58 HG12 HG22 ' A' ' 86' ' ' THR . 25.9 mt -81.54 124.51 39.02 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.141 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.434 HG13 ' HB2' ' A' ' 85' ' ' LYS . 43.1 pt -106.61 -12.5 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.503 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -154.33 145.42 22.75 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -177.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.465 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.2 mt -138.68 121.43 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.299 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.647 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 58.2 26.5 13.88 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.071 1.348 . . . . 0.0 111.711 174.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.88 -5.41 58.07 Favored Glycine 0 C--O 1.241 0.555 0 C-N-CA 120.025 -1.084 . . . . 0.0 113.774 177.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.401 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.8 pt20 -110.91 128.74 55.91 Favored 'General case' 0 CA--C 1.499 -0.992 0 CA-C-N 117.609 0.705 . . . . 0.0 109.554 177.668 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -72.89 112.74 9.2 Favored 'General case' 0 N--CA 1.42 -1.949 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -179.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 32.7 m -102.21 10.77 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.964 0 CA-C-O 121.634 0.731 . . . . 0.0 109.64 -175.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 p -71.69 -16.46 18.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.608 -177.241 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.63 9.87 21.09 Favored 'General case' 0 C--O 1.244 0.796 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.511 177.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' ' 63' ' ' VAL . 82.5 m -94.37 139.58 22.47 Favored Pre-proline 0 N--CA 1.405 -2.678 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -57.29 144.07 92.02 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.393 2.062 . . . . 0.0 110.483 177.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HB2' ' HA ' ' A' ' 32' ' ' ASN . 35.0 p80 -51.73 -41.1 61.27 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 -177.796 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -68.01 -35.0 77.57 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 -178.545 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 15.4 tttm -68.87 -44.65 72.88 Favored 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.465 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 63.8 mt -53.1 -45.06 53.05 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 O-C-N 123.722 0.639 . . . . 0.0 109.747 176.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.5 t -68.79 -32.31 54.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.452 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.2 t-160 -72.7 -38.99 67.34 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -175.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.9 mt -67.99 -50.75 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.675 177.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.3 mt -59.95 -30.92 69.4 Favored 'General case' 0 C--O 1.199 -1.578 0 CA-C-O 120.964 0.411 . . . . 0.0 111.414 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.448 ' O ' HD22 ' A' ' 22' ' ' LEU . 34.1 t -70.41 -26.29 63.62 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.281 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -123.53 8.5 8.96 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -172.186 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -99.09 122.17 41.96 Favored 'General case' 0 C--O 1.204 -1.335 0 CA-C-N 118.259 0.481 . . . . 0.0 109.744 177.539 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.504 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -115.42 169.96 5.78 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 CA-C-N 119.058 0.844 . . . . 0.0 109.527 177.342 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.5 -159.27 19.23 Favored Glycine 0 N--CA 1.434 -1.496 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 16' ' ' LEU . 38.6 mt-10 -80.65 111.92 17.54 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.76 ' HB ' HG22 ' A' ' 17' ' ' ILE . 62.0 mt -115.42 117.39 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -173.444 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -90.16 111.71 22.95 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 25.7 mtm -111.05 160.39 16.9 Favored 'General case' 0 C--N 1.278 -2.505 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.434 ' HB2' HG13 ' A' ' 56' ' ' ILE . 70.1 mmtt -121.95 125.15 45.71 Favored 'General case' 0 CA--C 1.47 -2.12 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 176.499 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.58 HG22 HG12 ' A' ' 55' ' ' ILE . 66.1 p -123.68 141.6 51.87 Favored 'General case' 0 C--N 1.265 -3.108 0 C-N-CA 120.195 -0.602 . . . . 0.0 110.451 -177.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 53' ' ' HIS . 75.2 mtp -116.53 171.38 4.82 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.158 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -75.51 29.67 0.37 Allowed 'Trans proline' 0 C--N 1.363 1.313 0 C-N-CA 122.823 2.348 . . . . 0.0 112.431 179.007 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.456 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.47 55.19 4.25 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.235 1.414 . . . . 0.0 111.526 -179.161 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.422 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 174.566 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.509 -0.611 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 97.9 m -110.34 109.13 19.44 Favored 'General case' 0 N--CA 1.421 -1.908 0 CA-C-O 121.21 0.528 . . . . 0.0 110.774 -179.392 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -102.26 -18.56 15.41 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.296 175.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 130.16 73.1 0.13 Allowed Glycine 0 CA--C 1.491 -1.417 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 68.91 86.79 0.13 Allowed 'General case' 0 CA--C 1.501 -0.931 0 CA-C-O 122.587 1.184 . . . . 0.0 110.937 -175.222 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.493 HG22 ' HG2' ' A' ' 87' ' ' MET . 79.8 t -125.16 130.56 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.827 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -175.382 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.8 m -112.21 106.02 14.5 Favored 'General case' 2 N--CA 1.371 -4.395 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 178.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.432 HG23 ' HD3' ' A' ' 85' ' ' LYS . 28.9 m -79.47 135.28 36.61 Favored 'General case' 0 N--CA 1.395 -3.198 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.32 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.2 t -114.47 134.38 57.61 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.024 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.142 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 81' ' ' GLU . 15.4 tp -119.65 104.49 10.31 Favored 'General case' 0 N--CA 1.396 -3.166 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 172.603 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -103.15 126.79 57.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.054 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -175.09 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.497 ' HG2' HH11 ' A' ' 18' ' ' ARG . 0.5 OUTLIER -95.43 122.03 37.73 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.921 -178.32 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.496 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 64.8 ttt180 -128.04 105.43 20.22 Favored Pre-proline 0 C--N 1.285 -2.226 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.05 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -52.31 -48.03 23.86 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 122.721 2.281 . . . . 0.0 113.372 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -167.93 -172.34 1.8 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.5 mt -70.04 -21.48 63.17 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -173.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.1 mpt_? -72.48 -13.02 61.33 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.305 0.574 . . . . 0.0 110.87 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -103.91 121.94 44.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.251 69.3 mt-30 -103.6 157.54 16.99 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 119.048 -1.061 . . . . 0.0 113.652 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.707 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.5 mm? -44.77 -58.42 3.1 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 126.708 2.003 . . . . 0.0 111.704 -174.13 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.64 32.43 6.59 Favored Glycine 0 N--CA 1.427 -1.908 0 C-N-CA 119.86 -1.162 . . . . 0.0 112.256 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -159.24 161.45 36.02 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.1 t -119.9 124.03 45.04 Favored 'General case' 0 N--CA 1.415 -2.189 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -117.86 135.01 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.287 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -178.371 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -120.88 112.53 18.9 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.808 176.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.38 12.27 8.27 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 114.597 -1.183 . . . . 0.0 110.97 177.272 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.47 -4.86 31.25 Favored Glycine 0 C--O 1.206 -1.635 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.106 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.8 mp -109.25 126.57 66.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 122.117 -0.637 . . . . 0.0 109.617 -178.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 54.6 mt -71.21 115.05 10.5 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.804 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 25.2 t -101.21 -28.98 12.36 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.294 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -150.49 150.42 31.27 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.273 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 154.84 45.16 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -178.467 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.0 ttt -101.89 121.67 42.56 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.445 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 1.2 tmt_? -69.22 128.88 38.16 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.617 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.71 86.41 Favored Glycine 0 C--N 1.311 -0.83 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 -178.172 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.497 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -82.48 161.96 41.28 Favored Glycine 0 N--CA 1.433 -1.542 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.778 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -60.8 -30.12 46.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.0 98.01 Favored 'General case' 0 N--CA 1.439 -1.002 0 O-C-N 123.264 0.353 . . . . 0.0 111.07 177.109 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.438 ' OE2' ' HA ' ' A' ' 40' ' ' ARG . 36.4 tt0 -58.66 -47.84 83.07 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 177.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.497 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 22.3 mtt180 -63.16 -39.67 95.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.155 -1.384 . . . . 0.0 109.23 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -64.3 -30.82 78.89 Favored Glycine 0 C--O 1.248 0.979 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.48 -178.255 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 115.61 9.89 12.14 Favored Glycine 0 N--CA 1.439 -1.137 0 C-N-CA 120.073 -1.06 . . . . 0.0 111.489 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 88.5 t -71.84 134.7 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.084 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -143.51 146.32 33.28 Favored 'General case' 0 CA--C 1.495 -1.148 0 C-N-CA 123.666 0.786 . . . . 0.0 109.674 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -67.36 144.34 14.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 CA-C-N 114.15 -1.386 . . . . 0.0 111.136 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.94 61.79 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.911 -0.661 . . . . 0.0 111.475 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -120.39 148.65 43.5 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' THR . 42.2 ttp180 -106.35 132.53 52.27 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.536 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.63 HD13 HG22 ' A' ' 86' ' ' THR . 18.2 mm -75.48 114.61 15.78 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 175.584 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.1 pt -101.03 -15.23 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.808 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 179.001 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 84' ' ' MET . 38.1 tt0 -156.37 146.12 20.99 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.619 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.489 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.5 mt -140.8 122.5 14.63 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 O-C-N 124.388 1.055 . . . . 0.0 108.521 178.302 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 59.32 23.18 11.61 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.708 1.203 . . . . 0.0 111.626 172.19 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.01 -9.96 40.05 Favored Glycine 0 N--CA 1.439 -1.14 0 C-N-CA 120.535 -0.841 . . . . 0.0 114.061 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.13 134.44 52.72 Favored 'General case' 0 CA--C 1.494 -1.203 0 CA-C-N 118.34 1.07 . . . . 0.0 110.752 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -72.53 112.59 8.72 Favored 'General case' 0 N--CA 1.423 -1.787 0 CA-C-O 121.337 0.589 . . . . 0.0 109.692 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.65 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 25.1 m -109.15 19.38 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-O 122.312 1.053 . . . . 0.0 108.932 -175.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.12 -18.6 19.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.388 -176.546 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.88 12.03 12.76 Favored 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.669 0.747 . . . . 0.0 109.009 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.65 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 97.3 m -83.88 136.74 41.26 Favored Pre-proline 0 N--CA 1.417 -2.083 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.44 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' THR . 43.0 Cg_exo -60.12 154.87 48.58 Favored 'Trans proline' 0 C--O 1.241 0.662 0 C-N-CA 122.928 2.419 . . . . 0.0 112.912 177.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -45.3 -55.7 5.65 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.715 1.606 . . . . 0.0 111.151 178.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -58.85 -43.6 90.79 Favored 'General case' 0 C--N 1.311 -1.095 0 O-C-N 124.307 1.004 . . . . 0.0 110.546 -175.727 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -62.21 -54.34 42.35 Favored 'General case' 0 CA--C 1.477 -1.835 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.883 -178.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 73.0 mt -52.01 -42.74 35.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 O-C-N 124.177 0.923 . . . . 0.0 110.383 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 83.6 t -71.66 -39.32 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.657 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 53.8 t60 -69.8 -41.55 74.91 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.519 0.676 . . . . 0.0 109.903 -176.685 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.6 mt -69.52 -44.03 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 CA-C-N 114.674 -1.148 . . . . 0.0 110.314 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 60.1 mt -59.99 -44.05 94.76 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.829 0.347 . . . . 0.0 111.086 173.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.404 ' C ' HH12 ' A' ' 19' ' ' ARG . 34.6 t -59.16 -27.44 65.66 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 123.49 0.716 . . . . 0.0 112.216 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -109.39 -2.74 17.57 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -176.611 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.496 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -97.68 130.82 44.65 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.478 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 m -128.3 179.73 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.65 -161.96 28.78 Favored Glycine 0 CA--C 1.489 -1.563 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -178.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.505 ' HB3' HD11 ' A' ' 16' ' ' LEU . 27.9 mt-10 -75.89 119.15 19.47 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 172.633 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.7 ' HB ' HG22 ' A' ' 17' ' ' ILE . 63.1 mt -117.19 117.63 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.711 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.246 -173.601 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -82.98 111.8 19.17 Favored 'General case' 0 CA--C 1.492 -1.257 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.603 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.413 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 28.4 mtm -117.55 156.54 27.9 Favored 'General case' 0 C--N 1.269 -2.914 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 173.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.432 ' HD3' HG23 ' A' ' 14' ' ' THR . 35.6 mmtm -123.07 121.65 36.55 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.63 HG22 HD13 ' A' ' 55' ' ' ILE . 68.3 p -116.93 141.49 48.16 Favored 'General case' 0 C--N 1.266 -3.04 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.712 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.493 ' HG2' HG22 ' A' ' 12' ' ' VAL . 85.0 mtp -119.72 170.31 7.04 Favored Pre-proline 0 C--O 1.211 -0.937 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 178.259 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.69 26.64 0.2 Allowed 'Trans proline' 0 CA--C 1.559 1.767 0 C-N-CA 122.865 2.377 . . . . 0.0 113.286 178.252 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.41 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.39 34.83 18.11 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.586 1.154 . . . . 0.0 111.08 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.418 -2.027 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.396 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 . . . . . 0 CA--C 1.497 -1.071 0 CA-C-O 121.518 0.675 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 t -148.72 158.37 44.1 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 179.562 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 26.3 mmt -85.14 82.25 8.49 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.558 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.65 145.13 17.76 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 16.8 m120 62.52 58.82 1.6 Allowed 'General case' 0 CA--C 1.487 -1.466 0 C-N-CA 123.872 0.869 . . . . 0.0 109.619 -176.321 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 86' ' ' THR . 39.9 t -141.48 126.13 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.974 0 CA-C-N 114.328 -1.306 . . . . 0.0 108.765 -175.099 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 85.1 m -111.42 113.44 25.89 Favored 'General case' 2 N--CA 1.376 -4.137 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 176.458 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.6 m -85.23 137.94 32.66 Favored 'General case' 0 N--CA 1.398 -3.07 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.468 HG11 ' HE2' ' A' ' 84' ' ' MET . 25.4 t -118.01 139.22 46.04 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.955 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.737 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 82' ' ' ILE . 19.4 tp -121.14 112.46 18.71 Favored 'General case' 0 N--CA 1.383 -3.803 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.976 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.581 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -98.61 122.44 50.31 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 N-CA-C 106.949 -1.5 . . . . 0.0 106.949 176.314 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.7 mtp180 -107.18 102.07 11.42 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-O 122.661 1.22 . . . . 0.0 109.276 173.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.509 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 74.1 ttt180 -103.75 109.46 62.18 Favored Pre-proline 0 C--N 1.272 -2.802 0 CA-C-N 112.523 -2.126 . . . . 0.0 109.716 -176.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -54.11 -50.8 12.34 Favored 'Trans proline' 0 CA--C 1.542 0.904 0 C-N-CA 122.602 2.201 . . . . 0.0 111.993 178.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -164.88 -172.57 2.64 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.406 HD23 ' CG1' ' A' ' 79' ' ' VAL . 55.6 mt -69.01 -17.26 63.89 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -173.241 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 -64.55 -23.04 67.14 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.3 0.571 . . . . 0.0 110.676 176.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -105.85 113.16 26.54 Favored 'General case' 0 N--CA 1.422 -1.859 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -178.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -92.14 161.93 14.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.618 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -52.75 -57.11 11.22 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 124.467 1.107 . . . . 0.0 110.662 -173.565 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.57 23.92 10.57 Favored Glycine 0 N--CA 1.434 -1.486 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.861 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -145.94 155.54 42.92 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.0 m -108.6 137.06 47.16 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.92 136.89 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-O 121.49 0.662 . . . . 0.0 110.622 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.468 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 4.2 pp0? -128.41 121.15 28.37 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 176.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 63.56 4.27 1.74 Allowed 'General case' 0 N--CA 1.503 2.197 0 C-N-CA 125.101 1.36 . . . . 0.0 111.983 -172.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 104.58 1.07 43.34 Favored Glycine 0 N--CA 1.438 -1.205 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -174.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -102.35 124.05 56.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.688 HD13 HG13 ' A' ' 49' ' ' VAL . 68.1 mt -65.76 117.14 5.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 C-N-CA 124.184 0.994 . . . . 0.0 110.576 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 41.8 t -101.55 -28.33 12.6 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.851 -175.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.1 t -154.56 156.58 36.86 Favored 'General case' 0 C--O 1.246 0.876 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.4 HD21 ' HA ' ' A' ' 45' ' ' GLU . 57.5 tp -134.43 140.11 46.02 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 123.624 0.77 . . . . 0.0 109.826 -178.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.3 tpt -91.89 127.0 37.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.152 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -76.39 135.33 39.48 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -178.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.39 1.06 86.26 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 121.217 -0.516 . . . . 0.0 111.958 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -93.6 167.52 28.59 Favored Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.8 pt -56.75 -36.42 49.16 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.96 0 N-CA-C 113.226 0.825 . . . . 0.0 113.226 178.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.581 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.65 -37.61 79.17 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.4 ' HA ' HD21 ' A' ' 38' ' ' LEU . 14.1 tt0 -61.26 -49.26 77.79 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.096 0.95 . . . . 0.0 108.822 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -76.77 -16.32 59.51 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 114.199 -1.364 . . . . 0.0 111.198 -176.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.59 -19.55 70.84 Favored Glycine 0 N--CA 1.432 -1.618 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.603 176.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.74 16.99 20.43 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.239 177.401 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.688 HG13 HD13 ' A' ' 35' ' ' ILE . 51.0 t -69.5 133.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 CA-C-O 120.922 0.391 . . . . 0.0 110.561 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 20.9 mmt180 -132.38 137.03 47.2 Favored 'General case' 0 CA--C 1.484 -1.577 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.335 178.515 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.7 t -72.23 147.51 10.32 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.68 0 CA-C-N 113.913 -1.494 . . . . 0.0 110.115 -178.484 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.0 23.38 45.5 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.538 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 17.1 m-70 -121.83 139.62 53.39 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.199 -0.5 . . . . 0.0 111.377 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.555 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 9.0 ttm180 -94.39 120.82 35.2 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.227 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 86' ' ' THR . 41.6 mt -76.24 122.09 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 175.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.9 pt -102.61 -14.5 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.552 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.251 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.524 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.5 tt0 -161.38 142.88 11.56 Favored 'General case' 0 CA--C 1.485 -1.531 0 C-N-CA 120.046 -0.661 . . . . 0.0 110.148 -174.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 75.4 mt -133.26 123.06 46.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 t30 73.38 -21.18 0.26 Allowed 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.988 1.315 . . . . 0.0 112.663 172.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 143.42 -8.31 2.09 Favored Glycine 0 N--CA 1.438 -1.23 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -175.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.466 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 20.4 pt20 -107.87 123.48 48.65 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.112 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 m -69.79 111.76 5.77 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 121.512 0.672 . . . . 0.0 109.71 179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 34.0 m -103.47 16.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 CA-C-O 122.062 0.934 . . . . 0.0 109.346 -175.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -71.7 -17.91 19.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.56 -179.263 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.69 11.92 21.08 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.15 -0.932 . . . . 0.0 109.206 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.461 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.5 m -101.9 137.81 19.62 Favored Pre-proline 0 N--CA 1.408 -2.557 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.413 ' O ' HG13 ' A' ' 71' ' ' ILE . 73.9 Cg_endo -76.64 168.08 24.32 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 122.58 2.186 . . . . 0.0 112.551 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -44.62 -55.01 5.55 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 124.977 1.311 . . . . 0.0 111.617 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -56.82 -43.61 81.21 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.352 1.032 . . . . 0.0 110.824 -173.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.0 mtpt -73.54 -45.89 50.82 Favored 'General case' 0 CA--C 1.485 -1.521 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 67' ' ' PRO . 61.7 mt -54.67 -39.86 48.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 121.135 0.493 . . . . 0.0 109.741 178.402 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.74 -37.59 69.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.479 177.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -64.59 -39.75 94.29 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -177.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.9 mt -71.06 -53.34 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.675 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.979 -179.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.7 mt -56.39 -41.77 76.81 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 10.8 t -63.0 -29.42 70.81 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 123.336 0.655 . . . . 0.0 111.71 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -104.63 -13.39 15.98 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.46 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.509 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.87 133.99 34.8 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.316 -0.554 . . . . 0.0 112.494 -174.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.406 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.5 m -137.44 175.81 8.79 Favored 'Isoleucine or valine' 0 C--O 1.248 1.02 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.45 -161.94 19.75 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -77.29 107.76 9.93 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 173.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.481 ' O ' HD12 ' A' ' 16' ' ' LEU . 82.3 mt -107.86 116.67 51.83 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -174.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -97.78 110.2 22.82 Favored 'General case' 0 CA--C 1.453 -2.753 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.524 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 11.3 ttp -112.91 141.38 46.81 Favored 'General case' 1 C--N 1.242 -4.097 0 N-CA-C 105.739 -1.949 . . . . 0.0 105.739 -174.965 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm -121.42 130.39 53.56 Favored 'General case' 0 CA--C 1.452 -2.805 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 -177.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 38.5 p -126.34 153.17 45.25 Favored 'General case' 0 C--N 1.275 -2.656 0 O-C-N 123.532 0.52 . . . . 0.0 110.015 -174.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.453 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.8 mtp -122.08 168.76 10.78 Favored Pre-proline 0 C--N 1.301 -1.526 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 176.354 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.94 22.33 0.31 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 123.137 2.558 . . . . 0.0 112.595 178.642 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.555 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 73.28 3.51 4.64 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 126.075 1.75 . . . . 0.0 113.645 177.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.609 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 175.619 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 . . . . . 0 CA--C 1.516 -0.353 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -99.82 122.25 42.5 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -90.37 137.16 32.58 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.368 0.418 . . . . 0.0 110.717 -173.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.15 -150.68 18.14 Favored Glycine 0 C--N 1.303 -1.299 0 C-N-CA 120.794 -0.717 . . . . 0.0 111.71 175.092 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.2 m120 -91.29 99.54 12.5 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.471 HG22 ' HG2' ' A' ' 87' ' ' MET . 55.7 t -128.58 129.68 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.628 -175.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.3 m -117.77 113.73 22.26 Favored 'General case' 0 N--CA 1.391 -3.392 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.602 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.3 m -81.42 128.83 34.29 Favored 'General case' 0 N--CA 1.398 -3.042 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.333 -178.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.456 HG11 ' CG2' ' A' ' 49' ' ' VAL . 53.1 t -110.2 136.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.767 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.058 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.491 HD11 ' HB3' ' A' ' 81' ' ' GLU . 21.3 tp -119.07 109.37 15.83 Favored 'General case' 0 N--CA 1.384 -3.767 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 172.776 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.587 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.7 136.07 31.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -115.45 103.75 11.07 Favored 'General case' 0 C--N 1.287 -2.13 0 CA-C-O 122.195 0.998 . . . . 0.0 110.796 178.137 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.433 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 66.0 ttt180 -103.12 113.42 65.85 Favored Pre-proline 0 C--N 1.283 -2.292 0 CA-C-N 113.408 -1.724 . . . . 0.0 109.952 -175.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.8 -56.06 2.49 Favored 'Trans proline' 0 CA--C 1.552 1.414 0 C-N-CA 122.937 2.425 . . . . 0.0 113.991 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.55 -175.59 5.49 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' CG1' ' A' ' 79' ' ' VAL . 61.3 mt -71.06 -17.87 62.58 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -173.036 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -79.0 -11.19 60.0 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 121.618 0.723 . . . . 0.0 111.04 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -97.66 143.01 28.75 Favored 'General case' 0 N--CA 1.403 -2.799 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.678 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -97.07 -157.27 0.58 Allowed 'General case' 0 C--N 1.26 -3.325 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -93.83 -51.24 4.98 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.25 6.47 Favored Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.003 177.153 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -149.26 157.18 43.13 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.5 m -105.44 121.92 44.91 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 178.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.28 130.72 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.757 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.332 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -111.0 102.44 10.91 Favored 'General case' 0 C--N 1.287 -2.132 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 178.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 67.23 14.84 9.87 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.16 175.726 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.52 -3.17 23.39 Favored Glycine 0 N--CA 1.438 -1.208 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.94 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 3.1 mp -114.48 122.27 68.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 O-C-N 122.389 -0.477 . . . . 0.0 109.869 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.721 HD13 HG13 ' A' ' 49' ' ' VAL . 55.5 mt -65.24 111.22 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 123.647 0.779 . . . . 0.0 109.475 179.032 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -105.6 -19.41 13.78 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.988 -176.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 m -149.2 150.42 32.59 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 121.667 -0.645 . . . . 0.0 109.84 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.414 HD21 ' HA ' ' A' ' 45' ' ' GLU . 65.0 tp -135.63 141.51 45.07 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 120.88 0.371 . . . . 0.0 110.738 -177.796 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.7 ttt -82.55 103.43 12.07 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -79.51 107.14 12.06 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.535 0.683 . . . . 0.0 110.082 -174.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.23 11.35 Favored Glycine 0 N--CA 1.433 -1.552 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -175.172 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.77 178.49 53.68 Favored Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.097 -0.551 . . . . 0.0 111.782 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.414 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.5 OUTLIER -58.1 -41.15 79.88 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.927 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -177.479 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.74 -37.91 88.44 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.635 0.255 . . . . 0.0 111.616 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.414 ' HA ' HD21 ' A' ' 38' ' ' LEU . 3.6 tm-20 -61.78 -46.4 89.71 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 178.339 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.9 mtt-85 -74.77 -25.1 58.84 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.615 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.5 -19.2 79.93 Favored Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.455 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.65 7.88 29.13 Favored Glycine 0 CA--C 1.507 -0.44 0 C-N-CA 120.137 -1.03 . . . . 0.0 112.256 177.184 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.721 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -73.58 135.47 27.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.1 mmt-85 -137.72 155.42 49.11 Favored 'General case' 0 CA--C 1.492 -1.283 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 176.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 74.1 t -80.7 139.38 18.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.382 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.141 -175.186 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.33 6.08 51.43 Favored Glycine 0 CA--C 1.497 -1.034 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.479 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.581 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 47.6 m80 -106.23 142.88 35.17 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 115.099 -0.55 . . . . 0.0 111.228 179.234 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.49 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 39.2 ttm180 -99.18 132.66 44.34 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 171.618 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.481 HG12 HG22 ' A' ' 86' ' ' THR . 28.0 mt -85.68 123.37 39.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.467 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 176.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.6 pt -102.99 -12.92 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.199 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.291 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 84' ' ' MET . 36.9 tt0 -154.35 141.68 19.6 Favored 'General case' 0 CA--C 1.479 -1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -178.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.495 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.8 mt -140.91 124.4 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 124.407 1.067 . . . . 0.0 108.155 177.196 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 68.55 13.92 9.01 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.892 0.853 . . . . 0.0 110.287 171.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.7 -2.73 49.07 Favored Glycine 0 N--CA 1.437 -1.25 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.934 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.441 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.4 pt20 -112.85 130.98 55.9 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.617 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 33.2 t -68.38 114.23 6.64 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.602 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.7 m -108.84 17.08 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 CA-C-O 121.884 0.85 . . . . 0.0 109.394 -176.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -71.34 -15.22 18.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.841 -1.072 . . . . 0.0 112.04 -175.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -120.01 7.31 10.86 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.216 0.531 . . . . 0.0 109.568 175.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.602 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.9 m -80.8 138.07 50.4 Favored Pre-proline 0 N--CA 1.418 -2.042 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.243 -177.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.98 157.27 44.64 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 123.081 2.52 . . . . 0.0 113.223 178.582 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -45.96 -55.86 6.24 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 125.972 1.709 . . . . 0.0 110.61 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -54.09 -51.83 62.9 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 124.492 1.117 . . . . 0.0 110.813 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.536 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.9 mptt -58.93 -54.0 52.09 Favored 'General case' 0 CA--C 1.486 -1.482 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.812 -176.427 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 70.4 mt -50.71 -43.28 23.9 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 124.312 1.007 . . . . 0.0 110.358 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.0 t -73.2 -36.86 51.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.744 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -73.45 -37.69 65.73 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.348 0.594 . . . . 0.0 109.903 -175.097 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.1 mt -68.53 -47.64 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.307 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 59.2 mt -58.28 -40.32 81.59 Favored 'General case' 0 C--O 1.212 -0.905 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.492 176.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.3 t -62.25 -26.99 68.69 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -105.98 -17.3 14.39 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.433 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.9 127.25 35.97 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.688 -176.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.5 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -127.53 -179.38 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.11 -155.61 24.58 Favored Glycine 0 CA--C 1.493 -1.292 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.491 ' HB3' HD11 ' A' ' 16' ' ' LEU . 45.3 mt-10 -77.69 108.52 10.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 174.741 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.587 ' HB ' HG22 ' A' ' 17' ' ' ILE . 64.6 mt -109.63 117.72 55.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -176.154 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 39.8 m-70 -93.05 116.93 29.5 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 -178.512 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.465 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.0 mtm -120.2 156.84 30.32 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 177.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.467 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 68.8 mmtt -121.47 123.81 42.93 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 176.35 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.581 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 72.1 p -119.36 139.84 51.33 Favored 'General case' 0 C--N 1.27 -2.875 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.208 -177.437 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.471 ' HG2' HG22 ' A' ' 12' ' ' VAL . 82.9 mtp -120.85 171.72 5.57 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -72.1 24.91 0.26 Allowed 'Trans proline' 0 N--CA 1.497 1.728 0 C-N-CA 123.09 2.527 . . . . 0.0 112.88 177.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.49 ' HA ' ' CB ' ' A' ' 54' ' ' ARG . . . 71.33 20.59 4.93 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 125.127 1.371 . . . . 0.0 112.803 177.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.762 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.021 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 . . . . . 0 CA--C 1.514 -0.416 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.1 t -135.69 159.41 41.72 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.15 0.5 . . . . 0.0 109.763 -178.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 25.5 mmt -120.26 -177.74 3.51 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -178.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.72 -103.28 0.89 Allowed Glycine 0 CA--C 1.501 -0.817 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.405 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -101.27 108.1 19.66 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -130.66 133.7 63.06 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 CA-C-O 122.315 1.055 . . . . 0.0 111.861 -172.298 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.4 m -127.9 121.94 31.27 Favored 'General case' 0 N--CA 1.392 -3.355 0 CA-C-N 113.262 -1.79 . . . . 0.0 106.864 176.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 m -82.82 141.92 31.93 Favored 'General case' 0 N--CA 1.404 -2.774 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.574 -176.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' CG2' ' A' ' 49' ' ' VAL . 56.1 t -116.47 136.65 52.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.067 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.412 HD12 ' O ' ' A' ' 82' ' ' ILE . 29.1 tp -122.1 119.73 32.2 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-O 121.961 0.886 . . . . 0.0 109.886 175.445 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.557 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -97.49 134.13 36.68 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.098 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.418 178.594 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.02 101.34 10.16 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 171.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.531 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.0 ttt180 -108.31 107.97 60.67 Favored Pre-proline 0 C--N 1.282 -2.341 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.451 -178.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -58.03 -41.09 71.71 Favored 'Trans proline' 0 CA--C 1.546 1.117 0 C-N-CA 122.607 2.205 . . . . 0.0 113.423 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -167.17 176.64 6.67 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.45 HD23 ' CG1' ' A' ' 79' ' ' VAL . 73.1 mt -68.95 -22.39 64.13 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 125.152 1.381 . . . . 0.0 111.213 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.424 ' HA ' ' NE ' ' A' ' 23' ' ' ARG . 7.3 mmp_? -59.11 -21.89 59.98 Favored 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.058 0.848 . . . . 0.0 110.233 174.234 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -103.89 118.35 36.49 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 104.899 -2.26 . . . . 0.0 104.899 178.467 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.22 168.79 10.69 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.587 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -64.05 -59.85 3.97 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.221 0.534 . . . . 0.0 111.282 -171.014 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.445 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 103.45 34.63 3.82 Favored Glycine 0 N--CA 1.431 -1.658 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.287 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -155.43 157.39 36.94 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.6 m -117.34 136.04 53.42 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.85 128.15 64.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.772 0.796 . . . . 0.0 112.923 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -121.45 115.44 22.88 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.454 176.641 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 68.99 2.6 3.65 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 125.538 1.535 . . . . 0.0 112.283 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 118.42 -12.6 12.38 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -96.43 128.17 47.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 O-C-N 122.385 -0.479 . . . . 0.0 110.548 -179.109 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.746 HD13 HG13 ' A' ' 49' ' ' VAL . 72.9 mt -68.31 114.45 5.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 124.458 1.103 . . . . 0.0 109.608 176.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.5 t -98.63 -23.78 15.34 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.006 -177.287 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.8 p -156.52 152.06 26.87 Favored 'General case' 0 C--N 1.322 -0.629 0 O-C-N 122.297 -0.252 . . . . 0.0 111.316 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.445 HD12 ' O ' ' A' ' 27' ' ' GLY . 48.7 tp -125.91 148.55 49.18 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 124.356 1.062 . . . . 0.0 109.072 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -105.88 123.52 48.09 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.376 0.608 . . . . 0.0 110.692 -179.312 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 20.4 tpp85 -60.36 130.84 48.59 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.23 176.587 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.05 5.99 89.25 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.856 178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.58 161.2 27.15 Favored Glycine 0 N--CA 1.423 -2.179 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 pt -60.24 -32.61 51.12 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.98 0 C-N-CA 120.764 -0.375 . . . . 0.0 111.947 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.83 -38.85 86.88 Favored 'General case' 0 N--CA 1.443 -0.779 0 C-N-CA 122.986 0.514 . . . . 0.0 111.812 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.44 ' HA ' HD21 ' A' ' 38' ' ' LEU . 44.4 tt0 -64.31 -38.88 92.6 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -90.48 -0.41 57.65 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.902 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.31 -19.56 38.35 Favored Glycine 0 N--CA 1.433 -1.504 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 175.783 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.16 9.01 26.6 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.103 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.746 HG13 HD13 ' A' ' 35' ' ' ILE . 60.0 t -69.82 140.01 19.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 13.9 mmt180 -145.08 141.8 29.14 Favored 'General case' 0 CA--C 1.49 -1.354 0 C-N-CA 123.406 0.682 . . . . 0.0 110.989 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.74 139.9 20.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.783 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.18 14.29 59.17 Favored Glycine 0 C--N 1.305 -1.147 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.558 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -108.71 133.85 52.23 Favored 'General case' 0 N--CA 1.428 -1.575 0 CA-C-O 121.32 0.581 . . . . 0.0 111.611 178.284 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -92.76 114.79 27.44 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.492 -1.231 . . . . 0.0 108.085 177.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 30.2 mt -78.54 122.9 34.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.312 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 62' ' ' SER . 37.2 pt -106.43 -11.79 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.505 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.568 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.8 tt0 -154.76 144.91 21.87 Favored 'General case' 0 CA--C 1.479 -1.778 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.107 -177.015 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -141.82 125.15 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 174.57 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 69.43 -2.72 1.8 Allowed 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.991 1.317 . . . . 0.0 112.846 172.583 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.43 -4.11 10.25 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.968 -178.27 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -112.28 130.68 55.86 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 10.5 p -73.0 108.3 5.82 Favored 'General case' 0 N--CA 1.425 -1.68 0 CA-C-O 121.795 0.807 . . . . 0.0 110.285 177.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.552 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.6 m -98.86 16.52 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-O 122.271 1.034 . . . . 0.0 110.053 -172.567 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.6 p -75.58 -10.27 13.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.072 -177.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.95 16.33 10.88 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.063 -0.972 . . . . 0.0 108.495 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.7 m -103.26 135.22 19.43 Favored Pre-proline 0 N--CA 1.407 -2.577 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.49 159.81 52.18 Favored 'Trans proline' 0 C--O 1.244 0.802 0 C-N-CA 122.258 1.972 . . . . 0.0 112.596 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -43.15 -54.84 4.22 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.87 1.668 . . . . 0.0 112.177 -178.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -56.39 -47.03 79.79 Favored 'General case' 0 CA--C 1.497 -1.067 0 O-C-N 124.027 0.83 . . . . 0.0 110.663 -175.219 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.468 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 12.6 mptt -63.76 -54.21 38.92 Favored 'General case' 0 N--CA 1.426 -1.639 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.682 -177.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.5 mt -51.08 -44.75 29.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 O-C-N 124.098 0.874 . . . . 0.0 110.112 179.335 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.4 t -71.53 -36.82 61.67 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.746 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -72.81 -40.57 65.74 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -174.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 46.0 mt -66.0 -46.26 88.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.895 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.9 mt -58.5 -41.04 84.47 Favored 'General case' 0 C--O 1.214 -0.811 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.554 175.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 50.8 m -63.06 -27.61 69.52 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.2 m-80 -104.45 -10.65 17.55 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -175.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.39 133.4 36.68 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.76 -178.409 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.45 ' CG1' HD23 ' A' ' 22' ' ' LEU . 3.1 m -129.69 -178.57 2.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.583 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 175.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.57 -154.82 33.14 Favored Glycine 0 CA--C 1.488 -1.624 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -73.51 112.64 9.79 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 121.592 0.711 . . . . 0.0 109.722 174.28 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.412 ' O ' HD12 ' A' ' 16' ' ' LEU . 74.9 mt -118.11 117.47 54.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.358 0 CA-C-N 115.328 -0.851 . . . . 0.0 108.711 -177.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -88.38 129.98 35.27 Favored 'General case' 0 CA--C 1.473 -2.013 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.201 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.453 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.3 mtm -129.19 153.3 47.87 Favored 'General case' 0 C--N 1.262 -3.209 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 171.148 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 62.9 mmtt -119.18 122.61 42.39 Favored 'General case' 0 C--N 1.268 -2.975 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 177.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 52.7 p -121.82 143.61 49.3 Favored 'General case' 0 C--N 1.267 -2.992 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.102 -177.332 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.556 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.3 mtp -111.22 164.07 15.85 Favored Pre-proline 0 C--N 1.303 -1.421 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 178.152 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -78.33 29.68 0.45 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 122.786 2.324 . . . . 0.0 109.3 172.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.556 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.97 11.5 8.39 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 127.015 2.126 . . . . 0.0 112.017 -178.7 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.204 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.517 -0.293 0 CA-C-O 121.405 0.621 . . . . 0.0 110.006 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.8 m -155.61 93.51 1.49 Allowed 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 175.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 28.3 ttt -64.81 -60.49 3.02 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.648 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.65 99.96 0.13 Allowed Glycine 0 CA--C 1.493 -1.325 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.098 -179.458 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.438 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 88.9 m-20 63.48 89.88 0.09 Allowed 'General case' 0 CA--C 1.502 -0.894 0 CA-C-O 121.844 0.831 . . . . 0.0 109.853 -175.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.4 t -122.79 122.19 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 CA-C-O 121.885 0.85 . . . . 0.0 109.518 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.9 m -108.49 108.81 19.89 Favored 'General case' 0 C--N 1.246 -3.916 0 CA-C-N 113.332 -1.758 . . . . 0.0 107.133 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 85' ' ' LYS . 15.9 m -79.43 132.63 36.43 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.435 178.447 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.479 HG11 ' HE2' ' A' ' 84' ' ' MET . 37.2 t -111.17 140.65 29.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.335 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.517 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 15.1 tp -122.83 112.76 18.27 Favored 'General case' 0 N--CA 1.379 -3.983 0 C-N-CA 119.286 -0.966 . . . . 0.0 108.814 172.781 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.89 129.21 49.58 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.968 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.58 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -111.84 102.78 11.03 Favored 'General case' 0 N--CA 1.406 -2.64 0 CA-C-O 122.506 1.145 . . . . 0.0 109.667 174.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.612 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.3 ttt180 -112.38 110.79 52.9 Favored Pre-proline 0 C--N 1.276 -2.609 0 CA-C-N 112.752 -2.022 . . . . 0.0 110.718 -176.596 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -57.46 -51.88 7.49 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 122.567 2.178 . . . . 0.0 112.577 178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.47 ' OD2' ' HG2' ' A' ' 23' ' ' ARG . 1.0 OUTLIER -158.56 -174.0 4.57 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.838 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.427 HD23 HG12 ' A' ' 79' ' ' VAL . 46.6 mt -72.08 -14.16 61.78 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.47 ' HG2' ' OD2' ' A' ' 21' ' ' ASP . 18.5 mmt180 -66.31 -23.95 66.46 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.828 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -94.4 110.18 21.98 Favored 'General case' 0 CA--C 1.48 -1.72 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 176.051 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -92.19 155.44 18.01 Favored 'General case' 0 C--N 1.281 -2.388 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.806 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.657 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.2 mm? -50.78 -61.76 2.02 Favored 'General case' 0 C--O 1.237 0.428 0 O-C-N 124.913 1.383 . . . . 0.0 110.642 -175.143 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.48 -10.77 35.95 Favored Glycine 0 N--CA 1.434 -1.496 0 C-N-CA 120.66 -0.781 . . . . 0.0 111.579 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.422 ' CE1' ' HB3' ' A' ' 26' ' ' LEU . 50.6 p90 -112.89 151.76 30.1 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.023 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 t -107.08 122.38 46.36 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -112.44 131.35 64.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 CA-C-O 121.576 0.703 . . . . 0.0 112.18 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -131.52 122.14 25.65 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 114.495 -1.229 . . . . 0.0 107.843 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.46 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 88.0 m-20 66.89 13.98 9.65 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-O 121.902 0.858 . . . . 0.0 111.752 177.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.46 -6.72 65.71 Favored Glycine 0 N--CA 1.432 -1.616 0 CA-C-N 115.175 -0.92 . . . . 0.0 111.313 -178.179 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.14 128.82 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-O 121.223 0.535 . . . . 0.0 110.22 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.645 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -67.11 111.01 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.221 175.289 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -95.57 -27.99 15.07 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.645 -175.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.4 m -150.47 158.91 44.69 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 121.959 -0.463 . . . . 0.0 110.072 -177.65 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.2 tp -142.85 135.44 27.71 Favored 'General case' 0 C--O 1.239 0.529 0 O-C-N 123.835 0.709 . . . . 0.0 111.258 -178.014 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ttt -82.3 121.92 27.29 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 176.125 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -74.33 122.86 23.57 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.056 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.17 -3.22 72.63 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -177.462 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -83.47 170.31 48.43 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.7 pt -63.03 -37.29 78.98 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.399 0 CA-C-N 117.311 0.556 . . . . 0.0 111.899 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.497 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -55.23 -45.56 75.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.521 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -62.78 -43.15 99.56 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.507 0.67 . . . . 0.0 109.936 178.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -73.76 -20.25 60.55 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.125 -0.943 . . . . 0.0 111.778 -179.679 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.26 -19.13 57.82 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.963 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.62 15.59 22.33 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.277 -0.963 . . . . 0.0 112.456 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.645 HG13 HD13 ' A' ' 35' ' ' ILE . 79.2 t -75.39 122.8 29.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 8.1 mmm180 -122.39 150.87 41.84 Favored 'General case' 0 CA--C 1.474 -1.957 0 CA-C-O 121.348 0.594 . . . . 0.0 110.416 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 78.1 t -78.25 141.4 15.53 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.772 0 CA-C-N 114.018 -1.446 . . . . 0.0 109.424 -176.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.85 30.03 33.22 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -175.128 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.2 m170 -123.31 135.06 54.03 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.803 -0.698 . . . . 0.0 109.915 177.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.7 ttp180 -97.91 123.89 42.1 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 177.553 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.603 HG12 HG22 ' A' ' 86' ' ' THR . 32.6 mt -79.04 127.12 39.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 O-C-N 123.852 0.72 . . . . 0.0 109.779 178.087 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 41.6 pt -109.75 -13.93 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.95 143.11 16.74 Favored 'General case' 0 CA--C 1.483 -1.634 0 C-N-CA 120.025 -0.67 . . . . 0.0 109.314 -175.593 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.467 ' CD1' HG21 ' A' ' 63' ' ' VAL . 66.3 mt -137.71 127.84 36.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.206 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 70.84 -18.66 0.25 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.846 1.259 . . . . 0.0 113.485 172.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 130.59 8.41 3.16 Favored Glycine 0 C--N 1.299 -1.52 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -176.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -118.74 139.85 50.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 176.034 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.7 t -77.44 108.11 10.36 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.537 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.8 m -101.04 8.57 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.231 0 CA-C-O 121.966 0.889 . . . . 0.0 109.384 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.03 -12.19 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.783 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.156 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.19 14.52 16.97 Favored 'General case' 0 N--CA 1.437 -1.093 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.735 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 80.3 m -102.9 138.63 19.62 Favored Pre-proline 0 N--CA 1.409 -2.511 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.407 ' O ' HG13 ' A' ' 71' ' ' ILE . 59.4 Cg_exo -49.94 139.9 32.44 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.813 2.342 . . . . 0.0 110.751 176.442 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.46 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 32.6 p80 -51.66 -42.76 62.35 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -176.533 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -69.26 -37.59 77.98 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.665 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 tttm -60.13 -44.88 94.58 Favored 'General case' 0 CA--C 1.492 -1.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.907 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 67' ' ' PRO . 66.1 mt -52.05 -44.5 39.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 O-C-N 124.006 0.816 . . . . 0.0 109.762 178.662 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 96.8 t -67.24 -34.92 72.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.69 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.3 t-160 -74.29 -39.51 62.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 54.1 mt -65.7 -49.16 79.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.84 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 77.6 mt -57.12 -41.14 78.46 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.105 0.479 . . . . 0.0 110.985 175.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.5 t -57.08 -36.7 70.9 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 123.808 0.843 . . . . 0.0 111.53 178.381 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -98.6 -11.45 22.11 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -176.459 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.612 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -86.89 131.01 34.23 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -173.501 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.427 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -134.64 179.01 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.454 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.99 -159.74 22.18 Favored Glycine 0 CA--C 1.496 -1.13 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.413 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.2 mp0 -78.98 108.11 12.22 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 171.409 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 17' ' ' ILE . 88.6 mt -104.47 117.27 49.78 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.471 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -175.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -100.02 111.3 23.6 Favored 'General case' 0 CA--C 1.479 -1.788 0 N-CA-C 105.014 -2.217 . . . . 0.0 105.014 -176.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.479 ' HE2' HG11 ' A' ' 15' ' ' VAL . 23.2 ttp -122.95 148.63 45.26 Favored 'General case' 0 C--N 1.257 -3.45 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -173.379 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.465 ' HD3' HG23 ' A' ' 14' ' ' THR . 29.0 mmtm -117.88 128.36 54.75 Favored 'General case' 0 CA--C 1.474 -1.971 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -177.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.603 HG22 HG12 ' A' ' 55' ' ' ILE . 54.0 p -127.74 143.39 51.14 Favored 'General case' 0 C--N 1.277 -2.567 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.429 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.498 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.5 mtp -112.9 168.72 7.27 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 177.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 12.8 Cg_exo -74.48 30.05 0.34 Allowed 'Trans proline' 0 N--CA 1.489 1.238 0 C-N-CA 122.997 2.465 . . . . 0.0 111.578 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.498 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 68.31 23.46 7.69 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 126.308 1.843 . . . . 0.0 111.815 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.419 -1.984 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.991 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 . . . . . 0 N--CA 1.433 -1.29 0 CA-C-O 121.408 0.623 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t -128.59 126.81 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.373 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.465 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.8 m -118.09 107.24 13.75 Favored 'General case' 0 C--N 1.251 -3.716 0 CA-C-N 113.628 -1.624 . . . . 0.0 107.661 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.9 m -79.07 140.74 37.81 Favored 'General case' 0 N--CA 1.401 -2.908 0 CA-C-N 115.487 -0.778 . . . . 0.0 109.8 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -122.45 136.68 58.49 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.117 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.322 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.464 ' O ' ' HA2' ' A' ' 47' ' ' GLY . 29.9 tp -115.64 115.96 27.29 Favored 'General case' 0 N--CA 1.396 -3.152 0 C-N-CA 120.205 -0.598 . . . . 0.0 109.446 173.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.611 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -98.59 130.95 46.66 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.05 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.661 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 55.5 mtp180 -115.57 101.38 8.81 Favored 'General case' 0 N--CA 1.408 -2.572 0 CA-C-O 122.446 1.117 . . . . 0.0 108.829 171.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.475 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 75.3 ttt180 -100.79 119.48 58.28 Favored Pre-proline 0 C--N 1.275 -2.656 0 CA-C-N 112.939 -1.937 . . . . 0.0 111.896 -174.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.89 -48.48 12.43 Favored 'Trans proline' 0 CA--C 1.545 1.029 0 C-N-CA 122.92 2.414 . . . . 0.0 112.983 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -165.92 -175.15 3.28 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.427 HD22 ' O ' ' A' ' 76' ' ' SER . 59.0 mt -73.7 -11.73 60.5 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 115.064 1.505 . . . . 0.0 115.064 -173.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -86.68 -12.42 48.43 Favored 'General case' 0 C--N 1.292 -1.901 0 CA-C-O 121.743 0.782 . . . . 0.0 111.0 177.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -97.25 89.93 4.93 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 173.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -77.47 161.76 27.7 Favored 'General case' 0 N--CA 1.415 -2.218 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.094 -177.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.713 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.4 mm? -45.89 -48.84 16.03 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 125.444 1.498 . . . . 0.0 111.55 -171.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.08 13.65 45.17 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 119.714 -1.231 . . . . 0.0 111.568 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -137.31 148.57 46.44 Favored 'General case' 0 N--CA 1.426 -1.643 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 175.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.2 m -96.46 122.54 39.46 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -120.52 143.22 33.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -130.88 114.7 15.6 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 173.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 68' ' ' HIS . 93.3 m-20 64.9 14.45 9.26 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.563 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.55 -3.21 34.46 Favored Glycine 0 N--CA 1.434 -1.48 0 C-N-CA 120.52 -0.847 . . . . 0.0 111.737 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.58 124.55 66.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 O-C-N 121.964 -0.727 . . . . 0.0 110.769 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.662 HD13 HG13 ' A' ' 49' ' ' VAL . 61.9 mt -69.05 116.72 10.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 114.513 -1.221 . . . . 0.0 110.576 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -97.59 -32.23 11.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.583 -177.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.9 t -155.01 153.47 31.04 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.3 tp -132.13 130.85 41.69 Favored 'General case' 0 C--O 1.243 0.718 0 C-N-CA 123.197 0.599 . . . . 0.0 110.478 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -84.75 115.54 22.76 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 175.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -70.84 134.96 47.77 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -177.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.14 -2.72 75.69 Favored Glycine 0 C--N 1.302 -1.317 0 C-N-CA 121.193 -0.527 . . . . 0.0 111.802 -175.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.04 168.6 31.45 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.411 HG13 ' O ' ' A' ' 26' ' ' LEU . 3.0 pt -57.15 -36.82 52.88 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.611 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -61.65 -35.51 78.13 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -66.28 -41.46 89.82 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -66.91 -31.76 72.57 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 114.254 -1.339 . . . . 0.0 109.891 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -70.93 -27.3 72.46 Favored Glycine 0 N--CA 1.44 -1.1 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.822 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.6 21.46 10.47 Favored Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.662 HG13 HD13 ' A' ' 35' ' ' ILE . 73.8 t -77.74 137.39 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 48.8 mmt-85 -136.07 146.89 47.55 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.92 140.51 19.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 CA-C-N 114.281 -1.327 . . . . 0.0 109.708 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 25.11 27.85 Favored Glycine 0 N--CA 1.431 -1.643 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 -178.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.546 ' HB2' HD12 ' A' ' 35' ' ' ILE . 6.8 m170 -119.18 144.95 46.4 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.901 -0.65 . . . . 0.0 110.227 176.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 43.4 ttp180 -107.21 124.06 49.19 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.338 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 86' ' ' THR . 28.7 mm -72.96 115.09 13.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.444 HG21 ' SD ' ' A' ' 87' ' ' MET 0.275 2.1 pp -103.65 -18.08 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.752 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' MET . 33.1 tt0 -154.0 146.77 24.29 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.468 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.5 mt -139.47 119.47 13.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 O-C-N 124.25 0.969 . . . . 0.0 109.153 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 96.7 m-20 46.9 33.25 2.13 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 115.186 1.55 . . . . 0.0 115.186 178.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.84 -0.99 41.7 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.087 -1.054 . . . . 0.0 114.035 175.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -119.67 125.78 49.53 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 117.834 0.817 . . . . 0.0 109.95 175.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -69.28 110.76 4.78 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.549 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.2 m -103.11 13.56 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.707 0.765 . . . . 0.0 110.089 -174.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.8 -15.38 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.747 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.355 -176.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -117.32 14.63 14.77 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.794 0.807 . . . . 0.0 109.153 176.112 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.549 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.9 m -93.64 140.28 23.04 Favored Pre-proline 0 N--CA 1.411 -2.402 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -70.16 161.72 44.95 Favored 'Trans proline' 0 CA--C 1.544 1.024 0 C-N-CA 121.862 1.708 . . . . 0.0 113.225 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.428 ' HB2' ' OD1' ' A' ' 32' ' ' ASN . 4.2 t60 -42.63 -56.28 3.19 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.994 2.118 . . . . 0.0 111.997 -178.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.84 -50.97 71.49 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.298 0.999 . . . . 0.0 110.858 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.583 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -58.75 -54.01 51.92 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.361 -178.82 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.7 mt -51.81 -45.12 38.13 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 O-C-N 123.978 0.799 . . . . 0.0 110.811 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.29 -39.52 76.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.291 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.1 t60 -68.39 -37.63 80.58 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.032 0.444 . . . . 0.0 109.881 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 24.1 mt -66.44 -49.79 72.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.198 177.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 79.9 mt -62.18 -40.05 94.72 Favored 'General case' 0 C--O 1.216 -0.693 0 CA-C-O 120.891 0.377 . . . . 0.0 111.538 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 22.8 t -63.85 -27.3 69.07 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -107.56 -7.19 16.59 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -175.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.466 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.14 135.51 33.92 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.382 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.475 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -134.97 177.12 7.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.162 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.76 -153.53 27.23 Favored Glycine 0 CA--C 1.477 -2.289 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.1 108.24 7.71 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.479 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 89.7 mt -111.41 119.39 59.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.955 -1.021 . . . . 0.0 109.991 -176.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 31.5 m80 -98.02 116.91 31.21 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.403 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 27.7 mtm -121.11 158.83 27.06 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -123.82 123.69 41.02 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.666 HG22 HD13 ' A' ' 55' ' ' ILE . 44.1 p -120.24 149.14 42.75 Favored 'General case' 0 C--N 1.262 -3.199 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.993 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.462 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -120.15 164.69 21.08 Favored Pre-proline 0 C--N 1.291 -1.94 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 176.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -70.27 28.71 0.19 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 123.308 2.672 . . . . 0.0 112.967 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.462 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.52 11.25 5.49 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.811 1.644 . . . . 0.0 113.671 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.302 -1.468 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.065 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.515 ' O ' ' HA ' ' A' ' 87' ' ' MET . 40.8 m-80 . . . . . 0 CA--C 1.477 -1.847 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.533 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 76.1 t -103.72 114.7 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.524 0 CA-C-N 114.32 -1.309 . . . . 0.0 108.732 -174.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 73.7 m -108.91 111.75 23.61 Favored 'General case' 2 C--N 1.223 -4.912 0 CA-C-N 112.723 -2.035 . . . . 0.0 106.89 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.6 m -80.44 140.54 35.93 Favored 'General case' 0 N--CA 1.394 -3.259 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.739 -178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.422 HG11 ' CG2' ' A' ' 49' ' ' VAL . 54.3 t -122.02 127.15 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.396 -3.133 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.113 178.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.515 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 25.6 tp -110.45 116.22 31.02 Favored 'General case' 0 N--CA 1.387 -3.583 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 172.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.623 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -104.74 137.16 35.17 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.262 0 N-CA-C 106.074 -1.825 . . . . 0.0 106.074 178.16 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -109.3 104.02 13.07 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-O 121.839 0.828 . . . . 0.0 110.472 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.463 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.8 ttt180 -106.92 114.03 62.01 Favored Pre-proline 0 N--CA 1.415 -2.181 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.954 -177.021 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.88 -55.4 2.7 Favored 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 122.835 2.357 . . . . 0.0 112.982 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -161.5 -173.26 3.7 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -177.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 41.3 mt -71.01 -18.71 62.58 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -175.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 12.4 mmt-85 -61.58 -31.49 71.55 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.718 0.77 . . . . 0.0 109.544 174.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -94.45 130.69 40.72 Favored 'General case' 0 N--CA 1.419 -1.995 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -107.13 165.32 11.45 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 177.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.703 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.3 mm? -51.47 -53.63 35.34 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 124.754 1.283 . . . . 0.0 111.308 -172.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.414 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 99.3 32.17 5.89 Favored Glycine 0 N--CA 1.424 -2.148 0 C-N-CA 119.936 -1.126 . . . . 0.0 111.838 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -158.6 161.69 37.25 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -116.02 122.49 45.36 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -110.21 136.45 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.463 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -125.14 116.48 22.11 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' HIS . 83.3 m-20 67.09 8.92 6.53 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.674 0.789 . . . . 0.0 112.336 -179.461 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.26 -0.93 40.45 Favored Glycine 0 N--CA 1.439 -1.136 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.86 123.43 65.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.935 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.653 HD13 HG13 ' A' ' 49' ' ' VAL . 72.6 mt -60.91 112.62 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 123.92 0.888 . . . . 0.0 110.951 178.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -83.35 -43.37 16.02 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.136 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.9 p -154.05 160.67 42.09 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.204 -179.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.414 HD12 ' O ' ' A' ' 27' ' ' GLY . 53.6 tp -125.92 133.26 51.92 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 123.773 0.67 . . . . 0.0 110.249 -178.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.8 ttt -74.31 107.33 6.41 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.1 tpt180 -60.98 119.58 8.56 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 124.375 1.07 . . . . 0.0 110.775 -176.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.63 1.42 74.17 Favored Glycine 0 N--CA 1.442 -0.911 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.116 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.65 174.44 46.46 Favored Glycine 0 C--O 1.25 1.107 0 C-N-CA 121.248 -0.501 . . . . 0.0 113.239 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.464 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.64 -33.83 64.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 112.839 0.681 . . . . 0.0 112.839 -177.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.17 -39.25 94.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.183 0.516 . . . . 0.0 110.932 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -71.45 -33.05 69.02 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.405 ' HA ' ' NE ' ' A' ' 46' ' ' ARG . 1.9 mmp_? -66.67 -33.08 74.85 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.485 172.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.87 -14.17 82.86 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.537 -0.756 . . . . 0.0 112.956 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.84 30.06 9.3 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.525 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.653 HG13 HD13 ' A' ' 35' ' ' ILE . 54.2 t -77.22 143.88 12.31 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.415 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 23.9 mmm180 -135.74 140.65 44.53 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-O 121.282 0.563 . . . . 0.0 109.745 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.8 t -73.12 143.49 13.78 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 114.232 -1.349 . . . . 0.0 110.375 -178.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.69 18.69 59.54 Favored Glycine 0 CA--C 1.501 -0.794 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -177.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.9 m170 -109.96 139.79 44.67 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.011 -0.594 . . . . 0.0 110.543 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 20.8 ttt180 -101.33 117.26 34.6 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.599 HG12 HG22 ' A' ' 86' ' ' THR . 33.6 mt -76.03 126.84 37.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.424 HG13 ' HB2' ' A' ' 85' ' ' LYS . 41.5 pt -107.78 -14.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.229 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.6 tt0 -156.28 144.6 19.87 Favored 'General case' 0 CA--C 1.491 -1.293 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.66 -173.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.461 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.6 mt -140.35 122.15 15.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 C-N-CA 124.367 1.067 . . . . 0.0 108.22 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.1 m120 65.5 4.76 2.89 Favored 'General case' 0 N--CA 1.501 2.081 0 C-N-CA 125.505 1.522 . . . . 0.0 112.671 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.96 5.5 35.39 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.432 ' O ' HG13 ' A' ' 63' ' ' VAL . 8.9 tt0 -104.79 116.32 31.81 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.466 1.106 . . . . 0.0 108.402 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.6 t -70.16 109.53 4.67 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.52 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.1 m -105.32 14.51 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.551 0 CA-C-O 121.64 0.733 . . . . 0.0 109.173 -175.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -69.51 -21.66 24.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.952 -175.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.79 -1.03 22.98 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.504 0.668 . . . . 0.0 109.91 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.52 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 90.4 m -78.96 137.04 57.52 Favored Pre-proline 0 N--CA 1.406 -2.662 0 C-N-CA 124.793 1.237 . . . . 0.0 108.755 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.2 147.18 91.87 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.051 1.834 . . . . 0.0 110.929 178.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.569 ' HB3' ' HA ' ' A' ' 32' ' ' ASN . 6.7 p-80 -48.98 -39.08 25.18 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.092 0.957 . . . . 0.0 113.063 -176.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -68.64 -38.02 80.14 Favored 'General case' 0 N--CA 1.435 -1.192 0 O-C-N 123.491 0.494 . . . . 0.0 110.508 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 35.8 mttp -67.34 -46.14 74.32 Favored 'General case' 0 CA--C 1.478 -1.813 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.549 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.2 mt -53.24 -41.1 41.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 O-C-N 124.054 0.846 . . . . 0.0 109.549 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.2 t -71.75 -37.11 61.3 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.097 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -68.83 -40.67 79.34 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-O 121.315 0.579 . . . . 0.0 110.063 -176.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 37.2 mt -65.65 -51.51 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 CA-C-N 114.548 -1.206 . . . . 0.0 109.786 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.9 mt -58.45 -40.87 83.76 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.345 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -58.65 -28.61 65.85 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 123.381 0.672 . . . . 0.0 111.885 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -119.06 -6.11 10.48 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 115.16 1.541 . . . . 0.0 115.16 -172.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.463 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 130.75 36.28 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.923 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.2 m -127.04 177.02 6.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.5 -152.5 20.39 Favored Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.472 ' HB3' HD11 ' A' ' 16' ' ' LEU . 41.8 mt-10 -84.23 114.06 21.55 Favored 'General case' 0 N--CA 1.425 -1.724 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 174.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.623 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.2 mt -114.55 117.08 54.51 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.402 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -175.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -90.2 111.64 22.87 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.478 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 26.1 mtm -114.21 156.54 24.11 Favored 'General case' 0 C--N 1.269 -2.904 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 175.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.533 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 69.0 mmtt -122.48 124.6 43.97 Favored 'General case' 0 C--N 1.275 -2.671 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.599 HG22 HG12 ' A' ' 55' ' ' ILE . 43.8 p -121.61 141.22 51.32 Favored 'General case' 0 C--N 1.269 -2.935 0 C-N-CA 120.716 -0.393 . . . . 0.0 110.346 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.515 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 43.6 mtm -114.39 167.51 9.51 Favored Pre-proline 0 C--N 1.306 -1.296 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 72.6 Cg_endo -74.71 31.31 0.35 Allowed 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.374 2.05 . . . . 0.0 111.858 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.439 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.16 34.13 19.05 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.912 1.285 . . . . 0.0 110.66 -178.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.779 0 CA-C-N 114.142 -1.39 . . . . 0.0 107.932 178.636 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' A' ' 87' ' ' MET . 21.1 m120 . . . . . 0 CA--C 1.482 -1.647 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 86' ' ' THR . 95.3 t -113.79 126.43 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.675 0 CA-C-O 121.932 0.872 . . . . 0.0 110.213 -174.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.3 m -118.62 121.02 39.19 Favored 'General case' 0 C--N 1.249 -3.79 0 CA-C-N 113.602 -1.635 . . . . 0.0 106.843 176.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -88.45 140.92 28.97 Favored 'General case' 0 N--CA 1.402 -2.871 0 CA-C-N 114.779 -1.1 . . . . 0.0 109.656 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 47' ' ' GLY . 54.5 t -119.0 137.78 51.87 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.594 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.463 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.508 HD11 ' HB3' ' A' ' 81' ' ' GLU . 24.5 tp -124.28 112.39 16.95 Favored 'General case' 0 N--CA 1.386 -3.653 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 172.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.61 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.01 138.75 21.84 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.946 0 N-CA-C 106.244 -1.762 . . . . 0.0 106.244 -179.364 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.28 108.98 19.77 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 67.2 ttt180 -116.58 110.08 42.98 Favored Pre-proline 0 C--N 1.284 -2.247 0 C-N-CA 120.249 -0.581 . . . . 0.0 112.024 -176.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -57.9 -41.02 73.37 Favored 'Trans proline' 0 CA--C 1.546 1.084 0 C-N-CA 122.634 2.223 . . . . 0.0 113.102 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 22' ' ' LEU . 17.6 t70 -171.71 -175.46 1.56 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -177.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.507 HD22 ' O ' ' A' ' 76' ' ' SER . 68.7 mt -81.1 -11.62 59.45 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 125.164 1.386 . . . . 0.0 110.39 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.418 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 76.8 mtt180 -73.74 -16.03 61.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.361 175.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -103.5 138.63 39.95 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -110.67 160.95 16.23 Favored 'General case' 0 C--N 1.277 -2.575 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.656 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -55.91 -55.6 30.7 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 124.635 1.209 . . . . 0.0 111.079 -172.152 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.0 19.54 14.68 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.995 -178.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -146.37 162.81 37.38 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 176.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.2 m -123.21 129.73 51.79 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -114.57 136.97 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -122.43 115.63 22.58 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 61.47 16.0 7.17 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 124.764 1.226 . . . . 0.0 112.091 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.92 3.6 45.59 Favored Glycine 0 C--O 1.219 -0.805 0 C-N-CA 121.002 -0.618 . . . . 0.0 111.689 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.34 123.12 71.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.763 HD13 HG13 ' A' ' 49' ' ' VAL . 57.6 mt -62.44 118.24 4.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 123.553 0.741 . . . . 0.0 109.524 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.2 t -110.56 -16.2 13.71 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.185 -174.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.2 t -153.74 154.34 33.87 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 tp -146.35 147.56 31.45 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -108.72 119.02 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 121.132 0.491 . . . . 0.0 110.573 177.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.6 tmt_? -61.03 131.43 50.59 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.337 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.04 -18.0 58.21 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.342 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.85 161.58 47.91 Favored Glycine 0 N--CA 1.436 -1.327 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -176.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.63 -33.38 39.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.9 0 N-CA-C 113.721 1.008 . . . . 0.0 113.721 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.15 -41.39 99.27 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 111.646 0.239 . . . . 0.0 111.646 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.63 -42.79 95.23 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-O 121.717 0.77 . . . . 0.0 109.204 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 25.1 mtp180 -71.98 -13.19 61.55 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.188 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.41 ' O ' HG13 ' A' ' 15' ' ' VAL . . . -89.01 -13.36 62.33 Favored Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.14 176.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.02 13.81 44.81 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.359 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.763 HG13 HD13 ' A' ' 35' ' ' ILE . 57.9 t -69.67 137.02 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -134.01 147.16 50.93 Favored 'General case' 0 CA--C 1.48 -1.715 0 CA-C-O 121.329 0.585 . . . . 0.0 109.555 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -78.79 141.76 14.98 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.744 0 CA-C-N 114.159 -1.382 . . . . 0.0 109.636 -177.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 24.41 38.33 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m-70 -118.86 134.84 54.89 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.064 -0.568 . . . . 0.0 110.876 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.465 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 47.8 ttm-85 -93.23 123.45 36.52 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.447 HG12 HG22 ' A' ' 86' ' ' THR . 31.4 mt -79.22 125.86 38.73 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 39.2 pt -101.56 -16.44 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.413 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.2 tt0 -158.0 144.26 17.45 Favored 'General case' 0 CA--C 1.486 -1.497 0 C-N-CA 120.079 -0.649 . . . . 0.0 109.29 -176.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 63' ' ' VAL . 79.1 mt -143.87 125.71 10.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 124.567 1.167 . . . . 0.0 108.256 178.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.75 18.73 8.87 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 124.04 0.936 . . . . 0.0 112.602 170.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.29 -0.34 40.6 Favored Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.833 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -119.07 132.78 56.05 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.931 -0.746 . . . . 0.0 110.173 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.3 m -75.32 107.87 7.72 Favored 'General case' 0 N--CA 1.422 -1.828 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.568 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.9 m -99.65 12.64 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 CA-C-O 121.857 0.837 . . . . 0.0 110.118 -172.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -66.48 -20.55 27.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.437 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.1 12.1 12.59 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.648 -0.706 . . . . 0.0 109.541 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 84.8 m -93.6 136.19 24.37 Favored Pre-proline 0 N--CA 1.415 -2.216 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.409 ' O ' HG13 ' A' ' 71' ' ' ILE . 61.9 Cg_endo -74.76 164.42 33.65 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 122.202 1.935 . . . . 0.0 112.553 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -43.19 -55.35 3.99 Favored 'General case' 0 C--O 1.218 -0.593 0 C-N-CA 126.034 1.734 . . . . 0.0 112.147 -178.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -55.27 -45.77 76.15 Favored 'General case' 0 C--N 1.316 -0.883 0 O-C-N 123.925 0.766 . . . . 0.0 111.387 -174.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.418 ' O ' HD12 ' A' ' 74' ' ' ILE . 12.4 mptt -66.12 -54.87 20.22 Favored 'General case' 0 CA--C 1.483 -1.615 0 O-C-N 123.964 0.79 . . . . 0.0 110.739 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.409 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.8 mt -51.98 -42.04 33.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 O-C-N 124.253 0.971 . . . . 0.0 109.857 -179.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.8 t -72.11 -43.29 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.566 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 71.2 t60 -64.87 -43.01 94.34 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.348 0.594 . . . . 0.0 110.184 -177.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.418 HD12 ' O ' ' A' ' 70' ' ' LYS . 14.3 mt -69.09 -42.24 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.524 -178.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 67.4 mt -61.91 -46.15 90.6 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.895 0.379 . . . . 0.0 110.84 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.507 ' O ' HD22 ' A' ' 22' ' ' LEU . 23.0 t -60.7 -27.69 68.07 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 124.209 1.004 . . . . 0.0 111.802 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -87.98 -36.56 16.99 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 120.626 -0.43 . . . . 0.0 112.045 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.481 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -77.93 136.33 37.99 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 113.401 0.889 . . . . 0.0 113.401 -172.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.467 HG12 HD23 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -131.98 175.26 11.7 Favored 'Isoleucine or valine' 0 C--O 1.245 0.849 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 175.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.57 -154.75 25.23 Favored Glycine 0 CA--C 1.483 -1.911 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.508 ' HB3' HD11 ' A' ' 16' ' ' LEU . 51.5 mt-10 -75.0 108.97 8.07 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 174.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 17' ' ' ILE . 59.9 mt -112.36 118.15 57.06 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -84.54 130.53 34.73 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.458 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.0 mtm -135.34 152.31 51.34 Favored 'General case' 0 C--N 1.282 -2.344 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 170.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 8.9 mmmt -122.28 121.35 36.56 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.481 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.7 p -119.27 153.0 35.71 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.093 -176.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.541 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 50.3 mtm -123.06 169.13 10.52 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 7.7 Cg_exo -74.3 35.64 0.4 Allowed 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 123.158 2.572 . . . . 0.0 112.333 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.465 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.02 59.87 2.63 Favored 'General case' 0 N--CA 1.433 -1.302 0 C-N-CA 126.072 1.749 . . . . 0.0 112.958 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.161 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 171.316 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 . . . . . 0 CA--C 1.493 -1.212 0 CA-C-O 121.93 0.871 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.476 HG11 ' HD2' ' A' ' 85' ' ' LYS . 50.1 t -145.2 128.13 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 70.1 m -110.54 107.27 16.84 Favored 'General case' 0 C--N 1.245 -3.974 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 176.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 32.8 m -78.96 130.99 36.18 Favored 'General case' 0 N--CA 1.396 -3.132 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.484 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.8 t -111.02 137.54 43.05 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.717 0 CA-C-N 114.468 -1.242 . . . . 0.0 108.124 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.4 tp -121.92 111.87 17.61 Favored 'General case' 1 N--CA 1.374 -4.266 0 C-N-CA 119.062 -1.055 . . . . 0.0 108.353 172.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.521 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.25 128.61 48.34 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.292 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 178.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 67.4 mtp180 -115.04 102.14 9.66 Favored 'General case' 0 CA--C 1.457 -2.62 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 174.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.4 ttt180 -98.64 123.61 49.26 Favored Pre-proline 0 C--N 1.262 -3.214 0 CA-C-N 112.999 -1.91 . . . . 0.0 111.048 -174.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.39 -55.63 2.04 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 122.553 2.168 . . . . 0.0 113.457 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -166.15 -178.22 4.51 Favored 'General case' 0 C--O 1.247 0.963 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 -175.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.41 HD23 HG12 ' A' ' 79' ' ' VAL . 46.0 mt -68.31 -16.55 63.99 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -175.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -84.37 -12.25 54.83 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.876 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -93.48 128.42 39.57 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 176.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.289 0.0 OUTLIER -103.3 158.98 15.95 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.571 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -58.91 -53.69 55.6 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.175 -168.318 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.01 26.7 8.24 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.338 -1.41 . . . . 0.0 112.789 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -145.79 154.26 41.83 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 173.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 10.2 m -106.78 122.12 45.74 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -114.71 139.91 38.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.224 -0.59 . . . . 0.0 110.385 -178.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.413 ' HG2' ' HB2' ' A' ' 36' ' ' CYS . 16.8 pt20 -130.57 126.3 36.36 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.061 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 16.4 m120 62.0 6.85 1.86 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 124.391 1.076 . . . . 0.0 112.945 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 6.45 53.36 Favored Glycine 0 C--O 1.214 -1.102 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -175.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.42 128.12 70.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.656 HD13 HG13 ' A' ' 49' ' ' VAL . 52.6 mt -70.21 116.11 10.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 C-N-CA 124.407 1.083 . . . . 0.0 110.49 -177.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.413 ' HB2' ' HG2' ' A' ' 31' ' ' GLN . 36.3 t -99.53 -24.41 14.77 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.064 -175.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 34.1 t -157.12 152.39 26.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 -178.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -133.84 140.51 46.92 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -94.6 115.68 27.85 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.437 ' HD2' ' N ' ' A' ' 41' ' ' GLY . 1.7 tmm_? -65.62 131.3 46.03 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' ' HD2' ' A' ' 40' ' ' ARG . . . 91.89 -4.79 78.87 Favored Glycine 0 N--CA 1.437 -1.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.303 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.25 170.33 40.89 Favored Glycine 0 C--O 1.253 1.292 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -61.8 -34.85 64.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.935 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.74 -43.19 94.36 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.196 0.31 . . . . 0.0 111.659 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -65.91 -41.59 91.23 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.094 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -66.28 -35.29 80.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.943 178.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.74 -29.76 75.21 Favored Glycine 0 N--CA 1.44 -1.065 0 CA-C-N 115.177 -0.92 . . . . 0.0 112.641 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 114.67 14.65 8.59 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.213 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.656 HG13 HD13 ' A' ' 35' ' ' ILE . 68.9 t -70.24 137.69 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.458 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.1 mmt85 -136.02 145.16 45.76 Favored 'General case' 0 CA--C 1.477 -1.853 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -178.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.1 t -74.23 139.9 18.5 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.84 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.608 -177.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.15 9.15 65.82 Favored Glycine 0 N--CA 1.436 -1.336 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -178.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.543 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -101.93 148.25 25.56 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.275 -0.462 . . . . 0.0 111.412 -179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 70.7 ttt180 -105.46 123.39 47.81 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.65 HD13 HG22 ' A' ' 86' ' ' THR . 24.5 mm -74.11 117.98 18.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.439 HG13 ' HB2' ' A' ' 85' ' ' LYS . 24.5 pt -105.28 -20.34 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.681 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 179.433 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.3 tt0 -151.84 146.48 25.71 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.49 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.0 mt -143.56 121.69 6.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 O-C-N 124.362 1.039 . . . . 0.0 108.647 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.435 HD22 HG12 ' A' ' 82' ' ' ILE . 5.1 t-20 63.93 8.67 4.04 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 125.556 1.542 . . . . 0.0 111.953 173.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.13 1.35 23.74 Favored Glycine 0 N--CA 1.43 -1.754 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.615 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -116.58 136.56 52.87 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 117.797 0.799 . . . . 0.0 109.92 177.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.8 m -75.56 108.99 8.75 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.539 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.0 m -102.96 11.48 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.697 0 CA-C-O 122.145 0.974 . . . . 0.0 109.423 -174.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 p -70.93 -14.78 18.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 114.332 -1.304 . . . . 0.0 110.093 -179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.95 13.68 13.1 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.264 179.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.539 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.1 m -101.32 135.26 19.91 Favored Pre-proline 0 N--CA 1.416 -2.163 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -66.21 156.15 66.33 Favored 'Trans proline' 0 C--O 1.244 0.821 0 C-N-CA 121.916 1.744 . . . . 0.0 111.743 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -43.11 -52.5 5.4 Favored 'General case' 0 C--O 1.221 -0.442 0 C-N-CA 125.525 1.53 . . . . 0.0 112.903 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -58.33 -42.74 87.48 Favored 'General case' 0 C--N 1.311 -1.087 0 O-C-N 123.917 0.761 . . . . 0.0 111.068 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.552 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -66.8 -53.77 29.45 Favored 'General case' 0 C--O 1.202 -1.413 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 178.53 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 53.4 mt -50.14 -42.29 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-O 120.984 0.421 . . . . 0.0 110.338 178.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.1 t -70.03 -37.9 73.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.982 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -69.16 -39.71 78.62 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.42 -53.44 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 95.6 mt -60.58 -32.79 71.87 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-O 120.853 0.358 . . . . 0.0 111.531 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.8 t -63.72 -37.07 85.97 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 123.362 0.665 . . . . 0.0 111.282 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -110.24 -9.98 14.65 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -171.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.49 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.01 129.87 35.57 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 122.156 -0.34 . . . . 0.0 110.826 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.428 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -128.75 176.26 8.43 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 177.648 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 89.69 -161.21 29.48 Favored Glycine 0 CA--C 1.498 -0.98 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -75.57 108.66 8.54 Favored 'General case' 0 C--O 1.249 1.074 0 C-N-CA 124.048 0.939 . . . . 0.0 108.903 175.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.487 HD12 HG22 ' A' ' 17' ' ' ILE . 72.3 mt -116.25 117.52 55.76 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.42 -174.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 34.5 m80 -84.76 117.0 23.57 Favored 'General case' 0 CA--C 1.486 -1.491 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.505 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 14.2 mtp -118.49 145.18 45.48 Favored 'General case' 0 C--N 1.25 -3.735 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' HG11 ' A' ' 12' ' ' VAL . 69.3 mmtt -118.09 123.97 46.92 Favored 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.65 HG22 HD13 ' A' ' 55' ' ' ILE . 68.0 p -118.97 139.86 50.97 Favored 'General case' 0 C--N 1.27 -2.852 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.903 178.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.46 ' HG2' HG22 ' A' ' 12' ' ' VAL . 90.6 mtp -113.58 166.54 11.07 Favored Pre-proline 0 C--N 1.299 -1.626 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 178.287 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -72.74 31.49 0.29 Allowed 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 123.047 2.498 . . . . 0.0 112.49 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 56.33 57.23 5.1 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 122.536 1.16 . . . . 0.0 111.324 -177.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 113.492 -1.685 . . . . 0.0 107.321 176.757 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 . . . . . 0 CA--C 1.492 -1.26 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.424 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 57.2 t -114.88 126.88 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.946 0 CA-C-N 114.016 -1.447 . . . . 0.0 108.898 -173.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 53.7 m -116.05 113.63 23.45 Favored 'General case' 1 C--N 1.241 -4.137 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.627 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.5 m -82.39 138.65 34.4 Favored 'General case' 0 N--CA 1.406 -2.663 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.151 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 49' ' ' VAL . 56.2 t -116.04 139.77 41.1 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.796 0 CA-C-N 114.574 -1.194 . . . . 0.0 108.582 178.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.52 HD11 ' HB3' ' A' ' 81' ' ' GLU . 17.8 tp -125.32 116.89 22.63 Favored 'General case' 0 N--CA 1.404 -2.762 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 81' ' ' GLU . 0.3 OUTLIER -98.11 141.63 15.82 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.782 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.859 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -113.61 102.98 10.79 Favored 'General case' 0 CA--C 1.489 -1.4 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 69.6 ttt180 -111.42 101.66 51.26 Favored Pre-proline 0 C--N 1.274 -2.686 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.765 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -58.6 -33.85 98.45 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.618 2.212 . . . . 0.0 113.985 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -169.15 175.58 5.64 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.516 HD23 HG12 ' A' ' 79' ' ' VAL . 63.4 mt -65.01 -18.23 65.12 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.9 mtt85 -74.25 -12.38 60.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 121.459 0.647 . . . . 0.0 112.084 178.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -99.54 95.75 7.2 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 174.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -84.58 152.29 23.96 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.763 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -41.68 -60.9 1.21 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 126.068 1.747 . . . . 0.0 111.654 -172.541 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 109.64 -3.81 30.79 Favored Glycine 0 N--CA 1.432 -1.614 0 C-N-CA 119.828 -1.177 . . . . 0.0 112.793 176.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -117.39 156.77 27.32 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 122.191 -0.593 . . . . 0.0 109.663 178.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.0 t -108.82 131.43 54.99 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.23 134.53 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 -177.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.457 ' HG3' ' HB2' ' A' ' 36' ' ' CYS 0.266 1.0 OUTLIER -126.17 120.39 29.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.046 0.45 . . . . 0.0 110.84 175.258 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 65.09 13.03 8.42 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 124.259 1.023 . . . . 0.0 110.81 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.68 -1.96 52.75 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.383 -177.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -108.08 121.57 61.25 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 O-C-N 122.315 -0.521 . . . . 0.0 110.303 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.724 HD13 HG13 ' A' ' 49' ' ' VAL . 64.3 mt -60.32 117.11 2.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 C-N-CA 124.746 1.219 . . . . 0.0 110.274 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.457 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 34.0 t -98.18 -44.03 6.76 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.689 -174.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 36.4 p -142.26 155.4 45.23 Favored 'General case' 0 C--O 1.248 1.011 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -131.91 146.24 51.99 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 123.25 0.62 . . . . 0.0 110.008 -177.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.8 ttt -90.3 112.48 24.06 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.446 ' HD3' ' N ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -75.57 123.73 26.0 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.759 -172.01 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.446 ' N ' ' HD3' ' A' ' 40' ' ' ARG . . . 103.65 -14.96 53.42 Favored Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.308 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.11 178.08 54.11 Favored Glycine 0 C--O 1.253 1.282 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -178.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 pt -53.72 -37.59 32.53 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.07 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.24 93.46 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -63.92 -46.5 84.51 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.464 0.649 . . . . 0.0 109.603 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -76.08 -17.4 59.64 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.979 -179.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -73.9 -29.38 63.1 Favored Glycine 0 N--CA 1.432 -1.569 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.794 175.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 111.43 12.19 15.76 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.027 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.724 HG13 HD13 ' A' ' 35' ' ' ILE . 73.1 t -67.94 134.26 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.6 mmt85 -131.03 142.5 50.32 Favored 'General case' 0 CA--C 1.487 -1.453 0 CA-C-O 121.155 0.503 . . . . 0.0 109.909 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 41.7 t -79.05 137.26 22.15 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.21 -176.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.36 22.71 33.82 Favored Glycine 0 CA--C 1.5 -0.865 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -175.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m170 -116.59 135.34 53.89 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.873 -0.664 . . . . 0.0 112.192 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.583 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 33.8 ttm-85 -92.59 122.69 35.27 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.565 HG12 HG22 ' A' ' 86' ' ' THR . 30.1 mt -80.64 127.82 39.15 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 35.2 pt -107.0 -16.5 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 84' ' ' MET . 32.1 tt0 -154.98 144.62 21.42 Favored 'General case' 0 CA--C 1.48 -1.717 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.382 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 67.5 mt -139.52 125.88 23.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 64.59 6.68 3.31 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.598 1.159 . . . . 0.0 112.31 173.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.4 -9.63 19.93 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.718 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.474 ' O ' HG13 ' A' ' 63' ' ' VAL . 17.4 pt20 -108.11 126.09 52.35 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-O 120.961 0.41 . . . . 0.0 110.989 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 31.9 t -64.85 113.46 3.83 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 177.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.618 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 30.9 m -110.61 13.53 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 121.169 0.509 . . . . 0.0 109.986 -176.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -67.54 -17.65 22.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 115.216 -0.902 . . . . 0.0 112.714 -173.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.64 16.64 5.88 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.708 0.766 . . . . 0.0 109.124 177.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.618 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.2 m -84.35 141.46 39.66 Favored Pre-proline 0 N--CA 1.416 -2.125 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.609 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.437 ' O ' HG13 ' A' ' 71' ' ' ILE . 71.6 Cg_exo -48.96 143.71 17.07 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.907 2.405 . . . . 0.0 112.247 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -49.91 -50.83 44.75 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 124.757 1.223 . . . . 0.0 111.529 -178.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -68.23 -32.23 72.29 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.1 mttm -62.91 -53.84 47.84 Favored 'General case' 0 CA--C 1.48 -1.718 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.793 176.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.437 HG13 ' O ' ' A' ' 67' ' ' PRO . 58.1 mt -50.01 -41.9 18.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 124.016 0.822 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 65.7 t -72.93 -37.19 53.47 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.533 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -65.23 -45.06 86.17 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 123.534 0.733 . . . . 0.0 109.594 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.74 -49.39 84.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.252 0 O-C-N 123.644 0.59 . . . . 0.0 109.412 178.136 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.2 mt -62.15 -45.31 94.01 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.7 t -61.98 -27.4 68.83 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 123.622 0.769 . . . . 0.0 112.144 -178.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -103.09 -13.23 16.9 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.666 0.987 . . . . 0.0 113.666 -176.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 134.63 34.16 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.047 -177.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.516 HG12 HD23 ' A' ' 22' ' ' LEU . 1.3 m -128.49 175.8 9.28 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 176.05 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.38 -159.66 27.46 Favored Glycine 0 N--CA 1.432 -1.605 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.52 ' HB3' HD11 ' A' ' 16' ' ' LEU . 44.9 mt-10 -79.35 113.4 17.46 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 173.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 67.7 mt -115.65 118.56 59.17 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.942 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.763 -172.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -81.18 135.94 35.82 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.497 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.7 mtm -133.34 150.63 51.85 Favored 'General case' 0 C--N 1.263 -3.178 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.424 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 66.1 mmtt -117.72 121.26 40.37 Favored 'General case' 0 C--N 1.262 -3.201 0 N-CA-C 106.238 -1.764 . . . . 0.0 106.238 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.566 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.2 p -122.6 146.24 47.62 Favored 'General case' 0 C--N 1.264 -3.116 0 C-N-CA 120.258 -0.577 . . . . 0.0 110.479 -178.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.495 ' C ' ' H ' ' A' ' 89' ' ' ALA . 58.3 mtm -120.41 168.16 11.17 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_exo -68.2 32.42 0.15 Allowed 'Trans proline' 0 N--CA 1.509 2.41 0 C-N-CA 123.49 2.794 . . . . 0.0 112.668 176.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.583 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 67.29 27.36 8.31 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 126.442 1.897 . . . . 0.0 113.422 177.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.409 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.483 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 . . . . . 0 CA--C 1.491 -1.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.619 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.453 HG22 ' HG2' ' A' ' 87' ' ' MET . 54.0 t -139.46 129.19 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.149 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 89.0 m -119.41 108.53 14.68 Favored 'General case' 0 N--CA 1.39 -3.46 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.185 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 18.6 m -78.69 134.25 37.12 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.934 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.412 HG11 ' CG2' ' A' ' 49' ' ' VAL . 51.3 t -115.86 136.86 51.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.137 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.378 -177.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.474 HD11 ' HB3' ' A' ' 81' ' ' GLU . 25.9 tp -118.81 110.67 17.5 Favored 'General case' 0 N--CA 1.4 -2.958 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 174.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -99.23 137.89 25.31 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.312 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.219 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.12 103.38 12.57 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.455 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.1 ttt180 -109.03 111.53 60.45 Favored Pre-proline 0 C--N 1.291 -1.947 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.315 -177.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -58.93 -44.12 37.91 Favored 'Trans proline' 0 CA--C 1.549 1.241 0 C-N-CA 122.311 2.007 . . . . 0.0 113.743 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -167.21 -176.99 3.51 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -176.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.4 HD23 HG12 ' A' ' 79' ' ' VAL . 65.9 mt -76.88 -10.02 59.08 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 124.892 1.277 . . . . 0.0 110.292 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 34.5 mtt180 -69.03 -19.35 64.11 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 114.295 -1.32 . . . . 0.0 108.064 176.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -114.21 157.81 22.18 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 104.997 -2.223 . . . . 0.0 104.997 177.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -121.63 -168.42 1.69 Allowed 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.596 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -75.25 -57.61 3.79 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -175.58 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 110.06 20.21 7.67 Favored Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.788 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -143.84 148.8 36.03 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.0 t -99.84 131.43 45.81 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.54 138.45 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -176.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -117.94 105.91 12.4 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 176.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 61.29 23.23 13.48 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 122.015 0.912 . . . . 0.0 110.846 177.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.91 -4.91 39.24 Favored Glycine 0 N--CA 1.439 -1.125 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.413 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.425 HG13 ' HB2' ' A' ' 54' ' ' ARG . 2.7 mp -105.93 120.13 56.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 O-C-N 122.18 -0.6 . . . . 0.0 110.013 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.774 HD13 HG13 ' A' ' 49' ' ' VAL . 55.1 mt -61.35 115.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 C-N-CA 123.447 0.699 . . . . 0.0 110.244 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -98.23 -31.77 11.9 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.042 -175.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.1 m -150.6 155.05 38.65 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.9 tp -136.7 138.88 41.5 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 123.534 0.734 . . . . 0.0 109.525 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 49.4 ttm -91.48 119.29 31.32 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.9 131.76 45.62 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.92 -8.45 79.78 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.34 162.98 37.02 Favored Glycine 0 N--CA 1.432 -1.582 0 C-N-CA 121.318 -0.467 . . . . 0.0 112.167 -178.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -30.43 41.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -179.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.02 -42.44 89.64 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.69 0.281 . . . . 0.0 110.889 178.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -63.71 -41.48 98.08 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.63 -8.44 55.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.673 -1.149 . . . . 0.0 111.281 178.161 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.55 -22.52 28.73 Favored Glycine 0 N--CA 1.429 -1.794 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 178.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.02 8.5 29.54 Favored Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.959 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.774 HG13 HD13 ' A' ' 35' ' ' ILE . 58.5 t -65.59 135.92 27.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 12.6 mmm180 -133.42 146.12 50.9 Favored 'General case' 0 CA--C 1.48 -1.738 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 77.0 t -77.37 139.9 17.95 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 114.181 -1.372 . . . . 0.0 109.202 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.4 -2.04 62.7 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -177.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.524 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 10.2 m170 -95.43 140.83 29.74 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 115.041 -0.58 . . . . 0.0 110.928 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.441 ' HB3' ' HA ' ' A' ' 89' ' ' ALA . 25.8 ttt85 -101.18 131.83 46.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 173.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.522 HG12 HG22 ' A' ' 86' ' ' THR . 33.0 mt -82.99 127.27 39.84 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 30.9 pt -104.3 -15.34 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.268 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.944 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.404 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.7 tt0 -155.9 144.34 20.12 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 119.763 -0.775 . . . . 0.0 108.984 -174.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.1 mt -140.67 121.83 14.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 124.293 0.996 . . . . 0.0 108.475 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 68.29 7.68 6.09 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 124.095 0.958 . . . . 0.0 111.769 172.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.4 2.09 33.13 Favored Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.397 -178.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 21.1 pt20 -113.88 125.31 53.91 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 177.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 40.1 t -63.82 119.14 9.42 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.469 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 24.3 m -114.35 14.12 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.123 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.5 p -70.12 -20.76 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.802 -176.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.66 9.56 16.51 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.751 0.786 . . . . 0.0 109.453 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 76.8 m -86.37 138.51 34.11 Favored Pre-proline 0 N--CA 1.407 -2.621 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.742 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.29 158.09 58.65 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.185 1.923 . . . . 0.0 112.837 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 45.3 p-80 -48.6 -49.65 35.94 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.121 1.368 . . . . 0.0 114.042 -174.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.0 -37.89 78.96 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 120.451 0.167 . . . . 0.0 110.599 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 9.9 mttm -61.9 -49.85 74.53 Favored 'General case' 0 CA--C 1.492 -1.258 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 177.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.8 mt -54.32 -42.56 58.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 O-C-N 123.896 0.748 . . . . 0.0 110.173 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.34 -35.88 69.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.544 178.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.8 t-80 -68.9 -42.92 76.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.237 0.541 . . . . 0.0 109.581 -177.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 35.7 mt -63.71 -47.19 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.635 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.882 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.2 mt -61.32 -45.99 92.12 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.399 176.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -62.32 -27.49 69.08 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 123.174 0.59 . . . . 0.0 111.887 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -104.65 1.34 29.41 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -177.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.455 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -107.04 134.61 49.93 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.967 178.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.448 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.7 m -129.58 -177.34 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -157.14 30.58 Favored Glycine 0 CA--C 1.484 -1.886 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.023 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.474 ' HB3' HD11 ' A' ' 16' ' ' LEU . 50.4 mt-10 -80.52 112.89 18.3 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.167 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.653 ' HB ' HG22 ' A' ' 17' ' ' ILE . 56.5 mt -117.3 118.12 57.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -173.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -90.49 118.43 29.96 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.404 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 24.3 mtm -117.54 158.42 24.61 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.298 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.3 mtmm -123.86 121.97 36.77 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.524 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.2 p -119.86 150.02 41.13 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.624 -175.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.466 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.6 mtp -130.13 168.63 15.96 Favored Pre-proline 0 C--N 1.313 -0.978 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 57.7 Cg_endo -71.04 29.5 0.22 Allowed 'Trans proline' 0 CA--C 1.565 2.058 0 C-N-CA 122.762 2.308 . . . . 0.0 112.61 175.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.466 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.0 -2.36 2.37 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 126.384 1.874 . . . . 0.0 112.59 179.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.474 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 178.235 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 . . . . . 0 N--CA 1.444 -0.736 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.3 t -133.13 134.86 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 123.554 0.742 . . . . 0.0 109.273 -174.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 34.4 m -121.74 120.13 33.76 Favored 'General case' 0 N--CA 1.391 -3.388 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 176.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.6 m -90.67 141.08 29.16 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.127 0.965 . . . . 0.0 110.091 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.608 HG11 ' HE2' ' A' ' 84' ' ' MET . 43.8 t -118.42 135.96 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.06 0 CA-C-N 114.425 -1.261 . . . . 0.0 108.857 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.451 HD12 ' O ' ' A' ' 82' ' ' ILE . 24.9 tp -119.86 110.38 16.68 Favored 'General case' 0 N--CA 1.382 -3.87 0 C-N-CA 119.18 -1.008 . . . . 0.0 108.797 173.044 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.476 HG22 HD12 ' A' ' 82' ' ' ILE . 0.3 OUTLIER -98.14 125.94 51.28 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.021 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.081 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 82.1 mtp180 -113.29 102.77 10.66 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.541 HH12 ' HA ' ' A' ' 76' ' ' SER . 48.2 ttt180 -98.3 112.8 63.04 Favored Pre-proline 0 C--N 1.269 -2.925 0 CA-C-N 112.77 -2.014 . . . . 0.0 110.846 -174.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.37 -39.2 86.19 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.833 2.355 . . . . 0.0 113.909 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -166.62 -178.72 4.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -177.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.545 HD23 ' CG1' ' A' ' 79' ' ' VAL . 52.8 mt -75.36 -18.09 60.06 Favored 'General case' 0 CA--C 1.495 -1.141 0 C-N-CA 124.954 1.301 . . . . 0.0 111.024 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.59 ' HD2' ' N ' ' A' ' 23' ' ' ARG . 4.8 mpt_? -82.02 -11.5 58.79 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.923 176.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -99.16 89.3 4.19 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.682 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.53 165.79 23.97 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 123.639 0.587 . . . . 0.0 110.938 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -69.31 -58.8 3.55 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.46 -169.785 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 103.19 38.28 2.9 Favored Glycine 0 N--CA 1.424 -2.114 0 C-N-CA 120.062 -1.066 . . . . 0.0 111.933 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -154.2 153.63 32.1 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 174.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 m -109.02 130.88 55.49 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -118.72 134.07 63.51 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 CA-C-O 121.36 0.6 . . . . 0.0 111.089 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -113.56 111.64 22.23 Favored 'General case' 0 C--N 1.312 -1.053 0 O-C-N 121.807 -0.558 . . . . 0.0 109.591 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.6 m-20 59.86 12.8 3.22 Favored 'General case' 0 N--CA 1.501 2.097 0 C-N-CA 125.076 1.35 . . . . 0.0 112.21 -177.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.59 0.42 30.79 Favored Glycine 0 C--O 1.215 -1.092 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.682 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 2.9 mp -108.17 118.33 55.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 122.438 -0.448 . . . . 0.0 109.878 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.779 HD13 HG13 ' A' ' 49' ' ' VAL . 46.8 mt -59.15 122.38 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 123.888 0.875 . . . . 0.0 110.861 178.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 13.4 t -103.29 -31.75 9.91 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.983 -176.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 55.1 p -151.17 160.62 43.75 Favored 'General case' 0 C--O 1.245 0.862 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 54.5 tp -137.97 129.46 27.95 Favored 'General case' 0 N--CA 1.443 -0.812 0 O-C-N 123.785 0.678 . . . . 0.0 109.867 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -76.03 112.54 12.57 Favored 'General case' 0 C--N 1.317 -0.837 0 O-C-N 123.782 0.676 . . . . 0.0 109.878 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.427 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.3 tpp85 -55.32 125.0 18.92 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.564 1.146 . . . . 0.0 111.005 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.02 -7.63 81.73 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.311 -0.859 . . . . 0.0 113.408 177.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.12 171.6 55.15 Favored Glycine 0 C--O 1.246 0.888 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.501 -176.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.5 pt -62.15 -33.04 56.59 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -57.16 -46.12 83.03 Favored 'General case' 0 N--CA 1.447 -0.608 0 CA-C-O 120.909 0.385 . . . . 0.0 110.445 178.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.427 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 36.2 tt0 -62.88 -47.15 84.55 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.573 0.701 . . . . 0.0 109.758 179.113 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 40.5 mtt180 -69.62 -18.06 63.57 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.807 -178.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.24 -24.81 50.49 Favored Glycine 0 N--CA 1.438 -1.187 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.001 176.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.95 12.23 12.75 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 179.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.779 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -68.57 137.28 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -135.61 150.25 49.6 Favored 'General case' 0 CA--C 1.474 -1.953 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.15 141.2 15.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.066 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.98 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.14 25.92 42.53 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -177.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.5 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.2 m170 -117.48 132.87 56.48 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.124 -0.538 . . . . 0.0 110.944 179.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 44.4 ttp180 -95.79 121.66 37.74 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.527 HG12 HG22 ' A' ' 86' ' ' THR . 44.7 mt -75.92 122.28 29.62 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.418 HG22 ' CG2' ' A' ' 64' ' ' VAL 0.265 2.4 pp -104.94 -5.93 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.76 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -178.314 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 26.6 tt0 -169.34 143.15 2.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.416 -179.325 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 84' ' ' MET . 88.4 mt -138.57 124.84 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 66.34 3.32 2.74 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.5 1.12 . . . . 0.0 112.436 172.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.26 -0.81 22.4 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.084 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.45 ' O ' HG13 ' A' ' 63' ' ' VAL . 12.7 pt20 -115.41 125.97 53.81 Favored 'General case' 0 CA--C 1.498 -1.022 0 O-C-N 122.273 -0.545 . . . . 0.0 110.166 176.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 m -71.03 109.6 5.22 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.519 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.6 m -101.77 18.28 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.993 0 CA-C-O 121.914 0.864 . . . . 0.0 110.538 -172.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.418 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.3 p -75.59 -8.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.91 -177.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -126.44 22.89 6.99 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.022 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.519 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 89.3 m -109.18 130.39 22.8 Favored Pre-proline 0 N--CA 1.407 -2.614 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -66.34 158.22 56.19 Favored 'Trans proline' 0 CA--C 1.543 0.925 0 C-N-CA 122.233 1.955 . . . . 0.0 112.797 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 33.1 t60 -42.86 -55.85 3.5 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.932 1.293 . . . . 0.0 113.5 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -65.83 -37.67 86.84 Favored 'General case' 0 N--CA 1.436 -1.16 0 O-C-N 123.42 0.45 . . . . 0.0 111.32 -173.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 6.5 mttm -61.75 -52.02 65.96 Favored 'General case' 0 N--CA 1.424 -1.728 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.345 174.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 55.7 mt -52.02 -45.61 41.14 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 O-C-N 124.026 0.829 . . . . 0.0 110.398 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.2 t -69.07 -34.04 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.818 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 17.3 t60 -72.41 -43.17 64.25 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 -176.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.6 mt -60.5 -49.75 83.1 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 CA-C-N 114.737 -1.12 . . . . 0.0 109.873 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.2 mt -58.96 -46.76 87.27 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.76 177.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.541 ' HA ' HH12 ' A' ' 19' ' ' ARG . 25.0 m -63.06 -26.5 68.87 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 113.08 0.77 . . . . 0.0 113.08 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.8 -18.85 20.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -98.8 133.92 42.43 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.535 0.207 . . . . 0.0 111.221 -176.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.545 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.2 m -134.27 179.65 4.12 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 87.88 -150.22 22.13 Favored Glycine 0 CA--C 1.497 -1.065 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.87 114.56 18.88 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.476 HD12 HG22 ' A' ' 17' ' ' ILE . 79.5 mt -117.88 118.03 56.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -90.85 115.75 28.15 Favored 'General case' 0 CA--C 1.463 -2.376 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.608 ' HE2' HG11 ' A' ' 15' ' ' VAL . 7.8 ttp -122.56 138.47 54.56 Favored 'General case' 1 N--CA 1.376 -4.148 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.816 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 32.9 mtmt -121.26 131.86 54.47 Favored 'General case' 0 CA--C 1.444 -3.133 0 C-N-CA 119.497 -0.881 . . . . 0.0 108.784 -176.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.527 HG22 HG12 ' A' ' 55' ' ' ILE . 49.7 p -125.97 155.16 41.81 Favored 'General case' 0 C--N 1.271 -2.825 0 O-C-N 123.993 0.808 . . . . 0.0 110.369 -174.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.472 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.8 mtp -120.47 170.55 6.95 Favored Pre-proline 0 C--N 1.296 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -75.98 29.83 0.39 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.85 2.367 . . . . 0.0 111.077 176.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.472 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 60.89 31.6 20.01 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.249 1.42 . . . . 0.0 110.624 -179.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.178 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.636 178.733 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.441 -0.885 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.1 t -120.31 132.15 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.17 0 CA-C-O 122.083 0.944 . . . . 0.0 109.727 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -127.12 115.55 19.31 Favored 'General case' 0 N--CA 1.387 -3.616 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.2 m -80.97 140.95 34.93 Favored 'General case' 0 N--CA 1.395 -3.186 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.813 -176.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.429 HG11 HG22 ' A' ' 49' ' ' VAL . 53.4 t -118.12 139.29 45.89 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.943 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.248 177.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.539 HD11 ' HB3' ' A' ' 81' ' ' GLU . 7.5 tp -126.42 105.41 8.75 Favored 'General case' 0 N--CA 1.404 -2.732 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.856 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.3 OUTLIER -99.71 134.8 37.76 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -178.863 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 -113.75 117.32 31.17 Favored 'General case' 0 C--N 1.294 -1.831 0 CA-C-O 121.954 0.883 . . . . 0.0 112.114 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.649 HH21 ' HA ' ' A' ' 25' ' ' GLN . 27.2 ttm180 -119.2 113.1 35.6 Favored Pre-proline 0 C--N 1.284 -2.272 0 CA-C-N 113.961 -1.472 . . . . 0.0 110.957 -178.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -61.74 -31.68 86.04 Favored 'Trans proline' 0 CA--C 1.547 1.16 0 C-N-CA 122.653 2.235 . . . . 0.0 113.091 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -178.8 173.68 1.22 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' HD3' ' A' ' 19' ' ' ARG . 47.5 mt -65.28 -9.83 27.32 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 115.666 1.728 . . . . 0.0 115.666 -173.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -76.16 -11.59 59.96 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.564 0.697 . . . . 0.0 110.794 176.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -107.08 98.56 8.2 Favored 'General case' 0 N--CA 1.423 -1.812 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . 0.649 ' HA ' HH21 ' A' ' 19' ' ' ARG . 2.5 pt20 -86.08 164.28 17.4 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.133 -1.427 . . . . 0.0 112.177 -177.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.638 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.58 -64.86 0.69 Allowed 'General case' 0 C--N 1.32 -0.698 0 O-C-N 124.984 1.427 . . . . 0.0 110.714 -173.353 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 101.69 29.48 6.21 Favored Glycine 0 N--CA 1.426 -2.021 0 C-N-CA 120.262 -0.971 . . . . 0.0 111.464 -176.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -152.35 167.14 29.66 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.4 m -131.25 140.92 49.92 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.53 121.41 50.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.902 0.858 . . . . 0.0 113.184 -173.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -120.07 128.08 53.16 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 64.2 -1.14 0.74 Allowed 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 124.451 1.1 . . . . 0.0 112.634 -174.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.81 -3.74 34.1 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -175.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -101.09 131.12 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.104 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 49' ' ' VAL . 71.4 mt -67.1 114.25 3.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 124.248 1.019 . . . . 0.0 110.615 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -85.54 -51.88 6.2 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.914 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.9 p -137.51 151.07 48.05 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.08 -176.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.63 141.37 46.58 Favored 'General case' 0 C--N 1.31 -1.109 0 O-C-N 123.779 0.674 . . . . 0.0 109.646 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.1 ttt -83.84 115.76 22.41 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -73.92 128.29 35.12 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 -177.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.4 -4.4 85.26 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.992 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.0 173.41 46.78 Favored Glycine 0 C--O 1.242 0.635 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.389 -178.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -61.84 -29.85 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.43 -48.69 71.89 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.309 177.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -65.93 -43.52 87.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.917 0.389 . . . . 0.0 110.796 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.5 mtp85 -72.37 -17.37 61.83 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 121.52 0.676 . . . . 0.0 110.153 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.03 -20.6 60.66 Favored Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.052 -0.976 . . . . 0.0 111.395 175.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.57 4.63 24.85 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 120.286 -0.959 . . . . 0.0 113.516 176.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 35' ' ' ILE . 69.7 t -64.43 142.53 16.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 9.9 mmt180 -140.33 139.78 35.49 Favored 'General case' 0 CA--C 1.491 -1.324 0 CA-C-O 121.257 0.551 . . . . 0.0 110.809 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.3 t -75.13 136.39 25.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 114.499 -1.228 . . . . 0.0 109.348 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.1 10.5 64.3 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -176.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.7 m170 -104.33 143.71 32.62 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.048 0.451 . . . . 0.0 110.945 177.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.518 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 76.0 ttt180 -103.78 114.97 29.63 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.017 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 86' ' ' THR . 23.1 mt -77.31 126.57 37.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-O 121.093 0.473 . . . . 0.0 110.048 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.44 HG22 ' CG2' ' A' ' 64' ' ' VAL . 2.4 pp -109.9 -5.43 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.945 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.985 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 17.2 tt0 -161.48 145.29 12.82 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.519 HD12 HG21 ' A' ' 63' ' ' VAL . 76.2 mt -145.12 120.5 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 O-C-N 124.454 1.096 . . . . 0.0 109.194 176.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 59.65 25.95 14.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.55 1.14 . . . . 0.0 112.276 169.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.39 -7.58 30.44 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 119.883 -1.151 . . . . 0.0 114.222 177.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -124.2 135.37 53.4 Favored 'General case' 0 CA--C 1.486 -1.487 0 CA-C-N 117.785 0.793 . . . . 0.0 110.672 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 21.6 t -74.05 120.14 19.22 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 177.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.599 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.0 m -110.43 19.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.541 0 CA-C-O 121.479 0.657 . . . . 0.0 110.757 -174.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.44 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.0 p -78.83 -18.32 13.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.619 0.723 . . . . 0.0 110.329 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.87 12.49 15.83 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.45 175.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.599 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.6 m -91.22 135.48 28.26 Favored Pre-proline 0 N--CA 1.414 -2.255 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.458 ' O ' HG13 ' A' ' 71' ' ' ILE . 10.0 Cg_endo -57.82 148.42 75.38 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 122.005 1.804 . . . . 0.0 111.789 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 26.4 t60 -48.17 -50.27 29.54 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.563 1.145 . . . . 0.0 112.775 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -61.7 -39.02 89.99 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.873 -177.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -63.49 -49.6 72.95 Favored 'General case' 0 CA--C 1.482 -1.638 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.678 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.458 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.4 mt -50.87 -45.75 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 O-C-N 124.3 1.0 . . . . 0.0 109.846 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.62 -35.44 61.15 Favored 'Isoleucine or valine' 0 C--O 1.242 0.664 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.041 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.3 t60 -70.4 -42.33 71.82 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -176.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 38.2 mt -64.97 -49.95 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.919 179.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 42.3 mt -55.75 -52.09 65.15 Favored 'General case' 0 CA--C 1.502 -0.882 0 O-C-N 123.756 0.66 . . . . 0.0 112.181 177.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.8 t -59.07 -26.03 64.28 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.654 0.612 . . . . 0.0 112.654 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.7 m-80 -111.2 4.28 19.11 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -175.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.425 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -98.86 125.87 44.37 Favored 'General case' 0 C--O 1.204 -1.314 0 O-C-N 121.333 -0.854 . . . . 0.0 110.813 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.516 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -118.08 174.08 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.77 -155.52 19.7 Favored Glycine 0 CA--C 1.497 -1.093 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.539 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.9 mp0 -89.49 109.61 20.53 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.856 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.4 mt -105.11 117.86 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.933 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -170.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.9 m80 -85.3 128.42 34.69 Favored 'General case' 0 CA--C 1.478 -1.801 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.442 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -129.29 153.55 47.71 Favored 'General case' 0 C--N 1.258 -3.38 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 170.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -120.4 120.54 36.24 Favored 'General case' 0 C--N 1.26 -3.316 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.575 HG22 HG12 ' A' ' 55' ' ' ILE . 46.8 p -119.35 143.59 47.32 Favored 'General case' 0 C--N 1.257 -3.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.598 -178.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.51 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.3 mtm -111.39 164.06 15.92 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 175.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.77 27.52 0.32 Allowed 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.57 2.18 . . . . 0.0 111.598 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 69.27 25.8 5.55 Favored 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 126.299 1.84 . . . . 0.0 112.866 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.42 -1.94 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 174.456 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.553 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 4.5 m-20 . . . . . 0 N--CA 1.469 0.504 0 CA-C-O 122.285 1.041 . . . . 0.0 111.824 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.5 t -114.38 126.84 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.445 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.59 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -116.92 117.55 30.01 Favored 'General case' 0 C--N 1.248 -3.807 0 CA-C-N 113.915 -1.493 . . . . 0.0 107.086 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 m -83.87 138.2 33.31 Favored 'General case' 0 N--CA 1.406 -2.641 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.422 -176.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.3 t -118.19 140.29 42.15 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.373 178.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 81' ' ' GLU . 23.9 tp -122.68 116.42 23.76 Favored 'General case' 0 N--CA 1.399 -3.009 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.132 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.455 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.13 139.04 20.47 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -178.945 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.4 HH11 HD23 ' A' ' 16' ' ' LEU . 0.0 OUTLIER -113.08 102.6 10.55 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 175.393 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.474 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.7 ttt180 -107.09 108.86 62.59 Favored Pre-proline 0 C--N 1.287 -2.121 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.241 -177.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -53.05 -55.87 3.3 Favored 'Trans proline' 0 CA--C 1.542 0.922 0 C-N-CA 122.788 2.325 . . . . 0.0 112.933 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -156.69 -176.98 6.27 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -177.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.464 HD23 ' CG1' ' A' ' 79' ' ' VAL . 68.7 mt -74.47 -14.37 60.82 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -172.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -82.11 -11.33 58.82 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-O 121.466 0.65 . . . . 0.0 110.15 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -94.7 121.07 35.89 Favored 'General case' 0 CA--C 1.487 -1.46 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.811 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -84.03 157.4 21.83 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 123.579 0.549 . . . . 0.0 110.353 177.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.576 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER -61.15 -44.01 97.98 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 124.29 0.994 . . . . 0.0 111.36 -171.434 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.28 26.04 9.74 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 119.639 -1.267 . . . . 0.0 113.42 178.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -151.94 167.87 26.98 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -124.55 134.05 53.11 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -125.57 138.47 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -173.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.407 ' HG2' ' O ' ' A' ' 34' ' ' ILE . 17.4 pt20 -105.44 92.79 4.34 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.794 0.806 . . . . 0.0 109.318 176.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 58.55 20.55 7.7 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 122.79 -10.23 9.02 Favored Glycine 0 C--O 1.218 -0.867 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.092 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.407 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 2.4 mp -106.33 118.44 53.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.742 HD13 HG13 ' A' ' 49' ' ' VAL . 65.5 mt -59.61 114.74 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 123.244 0.618 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 52.5 t -95.29 -37.8 10.83 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.468 -175.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 14.8 m -149.8 151.23 33.22 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -178.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.9 tp -121.26 136.09 55.02 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.8 ttm -83.94 118.37 23.96 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -68.64 125.61 27.1 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.189 -175.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.47 0.41 79.51 Favored Glycine 0 N--CA 1.425 -2.046 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.55 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.62 171.25 45.13 Favored Glycine 0 C--O 1.241 0.586 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.14 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.89 -31.05 51.05 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.041 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.455 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.27 -39.61 93.48 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.891 0.377 . . . . 0.0 110.478 177.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -63.4 -44.01 95.91 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 176.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -72.28 -6.14 40.98 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.061 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -98.81 -18.01 26.41 Favored Glycine 0 N--CA 1.433 -1.536 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.03 19.56 18.9 Favored Glycine 0 N--CA 1.433 -1.518 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.442 -179.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.742 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -65.32 145.62 13.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-O 120.88 0.371 . . . . 0.0 110.036 177.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 19.9 mmt85 -136.86 138.71 41.03 Favored 'General case' 0 CA--C 1.488 -1.409 0 C-N-CA 123.963 0.905 . . . . 0.0 108.852 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.2 t -76.24 148.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.806 -177.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.05 47.67 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -178.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.571 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.7 m170 -122.19 136.39 54.9 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.994 -178.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -94.12 123.0 37.22 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.505 HG12 HG22 ' A' ' 86' ' ' THR . 33.1 mt -79.24 121.17 31.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.45 HG21 ' SD ' ' A' ' 87' ' ' MET . 36.8 pt -100.63 -14.92 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.38 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.5 tt0 -156.79 141.16 16.62 Favored 'General case' 0 CA--C 1.477 -1.858 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -175.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.453 HD12 HG21 ' A' ' 63' ' ' VAL . 79.2 mt -140.75 126.34 19.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.14 14.52 9.68 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 124.058 0.943 . . . . 0.0 111.126 172.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.83 -1.96 48.51 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.877 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.445 ' O ' HG13 ' A' ' 63' ' ' VAL . 18.5 pt20 -115.57 130.6 56.93 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 117.106 0.453 . . . . 0.0 110.633 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.0 m -70.02 108.45 4.07 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.755 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.649 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.5 m -102.17 13.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.594 0 CA-C-O 122.133 0.968 . . . . 0.0 109.682 -175.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.9 p -73.53 -14.11 16.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 114.349 -1.296 . . . . 0.0 110.567 -177.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -125.68 19.82 7.9 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 122.21 1.005 . . . . 0.0 108.712 177.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.649 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.3 m -101.23 137.42 19.68 Favored Pre-proline 0 N--CA 1.413 -2.295 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.418 ' O ' HG13 ' A' ' 71' ' ' ILE . 57.3 Cg_endo -72.74 163.25 38.99 Favored 'Trans proline' 0 C--O 1.245 0.848 0 C-N-CA 122.035 1.824 . . . . 0.0 112.739 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -42.35 -57.85 2.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 127.249 2.22 . . . . 0.0 112.371 -177.327 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -68.15 -39.99 82.5 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.672 -174.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -59.18 -48.7 80.63 Favored 'General case' 0 CA--C 1.495 -1.164 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.535 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 67' ' ' PRO . 65.5 mt -51.9 -43.63 35.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 O-C-N 124.057 0.848 . . . . 0.0 110.329 178.558 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.1 t -73.09 -34.99 46.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.792 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.43 -46.08 77.68 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 123.517 0.727 . . . . 0.0 109.292 -177.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 23.6 mt -64.43 -47.06 90.99 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.706 0 CA-C-N 114.673 -1.149 . . . . 0.0 109.887 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 45.4 mt -58.43 -51.71 68.69 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.987 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 42.2 m -56.38 -27.84 57.41 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -102.31 -5.21 24.51 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.474 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -102.88 131.84 49.51 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.892 -0.505 . . . . 0.0 111.317 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.464 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.5 m -130.43 -174.78 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -154.77 29.21 Favored Glycine 0 CA--C 1.484 -1.863 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.412 ' HB3' HD11 ' A' ' 16' ' ' LEU . 34.4 mt-10 -78.7 115.7 18.57 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 78.1 mt -119.33 117.82 55.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -85.53 126.24 33.7 Favored 'General case' 0 CA--C 1.487 -1.448 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.484 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 20.8 mtm -124.35 152.26 43.36 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 173.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -119.91 122.96 42.4 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.571 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 45.6 p -120.83 139.95 52.43 Favored 'General case' 0 C--N 1.271 -2.846 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.638 -177.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.45 ' SD ' HG21 ' A' ' 56' ' ' ILE . 81.7 mtp -110.33 169.76 6.02 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.553 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 11.7 Cg_exo -74.84 30.27 0.35 Allowed 'Trans proline' 0 N--CA 1.486 1.054 0 C-N-CA 122.914 2.409 . . . . 0.0 112.619 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.436 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.9 60.18 2.24 Favored 'General case' 0 CA--C 1.496 -1.132 0 C-N-CA 125.242 1.417 . . . . 0.0 111.583 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -2.013 0 CA-C-N 113.236 -1.802 . . . . 0.0 106.6 172.571 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 . . . . . 0 CA--C 1.48 -1.724 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.525 HG11 ' HE3' ' A' ' 85' ' ' LYS . 71.4 t -118.64 137.22 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.379 -3.976 0 CA-C-O 122.256 1.027 . . . . 0.0 108.881 -173.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 m -118.72 105.88 12.01 Favored 'General case' 2 N--CA 1.368 -4.562 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 174.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.8 m -83.55 136.75 34.14 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 114.764 -1.107 . . . . 0.0 109.272 -176.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.98 141.88 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.47 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.344 -175.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 18.2 tp -125.45 116.5 21.92 Favored 'General case' 0 N--CA 1.396 -3.137 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.696 HD11 ' HA ' ' A' ' 44' ' ' ALA . 1.0 OUTLIER -99.29 129.61 49.49 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 175.535 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 74.6 mtp180 -113.1 101.36 9.38 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 122.813 1.292 . . . . 0.0 109.059 169.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -105.04 111.27 65.21 Favored Pre-proline 0 C--N 1.272 -2.785 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.462 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -56.17 -47.88 22.27 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 122.598 2.199 . . . . 0.0 113.05 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.39 178.59 10.14 Favored 'General case' 0 C--O 1.246 0.916 0 CA-C-O 120.893 0.378 . . . . 0.0 110.72 -177.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 ' CG1' ' A' ' 79' ' ' VAL . 53.7 mt -65.05 -21.99 66.91 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 115.637 1.717 . . . . 0.0 115.637 -173.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.402 ' HD3' ' HA ' ' A' ' 23' ' ' ARG . 67.2 mmt-85 -79.04 -11.12 59.99 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.17 0.509 . . . . 0.0 111.465 -179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -83.26 -20.34 34.68 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . 0.407 ' HB3' ' H ' ' A' ' 26' ' ' LEU . 15.0 mm100 57.05 -164.46 0.16 Allowed 'General case' 0 CA--C 1.511 -0.539 0 O-C-N 123.777 0.673 . . . . 0.0 111.648 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.479 ' O ' HG13 ' A' ' 43' ' ' ILE . 0.4 OUTLIER -97.4 -49.43 4.92 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.92 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.21 11.54 Favored Glycine 0 N--CA 1.432 -1.595 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.097 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -143.48 164.26 30.84 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 50.3 m -118.19 133.7 55.67 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 123.89 0.743 . . . . 0.0 109.239 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.57 131.58 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.222 0 CA-C-O 121.69 0.757 . . . . 0.0 110.89 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -120.72 128.85 53.31 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 62.08 2.95 0.87 Allowed 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 124.248 1.019 . . . . 0.0 112.917 -176.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.99 3.05 45.61 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -174.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.452 HG13 ' HB2' ' A' ' 54' ' ' ARG . 3.5 mp -114.08 125.03 71.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.732 HD13 HG13 ' A' ' 49' ' ' VAL . 50.4 mt -61.41 117.97 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 123.834 0.854 . . . . 0.0 110.14 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.9 t -101.98 -34.42 9.35 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.309 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 p -143.35 148.49 36.34 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.3 tp -128.32 132.27 48.64 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.6 ttp -85.45 108.11 17.73 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.57 141.43 58.77 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.449 -177.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.04 -15.38 48.98 Favored Glycine 0 C--N 1.303 -1.252 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.531 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.61 175.45 50.74 Favored Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.479 HG13 ' O ' ' A' ' 26' ' ' LEU . 1.3 pt -59.96 -34.47 56.4 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.748 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.696 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.81 -40.06 96.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -68.11 -36.71 80.19 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.601 0.715 . . . . 0.0 109.12 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -76.58 -23.88 53.51 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.511 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.34 -23.24 63.41 Favored Glycine 0 N--CA 1.438 -1.204 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.507 178.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.98 10.63 22.27 Favored Glycine 0 CA--C 1.501 -0.811 0 C-N-CA 120.231 -0.985 . . . . 0.0 112.883 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.732 HG13 HD13 ' A' ' 35' ' ' ILE . 66.0 t -66.78 135.78 27.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.418 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 20.4 mmt180 -133.45 142.72 48.44 Favored 'General case' 0 CA--C 1.481 -1.681 0 CA-C-O 121.165 0.507 . . . . 0.0 110.293 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.5 t -72.65 145.25 12.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.967 -178.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.9 21.08 56.65 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 -178.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.8 m170 -117.21 135.96 53.41 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 115.08 -0.56 . . . . 0.0 111.37 -179.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.469 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 34.8 ttp180 -97.73 123.72 41.78 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 177.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.587 HG12 HG22 ' A' ' 86' ' ' THR . 30.5 mt -78.62 123.43 35.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.401 ' HA ' ' HB ' ' A' ' 64' ' ' VAL . 36.3 pt -100.3 -16.69 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.848 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.6 tt0 -158.4 144.49 17.07 Favored 'General case' 0 CA--C 1.496 -1.134 0 C-N-CA 119.479 -0.889 . . . . 0.0 110.2 -174.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 63' ' ' VAL . 82.2 mt -139.91 118.09 11.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 124.674 1.233 . . . . 0.0 108.077 178.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 53.79 27.24 6.81 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 125.299 1.44 . . . . 0.0 114.472 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.55 -10.4 38.68 Favored Glycine 0 CA--C 1.496 -1.106 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.82 175.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 35.5 tt0 -100.54 122.38 43.14 Favored 'General case' 0 C--N 1.292 -1.928 0 CA-C-N 115.488 -0.356 . . . . 0.0 110.393 -177.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -71.32 108.62 4.87 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.555 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.7 m -102.45 10.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-O 121.667 0.746 . . . . 0.0 110.08 -175.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.401 ' HB ' ' HA ' ' A' ' 56' ' ' ILE . 4.0 p -72.02 -13.5 16.74 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 114.669 -1.15 . . . . 0.0 111.111 -177.275 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -123.04 13.66 9.77 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.111 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.555 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.8 m -96.9 136.55 21.55 Favored Pre-proline 0 N--CA 1.409 -2.521 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.449 ' O ' HG13 ' A' ' 71' ' ' ILE . 9.5 Cg_endo -56.81 150.01 56.8 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.351 2.034 . . . . 0.0 112.386 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.2 t60 -48.62 -48.25 39.49 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.453 1.101 . . . . 0.0 112.733 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -67.58 -35.49 79.1 Favored 'General case' 0 N--CA 1.435 -1.199 0 O-C-N 123.487 0.492 . . . . 0.0 110.621 -175.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 mttm -63.59 -49.45 73.29 Favored 'General case' 0 CA--C 1.484 -1.586 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.365 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.449 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.0 mt -53.59 -43.15 53.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 O-C-N 124.083 0.865 . . . . 0.0 109.918 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.7 t -71.91 -31.86 42.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.728 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -74.56 -41.04 61.26 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -175.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.7 mt -64.29 -47.75 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.407 ' HB3' HD21 ' A' ' 26' ' ' LEU . 81.7 mt -62.48 -35.23 78.66 Favored 'General case' 0 C--O 1.211 -0.928 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.437 176.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.5 t -63.21 -31.11 72.18 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 122.805 0.442 . . . . 0.0 111.693 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.76 -31.71 13.65 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -175.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.08 130.58 35.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -172.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.478 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -129.89 -179.41 3.16 Favored 'Isoleucine or valine' 0 C--O 1.243 0.732 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 174.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 86.6 -151.34 24.1 Favored Glycine 0 CA--C 1.488 -1.65 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -79.06 108.78 12.8 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.441 HD12 HG22 ' A' ' 17' ' ' ILE . 79.9 mt -111.16 118.82 58.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.746 -175.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -94.56 131.18 40.58 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -133.11 156.2 47.87 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 172.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.525 ' HE3' HG11 ' A' ' 12' ' ' VAL . 23.2 mmmt -124.47 120.33 31.71 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 105.547 -2.019 . . . . 0.0 105.547 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.587 HG22 HG12 ' A' ' 55' ' ' ILE . 33.4 p -119.64 146.68 45.33 Favored 'General case' 0 C--N 1.27 -2.848 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.259 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.501 ' C ' ' H ' ' A' ' 89' ' ' ALA . 49.8 mtm -118.21 169.9 7.11 Favored Pre-proline 0 C--N 1.298 -1.631 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 176.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -69.71 26.26 0.17 Allowed 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 123.336 2.691 . . . . 0.0 112.575 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.501 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 74.86 -1.27 3.13 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 126.538 1.935 . . . . 0.0 113.466 178.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.113 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 . . . . . 0 CA--C 1.495 -1.16 0 CA-C-O 121.836 0.826 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.4 HG22 ' HG2' ' A' ' 87' ' ' MET . 46.3 t -134.79 133.26 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.191 0 CA-C-N 114.603 -1.18 . . . . 0.0 108.033 -178.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 m -123.0 117.86 26.45 Favored 'General case' 0 C--N 1.261 -3.28 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 21.4 m -85.26 142.3 29.49 Favored 'General case' 0 C--N 1.265 -3.092 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.235 -175.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.63 132.0 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.129 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 13.8 tp -122.09 119.67 32.03 Favored 'General case' 0 N--CA 1.393 -3.281 0 CA-C-O 121.711 0.767 . . . . 0.0 109.991 173.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.485 HD12 ' HB ' ' A' ' 43' ' ' ILE . 1.1 mm -99.87 135.23 36.36 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.026 0 CA-C-N 114.24 -1.346 . . . . 0.0 108.652 176.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -115.16 101.24 8.79 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.514 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 73.4 ttt180 -99.22 115.23 65.86 Favored Pre-proline 0 C--N 1.284 -2.275 0 CA-C-N 113.621 -1.627 . . . . 0.0 110.94 -178.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_exo -61.29 -38.0 68.82 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.663 2.242 . . . . 0.0 114.065 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.91 -178.58 4.8 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.484 HD23 HG12 ' A' ' 79' ' ' VAL . 79.7 mt -76.69 -15.23 59.85 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 123.976 0.91 . . . . 0.0 111.277 -176.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -69.79 -16.15 63.24 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.993 176.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -97.97 121.27 39.69 Favored 'General case' 0 CA--C 1.481 -1.682 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 176.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 -97.48 156.96 16.26 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.611 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.659 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.0 OUTLIER -53.08 -65.62 0.53 Allowed 'General case' 0 C--N 1.323 -0.551 0 O-C-N 124.993 1.433 . . . . 0.0 110.778 -174.349 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.28 34.78 4.1 Favored Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 120.129 -1.034 . . . . 0.0 112.626 177.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -155.59 155.73 33.83 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.1 m -107.42 127.35 53.51 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -117.89 136.64 54.41 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 C-N-CA 119.839 -0.744 . . . . 0.0 109.203 179.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -121.92 109.95 15.26 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 60.33 13.34 3.94 Favored 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 124.036 0.934 . . . . 0.0 112.37 -176.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 113.09 -6.85 25.31 Favored Glycine 0 C--O 1.211 -1.323 0 C-N-CA 121.145 -0.55 . . . . 0.0 112.054 -178.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.5 mp -102.24 123.61 55.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.049 -0.677 . . . . 0.0 110.073 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.678 HD13 HG13 ' A' ' 49' ' ' VAL . 66.1 mt -64.14 112.13 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 C-N-CA 124.05 0.94 . . . . 0.0 109.71 178.328 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 22.6 t -91.59 -37.29 13.18 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.517 -174.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -152.8 157.33 40.61 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 66.4 tp -129.35 132.45 47.08 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 25.6 ttt -87.33 120.4 28.58 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.432 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 0.3 OUTLIER -69.59 136.27 51.05 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.779 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.28 -2.21 74.36 Favored Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.4 164.58 28.26 Favored Glycine 0 N--CA 1.436 -1.308 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.485 ' HB ' HD12 ' A' ' 17' ' ' ILE . 3.2 pt -60.81 -36.66 72.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.44 -39.5 70.38 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.014 0.435 . . . . 0.0 111.062 -178.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -67.03 -42.78 84.3 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.023 178.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.89 -37.3 86.9 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.747 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.66 -24.32 76.31 Favored Glycine 0 CA--C 1.516 0.12 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.754 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.75 28.91 5.77 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.409 -0.9 . . . . 0.0 112.564 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.678 HG13 HD13 ' A' ' 35' ' ' ILE . 60.7 t -77.45 142.65 13.93 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -136.21 145.14 45.36 Favored 'General case' 0 CA--C 1.49 -1.338 0 CA-C-O 121.202 0.525 . . . . 0.0 109.623 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.0 t -73.42 144.7 12.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.206 -178.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.83 20.17 58.39 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -179.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.458 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 13.6 m-70 -115.2 144.67 43.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 115.121 -0.539 . . . . 0.0 110.194 178.161 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -104.97 117.48 34.12 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.602 HG12 HG22 ' A' ' 86' ' ' THR . 29.6 mt -73.96 123.79 29.95 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.482 HG21 ' SD ' ' A' ' 87' ' ' MET . 2.4 pp -109.48 -4.13 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.384 -178.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 84' ' ' MET . 20.0 tt0 -160.59 146.7 15.12 Favored 'General case' 0 CA--C 1.486 -1.506 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.515 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.487 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.3 mt -142.71 120.69 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 172.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.447 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 8.5 m-20 55.07 27.45 9.42 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 177.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.75 -6.86 58.99 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.562 -0.828 . . . . 0.0 113.821 177.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.477 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 11.6 pt20 -107.96 136.36 47.8 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 t -80.98 108.86 15.02 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -178.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.612 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.1 m -100.02 15.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.88 0 CA-C-O 122.09 0.948 . . . . 0.0 109.455 -173.436 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.442 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.6 p -69.73 -21.79 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.876 -175.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.32 13.62 12.78 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.457 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.612 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.7 m -90.37 133.7 32.6 Favored Pre-proline 0 N--CA 1.412 -2.367 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -63.62 155.55 62.38 Favored 'Trans proline' 0 C--O 1.25 1.125 0 C-N-CA 122.178 1.919 . . . . 0.0 112.356 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.35 -53.38 8.65 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.04 1.336 . . . . 0.0 111.313 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -56.99 -43.43 81.71 Favored 'General case' 0 C--N 1.316 -0.855 0 O-C-N 123.903 0.752 . . . . 0.0 111.456 -176.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.45 -54.61 26.01 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.847 -178.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.4 mt -50.39 -43.04 21.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 O-C-N 123.862 0.726 . . . . 0.0 110.293 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 73.0 t -67.1 -40.93 86.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 72.5 t60 -64.74 -44.09 91.25 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.4 -50.93 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 O-C-N 123.592 0.558 . . . . 0.0 109.534 178.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.14 -31.56 72.73 Favored 'General case' 0 C--O 1.209 -1.054 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.418 ' O ' HD22 ' A' ' 22' ' ' LEU . 50.2 m -71.08 -27.45 63.63 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' HD22 ' A' ' 77' ' ' ASN . 0.8 OUTLIER -100.55 -11.46 20.07 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -174.845 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.514 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.77 132.56 38.04 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.237 -0.585 . . . . 0.0 112.031 -176.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.484 HG12 HD23 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -131.4 172.62 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.534 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 78.4 -151.05 35.86 Favored Glycine 0 CA--C 1.496 -1.119 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -176.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -59.11 108.78 0.73 Allowed 'General case' 0 C--O 1.245 0.857 0 C-N-CA 124.417 1.087 . . . . 0.0 111.362 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.447 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 85.4 mt -115.79 118.36 58.54 Favored 'Isoleucine or valine' 0 CA--C 1.456 -2.639 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 11.7 t-80 -106.65 115.87 30.94 Favored 'General case' 0 N--CA 1.385 -3.68 0 CA-C-N 113.199 -1.819 . . . . 0.0 109.456 -170.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 22.4 mtm -123.91 155.19 38.57 Favored 'General case' 0 C--N 1.261 -3.269 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 177.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 57.1 mmtt -122.06 124.26 43.52 Favored 'General case' 0 C--N 1.265 -3.087 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 175.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 55' ' ' ILE . 68.8 p -119.45 134.99 54.95 Favored 'General case' 0 C--N 1.262 -3.236 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.665 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.482 ' SD ' HG21 ' A' ' 56' ' ' ILE . 89.2 mtp -105.98 163.22 17.5 Favored Pre-proline 0 C--N 1.299 -1.619 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 176.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.64 14.48 0.32 Allowed 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 122.724 2.283 . . . . 0.0 113.157 178.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.402 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 65.37 22.94 12.02 Favored 'General case' 0 C--N 1.344 0.36 0 C-N-CA 124.427 1.091 . . . . 0.0 110.68 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.753 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.312 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 . . . . . 0 CA--C 1.506 -0.735 0 CA-C-O 121.933 0.873 . . . . 0.0 111.297 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -128.18 128.95 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.358 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.892 -175.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.7 m -115.58 108.19 16.11 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.178 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.4 m -78.7 135.83 37.27 Favored 'General case' 0 N--CA 1.395 -3.18 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.4 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.2 t -116.09 135.79 55.13 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.937 0 CA-C-N 114.793 -1.094 . . . . 0.0 108.478 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.5 tp -121.19 116.8 25.6 Favored 'General case' 0 N--CA 1.385 -3.698 0 C-N-CA 119.561 -0.856 . . . . 0.0 109.428 174.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.582 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.9 OUTLIER -97.55 133.94 37.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.352 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.592 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.6 mmm-85 -112.73 101.17 9.29 Favored 'General case' 0 N--CA 1.411 -2.398 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.2 ttt180 -100.88 110.8 61.95 Favored Pre-proline 0 C--N 1.282 -2.342 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.235 -178.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -54.88 -38.09 92.68 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 123.361 2.707 . . . . 0.0 113.663 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -176.73 -176.89 0.75 Allowed 'General case' 0 C--O 1.241 0.644 0 C-N-CA 123.367 0.667 . . . . 0.0 109.308 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 HG12 ' A' ' 79' ' ' VAL . 69.0 mt -73.28 -6.82 48.49 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -174.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -84.57 -13.98 50.18 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.06 0.457 . . . . 0.0 110.565 175.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -103.01 109.1 20.52 Favored 'General case' 0 CA--C 1.491 -1.326 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -82.4 162.73 22.05 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.275 178.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.1 mm? -52.14 -52.84 49.19 Favored 'General case' 0 C--N 1.321 -0.655 0 O-C-N 124.704 1.253 . . . . 0.0 110.65 -175.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.82 28.23 6.33 Favored Glycine 0 N--CA 1.436 -1.319 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.4 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -150.03 151.06 32.66 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m -104.57 124.64 49.67 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -113.95 141.64 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.528 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -177.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -119.06 102.04 8.45 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-O 121.711 0.767 . . . . 0.0 110.56 174.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 60.98 23.04 13.21 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-N 114.481 -1.236 . . . . 0.0 112.548 178.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.85 -11.01 20.87 Favored Glycine 0 N--CA 1.437 -1.268 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.421 178.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.5 119.3 58.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 117.302 0.551 . . . . 0.0 110.781 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.703 HD13 HG13 ' A' ' 49' ' ' VAL . 57.2 mt -59.43 111.93 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 124.193 0.997 . . . . 0.0 111.015 178.07 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 45.3 t -89.67 -38.26 14.01 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.595 -177.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.7 t -148.78 150.78 33.68 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 55.9 tp -122.57 137.55 54.86 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.3 tpp -86.2 120.1 27.19 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.73 129.46 39.86 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.306 -176.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.407 ' H ' ' CD ' ' A' ' 45' ' ' GLU . . . 87.27 -3.05 86.86 Favored Glycine 0 N--CA 1.421 -2.319 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.419 176.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.5 173.55 47.88 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.38 -0.914 . . . . 0.0 111.923 -176.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 26' ' ' LEU . 2.7 pt -59.17 -34.67 54.25 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.582 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.91 -39.11 88.12 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.709 0.29 . . . . 0.0 111.272 179.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 41' ' ' GLY . 45.0 tt0 -66.76 -41.24 88.06 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.826 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 43' ' ' ILE . 13.1 ptt180 -78.66 -16.22 57.57 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.012 -0.675 . . . . 0.0 111.81 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.95 -22.69 63.12 Favored Glycine 0 N--CA 1.433 -1.535 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.708 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.3 15.09 20.55 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.965 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.703 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -70.47 138.3 22.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.403 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 30.9 mmm180 -135.49 151.1 50.04 Favored 'General case' 0 CA--C 1.486 -1.484 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -79.68 145.52 9.16 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.106 -176.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.44 23.18 57.15 Favored Glycine 0 CA--C 1.501 -0.809 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -178.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.5 m170 -116.5 134.09 55.26 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 114.708 -0.746 . . . . 0.0 111.28 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.9 ttm180 -97.54 125.44 42.25 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.552 HG12 HG22 ' A' ' 86' ' ' THR . 34.2 mt -78.15 126.95 38.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 177.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 62' ' ' SER . 31.0 pt -106.91 -15.48 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.41 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.4 tt0 -155.62 145.81 21.68 Favored 'General case' 0 CA--C 1.481 -1.703 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.386 -173.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 74.5 mt -142.22 125.53 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.437 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 87.1 m-20 51.62 24.63 2.41 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 115.837 1.791 . . . . 0.0 115.837 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.86 -5.65 34.72 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.254 -0.974 . . . . 0.0 113.416 176.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.42 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.1 pt20 -115.34 129.33 56.56 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 117.42 0.61 . . . . 0.0 111.009 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 19.4 m -70.46 108.48 4.31 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.542 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.3 m -100.8 12.8 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 121.734 0.778 . . . . 0.0 109.575 -174.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -66.85 -16.22 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.562 -177.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.93 10.06 10.1 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-O 121.427 0.632 . . . . 0.0 109.576 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.7 m -85.43 141.42 36.74 Favored Pre-proline 0 N--CA 1.422 -1.841 0 C-N-CA 123.812 0.845 . . . . 0.0 109.214 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.75 147.32 81.11 Favored 'Trans proline' 0 C--O 1.239 0.525 0 C-N-CA 122.642 2.228 . . . . 0.0 112.697 179.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -42.97 -55.22 3.86 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 126.212 1.805 . . . . 0.0 111.168 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -58.5 -44.94 89.62 Favored 'General case' 0 CA--C 1.497 -1.09 0 O-C-N 123.362 0.414 . . . . 0.0 110.845 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.43 -55.07 39.34 Favored 'General case' 0 C--O 1.201 -1.479 0 O-C-N 123.861 0.725 . . . . 0.0 110.087 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 59.8 mt -50.38 -43.45 22.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 C-N-CA 123.554 0.742 . . . . 0.0 110.952 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.1 t -72.43 -36.12 53.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.829 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -70.67 -40.01 73.21 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 123.323 0.649 . . . . 0.0 109.611 -177.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.33 -49.51 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 176.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 85.2 mt -62.05 -46.27 89.88 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.6 m -64.32 -26.89 68.68 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -91.28 -19.79 22.6 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.09 139.04 31.03 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.837 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.478 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -132.38 178.55 5.45 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 174.04 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.9 -151.3 38.89 Favored Glycine 0 CA--C 1.48 -2.136 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -65.33 114.86 5.06 Favored 'General case' 0 CA--C 1.497 -1.096 0 O-C-N 124.693 0.878 . . . . 0.0 110.175 174.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.437 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 83.5 mt -118.62 117.29 54.0 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.703 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 175.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -99.48 120.08 39.05 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 -174.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.411 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 25.2 mtm -126.32 157.28 38.82 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -121.98 125.12 45.61 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 176.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.552 HG22 HG12 ' A' ' 55' ' ' ILE . 44.6 p -121.26 144.08 48.81 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.372 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.403 ' C ' ' H ' ' A' ' 89' ' ' ALA . 54.5 mtm -116.73 168.96 7.87 Favored Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -71.29 29.58 0.23 Allowed 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 123.056 2.504 . . . . 0.0 112.861 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.403 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 57.4 50.48 11.29 Favored 'General case' 0 C--O 1.245 0.855 0 CA-C-O 122.496 1.141 . . . . 0.0 110.332 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.92 0 CA-C-N 113.782 -1.554 . . . . 0.0 108.026 179.621 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.3 p30 . . . . . 0 CA--C 1.474 -1.957 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 69.5 t -95.68 128.62 46.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.505 0 CA-C-N 113.35 -1.75 . . . . 0.0 109.466 -173.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.1 m -122.45 109.2 14.07 Favored 'General case' 2 C--N 1.236 -4.33 0 CA-C-N 113.291 -1.777 . . . . 0.0 106.865 177.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -79.01 138.66 38.13 Favored 'General case' 0 N--CA 1.406 -2.674 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.154 -176.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.421 HG11 ' CG2' ' A' ' 49' ' ' VAL . 52.9 t -115.57 133.41 62.0 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.547 177.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.426 HD11 ' HB3' ' A' ' 81' ' ' GLU . 14.4 tp -121.17 116.13 24.37 Favored 'General case' 0 N--CA 1.396 -3.134 0 C-N-CA 119.989 -0.684 . . . . 0.0 110.005 176.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.57 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.6 OUTLIER -98.89 138.64 22.79 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.978 0 CA-C-N 114.563 -1.198 . . . . 0.0 108.02 178.256 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -115.13 101.73 9.25 Favored 'General case' 0 N--CA 1.414 -2.252 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 168.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.533 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 65.3 ttt180 -97.89 116.28 65.7 Favored Pre-proline 0 C--N 1.284 -2.26 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.001 -177.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -49.36 -54.43 5.46 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.034 2.49 . . . . 0.0 112.602 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.58 ' OD2' ' HG3' ' A' ' 23' ' ' ARG . 2.7 p-10 -173.1 -170.49 0.64 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.465 ' HA ' ' NH2' ' A' ' 19' ' ' ARG . 54.1 mt -68.6 -16.65 63.92 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -173.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.58 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 27.0 mtt180 -71.34 -12.23 61.32 Favored 'General case' 0 N--CA 1.481 1.087 0 CA-C-O 121.167 0.508 . . . . 0.0 110.785 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -113.98 143.36 44.87 Favored 'General case' 0 N--CA 1.427 -1.614 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -116.96 171.56 7.83 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.243 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.686 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -58.31 -61.93 2.21 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 125.124 1.369 . . . . 0.0 111.245 -173.081 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.61 37.99 3.1 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 119.794 -1.193 . . . . 0.0 112.129 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -154.7 163.02 40.86 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.8 m -117.94 128.62 54.98 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.47 138.76 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 120.864 0.364 . . . . 0.0 110.133 -176.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 19.9 pt20 -131.04 121.62 25.34 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.1 m120 63.58 13.44 7.28 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.206 1.002 . . . . 0.0 111.857 -175.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.51 1.91 58.93 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.412 -0.899 . . . . 0.0 111.138 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -106.07 119.88 56.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.726 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -62.06 116.83 2.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 C-N-CA 124.369 1.068 . . . . 0.0 110.099 177.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.8 t -96.11 -38.18 10.28 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.27 -176.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 13.3 p -149.06 152.38 36.11 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.279 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 53.4 tp -127.46 145.38 50.85 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 123.576 0.75 . . . . 0.0 109.506 -178.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.8 ttp -93.42 115.88 28.42 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.148 0.499 . . . . 0.0 109.893 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.425 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.0 tpp85 -65.58 118.68 9.86 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 124.726 1.21 . . . . 0.0 109.463 -179.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -12.99 59.13 Favored Glycine 0 C--N 1.305 -1.142 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.793 -177.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -79.93 161.04 45.37 Favored Glycine 0 C--O 1.245 0.814 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.929 -177.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -54.22 -37.69 36.8 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.756 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.57 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -56.1 -44.2 78.82 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.199 0.524 . . . . 0.0 110.903 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.425 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 44.0 tt0 -70.14 -38.8 75.6 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.469 -179.52 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 48.3 mtt180 -66.59 -34.16 77.28 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.104 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.44 -20.61 79.54 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.782 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.08 20.29 7.62 Favored Glycine 0 C--O 1.24 0.489 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.696 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.726 HG13 HD13 ' A' ' 35' ' ' ILE . 45.0 t -71.34 144.29 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.447 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.4 mmt180 -132.61 142.66 49.24 Favored 'General case' 0 CA--C 1.484 -1.57 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.8 t -74.26 142.71 14.41 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.561 0 CA-C-N 114.583 -1.189 . . . . 0.0 109.192 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.16 22.25 55.15 Favored Glycine 0 CA--C 1.498 -0.989 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.1 m170 -114.67 135.2 54.42 Favored 'General case' 0 N--CA 1.424 -1.764 0 CA-C-N 115.129 -0.536 . . . . 0.0 111.066 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.45 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 12.6 ttm-85 -93.96 125.3 38.51 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 26.1 mt -83.0 123.62 38.76 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.337 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 174.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.2 pt -103.25 -12.06 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.36 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.688 -178.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.2 tt0 -163.02 143.51 9.34 Favored 'General case' 0 CA--C 1.494 -1.176 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.633 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.428 HD12 HG21 ' A' ' 63' ' ' VAL . 90.8 mt -140.03 121.84 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 O-C-N 124.228 0.955 . . . . 0.0 109.222 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 53.32 32.48 13.71 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.203 1.401 . . . . 0.0 112.447 172.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.59 -1.34 52.97 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.284 -0.96 . . . . 0.0 114.551 177.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -123.89 130.44 52.61 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 118.311 1.056 . . . . 0.0 110.755 178.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.3 t -74.74 109.32 8.12 Favored 'General case' 0 N--CA 1.425 -1.692 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.464 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 29.2 m -99.68 16.6 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.387 0 CA-C-O 121.968 0.889 . . . . 0.0 109.661 -174.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.438 HG23 ' HD3' ' A' ' 54' ' ' ARG . 3.8 p -72.95 -9.82 13.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 114.44 -1.254 . . . . 0.0 111.194 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.53 19.19 5.74 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.464 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.1 m -100.66 137.96 19.99 Favored Pre-proline 0 N--CA 1.412 -2.331 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.456 ' O ' HG13 ' A' ' 71' ' ' ILE . 50.1 Cg_endo -69.44 158.07 58.71 Favored 'Trans proline' 0 C--O 1.246 0.885 0 C-N-CA 122.435 2.09 . . . . 0.0 112.999 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -42.69 -56.19 3.26 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 126.7 2.0 . . . . 0.0 112.152 -178.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.84 -38.77 89.78 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.433 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -60.25 -51.83 67.87 Favored 'General case' 0 CA--C 1.485 -1.546 0 C-N-CA 119.974 -0.691 . . . . 0.0 110.93 177.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.456 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.5 mt -50.99 -44.9 28.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 O-C-N 124.329 1.018 . . . . 0.0 110.263 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.0 t -72.68 -35.13 49.42 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.087 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.9 t60 -69.67 -40.2 76.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.389 0.614 . . . . 0.0 109.586 -176.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 29.4 mt -70.19 -43.59 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 CA-C-N 114.829 -1.078 . . . . 0.0 109.931 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.5 mt -59.39 -46.34 88.95 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.632 175.031 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.3 t -57.92 -28.06 63.92 Favored 'General case' 0 C--O 1.215 -0.712 0 C-N-CA 124.122 0.969 . . . . 0.0 111.686 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -99.81 -6.42 26.93 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -178.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -101.28 130.55 47.44 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.893 -0.723 . . . . 0.0 111.484 -178.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.429 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -128.94 178.99 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.285 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.23 -153.59 29.33 Favored Glycine 0 CA--C 1.495 -1.178 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.426 ' HB3' HD11 ' A' ' 16' ' ' LEU . 47.7 mt-10 -77.61 110.37 12.37 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-O 121.403 0.62 . . . . 0.0 109.67 177.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 74.6 mt -112.94 117.64 55.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -93.76 118.76 31.85 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.494 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.9 mtm -118.13 156.03 29.41 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 174.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -121.54 121.38 37.35 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 42.9 p -121.29 146.62 46.64 Favored 'General case' 0 C--N 1.26 -3.297 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.765 -177.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 41.6 mtm -126.58 168.71 13.64 Favored Pre-proline 0 C--N 1.31 -1.142 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -70.79 38.76 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.145 0 C-N-CA 123.812 3.008 . . . . 0.0 113.654 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 54.79 56.03 7.17 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 125.58 1.552 . . . . 0.0 114.139 177.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.299 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.32 172.136 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 . . . . . 0 CA--C 1.487 -1.473 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -127.28 127.45 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.453 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -115.92 113.21 23.0 Favored 'General case' 0 C--N 1.246 -3.896 0 N-CA-C 106.222 -1.77 . . . . 0.0 106.222 177.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.2 m -86.39 137.82 32.27 Favored 'General case' 0 N--CA 1.395 -3.178 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.995 -175.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.436 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.9 t -118.49 141.81 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.629 0 CA-C-N 114.64 -1.164 . . . . 0.0 109.045 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.495 HD11 ' HB3' ' A' ' 81' ' ' GLU . 11.5 tp -129.23 105.69 8.32 Favored 'General case' 0 N--CA 1.386 -3.643 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 171.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.652 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -99.57 127.99 51.81 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.033 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 -175.378 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.41 116.83 29.34 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.566 -177.099 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.467 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 61.6 ttt180 -119.15 116.06 34.15 Favored Pre-proline 0 C--N 1.292 -1.921 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.044 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -62.45 -48.93 6.62 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.422 2.082 . . . . 0.0 112.997 179.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 23' ' ' ARG . 2.8 p30 -159.76 -175.58 5.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.413 HD23 ' CG1' ' A' ' 79' ' ' VAL . 54.6 mt -71.43 -15.94 62.37 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -173.644 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 21' ' ' ASP . 4.0 mpt_? -80.8 -11.95 59.52 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.47 0.652 . . . . 0.0 109.717 -179.051 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -95.26 116.16 28.38 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -86.56 150.13 24.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.605 177.3 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.602 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.31 -49.91 66.04 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 124.953 1.408 . . . . 0.0 111.188 -172.761 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.72 37.8 3.85 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.047 178.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -161.11 164.89 30.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.488 ' HB3' ' OG ' ' A' ' 37' ' ' SER . 34.8 t -123.4 130.15 52.3 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.448 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.444 ' O ' ' HE1' ' A' ' 68' ' ' HIS . 0.8 OUTLIER -115.46 143.74 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.878 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.856 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -130.54 128.76 41.78 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.4 t30 59.39 11.97 2.46 Favored 'General case' 0 CA--C 1.573 1.83 0 C-N-CA 123.559 0.744 . . . . 0.0 112.353 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.58 3.72 55.08 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.66 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -118.09 124.86 73.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 49.0 mt -65.12 121.71 14.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 123.876 0.87 . . . . 0.0 110.548 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.4 t -109.58 -25.96 10.17 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.752 -177.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.488 ' OG ' ' HB3' ' A' ' 29' ' ' SER . 12.9 p -146.32 144.38 29.76 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 122.168 -0.332 . . . . 0.0 110.548 177.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 51.0 tp -125.74 133.64 52.02 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 123.767 0.827 . . . . 0.0 109.758 -177.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.1 ttm -75.21 119.18 18.99 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.173 0.511 . . . . 0.0 109.839 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 18.6 tpp180 -66.99 122.09 16.99 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.547 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.6 1.99 82.6 Favored Glycine 0 C--N 1.312 -0.767 0 C-N-CA 120.898 -0.667 . . . . 0.0 111.999 -178.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 46' ' ' ARG . . . -86.12 165.49 37.82 Favored Glycine 0 C--O 1.252 1.239 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.288 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.452 ' HB ' HD11 ' A' ' 17' ' ' ILE . 1.1 pt -61.91 -30.88 49.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.59 -45.33 94.58 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 120.94 0.4 . . . . 0.0 110.282 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -64.86 -42.21 95.05 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.785 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.5 ' HG2' ' O ' ' A' ' 42' ' ' GLY . 6.7 mmp_? -61.11 -39.4 89.84 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.712 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.2 -16.97 78.57 Favored Glycine 0 CA--C 1.524 0.646 0 CA-C-N 115.59 -0.732 . . . . 0.0 113.903 -178.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.14 12.1 22.64 Favored Glycine 0 C--O 1.241 0.588 0 C-N-CA 119.749 -1.215 . . . . 0.0 113.033 177.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 80.6 t -72.63 142.82 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -140.8 154.99 46.47 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.49 142.35 14.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.77 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 13.75 58.6 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -177.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -109.55 135.53 50.39 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 121.151 0.5 . . . . 0.0 111.419 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -95.2 122.94 38.4 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 176.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.415 HG12 HG22 ' A' ' 86' ' ' THR . 40.2 mt -82.78 122.73 37.7 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 62' ' ' SER . 32.4 pt -103.3 -14.97 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.004 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 178.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 84' ' ' MET . 30.7 tt0 -150.92 141.86 22.95 Favored 'General case' 0 CA--C 1.479 -1.762 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -176.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.513 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -143.2 122.0 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.539 0 O-C-N 124.64 1.213 . . . . 0.0 108.127 176.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 66.69 18.57 10.74 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.663 1.185 . . . . 0.0 110.927 171.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.69 -12.06 30.08 Favored Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.75 177.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.419 ' O ' HG13 ' A' ' 63' ' ' VAL . 13.3 pt20 -115.89 143.34 45.55 Favored 'General case' 0 CA--C 1.501 -0.941 0 CA-C-N 117.732 0.766 . . . . 0.0 112.602 -178.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 49.9 m -75.86 108.87 9.03 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.233 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.575 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 23.3 m -102.09 15.02 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 122.124 0.964 . . . . 0.0 109.226 -174.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 p -72.97 -17.96 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-N 114.792 -1.094 . . . . 0.0 110.614 -177.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.59 9.32 16.56 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.954 0.883 . . . . 0.0 109.817 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.575 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.1 m -90.85 137.0 27.05 Favored Pre-proline 0 N--CA 1.411 -2.422 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' ILE . 12.0 Cg_endo -64.37 154.51 70.99 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 121.676 1.584 . . . . 0.0 111.585 178.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.444 ' HE1' ' O ' ' A' ' 30' ' ' VAL . 69.0 t60 -47.73 -53.49 15.02 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.375 1.07 . . . . 0.0 113.633 -176.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -67.97 -31.76 71.7 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.58 -175.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.0 mttm -63.62 -50.55 68.93 Favored 'General case' 0 C--O 1.189 -2.095 0 C-N-CA 120.197 -0.601 . . . . 0.0 110.035 173.098 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.8 mt -50.3 -43.97 22.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 O-C-N 123.533 0.521 . . . . 0.0 110.223 177.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 86.7 t -69.1 -34.13 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.691 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.642 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -70.87 -42.56 69.9 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 123.381 0.672 . . . . 0.0 109.78 -177.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.9 mp -60.91 -48.68 87.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 80.8 mt -61.39 -46.47 90.02 Favored 'General case' 0 C--O 1.215 -0.753 0 N-CA-C 113.103 0.779 . . . . 0.0 113.103 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -61.73 -27.47 68.74 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -178.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -101.48 -19.19 15.64 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -176.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.447 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -91.54 132.21 36.44 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 122.022 -0.424 . . . . 0.0 111.569 -176.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.5 m -126.7 -176.37 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.49 -163.29 32.46 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.495 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.4 mp0 -75.58 122.06 23.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 171.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.652 ' HB ' HG22 ' A' ' 17' ' ' ILE . 70.7 mt -115.57 119.81 62.91 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.278 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -84.61 112.02 20.06 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 113.43 -1.714 . . . . 0.0 110.372 -174.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.602 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 13.5 mtp -120.57 143.9 48.38 Favored 'General case' 0 C--N 1.253 -3.612 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.745 178.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 12.1 mmmt -120.87 118.5 30.11 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 177.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 65.0 p -119.14 145.55 45.88 Favored 'General case' 0 C--N 1.282 -2.359 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.355 -176.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.464 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.3 mtp -115.8 163.9 19.41 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 178.096 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.42 24.33 0.23 Allowed 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.035 2.49 . . . . 0.0 112.352 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.464 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.41 22.91 13.48 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.4 1.48 . . . . 0.0 111.891 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.904 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 175.765 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.448 ' O ' ' HA ' ' A' ' 87' ' ' MET . 28.3 t-20 . . . . . 0 N--CA 1.428 -1.559 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.8 t -108.77 117.76 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.79 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.877 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -115.64 114.86 25.47 Favored 'General case' 1 C--N 1.24 -4.174 0 CA-C-N 113.25 -1.795 . . . . 0.0 106.923 178.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.0 m -79.09 141.84 36.98 Favored 'General case' 0 N--CA 1.406 -2.67 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.217 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.45 HG11 ' CG2' ' A' ' 49' ' ' VAL . 57.1 t -121.86 128.28 75.64 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.363 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.506 178.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.461 HD11 ' HB3' ' A' ' 81' ' ' GLU . 22.3 tp -109.37 112.46 24.6 Favored 'General case' 0 N--CA 1.402 -2.836 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 173.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.76 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 134.83 47.32 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.546 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.015 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.73 103.36 12.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-O 121.102 0.477 . . . . 0.0 109.72 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' HD2' ' HA ' ' A' ' 79' ' ' VAL . 34.0 ttm180 -100.83 113.74 65.73 Favored Pre-proline 0 C--N 1.29 -1.989 0 CA-C-N 115.63 -0.713 . . . . 0.0 110.307 177.76 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.61 -42.11 50.19 Favored 'Trans proline' 0 C--O 1.239 0.572 0 C-N-CA 122.281 1.987 . . . . 0.0 112.181 177.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -173.7 177.04 2.58 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -178.096 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.449 HD23 HG12 ' A' ' 79' ' ' VAL . 53.1 mt -67.01 -22.38 65.9 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 -171.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -71.67 -11.65 60.94 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-O 121.406 0.622 . . . . 0.0 111.426 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.3 -20.98 23.4 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.831 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . 0.495 ' C ' HH21 ' A' ' 19' ' ' ARG . 26.4 mt-30 54.09 -153.58 0.28 Allowed 'General case' 0 C--O 1.22 -0.453 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.448 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.432 ' O ' HG13 ' A' ' 43' ' ' ILE . 2.1 mm? -97.47 -57.55 2.22 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.802 0.811 . . . . 0.0 110.49 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.67 2.99 32.56 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 -174.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.415 ' CD1' ' HB3' ' A' ' 26' ' ' LEU . 39.1 p90 -137.83 152.18 48.84 Favored 'General case' 0 C--O 1.246 0.887 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 176.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -105.81 122.73 46.7 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -104.18 137.27 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -119.14 111.79 18.7 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 175.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 68' ' ' HIS . 95.3 m-20 65.86 9.13 5.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.352 178.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.0 -3.74 24.1 Favored Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -112.82 122.12 66.39 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.695 HD13 HG13 ' A' ' 49' ' ' VAL . 48.2 mt -60.43 116.14 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 123.625 0.77 . . . . 0.0 110.56 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.1 t -98.08 -33.2 11.25 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.013 -173.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 56.9 p -150.91 151.66 32.5 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 60.2 tp -135.42 137.88 42.7 Favored 'General case' 0 N--CA 1.441 -0.906 0 O-C-N 123.482 0.489 . . . . 0.0 110.829 -178.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 63.0 mtt -92.76 116.78 29.34 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.074 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -69.68 126.77 30.73 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 174.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.38 -21.5 39.13 Favored Glycine 0 N--CA 1.42 -2.427 0 C-N-CA 120.412 -0.899 . . . . 0.0 110.984 -174.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -78.91 159.04 45.28 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 177.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.567 ' HB ' HD11 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -55.12 -30.7 24.53 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.866 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.315 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.75 -47.27 84.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 123.569 0.543 . . . . 0.0 111.099 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -67.15 -34.22 77.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.458 0.647 . . . . 0.0 109.492 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 47.8 mtt180 -75.51 -17.27 60.15 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.613 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.77 -37.57 8.53 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 121.74 17.76 3.77 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.026 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.695 HG13 HD13 ' A' ' 35' ' ' ILE . 59.2 t -71.1 141.56 16.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.462 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.8 mmm180 -137.64 146.14 43.54 Favored 'General case' 0 CA--C 1.483 -1.619 0 CA-C-O 121.267 0.556 . . . . 0.0 110.649 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.1 t -69.35 147.07 12.21 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.484 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.52 28.56 47.3 Favored Glycine 0 CA--C 1.487 -1.694 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -123.85 129.03 50.36 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.883 -0.659 . . . . 0.0 111.175 -179.069 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.456 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 10.2 ttm180 -89.23 124.13 34.1 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 175.327 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.58 HG12 HG22 ' A' ' 86' ' ' THR . 25.9 mt -81.54 124.51 39.02 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.141 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.434 HG13 ' HB2' ' A' ' 85' ' ' LYS . 43.1 pt -106.61 -12.5 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.503 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -154.33 145.42 22.75 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -177.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.465 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.2 mt -138.68 121.43 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.299 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 58.2 26.5 13.88 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.071 1.348 . . . . 0.0 111.711 174.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.88 -5.41 58.07 Favored Glycine 0 C--O 1.241 0.555 0 C-N-CA 120.025 -1.084 . . . . 0.0 113.774 177.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.401 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.8 pt20 -110.91 128.74 55.91 Favored 'General case' 0 CA--C 1.499 -0.992 0 CA-C-N 117.609 0.705 . . . . 0.0 109.554 177.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -72.89 112.74 9.2 Favored 'General case' 0 N--CA 1.42 -1.949 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -179.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 32.7 m -102.21 10.77 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.964 0 CA-C-O 121.634 0.731 . . . . 0.0 109.64 -175.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 p -71.69 -16.46 18.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.608 -177.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.63 9.87 21.09 Favored 'General case' 0 C--O 1.244 0.796 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.511 177.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' ' 63' ' ' VAL . 82.5 m -94.37 139.58 22.47 Favored Pre-proline 0 N--CA 1.405 -2.678 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -57.29 144.07 92.02 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.393 2.062 . . . . 0.0 110.483 177.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HB2' ' HA ' ' A' ' 32' ' ' ASN . 35.0 p80 -51.73 -41.1 61.27 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 -177.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -68.01 -35.0 77.57 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 -178.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 15.4 tttm -68.87 -44.65 72.88 Favored 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.465 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 63.8 mt -53.1 -45.06 53.05 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 O-C-N 123.722 0.639 . . . . 0.0 109.747 176.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.5 t -68.79 -32.31 54.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.452 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.2 t-160 -72.7 -38.99 67.34 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -175.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.9 mt -67.99 -50.75 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.675 177.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.3 mt -59.95 -30.92 69.4 Favored 'General case' 0 C--O 1.199 -1.578 0 CA-C-O 120.964 0.411 . . . . 0.0 111.414 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.448 ' O ' HD22 ' A' ' 22' ' ' LEU . 34.1 t -70.41 -26.29 63.62 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.281 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -123.53 8.5 8.96 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -172.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -99.09 122.17 41.96 Favored 'General case' 0 C--O 1.204 -1.335 0 CA-C-N 118.259 0.481 . . . . 0.0 109.744 177.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.504 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -115.42 169.96 5.78 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 CA-C-N 119.058 0.844 . . . . 0.0 109.527 177.342 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.5 -159.27 19.23 Favored Glycine 0 N--CA 1.434 -1.496 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 16' ' ' LEU . 38.6 mt-10 -80.65 111.92 17.54 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.76 ' HB ' HG22 ' A' ' 17' ' ' ILE . 62.0 mt -115.42 117.39 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -173.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -90.16 111.71 22.95 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 25.7 mtm -111.05 160.39 16.9 Favored 'General case' 0 C--N 1.278 -2.505 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.434 ' HB2' HG13 ' A' ' 56' ' ' ILE . 70.1 mmtt -121.95 125.15 45.71 Favored 'General case' 0 CA--C 1.47 -2.12 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 176.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.58 HG22 HG12 ' A' ' 55' ' ' ILE . 66.1 p -123.68 141.6 51.87 Favored 'General case' 0 C--N 1.265 -3.108 0 C-N-CA 120.195 -0.602 . . . . 0.0 110.451 -177.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 53' ' ' HIS . 75.2 mtp -116.53 171.38 4.82 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.158 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -75.51 29.67 0.37 Allowed 'Trans proline' 0 C--N 1.363 1.313 0 C-N-CA 122.823 2.348 . . . . 0.0 112.431 179.007 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.456 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.47 55.19 4.25 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.235 1.414 . . . . 0.0 111.526 -179.161 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.422 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 174.566 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 CA--C 1.501 -0.931 0 CA-C-O 122.587 1.184 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.493 HG22 ' HG2' ' A' ' 87' ' ' MET . 79.8 t -125.16 130.56 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.827 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -175.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.8 m -112.21 106.02 14.5 Favored 'General case' 2 N--CA 1.371 -4.395 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 178.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.432 HG23 ' HD3' ' A' ' 85' ' ' LYS . 28.9 m -79.47 135.28 36.61 Favored 'General case' 0 N--CA 1.395 -3.198 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.32 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.2 t -114.47 134.38 57.61 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.024 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.142 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 81' ' ' GLU . 15.4 tp -119.65 104.49 10.31 Favored 'General case' 0 N--CA 1.396 -3.166 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 172.603 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -103.15 126.79 57.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.054 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -175.09 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.497 ' HG2' HH11 ' A' ' 18' ' ' ARG . 0.5 OUTLIER -95.43 122.03 37.73 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.921 -178.32 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.496 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 64.8 ttt180 -128.04 105.43 20.22 Favored Pre-proline 0 C--N 1.285 -2.226 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.05 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -52.31 -48.03 23.86 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 122.721 2.281 . . . . 0.0 113.372 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -167.93 -172.34 1.8 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.5 mt -70.04 -21.48 63.17 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -173.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.1 mpt_? -72.48 -13.02 61.33 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.305 0.574 . . . . 0.0 110.87 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -103.91 121.94 44.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.251 69.3 mt-30 -103.6 157.54 16.99 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 119.048 -1.061 . . . . 0.0 113.652 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.707 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.5 mm? -44.77 -58.42 3.1 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 126.708 2.003 . . . . 0.0 111.704 -174.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.64 32.43 6.59 Favored Glycine 0 N--CA 1.427 -1.908 0 C-N-CA 119.86 -1.162 . . . . 0.0 112.256 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -159.24 161.45 36.02 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.1 t -119.9 124.03 45.04 Favored 'General case' 0 N--CA 1.415 -2.189 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -117.86 135.01 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.287 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -178.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -120.88 112.53 18.9 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.808 176.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.38 12.27 8.27 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 114.597 -1.183 . . . . 0.0 110.97 177.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.47 -4.86 31.25 Favored Glycine 0 C--O 1.206 -1.635 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.106 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.8 mp -109.25 126.57 66.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 122.117 -0.637 . . . . 0.0 109.617 -178.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 54.6 mt -71.21 115.05 10.5 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.804 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 25.2 t -101.21 -28.98 12.36 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.294 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -150.49 150.42 31.27 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.273 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 154.84 45.16 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -178.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.0 ttt -101.89 121.67 42.56 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.445 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 1.2 tmt_? -69.22 128.88 38.16 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.71 86.41 Favored Glycine 0 C--N 1.311 -0.83 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 -178.172 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.497 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -82.48 161.96 41.28 Favored Glycine 0 N--CA 1.433 -1.542 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -60.8 -30.12 46.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.0 98.01 Favored 'General case' 0 N--CA 1.439 -1.002 0 O-C-N 123.264 0.353 . . . . 0.0 111.07 177.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.438 ' OE2' ' HA ' ' A' ' 40' ' ' ARG . 36.4 tt0 -58.66 -47.84 83.07 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 177.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.497 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 22.3 mtt180 -63.16 -39.67 95.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.155 -1.384 . . . . 0.0 109.23 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -64.3 -30.82 78.89 Favored Glycine 0 C--O 1.248 0.979 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.48 -178.255 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 115.61 9.89 12.14 Favored Glycine 0 N--CA 1.439 -1.137 0 C-N-CA 120.073 -1.06 . . . . 0.0 111.489 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 88.5 t -71.84 134.7 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -143.51 146.32 33.28 Favored 'General case' 0 CA--C 1.495 -1.148 0 C-N-CA 123.666 0.786 . . . . 0.0 109.674 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -67.36 144.34 14.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 CA-C-N 114.15 -1.386 . . . . 0.0 111.136 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.94 61.79 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.911 -0.661 . . . . 0.0 111.475 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -120.39 148.65 43.5 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' THR . 42.2 ttp180 -106.35 132.53 52.27 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.536 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.63 HD13 HG22 ' A' ' 86' ' ' THR . 18.2 mm -75.48 114.61 15.78 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 175.584 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.1 pt -101.03 -15.23 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.808 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 179.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 84' ' ' MET . 38.1 tt0 -156.37 146.12 20.99 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.489 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.5 mt -140.8 122.5 14.63 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 O-C-N 124.388 1.055 . . . . 0.0 108.521 178.302 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 59.32 23.18 11.61 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.708 1.203 . . . . 0.0 111.626 172.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.01 -9.96 40.05 Favored Glycine 0 N--CA 1.439 -1.14 0 C-N-CA 120.535 -0.841 . . . . 0.0 114.061 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.13 134.44 52.72 Favored 'General case' 0 CA--C 1.494 -1.203 0 CA-C-N 118.34 1.07 . . . . 0.0 110.752 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -72.53 112.59 8.72 Favored 'General case' 0 N--CA 1.423 -1.787 0 CA-C-O 121.337 0.589 . . . . 0.0 109.692 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.65 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 25.1 m -109.15 19.38 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-O 122.312 1.053 . . . . 0.0 108.932 -175.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.12 -18.6 19.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.388 -176.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.88 12.03 12.76 Favored 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.669 0.747 . . . . 0.0 109.009 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.65 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 97.3 m -83.88 136.74 41.26 Favored Pre-proline 0 N--CA 1.417 -2.083 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.44 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' THR . 43.0 Cg_exo -60.12 154.87 48.58 Favored 'Trans proline' 0 C--O 1.241 0.662 0 C-N-CA 122.928 2.419 . . . . 0.0 112.912 177.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -45.3 -55.7 5.65 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.715 1.606 . . . . 0.0 111.151 178.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -58.85 -43.6 90.79 Favored 'General case' 0 C--N 1.311 -1.095 0 O-C-N 124.307 1.004 . . . . 0.0 110.546 -175.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -62.21 -54.34 42.35 Favored 'General case' 0 CA--C 1.477 -1.835 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.883 -178.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 73.0 mt -52.01 -42.74 35.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 O-C-N 124.177 0.923 . . . . 0.0 110.383 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 83.6 t -71.66 -39.32 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.657 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 53.8 t60 -69.8 -41.55 74.91 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.519 0.676 . . . . 0.0 109.903 -176.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.6 mt -69.52 -44.03 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 CA-C-N 114.674 -1.148 . . . . 0.0 110.314 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 60.1 mt -59.99 -44.05 94.76 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.829 0.347 . . . . 0.0 111.086 173.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.404 ' C ' HH12 ' A' ' 19' ' ' ARG . 34.6 t -59.16 -27.44 65.66 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 123.49 0.716 . . . . 0.0 112.216 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -109.39 -2.74 17.57 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -176.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.496 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -97.68 130.82 44.65 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.478 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 m -128.3 179.73 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.65 -161.96 28.78 Favored Glycine 0 CA--C 1.489 -1.563 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -178.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.505 ' HB3' HD11 ' A' ' 16' ' ' LEU . 27.9 mt-10 -75.89 119.15 19.47 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 172.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.7 ' HB ' HG22 ' A' ' 17' ' ' ILE . 63.1 mt -117.19 117.63 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.711 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.246 -173.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -82.98 111.8 19.17 Favored 'General case' 0 CA--C 1.492 -1.257 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.603 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.413 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 28.4 mtm -117.55 156.54 27.9 Favored 'General case' 0 C--N 1.269 -2.914 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 173.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.432 ' HD3' HG23 ' A' ' 14' ' ' THR . 35.6 mmtm -123.07 121.65 36.55 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.63 HG22 HD13 ' A' ' 55' ' ' ILE . 68.3 p -116.93 141.49 48.16 Favored 'General case' 0 C--N 1.266 -3.04 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.712 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.493 ' HG2' HG22 ' A' ' 12' ' ' VAL . 85.0 mtp -119.72 170.31 7.04 Favored Pre-proline 0 C--O 1.211 -0.937 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 178.259 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.69 26.64 0.2 Allowed 'Trans proline' 0 CA--C 1.559 1.767 0 C-N-CA 122.865 2.377 . . . . 0.0 113.286 178.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.41 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.39 34.83 18.11 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.586 1.154 . . . . 0.0 111.08 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.418 -2.027 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.396 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 16.8 m120 . . . . . 0 CA--C 1.487 -1.466 0 CA-C-O 121.715 0.769 . . . . 0.0 109.619 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 86' ' ' THR . 39.9 t -141.48 126.13 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.974 0 CA-C-N 114.328 -1.306 . . . . 0.0 108.765 -175.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 85.1 m -111.42 113.44 25.89 Favored 'General case' 2 N--CA 1.376 -4.137 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 176.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.6 m -85.23 137.94 32.66 Favored 'General case' 0 N--CA 1.398 -3.07 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.468 HG11 ' HE2' ' A' ' 84' ' ' MET . 25.4 t -118.01 139.22 46.04 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.955 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 82' ' ' ILE . 19.4 tp -121.14 112.46 18.71 Favored 'General case' 0 N--CA 1.383 -3.803 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.976 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.581 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -98.61 122.44 50.31 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 N-CA-C 106.949 -1.5 . . . . 0.0 106.949 176.314 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.7 mtp180 -107.18 102.07 11.42 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-O 122.661 1.22 . . . . 0.0 109.276 173.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.509 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 74.1 ttt180 -103.75 109.46 62.18 Favored Pre-proline 0 C--N 1.272 -2.802 0 CA-C-N 112.523 -2.126 . . . . 0.0 109.716 -176.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -54.11 -50.8 12.34 Favored 'Trans proline' 0 CA--C 1.542 0.904 0 C-N-CA 122.602 2.201 . . . . 0.0 111.993 178.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -164.88 -172.57 2.64 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.406 HD23 ' CG1' ' A' ' 79' ' ' VAL . 55.6 mt -69.01 -17.26 63.89 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -173.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 -64.55 -23.04 67.14 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.3 0.571 . . . . 0.0 110.676 176.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -105.85 113.16 26.54 Favored 'General case' 0 N--CA 1.422 -1.859 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -178.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -92.14 161.93 14.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.618 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -52.75 -57.11 11.22 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 124.467 1.107 . . . . 0.0 110.662 -173.565 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.57 23.92 10.57 Favored Glycine 0 N--CA 1.434 -1.486 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.861 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -145.94 155.54 42.92 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.0 m -108.6 137.06 47.16 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.92 136.89 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-O 121.49 0.662 . . . . 0.0 110.622 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.468 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 0.0 OUTLIER -128.41 121.15 28.37 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 176.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 63.56 4.27 1.74 Allowed 'General case' 0 N--CA 1.503 2.197 0 C-N-CA 125.101 1.36 . . . . 0.0 111.983 -172.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 104.58 1.07 43.34 Favored Glycine 0 N--CA 1.438 -1.205 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -174.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -102.35 124.05 56.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.688 HD13 HG13 ' A' ' 49' ' ' VAL . 68.1 mt -65.76 117.14 5.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 C-N-CA 124.184 0.994 . . . . 0.0 110.576 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 41.8 t -101.55 -28.33 12.6 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.851 -175.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.1 t -154.56 156.58 36.86 Favored 'General case' 0 C--O 1.246 0.876 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.4 HD21 ' HA ' ' A' ' 45' ' ' GLU . 57.5 tp -134.43 140.11 46.02 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 123.624 0.77 . . . . 0.0 109.826 -178.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.3 tpt -91.89 127.0 37.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -76.39 135.33 39.48 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -178.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.39 1.06 86.26 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 121.217 -0.516 . . . . 0.0 111.958 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -93.6 167.52 28.59 Favored Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.8 pt -56.75 -36.42 49.16 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.96 0 N-CA-C 113.226 0.825 . . . . 0.0 113.226 178.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.581 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.65 -37.61 79.17 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.4 ' HA ' HD21 ' A' ' 38' ' ' LEU . 14.1 tt0 -61.26 -49.26 77.79 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.096 0.95 . . . . 0.0 108.822 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -76.77 -16.32 59.51 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 114.199 -1.364 . . . . 0.0 111.198 -176.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.59 -19.55 70.84 Favored Glycine 0 N--CA 1.432 -1.618 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.603 176.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.74 16.99 20.43 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.239 177.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.688 HG13 HD13 ' A' ' 35' ' ' ILE . 51.0 t -69.5 133.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 CA-C-O 120.922 0.391 . . . . 0.0 110.561 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 20.9 mmt180 -132.38 137.03 47.2 Favored 'General case' 0 CA--C 1.484 -1.577 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.335 178.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.7 t -72.23 147.51 10.32 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.68 0 CA-C-N 113.913 -1.494 . . . . 0.0 110.115 -178.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.0 23.38 45.5 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.538 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 17.1 m-70 -121.83 139.62 53.39 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.199 -0.5 . . . . 0.0 111.377 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.555 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 9.0 ttm180 -94.39 120.82 35.2 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.227 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 86' ' ' THR . 41.6 mt -76.24 122.09 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 175.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.9 pt -102.61 -14.5 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.552 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.251 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.524 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.5 tt0 -161.38 142.88 11.56 Favored 'General case' 0 CA--C 1.485 -1.531 0 C-N-CA 120.046 -0.661 . . . . 0.0 110.148 -174.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 75.4 mt -133.26 123.06 46.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 73.38 -21.18 0.26 Allowed 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.988 1.315 . . . . 0.0 112.663 172.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 143.42 -8.31 2.09 Favored Glycine 0 N--CA 1.438 -1.23 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -175.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.466 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 20.4 pt20 -107.87 123.48 48.65 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 m -69.79 111.76 5.77 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 121.512 0.672 . . . . 0.0 109.71 179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 34.0 m -103.47 16.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 CA-C-O 122.062 0.934 . . . . 0.0 109.346 -175.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -71.7 -17.91 19.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.56 -179.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.69 11.92 21.08 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.15 -0.932 . . . . 0.0 109.206 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.461 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.5 m -101.9 137.81 19.62 Favored Pre-proline 0 N--CA 1.408 -2.557 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.413 ' O ' HG13 ' A' ' 71' ' ' ILE . 73.9 Cg_endo -76.64 168.08 24.32 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 122.58 2.186 . . . . 0.0 112.551 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -44.62 -55.01 5.55 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 124.977 1.311 . . . . 0.0 111.617 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -56.82 -43.61 81.21 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.352 1.032 . . . . 0.0 110.824 -173.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.0 mtpt -73.54 -45.89 50.82 Favored 'General case' 0 CA--C 1.485 -1.521 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 67' ' ' PRO . 61.7 mt -54.67 -39.86 48.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 121.135 0.493 . . . . 0.0 109.741 178.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.74 -37.59 69.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.479 177.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -64.59 -39.75 94.29 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -177.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.9 mt -71.06 -53.34 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.675 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.979 -179.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.7 mt -56.39 -41.77 76.81 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 10.8 t -63.0 -29.42 70.81 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 123.336 0.655 . . . . 0.0 111.71 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -104.63 -13.39 15.98 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.46 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.509 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.87 133.99 34.8 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.316 -0.554 . . . . 0.0 112.494 -174.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.406 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.5 m -137.44 175.81 8.79 Favored 'Isoleucine or valine' 0 C--O 1.248 1.02 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.45 -161.94 19.75 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -77.29 107.76 9.93 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 173.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.481 ' O ' HD12 ' A' ' 16' ' ' LEU . 82.3 mt -107.86 116.67 51.83 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -174.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -97.78 110.2 22.82 Favored 'General case' 0 CA--C 1.453 -2.753 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.524 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 11.3 ttp -112.91 141.38 46.81 Favored 'General case' 1 C--N 1.242 -4.097 0 N-CA-C 105.739 -1.949 . . . . 0.0 105.739 -174.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm -121.42 130.39 53.56 Favored 'General case' 0 CA--C 1.452 -2.805 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 -177.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 38.5 p -126.34 153.17 45.25 Favored 'General case' 0 C--N 1.275 -2.656 0 O-C-N 123.532 0.52 . . . . 0.0 110.015 -174.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.453 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.8 mtp -122.08 168.76 10.78 Favored Pre-proline 0 C--N 1.301 -1.526 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 176.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.94 22.33 0.31 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 123.137 2.558 . . . . 0.0 112.595 178.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.555 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 73.28 3.51 4.64 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 126.075 1.75 . . . . 0.0 113.645 177.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.609 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 175.619 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.2 m120 . . . . . 0 CA--C 1.491 -1.304 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.471 HG22 ' HG2' ' A' ' 87' ' ' MET . 55.7 t -128.58 129.68 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.628 -175.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.3 m -117.77 113.73 22.26 Favored 'General case' 0 N--CA 1.391 -3.392 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.602 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.3 m -81.42 128.83 34.29 Favored 'General case' 0 N--CA 1.398 -3.042 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.333 -178.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.456 HG11 ' CG2' ' A' ' 49' ' ' VAL . 53.1 t -110.2 136.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.767 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.058 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.491 HD11 ' HB3' ' A' ' 81' ' ' GLU . 21.3 tp -119.07 109.37 15.83 Favored 'General case' 0 N--CA 1.384 -3.767 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 172.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.587 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.7 136.07 31.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -115.45 103.75 11.07 Favored 'General case' 0 C--N 1.287 -2.13 0 CA-C-O 122.195 0.998 . . . . 0.0 110.796 178.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.433 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 66.0 ttt180 -103.12 113.42 65.85 Favored Pre-proline 0 C--N 1.283 -2.292 0 CA-C-N 113.408 -1.724 . . . . 0.0 109.952 -175.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.8 -56.06 2.49 Favored 'Trans proline' 0 CA--C 1.552 1.414 0 C-N-CA 122.937 2.425 . . . . 0.0 113.991 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.55 -175.59 5.49 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' CG1' ' A' ' 79' ' ' VAL . 61.3 mt -71.06 -17.87 62.58 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -173.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -79.0 -11.19 60.0 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 121.618 0.723 . . . . 0.0 111.04 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -97.66 143.01 28.75 Favored 'General case' 0 N--CA 1.403 -2.799 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -97.07 -157.27 0.58 Allowed 'General case' 0 C--N 1.26 -3.325 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -93.83 -51.24 4.98 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.25 6.47 Favored Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.003 177.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -149.26 157.18 43.13 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.5 m -105.44 121.92 44.91 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 178.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.28 130.72 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.757 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -111.0 102.44 10.91 Favored 'General case' 0 C--N 1.287 -2.132 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 178.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 67.23 14.84 9.87 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.16 175.726 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.52 -3.17 23.39 Favored Glycine 0 N--CA 1.438 -1.208 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.94 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 3.1 mp -114.48 122.27 68.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 O-C-N 122.389 -0.477 . . . . 0.0 109.869 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.721 HD13 HG13 ' A' ' 49' ' ' VAL . 55.5 mt -65.24 111.22 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 123.647 0.779 . . . . 0.0 109.475 179.032 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -105.6 -19.41 13.78 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.988 -176.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 m -149.2 150.42 32.59 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 121.667 -0.645 . . . . 0.0 109.84 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.414 HD21 ' HA ' ' A' ' 45' ' ' GLU . 65.0 tp -135.63 141.51 45.07 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 120.88 0.371 . . . . 0.0 110.738 -177.796 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.7 ttt -82.55 103.43 12.07 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -79.51 107.14 12.06 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.535 0.683 . . . . 0.0 110.082 -174.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.23 11.35 Favored Glycine 0 N--CA 1.433 -1.552 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -175.172 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.77 178.49 53.68 Favored Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.097 -0.551 . . . . 0.0 111.782 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.414 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.5 OUTLIER -58.1 -41.15 79.88 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.927 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -177.479 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.74 -37.91 88.44 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.635 0.255 . . . . 0.0 111.616 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.414 ' HA ' HD21 ' A' ' 38' ' ' LEU . 3.6 tm-20 -61.78 -46.4 89.71 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 178.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.9 mtt-85 -74.77 -25.1 58.84 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.615 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.5 -19.2 79.93 Favored Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.455 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.65 7.88 29.13 Favored Glycine 0 CA--C 1.507 -0.44 0 C-N-CA 120.137 -1.03 . . . . 0.0 112.256 177.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.721 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -73.58 135.47 27.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.1 mmt-85 -137.72 155.42 49.11 Favored 'General case' 0 CA--C 1.492 -1.283 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 176.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 74.1 t -80.7 139.38 18.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.382 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.141 -175.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.33 6.08 51.43 Favored Glycine 0 CA--C 1.497 -1.034 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.479 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.581 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 74.8 m-70 -106.23 142.88 35.17 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 115.099 -0.55 . . . . 0.0 111.228 179.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.49 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 39.2 ttm180 -99.18 132.66 44.34 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 171.618 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.481 HG12 HG22 ' A' ' 86' ' ' THR . 28.0 mt -85.68 123.37 39.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.467 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 176.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.6 pt -102.99 -12.92 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.199 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.291 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 84' ' ' MET . 36.9 tt0 -154.35 141.68 19.6 Favored 'General case' 0 CA--C 1.479 -1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -178.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.495 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.8 mt -140.91 124.4 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 124.407 1.067 . . . . 0.0 108.155 177.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 68.55 13.92 9.01 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.892 0.853 . . . . 0.0 110.287 171.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.7 -2.73 49.07 Favored Glycine 0 N--CA 1.437 -1.25 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.934 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.441 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.4 pt20 -112.85 130.98 55.9 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.617 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 33.2 t -68.38 114.23 6.64 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.602 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.7 m -108.84 17.08 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 CA-C-O 121.884 0.85 . . . . 0.0 109.394 -176.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -71.34 -15.22 18.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.841 -1.072 . . . . 0.0 112.04 -175.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -120.01 7.31 10.86 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.216 0.531 . . . . 0.0 109.568 175.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.602 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.9 m -80.8 138.07 50.4 Favored Pre-proline 0 N--CA 1.418 -2.042 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.243 -177.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.98 157.27 44.64 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 123.081 2.52 . . . . 0.0 113.223 178.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -45.96 -55.86 6.24 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 125.972 1.709 . . . . 0.0 110.61 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -54.09 -51.83 62.9 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 124.492 1.117 . . . . 0.0 110.813 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.536 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.9 mptt -58.93 -54.0 52.09 Favored 'General case' 0 CA--C 1.486 -1.482 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.812 -176.427 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 70.4 mt -50.71 -43.28 23.9 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 124.312 1.007 . . . . 0.0 110.358 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.0 t -73.2 -36.86 51.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.744 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -73.45 -37.69 65.73 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.348 0.594 . . . . 0.0 109.903 -175.097 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.1 mt -68.53 -47.64 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.307 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 59.2 mt -58.28 -40.32 81.59 Favored 'General case' 0 C--O 1.212 -0.905 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.492 176.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.3 t -62.25 -26.99 68.69 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -105.98 -17.3 14.39 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.433 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.9 127.25 35.97 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.688 -176.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.5 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -127.53 -179.38 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.11 -155.61 24.58 Favored Glycine 0 CA--C 1.493 -1.292 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.491 ' HB3' HD11 ' A' ' 16' ' ' LEU . 45.3 mt-10 -77.69 108.52 10.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 174.741 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.587 ' HB ' HG22 ' A' ' 17' ' ' ILE . 64.6 mt -109.63 117.72 55.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -176.154 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 39.8 m-70 -93.05 116.93 29.5 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 -178.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.465 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.0 mtm -120.2 156.84 30.32 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 177.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.467 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 68.8 mmtt -121.47 123.81 42.93 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 176.35 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.581 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 72.1 p -119.36 139.84 51.33 Favored 'General case' 0 C--N 1.27 -2.875 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.208 -177.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.471 ' HG2' HG22 ' A' ' 12' ' ' VAL . 82.9 mtp -120.85 171.72 5.57 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -72.1 24.91 0.26 Allowed 'Trans proline' 0 N--CA 1.497 1.728 0 C-N-CA 123.09 2.527 . . . . 0.0 112.88 177.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.49 ' HA ' ' CB ' ' A' ' 54' ' ' ARG . . . 71.33 20.59 4.93 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 125.127 1.371 . . . . 0.0 112.803 177.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.762 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.021 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 CA--C 1.49 -1.344 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -130.66 133.7 63.06 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 CA-C-O 122.315 1.055 . . . . 0.0 111.861 -172.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.4 m -127.9 121.94 31.27 Favored 'General case' 0 N--CA 1.392 -3.355 0 CA-C-N 113.262 -1.79 . . . . 0.0 106.864 176.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 m -82.82 141.92 31.93 Favored 'General case' 0 N--CA 1.404 -2.774 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.574 -176.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' CG2' ' A' ' 49' ' ' VAL . 56.1 t -116.47 136.65 52.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.067 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.412 HD12 ' O ' ' A' ' 82' ' ' ILE . 29.1 tp -122.1 119.73 32.2 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-O 121.961 0.886 . . . . 0.0 109.886 175.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.557 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -97.49 134.13 36.68 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.098 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.418 178.594 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.02 101.34 10.16 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 171.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.531 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.0 ttt180 -108.31 107.97 60.67 Favored Pre-proline 0 C--N 1.282 -2.341 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.451 -178.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -58.03 -41.09 71.71 Favored 'Trans proline' 0 CA--C 1.546 1.117 0 C-N-CA 122.607 2.205 . . . . 0.0 113.423 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -167.17 176.64 6.67 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.45 HD23 ' CG1' ' A' ' 79' ' ' VAL . 73.1 mt -68.95 -22.39 64.13 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 125.152 1.381 . . . . 0.0 111.213 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.424 ' HA ' ' NE ' ' A' ' 23' ' ' ARG . 7.3 mmp_? -59.11 -21.89 59.98 Favored 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.058 0.848 . . . . 0.0 110.233 174.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -103.89 118.35 36.49 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 104.899 -2.26 . . . . 0.0 104.899 178.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.22 168.79 10.69 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.587 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -64.05 -59.85 3.97 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.221 0.534 . . . . 0.0 111.282 -171.014 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.445 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 103.45 34.63 3.82 Favored Glycine 0 N--CA 1.431 -1.658 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.287 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -155.43 157.39 36.94 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.6 m -117.34 136.04 53.42 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.85 128.15 64.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.772 0.796 . . . . 0.0 112.923 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -121.45 115.44 22.88 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.454 176.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 68.99 2.6 3.65 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 125.538 1.535 . . . . 0.0 112.283 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 118.42 -12.6 12.38 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -96.43 128.17 47.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 O-C-N 122.385 -0.479 . . . . 0.0 110.548 -179.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.746 HD13 HG13 ' A' ' 49' ' ' VAL . 72.9 mt -68.31 114.45 5.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 124.458 1.103 . . . . 0.0 109.608 176.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.5 t -98.63 -23.78 15.34 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.006 -177.287 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.8 p -156.52 152.06 26.87 Favored 'General case' 0 C--N 1.322 -0.629 0 O-C-N 122.297 -0.252 . . . . 0.0 111.316 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.445 HD12 ' O ' ' A' ' 27' ' ' GLY . 48.7 tp -125.91 148.55 49.18 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 124.356 1.062 . . . . 0.0 109.072 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -105.88 123.52 48.09 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.376 0.608 . . . . 0.0 110.692 -179.312 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 20.4 tpp85 -60.36 130.84 48.59 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.23 176.587 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.05 5.99 89.25 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.856 178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.58 161.2 27.15 Favored Glycine 0 N--CA 1.423 -2.179 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 pt -60.24 -32.61 51.12 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.98 0 C-N-CA 120.764 -0.375 . . . . 0.0 111.947 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.83 -38.85 86.88 Favored 'General case' 0 N--CA 1.443 -0.779 0 C-N-CA 122.986 0.514 . . . . 0.0 111.812 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.44 ' HA ' HD21 ' A' ' 38' ' ' LEU . 44.4 tt0 -64.31 -38.88 92.6 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -90.48 -0.41 57.65 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.902 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.31 -19.56 38.35 Favored Glycine 0 N--CA 1.433 -1.504 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 175.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.16 9.01 26.6 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.103 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.746 HG13 HD13 ' A' ' 35' ' ' ILE . 60.0 t -69.82 140.01 19.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 13.9 mmt180 -145.08 141.8 29.14 Favored 'General case' 0 CA--C 1.49 -1.354 0 C-N-CA 123.406 0.682 . . . . 0.0 110.989 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.74 139.9 20.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.783 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.18 14.29 59.17 Favored Glycine 0 C--N 1.305 -1.147 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.558 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -108.71 133.85 52.23 Favored 'General case' 0 N--CA 1.428 -1.575 0 CA-C-O 121.32 0.581 . . . . 0.0 111.611 178.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -92.76 114.79 27.44 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.492 -1.231 . . . . 0.0 108.085 177.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 30.2 mt -78.54 122.9 34.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 62' ' ' SER . 37.2 pt -106.43 -11.79 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.505 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.568 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.8 tt0 -154.76 144.91 21.87 Favored 'General case' 0 CA--C 1.479 -1.778 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.107 -177.015 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -141.82 125.15 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 174.57 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 69.43 -2.72 1.8 Allowed 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.991 1.317 . . . . 0.0 112.846 172.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.43 -4.11 10.25 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.968 -178.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -112.28 130.68 55.86 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 10.5 p -73.0 108.3 5.82 Favored 'General case' 0 N--CA 1.425 -1.68 0 CA-C-O 121.795 0.807 . . . . 0.0 110.285 177.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.552 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.6 m -98.86 16.52 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-O 122.271 1.034 . . . . 0.0 110.053 -172.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.6 p -75.58 -10.27 13.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.072 -177.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.95 16.33 10.88 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.063 -0.972 . . . . 0.0 108.495 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.7 m -103.26 135.22 19.43 Favored Pre-proline 0 N--CA 1.407 -2.577 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.49 159.81 52.18 Favored 'Trans proline' 0 C--O 1.244 0.802 0 C-N-CA 122.258 1.972 . . . . 0.0 112.596 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -43.15 -54.84 4.22 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.87 1.668 . . . . 0.0 112.177 -178.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -56.39 -47.03 79.79 Favored 'General case' 0 CA--C 1.497 -1.067 0 O-C-N 124.027 0.83 . . . . 0.0 110.663 -175.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.468 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 12.6 mptt -63.76 -54.21 38.92 Favored 'General case' 0 N--CA 1.426 -1.639 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.682 -177.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.5 mt -51.08 -44.75 29.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 O-C-N 124.098 0.874 . . . . 0.0 110.112 179.335 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.4 t -71.53 -36.82 61.67 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.746 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -72.81 -40.57 65.74 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -174.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 46.0 mt -66.0 -46.26 88.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.895 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.9 mt -58.5 -41.04 84.47 Favored 'General case' 0 C--O 1.214 -0.811 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.554 175.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 50.8 m -63.06 -27.61 69.52 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.2 m-80 -104.45 -10.65 17.55 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -175.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.39 133.4 36.68 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.76 -178.409 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.45 ' CG1' HD23 ' A' ' 22' ' ' LEU . 3.1 m -129.69 -178.57 2.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.583 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 175.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.57 -154.82 33.14 Favored Glycine 0 CA--C 1.488 -1.624 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -73.51 112.64 9.79 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 121.592 0.711 . . . . 0.0 109.722 174.28 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.412 ' O ' HD12 ' A' ' 16' ' ' LEU . 74.9 mt -118.11 117.47 54.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.358 0 CA-C-N 115.328 -0.851 . . . . 0.0 108.711 -177.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -88.38 129.98 35.27 Favored 'General case' 0 CA--C 1.473 -2.013 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.201 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.453 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.3 mtm -129.19 153.3 47.87 Favored 'General case' 0 C--N 1.262 -3.209 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 171.148 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 62.9 mmtt -119.18 122.61 42.39 Favored 'General case' 0 C--N 1.268 -2.975 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 177.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 52.7 p -121.82 143.61 49.3 Favored 'General case' 0 C--N 1.267 -2.992 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.102 -177.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.556 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.3 mtp -111.22 164.07 15.85 Favored Pre-proline 0 C--N 1.303 -1.421 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 178.152 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -78.33 29.68 0.45 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 122.786 2.324 . . . . 0.0 109.3 172.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.556 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.97 11.5 8.39 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 127.015 2.126 . . . . 0.0 112.017 -178.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.204 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.438 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 88.9 m-20 . . . . . 0 CA--C 1.502 -0.894 0 CA-C-O 121.844 0.831 . . . . 0.0 109.853 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.4 t -122.79 122.19 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 CA-C-O 121.885 0.85 . . . . 0.0 109.518 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.9 m -108.49 108.81 19.89 Favored 'General case' 0 C--N 1.246 -3.916 0 CA-C-N 113.332 -1.758 . . . . 0.0 107.133 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 85' ' ' LYS . 15.9 m -79.43 132.63 36.43 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.435 178.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.479 HG11 ' HE2' ' A' ' 84' ' ' MET . 37.2 t -111.17 140.65 29.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.335 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.517 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 15.1 tp -122.83 112.76 18.27 Favored 'General case' 0 N--CA 1.379 -3.983 0 C-N-CA 119.286 -0.966 . . . . 0.0 108.814 172.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.89 129.21 49.58 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.968 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.58 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -111.84 102.78 11.03 Favored 'General case' 0 N--CA 1.406 -2.64 0 CA-C-O 122.506 1.145 . . . . 0.0 109.667 174.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.612 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.3 ttt180 -112.38 110.79 52.9 Favored Pre-proline 0 C--N 1.276 -2.609 0 CA-C-N 112.752 -2.022 . . . . 0.0 110.718 -176.596 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -57.46 -51.88 7.49 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 122.567 2.178 . . . . 0.0 112.577 178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.47 ' OD2' ' HG2' ' A' ' 23' ' ' ARG . 1.0 OUTLIER -158.56 -174.0 4.57 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.838 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.427 HD23 HG12 ' A' ' 79' ' ' VAL . 46.6 mt -72.08 -14.16 61.78 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.47 ' HG2' ' OD2' ' A' ' 21' ' ' ASP . 18.5 mmt180 -66.31 -23.95 66.46 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -94.4 110.18 21.98 Favored 'General case' 0 CA--C 1.48 -1.72 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 176.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -92.19 155.44 18.01 Favored 'General case' 0 C--N 1.281 -2.388 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.806 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.657 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.2 mm? -50.78 -61.76 2.02 Favored 'General case' 0 C--O 1.237 0.428 0 O-C-N 124.913 1.383 . . . . 0.0 110.642 -175.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.48 -10.77 35.95 Favored Glycine 0 N--CA 1.434 -1.496 0 C-N-CA 120.66 -0.781 . . . . 0.0 111.579 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.422 ' CE1' ' HB3' ' A' ' 26' ' ' LEU . 50.6 p90 -112.89 151.76 30.1 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.023 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 t -107.08 122.38 46.36 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -112.44 131.35 64.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 CA-C-O 121.576 0.703 . . . . 0.0 112.18 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -131.52 122.14 25.65 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 114.495 -1.229 . . . . 0.0 107.843 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.46 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 88.0 m-20 66.89 13.98 9.65 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-O 121.902 0.858 . . . . 0.0 111.752 177.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.46 -6.72 65.71 Favored Glycine 0 N--CA 1.432 -1.616 0 CA-C-N 115.175 -0.92 . . . . 0.0 111.313 -178.179 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.14 128.82 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-O 121.223 0.535 . . . . 0.0 110.22 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.645 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -67.11 111.01 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.221 175.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -95.57 -27.99 15.07 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.645 -175.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.4 m -150.47 158.91 44.69 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 121.959 -0.463 . . . . 0.0 110.072 -177.65 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.2 tp -142.85 135.44 27.71 Favored 'General case' 0 C--O 1.239 0.529 0 O-C-N 123.835 0.709 . . . . 0.0 111.258 -178.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ttt -82.3 121.92 27.29 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 176.125 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -74.33 122.86 23.57 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.056 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.17 -3.22 72.63 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -177.462 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -83.47 170.31 48.43 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.7 pt -63.03 -37.29 78.98 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.399 0 CA-C-N 117.311 0.556 . . . . 0.0 111.899 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.497 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -55.23 -45.56 75.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -62.78 -43.15 99.56 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.507 0.67 . . . . 0.0 109.936 178.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -73.76 -20.25 60.55 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.125 -0.943 . . . . 0.0 111.778 -179.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.26 -19.13 57.82 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.963 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.62 15.59 22.33 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.277 -0.963 . . . . 0.0 112.456 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.645 HG13 HD13 ' A' ' 35' ' ' ILE . 79.2 t -75.39 122.8 29.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 8.1 mmm180 -122.39 150.87 41.84 Favored 'General case' 0 CA--C 1.474 -1.957 0 CA-C-O 121.348 0.594 . . . . 0.0 110.416 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 78.1 t -78.25 141.4 15.53 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.772 0 CA-C-N 114.018 -1.446 . . . . 0.0 109.424 -176.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.85 30.03 33.22 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -175.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.2 m170 -123.31 135.06 54.03 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.803 -0.698 . . . . 0.0 109.915 177.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.7 ttp180 -97.91 123.89 42.1 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 177.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.603 HG12 HG22 ' A' ' 86' ' ' THR . 32.6 mt -79.04 127.12 39.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 O-C-N 123.852 0.72 . . . . 0.0 109.779 178.087 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 41.6 pt -109.75 -13.93 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.95 143.11 16.74 Favored 'General case' 0 CA--C 1.483 -1.634 0 C-N-CA 120.025 -0.67 . . . . 0.0 109.314 -175.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.467 ' CD1' HG21 ' A' ' 63' ' ' VAL . 66.3 mt -137.71 127.84 36.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 70.84 -18.66 0.25 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.846 1.259 . . . . 0.0 113.485 172.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 130.59 8.41 3.16 Favored Glycine 0 C--N 1.299 -1.52 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -176.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -118.74 139.85 50.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 176.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.7 t -77.44 108.11 10.36 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.537 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.8 m -101.04 8.57 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.231 0 CA-C-O 121.966 0.889 . . . . 0.0 109.384 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.03 -12.19 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.783 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.156 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.19 14.52 16.97 Favored 'General case' 0 N--CA 1.437 -1.093 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.735 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 80.3 m -102.9 138.63 19.62 Favored Pre-proline 0 N--CA 1.409 -2.511 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.407 ' O ' HG13 ' A' ' 71' ' ' ILE . 59.4 Cg_exo -49.94 139.9 32.44 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.813 2.342 . . . . 0.0 110.751 176.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.46 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 32.6 p80 -51.66 -42.76 62.35 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -176.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -69.26 -37.59 77.98 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.665 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 tttm -60.13 -44.88 94.58 Favored 'General case' 0 CA--C 1.492 -1.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.907 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 67' ' ' PRO . 66.1 mt -52.05 -44.5 39.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 O-C-N 124.006 0.816 . . . . 0.0 109.762 178.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 96.8 t -67.24 -34.92 72.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.69 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.3 t-160 -74.29 -39.51 62.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 54.1 mt -65.7 -49.16 79.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.84 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 77.6 mt -57.12 -41.14 78.46 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.105 0.479 . . . . 0.0 110.985 175.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.5 t -57.08 -36.7 70.9 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 123.808 0.843 . . . . 0.0 111.53 178.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -98.6 -11.45 22.11 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -176.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.612 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -86.89 131.01 34.23 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -173.501 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.427 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -134.64 179.01 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.99 -159.74 22.18 Favored Glycine 0 CA--C 1.496 -1.13 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.413 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.2 mp0 -78.98 108.11 12.22 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 171.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 17' ' ' ILE . 88.6 mt -104.47 117.27 49.78 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.471 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -175.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -100.02 111.3 23.6 Favored 'General case' 0 CA--C 1.479 -1.788 0 N-CA-C 105.014 -2.217 . . . . 0.0 105.014 -176.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.479 ' HE2' HG11 ' A' ' 15' ' ' VAL . 23.2 ttp -122.95 148.63 45.26 Favored 'General case' 0 C--N 1.257 -3.45 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -173.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.465 ' HD3' HG23 ' A' ' 14' ' ' THR . 29.0 mmtm -117.88 128.36 54.75 Favored 'General case' 0 CA--C 1.474 -1.971 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -177.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.603 HG22 HG12 ' A' ' 55' ' ' ILE . 54.0 p -127.74 143.39 51.14 Favored 'General case' 0 C--N 1.277 -2.567 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.429 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.498 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.5 mtp -112.9 168.72 7.27 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 177.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 12.8 Cg_exo -74.48 30.05 0.34 Allowed 'Trans proline' 0 N--CA 1.489 1.238 0 C-N-CA 122.997 2.465 . . . . 0.0 111.578 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.498 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 68.31 23.46 7.69 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 126.308 1.843 . . . . 0.0 111.815 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.419 -1.984 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.991 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.504 -0.819 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.8 m 61.22 77.13 0.34 Allowed 'General case' 0 C--O 1.246 0.895 0 O-C-N 124.285 0.99 . . . . 0.0 110.166 -178.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 50.2 mtt -119.2 141.6 48.74 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.744 -174.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.68 -125.65 8.47 Favored Glycine 0 CA--C 1.487 -1.665 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.254 169.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -96.54 91.74 5.92 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.408 0.623 . . . . 0.0 110.588 -177.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t -128.59 126.81 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.373 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.465 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.8 m -118.09 107.24 13.75 Favored 'General case' 0 C--N 1.251 -3.716 0 CA-C-N 113.628 -1.624 . . . . 0.0 107.661 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.9 m -79.07 140.74 37.81 Favored 'General case' 0 N--CA 1.401 -2.908 0 CA-C-N 115.487 -0.778 . . . . 0.0 109.8 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -122.45 136.68 58.49 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.117 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.322 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.464 ' O ' ' HA2' ' A' ' 47' ' ' GLY . 29.9 tp -115.64 115.96 27.29 Favored 'General case' 0 N--CA 1.396 -3.152 0 C-N-CA 120.205 -0.598 . . . . 0.0 109.446 173.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.611 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -98.59 130.95 46.66 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.05 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.661 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 55.5 mtp180 -115.57 101.38 8.81 Favored 'General case' 0 N--CA 1.408 -2.572 0 CA-C-O 122.446 1.117 . . . . 0.0 108.829 171.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.475 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 75.3 ttt180 -100.79 119.48 58.28 Favored Pre-proline 0 C--N 1.275 -2.656 0 CA-C-N 112.939 -1.937 . . . . 0.0 111.896 -174.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.89 -48.48 12.43 Favored 'Trans proline' 0 CA--C 1.545 1.029 0 C-N-CA 122.92 2.414 . . . . 0.0 112.983 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -165.92 -175.15 3.28 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.427 HD22 ' O ' ' A' ' 76' ' ' SER . 59.0 mt -73.7 -11.73 60.5 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 115.064 1.505 . . . . 0.0 115.064 -173.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -86.68 -12.42 48.43 Favored 'General case' 0 C--N 1.292 -1.901 0 CA-C-O 121.743 0.782 . . . . 0.0 111.0 177.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -97.25 89.93 4.93 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 173.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -77.47 161.76 27.7 Favored 'General case' 0 N--CA 1.415 -2.218 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.094 -177.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.713 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.4 mm? -45.89 -48.84 16.03 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 125.444 1.498 . . . . 0.0 111.55 -171.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.08 13.65 45.17 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 119.714 -1.231 . . . . 0.0 111.568 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -137.31 148.57 46.44 Favored 'General case' 0 N--CA 1.426 -1.643 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 175.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.2 m -96.46 122.54 39.46 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -120.52 143.22 33.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -130.88 114.7 15.6 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 173.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 68' ' ' HIS . 93.3 m-20 64.9 14.45 9.26 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.563 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.55 -3.21 34.46 Favored Glycine 0 N--CA 1.434 -1.48 0 C-N-CA 120.52 -0.847 . . . . 0.0 111.737 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.58 124.55 66.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 O-C-N 121.964 -0.727 . . . . 0.0 110.769 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.662 HD13 HG13 ' A' ' 49' ' ' VAL . 61.9 mt -69.05 116.72 10.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 114.513 -1.221 . . . . 0.0 110.576 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -97.59 -32.23 11.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.583 -177.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.9 t -155.01 153.47 31.04 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.3 tp -132.13 130.85 41.69 Favored 'General case' 0 C--O 1.243 0.718 0 C-N-CA 123.197 0.599 . . . . 0.0 110.478 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -84.75 115.54 22.76 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 175.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -70.84 134.96 47.77 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -177.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.14 -2.72 75.69 Favored Glycine 0 C--N 1.302 -1.317 0 C-N-CA 121.193 -0.527 . . . . 0.0 111.802 -175.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.04 168.6 31.45 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.411 HG13 ' O ' ' A' ' 26' ' ' LEU . 3.0 pt -57.15 -36.82 52.88 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.611 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -61.65 -35.51 78.13 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -66.28 -41.46 89.82 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -66.91 -31.76 72.57 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 114.254 -1.339 . . . . 0.0 109.891 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -70.93 -27.3 72.46 Favored Glycine 0 N--CA 1.44 -1.1 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.822 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.6 21.46 10.47 Favored Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.662 HG13 HD13 ' A' ' 35' ' ' ILE . 73.8 t -77.74 137.39 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 48.8 mmt-85 -136.07 146.89 47.55 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.92 140.51 19.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 CA-C-N 114.281 -1.327 . . . . 0.0 109.708 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 25.11 27.85 Favored Glycine 0 N--CA 1.431 -1.643 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 -178.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.546 ' HB2' HD12 ' A' ' 35' ' ' ILE . 6.8 m170 -119.18 144.95 46.4 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.901 -0.65 . . . . 0.0 110.227 176.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 43.4 ttp180 -107.21 124.06 49.19 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.338 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 86' ' ' THR . 28.7 mm -72.96 115.09 13.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.444 HG21 ' SD ' ' A' ' 87' ' ' MET 0.275 2.1 pp -103.65 -18.08 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.752 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' MET . 33.1 tt0 -154.0 146.77 24.29 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.468 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.5 mt -139.47 119.47 13.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 O-C-N 124.25 0.969 . . . . 0.0 109.153 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 96.7 m-20 46.9 33.25 2.13 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 115.186 1.55 . . . . 0.0 115.186 178.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.84 -0.99 41.7 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.087 -1.054 . . . . 0.0 114.035 175.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -119.67 125.78 49.53 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 117.834 0.817 . . . . 0.0 109.95 175.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -69.28 110.76 4.78 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.549 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.2 m -103.11 13.56 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.707 0.765 . . . . 0.0 110.089 -174.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.0 p -72.8 -15.38 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.747 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.355 -176.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -117.32 14.63 14.77 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.794 0.807 . . . . 0.0 109.153 176.112 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.549 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.9 m -93.64 140.28 23.04 Favored Pre-proline 0 N--CA 1.411 -2.402 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -70.16 161.72 44.95 Favored 'Trans proline' 0 CA--C 1.544 1.024 0 C-N-CA 121.862 1.708 . . . . 0.0 113.225 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.428 ' HB2' ' OD1' ' A' ' 32' ' ' ASN . 4.2 t60 -42.63 -56.28 3.19 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.994 2.118 . . . . 0.0 111.997 -178.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.84 -50.97 71.49 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.298 0.999 . . . . 0.0 110.858 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.583 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -58.75 -54.01 51.92 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.361 -178.82 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.7 mt -51.81 -45.12 38.13 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 O-C-N 123.978 0.799 . . . . 0.0 110.811 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.29 -39.52 76.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.291 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.1 t60 -68.39 -37.63 80.58 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.032 0.444 . . . . 0.0 109.881 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 24.1 mt -66.44 -49.79 72.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.198 177.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 79.9 mt -62.18 -40.05 94.72 Favored 'General case' 0 C--O 1.216 -0.693 0 CA-C-O 120.891 0.377 . . . . 0.0 111.538 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 22.8 t -63.85 -27.3 69.07 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -107.56 -7.19 16.59 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -175.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.466 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.14 135.51 33.92 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.382 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.475 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -134.97 177.12 7.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.162 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.76 -153.53 27.23 Favored Glycine 0 CA--C 1.477 -2.289 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.1 108.24 7.71 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.479 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 89.7 mt -111.41 119.39 59.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.955 -1.021 . . . . 0.0 109.991 -176.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 31.5 m80 -98.02 116.91 31.21 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.403 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 27.7 mtm -121.11 158.83 27.06 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -123.82 123.69 41.02 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.666 HG22 HD13 ' A' ' 55' ' ' ILE . 44.1 p -120.24 149.14 42.75 Favored 'General case' 0 C--N 1.262 -3.199 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.993 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.462 ' C ' ' H ' ' A' ' 89' ' ' ALA . 90.6 mtp -120.15 164.69 21.08 Favored Pre-proline 0 C--N 1.291 -1.94 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 176.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -70.27 28.71 0.19 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 123.308 2.672 . . . . 0.0 112.967 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.462 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.52 11.25 5.49 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.811 1.644 . . . . 0.0 113.671 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.302 -1.468 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.065 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.554 ' HA ' HD12 ' A' ' 56' ' ' ILE . 2.7 tm-20 . . . . . 0 C--O 1.219 -0.547 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 18.5 m -77.42 -44.17 30.04 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 17.0 ptp -113.48 165.78 12.15 Favored 'General case' 0 C--O 1.249 1.078 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.104 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.66 -145.73 16.36 Favored Glycine 0 N--CA 1.422 -2.292 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 174.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.515 ' O ' ' HA ' ' A' ' 87' ' ' MET . 40.8 m-80 -107.18 85.84 2.2 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 174.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.533 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 76.1 t -103.72 114.7 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.524 0 CA-C-N 114.32 -1.309 . . . . 0.0 108.732 -174.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 73.7 m -108.91 111.75 23.61 Favored 'General case' 2 C--N 1.223 -4.912 0 CA-C-N 112.723 -2.035 . . . . 0.0 106.89 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.6 m -80.44 140.54 35.93 Favored 'General case' 0 N--CA 1.394 -3.259 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.739 -178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.422 HG11 ' CG2' ' A' ' 49' ' ' VAL . 54.3 t -122.02 127.15 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.396 -3.133 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.113 178.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.515 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 25.6 tp -110.45 116.22 31.02 Favored 'General case' 0 N--CA 1.387 -3.583 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 172.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.623 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -104.74 137.16 35.17 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.262 0 N-CA-C 106.074 -1.825 . . . . 0.0 106.074 178.16 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -109.3 104.02 13.07 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-O 121.839 0.828 . . . . 0.0 110.472 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.463 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 75.8 ttt180 -106.92 114.03 62.01 Favored Pre-proline 0 N--CA 1.415 -2.181 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.954 -177.021 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.88 -55.4 2.7 Favored 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 122.835 2.357 . . . . 0.0 112.982 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -161.5 -173.26 3.7 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -177.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 41.3 mt -71.01 -18.71 62.58 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -175.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 12.4 mmt-85 -61.58 -31.49 71.55 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.718 0.77 . . . . 0.0 109.544 174.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -94.45 130.69 40.72 Favored 'General case' 0 N--CA 1.419 -1.995 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -107.13 165.32 11.45 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 177.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.703 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.3 mm? -51.47 -53.63 35.34 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 124.754 1.283 . . . . 0.0 111.308 -172.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.414 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 99.3 32.17 5.89 Favored Glycine 0 N--CA 1.424 -2.148 0 C-N-CA 119.936 -1.126 . . . . 0.0 111.838 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -158.6 161.69 37.25 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -116.02 122.49 45.36 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -110.21 136.45 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.463 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -125.14 116.48 22.11 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' HIS . 83.3 m-20 67.09 8.92 6.53 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.674 0.789 . . . . 0.0 112.336 -179.461 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.26 -0.93 40.45 Favored Glycine 0 N--CA 1.439 -1.136 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.86 123.43 65.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.935 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.653 HD13 HG13 ' A' ' 49' ' ' VAL . 72.6 mt -60.91 112.62 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 123.92 0.888 . . . . 0.0 110.951 178.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -83.35 -43.37 16.02 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.136 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.9 p -154.05 160.67 42.09 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.204 -179.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.414 HD12 ' O ' ' A' ' 27' ' ' GLY . 53.6 tp -125.92 133.26 51.92 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 123.773 0.67 . . . . 0.0 110.249 -178.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.8 ttt -74.31 107.33 6.41 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.1 tpt180 -60.98 119.58 8.56 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 124.375 1.07 . . . . 0.0 110.775 -176.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.63 1.42 74.17 Favored Glycine 0 N--CA 1.442 -0.911 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.116 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.65 174.44 46.46 Favored Glycine 0 C--O 1.25 1.107 0 C-N-CA 121.248 -0.501 . . . . 0.0 113.239 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.464 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.64 -33.83 64.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 112.839 0.681 . . . . 0.0 112.839 -177.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.17 -39.25 94.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.183 0.516 . . . . 0.0 110.932 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -71.45 -33.05 69.02 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.405 ' HA ' ' NE ' ' A' ' 46' ' ' ARG . 1.9 mmp_? -66.67 -33.08 74.85 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.485 172.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.87 -14.17 82.86 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.537 -0.756 . . . . 0.0 112.956 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.84 30.06 9.3 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.525 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.653 HG13 HD13 ' A' ' 35' ' ' ILE . 54.2 t -77.22 143.88 12.31 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.415 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 23.9 mmm180 -135.74 140.65 44.53 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-O 121.282 0.563 . . . . 0.0 109.745 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.8 t -73.12 143.49 13.78 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 114.232 -1.349 . . . . 0.0 110.375 -178.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.69 18.69 59.54 Favored Glycine 0 CA--C 1.501 -0.794 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -177.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.9 m170 -109.96 139.79 44.67 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.011 -0.594 . . . . 0.0 110.543 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 20.8 ttt180 -101.33 117.26 34.6 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.599 HG12 HG22 ' A' ' 86' ' ' THR . 33.6 mt -76.03 126.84 37.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.554 HD12 ' HA ' ' A' ' 7' ' ' GLU . 41.5 pt -107.78 -14.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.229 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.6 tt0 -156.28 144.6 19.87 Favored 'General case' 0 CA--C 1.491 -1.293 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.66 -173.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.461 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.6 mt -140.35 122.15 15.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 C-N-CA 124.367 1.067 . . . . 0.0 108.22 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.1 m120 65.5 4.76 2.89 Favored 'General case' 0 N--CA 1.501 2.081 0 C-N-CA 125.505 1.522 . . . . 0.0 112.671 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.96 5.5 35.39 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.432 ' O ' HG13 ' A' ' 63' ' ' VAL . 8.9 tt0 -104.79 116.32 31.81 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.466 1.106 . . . . 0.0 108.402 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.6 t -70.16 109.53 4.67 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.52 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.1 m -105.32 14.51 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.551 0 CA-C-O 121.64 0.733 . . . . 0.0 109.173 -175.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -69.51 -21.66 24.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.952 -175.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.79 -1.03 22.98 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.504 0.668 . . . . 0.0 109.91 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.52 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 90.4 m -78.96 137.04 57.52 Favored Pre-proline 0 N--CA 1.406 -2.662 0 C-N-CA 124.793 1.237 . . . . 0.0 108.755 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.2 147.18 91.87 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.051 1.834 . . . . 0.0 110.929 178.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.569 ' HB3' ' HA ' ' A' ' 32' ' ' ASN . 6.7 p-80 -48.98 -39.08 25.18 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.092 0.957 . . . . 0.0 113.063 -176.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -68.64 -38.02 80.14 Favored 'General case' 0 N--CA 1.435 -1.192 0 O-C-N 123.491 0.494 . . . . 0.0 110.508 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 35.8 mttp -67.34 -46.14 74.32 Favored 'General case' 0 CA--C 1.478 -1.813 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.549 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.2 mt -53.24 -41.1 41.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 O-C-N 124.054 0.846 . . . . 0.0 109.549 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.2 t -71.75 -37.11 61.3 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.097 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -68.83 -40.67 79.34 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-O 121.315 0.579 . . . . 0.0 110.063 -176.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 37.2 mt -65.65 -51.51 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 CA-C-N 114.548 -1.206 . . . . 0.0 109.786 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.9 mt -58.45 -40.87 83.76 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.345 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -58.65 -28.61 65.85 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 123.381 0.672 . . . . 0.0 111.885 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -119.06 -6.11 10.48 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 115.16 1.541 . . . . 0.0 115.16 -172.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.463 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 130.75 36.28 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.923 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.2 m -127.04 177.02 6.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.5 -152.5 20.39 Favored Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.472 ' HB3' HD11 ' A' ' 16' ' ' LEU . 41.8 mt-10 -84.23 114.06 21.55 Favored 'General case' 0 N--CA 1.425 -1.724 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 174.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.623 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.2 mt -114.55 117.08 54.51 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.402 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -175.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -90.2 111.64 22.87 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.478 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 26.1 mtm -114.21 156.54 24.11 Favored 'General case' 0 C--N 1.269 -2.904 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 175.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.533 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 69.0 mmtt -122.48 124.6 43.97 Favored 'General case' 0 C--N 1.275 -2.671 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.599 HG22 HG12 ' A' ' 55' ' ' ILE . 43.8 p -121.61 141.22 51.32 Favored 'General case' 0 C--N 1.269 -2.935 0 C-N-CA 120.716 -0.393 . . . . 0.0 110.346 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.515 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 43.6 mtm -114.39 167.51 9.51 Favored Pre-proline 0 C--N 1.306 -1.296 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 72.6 Cg_endo -74.71 31.31 0.35 Allowed 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.374 2.05 . . . . 0.0 111.858 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.439 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.16 34.13 19.05 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.912 1.285 . . . . 0.0 110.66 -178.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.779 0 CA-C-N 114.142 -1.39 . . . . 0.0 107.932 178.636 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.496 -1.132 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.8 m 62.59 27.59 16.27 Favored 'General case' 0 CA--C 1.562 1.434 0 CA-C-O 122.369 1.081 . . . . 0.0 109.048 -178.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 45.6 ttm -140.78 94.49 2.72 Favored 'General case' 0 N--CA 1.439 -0.987 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -177.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.85 -99.07 0.41 Allowed Glycine 0 N--CA 1.429 -1.826 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' A' ' 87' ' ' MET . 21.1 m120 -125.94 97.06 4.96 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 176.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 86' ' ' THR . 95.3 t -113.79 126.43 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.675 0 CA-C-O 121.932 0.872 . . . . 0.0 110.213 -174.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.3 m -118.62 121.02 39.19 Favored 'General case' 0 C--N 1.249 -3.79 0 CA-C-N 113.602 -1.635 . . . . 0.0 106.843 176.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -88.45 140.92 28.97 Favored 'General case' 0 N--CA 1.402 -2.871 0 CA-C-N 114.779 -1.1 . . . . 0.0 109.656 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 47' ' ' GLY . 54.5 t -119.0 137.78 51.87 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.594 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.463 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.508 HD11 ' HB3' ' A' ' 81' ' ' GLU . 24.5 tp -124.28 112.39 16.95 Favored 'General case' 0 N--CA 1.386 -3.653 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 172.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.61 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.01 138.75 21.84 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.946 0 N-CA-C 106.244 -1.762 . . . . 0.0 106.244 -179.364 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.28 108.98 19.77 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 67.2 ttt180 -116.58 110.08 42.98 Favored Pre-proline 0 C--N 1.284 -2.247 0 C-N-CA 120.249 -0.581 . . . . 0.0 112.024 -176.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -57.9 -41.02 73.37 Favored 'Trans proline' 0 CA--C 1.546 1.084 0 C-N-CA 122.634 2.223 . . . . 0.0 113.102 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 22' ' ' LEU . 17.6 t70 -171.71 -175.46 1.56 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -177.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.507 HD22 ' O ' ' A' ' 76' ' ' SER . 68.7 mt -81.1 -11.62 59.45 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 125.164 1.386 . . . . 0.0 110.39 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.418 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 76.8 mtt180 -73.74 -16.03 61.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.361 175.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -103.5 138.63 39.95 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -110.67 160.95 16.23 Favored 'General case' 0 C--N 1.277 -2.575 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.656 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -55.91 -55.6 30.7 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 124.635 1.209 . . . . 0.0 111.079 -172.152 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.0 19.54 14.68 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.995 -178.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -146.37 162.81 37.38 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 176.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.2 m -123.21 129.73 51.79 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -114.57 136.97 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -122.43 115.63 22.58 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 61.47 16.0 7.17 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 124.764 1.226 . . . . 0.0 112.091 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.92 3.6 45.59 Favored Glycine 0 C--O 1.219 -0.805 0 C-N-CA 121.002 -0.618 . . . . 0.0 111.689 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.34 123.12 71.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.763 HD13 HG13 ' A' ' 49' ' ' VAL . 57.6 mt -62.44 118.24 4.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 123.553 0.741 . . . . 0.0 109.524 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.2 t -110.56 -16.2 13.71 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.185 -174.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 32.2 t -153.74 154.34 33.87 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 tp -146.35 147.56 31.45 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -108.72 119.02 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 121.132 0.491 . . . . 0.0 110.573 177.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.6 tmt_? -61.03 131.43 50.59 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.337 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.04 -18.0 58.21 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.342 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.85 161.58 47.91 Favored Glycine 0 N--CA 1.436 -1.327 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -176.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.63 -33.38 39.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.9 0 N-CA-C 113.721 1.008 . . . . 0.0 113.721 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.15 -41.39 99.27 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 111.646 0.239 . . . . 0.0 111.646 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.63 -42.79 95.23 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-O 121.717 0.77 . . . . 0.0 109.204 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 25.1 mtp180 -71.98 -13.19 61.55 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.188 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.41 ' O ' HG13 ' A' ' 15' ' ' VAL . . . -89.01 -13.36 62.33 Favored Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.14 176.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.02 13.81 44.81 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.359 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.763 HG13 HD13 ' A' ' 35' ' ' ILE . 57.9 t -69.67 137.02 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -134.01 147.16 50.93 Favored 'General case' 0 CA--C 1.48 -1.715 0 CA-C-O 121.329 0.585 . . . . 0.0 109.555 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -78.79 141.76 14.98 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.744 0 CA-C-N 114.159 -1.382 . . . . 0.0 109.636 -177.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 24.41 38.33 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m-70 -118.86 134.84 54.89 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.064 -0.568 . . . . 0.0 110.876 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.465 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 47.8 ttm-85 -93.23 123.45 36.52 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.447 HG12 HG22 ' A' ' 86' ' ' THR . 31.4 mt -79.22 125.86 38.73 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 39.2 pt -101.56 -16.44 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.413 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.2 tt0 -158.0 144.26 17.45 Favored 'General case' 0 CA--C 1.486 -1.497 0 C-N-CA 120.079 -0.649 . . . . 0.0 109.29 -176.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 63' ' ' VAL . 79.1 mt -143.87 125.71 10.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 124.567 1.167 . . . . 0.0 108.256 178.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.75 18.73 8.87 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 124.04 0.936 . . . . 0.0 112.602 170.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.29 -0.34 40.6 Favored Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.833 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -119.07 132.78 56.05 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.931 -0.746 . . . . 0.0 110.173 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.3 m -75.32 107.87 7.72 Favored 'General case' 0 N--CA 1.422 -1.828 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.568 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.9 m -99.65 12.64 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 CA-C-O 121.857 0.837 . . . . 0.0 110.118 -172.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.7 p -66.48 -20.55 27.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.437 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.1 12.1 12.59 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.648 -0.706 . . . . 0.0 109.541 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 84.8 m -93.6 136.19 24.37 Favored Pre-proline 0 N--CA 1.415 -2.216 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.409 ' O ' HG13 ' A' ' 71' ' ' ILE . 61.9 Cg_endo -74.76 164.42 33.65 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 122.202 1.935 . . . . 0.0 112.553 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -43.19 -55.35 3.99 Favored 'General case' 0 C--O 1.218 -0.593 0 C-N-CA 126.034 1.734 . . . . 0.0 112.147 -178.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -55.27 -45.77 76.15 Favored 'General case' 0 C--N 1.316 -0.883 0 O-C-N 123.925 0.766 . . . . 0.0 111.387 -174.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.418 ' O ' HD12 ' A' ' 74' ' ' ILE . 12.4 mptt -66.12 -54.87 20.22 Favored 'General case' 0 CA--C 1.483 -1.615 0 O-C-N 123.964 0.79 . . . . 0.0 110.739 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.409 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.8 mt -51.98 -42.04 33.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 O-C-N 124.253 0.971 . . . . 0.0 109.857 -179.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 77.8 t -72.11 -43.29 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.566 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 71.2 t60 -64.87 -43.01 94.34 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.348 0.594 . . . . 0.0 110.184 -177.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.418 HD12 ' O ' ' A' ' 70' ' ' LYS . 14.3 mt -69.09 -42.24 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.524 -178.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 67.4 mt -61.91 -46.15 90.6 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.895 0.379 . . . . 0.0 110.84 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.507 ' O ' HD22 ' A' ' 22' ' ' LEU . 23.0 t -60.7 -27.69 68.07 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 124.209 1.004 . . . . 0.0 111.802 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -87.98 -36.56 16.99 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 120.626 -0.43 . . . . 0.0 112.045 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.481 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -77.93 136.33 37.99 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 113.401 0.889 . . . . 0.0 113.401 -172.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.467 HG12 HD23 ' A' ' 22' ' ' LEU . 1.0 OUTLIER -131.98 175.26 11.7 Favored 'Isoleucine or valine' 0 C--O 1.245 0.849 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 175.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.57 -154.75 25.23 Favored Glycine 0 CA--C 1.483 -1.911 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.508 ' HB3' HD11 ' A' ' 16' ' ' LEU . 51.5 mt-10 -75.0 108.97 8.07 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 174.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 17' ' ' ILE . 59.9 mt -112.36 118.15 57.06 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -84.54 130.53 34.73 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.458 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.0 mtm -135.34 152.31 51.34 Favored 'General case' 0 C--N 1.282 -2.344 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 170.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 8.9 mmmt -122.28 121.35 36.56 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.481 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.7 p -119.27 153.0 35.71 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.093 -176.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.541 ' HA ' ' O ' ' A' ' 11' ' ' ASN . 50.3 mtm -123.06 169.13 10.52 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 7.7 Cg_exo -74.3 35.64 0.4 Allowed 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 123.158 2.572 . . . . 0.0 112.333 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.465 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.02 59.87 2.63 Favored 'General case' 0 N--CA 1.433 -1.302 0 C-N-CA 126.072 1.749 . . . . 0.0 112.958 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.161 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 171.316 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 . . . . . 0 C--O 1.235 0.319 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 25.2 m -120.17 100.93 7.48 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 64.9 mtt -94.23 -25.63 16.99 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.663 -177.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.77 -91.2 0.54 Allowed Glycine 0 N--CA 1.439 -1.123 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -77.91 82.71 4.26 Favored 'General case' 0 CA--C 1.493 -1.212 0 CA-C-O 121.93 0.871 . . . . 0.0 111.247 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.476 HG11 ' HD2' ' A' ' 85' ' ' LYS . 50.1 t -145.2 128.13 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 70.1 m -110.54 107.27 16.84 Favored 'General case' 0 C--N 1.245 -3.974 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 176.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 32.8 m -78.96 130.99 36.18 Favored 'General case' 0 N--CA 1.396 -3.132 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.484 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.8 t -111.02 137.54 43.05 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.717 0 CA-C-N 114.468 -1.242 . . . . 0.0 108.124 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.4 tp -121.92 111.87 17.61 Favored 'General case' 1 N--CA 1.374 -4.266 0 C-N-CA 119.062 -1.055 . . . . 0.0 108.353 172.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.521 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.25 128.61 48.34 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.292 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 178.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 67.4 mtp180 -115.04 102.14 9.66 Favored 'General case' 0 CA--C 1.457 -2.62 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 174.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.4 ttt180 -98.64 123.61 49.26 Favored Pre-proline 0 C--N 1.262 -3.214 0 CA-C-N 112.999 -1.91 . . . . 0.0 111.048 -174.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.39 -55.63 2.04 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 122.553 2.168 . . . . 0.0 113.457 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -166.15 -178.22 4.51 Favored 'General case' 0 C--O 1.247 0.963 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 -175.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.41 HD23 HG12 ' A' ' 79' ' ' VAL . 46.0 mt -68.31 -16.55 63.99 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -175.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -84.37 -12.25 54.83 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.876 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -93.48 128.42 39.57 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 176.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.289 0.0 OUTLIER -103.3 158.98 15.95 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.571 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -58.91 -53.69 55.6 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.175 -168.318 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.01 26.7 8.24 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.338 -1.41 . . . . 0.0 112.789 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -145.79 154.26 41.83 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 173.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 10.2 m -106.78 122.12 45.74 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -114.71 139.91 38.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.224 -0.59 . . . . 0.0 110.385 -178.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.413 ' HG2' ' HB2' ' A' ' 36' ' ' CYS . 16.8 pt20 -130.57 126.3 36.36 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.061 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 16.4 m120 62.0 6.85 1.86 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 124.391 1.076 . . . . 0.0 112.945 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 6.45 53.36 Favored Glycine 0 C--O 1.214 -1.102 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -175.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.42 128.12 70.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.656 HD13 HG13 ' A' ' 49' ' ' VAL . 52.6 mt -70.21 116.11 10.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 C-N-CA 124.407 1.083 . . . . 0.0 110.49 -177.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.413 ' HB2' ' HG2' ' A' ' 31' ' ' GLN . 36.3 t -99.53 -24.41 14.77 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.064 -175.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 34.1 t -157.12 152.39 26.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 -178.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -133.84 140.51 46.92 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 14.2 tpt -94.6 115.68 27.85 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.437 ' HD2' ' N ' ' A' ' 41' ' ' GLY . 1.7 tmm_? -65.62 131.3 46.03 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' ' HD2' ' A' ' 40' ' ' ARG . . . 91.89 -4.79 78.87 Favored Glycine 0 N--CA 1.437 -1.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.303 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.25 170.33 40.89 Favored Glycine 0 C--O 1.253 1.292 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -61.8 -34.85 64.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.935 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.74 -43.19 94.36 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.196 0.31 . . . . 0.0 111.659 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -65.91 -41.59 91.23 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.094 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -66.28 -35.29 80.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.943 178.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.74 -29.76 75.21 Favored Glycine 0 N--CA 1.44 -1.065 0 CA-C-N 115.177 -0.92 . . . . 0.0 112.641 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 114.67 14.65 8.59 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.213 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.656 HG13 HD13 ' A' ' 35' ' ' ILE . 68.9 t -70.24 137.69 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.458 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.1 mmt85 -136.02 145.16 45.76 Favored 'General case' 0 CA--C 1.477 -1.853 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -178.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.1 t -74.23 139.9 18.5 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.84 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.608 -177.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.15 9.15 65.82 Favored Glycine 0 N--CA 1.436 -1.336 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -178.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.543 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -101.93 148.25 25.56 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.275 -0.462 . . . . 0.0 111.412 -179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 70.7 ttt180 -105.46 123.39 47.81 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.65 HD13 HG22 ' A' ' 86' ' ' THR . 24.5 mm -74.11 117.98 18.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.439 HG13 ' HB2' ' A' ' 85' ' ' LYS . 24.5 pt -105.28 -20.34 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.681 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 179.433 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 34.3 tt0 -151.84 146.48 25.71 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.49 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.0 mt -143.56 121.69 6.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 O-C-N 124.362 1.039 . . . . 0.0 108.647 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.435 HD22 HG12 ' A' ' 82' ' ' ILE . 5.1 t-20 63.93 8.67 4.04 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 125.556 1.542 . . . . 0.0 111.953 173.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.13 1.35 23.74 Favored Glycine 0 N--CA 1.43 -1.754 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.615 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -116.58 136.56 52.87 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 117.797 0.799 . . . . 0.0 109.92 177.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.8 m -75.56 108.99 8.75 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.539 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.0 m -102.96 11.48 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.697 0 CA-C-O 122.145 0.974 . . . . 0.0 109.423 -174.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 p -70.93 -14.78 18.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 114.332 -1.304 . . . . 0.0 110.093 -179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.95 13.68 13.1 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.264 179.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.539 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.1 m -101.32 135.26 19.91 Favored Pre-proline 0 N--CA 1.416 -2.163 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -66.21 156.15 66.33 Favored 'Trans proline' 0 C--O 1.244 0.821 0 C-N-CA 121.916 1.744 . . . . 0.0 111.743 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -43.11 -52.5 5.4 Favored 'General case' 0 C--O 1.221 -0.442 0 C-N-CA 125.525 1.53 . . . . 0.0 112.903 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -58.33 -42.74 87.48 Favored 'General case' 0 C--N 1.311 -1.087 0 O-C-N 123.917 0.761 . . . . 0.0 111.068 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.552 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -66.8 -53.77 29.45 Favored 'General case' 0 C--O 1.202 -1.413 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 178.53 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 53.4 mt -50.14 -42.29 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-O 120.984 0.421 . . . . 0.0 110.338 178.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.1 t -70.03 -37.9 73.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.982 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -69.16 -39.71 78.62 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.42 -53.44 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 95.6 mt -60.58 -32.79 71.87 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-O 120.853 0.358 . . . . 0.0 111.531 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.8 t -63.72 -37.07 85.97 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 123.362 0.665 . . . . 0.0 111.282 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -110.24 -9.98 14.65 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -171.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.49 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.01 129.87 35.57 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 122.156 -0.34 . . . . 0.0 110.826 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.428 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -128.75 176.26 8.43 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 177.648 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 89.69 -161.21 29.48 Favored Glycine 0 CA--C 1.498 -0.98 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -75.57 108.66 8.54 Favored 'General case' 0 C--O 1.249 1.074 0 C-N-CA 124.048 0.939 . . . . 0.0 108.903 175.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.487 HD12 HG22 ' A' ' 17' ' ' ILE . 72.3 mt -116.25 117.52 55.76 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.42 -174.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 34.5 m80 -84.76 117.0 23.57 Favored 'General case' 0 CA--C 1.486 -1.491 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.505 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 14.2 mtp -118.49 145.18 45.48 Favored 'General case' 0 C--N 1.25 -3.735 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' HG11 ' A' ' 12' ' ' VAL . 69.3 mmtt -118.09 123.97 46.92 Favored 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.65 HG22 HD13 ' A' ' 55' ' ' ILE . 68.0 p -118.97 139.86 50.97 Favored 'General case' 0 C--N 1.27 -2.852 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.903 178.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.46 ' HG2' HG22 ' A' ' 12' ' ' VAL . 90.6 mtp -113.58 166.54 11.07 Favored Pre-proline 0 C--N 1.299 -1.626 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 178.287 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -72.74 31.49 0.29 Allowed 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 123.047 2.498 . . . . 0.0 112.49 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 56.33 57.23 5.1 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 122.536 1.16 . . . . 0.0 111.324 -177.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 113.492 -1.685 . . . . 0.0 107.321 176.757 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 49.4 m -101.63 -24.36 14.12 Favored 'General case' 0 CA--C 1.551 1.006 0 CA-C-O 121.211 0.529 . . . . 0.0 110.242 174.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 60.4 ttp -173.95 -46.24 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.07 -132.19 2.36 Favored Glycine 0 N--CA 1.421 -2.36 0 N-CA-C 108.477 -1.849 . . . . 0.0 108.477 175.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -89.16 89.96 8.17 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.424 ' CG1' ' HD2' ' A' ' 85' ' ' LYS . 57.2 t -114.88 126.88 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.946 0 CA-C-N 114.016 -1.447 . . . . 0.0 108.898 -173.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 53.7 m -116.05 113.63 23.45 Favored 'General case' 1 C--N 1.241 -4.137 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.627 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.5 m -82.39 138.65 34.4 Favored 'General case' 0 N--CA 1.406 -2.663 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.151 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 49' ' ' VAL . 56.2 t -116.04 139.77 41.1 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.796 0 CA-C-N 114.574 -1.194 . . . . 0.0 108.582 178.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.52 HD11 ' HB3' ' A' ' 81' ' ' GLU . 17.8 tp -125.32 116.89 22.63 Favored 'General case' 0 N--CA 1.404 -2.762 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 81' ' ' GLU . 0.3 OUTLIER -98.11 141.63 15.82 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.782 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.859 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -113.61 102.98 10.79 Favored 'General case' 0 CA--C 1.489 -1.4 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 69.6 ttt180 -111.42 101.66 51.26 Favored Pre-proline 0 C--N 1.274 -2.686 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.765 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -58.6 -33.85 98.45 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.618 2.212 . . . . 0.0 113.985 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -169.15 175.58 5.64 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.516 HD23 HG12 ' A' ' 79' ' ' VAL . 63.4 mt -65.01 -18.23 65.12 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.9 mtt85 -74.25 -12.38 60.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 121.459 0.647 . . . . 0.0 112.084 178.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -99.54 95.75 7.2 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 174.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -84.58 152.29 23.96 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.763 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.8 OUTLIER -41.68 -60.9 1.21 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 126.068 1.747 . . . . 0.0 111.654 -172.541 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 109.64 -3.81 30.79 Favored Glycine 0 N--CA 1.432 -1.614 0 C-N-CA 119.828 -1.177 . . . . 0.0 112.793 176.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -117.39 156.77 27.32 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 122.191 -0.593 . . . . 0.0 109.663 178.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.0 t -108.82 131.43 54.99 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.23 134.53 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 -177.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.457 ' HG3' ' HB2' ' A' ' 36' ' ' CYS 0.266 1.0 OUTLIER -126.17 120.39 29.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.046 0.45 . . . . 0.0 110.84 175.258 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 65.09 13.03 8.42 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 124.259 1.023 . . . . 0.0 110.81 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.68 -1.96 52.75 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.383 -177.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -108.08 121.57 61.25 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 O-C-N 122.315 -0.521 . . . . 0.0 110.303 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.724 HD13 HG13 ' A' ' 49' ' ' VAL . 64.3 mt -60.32 117.11 2.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 C-N-CA 124.746 1.219 . . . . 0.0 110.274 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.457 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 34.0 t -98.18 -44.03 6.76 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.689 -174.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 36.4 p -142.26 155.4 45.23 Favored 'General case' 0 C--O 1.248 1.011 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.2 tp -131.91 146.24 51.99 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 123.25 0.62 . . . . 0.0 110.008 -177.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.8 ttt -90.3 112.48 24.06 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.446 ' HD3' ' N ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -75.57 123.73 26.0 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.759 -172.01 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.446 ' N ' ' HD3' ' A' ' 40' ' ' ARG . . . 103.65 -14.96 53.42 Favored Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.308 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.11 178.08 54.11 Favored Glycine 0 C--O 1.253 1.282 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -178.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 pt -53.72 -37.59 32.53 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.07 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.24 93.46 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -63.92 -46.5 84.51 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.464 0.649 . . . . 0.0 109.603 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -76.08 -17.4 59.64 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.979 -179.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 16' ' ' LEU . . . -73.9 -29.38 63.1 Favored Glycine 0 N--CA 1.432 -1.569 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.794 175.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 111.43 12.19 15.76 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.027 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.724 HG13 HD13 ' A' ' 35' ' ' ILE . 73.1 t -67.94 134.26 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.6 mmt85 -131.03 142.5 50.32 Favored 'General case' 0 CA--C 1.487 -1.453 0 CA-C-O 121.155 0.503 . . . . 0.0 109.909 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 41.7 t -79.05 137.26 22.15 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.21 -176.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.36 22.71 33.82 Favored Glycine 0 CA--C 1.5 -0.865 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -175.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.9 m170 -116.59 135.34 53.89 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.873 -0.664 . . . . 0.0 112.192 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.583 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 33.8 ttm-85 -92.59 122.69 35.27 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.565 HG12 HG22 ' A' ' 86' ' ' THR . 30.1 mt -80.64 127.82 39.15 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 35.2 pt -107.0 -16.5 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 84' ' ' MET . 32.1 tt0 -154.98 144.62 21.42 Favored 'General case' 0 CA--C 1.48 -1.717 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.382 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 67.5 mt -139.52 125.88 23.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 64.59 6.68 3.31 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.598 1.159 . . . . 0.0 112.31 173.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.4 -9.63 19.93 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.718 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.474 ' O ' HG13 ' A' ' 63' ' ' VAL . 17.4 pt20 -108.11 126.09 52.35 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-O 120.961 0.41 . . . . 0.0 110.989 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 31.9 t -64.85 113.46 3.83 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 177.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.618 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 30.9 m -110.61 13.53 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 121.169 0.509 . . . . 0.0 109.986 -176.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -67.54 -17.65 22.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 115.216 -0.902 . . . . 0.0 112.714 -173.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.64 16.64 5.88 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.708 0.766 . . . . 0.0 109.124 177.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.618 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.2 m -84.35 141.46 39.66 Favored Pre-proline 0 N--CA 1.416 -2.125 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.609 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.437 ' O ' HG13 ' A' ' 71' ' ' ILE . 71.6 Cg_exo -48.96 143.71 17.07 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.907 2.405 . . . . 0.0 112.247 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -49.91 -50.83 44.75 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 124.757 1.223 . . . . 0.0 111.529 -178.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -68.23 -32.23 72.29 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.1 mttm -62.91 -53.84 47.84 Favored 'General case' 0 CA--C 1.48 -1.718 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.793 176.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.437 HG13 ' O ' ' A' ' 67' ' ' PRO . 58.1 mt -50.01 -41.9 18.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 124.016 0.822 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 65.7 t -72.93 -37.19 53.47 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.533 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -65.23 -45.06 86.17 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 123.534 0.733 . . . . 0.0 109.594 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.74 -49.39 84.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.252 0 O-C-N 123.644 0.59 . . . . 0.0 109.412 178.136 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 74.2 mt -62.15 -45.31 94.01 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.7 t -61.98 -27.4 68.83 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 123.622 0.769 . . . . 0.0 112.144 -178.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -103.09 -13.23 16.9 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.666 0.987 . . . . 0.0 113.666 -176.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.17 134.63 34.16 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.047 -177.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.516 HG12 HD23 ' A' ' 22' ' ' LEU . 1.3 m -128.49 175.8 9.28 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 176.05 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.38 -159.66 27.46 Favored Glycine 0 N--CA 1.432 -1.605 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.52 ' HB3' HD11 ' A' ' 16' ' ' LEU . 44.9 mt-10 -79.35 113.4 17.46 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 173.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 67.7 mt -115.65 118.56 59.17 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.942 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.763 -172.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -81.18 135.94 35.82 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.497 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 21.7 mtm -133.34 150.63 51.85 Favored 'General case' 0 C--N 1.263 -3.178 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.424 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 66.1 mmtt -117.72 121.26 40.37 Favored 'General case' 0 C--N 1.262 -3.201 0 N-CA-C 106.238 -1.764 . . . . 0.0 106.238 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.566 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 37.2 p -122.6 146.24 47.62 Favored 'General case' 0 C--N 1.264 -3.116 0 C-N-CA 120.258 -0.577 . . . . 0.0 110.479 -178.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.495 ' C ' ' H ' ' A' ' 89' ' ' ALA . 58.3 mtm -120.41 168.16 11.17 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_exo -68.2 32.42 0.15 Allowed 'Trans proline' 0 N--CA 1.509 2.41 0 C-N-CA 123.49 2.794 . . . . 0.0 112.668 176.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.583 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 67.29 27.36 8.31 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 126.442 1.897 . . . . 0.0 113.422 177.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.409 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 173.483 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.505 -0.754 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.432 HG21 ' SD ' ' A' ' 87' ' ' MET . 13.9 t -98.75 171.08 8.32 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 41.4 ttm -162.72 156.94 21.05 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -176.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.28 -95.41 0.55 Allowed Glycine 0 N--CA 1.432 -1.615 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.518 178.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -103.55 101.18 11.04 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 120.95 0.405 . . . . 0.0 110.619 -178.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.453 HG22 ' HG2' ' A' ' 87' ' ' MET . 54.0 t -139.46 129.19 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.149 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 89.0 m -119.41 108.53 14.68 Favored 'General case' 0 N--CA 1.39 -3.46 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.185 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 18.6 m -78.69 134.25 37.12 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.934 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.412 HG11 ' CG2' ' A' ' 49' ' ' VAL . 51.3 t -115.86 136.86 51.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.137 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.378 -177.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.474 HD11 ' HB3' ' A' ' 81' ' ' GLU . 25.9 tp -118.81 110.67 17.5 Favored 'General case' 0 N--CA 1.4 -2.958 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 174.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -99.23 137.89 25.31 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.312 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.219 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.12 103.38 12.57 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.455 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.1 ttt180 -109.03 111.53 60.45 Favored Pre-proline 0 C--N 1.291 -1.947 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.315 -177.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -58.93 -44.12 37.91 Favored 'Trans proline' 0 CA--C 1.549 1.241 0 C-N-CA 122.311 2.007 . . . . 0.0 113.743 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -167.21 -176.99 3.51 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -176.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.4 HD23 HG12 ' A' ' 79' ' ' VAL . 65.9 mt -76.88 -10.02 59.08 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 124.892 1.277 . . . . 0.0 110.292 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 34.5 mtt180 -69.03 -19.35 64.11 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 114.295 -1.32 . . . . 0.0 108.064 176.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -114.21 157.81 22.18 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 104.997 -2.223 . . . . 0.0 104.997 177.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -121.63 -168.42 1.69 Allowed 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.596 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -75.25 -57.61 3.79 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -175.58 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 110.06 20.21 7.67 Favored Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.788 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -143.84 148.8 36.03 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.0 t -99.84 131.43 45.81 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.54 138.45 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -176.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -117.94 105.91 12.4 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 176.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 61.29 23.23 13.48 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 122.015 0.912 . . . . 0.0 110.846 177.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 105.91 -4.91 39.24 Favored Glycine 0 N--CA 1.439 -1.125 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.413 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.425 HG13 ' HB2' ' A' ' 54' ' ' ARG . 2.7 mp -105.93 120.13 56.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 O-C-N 122.18 -0.6 . . . . 0.0 110.013 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.774 HD13 HG13 ' A' ' 49' ' ' VAL . 55.1 mt -61.35 115.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 C-N-CA 123.447 0.699 . . . . 0.0 110.244 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -98.23 -31.77 11.9 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.042 -175.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.1 m -150.6 155.05 38.65 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.9 tp -136.7 138.88 41.5 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 123.534 0.734 . . . . 0.0 109.525 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 49.4 ttm -91.48 119.29 31.32 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.9 131.76 45.62 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.92 -8.45 79.78 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.34 162.98 37.02 Favored Glycine 0 N--CA 1.432 -1.582 0 C-N-CA 121.318 -0.467 . . . . 0.0 112.167 -178.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -30.43 41.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -179.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.02 -42.44 89.64 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.69 0.281 . . . . 0.0 110.889 178.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -63.71 -41.48 98.08 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.63 -8.44 55.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.673 -1.149 . . . . 0.0 111.281 178.161 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.55 -22.52 28.73 Favored Glycine 0 N--CA 1.429 -1.794 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 178.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.02 8.5 29.54 Favored Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.959 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.774 HG13 HD13 ' A' ' 35' ' ' ILE . 58.5 t -65.59 135.92 27.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 12.6 mmm180 -133.42 146.12 50.9 Favored 'General case' 0 CA--C 1.48 -1.738 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 77.0 t -77.37 139.9 17.95 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 114.181 -1.372 . . . . 0.0 109.202 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.4 -2.04 62.7 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -177.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.524 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 10.2 m170 -95.43 140.83 29.74 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 115.041 -0.58 . . . . 0.0 110.928 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.441 ' HB3' ' HA ' ' A' ' 89' ' ' ALA . 25.8 ttt85 -101.18 131.83 46.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 173.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.522 HG12 HG22 ' A' ' 86' ' ' THR . 33.0 mt -82.99 127.27 39.84 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 30.9 pt -104.3 -15.34 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.268 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.944 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.404 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.7 tt0 -155.9 144.34 20.12 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 119.763 -0.775 . . . . 0.0 108.984 -174.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 67.1 mt -140.67 121.83 14.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 124.293 0.996 . . . . 0.0 108.475 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 68.29 7.68 6.09 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 124.095 0.958 . . . . 0.0 111.769 172.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.4 2.09 33.13 Favored Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.397 -178.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 21.1 pt20 -113.88 125.31 53.91 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 177.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 40.1 t -63.82 119.14 9.42 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.469 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 24.3 m -114.35 14.12 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.123 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.5 p -70.12 -20.76 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.802 -176.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.66 9.56 16.51 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.751 0.786 . . . . 0.0 109.453 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 76.8 m -86.37 138.51 34.11 Favored Pre-proline 0 N--CA 1.407 -2.621 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.742 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.29 158.09 58.65 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.185 1.923 . . . . 0.0 112.837 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 45.3 p-80 -48.6 -49.65 35.94 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.121 1.368 . . . . 0.0 114.042 -174.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.0 -37.89 78.96 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 120.451 0.167 . . . . 0.0 110.599 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 9.9 mttm -61.9 -49.85 74.53 Favored 'General case' 0 CA--C 1.492 -1.258 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 177.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.8 mt -54.32 -42.56 58.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 O-C-N 123.896 0.748 . . . . 0.0 110.173 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.34 -35.88 69.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.544 178.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.8 t-80 -68.9 -42.92 76.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.237 0.541 . . . . 0.0 109.581 -177.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 35.7 mt -63.71 -47.19 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.635 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.882 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.2 mt -61.32 -45.99 92.12 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.399 176.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -62.32 -27.49 69.08 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 123.174 0.59 . . . . 0.0 111.887 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -104.65 1.34 29.41 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -177.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.455 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -107.04 134.61 49.93 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.967 178.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.448 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.7 m -129.58 -177.34 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -157.14 30.58 Favored Glycine 0 CA--C 1.484 -1.886 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.023 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.474 ' HB3' HD11 ' A' ' 16' ' ' LEU . 50.4 mt-10 -80.52 112.89 18.3 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.167 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.653 ' HB ' HG22 ' A' ' 17' ' ' ILE . 56.5 mt -117.3 118.12 57.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -173.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -90.49 118.43 29.96 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.404 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 24.3 mtm -117.54 158.42 24.61 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.298 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.3 mtmm -123.86 121.97 36.77 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.524 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 46.2 p -119.86 150.02 41.13 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.624 -175.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.466 ' C ' ' H ' ' A' ' 89' ' ' ALA . 75.6 mtp -130.13 168.63 15.96 Favored Pre-proline 0 C--N 1.313 -0.978 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 87' ' ' MET . 57.7 Cg_endo -71.04 29.5 0.22 Allowed 'Trans proline' 0 CA--C 1.565 2.058 0 C-N-CA 122.762 2.308 . . . . 0.0 112.61 175.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.466 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 71.0 -2.36 2.37 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 126.384 1.874 . . . . 0.0 112.59 179.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.474 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 178.235 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.506 -0.717 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.483 HG21 ' SD ' ' A' ' 87' ' ' MET . 65.5 m -89.97 125.16 35.28 Favored 'General case' 0 N--CA 1.417 -2.101 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 176.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 65.9 mtt -116.22 125.59 52.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.76 -116.11 0.7 Allowed Glycine 0 N--CA 1.428 -1.864 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -109.74 106.03 15.51 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.3 t -133.13 134.86 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 123.554 0.742 . . . . 0.0 109.273 -174.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 34.4 m -121.74 120.13 33.76 Favored 'General case' 0 N--CA 1.391 -3.388 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 176.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.6 m -90.67 141.08 29.16 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.127 0.965 . . . . 0.0 110.091 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.608 HG11 ' HE2' ' A' ' 84' ' ' MET . 43.8 t -118.42 135.96 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.06 0 CA-C-N 114.425 -1.261 . . . . 0.0 108.857 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.451 HD12 ' O ' ' A' ' 82' ' ' ILE . 24.9 tp -119.86 110.38 16.68 Favored 'General case' 0 N--CA 1.382 -3.87 0 C-N-CA 119.18 -1.008 . . . . 0.0 108.797 173.044 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.476 HG22 HD12 ' A' ' 82' ' ' ILE . 0.3 OUTLIER -98.14 125.94 51.28 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.021 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.081 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 82.1 mtp180 -113.29 102.77 10.66 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.541 HH12 ' HA ' ' A' ' 76' ' ' SER . 48.2 ttt180 -98.3 112.8 63.04 Favored Pre-proline 0 C--N 1.269 -2.925 0 CA-C-N 112.77 -2.014 . . . . 0.0 110.846 -174.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.37 -39.2 86.19 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.833 2.355 . . . . 0.0 113.909 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -166.62 -178.72 4.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -177.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.545 HD23 ' CG1' ' A' ' 79' ' ' VAL . 52.8 mt -75.36 -18.09 60.06 Favored 'General case' 0 CA--C 1.495 -1.141 0 C-N-CA 124.954 1.301 . . . . 0.0 111.024 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.59 ' HD2' ' N ' ' A' ' 23' ' ' ARG . 4.8 mpt_? -82.02 -11.5 58.79 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.923 176.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -99.16 89.3 4.19 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.682 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.53 165.79 23.97 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 123.639 0.587 . . . . 0.0 110.938 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -69.31 -58.8 3.55 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.46 -169.785 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 103.19 38.28 2.9 Favored Glycine 0 N--CA 1.424 -2.114 0 C-N-CA 120.062 -1.066 . . . . 0.0 111.933 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -154.2 153.63 32.1 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 174.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 m -109.02 130.88 55.49 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -118.72 134.07 63.51 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 CA-C-O 121.36 0.6 . . . . 0.0 111.089 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -113.56 111.64 22.23 Favored 'General case' 0 C--N 1.312 -1.053 0 O-C-N 121.807 -0.558 . . . . 0.0 109.591 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.6 m-20 59.86 12.8 3.22 Favored 'General case' 0 N--CA 1.501 2.097 0 C-N-CA 125.076 1.35 . . . . 0.0 112.21 -177.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.59 0.42 30.79 Favored Glycine 0 C--O 1.215 -1.092 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.682 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 2.9 mp -108.17 118.33 55.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 122.438 -0.448 . . . . 0.0 109.878 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.779 HD13 HG13 ' A' ' 49' ' ' VAL . 46.8 mt -59.15 122.38 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 123.888 0.875 . . . . 0.0 110.861 178.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 13.4 t -103.29 -31.75 9.91 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.983 -176.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 55.1 p -151.17 160.62 43.75 Favored 'General case' 0 C--O 1.245 0.862 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 54.5 tp -137.97 129.46 27.95 Favored 'General case' 0 N--CA 1.443 -0.812 0 O-C-N 123.785 0.678 . . . . 0.0 109.867 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -76.03 112.54 12.57 Favored 'General case' 0 C--N 1.317 -0.837 0 O-C-N 123.782 0.676 . . . . 0.0 109.878 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.427 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.3 tpp85 -55.32 125.0 18.92 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.564 1.146 . . . . 0.0 111.005 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.02 -7.63 81.73 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.311 -0.859 . . . . 0.0 113.408 177.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -78.12 171.6 55.15 Favored Glycine 0 C--O 1.246 0.888 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.501 -176.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.5 pt -62.15 -33.04 56.59 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -57.16 -46.12 83.03 Favored 'General case' 0 N--CA 1.447 -0.608 0 CA-C-O 120.909 0.385 . . . . 0.0 110.445 178.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.427 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 36.2 tt0 -62.88 -47.15 84.55 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.573 0.701 . . . . 0.0 109.758 179.113 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 40.5 mtt180 -69.62 -18.06 63.57 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.807 -178.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.24 -24.81 50.49 Favored Glycine 0 N--CA 1.438 -1.187 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.001 176.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.95 12.23 12.75 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 179.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.779 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -68.57 137.28 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -135.61 150.25 49.6 Favored 'General case' 0 CA--C 1.474 -1.953 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.15 141.2 15.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.066 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.98 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.14 25.92 42.53 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -177.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.5 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.2 m170 -117.48 132.87 56.48 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.124 -0.538 . . . . 0.0 110.944 179.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 44.4 ttp180 -95.79 121.66 37.74 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.527 HG12 HG22 ' A' ' 86' ' ' THR . 44.7 mt -75.92 122.28 29.62 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.418 HG22 ' CG2' ' A' ' 64' ' ' VAL 0.265 2.4 pp -104.94 -5.93 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.76 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -178.314 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.505 ' O ' ' HA ' ' A' ' 84' ' ' MET . 26.6 tt0 -169.34 143.15 2.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.416 -179.325 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 84' ' ' MET . 88.4 mt -138.57 124.84 24.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 66.34 3.32 2.74 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.5 1.12 . . . . 0.0 112.436 172.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.26 -0.81 22.4 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.084 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.45 ' O ' HG13 ' A' ' 63' ' ' VAL . 12.7 pt20 -115.41 125.97 53.81 Favored 'General case' 0 CA--C 1.498 -1.022 0 O-C-N 122.273 -0.545 . . . . 0.0 110.166 176.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 m -71.03 109.6 5.22 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.519 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 34.6 m -101.77 18.28 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.993 0 CA-C-O 121.914 0.864 . . . . 0.0 110.538 -172.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.418 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.3 p -75.59 -8.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.91 -177.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -126.44 22.89 6.99 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.022 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.519 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 89.3 m -109.18 130.39 22.8 Favored Pre-proline 0 N--CA 1.407 -2.614 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -66.34 158.22 56.19 Favored 'Trans proline' 0 CA--C 1.543 0.925 0 C-N-CA 122.233 1.955 . . . . 0.0 112.797 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 33.1 t60 -42.86 -55.85 3.5 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.932 1.293 . . . . 0.0 113.5 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -65.83 -37.67 86.84 Favored 'General case' 0 N--CA 1.436 -1.16 0 O-C-N 123.42 0.45 . . . . 0.0 111.32 -173.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 6.5 mttm -61.75 -52.02 65.96 Favored 'General case' 0 N--CA 1.424 -1.728 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.345 174.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 55.7 mt -52.02 -45.61 41.14 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 O-C-N 124.026 0.829 . . . . 0.0 110.398 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.2 t -69.07 -34.04 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.818 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 17.3 t60 -72.41 -43.17 64.25 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 -176.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.6 mt -60.5 -49.75 83.1 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 CA-C-N 114.737 -1.12 . . . . 0.0 109.873 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.2 mt -58.96 -46.76 87.27 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.76 177.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.541 ' HA ' HH12 ' A' ' 19' ' ' ARG . 25.0 m -63.06 -26.5 68.87 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 113.08 0.77 . . . . 0.0 113.08 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.8 -18.85 20.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -98.8 133.92 42.43 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.535 0.207 . . . . 0.0 111.221 -176.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.545 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.2 m -134.27 179.65 4.12 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 87.88 -150.22 22.13 Favored Glycine 0 CA--C 1.497 -1.065 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.87 114.56 18.88 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.476 HD12 HG22 ' A' ' 17' ' ' ILE . 79.5 mt -117.88 118.03 56.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -90.85 115.75 28.15 Favored 'General case' 0 CA--C 1.463 -2.376 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.608 ' HE2' HG11 ' A' ' 15' ' ' VAL . 7.8 ttp -122.56 138.47 54.56 Favored 'General case' 1 N--CA 1.376 -4.148 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.816 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 32.9 mtmt -121.26 131.86 54.47 Favored 'General case' 0 CA--C 1.444 -3.133 0 C-N-CA 119.497 -0.881 . . . . 0.0 108.784 -176.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.527 HG22 HG12 ' A' ' 55' ' ' ILE . 49.7 p -125.97 155.16 41.81 Favored 'General case' 0 C--N 1.271 -2.825 0 O-C-N 123.993 0.808 . . . . 0.0 110.369 -174.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.483 ' SD ' HG21 ' A' ' 8' ' ' THR . 88.8 mtp -120.47 170.55 6.95 Favored Pre-proline 0 C--N 1.296 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -75.98 29.83 0.39 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.85 2.367 . . . . 0.0 111.077 176.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.472 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 60.89 31.6 20.01 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.249 1.42 . . . . 0.0 110.624 -179.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.178 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.636 178.733 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.483 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.499 HG23 ' HB ' ' A' ' 12' ' ' VAL . 97.4 m 83.29 93.69 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 124.253 1.021 . . . . 0.0 112.561 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.2 mmt -136.94 83.11 1.98 Allowed 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.005 171.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 154.85 -141.22 7.97 Favored Glycine 0 N--CA 1.412 -2.955 0 N-CA-C 108.502 -1.839 . . . . 0.0 108.502 -177.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -112.83 98.2 7.04 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.499 ' HB ' HG23 ' A' ' 8' ' ' THR . 70.1 t -120.31 132.15 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.17 0 CA-C-O 122.083 0.944 . . . . 0.0 109.727 -173.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -127.12 115.55 19.31 Favored 'General case' 0 N--CA 1.387 -3.616 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.2 m -80.97 140.95 34.93 Favored 'General case' 0 N--CA 1.395 -3.186 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.813 -176.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.429 HG11 HG22 ' A' ' 49' ' ' VAL . 53.4 t -118.12 139.29 45.89 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.943 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.248 177.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.539 HD11 ' HB3' ' A' ' 81' ' ' GLU . 7.5 tp -126.42 105.41 8.75 Favored 'General case' 0 N--CA 1.404 -2.732 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.856 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.3 OUTLIER -99.71 134.8 37.76 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -178.863 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 -113.75 117.32 31.17 Favored 'General case' 0 C--N 1.294 -1.831 0 CA-C-O 121.954 0.883 . . . . 0.0 112.114 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.649 HH21 ' HA ' ' A' ' 25' ' ' GLN . 27.2 ttm180 -119.2 113.1 35.6 Favored Pre-proline 0 C--N 1.284 -2.272 0 CA-C-N 113.961 -1.472 . . . . 0.0 110.957 -178.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -61.74 -31.68 86.04 Favored 'Trans proline' 0 CA--C 1.547 1.16 0 C-N-CA 122.653 2.235 . . . . 0.0 113.091 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -178.8 173.68 1.22 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' HD3' ' A' ' 19' ' ' ARG . 47.5 mt -65.28 -9.83 27.32 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 115.666 1.728 . . . . 0.0 115.666 -173.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -76.16 -11.59 59.96 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.564 0.697 . . . . 0.0 110.794 176.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -107.08 98.56 8.2 Favored 'General case' 0 N--CA 1.423 -1.812 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . 0.649 ' HA ' HH21 ' A' ' 19' ' ' ARG . 2.5 pt20 -86.08 164.28 17.4 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.133 -1.427 . . . . 0.0 112.177 -177.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.638 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.58 -64.86 0.69 Allowed 'General case' 0 C--N 1.32 -0.698 0 O-C-N 124.984 1.427 . . . . 0.0 110.714 -173.353 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 101.69 29.48 6.21 Favored Glycine 0 N--CA 1.426 -2.021 0 C-N-CA 120.262 -0.971 . . . . 0.0 111.464 -176.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -152.35 167.14 29.66 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.4 m -131.25 140.92 49.92 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.53 121.41 50.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.902 0.858 . . . . 0.0 113.184 -173.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -120.07 128.08 53.16 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 64.2 -1.14 0.74 Allowed 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 124.451 1.1 . . . . 0.0 112.634 -174.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.81 -3.74 34.1 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -175.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -101.09 131.12 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.104 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 49' ' ' VAL . 71.4 mt -67.1 114.25 3.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 124.248 1.019 . . . . 0.0 110.615 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -85.54 -51.88 6.2 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.914 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.9 p -137.51 151.07 48.05 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.08 -176.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.63 141.37 46.58 Favored 'General case' 0 C--N 1.31 -1.109 0 O-C-N 123.779 0.674 . . . . 0.0 109.646 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 26.1 ttt -83.84 115.76 22.41 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -73.92 128.29 35.12 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 -177.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.4 -4.4 85.26 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.992 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.0 173.41 46.78 Favored Glycine 0 C--O 1.242 0.635 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.389 -178.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -61.84 -29.85 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.43 -48.69 71.89 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.309 177.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -65.93 -43.52 87.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.917 0.389 . . . . 0.0 110.796 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.5 mtp85 -72.37 -17.37 61.83 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 121.52 0.676 . . . . 0.0 110.153 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.03 -20.6 60.66 Favored Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.052 -0.976 . . . . 0.0 111.395 175.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 112.57 4.63 24.85 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 120.286 -0.959 . . . . 0.0 113.516 176.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 35' ' ' ILE . 69.7 t -64.43 142.53 16.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 9.9 mmt180 -140.33 139.78 35.49 Favored 'General case' 0 CA--C 1.491 -1.324 0 CA-C-O 121.257 0.551 . . . . 0.0 110.809 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.3 t -75.13 136.39 25.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 114.499 -1.228 . . . . 0.0 109.348 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.1 10.5 64.3 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -176.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.7 m170 -104.33 143.71 32.62 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.048 0.451 . . . . 0.0 110.945 177.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.518 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 76.0 ttt180 -103.78 114.97 29.63 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.017 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 86' ' ' THR . 23.1 mt -77.31 126.57 37.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-O 121.093 0.473 . . . . 0.0 110.048 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.44 HG22 ' CG2' ' A' ' 64' ' ' VAL . 2.4 pp -109.9 -5.43 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.945 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.985 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 17.2 tt0 -161.48 145.29 12.82 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.519 HD12 HG21 ' A' ' 63' ' ' VAL . 76.2 mt -145.12 120.5 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 O-C-N 124.454 1.096 . . . . 0.0 109.194 176.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 59.65 25.95 14.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.55 1.14 . . . . 0.0 112.276 169.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.39 -7.58 30.44 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 119.883 -1.151 . . . . 0.0 114.222 177.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -124.2 135.37 53.4 Favored 'General case' 0 CA--C 1.486 -1.487 0 CA-C-N 117.785 0.793 . . . . 0.0 110.672 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 21.6 t -74.05 120.14 19.22 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 177.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.599 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.0 m -110.43 19.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.541 0 CA-C-O 121.479 0.657 . . . . 0.0 110.757 -174.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.44 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.0 p -78.83 -18.32 13.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.619 0.723 . . . . 0.0 110.329 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.87 12.49 15.83 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.45 175.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.599 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.6 m -91.22 135.48 28.26 Favored Pre-proline 0 N--CA 1.414 -2.255 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.458 ' O ' HG13 ' A' ' 71' ' ' ILE . 10.0 Cg_endo -57.82 148.42 75.38 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 122.005 1.804 . . . . 0.0 111.789 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 26.4 t60 -48.17 -50.27 29.54 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.563 1.145 . . . . 0.0 112.775 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -61.7 -39.02 89.99 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.873 -177.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -63.49 -49.6 72.95 Favored 'General case' 0 CA--C 1.482 -1.638 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.678 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.458 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.4 mt -50.87 -45.75 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 O-C-N 124.3 1.0 . . . . 0.0 109.846 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.62 -35.44 61.15 Favored 'Isoleucine or valine' 0 C--O 1.242 0.664 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.041 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.3 t60 -70.4 -42.33 71.82 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -176.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 38.2 mt -64.97 -49.95 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.919 179.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 42.3 mt -55.75 -52.09 65.15 Favored 'General case' 0 CA--C 1.502 -0.882 0 O-C-N 123.756 0.66 . . . . 0.0 112.181 177.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.8 t -59.07 -26.03 64.28 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.654 0.612 . . . . 0.0 112.654 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.7 m-80 -111.2 4.28 19.11 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -175.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.425 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -98.86 125.87 44.37 Favored 'General case' 0 C--O 1.204 -1.314 0 O-C-N 121.333 -0.854 . . . . 0.0 110.813 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.516 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -118.08 174.08 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.77 -155.52 19.7 Favored Glycine 0 CA--C 1.497 -1.093 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.539 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.9 mp0 -89.49 109.61 20.53 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.856 ' HB ' HG22 ' A' ' 17' ' ' ILE . 65.4 mt -105.11 117.86 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.933 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -170.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.9 m80 -85.3 128.42 34.69 Favored 'General case' 0 CA--C 1.478 -1.801 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.442 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -129.29 153.55 47.71 Favored 'General case' 0 C--N 1.258 -3.38 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 170.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -120.4 120.54 36.24 Favored 'General case' 0 C--N 1.26 -3.316 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.575 HG22 HG12 ' A' ' 55' ' ' ILE . 46.8 p -119.35 143.59 47.32 Favored 'General case' 0 C--N 1.257 -3.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.598 -178.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.51 ' C ' ' H ' ' A' ' 89' ' ' ALA . 41.3 mtm -111.39 164.06 15.92 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 175.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.77 27.52 0.32 Allowed 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.57 2.18 . . . . 0.0 111.598 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 69.27 25.8 5.55 Favored 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 126.299 1.84 . . . . 0.0 112.866 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.42 -1.94 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 174.456 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 . . . . . 0 CA--C 1.541 0.625 0 CA-C-O 121.6 0.714 . . . . 0.0 109.222 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.1 t -146.89 148.22 31.6 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.139 -0.976 . . . . 0.0 110.984 -178.182 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.9 mtm -115.4 6.84 14.91 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 173.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.79 84.88 0.26 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.648 -179.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.553 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 4.5 m-20 63.22 88.26 0.1 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 122.285 1.041 . . . . 0.0 111.824 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.5 t -114.38 126.84 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.445 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.59 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -116.92 117.55 30.01 Favored 'General case' 0 C--N 1.248 -3.807 0 CA-C-N 113.915 -1.493 . . . . 0.0 107.086 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 m -83.87 138.2 33.31 Favored 'General case' 0 N--CA 1.406 -2.641 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.422 -176.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.3 t -118.19 140.29 42.15 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.373 178.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 81' ' ' GLU . 23.9 tp -122.68 116.42 23.76 Favored 'General case' 0 N--CA 1.399 -3.009 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.132 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.455 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.3 OUTLIER -97.13 139.04 20.47 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -178.945 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.4 HH11 HD23 ' A' ' 16' ' ' LEU . 0.0 OUTLIER -113.08 102.6 10.55 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 175.393 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.474 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.7 ttt180 -107.09 108.86 62.59 Favored Pre-proline 0 C--N 1.287 -2.121 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.241 -177.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -53.05 -55.87 3.3 Favored 'Trans proline' 0 CA--C 1.542 0.922 0 C-N-CA 122.788 2.325 . . . . 0.0 112.933 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -156.69 -176.98 6.27 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -177.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.464 HD23 ' CG1' ' A' ' 79' ' ' VAL . 68.7 mt -74.47 -14.37 60.82 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -172.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -82.11 -11.33 58.82 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-O 121.466 0.65 . . . . 0.0 110.15 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -94.7 121.07 35.89 Favored 'General case' 0 CA--C 1.487 -1.46 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.811 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -84.03 157.4 21.83 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 123.579 0.549 . . . . 0.0 110.353 177.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.576 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER -61.15 -44.01 97.98 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 124.29 0.994 . . . . 0.0 111.36 -171.434 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.28 26.04 9.74 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 119.639 -1.267 . . . . 0.0 113.42 178.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -151.94 167.87 26.98 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -124.55 134.05 53.11 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -125.57 138.47 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -173.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.407 ' HG2' ' O ' ' A' ' 34' ' ' ILE . 17.4 pt20 -105.44 92.79 4.34 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.794 0.806 . . . . 0.0 109.318 176.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 58.55 20.55 7.7 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 122.79 -10.23 9.02 Favored Glycine 0 C--O 1.218 -0.867 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.092 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.407 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 2.4 mp -106.33 118.44 53.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.742 HD13 HG13 ' A' ' 49' ' ' VAL . 65.5 mt -59.61 114.74 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 123.244 0.618 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 52.5 t -95.29 -37.8 10.83 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.468 -175.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 14.8 m -149.8 151.23 33.22 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -178.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.9 tp -121.26 136.09 55.02 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.8 ttm -83.94 118.37 23.96 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -68.64 125.61 27.1 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.189 -175.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.47 0.41 79.51 Favored Glycine 0 N--CA 1.425 -2.046 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.55 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.62 171.25 45.13 Favored Glycine 0 C--O 1.241 0.586 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.14 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.89 -31.05 51.05 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.041 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.455 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.27 -39.61 93.48 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.891 0.377 . . . . 0.0 110.478 177.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -63.4 -44.01 95.91 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 176.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -72.28 -6.14 40.98 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.061 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -98.81 -18.01 26.41 Favored Glycine 0 N--CA 1.433 -1.536 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.03 19.56 18.9 Favored Glycine 0 N--CA 1.433 -1.518 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.442 -179.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.742 HG13 HD13 ' A' ' 35' ' ' ILE . 53.9 t -65.32 145.62 13.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-O 120.88 0.371 . . . . 0.0 110.036 177.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 19.9 mmt85 -136.86 138.71 41.03 Favored 'General case' 0 CA--C 1.488 -1.409 0 C-N-CA 123.963 0.905 . . . . 0.0 108.852 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.2 t -76.24 148.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.806 -177.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.05 47.67 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -178.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.571 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.7 m170 -122.19 136.39 54.9 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.994 -178.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -94.12 123.0 37.22 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.505 HG12 HG22 ' A' ' 86' ' ' THR . 33.1 mt -79.24 121.17 31.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.45 HG21 ' SD ' ' A' ' 87' ' ' MET . 36.8 pt -100.63 -14.92 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.38 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.5 tt0 -156.79 141.16 16.62 Favored 'General case' 0 CA--C 1.477 -1.858 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -175.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.453 HD12 HG21 ' A' ' 63' ' ' VAL . 79.2 mt -140.75 126.34 19.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.14 14.52 9.68 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 124.058 0.943 . . . . 0.0 111.126 172.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.83 -1.96 48.51 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.877 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.445 ' O ' HG13 ' A' ' 63' ' ' VAL . 18.5 pt20 -115.57 130.6 56.93 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 117.106 0.453 . . . . 0.0 110.633 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.0 m -70.02 108.45 4.07 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.755 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.649 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.5 m -102.17 13.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.594 0 CA-C-O 122.133 0.968 . . . . 0.0 109.682 -175.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.9 p -73.53 -14.11 16.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 114.349 -1.296 . . . . 0.0 110.567 -177.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -125.68 19.82 7.9 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 122.21 1.005 . . . . 0.0 108.712 177.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.649 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.3 m -101.23 137.42 19.68 Favored Pre-proline 0 N--CA 1.413 -2.295 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.418 ' O ' HG13 ' A' ' 71' ' ' ILE . 57.3 Cg_endo -72.74 163.25 38.99 Favored 'Trans proline' 0 C--O 1.245 0.848 0 C-N-CA 122.035 1.824 . . . . 0.0 112.739 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -42.35 -57.85 2.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 127.249 2.22 . . . . 0.0 112.371 -177.327 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -68.15 -39.99 82.5 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.672 -174.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -59.18 -48.7 80.63 Favored 'General case' 0 CA--C 1.495 -1.164 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.535 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 67' ' ' PRO . 65.5 mt -51.9 -43.63 35.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 O-C-N 124.057 0.848 . . . . 0.0 110.329 178.558 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.1 t -73.09 -34.99 46.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.792 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.43 -46.08 77.68 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 123.517 0.727 . . . . 0.0 109.292 -177.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 23.6 mt -64.43 -47.06 90.99 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.706 0 CA-C-N 114.673 -1.149 . . . . 0.0 109.887 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 45.4 mt -58.43 -51.71 68.69 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.987 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.427 ' O ' HD22 ' A' ' 22' ' ' LEU . 42.2 m -56.38 -27.84 57.41 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -102.31 -5.21 24.51 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.474 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -102.88 131.84 49.51 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.892 -0.505 . . . . 0.0 111.317 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.464 ' CG1' HD23 ' A' ' 22' ' ' LEU . 2.5 m -130.43 -174.78 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -154.77 29.21 Favored Glycine 0 CA--C 1.484 -1.863 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.412 ' HB3' HD11 ' A' ' 16' ' ' LEU . 34.4 mt-10 -78.7 115.7 18.57 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 78.1 mt -119.33 117.82 55.37 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -85.53 126.24 33.7 Favored 'General case' 0 CA--C 1.487 -1.448 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.484 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 20.8 mtm -124.35 152.26 43.36 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 173.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -119.91 122.96 42.4 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.571 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 45.6 p -120.83 139.95 52.43 Favored 'General case' 0 C--N 1.271 -2.846 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.638 -177.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.45 ' SD ' HG21 ' A' ' 56' ' ' ILE . 81.7 mtp -110.33 169.76 6.02 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.553 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 11.7 Cg_exo -74.84 30.27 0.35 Allowed 'Trans proline' 0 N--CA 1.486 1.054 0 C-N-CA 122.914 2.409 . . . . 0.0 112.619 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.436 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 59.9 60.18 2.24 Favored 'General case' 0 CA--C 1.496 -1.132 0 C-N-CA 125.242 1.417 . . . . 0.0 111.583 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -2.013 0 CA-C-N 113.236 -1.802 . . . . 0.0 106.6 172.571 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 . . . . . 0 C--O 1.234 0.282 0 CA-C-O 120.652 0.263 . . . . 0.0 110.833 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.1 t -131.71 157.25 44.26 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 178.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.5 tpt 57.55 63.88 1.72 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 121.975 0.893 . . . . 0.0 110.128 -177.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.58 -119.69 4.15 Favored Glycine 0 CA--C 1.499 -0.951 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -103.48 96.2 6.58 Favored 'General case' 0 CA--C 1.48 -1.724 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.525 HG11 ' HE3' ' A' ' 85' ' ' LYS . 71.4 t -118.64 137.22 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.379 -3.976 0 CA-C-O 122.256 1.027 . . . . 0.0 108.881 -173.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 m -118.72 105.88 12.01 Favored 'General case' 2 N--CA 1.368 -4.562 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 174.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.8 m -83.55 136.75 34.14 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 114.764 -1.107 . . . . 0.0 109.272 -176.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.98 141.88 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.47 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.344 -175.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 18.2 tp -125.45 116.5 21.92 Favored 'General case' 0 N--CA 1.396 -3.137 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.696 HD11 ' HA ' ' A' ' 44' ' ' ALA . 1.0 OUTLIER -99.29 129.61 49.49 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 175.535 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 80' ' ' GLY . 74.6 mtp180 -113.1 101.36 9.38 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 122.813 1.292 . . . . 0.0 109.059 169.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -105.04 111.27 65.21 Favored Pre-proline 0 C--N 1.272 -2.785 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.462 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -56.17 -47.88 22.27 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 122.598 2.199 . . . . 0.0 113.05 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.39 178.59 10.14 Favored 'General case' 0 C--O 1.246 0.916 0 CA-C-O 120.893 0.378 . . . . 0.0 110.72 -177.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 ' CG1' ' A' ' 79' ' ' VAL . 53.7 mt -65.05 -21.99 66.91 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 115.637 1.717 . . . . 0.0 115.637 -173.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.402 ' HD3' ' HA ' ' A' ' 23' ' ' ARG . 67.2 mmt-85 -79.04 -11.12 59.99 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.17 0.509 . . . . 0.0 111.465 -179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -83.26 -20.34 34.68 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . 0.407 ' HB3' ' H ' ' A' ' 26' ' ' LEU . 15.0 mm100 57.05 -164.46 0.16 Allowed 'General case' 0 CA--C 1.511 -0.539 0 O-C-N 123.777 0.673 . . . . 0.0 111.648 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.479 ' O ' HG13 ' A' ' 43' ' ' ILE . 0.4 OUTLIER -97.4 -49.43 4.92 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.92 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.21 11.54 Favored Glycine 0 N--CA 1.432 -1.595 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.097 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -143.48 164.26 30.84 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 50.3 m -118.19 133.7 55.67 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 123.89 0.743 . . . . 0.0 109.239 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.57 131.58 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.222 0 CA-C-O 121.69 0.757 . . . . 0.0 110.89 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -120.72 128.85 53.31 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 62.08 2.95 0.87 Allowed 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 124.248 1.019 . . . . 0.0 112.917 -176.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.99 3.05 45.61 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -174.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.452 HG13 ' HB2' ' A' ' 54' ' ' ARG . 3.5 mp -114.08 125.03 71.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.732 HD13 HG13 ' A' ' 49' ' ' VAL . 50.4 mt -61.41 117.97 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 123.834 0.854 . . . . 0.0 110.14 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.9 t -101.98 -34.42 9.35 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.309 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 p -143.35 148.49 36.34 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.3 tp -128.32 132.27 48.64 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.6 ttp -85.45 108.11 17.73 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.57 141.43 58.77 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.449 -177.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.04 -15.38 48.98 Favored Glycine 0 C--N 1.303 -1.252 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.531 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.61 175.45 50.74 Favored Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.479 HG13 ' O ' ' A' ' 26' ' ' LEU . 1.3 pt -59.96 -34.47 56.4 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.748 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.696 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -62.81 -40.06 96.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -68.11 -36.71 80.19 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.601 0.715 . . . . 0.0 109.12 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -76.58 -23.88 53.51 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.511 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.34 -23.24 63.41 Favored Glycine 0 N--CA 1.438 -1.204 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.507 178.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.98 10.63 22.27 Favored Glycine 0 CA--C 1.501 -0.811 0 C-N-CA 120.231 -0.985 . . . . 0.0 112.883 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.732 HG13 HD13 ' A' ' 35' ' ' ILE . 66.0 t -66.78 135.78 27.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.418 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 20.4 mmt180 -133.45 142.72 48.44 Favored 'General case' 0 CA--C 1.481 -1.681 0 CA-C-O 121.165 0.507 . . . . 0.0 110.293 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.5 t -72.65 145.25 12.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.967 -178.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.9 21.08 56.65 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 -178.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.8 m170 -117.21 135.96 53.41 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 115.08 -0.56 . . . . 0.0 111.37 -179.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.469 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 34.8 ttp180 -97.73 123.72 41.78 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 177.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.587 HG12 HG22 ' A' ' 86' ' ' THR . 30.5 mt -78.62 123.43 35.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.401 ' HA ' ' HB ' ' A' ' 64' ' ' VAL . 36.3 pt -100.3 -16.69 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.848 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 84' ' ' MET . 35.6 tt0 -158.4 144.49 17.07 Favored 'General case' 0 CA--C 1.496 -1.134 0 C-N-CA 119.479 -0.889 . . . . 0.0 110.2 -174.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 63' ' ' VAL . 82.2 mt -139.91 118.09 11.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 124.674 1.233 . . . . 0.0 108.077 178.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 53.79 27.24 6.81 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 125.299 1.44 . . . . 0.0 114.472 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.55 -10.4 38.68 Favored Glycine 0 CA--C 1.496 -1.106 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.82 175.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 35.5 tt0 -100.54 122.38 43.14 Favored 'General case' 0 C--N 1.292 -1.928 0 CA-C-N 115.488 -0.356 . . . . 0.0 110.393 -177.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -71.32 108.62 4.87 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.555 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 33.7 m -102.45 10.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-O 121.667 0.746 . . . . 0.0 110.08 -175.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.401 ' HB ' ' HA ' ' A' ' 56' ' ' ILE . 4.0 p -72.02 -13.5 16.74 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 114.669 -1.15 . . . . 0.0 111.111 -177.275 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -123.04 13.66 9.77 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.111 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.555 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 99.8 m -96.9 136.55 21.55 Favored Pre-proline 0 N--CA 1.409 -2.521 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.449 ' O ' HG13 ' A' ' 71' ' ' ILE . 9.5 Cg_endo -56.81 150.01 56.8 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.351 2.034 . . . . 0.0 112.386 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 42.2 t60 -48.62 -48.25 39.49 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.453 1.101 . . . . 0.0 112.733 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -67.58 -35.49 79.1 Favored 'General case' 0 N--CA 1.435 -1.199 0 O-C-N 123.487 0.492 . . . . 0.0 110.621 -175.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 mttm -63.59 -49.45 73.29 Favored 'General case' 0 CA--C 1.484 -1.586 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.365 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.449 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.0 mt -53.59 -43.15 53.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 O-C-N 124.083 0.865 . . . . 0.0 109.918 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.7 t -71.91 -31.86 42.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.728 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -74.56 -41.04 61.26 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -175.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.7 mt -64.29 -47.75 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.407 ' HB3' HD21 ' A' ' 26' ' ' LEU . 81.7 mt -62.48 -35.23 78.66 Favored 'General case' 0 C--O 1.211 -0.928 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.437 176.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.5 t -63.21 -31.11 72.18 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 122.805 0.442 . . . . 0.0 111.693 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.76 -31.71 13.65 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -175.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.08 130.58 35.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -172.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.478 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -129.89 -179.41 3.16 Favored 'Isoleucine or valine' 0 C--O 1.243 0.732 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 174.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . 86.6 -151.34 24.1 Favored Glycine 0 CA--C 1.488 -1.65 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -79.06 108.78 12.8 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.441 HD12 HG22 ' A' ' 17' ' ' ILE . 79.9 mt -111.16 118.82 58.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.746 -175.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -94.56 131.18 40.58 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.5 mtm -133.11 156.2 47.87 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 172.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.525 ' HE3' HG11 ' A' ' 12' ' ' VAL . 23.2 mmmt -124.47 120.33 31.71 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 105.547 -2.019 . . . . 0.0 105.547 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.587 HG22 HG12 ' A' ' 55' ' ' ILE . 33.4 p -119.64 146.68 45.33 Favored 'General case' 0 C--N 1.27 -2.848 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.259 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.501 ' C ' ' H ' ' A' ' 89' ' ' ALA . 49.8 mtm -118.21 169.9 7.11 Favored Pre-proline 0 C--N 1.298 -1.631 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 176.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -69.71 26.26 0.17 Allowed 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 123.336 2.691 . . . . 0.0 112.575 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.501 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 74.86 -1.27 3.13 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 126.538 1.935 . . . . 0.0 113.466 178.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.113 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 . . . . . 0 CA--C 1.531 0.227 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.1 p -72.15 93.1 1.4 Allowed 'General case' 0 N--CA 1.438 -1.055 0 CA-C-O 121.137 0.494 . . . . 0.0 111.183 176.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 25.1 ttt -81.02 -57.62 3.45 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.436 0.636 . . . . 0.0 109.825 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.44 -155.16 6.54 Favored Glycine 0 N--CA 1.425 -2.056 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.078 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.03 96.07 7.63 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-O 121.836 0.826 . . . . 0.0 110.196 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.4 HG22 ' HG2' ' A' ' 87' ' ' MET . 46.3 t -134.79 133.26 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.191 0 CA-C-N 114.603 -1.18 . . . . 0.0 108.033 -178.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 m -123.0 117.86 26.45 Favored 'General case' 0 C--N 1.261 -3.28 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 21.4 m -85.26 142.3 29.49 Favored 'General case' 0 C--N 1.265 -3.092 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.235 -175.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.63 132.0 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.129 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 13.8 tp -122.09 119.67 32.03 Favored 'General case' 0 N--CA 1.393 -3.281 0 CA-C-O 121.711 0.767 . . . . 0.0 109.991 173.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.485 HD12 ' HB ' ' A' ' 43' ' ' ILE . 1.1 mm -99.87 135.23 36.36 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.026 0 CA-C-N 114.24 -1.346 . . . . 0.0 108.652 176.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -115.16 101.24 8.79 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.514 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 73.4 ttt180 -99.22 115.23 65.86 Favored Pre-proline 0 C--N 1.284 -2.275 0 CA-C-N 113.621 -1.627 . . . . 0.0 110.94 -178.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_exo -61.29 -38.0 68.82 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.663 2.242 . . . . 0.0 114.065 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.91 -178.58 4.8 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.484 HD23 HG12 ' A' ' 79' ' ' VAL . 79.7 mt -76.69 -15.23 59.85 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 123.976 0.91 . . . . 0.0 111.277 -176.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -69.79 -16.15 63.24 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.993 176.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -97.97 121.27 39.69 Favored 'General case' 0 CA--C 1.481 -1.682 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 176.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 -97.48 156.96 16.26 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.611 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.659 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.0 OUTLIER -53.08 -65.62 0.53 Allowed 'General case' 0 C--N 1.323 -0.551 0 O-C-N 124.993 1.433 . . . . 0.0 110.778 -174.349 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.28 34.78 4.1 Favored Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 120.129 -1.034 . . . . 0.0 112.626 177.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -155.59 155.73 33.83 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.1 m -107.42 127.35 53.51 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -117.89 136.64 54.41 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 C-N-CA 119.839 -0.744 . . . . 0.0 109.203 179.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -121.92 109.95 15.26 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 60.33 13.34 3.94 Favored 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 124.036 0.934 . . . . 0.0 112.37 -176.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 113.09 -6.85 25.31 Favored Glycine 0 C--O 1.211 -1.323 0 C-N-CA 121.145 -0.55 . . . . 0.0 112.054 -178.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.5 mp -102.24 123.61 55.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.049 -0.677 . . . . 0.0 110.073 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.678 HD13 HG13 ' A' ' 49' ' ' VAL . 66.1 mt -64.14 112.13 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 C-N-CA 124.05 0.94 . . . . 0.0 109.71 178.328 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 22.6 t -91.59 -37.29 13.18 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.517 -174.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -152.8 157.33 40.61 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 66.4 tp -129.35 132.45 47.08 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 25.6 ttt -87.33 120.4 28.58 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.432 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 0.3 OUTLIER -69.59 136.27 51.05 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.779 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.28 -2.21 74.36 Favored Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -92.4 164.58 28.26 Favored Glycine 0 N--CA 1.436 -1.308 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.485 ' HB ' HD12 ' A' ' 17' ' ' ILE . 3.2 pt -60.81 -36.66 72.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -55.44 -39.5 70.38 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.014 0.435 . . . . 0.0 111.062 -178.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -67.03 -42.78 84.3 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.023 178.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.89 -37.3 86.9 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.747 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.66 -24.32 76.31 Favored Glycine 0 CA--C 1.516 0.12 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.754 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.75 28.91 5.77 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.409 -0.9 . . . . 0.0 112.564 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.678 HG13 HD13 ' A' ' 35' ' ' ILE . 60.7 t -77.45 142.65 13.93 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -136.21 145.14 45.36 Favored 'General case' 0 CA--C 1.49 -1.338 0 CA-C-O 121.202 0.525 . . . . 0.0 109.623 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 54.0 t -73.42 144.7 12.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.206 -178.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.83 20.17 58.39 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -179.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.458 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 13.6 m-70 -115.2 144.67 43.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 115.121 -0.539 . . . . 0.0 110.194 178.161 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -104.97 117.48 34.12 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.602 HG12 HG22 ' A' ' 86' ' ' THR . 29.6 mt -73.96 123.79 29.95 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.482 HG21 ' SD ' ' A' ' 87' ' ' MET . 2.4 pp -109.48 -4.13 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.384 -178.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 84' ' ' MET . 20.0 tt0 -160.59 146.7 15.12 Favored 'General case' 0 CA--C 1.486 -1.506 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.515 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.487 ' CD1' HG21 ' A' ' 63' ' ' VAL . 79.3 mt -142.71 120.69 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 172.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.447 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 8.5 m-20 55.07 27.45 9.42 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 177.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.75 -6.86 58.99 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.562 -0.828 . . . . 0.0 113.821 177.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.477 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 11.6 pt20 -107.96 136.36 47.8 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 t -80.98 108.86 15.02 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -178.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.612 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 20.1 m -100.02 15.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.88 0 CA-C-O 122.09 0.948 . . . . 0.0 109.455 -173.436 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.442 ' CG2' HG22 ' A' ' 56' ' ' ILE . 4.6 p -69.73 -21.79 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.876 -175.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -119.32 13.62 12.78 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.457 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.612 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.7 m -90.37 133.7 32.6 Favored Pre-proline 0 N--CA 1.412 -2.367 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -63.62 155.55 62.38 Favored 'Trans proline' 0 C--O 1.25 1.125 0 C-N-CA 122.178 1.919 . . . . 0.0 112.356 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.35 -53.38 8.65 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.04 1.336 . . . . 0.0 111.313 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -56.99 -43.43 81.71 Favored 'General case' 0 C--N 1.316 -0.855 0 O-C-N 123.903 0.752 . . . . 0.0 111.456 -176.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.45 -54.61 26.01 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.847 -178.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 58.4 mt -50.39 -43.04 21.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 O-C-N 123.862 0.726 . . . . 0.0 110.293 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 73.0 t -67.1 -40.93 86.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 72.5 t60 -64.74 -44.09 91.25 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.4 -50.93 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 O-C-N 123.592 0.558 . . . . 0.0 109.534 178.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.14 -31.56 72.73 Favored 'General case' 0 C--O 1.209 -1.054 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.418 ' O ' HD22 ' A' ' 22' ' ' LEU . 50.2 m -71.08 -27.45 63.63 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' HD22 ' A' ' 77' ' ' ASN . 0.8 OUTLIER -100.55 -11.46 20.07 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -174.845 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.514 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.77 132.56 38.04 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.237 -0.585 . . . . 0.0 112.031 -176.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.484 HG12 HD23 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -131.4 172.62 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.534 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 78.4 -151.05 35.86 Favored Glycine 0 CA--C 1.496 -1.119 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -176.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -59.11 108.78 0.73 Allowed 'General case' 0 C--O 1.245 0.857 0 C-N-CA 124.417 1.087 . . . . 0.0 111.362 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.447 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 85.4 mt -115.79 118.36 58.54 Favored 'Isoleucine or valine' 0 CA--C 1.456 -2.639 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 11.7 t-80 -106.65 115.87 30.94 Favored 'General case' 0 N--CA 1.385 -3.68 0 CA-C-N 113.199 -1.819 . . . . 0.0 109.456 -170.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 22.4 mtm -123.91 155.19 38.57 Favored 'General case' 0 C--N 1.261 -3.269 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 177.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 57.1 mmtt -122.06 124.26 43.52 Favored 'General case' 0 C--N 1.265 -3.087 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 175.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 55' ' ' ILE . 68.8 p -119.45 134.99 54.95 Favored 'General case' 0 C--N 1.262 -3.236 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.665 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.482 ' SD ' HG21 ' A' ' 56' ' ' ILE . 89.2 mtp -105.98 163.22 17.5 Favored Pre-proline 0 C--N 1.299 -1.619 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 176.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.64 14.48 0.32 Allowed 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 122.724 2.283 . . . . 0.0 113.157 178.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.402 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 65.37 22.94 12.02 Favored 'General case' 0 C--N 1.344 0.36 0 C-N-CA 124.427 1.091 . . . . 0.0 110.68 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.753 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.312 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 CA--C 1.509 -0.615 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 58.5 m 64.93 140.11 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 CA-C-O 122.11 0.957 . . . . 0.0 113.545 175.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . 0.431 ' HB2' ' SD ' ' A' ' 87' ' ' MET . 1.5 mpt? -87.56 -68.3 0.76 Allowed 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 174.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.63 122.51 0.69 Allowed Glycine 0 CA--C 1.489 -1.584 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 62.19 92.09 0.06 Allowed 'General case' 0 CA--C 1.506 -0.735 0 CA-C-O 121.933 0.873 . . . . 0.0 111.297 -175.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -128.18 128.95 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.358 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.892 -175.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.7 m -115.58 108.19 16.11 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.178 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.4 m -78.7 135.83 37.27 Favored 'General case' 0 N--CA 1.395 -3.18 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.4 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.2 t -116.09 135.79 55.13 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.937 0 CA-C-N 114.793 -1.094 . . . . 0.0 108.478 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 23.5 tp -121.19 116.8 25.6 Favored 'General case' 0 N--CA 1.385 -3.698 0 C-N-CA 119.561 -0.856 . . . . 0.0 109.428 174.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.582 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.9 OUTLIER -97.55 133.94 37.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.352 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.592 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.6 mmm-85 -112.73 101.17 9.29 Favored 'General case' 0 N--CA 1.411 -2.398 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.547 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.2 ttt180 -100.88 110.8 61.95 Favored Pre-proline 0 C--N 1.282 -2.342 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.235 -178.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -54.88 -38.09 92.68 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 123.361 2.707 . . . . 0.0 113.663 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -176.73 -176.89 0.75 Allowed 'General case' 0 C--O 1.241 0.644 0 C-N-CA 123.367 0.667 . . . . 0.0 109.308 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.478 HD23 HG12 ' A' ' 79' ' ' VAL . 69.0 mt -73.28 -6.82 48.49 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -174.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -84.57 -13.98 50.18 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.06 0.457 . . . . 0.0 110.565 175.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -103.01 109.1 20.52 Favored 'General case' 0 CA--C 1.491 -1.326 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -82.4 162.73 22.05 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.275 178.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.683 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.1 mm? -52.14 -52.84 49.19 Favored 'General case' 0 C--N 1.321 -0.655 0 O-C-N 124.704 1.253 . . . . 0.0 110.65 -175.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.82 28.23 6.33 Favored Glycine 0 N--CA 1.436 -1.319 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.4 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -150.03 151.06 32.66 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m -104.57 124.64 49.67 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -113.95 141.64 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.528 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -177.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -119.06 102.04 8.45 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-O 121.711 0.767 . . . . 0.0 110.56 174.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 60.98 23.04 13.21 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-N 114.481 -1.236 . . . . 0.0 112.548 178.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.85 -11.01 20.87 Favored Glycine 0 N--CA 1.437 -1.268 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.421 178.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.5 119.3 58.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 117.302 0.551 . . . . 0.0 110.781 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.703 HD13 HG13 ' A' ' 49' ' ' VAL . 57.2 mt -59.43 111.93 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 124.193 0.997 . . . . 0.0 111.015 178.07 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 45.3 t -89.67 -38.26 14.01 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.595 -177.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.7 t -148.78 150.78 33.68 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 55.9 tp -122.57 137.55 54.86 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.3 tpp -86.2 120.1 27.19 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.73 129.46 39.86 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.306 -176.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.407 ' H ' ' CD ' ' A' ' 45' ' ' GLU . . . 87.27 -3.05 86.86 Favored Glycine 0 N--CA 1.421 -2.319 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.419 176.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -85.5 173.55 47.88 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.38 -0.914 . . . . 0.0 111.923 -176.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 26' ' ' LEU . 2.7 pt -59.17 -34.67 54.25 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.582 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.91 -39.11 88.12 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.709 0.29 . . . . 0.0 111.272 179.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 41' ' ' GLY . 45.0 tt0 -66.76 -41.24 88.06 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.826 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 43' ' ' ILE . 13.1 ptt180 -78.66 -16.22 57.57 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.012 -0.675 . . . . 0.0 111.81 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.95 -22.69 63.12 Favored Glycine 0 N--CA 1.433 -1.535 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.708 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.3 15.09 20.55 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.965 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.703 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -70.47 138.3 22.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.403 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 30.9 mmm180 -135.49 151.1 50.04 Favored 'General case' 0 CA--C 1.486 -1.484 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -79.68 145.52 9.16 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.106 -176.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.44 23.18 57.15 Favored Glycine 0 CA--C 1.501 -0.809 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -178.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.5 m170 -116.5 134.09 55.26 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 114.708 -0.746 . . . . 0.0 111.28 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.9 ttm180 -97.54 125.44 42.25 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.552 HG12 HG22 ' A' ' 86' ' ' THR . 34.2 mt -78.15 126.95 38.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 177.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 62' ' ' SER . 31.0 pt -106.91 -15.48 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.41 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.4 tt0 -155.62 145.81 21.68 Favored 'General case' 0 CA--C 1.481 -1.703 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.386 -173.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 74.5 mt -142.22 125.53 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.437 ' OD1' ' HA ' ' A' ' 82' ' ' ILE . 87.1 m-20 51.62 24.63 2.41 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 115.837 1.791 . . . . 0.0 115.837 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.86 -5.65 34.72 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.254 -0.974 . . . . 0.0 113.416 176.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.42 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.1 pt20 -115.34 129.33 56.56 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 117.42 0.61 . . . . 0.0 111.009 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 19.4 m -70.46 108.48 4.31 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.542 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 32.3 m -100.8 12.8 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 121.734 0.778 . . . . 0.0 109.575 -174.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -66.85 -16.22 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.562 -177.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.93 10.06 10.1 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-O 121.427 0.632 . . . . 0.0 109.576 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 54.7 m -85.43 141.42 36.74 Favored Pre-proline 0 N--CA 1.422 -1.841 0 C-N-CA 123.812 0.845 . . . . 0.0 109.214 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.75 147.32 81.11 Favored 'Trans proline' 0 C--O 1.239 0.525 0 C-N-CA 122.642 2.228 . . . . 0.0 112.697 179.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -42.97 -55.22 3.86 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 126.212 1.805 . . . . 0.0 111.168 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -58.5 -44.94 89.62 Favored 'General case' 0 CA--C 1.497 -1.09 0 O-C-N 123.362 0.414 . . . . 0.0 110.845 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.43 -55.07 39.34 Favored 'General case' 0 C--O 1.201 -1.479 0 O-C-N 123.861 0.725 . . . . 0.0 110.087 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 59.8 mt -50.38 -43.45 22.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 C-N-CA 123.554 0.742 . . . . 0.0 110.952 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.1 t -72.43 -36.12 53.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.829 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -70.67 -40.01 73.21 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 123.323 0.649 . . . . 0.0 109.611 -177.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.33 -49.51 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 176.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 85.2 mt -62.05 -46.27 89.88 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.6 m -64.32 -26.89 68.68 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -91.28 -19.79 22.6 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.547 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -92.09 139.04 31.03 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.837 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.478 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -132.38 178.55 5.45 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 174.04 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.9 -151.3 38.89 Favored Glycine 0 CA--C 1.48 -2.136 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -65.33 114.86 5.06 Favored 'General case' 0 CA--C 1.497 -1.096 0 O-C-N 124.693 0.878 . . . . 0.0 110.175 174.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.437 ' HA ' ' OD1' ' A' ' 59' ' ' ASN . 83.5 mt -118.62 117.29 54.0 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.703 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 175.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -99.48 120.08 39.05 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 -174.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.411 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 25.2 mtm -126.32 157.28 38.82 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -121.98 125.12 45.61 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 176.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.552 HG22 HG12 ' A' ' 55' ' ' ILE . 44.6 p -121.26 144.08 48.81 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.372 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.431 ' SD ' ' HB2' ' A' ' 9' ' ' MET . 54.5 mtm -116.73 168.96 7.87 Favored Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -71.29 29.58 0.23 Allowed 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 123.056 2.504 . . . . 0.0 112.861 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.403 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 57.4 50.48 11.29 Favored 'General case' 0 C--O 1.245 0.855 0 CA-C-O 122.496 1.141 . . . . 0.0 110.332 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.92 0 CA-C-N 113.782 -1.554 . . . . 0.0 108.026 179.621 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 . . . . . 0 C--O 1.241 0.628 0 CA-C-O 121.309 0.575 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 t -115.39 146.61 41.43 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 172.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 43.4 ttm -147.42 127.65 13.85 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 118.315 -1.354 . . . . 0.0 113.401 -170.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.4 -79.2 0.07 OUTLIER Glycine 0 CA--C 1.491 -1.455 0 N-CA-C 106.84 -2.504 . . . . 0.0 106.84 172.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -150.4 110.54 4.15 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 168.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 69.5 t -95.68 128.62 46.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.505 0 CA-C-N 113.35 -1.75 . . . . 0.0 109.466 -173.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.1 m -122.45 109.2 14.07 Favored 'General case' 2 C--N 1.236 -4.33 0 CA-C-N 113.291 -1.777 . . . . 0.0 106.865 177.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -79.01 138.66 38.13 Favored 'General case' 0 N--CA 1.406 -2.674 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.154 -176.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.421 HG11 ' CG2' ' A' ' 49' ' ' VAL . 52.9 t -115.57 133.41 62.0 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.547 177.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.426 HD11 ' HB3' ' A' ' 81' ' ' GLU . 14.4 tp -121.17 116.13 24.37 Favored 'General case' 0 N--CA 1.396 -3.134 0 C-N-CA 119.989 -0.684 . . . . 0.0 110.005 176.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.57 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.6 OUTLIER -98.89 138.64 22.79 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.978 0 CA-C-N 114.563 -1.198 . . . . 0.0 108.02 178.256 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -115.13 101.73 9.25 Favored 'General case' 0 N--CA 1.414 -2.252 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 168.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.533 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 65.3 ttt180 -97.89 116.28 65.7 Favored Pre-proline 0 C--N 1.284 -2.26 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.001 -177.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -49.36 -54.43 5.46 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.034 2.49 . . . . 0.0 112.602 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.58 ' OD2' ' HG3' ' A' ' 23' ' ' ARG . 2.7 p-10 -173.1 -170.49 0.64 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.465 ' HA ' ' NH2' ' A' ' 19' ' ' ARG . 54.1 mt -68.6 -16.65 63.92 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -173.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.58 ' HG3' ' OD2' ' A' ' 21' ' ' ASP . 27.0 mtt180 -71.34 -12.23 61.32 Favored 'General case' 0 N--CA 1.481 1.087 0 CA-C-O 121.167 0.508 . . . . 0.0 110.785 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -113.98 143.36 44.87 Favored 'General case' 0 N--CA 1.427 -1.614 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -116.96 171.56 7.83 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.243 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.686 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -58.31 -61.93 2.21 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 125.124 1.369 . . . . 0.0 111.245 -173.081 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 102.61 37.99 3.1 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 119.794 -1.193 . . . . 0.0 112.129 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -154.7 163.02 40.86 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.8 m -117.94 128.62 54.98 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.47 138.76 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 120.864 0.364 . . . . 0.0 110.133 -176.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 19.9 pt20 -131.04 121.62 25.34 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.1 m120 63.58 13.44 7.28 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.206 1.002 . . . . 0.0 111.857 -175.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.51 1.91 58.93 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.412 -0.899 . . . . 0.0 111.138 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -106.07 119.88 56.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.726 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -62.06 116.83 2.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 C-N-CA 124.369 1.068 . . . . 0.0 110.099 177.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.8 t -96.11 -38.18 10.28 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.27 -176.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 13.3 p -149.06 152.38 36.11 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.279 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 53.4 tp -127.46 145.38 50.85 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 123.576 0.75 . . . . 0.0 109.506 -178.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 59.8 ttp -93.42 115.88 28.42 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.148 0.499 . . . . 0.0 109.893 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.425 ' HD3' ' OE1' ' A' ' 45' ' ' GLU . 19.0 tpp85 -65.58 118.68 9.86 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 124.726 1.21 . . . . 0.0 109.463 -179.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -12.99 59.13 Favored Glycine 0 C--N 1.305 -1.142 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.793 -177.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -79.93 161.04 45.37 Favored Glycine 0 C--O 1.245 0.814 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.929 -177.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 pt -54.22 -37.69 36.8 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.756 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.57 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -56.1 -44.2 78.82 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.199 0.524 . . . . 0.0 110.903 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.425 ' OE1' ' HD3' ' A' ' 40' ' ' ARG . 44.0 tt0 -70.14 -38.8 75.6 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.469 -179.52 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 48.3 mtt180 -66.59 -34.16 77.28 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.104 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.44 -20.61 79.54 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.782 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.08 20.29 7.62 Favored Glycine 0 C--O 1.24 0.489 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.696 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.726 HG13 HD13 ' A' ' 35' ' ' ILE . 45.0 t -71.34 144.29 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.447 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 27.4 mmt180 -132.61 142.66 49.24 Favored 'General case' 0 CA--C 1.484 -1.57 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.8 t -74.26 142.71 14.41 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.561 0 CA-C-N 114.583 -1.189 . . . . 0.0 109.192 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.16 22.25 55.15 Favored Glycine 0 CA--C 1.498 -0.989 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 5.1 m170 -114.67 135.2 54.42 Favored 'General case' 0 N--CA 1.424 -1.764 0 CA-C-N 115.129 -0.536 . . . . 0.0 111.066 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.45 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 12.6 ttm-85 -93.96 125.3 38.51 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 175.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 26.1 mt -83.0 123.62 38.76 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.337 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 174.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.2 pt -103.25 -12.06 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.36 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.688 -178.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' A' ' 84' ' ' MET . 37.2 tt0 -163.02 143.51 9.34 Favored 'General case' 0 CA--C 1.494 -1.176 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.633 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.428 HD12 HG21 ' A' ' 63' ' ' VAL . 90.8 mt -140.03 121.84 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 O-C-N 124.228 0.955 . . . . 0.0 109.222 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 53.32 32.48 13.71 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.203 1.401 . . . . 0.0 112.447 172.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.59 -1.34 52.97 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.284 -0.96 . . . . 0.0 114.551 177.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -123.89 130.44 52.61 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 118.311 1.056 . . . . 0.0 110.755 178.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.3 t -74.74 109.32 8.12 Favored 'General case' 0 N--CA 1.425 -1.692 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.464 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 29.2 m -99.68 16.6 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.387 0 CA-C-O 121.968 0.889 . . . . 0.0 109.661 -174.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.438 HG23 ' HD3' ' A' ' 54' ' ' ARG . 3.8 p -72.95 -9.82 13.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 114.44 -1.254 . . . . 0.0 111.194 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.53 19.19 5.74 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.464 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 98.1 m -100.66 137.96 19.99 Favored Pre-proline 0 N--CA 1.412 -2.331 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.456 ' O ' HG13 ' A' ' 71' ' ' ILE . 50.1 Cg_endo -69.44 158.07 58.71 Favored 'Trans proline' 0 C--O 1.246 0.885 0 C-N-CA 122.435 2.09 . . . . 0.0 112.999 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -42.69 -56.19 3.26 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 126.7 2.0 . . . . 0.0 112.152 -178.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.84 -38.77 89.78 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.433 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -60.25 -51.83 67.87 Favored 'General case' 0 CA--C 1.485 -1.546 0 C-N-CA 119.974 -0.691 . . . . 0.0 110.93 177.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.456 HG13 ' O ' ' A' ' 67' ' ' PRO . 55.5 mt -50.99 -44.9 28.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 O-C-N 124.329 1.018 . . . . 0.0 110.263 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.0 t -72.68 -35.13 49.42 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.087 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 11.9 t60 -69.67 -40.2 76.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.389 0.614 . . . . 0.0 109.586 -176.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 29.4 mt -70.19 -43.59 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 CA-C-N 114.829 -1.078 . . . . 0.0 109.931 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.5 mt -59.39 -46.34 88.95 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.632 175.031 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.3 t -57.92 -28.06 63.92 Favored 'General case' 0 C--O 1.215 -0.712 0 C-N-CA 124.122 0.969 . . . . 0.0 111.686 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -99.81 -6.42 26.93 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -178.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.533 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -101.28 130.55 47.44 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.893 -0.723 . . . . 0.0 111.484 -178.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.429 ' HA ' ' HB3' ' A' ' 19' ' ' ARG . 1.0 OUTLIER -128.94 178.99 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.285 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.23 -153.59 29.33 Favored Glycine 0 CA--C 1.495 -1.178 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.426 ' HB3' HD11 ' A' ' 16' ' ' LEU . 47.7 mt-10 -77.61 110.37 12.37 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-O 121.403 0.62 . . . . 0.0 109.67 177.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 16' ' ' LEU . 74.6 mt -112.94 117.64 55.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -93.76 118.76 31.85 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.494 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.9 mtm -118.13 156.03 29.41 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 174.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -121.54 121.38 37.35 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 42.9 p -121.29 146.62 46.64 Favored 'General case' 0 C--N 1.26 -3.297 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.765 -177.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 41.6 mtm -126.58 168.71 13.64 Favored Pre-proline 0 C--N 1.31 -1.142 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -70.79 38.76 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.145 0 C-N-CA 123.812 3.008 . . . . 0.0 113.654 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 54.79 56.03 7.17 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 125.58 1.552 . . . . 0.0 114.139 177.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.299 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.32 172.136 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.238 0.476 0 CA-C-O 120.874 0.369 . . . . 0.0 111.806 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.2 t -139.63 107.06 5.54 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 122.113 0.959 . . . . 0.0 108.937 175.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 26.8 ttt -108.83 -34.69 6.59 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.111 -177.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.2 -107.46 0.2 Allowed Glycine 0 N--CA 1.417 -2.57 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -127.1 106.99 9.64 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -127.28 127.45 69.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.453 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 51.9 m -115.92 113.21 23.0 Favored 'General case' 0 C--N 1.246 -3.896 0 N-CA-C 106.222 -1.77 . . . . 0.0 106.222 177.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.2 m -86.39 137.82 32.27 Favored 'General case' 0 N--CA 1.395 -3.178 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.995 -175.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.436 ' HB ' ' HB2' ' A' ' 84' ' ' MET . 55.9 t -118.49 141.81 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.629 0 CA-C-N 114.64 -1.164 . . . . 0.0 109.045 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.495 HD11 ' HB3' ' A' ' 81' ' ' GLU . 11.5 tp -129.23 105.69 8.32 Favored 'General case' 0 N--CA 1.386 -3.643 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 171.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.652 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -99.57 127.99 51.81 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.033 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 -175.378 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.41 116.83 29.34 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.566 -177.099 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.467 ' HD3' ' HA ' ' A' ' 79' ' ' VAL . 61.6 ttt180 -119.15 116.06 34.15 Favored Pre-proline 0 C--N 1.292 -1.921 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.044 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -62.45 -48.93 6.62 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.422 2.082 . . . . 0.0 112.997 179.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 23' ' ' ARG . 2.8 p30 -159.76 -175.58 5.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.413 HD23 ' CG1' ' A' ' 79' ' ' VAL . 54.6 mt -71.43 -15.94 62.37 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -173.644 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 21' ' ' ASP . 4.0 mpt_? -80.8 -11.95 59.52 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.47 0.652 . . . . 0.0 109.717 -179.051 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -95.26 116.16 28.38 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -86.56 150.13 24.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.605 177.3 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.602 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.5 OUTLIER -53.31 -49.91 66.04 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 124.953 1.408 . . . . 0.0 111.188 -172.761 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.72 37.8 3.85 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.047 178.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -161.11 164.89 30.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.488 ' HB3' ' OG ' ' A' ' 37' ' ' SER . 34.8 t -123.4 130.15 52.3 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.448 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.444 ' O ' ' HE1' ' A' ' 68' ' ' HIS . 0.8 OUTLIER -115.46 143.74 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.878 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.856 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -130.54 128.76 41.78 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.4 t30 59.39 11.97 2.46 Favored 'General case' 0 CA--C 1.573 1.83 0 C-N-CA 123.559 0.744 . . . . 0.0 112.353 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.58 3.72 55.08 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.66 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -118.09 124.86 73.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 49.0 mt -65.12 121.71 14.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 123.876 0.87 . . . . 0.0 110.548 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.4 t -109.58 -25.96 10.17 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.752 -177.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.488 ' OG ' ' HB3' ' A' ' 29' ' ' SER . 12.9 p -146.32 144.38 29.76 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 122.168 -0.332 . . . . 0.0 110.548 177.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 51.0 tp -125.74 133.64 52.02 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 123.767 0.827 . . . . 0.0 109.758 -177.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 50.1 ttm -75.21 119.18 18.99 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.173 0.511 . . . . 0.0 109.839 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 18.6 tpp180 -66.99 122.09 16.99 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.547 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.6 1.99 82.6 Favored Glycine 0 C--N 1.312 -0.767 0 C-N-CA 120.898 -0.667 . . . . 0.0 111.999 -178.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 46' ' ' ARG . . . -86.12 165.49 37.82 Favored Glycine 0 C--O 1.252 1.239 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.288 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.452 ' HB ' HD11 ' A' ' 17' ' ' ILE . 1.1 pt -61.91 -30.88 49.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -61.59 -45.33 94.58 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 120.94 0.4 . . . . 0.0 110.282 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -64.86 -42.21 95.05 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.785 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.5 ' HG2' ' O ' ' A' ' 42' ' ' GLY . 6.7 mmp_? -61.11 -39.4 89.84 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.712 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -73.2 -16.97 78.57 Favored Glycine 0 CA--C 1.524 0.646 0 CA-C-N 115.59 -0.732 . . . . 0.0 113.903 -178.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.14 12.1 22.64 Favored Glycine 0 C--O 1.241 0.588 0 C-N-CA 119.749 -1.215 . . . . 0.0 113.033 177.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 80.6 t -72.63 142.82 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.4 mmm-85 -140.8 154.99 46.47 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 42.6 t -76.49 142.35 14.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.77 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 13.75 58.6 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -177.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.516 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -109.55 135.53 50.39 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 121.151 0.5 . . . . 0.0 111.419 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -95.2 122.94 38.4 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 176.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.415 HG12 HG22 ' A' ' 86' ' ' THR . 40.2 mt -82.78 122.73 37.7 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 62' ' ' SER . 32.4 pt -103.3 -14.97 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.004 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 178.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 84' ' ' MET . 30.7 tt0 -150.92 141.86 22.95 Favored 'General case' 0 CA--C 1.479 -1.762 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -176.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.513 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -143.2 122.0 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.539 0 O-C-N 124.64 1.213 . . . . 0.0 108.127 176.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 66.69 18.57 10.74 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 124.663 1.185 . . . . 0.0 110.927 171.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 110.69 -12.06 30.08 Favored Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.75 177.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.419 ' O ' HG13 ' A' ' 63' ' ' VAL . 13.3 pt20 -115.89 143.34 45.55 Favored 'General case' 0 CA--C 1.501 -0.941 0 CA-C-N 117.732 0.766 . . . . 0.0 112.602 -178.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 49.9 m -75.86 108.87 9.03 Favored 'General case' 0 N--CA 1.428 -1.528 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.233 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.575 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 23.3 m -102.09 15.02 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 122.124 0.964 . . . . 0.0 109.226 -174.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 p -72.97 -17.96 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-N 114.792 -1.094 . . . . 0.0 110.614 -177.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -114.59 9.32 16.56 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.954 0.883 . . . . 0.0 109.817 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.575 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 94.1 m -90.85 137.0 27.05 Favored Pre-proline 0 N--CA 1.411 -2.422 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' ILE . 12.0 Cg_endo -64.37 154.51 70.99 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 121.676 1.584 . . . . 0.0 111.585 178.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.444 ' HE1' ' O ' ' A' ' 30' ' ' VAL . 69.0 t60 -47.73 -53.49 15.02 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.375 1.07 . . . . 0.0 113.633 -176.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -67.97 -31.76 71.7 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.58 -175.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.0 mttm -63.62 -50.55 68.93 Favored 'General case' 0 C--O 1.189 -2.095 0 C-N-CA 120.197 -0.601 . . . . 0.0 110.035 173.098 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 67' ' ' PRO . 57.8 mt -50.3 -43.97 22.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 O-C-N 123.533 0.521 . . . . 0.0 110.223 177.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 86.7 t -69.1 -34.13 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.691 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.642 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -70.87 -42.56 69.9 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 123.381 0.672 . . . . 0.0 109.78 -177.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.9 mp -60.91 -48.68 87.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 80.8 mt -61.39 -46.47 90.02 Favored 'General case' 0 C--O 1.215 -0.753 0 N-CA-C 113.103 0.779 . . . . 0.0 113.103 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -61.73 -27.47 68.74 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -178.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 39.3 m-80 -101.48 -19.19 15.64 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -176.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.447 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -91.54 132.21 36.44 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 122.022 -0.424 . . . . 0.0 111.569 -176.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 19' ' ' ARG . 1.5 m -126.7 -176.37 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 88.49 -163.29 32.46 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.495 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.4 mp0 -75.58 122.06 23.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 171.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.652 ' HB ' HG22 ' A' ' 17' ' ' ILE . 70.7 mt -115.57 119.81 62.91 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.278 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -84.61 112.02 20.06 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 113.43 -1.714 . . . . 0.0 110.372 -174.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.602 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 13.5 mtp -120.57 143.9 48.38 Favored 'General case' 0 C--N 1.253 -3.612 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.745 178.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 12.1 mmmt -120.87 118.5 30.11 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 177.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 65.0 p -119.14 145.55 45.88 Favored 'General case' 0 C--N 1.282 -2.359 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.355 -176.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.464 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.3 mtp -115.8 163.9 19.41 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 178.096 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.42 24.33 0.23 Allowed 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.035 2.49 . . . . 0.0 112.352 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.464 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 63.41 22.91 13.48 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.4 1.48 . . . . 0.0 111.891 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.904 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 175.765 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 . . . . . 0 CA--C 1.509 -0.606 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -150.07 103.2 3.17 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 124.23 1.012 . . . . 0.0 108.603 173.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 16.2 tpt -88.27 123.56 33.0 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 121.179 0.514 . . . . 0.0 111.631 -177.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.92 -165.27 23.98 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 176.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.448 ' O ' ' HA ' ' A' ' 87' ' ' MET . 28.3 t-20 -94.62 87.12 4.98 Favored 'General case' 0 C--N 1.28 -2.419 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.8 t -108.77 117.76 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.79 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.877 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.8 m -115.64 114.86 25.47 Favored 'General case' 1 C--N 1.24 -4.174 0 CA-C-N 113.25 -1.795 . . . . 0.0 106.923 178.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.0 m -79.09 141.84 36.98 Favored 'General case' 0 N--CA 1.406 -2.67 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.217 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.45 HG11 ' CG2' ' A' ' 49' ' ' VAL . 57.1 t -121.86 128.28 75.64 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.363 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.506 178.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.461 HD11 ' HB3' ' A' ' 81' ' ' GLU . 22.3 tp -109.37 112.46 24.6 Favored 'General case' 0 N--CA 1.402 -2.836 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 173.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.76 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 134.83 47.32 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.546 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.015 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.73 103.36 12.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-O 121.102 0.477 . . . . 0.0 109.72 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' HD2' ' HA ' ' A' ' 79' ' ' VAL . 34.0 ttm180 -100.83 113.74 65.73 Favored Pre-proline 0 C--N 1.29 -1.989 0 CA-C-N 115.63 -0.713 . . . . 0.0 110.307 177.76 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.61 -42.11 50.19 Favored 'Trans proline' 0 C--O 1.239 0.572 0 C-N-CA 122.281 1.987 . . . . 0.0 112.181 177.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -173.7 177.04 2.58 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -178.096 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.449 HD23 HG12 ' A' ' 79' ' ' VAL . 53.1 mt -67.01 -22.38 65.9 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 -171.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -71.67 -11.65 60.94 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-O 121.406 0.622 . . . . 0.0 111.426 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.3 -20.98 23.4 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.831 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . 0.495 ' C ' HH21 ' A' ' 19' ' ' ARG . 26.4 mt-30 54.09 -153.58 0.28 Allowed 'General case' 0 C--O 1.22 -0.453 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.448 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.432 ' O ' HG13 ' A' ' 43' ' ' ILE . 2.1 mm? -97.47 -57.55 2.22 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.802 0.811 . . . . 0.0 110.49 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.67 2.99 32.56 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 -174.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.415 ' CD1' ' HB3' ' A' ' 26' ' ' LEU . 39.1 p90 -137.83 152.18 48.84 Favored 'General case' 0 C--O 1.246 0.887 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 176.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 53.5 m -105.81 122.73 46.7 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -104.18 137.27 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -119.14 111.79 18.7 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 175.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 68' ' ' HIS . 95.3 m-20 65.86 9.13 5.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.352 178.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.0 -3.74 24.1 Favored Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.9 mp -112.82 122.12 66.39 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.695 HD13 HG13 ' A' ' 49' ' ' VAL . 48.2 mt -60.43 116.14 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 123.625 0.77 . . . . 0.0 110.56 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.1 t -98.08 -33.2 11.25 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.013 -173.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 56.9 p -150.91 151.66 32.5 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 60.2 tp -135.42 137.88 42.7 Favored 'General case' 0 N--CA 1.441 -0.906 0 O-C-N 123.482 0.489 . . . . 0.0 110.829 -178.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 63.0 mtt -92.76 116.78 29.34 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.074 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -69.68 126.77 30.73 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 174.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.38 -21.5 39.13 Favored Glycine 0 N--CA 1.42 -2.427 0 C-N-CA 120.412 -0.899 . . . . 0.0 110.984 -174.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -78.91 159.04 45.28 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 177.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.567 ' HB ' HD11 ' A' ' 17' ' ' ILE . 0.4 OUTLIER -55.12 -30.7 24.53 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.866 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.315 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.75 -47.27 84.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 123.569 0.543 . . . . 0.0 111.099 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -67.15 -34.22 77.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.458 0.647 . . . . 0.0 109.492 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 47.8 mtt180 -75.51 -17.27 60.15 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.613 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.77 -37.57 8.53 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 121.74 17.76 3.77 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.026 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.695 HG13 HD13 ' A' ' 35' ' ' ILE . 59.2 t -71.1 141.56 16.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.462 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 11.8 mmm180 -137.64 146.14 43.54 Favored 'General case' 0 CA--C 1.483 -1.619 0 CA-C-O 121.267 0.556 . . . . 0.0 110.649 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.1 t -69.35 147.07 12.21 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.484 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.52 28.56 47.3 Favored Glycine 0 CA--C 1.487 -1.694 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.6 m170 -123.85 129.03 50.36 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.883 -0.659 . . . . 0.0 111.175 -179.069 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.456 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 10.2 ttm180 -89.23 124.13 34.1 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 175.327 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.58 HG12 HG22 ' A' ' 86' ' ' THR . 25.9 mt -81.54 124.51 39.02 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.141 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.434 HG13 ' HB2' ' A' ' 85' ' ' LYS . 43.1 pt -106.61 -12.5 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.503 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -154.33 145.42 22.75 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -177.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.465 ' CD1' HG21 ' A' ' 63' ' ' VAL . 80.2 mt -138.68 121.43 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.299 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 58.2 26.5 13.88 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.071 1.348 . . . . 0.0 111.711 174.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 99.88 -5.41 58.07 Favored Glycine 0 C--O 1.241 0.555 0 C-N-CA 120.025 -1.084 . . . . 0.0 113.774 177.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.401 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.8 pt20 -110.91 128.74 55.91 Favored 'General case' 0 CA--C 1.499 -0.992 0 CA-C-N 117.609 0.705 . . . . 0.0 109.554 177.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -72.89 112.74 9.2 Favored 'General case' 0 N--CA 1.42 -1.949 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -179.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 32.7 m -102.21 10.77 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.964 0 CA-C-O 121.634 0.731 . . . . 0.0 109.64 -175.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 p -71.69 -16.46 18.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.608 -177.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.63 9.87 21.09 Favored 'General case' 0 C--O 1.244 0.796 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.511 177.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' ' 63' ' ' VAL . 82.5 m -94.37 139.58 22.47 Favored Pre-proline 0 N--CA 1.405 -2.678 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -57.29 144.07 92.02 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.393 2.062 . . . . 0.0 110.483 177.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HB2' ' HA ' ' A' ' 32' ' ' ASN . 35.0 p80 -51.73 -41.1 61.27 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 -177.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -68.01 -35.0 77.57 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 -178.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 15.4 tttm -68.87 -44.65 72.88 Favored 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.465 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 63.8 mt -53.1 -45.06 53.05 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 O-C-N 123.722 0.639 . . . . 0.0 109.747 176.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.5 t -68.79 -32.31 54.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.452 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.2 t-160 -72.7 -38.99 67.34 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -175.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.9 mt -67.99 -50.75 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.675 177.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.3 mt -59.95 -30.92 69.4 Favored 'General case' 0 C--O 1.199 -1.578 0 CA-C-O 120.964 0.411 . . . . 0.0 111.414 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.448 ' O ' HD22 ' A' ' 22' ' ' LEU . 34.1 t -70.41 -26.29 63.62 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.281 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -123.53 8.5 8.96 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -172.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 19' ' ' ARG . . . -99.09 122.17 41.96 Favored 'General case' 0 C--O 1.204 -1.335 0 CA-C-N 118.259 0.481 . . . . 0.0 109.744 177.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.504 ' HA ' ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -115.42 169.96 5.78 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 CA-C-N 119.058 0.844 . . . . 0.0 109.527 177.342 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.5 -159.27 19.23 Favored Glycine 0 N--CA 1.434 -1.496 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 16' ' ' LEU . 38.6 mt-10 -80.65 111.92 17.54 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.76 ' HB ' HG22 ' A' ' 17' ' ' ILE . 62.0 mt -115.42 117.39 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -173.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -90.16 111.71 22.95 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 25.7 mtm -111.05 160.39 16.9 Favored 'General case' 0 C--N 1.278 -2.505 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.434 ' HB2' HG13 ' A' ' 56' ' ' ILE . 70.1 mmtt -121.95 125.15 45.71 Favored 'General case' 0 CA--C 1.47 -2.12 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 176.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.58 HG22 HG12 ' A' ' 55' ' ' ILE . 66.1 p -123.68 141.6 51.87 Favored 'General case' 0 C--N 1.265 -3.108 0 C-N-CA 120.195 -0.602 . . . . 0.0 110.451 -177.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 53' ' ' HIS . 75.2 mtp -116.53 171.38 4.82 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.158 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -75.51 29.67 0.37 Allowed 'Trans proline' 0 C--N 1.363 1.313 0 C-N-CA 122.823 2.348 . . . . 0.0 112.431 179.007 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.456 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 59.47 55.19 4.25 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.235 1.414 . . . . 0.0 111.526 -179.161 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.422 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 174.566 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.509 -0.611 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 97.9 m -110.34 109.13 19.44 Favored 'General case' 0 N--CA 1.421 -1.908 0 CA-C-O 121.21 0.528 . . . . 0.0 110.774 -179.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -102.26 -18.56 15.41 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.296 175.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 130.16 73.1 0.13 Allowed Glycine 0 CA--C 1.491 -1.417 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 68.91 86.79 0.13 Allowed 'General case' 0 CA--C 1.501 -0.931 0 CA-C-O 122.587 1.184 . . . . 0.0 110.937 -175.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.493 HG22 ' HG2' ' A' ' 87' ' ' MET . 79.8 t -125.16 130.56 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.827 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -175.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.8 m -112.21 106.02 14.5 Favored 'General case' 2 N--CA 1.371 -4.395 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 178.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.432 HG23 ' HD3' ' A' ' 85' ' ' LYS . 28.9 m -79.47 135.28 36.61 Favored 'General case' 0 N--CA 1.395 -3.198 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.32 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 55.2 t -114.47 134.38 57.61 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.024 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.142 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 81' ' ' GLU . 15.4 tp -119.65 104.49 10.31 Favored 'General case' 0 N--CA 1.396 -3.166 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 172.603 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -103.15 126.79 57.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.054 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -175.09 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.497 ' HG2' HH11 ' A' ' 18' ' ' ARG . 0.5 OUTLIER -95.43 122.03 37.73 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.921 -178.32 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.496 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 64.8 ttt180 -128.04 105.43 20.22 Favored Pre-proline 0 C--N 1.285 -2.226 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.05 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -52.31 -48.03 23.86 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 122.721 2.281 . . . . 0.0 113.372 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -167.93 -172.34 1.8 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 46.5 mt -70.04 -21.48 63.17 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -173.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 9.1 mpt_? -72.48 -13.02 61.33 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.305 0.574 . . . . 0.0 110.87 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -103.91 121.94 44.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . 0.251 69.3 mt-30 -103.6 157.54 16.99 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 119.048 -1.061 . . . . 0.0 113.652 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.707 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.5 mm? -44.77 -58.42 3.1 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 126.708 2.003 . . . . 0.0 111.704 -174.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.64 32.43 6.59 Favored Glycine 0 N--CA 1.427 -1.908 0 C-N-CA 119.86 -1.162 . . . . 0.0 112.256 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -159.24 161.45 36.02 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.1 t -119.9 124.03 45.04 Favored 'General case' 0 N--CA 1.415 -2.189 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -117.86 135.01 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.287 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -178.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -120.88 112.53 18.9 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.808 176.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.38 12.27 8.27 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 114.597 -1.183 . . . . 0.0 110.97 177.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.47 -4.86 31.25 Favored Glycine 0 C--O 1.206 -1.635 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.106 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.8 mp -109.25 126.57 66.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 122.117 -0.637 . . . . 0.0 109.617 -178.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.591 HD13 HG13 ' A' ' 49' ' ' VAL . 54.6 mt -71.21 115.05 10.5 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.804 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 25.2 t -101.21 -28.98 12.36 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.294 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -150.49 150.42 31.27 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.273 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 154.84 45.16 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -178.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.0 ttt -101.89 121.67 42.56 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.445 ' HD3' ' C ' ' A' ' 40' ' ' ARG . 1.2 tmt_? -69.22 128.88 38.16 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.71 86.41 Favored Glycine 0 C--N 1.311 -0.83 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 -178.172 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.497 ' O ' ' HG3' ' A' ' 46' ' ' ARG . . . -82.48 161.96 41.28 Favored Glycine 0 N--CA 1.433 -1.542 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.2 pt -60.8 -30.12 46.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.0 98.01 Favored 'General case' 0 N--CA 1.439 -1.002 0 O-C-N 123.264 0.353 . . . . 0.0 111.07 177.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.438 ' OE2' ' HA ' ' A' ' 40' ' ' ARG . 36.4 tt0 -58.66 -47.84 83.07 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 177.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.497 ' HG3' ' O ' ' A' ' 42' ' ' GLY . 22.3 mtt180 -63.16 -39.67 95.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.155 -1.384 . . . . 0.0 109.23 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -64.3 -30.82 78.89 Favored Glycine 0 C--O 1.248 0.979 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.48 -178.255 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 115.61 9.89 12.14 Favored Glycine 0 N--CA 1.439 -1.137 0 C-N-CA 120.073 -1.06 . . . . 0.0 111.489 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.591 HG13 HD13 ' A' ' 35' ' ' ILE . 88.5 t -71.84 134.7 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -143.51 146.32 33.28 Favored 'General case' 0 CA--C 1.495 -1.148 0 C-N-CA 123.666 0.786 . . . . 0.0 109.674 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.8 t -67.36 144.34 14.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 CA-C-N 114.15 -1.386 . . . . 0.0 111.136 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.94 61.79 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.911 -0.661 . . . . 0.0 111.475 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -120.39 148.65 43.5 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' THR . 42.2 ttp180 -106.35 132.53 52.27 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.536 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.63 HD13 HG22 ' A' ' 86' ' ' THR . 18.2 mm -75.48 114.61 15.78 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 175.584 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.1 pt -101.03 -15.23 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.808 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 179.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 84' ' ' MET . 38.1 tt0 -156.37 146.12 20.99 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.489 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.5 mt -140.8 122.5 14.63 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 O-C-N 124.388 1.055 . . . . 0.0 108.521 178.302 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 59.32 23.18 11.61 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.708 1.203 . . . . 0.0 111.626 172.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.01 -9.96 40.05 Favored Glycine 0 N--CA 1.439 -1.14 0 C-N-CA 120.535 -0.841 . . . . 0.0 114.061 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.13 134.44 52.72 Favored 'General case' 0 CA--C 1.494 -1.203 0 CA-C-N 118.34 1.07 . . . . 0.0 110.752 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -72.53 112.59 8.72 Favored 'General case' 0 N--CA 1.423 -1.787 0 CA-C-O 121.337 0.589 . . . . 0.0 109.692 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.65 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 25.1 m -109.15 19.38 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-O 122.312 1.053 . . . . 0.0 108.932 -175.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.12 -18.6 19.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.388 -176.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -118.88 12.03 12.76 Favored 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.669 0.747 . . . . 0.0 109.009 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.65 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 97.3 m -83.88 136.74 41.26 Favored Pre-proline 0 N--CA 1.417 -2.083 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.44 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' THR . 43.0 Cg_exo -60.12 154.87 48.58 Favored 'Trans proline' 0 C--O 1.241 0.662 0 C-N-CA 122.928 2.419 . . . . 0.0 112.912 177.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -45.3 -55.7 5.65 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.715 1.606 . . . . 0.0 111.151 178.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -58.85 -43.6 90.79 Favored 'General case' 0 C--N 1.311 -1.095 0 O-C-N 124.307 1.004 . . . . 0.0 110.546 -175.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -62.21 -54.34 42.35 Favored 'General case' 0 CA--C 1.477 -1.835 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.883 -178.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 73.0 mt -52.01 -42.74 35.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 O-C-N 124.177 0.923 . . . . 0.0 110.383 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 83.6 t -71.66 -39.32 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.657 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 53.8 t60 -69.8 -41.55 74.91 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.519 0.676 . . . . 0.0 109.903 -176.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.6 mt -69.52 -44.03 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 CA-C-N 114.674 -1.148 . . . . 0.0 110.314 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 60.1 mt -59.99 -44.05 94.76 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.829 0.347 . . . . 0.0 111.086 173.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.404 ' C ' HH12 ' A' ' 19' ' ' ARG . 34.6 t -59.16 -27.44 65.66 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 123.49 0.716 . . . . 0.0 112.216 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -109.39 -2.74 17.57 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -176.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.496 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -97.68 130.82 44.65 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.478 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 m -128.3 179.73 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.65 -161.96 28.78 Favored Glycine 0 CA--C 1.489 -1.563 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -178.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.505 ' HB3' HD11 ' A' ' 16' ' ' LEU . 27.9 mt-10 -75.89 119.15 19.47 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 172.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.7 ' HB ' HG22 ' A' ' 17' ' ' ILE . 63.1 mt -117.19 117.63 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.711 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.246 -173.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -82.98 111.8 19.17 Favored 'General case' 0 CA--C 1.492 -1.257 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.603 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.413 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 28.4 mtm -117.55 156.54 27.9 Favored 'General case' 0 C--N 1.269 -2.914 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 173.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.432 ' HD3' HG23 ' A' ' 14' ' ' THR . 35.6 mmtm -123.07 121.65 36.55 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.63 HG22 HD13 ' A' ' 55' ' ' ILE . 68.3 p -116.93 141.49 48.16 Favored 'General case' 0 C--N 1.266 -3.04 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.712 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.493 ' HG2' HG22 ' A' ' 12' ' ' VAL . 85.0 mtp -119.72 170.31 7.04 Favored Pre-proline 0 C--O 1.211 -0.937 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 178.259 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.69 26.64 0.2 Allowed 'Trans proline' 0 CA--C 1.559 1.767 0 C-N-CA 122.865 2.377 . . . . 0.0 113.286 178.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.41 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 61.39 34.83 18.11 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.586 1.154 . . . . 0.0 111.08 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.418 -2.027 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.396 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 . . . . . 0 CA--C 1.497 -1.071 0 CA-C-O 121.518 0.675 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 t -148.72 158.37 44.1 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 179.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 26.3 mmt -85.14 82.25 8.49 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.558 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.65 145.13 17.76 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 16.8 m120 62.52 58.82 1.6 Allowed 'General case' 0 CA--C 1.487 -1.466 0 C-N-CA 123.872 0.869 . . . . 0.0 109.619 -176.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 86' ' ' THR . 39.9 t -141.48 126.13 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.974 0 CA-C-N 114.328 -1.306 . . . . 0.0 108.765 -175.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 85.1 m -111.42 113.44 25.89 Favored 'General case' 2 N--CA 1.376 -4.137 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 176.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.6 m -85.23 137.94 32.66 Favored 'General case' 0 N--CA 1.398 -3.07 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.468 HG11 ' HE2' ' A' ' 84' ' ' MET . 25.4 t -118.01 139.22 46.04 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.955 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 82' ' ' ILE . 19.4 tp -121.14 112.46 18.71 Favored 'General case' 0 N--CA 1.383 -3.803 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.976 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.581 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -98.61 122.44 50.31 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 N-CA-C 106.949 -1.5 . . . . 0.0 106.949 176.314 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.7 mtp180 -107.18 102.07 11.42 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-O 122.661 1.22 . . . . 0.0 109.276 173.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.509 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 74.1 ttt180 -103.75 109.46 62.18 Favored Pre-proline 0 C--N 1.272 -2.802 0 CA-C-N 112.523 -2.126 . . . . 0.0 109.716 -176.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -54.11 -50.8 12.34 Favored 'Trans proline' 0 CA--C 1.542 0.904 0 C-N-CA 122.602 2.201 . . . . 0.0 111.993 178.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -164.88 -172.57 2.64 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.406 HD23 ' CG1' ' A' ' 79' ' ' VAL . 55.6 mt -69.01 -17.26 63.89 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -173.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 -64.55 -23.04 67.14 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.3 0.571 . . . . 0.0 110.676 176.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -105.85 113.16 26.54 Favored 'General case' 0 N--CA 1.422 -1.859 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -178.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -92.14 161.93 14.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.618 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.2 OUTLIER -52.75 -57.11 11.22 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 124.467 1.107 . . . . 0.0 110.662 -173.565 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.57 23.92 10.57 Favored Glycine 0 N--CA 1.434 -1.486 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.861 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -145.94 155.54 42.92 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.0 m -108.6 137.06 47.16 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.92 136.89 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-O 121.49 0.662 . . . . 0.0 110.622 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.468 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 0.0 OUTLIER -128.41 121.15 28.37 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 176.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 63.56 4.27 1.74 Allowed 'General case' 0 N--CA 1.503 2.197 0 C-N-CA 125.101 1.36 . . . . 0.0 111.983 -172.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 104.58 1.07 43.34 Favored Glycine 0 N--CA 1.438 -1.205 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -174.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.0 mp -102.35 124.05 56.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.688 HD13 HG13 ' A' ' 49' ' ' VAL . 68.1 mt -65.76 117.14 5.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 C-N-CA 124.184 0.994 . . . . 0.0 110.576 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 31' ' ' GLN . 41.8 t -101.55 -28.33 12.6 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.851 -175.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.1 t -154.56 156.58 36.86 Favored 'General case' 0 C--O 1.246 0.876 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.4 HD21 ' HA ' ' A' ' 45' ' ' GLU . 57.5 tp -134.43 140.11 46.02 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 123.624 0.77 . . . . 0.0 109.826 -178.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.3 tpt -91.89 127.0 37.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -76.39 135.33 39.48 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -178.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.39 1.06 86.26 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 121.217 -0.516 . . . . 0.0 111.958 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -93.6 167.52 28.59 Favored Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.8 pt -56.75 -36.42 49.16 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.96 0 N-CA-C 113.226 0.825 . . . . 0.0 113.226 178.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.581 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -59.65 -37.61 79.17 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.4 ' HA ' HD21 ' A' ' 38' ' ' LEU . 14.1 tt0 -61.26 -49.26 77.79 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.096 0.95 . . . . 0.0 108.822 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -76.77 -16.32 59.51 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 114.199 -1.364 . . . . 0.0 111.198 -176.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.59 -19.55 70.84 Favored Glycine 0 N--CA 1.432 -1.618 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.603 176.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.74 16.99 20.43 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.239 177.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.688 HG13 HD13 ' A' ' 35' ' ' ILE . 51.0 t -69.5 133.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 CA-C-O 120.922 0.391 . . . . 0.0 110.561 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 20.9 mmt180 -132.38 137.03 47.2 Favored 'General case' 0 CA--C 1.484 -1.577 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.335 178.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.7 t -72.23 147.51 10.32 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.68 0 CA-C-N 113.913 -1.494 . . . . 0.0 110.115 -178.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.0 23.38 45.5 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.538 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 17.1 m-70 -121.83 139.62 53.39 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.199 -0.5 . . . . 0.0 111.377 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.555 ' HB2' ' HA ' ' A' ' 89' ' ' ALA . 9.0 ttm180 -94.39 120.82 35.2 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.227 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 86' ' ' THR . 41.6 mt -76.24 122.09 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 175.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 36.9 pt -102.61 -14.5 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.552 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.251 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.524 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.5 tt0 -161.38 142.88 11.56 Favored 'General case' 0 CA--C 1.485 -1.531 0 C-N-CA 120.046 -0.661 . . . . 0.0 110.148 -174.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 61' ' ' GLN . 75.4 mt -133.26 123.06 46.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 73.38 -21.18 0.26 Allowed 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.988 1.315 . . . . 0.0 112.663 172.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 143.42 -8.31 2.09 Favored Glycine 0 N--CA 1.438 -1.23 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -175.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.466 ' HG2' ' O ' ' A' ' 58' ' ' ILE . 20.4 pt20 -107.87 123.48 48.65 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 m -69.79 111.76 5.77 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 121.512 0.672 . . . . 0.0 109.71 179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 58' ' ' ILE . 34.0 m -103.47 16.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 CA-C-O 122.062 0.934 . . . . 0.0 109.346 -175.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.2 p -71.7 -17.91 19.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.56 -179.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.69 11.92 21.08 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.15 -0.932 . . . . 0.0 109.206 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.461 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.5 m -101.9 137.81 19.62 Favored Pre-proline 0 N--CA 1.408 -2.557 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.413 ' O ' HG13 ' A' ' 71' ' ' ILE . 73.9 Cg_endo -76.64 168.08 24.32 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 122.58 2.186 . . . . 0.0 112.551 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -44.62 -55.01 5.55 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 124.977 1.311 . . . . 0.0 111.617 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -56.82 -43.61 81.21 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.352 1.032 . . . . 0.0 110.824 -173.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.0 mtpt -73.54 -45.89 50.82 Favored 'General case' 0 CA--C 1.485 -1.521 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 67' ' ' PRO . 61.7 mt -54.67 -39.86 48.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 121.135 0.493 . . . . 0.0 109.741 178.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.74 -37.59 69.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.479 177.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -64.59 -39.75 94.29 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -177.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 25.9 mt -71.06 -53.34 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.675 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.979 -179.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 72.7 mt -56.39 -41.77 76.81 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 10.8 t -63.0 -29.42 70.81 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 123.336 0.655 . . . . 0.0 111.71 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -104.63 -13.39 15.98 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.46 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.509 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -90.87 133.99 34.8 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.316 -0.554 . . . . 0.0 112.494 -174.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.406 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.5 m -137.44 175.81 8.79 Favored 'Isoleucine or valine' 0 C--O 1.248 1.02 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.45 -161.94 19.75 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -77.29 107.76 9.93 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 173.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.481 ' O ' HD12 ' A' ' 16' ' ' LEU . 82.3 mt -107.86 116.67 51.83 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -174.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -97.78 110.2 22.82 Favored 'General case' 0 CA--C 1.453 -2.753 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.524 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 11.3 ttp -112.91 141.38 46.81 Favored 'General case' 1 C--N 1.242 -4.097 0 N-CA-C 105.739 -1.949 . . . . 0.0 105.739 -174.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm -121.42 130.39 53.56 Favored 'General case' 0 CA--C 1.452 -2.805 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 -177.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 38.5 p -126.34 153.17 45.25 Favored 'General case' 0 C--N 1.275 -2.656 0 O-C-N 123.532 0.52 . . . . 0.0 110.015 -174.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.453 ' C ' ' H ' ' A' ' 89' ' ' ALA . 81.8 mtp -122.08 168.76 10.78 Favored Pre-proline 0 C--N 1.301 -1.526 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 176.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.94 22.33 0.31 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 123.137 2.558 . . . . 0.0 112.595 178.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.555 ' HA ' ' HB2' ' A' ' 54' ' ' ARG . . . 73.28 3.51 4.64 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 126.075 1.75 . . . . 0.0 113.645 177.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.609 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 175.619 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 . . . . . 0 CA--C 1.516 -0.353 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -99.82 122.25 42.5 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -90.37 137.16 32.58 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.368 0.418 . . . . 0.0 110.717 -173.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.15 -150.68 18.14 Favored Glycine 0 C--N 1.303 -1.299 0 C-N-CA 120.794 -0.717 . . . . 0.0 111.71 175.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.2 m120 -91.29 99.54 12.5 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.471 HG22 ' HG2' ' A' ' 87' ' ' MET . 55.7 t -128.58 129.68 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.628 -175.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.3 m -117.77 113.73 22.26 Favored 'General case' 0 N--CA 1.391 -3.392 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.602 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.3 m -81.42 128.83 34.29 Favored 'General case' 0 N--CA 1.398 -3.042 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.333 -178.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.456 HG11 ' CG2' ' A' ' 49' ' ' VAL . 53.1 t -110.2 136.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.767 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.058 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.491 HD11 ' HB3' ' A' ' 81' ' ' GLU . 21.3 tp -119.07 109.37 15.83 Favored 'General case' 0 N--CA 1.384 -3.767 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 172.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.587 HG22 ' HB ' ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.7 136.07 31.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -115.45 103.75 11.07 Favored 'General case' 0 C--N 1.287 -2.13 0 CA-C-O 122.195 0.998 . . . . 0.0 110.796 178.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.433 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 66.0 ttt180 -103.12 113.42 65.85 Favored Pre-proline 0 C--N 1.283 -2.292 0 CA-C-N 113.408 -1.724 . . . . 0.0 109.952 -175.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.8 -56.06 2.49 Favored 'Trans proline' 0 CA--C 1.552 1.414 0 C-N-CA 122.937 2.425 . . . . 0.0 113.991 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.55 -175.59 5.49 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.5 HD23 ' CG1' ' A' ' 79' ' ' VAL . 61.3 mt -71.06 -17.87 62.58 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -173.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -79.0 -11.19 60.0 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 121.618 0.723 . . . . 0.0 111.04 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -97.66 143.01 28.75 Favored 'General case' 0 N--CA 1.403 -2.799 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -97.07 -157.27 0.58 Allowed 'General case' 0 C--N 1.26 -3.325 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -93.83 -51.24 4.98 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.25 6.47 Favored Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.003 177.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -149.26 157.18 43.13 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.5 m -105.44 121.92 44.91 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 178.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.28 130.72 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.757 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -111.0 102.44 10.91 Favored 'General case' 0 C--N 1.287 -2.132 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 178.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 67.23 14.84 9.87 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.16 175.726 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 114.52 -3.17 23.39 Favored Glycine 0 N--CA 1.438 -1.208 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.94 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 54' ' ' ARG . 3.1 mp -114.48 122.27 68.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 O-C-N 122.389 -0.477 . . . . 0.0 109.869 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.721 HD13 HG13 ' A' ' 49' ' ' VAL . 55.5 mt -65.24 111.22 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 123.647 0.779 . . . . 0.0 109.475 179.032 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 49.7 t -105.6 -19.41 13.78 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.988 -176.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 m -149.2 150.42 32.59 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 121.667 -0.645 . . . . 0.0 109.84 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.414 HD21 ' HA ' ' A' ' 45' ' ' GLU . 65.0 tp -135.63 141.51 45.07 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 120.88 0.371 . . . . 0.0 110.738 -177.796 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.7 ttt -82.55 103.43 12.07 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -79.51 107.14 12.06 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.535 0.683 . . . . 0.0 110.082 -174.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.23 11.35 Favored Glycine 0 N--CA 1.433 -1.552 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -175.172 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.77 178.49 53.68 Favored Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.097 -0.551 . . . . 0.0 111.782 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.414 ' HB ' ' CD1' ' A' ' 17' ' ' ILE . 0.5 OUTLIER -58.1 -41.15 79.88 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.927 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -177.479 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.74 -37.91 88.44 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.635 0.255 . . . . 0.0 111.616 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.414 ' HA ' HD21 ' A' ' 38' ' ' LEU . 3.6 tm-20 -61.78 -46.4 89.71 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 178.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.9 mtt-85 -74.77 -25.1 58.84 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.615 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -74.5 -19.2 79.93 Favored Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.455 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.65 7.88 29.13 Favored Glycine 0 CA--C 1.507 -0.44 0 C-N-CA 120.137 -1.03 . . . . 0.0 112.256 177.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.721 HG13 HD13 ' A' ' 35' ' ' ILE . 73.2 t -73.58 135.47 27.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.1 mmt-85 -137.72 155.42 49.11 Favored 'General case' 0 CA--C 1.492 -1.283 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 176.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 74.1 t -80.7 139.38 18.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.382 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.141 -175.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.33 6.08 51.43 Favored Glycine 0 CA--C 1.497 -1.034 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -177.479 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.581 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 74.8 m-70 -106.23 142.88 35.17 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 115.099 -0.55 . . . . 0.0 111.228 179.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.49 ' CB ' ' HA ' ' A' ' 89' ' ' ALA . 39.2 ttm180 -99.18 132.66 44.34 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 171.618 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.481 HG12 HG22 ' A' ' 86' ' ' THR . 28.0 mt -85.68 123.37 39.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.467 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 176.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 26.6 pt -102.99 -12.92 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.199 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.291 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 84' ' ' MET . 36.9 tt0 -154.35 141.68 19.6 Favored 'General case' 0 CA--C 1.479 -1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -178.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.495 ' CD1' HG21 ' A' ' 63' ' ' VAL . 71.8 mt -140.91 124.4 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 124.407 1.067 . . . . 0.0 108.155 177.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 68.55 13.92 9.01 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.892 0.853 . . . . 0.0 110.287 171.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.7 -2.73 49.07 Favored Glycine 0 N--CA 1.437 -1.25 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.934 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.441 ' O ' HG13 ' A' ' 63' ' ' VAL . 20.4 pt20 -112.85 130.98 55.9 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.617 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 33.2 t -68.38 114.23 6.64 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.602 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.7 m -108.84 17.08 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 CA-C-O 121.884 0.85 . . . . 0.0 109.394 -176.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 5.8 p -71.34 -15.22 18.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.841 -1.072 . . . . 0.0 112.04 -175.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -120.01 7.31 10.86 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.216 0.531 . . . . 0.0 109.568 175.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.602 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 95.9 m -80.8 138.07 50.4 Favored Pre-proline 0 N--CA 1.418 -2.042 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.243 -177.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.98 157.27 44.64 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 123.081 2.52 . . . . 0.0 113.223 178.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -45.96 -55.86 6.24 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 125.972 1.709 . . . . 0.0 110.61 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -54.09 -51.83 62.9 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 124.492 1.117 . . . . 0.0 110.813 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.536 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 7.9 mptt -58.93 -54.0 52.09 Favored 'General case' 0 CA--C 1.486 -1.482 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.812 -176.427 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 70.4 mt -50.71 -43.28 23.9 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 124.312 1.007 . . . . 0.0 110.358 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.0 t -73.2 -36.86 51.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.744 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -73.45 -37.69 65.73 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.348 0.594 . . . . 0.0 109.903 -175.097 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 41.1 mt -68.53 -47.64 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.78 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.307 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 59.2 mt -58.28 -40.32 81.59 Favored 'General case' 0 C--O 1.212 -0.905 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.492 176.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.3 t -62.25 -26.99 68.69 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -105.98 -17.3 14.39 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.433 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -89.9 127.25 35.97 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.688 -176.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.5 ' CG1' HD23 ' A' ' 22' ' ' LEU . 1.8 m -127.53 -179.38 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.11 -155.61 24.58 Favored Glycine 0 CA--C 1.493 -1.292 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.491 ' HB3' HD11 ' A' ' 16' ' ' LEU . 45.3 mt-10 -77.69 108.52 10.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 174.741 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.587 ' HB ' HG22 ' A' ' 17' ' ' ILE . 64.6 mt -109.63 117.72 55.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -176.154 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 39.8 m-70 -93.05 116.93 29.5 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 -178.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.465 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.0 mtm -120.2 156.84 30.32 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 177.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.467 ' HD2' ' CG1' ' A' ' 12' ' ' VAL . 68.8 mmtt -121.47 123.81 42.93 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 176.35 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.581 ' HB ' ' HB3' ' A' ' 53' ' ' HIS . 72.1 p -119.36 139.84 51.33 Favored 'General case' 0 C--N 1.27 -2.875 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.208 -177.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.471 ' HG2' HG22 ' A' ' 12' ' ' VAL . 82.9 mtp -120.85 171.72 5.57 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -72.1 24.91 0.26 Allowed 'Trans proline' 0 N--CA 1.497 1.728 0 C-N-CA 123.09 2.527 . . . . 0.0 112.88 177.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.49 ' HA ' ' CB ' ' A' ' 54' ' ' ARG . . . 71.33 20.59 4.93 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 125.127 1.371 . . . . 0.0 112.803 177.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -1.762 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.021 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 . . . . . 0 CA--C 1.514 -0.416 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.1 t -135.69 159.41 41.72 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.15 0.5 . . . . 0.0 109.763 -178.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 25.5 mmt -120.26 -177.74 3.51 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -178.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.72 -103.28 0.89 Allowed Glycine 0 CA--C 1.501 -0.817 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.405 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -101.27 108.1 19.66 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -130.66 133.7 63.06 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 CA-C-O 122.315 1.055 . . . . 0.0 111.861 -172.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.4 m -127.9 121.94 31.27 Favored 'General case' 0 N--CA 1.392 -3.355 0 CA-C-N 113.262 -1.79 . . . . 0.0 106.864 176.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 m -82.82 141.92 31.93 Favored 'General case' 0 N--CA 1.404 -2.774 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.574 -176.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' CG2' ' A' ' 49' ' ' VAL . 56.1 t -116.47 136.65 52.82 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.067 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.412 HD12 ' O ' ' A' ' 82' ' ' ILE . 29.1 tp -122.1 119.73 32.2 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-O 121.961 0.886 . . . . 0.0 109.886 175.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.557 HD11 ' HA ' ' A' ' 44' ' ' ALA . 0.7 OUTLIER -97.49 134.13 36.68 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.098 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.418 178.594 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.02 101.34 10.16 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 171.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.531 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 72.0 ttt180 -108.31 107.97 60.67 Favored Pre-proline 0 C--N 1.282 -2.341 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.451 -178.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -58.03 -41.09 71.71 Favored 'Trans proline' 0 CA--C 1.546 1.117 0 C-N-CA 122.607 2.205 . . . . 0.0 113.423 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -167.17 176.64 6.67 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.45 HD23 ' CG1' ' A' ' 79' ' ' VAL . 73.1 mt -68.95 -22.39 64.13 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 125.152 1.381 . . . . 0.0 111.213 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.424 ' HA ' ' NE ' ' A' ' 23' ' ' ARG . 7.3 mmp_? -59.11 -21.89 59.98 Favored 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.058 0.848 . . . . 0.0 110.233 174.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -103.89 118.35 36.49 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 104.899 -2.26 . . . . 0.0 104.899 178.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.22 168.79 10.69 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.587 HD22 ' H ' ' A' ' 26' ' ' LEU . 0.4 OUTLIER -64.05 -59.85 3.97 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.221 0.534 . . . . 0.0 111.282 -171.014 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.445 ' O ' HD12 ' A' ' 38' ' ' LEU . . . 103.45 34.63 3.82 Favored Glycine 0 N--CA 1.431 -1.658 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.287 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -155.43 157.39 36.94 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.6 m -117.34 136.04 53.42 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.85 128.15 64.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.772 0.796 . . . . 0.0 112.923 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -121.45 115.44 22.88 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.454 176.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 68.99 2.6 3.65 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 125.538 1.535 . . . . 0.0 112.283 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 118.42 -12.6 12.38 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mp -96.43 128.17 47.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 O-C-N 122.385 -0.479 . . . . 0.0 110.548 -179.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.746 HD13 HG13 ' A' ' 49' ' ' VAL . 72.9 mt -68.31 114.45 5.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 124.458 1.103 . . . . 0.0 109.608 176.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 36.5 t -98.63 -23.78 15.34 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.006 -177.287 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.8 p -156.52 152.06 26.87 Favored 'General case' 0 C--N 1.322 -0.629 0 O-C-N 122.297 -0.252 . . . . 0.0 111.316 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.445 HD12 ' O ' ' A' ' 27' ' ' GLY . 48.7 tp -125.91 148.55 49.18 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 124.356 1.062 . . . . 0.0 109.072 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.0 tpt -105.88 123.52 48.09 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.376 0.608 . . . . 0.0 110.692 -179.312 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 20.4 tpp85 -60.36 130.84 48.59 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.23 176.587 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.05 5.99 89.25 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.856 178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.58 161.2 27.15 Favored Glycine 0 N--CA 1.423 -2.179 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 pt -60.24 -32.61 51.12 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.98 0 C-N-CA 120.764 -0.375 . . . . 0.0 111.947 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -60.83 -38.85 86.88 Favored 'General case' 0 N--CA 1.443 -0.779 0 C-N-CA 122.986 0.514 . . . . 0.0 111.812 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.44 ' HA ' HD21 ' A' ' 38' ' ' LEU . 44.4 tt0 -64.31 -38.88 92.6 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -90.48 -0.41 57.65 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.902 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -92.31 -19.56 38.35 Favored Glycine 0 N--CA 1.433 -1.504 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 175.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.16 9.01 26.6 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.103 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.746 HG13 HD13 ' A' ' 35' ' ' ILE . 60.0 t -69.82 140.01 19.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 13.9 mmt180 -145.08 141.8 29.14 Favored 'General case' 0 CA--C 1.49 -1.354 0 C-N-CA 123.406 0.682 . . . . 0.0 110.989 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.74 139.9 20.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.783 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.18 14.29 59.17 Favored Glycine 0 C--N 1.305 -1.147 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.558 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 7.1 m170 -108.71 133.85 52.23 Favored 'General case' 0 N--CA 1.428 -1.575 0 CA-C-O 121.32 0.581 . . . . 0.0 111.611 178.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -92.76 114.79 27.44 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.492 -1.231 . . . . 0.0 108.085 177.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.564 HG12 HG22 ' A' ' 86' ' ' THR . 30.2 mt -78.54 122.9 34.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 62' ' ' SER . 37.2 pt -106.43 -11.79 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.505 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.568 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 84' ' ' MET . 31.8 tt0 -154.76 144.91 21.87 Favored 'General case' 0 CA--C 1.479 -1.778 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.107 -177.015 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' CD1' HG21 ' A' ' 63' ' ' VAL . 69.8 mt -141.82 125.15 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 174.57 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 69.43 -2.72 1.8 Allowed 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.991 1.317 . . . . 0.0 112.846 172.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.43 -4.11 10.25 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.968 -178.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -112.28 130.68 55.86 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 10.5 p -73.0 108.3 5.82 Favored 'General case' 0 N--CA 1.425 -1.68 0 CA-C-O 121.795 0.807 . . . . 0.0 110.285 177.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.552 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 28.6 m -98.86 16.52 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-O 122.271 1.034 . . . . 0.0 110.053 -172.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.6 p -75.58 -10.27 13.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.072 -177.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -121.95 16.33 10.88 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.063 -0.972 . . . . 0.0 108.495 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 85.7 m -103.26 135.22 19.43 Favored Pre-proline 0 N--CA 1.407 -2.577 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.49 159.81 52.18 Favored 'Trans proline' 0 C--O 1.244 0.802 0 C-N-CA 122.258 1.972 . . . . 0.0 112.596 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -43.15 -54.84 4.22 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.87 1.668 . . . . 0.0 112.177 -178.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -56.39 -47.03 79.79 Favored 'General case' 0 CA--C 1.497 -1.067 0 O-C-N 124.027 0.83 . . . . 0.0 110.663 -175.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.468 ' HB3' ' CG2' ' A' ' 66' ' ' THR . 12.6 mptt -63.76 -54.21 38.92 Favored 'General case' 0 N--CA 1.426 -1.639 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.682 -177.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 57.5 mt -51.08 -44.75 29.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 O-C-N 124.098 0.874 . . . . 0.0 110.112 179.335 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.4 t -71.53 -36.82 61.67 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.746 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -72.81 -40.57 65.74 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -174.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 46.0 mt -66.0 -46.26 88.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.895 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 64.9 mt -58.5 -41.04 84.47 Favored 'General case' 0 C--O 1.214 -0.811 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.554 175.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 50.8 m -63.06 -27.61 69.52 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.2 m-80 -104.45 -10.65 17.55 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -175.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -93.39 133.4 36.68 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.76 -178.409 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.45 ' CG1' HD23 ' A' ' 22' ' ' LEU . 3.1 m -129.69 -178.57 2.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.583 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 175.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.57 -154.82 33.14 Favored Glycine 0 CA--C 1.488 -1.624 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -73.51 112.64 9.79 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 121.592 0.711 . . . . 0.0 109.722 174.28 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.412 ' O ' HD12 ' A' ' 16' ' ' LEU . 74.9 mt -118.11 117.47 54.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.358 0 CA-C-N 115.328 -0.851 . . . . 0.0 108.711 -177.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -88.38 129.98 35.27 Favored 'General case' 0 CA--C 1.473 -2.013 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.201 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.453 ' HA ' ' O ' ' A' ' 57' ' ' GLU . 23.3 mtm -129.19 153.3 47.87 Favored 'General case' 0 C--N 1.262 -3.209 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 171.148 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 62.9 mmtt -119.18 122.61 42.39 Favored 'General case' 0 C--N 1.268 -2.975 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 177.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.564 HG22 HG12 ' A' ' 55' ' ' ILE . 52.7 p -121.82 143.61 49.3 Favored 'General case' 0 C--N 1.267 -2.992 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.102 -177.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.556 ' C ' ' H ' ' A' ' 89' ' ' ALA . 88.3 mtp -111.22 164.07 15.85 Favored Pre-proline 0 C--N 1.303 -1.421 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 178.152 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -78.33 29.68 0.45 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 122.786 2.324 . . . . 0.0 109.3 172.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.556 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 67.97 11.5 8.39 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 127.015 2.126 . . . . 0.0 112.017 -178.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.204 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.517 -0.293 0 CA-C-O 121.405 0.621 . . . . 0.0 110.006 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.8 m -155.61 93.51 1.49 Allowed 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 175.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 28.3 ttt -64.81 -60.49 3.02 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.65 99.96 0.13 Allowed Glycine 0 CA--C 1.493 -1.325 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.098 -179.458 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.438 ' O ' ' HD3' ' A' ' 88' ' ' PRO . 88.9 m-20 63.48 89.88 0.09 Allowed 'General case' 0 CA--C 1.502 -0.894 0 CA-C-O 121.844 0.831 . . . . 0.0 109.853 -175.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.4 t -122.79 122.19 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 CA-C-O 121.885 0.85 . . . . 0.0 109.518 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.9 m -108.49 108.81 19.89 Favored 'General case' 0 C--N 1.246 -3.916 0 CA-C-N 113.332 -1.758 . . . . 0.0 107.133 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 85' ' ' LYS . 15.9 m -79.43 132.63 36.43 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.435 178.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.479 HG11 ' HE2' ' A' ' 84' ' ' MET . 37.2 t -111.17 140.65 29.49 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.335 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.517 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 82' ' ' ILE . 15.1 tp -122.83 112.76 18.27 Favored 'General case' 0 N--CA 1.379 -3.983 0 C-N-CA 119.286 -0.966 . . . . 0.0 108.814 172.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -98.89 129.21 49.58 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.968 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.58 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -111.84 102.78 11.03 Favored 'General case' 0 N--CA 1.406 -2.64 0 CA-C-O 122.506 1.145 . . . . 0.0 109.667 174.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.612 ' HD3' ' O ' ' A' ' 78' ' ' ALA . 71.3 ttt180 -112.38 110.79 52.9 Favored Pre-proline 0 C--N 1.276 -2.609 0 CA-C-N 112.752 -2.022 . . . . 0.0 110.718 -176.596 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -57.46 -51.88 7.49 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 122.567 2.178 . . . . 0.0 112.577 178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.47 ' OD2' ' HG2' ' A' ' 23' ' ' ARG . 1.0 OUTLIER -158.56 -174.0 4.57 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.838 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.427 HD23 HG12 ' A' ' 79' ' ' VAL . 46.6 mt -72.08 -14.16 61.78 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.47 ' HG2' ' OD2' ' A' ' 21' ' ' ASP . 18.5 mmt180 -66.31 -23.95 66.46 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -94.4 110.18 21.98 Favored 'General case' 0 CA--C 1.48 -1.72 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 176.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -92.19 155.44 18.01 Favored 'General case' 0 C--N 1.281 -2.388 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.806 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.657 HD22 ' H ' ' A' ' 26' ' ' LEU . 1.2 mm? -50.78 -61.76 2.02 Favored 'General case' 0 C--O 1.237 0.428 0 O-C-N 124.913 1.383 . . . . 0.0 110.642 -175.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.48 -10.77 35.95 Favored Glycine 0 N--CA 1.434 -1.496 0 C-N-CA 120.66 -0.781 . . . . 0.0 111.579 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.422 ' CE1' ' HB3' ' A' ' 26' ' ' LEU . 50.6 p90 -112.89 151.76 30.1 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.023 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.3 t -107.08 122.38 46.36 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -112.44 131.35 64.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 CA-C-O 121.576 0.703 . . . . 0.0 112.18 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -131.52 122.14 25.65 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 114.495 -1.229 . . . . 0.0 107.843 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.46 ' HA ' ' CB ' ' A' ' 68' ' ' HIS . 88.0 m-20 66.89 13.98 9.65 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-O 121.902 0.858 . . . . 0.0 111.752 177.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.46 -6.72 65.71 Favored Glycine 0 N--CA 1.432 -1.616 0 CA-C-N 115.175 -0.92 . . . . 0.0 111.313 -178.179 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.14 128.82 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-O 121.223 0.535 . . . . 0.0 110.22 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.645 HD13 HG13 ' A' ' 49' ' ' VAL . 62.3 mt -67.11 111.01 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.221 175.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -95.57 -27.99 15.07 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.645 -175.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.4 m -150.47 158.91 44.69 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 121.959 -0.463 . . . . 0.0 110.072 -177.65 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.2 tp -142.85 135.44 27.71 Favored 'General case' 0 C--O 1.239 0.529 0 O-C-N 123.835 0.709 . . . . 0.0 111.258 -178.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ttt -82.3 121.92 27.29 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 176.125 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -74.33 122.86 23.57 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.056 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.17 -3.22 72.63 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -177.462 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -83.47 170.31 48.43 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.7 pt -63.03 -37.29 78.98 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.399 0 CA-C-N 117.311 0.556 . . . . 0.0 111.899 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.497 ' HA ' HD11 ' A' ' 17' ' ' ILE . . . -55.23 -45.56 75.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -62.78 -43.15 99.56 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.507 0.67 . . . . 0.0 109.936 178.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -73.76 -20.25 60.55 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.125 -0.943 . . . . 0.0 111.778 -179.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -86.26 -19.13 57.82 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.963 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.62 15.59 22.33 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.277 -0.963 . . . . 0.0 112.456 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.645 HG13 HD13 ' A' ' 35' ' ' ILE . 79.2 t -75.39 122.8 29.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 53' ' ' HIS . 8.1 mmm180 -122.39 150.87 41.84 Favored 'General case' 0 CA--C 1.474 -1.957 0 CA-C-O 121.348 0.594 . . . . 0.0 110.416 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 78.1 t -78.25 141.4 15.53 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.772 0 CA-C-N 114.018 -1.446 . . . . 0.0 109.424 -176.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.85 30.03 33.22 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -175.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 86' ' ' THR . 6.2 m170 -123.31 135.06 54.03 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.803 -0.698 . . . . 0.0 109.915 177.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.7 ttp180 -97.91 123.89 42.1 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 177.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.603 HG12 HG22 ' A' ' 86' ' ' THR . 32.6 mt -79.04 127.12 39.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 O-C-N 123.852 0.72 . . . . 0.0 109.779 178.087 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 41.6 pt -109.75 -13.93 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.95 143.11 16.74 Favored 'General case' 0 CA--C 1.483 -1.634 0 C-N-CA 120.025 -0.67 . . . . 0.0 109.314 -175.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.467 ' CD1' HG21 ' A' ' 63' ' ' VAL . 66.3 mt -137.71 127.84 36.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 70.84 -18.66 0.25 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.846 1.259 . . . . 0.0 113.485 172.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 130.59 8.41 3.16 Favored Glycine 0 C--N 1.299 -1.52 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -176.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -118.74 139.85 50.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 176.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 17.7 t -77.44 108.11 10.36 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.537 ' HA ' ' OG1' ' A' ' 66' ' ' THR . 21.8 m -101.04 8.57 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.231 0 CA-C-O 121.966 0.889 . . . . 0.0 109.384 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.03 -12.19 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.783 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.156 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.19 14.52 16.97 Favored 'General case' 0 N--CA 1.437 -1.093 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.735 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 63' ' ' VAL . 80.3 m -102.9 138.63 19.62 Favored Pre-proline 0 N--CA 1.409 -2.511 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.407 ' O ' HG13 ' A' ' 71' ' ' ILE . 59.4 Cg_exo -49.94 139.9 32.44 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.813 2.342 . . . . 0.0 110.751 176.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.46 ' CB ' ' HA ' ' A' ' 32' ' ' ASN . 32.6 p80 -51.66 -42.76 62.35 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -176.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -69.26 -37.59 77.98 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.665 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 tttm -60.13 -44.88 94.58 Favored 'General case' 0 CA--C 1.492 -1.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.907 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 67' ' ' PRO . 66.1 mt -52.05 -44.5 39.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 O-C-N 124.006 0.816 . . . . 0.0 109.762 178.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 96.8 t -67.24 -34.92 72.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.69 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 3.3 t-160 -74.29 -39.51 62.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 54.1 mt -65.7 -49.16 79.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.84 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 77.6 mt -57.12 -41.14 78.46 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.105 0.479 . . . . 0.0 110.985 175.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.5 t -57.08 -36.7 70.9 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 123.808 0.843 . . . . 0.0 111.53 178.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -98.6 -11.45 22.11 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -176.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.612 ' O ' ' HD3' ' A' ' 19' ' ' ARG . . . -86.89 131.01 34.23 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -173.501 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.427 HG12 HD23 ' A' ' 22' ' ' LEU . 1.1 m -134.64 179.01 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.99 -159.74 22.18 Favored Glycine 0 CA--C 1.496 -1.13 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.413 ' HB3' HD11 ' A' ' 16' ' ' LEU . 2.2 mp0 -78.98 108.11 12.22 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 171.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 17' ' ' ILE . 88.6 mt -104.47 117.27 49.78 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.471 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -175.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -100.02 111.3 23.6 Favored 'General case' 0 CA--C 1.479 -1.788 0 N-CA-C 105.014 -2.217 . . . . 0.0 105.014 -176.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.479 ' HE2' HG11 ' A' ' 15' ' ' VAL . 23.2 ttp -122.95 148.63 45.26 Favored 'General case' 0 C--N 1.257 -3.45 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -173.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.465 ' HD3' HG23 ' A' ' 14' ' ' THR . 29.0 mmtm -117.88 128.36 54.75 Favored 'General case' 0 CA--C 1.474 -1.971 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -177.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.603 HG22 HG12 ' A' ' 55' ' ' ILE . 54.0 p -127.74 143.39 51.14 Favored 'General case' 0 C--N 1.277 -2.567 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.429 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.498 ' C ' ' H ' ' A' ' 89' ' ' ALA . 85.5 mtp -112.9 168.72 7.27 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 177.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 11' ' ' ASN . 12.8 Cg_exo -74.48 30.05 0.34 Allowed 'Trans proline' 0 N--CA 1.489 1.238 0 C-N-CA 122.997 2.465 . . . . 0.0 111.578 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.498 ' H ' ' C ' ' A' ' 87' ' ' MET . . . 68.31 23.46 7.69 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 126.308 1.843 . . . . 0.0 111.815 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.419 -1.984 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.991 . . . . . . . . 0 0 . 1 stop_ save_